var images_info;if (!images_info) images_info =[]; images_info["50"]={"50001":{"type":"graphic_table","displayName":"Infection control isolation precautions","title":"Types of precautions for infection control","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types&nbsp;of&nbsp;precautions for infection control</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type of precaution </td> <td class=\"subtitle1\">Selected patients </td> <td class=\"subtitle1\">Major specifications </td> </tr> <tr> <td>Standard</td> <td>All patients</td> <td> <p>Perform hand hygiene before and after every patient contact*.</p> <p>Gloves, gowns, eye protection as required.</p> <p>Safe disposal or cleaning of instruments and linen.</p> <p>Cough etiquette: Patients and visitors should cover their nose or mouth when coughing, promptly dispose used tissues, and practice hand hygiene after contact with respiratory secretions.</p> </td> </tr> <tr> <td>Contact</td> <td> <p>Colonization of any bodily site with multidrug-resistant bacteria (MRSA, VRE, drug-resistant gram-negative organisms)</p> <p>Enteric infections (Norovirus, <em>Clostridium difficile</em>,&nbsp;<em>Escherichia coli</em> O157:H7)</p> <p>Viral infections (HSV, VZV, RSV<sup>&#182;</sup>, parainfluenza, enterovirus)</p> <p>Scabies</p> <p>Impetigo</p> <p>Noncontained abcesses or decubitus ulcers (especially for <em>Staphylococcus aureus</em> and group A <em>Streptococcus</em>)</p> </td> <td> <p><strong>In addition to standard precautions:</strong></p> <p>Private room preferred; cohorting allowed if necessary.</p> <p>Gloves required upon entering room. Change gloves after contact with contaminated secretions.</p> <p>Gown required if clothing may come into contact with the patient or environmental surfaces or if the patient has diarrhea.</p> <p>Minimize risk of environmental contamination during patient transport (eg, patient can be placed in a gown).</p> <p>Noncritical items should be dedicated to use for a single patient if possible.</p> </td> </tr> <tr> <td>Droplet</td> <td> <p><strong>Known or suspected:</strong></p> <p><em>Neisseria meningitidis</em></p> <p><em>Haemophilus influenzae</em> type B</p> <p><em>Mycoplasma pneumoniae</em></p> <p><em>Bordetella pertussis</em></p> <p>Diphtheria</p> <p>Pneumonic plague</p> <p>Influenza</p> <p>Rubella</p> <p>Mumps</p> <p>Adenovirus</p> <p>Parvovirus B19</p> </td> <td> <p><strong>In addition to standard precautions:</strong></p> <p>Private room preferred; cohorting allowed if necessary.</p> <p>Wear a mask when within&nbsp;three feet of the patient.</p> <p>Mask the patient during transport.</p> <p>Cough etiquette: Patients and visitors should cover their nose or mouth when coughing, promptly dispose used tissues, and practice hand hygiene after contact with respiratory secretions.</p> </td> </tr> <tr> <td>Airborne</td> <td> <p><strong>Known or suspected:</strong></p> <p>Tuberculosis</p> <p>Varicella</p> <p>Measles</p> <p>Smallpox</p> <p>SARS</p> <p>Ebola<sup>&#916;</sup></p> </td> <td> <p><strong>In addition to standard precautions:</strong></p> <p>Place the patient in an AIIR (a monitored negative pressure room with at least 6 to 12 air exchanges per hour).</p> <p>Room exhaust must be appropriately discharged outdoors or passed through a HEPA filter before recirculation within the hospital.</p> <p>A certified respirator must be worn when entering the room of a patient with diagnosed or suspected tuberculosis. Susceptible individuals should not enter the room of patients with confirmed or suspected measles or chickenpox.</p> <p>Transport of the patient should be minimized; the patient should be masked if transport within the hospital is unavoidable.</p> <p>Cough etiquette: Patients and visitors should cover their nose or mouth when coughing, promptly dispose used tissues, and practice hand hygiene after contact with respiratory secretions.</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This system of isolation precautions is recommended by the United States Healthcare Infection Control Practices Advisory Committee.</div><div class=\"graphic_footnotes\">MRSA: methicillin-resistant <EM innerHtml>S. aureus</EM>; VRE: vancomycin-resistant enterococci; RSV: respiratory syncytial virus; HSV: herpes simplex virus; VZV: varicella-zoster virus; SARS: severe acute respiratory syndrome; AIIR: airborne infection isolation room; HEPA: high-efficiency particulate aerator.<br />* Alcohol-based hand disinfectant is an acceptable alternative to soap and water in all situations EXCEPT in the setting of norovirus and&nbsp;<EM innerHtml>C. difficile <STRONG></STRONG></EM>infection, for which soap and water should be used.<br />¶ RSV may be transmitted by the droplet route but is primarily spread by direct contact with infectious respiratory secretions. Droplet precautions are not routinely warranted but are appropriate if the infecting agent is not known, if the patient may be coinfected with other pathogens that require droplet precautions, and/or if there is a chance of exposure to aerosols of infectious respiratory secretions.<br />Δ Refer to the UpToDate topic on prevention of Ebola virus infection for full discussion of infection control issues.</div><div class=\"graphic_reference\">Modified from Garner JS. Infect Control Hosp Epidemiol 1996; 17:53.</div><div id=\"graphicVersion\">Graphic 50001 Version 13.0</div></div></div>"},"50003":{"type":"graphic_diagnosticimage","displayName":"Extralobar sequestration at 32 weeks of gestation","title":"Extralobar sequestration at 32 weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Extralobar sequestration at 32 weeks of gestation</div><div class=\"cntnt\"><img style=\"width:586px; height:345px;\" src=\"images/OBGYN/50003_Extralobar_sequestration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound demonstrates a left lower lobe echogenic mass (A) with a systemic feeding vessel demonstrated with Doppler examination (B). A subtle high signal mass (arrow) is noted on magnetic resonance coronal (C) and sagittal (D) images. A linear low signal line through the mass represents a systemic feeding vessel. Postnatal CT images (E) axial and (F) sagittal reformatted image at 1 month of age demonstrate an enhancing mass (arrow) in left lower lobe region, abutting diaphragm with a feeding vessel originating from the descending aorta. A draining vein was identified coursing into the portal vein.</div><div class=\"graphic_reference\">Courtesy of Dorothy I Bulas, MD.</div><div id=\"graphicVersion\">Graphic 50003 Version 7.0</div></div></div>"},"50005":{"type":"graphic_table","displayName":"LD advocacy file contents","title":"File of documents that parents maintain when seeking special education services for their child","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">File of documents that parents maintain when seeking special education services for their child</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td>A copy of the child's school records, organized chronologically</td>\r\n        </tr>\r\n        <tr>\r\n            <td>A summary of the child's medical and developmental history</td>\r\n        </tr>\r\n        <tr>\r\n            <td>A copy of past diagnostic evaluations, including IQ tests, achievement tests, and tests of memory and language</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Copies of state and federal special education laws</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\">The telephone numbers and membership lists of local or state chapters of: </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">The Learning Disabilities Association of America (<a href=\"http://www.ldanatl.org/\" target=\"_blank\">www.ldanatl.org</a>) </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Council for Exceptional Children (<a href=\"http://www.cec.sped.org/\" target=\"_blank\">www.cec.sped.org</a>) </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Children and Adults with Attention Deficit/Hyperactivity Disorder (CHADD) (<a href=\"http://www.chadd.org/\" target=\"_blank\">www.chadd.org</a>) </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">National Joint Committee on Learning Disabilities (<a href=\"http://www.ldonline.org/njcld/index.html\" target=\"_blank\">www.ldonline.org/njcld/index.html</a>) </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\">Information related to special education laws, advocacy, and advocates who can assist the family at the admission, review, and dismissal (ARD) committee meeting may be obtained from the following organizations: </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">The Learning Disabilities Association of America (<a href=\"http://www.ldanatl.org/\" target=\"_blank\">www.ldanatl.org</a>) </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Council of Parent Attorneys and Advocates (<a href=\"http://www.copaa.net/\" target=\"_blank\">www.copaa.net</a>) </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Families and Advocates Partnership for Education (FAPE) (<a href=\"http://www.fape.org/\" target=\"_blank\">www.fape.org</a>) </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">LD OnLine (<a href=\"http://www.ldonline.org/\" target=\"_blank\">www.ldonline.org</a>) </td>\r\n        </tr>\r\n    </tbody>\r\n</table>\r\n<!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=53556&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_footnotes\">IQ: intelligence quotient.</div><div id=\"graphicVersion\">Graphic 50005 Version 3.0</div></div></div>"},"50006":{"type":"graphic_figure","displayName":"WHO weight for age boys 0 to 24 months","title":"Weight-for-age percentiles, boys 0 to 24 months, WHO growth standards","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Weight-for-age percentiles, boys 0 to 24 months, WHO growth standards</div><div class=\"cntnt\"><img style=\"width:573px; height:532px;\" src=\"images/PEDS/50006_WHO_wt_age_boys_0to2yrs_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">WHO: World Health Organization.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.</div><div id=\"graphicVersion\">Graphic 50006 Version 3.0</div></div></div>"},"50007":{"type":"graphic_diagnosticimage","displayName":"Oblique fracture of the middle toe","title":"Oblique fracture of the middle toe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oblique fracture of the middle toe</div><div class=\"cntnt\"><img style=\"width:313px; height:486px;\" src=\"images/EM/50007_Oblique_fx_prox_phalanx_3rd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Anterior posterior view. <br />(B) Oblique view.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 50007 Version 4.0</div></div></div>"},"50008":{"type":"graphic_figure","displayName":"Pancreatic decortication AGA","title":"Pancreatic decortication AGA","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic decortication AGA</div><div class=\"cntnt\"><img style=\"width:432px; height:311px;\" src=\"images/GAST/50008_Pancreatic_decortication_AG.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: American Gastroenterological Association (AGA) GTP slide set (2003), Pancreatic Disease. Authors: Gorelick F, Pandol S, Topazian M. Artist: Schoendorf J. Copyright &#169; 2003 American Gastroenterological Association.</div><div id=\"graphicVersion\">Graphic 50008 Version 3.0</div></div></div>"},"50009":{"type":"graphic_picture","displayName":"Rape","title":"Traumatic rape of child","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Traumatic rape of child</div><div class=\"cntnt\"><img style=\"width:504px; height:340px;\" src=\"images/EM/50009_Rape.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Injury unable to be assessed without sedation.</div><div class=\"graphic_reference\">Courtesy of Marc R. Laufer, MD.</div><div id=\"graphicVersion\">Graphic 50009 Version 4.0</div></div></div>"},"50012":{"type":"graphic_table","displayName":"Common fungal terminology","title":"Common fungal terminology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common fungal terminology</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Fungi -&nbsp;Plant-like organisms with no chlorophyll, with a definite nuclei and usually rigid cell walls.</td> </tr> <tr> <td>2. Hyphae -&nbsp;Long chains of cells that are aggregated into mats termed \"mycelium.\"</td> </tr> <tr> <td>3. Fungi reproduce by spores, which may be sexually (nuclear fusion, meiosis) formed or asexually (mitotically) formed.</td> </tr> <tr> <td class=\"sublist1_start\">4. Fungal classes according to their method of sexual reproduction.</td> </tr> <tr> <td class=\"sublist2\">a. Oomycetes produce motile, thick-walled sexual spores, one for each nuclear fusion (eg, the downy mildews). Some oomycetes produce unispore sacs called \"sporangia\" that become airborne. </td> </tr> <tr> <td class=\"sublist2\">b. Zygomycetes produce a single, large thick-walled sexual spore with each nuclear fusion. Zygomycetes also produce asexual spores in sporangia sacs (eg, <em>Rhizopus</em>, <em>Mucor</em>). </td> </tr> <tr> <td class=\"sublist2\">c. Ascomycetes produce eight sexual spores in a sac called an ascus and asexual spores called conidia (eg, <em>Leptosphaeria</em>, <em>Chaetomium</em>, <em>Venturia</em>).</td> </tr> <tr> <td class=\"sublist2\">d. Basidomycetes form sexual spores externally on pegs produced on structures called basidia.</td> </tr> <tr> <td class=\"sublist3\">i. Heterobasidiomycetes produce separate septate basidia (eg, rusts and smuts).</td> </tr> <tr> <td class=\"sublist3\">ii. Holobasidiomycetes produce single-celled, club-shaped basidia (eg, mushrooms and puffballs).</td> </tr> <tr> <td class=\"sublist2\">e. Deuteromycetes are fungi for which a sexual stage has not been identified (<em>Aspergillus</em>, <em>Stemphylium</em>, <em>Alternaria</em>, <em>Cladosporium</em>).</td> </tr> <tr> <td class=\"sublist2\">f. Myxomycetes are organisms with both plant and animal characteristics (eg, slime molds). The vegetative stage is an amoeba or multinucleate plasmodium that moves and ingests foods. </td> </tr> <tr> <td class=\"sublist2\">g. Actinomycetes are filamentous bacteria that produce dry airborne spores.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50012 Version 4.0</div></div></div>"},"50013":{"type":"graphic_diagnosticimage","displayName":"Aspergillus cortical infarct with hematoma","title":"<em>Aspergillus</em> cortical infarct with hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Aspergillus</em> cortical infarct with hematoma</div><div class=\"cntnt\"><img style=\"width:252px; height:288px;\" src=\"images/ID/50013_Asper_cort_infarct_hematoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 58-year-old man with a kidney transplant. Unenhanced computed tomography (CT) scan shows hematoma complicating a cortical infarct in left frontal lobe. Note intraventricular extension of hemorrhage. Autopsy showed <EM>Aspergillus</EM> thrombosis and vascular invasion. The patient died before cerebral angiography could be performed; a mycotic aneurysm could not be identified at autopsy.</div><div class=\"graphic_reference\">From: Ashdown BC, Tien RD, Felsberg GJ. Aspergillosis of the brain and paranasal sinuses in immunocompromised patients: CT and MR imaging findings. AJR Am J Roentgenol 1994; 162:155. Reprinted with permission from: the American Journal of Roentgenology.</div><div id=\"graphicVersion\">Graphic 50013 Version 12.0</div></div></div>"},"50014":{"type":"graphic_diagnosticimage","displayName":"Fusarium pneumonia x-ray","title":"<EM>Fusarium</EM> pneumonia radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Fusarium</EM> pneumonia radiograph</div><div class=\"cntnt\"><img style=\"width:433px; height:311px;\" src=\"images/ID/50014_Fusarium_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Alveolar infiltrates in a patient with <EM>Fusarium</EM> pneumonia.</div><div class=\"graphic_reference\">Reproduced from: Garnica M, Nucci M. Emerging fungal infections. In: Pulmonary involvement in patients with hematological malignancies, 1st Ed, Azoulay E (Ed), Springer-Verlag, Berlin Heidelberg 2011, with kind permission from Springer Science + Business Media B.V. Copyright © 2011.</div><div id=\"graphicVersion\">Graphic 50014 Version 5.0</div></div></div>"},"50016":{"type":"graphic_figure","displayName":"Actin signaling","title":"Pathomechanisms of proteinuria induced by GTPase dynamin cleavage by CatL","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Pathomechanisms of proteinuria induced by GTPase dynamin cleavage by CatL</div><div class=\"cntnt\"><img style=\"width:505px; height:516px;\" src=\"images/NEPH/50016_Actin_signaling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schematic shows the connections between the cortical actin cytoskeleton and components of the basolateral portion of a podocyte. The membrane domains are marked: apical cell membrane (green); the SD domain (blue); and the &quot;sole&quot; of the foot process (pink). LPS injection into mice induces CatL expression in the cytoplasm, which cleaves the active form of GTPase dynamin (represented here in its GTP-bound homotetrameric form). Dynamin binds actin-regulatory proteins including cortactin and the Arp2/3 complex, which catalyze actin filament assembly. Cleavage of dynamin generates a 40-kDa dynamin fragment (p40), which interferes with the normal function of dynamin and induces cytoskeleton reorganization, foot process effacement, and proteinuria.</div><div class=\"graphic_reference\">Reproduced with permission from: Ronco, P. Proteinuria: is it all in the foot?. J Clin Invest 2007; 117:2079. Copyright &#169;2007 American Society for Clinical Investigation.</div><div id=\"graphicVersion\">Graphic 50016 Version 1.0</div></div></div>"},"50017":{"type":"graphic_figure","displayName":"Low protein preserves GFR in DM","title":"Graph showing effect of dietary protein restriction on progression of diabetic nephropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Graph showing effect of dietary protein restriction on progression of diabetic nephropathy</div><div class=\"cntnt\"><img style=\"width:378px; height:208px;\" src=\"images/NEPH/50017_Low_protein_preserves_GFR_i.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dietary protein restriction - to about 0.6 g/kg per day or 30 to 40 percent lower than the control group - in two trials (left and right panels) of patients with type 1 diabetes and diabetic nephropathy led to a 75 percent reduction in the rate of loss of glomerular filtration rate (GFR) at 18 to 36 months.</div><div class=\"graphic_reference\">Data from: Walker JD, Bending JJ, Dodds RA, et al, Lancet 1989; 2:1411.<BR>Zeller K, Whittaker E, Sullivan L, et al. N Engl J Med 1991; 324:78.</div><div id=\"graphicVersion\">Graphic 50017 Version 3.0</div></div></div>"},"50018":{"type":"graphic_picture","displayName":"Electron micrograph of a normal glomerulus","title":"Electron micrograph of a normal glomerulus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"50021":{"type":"graphic_table","displayName":"Drug ratings in pregnancy (US Food and Drug Administration)","title":"Drug ratings in pregnancy (US Food and Drug Administration)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug ratings in pregnancy (US Food and Drug Administration)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Interpretation</td> </tr> <tr> <td class=\"centered divider_bottom\" rowspan=\"2\">A</td> <td class=\"sublist1_start\">Controlled human studies show no risk</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Controlled studies in pregnant women fail to demonstrate a risk to the fetus in the first trimester with no evidence of risk in later trimesters. The possibility of fetal harm appears remote.</td> </tr> <tr> <td class=\"centered divider_bottom\" rowspan=\"2\">B</td> <td class=\"sublist1_start\">No evidence of risk in studies</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Either animal reproduction studies have not demonstrated a fetal risk but there are no controlled studies in pregnant women or animal reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the first trimester and there is no evidence of a risk in later trimesters.</td> </tr> <tr> <td class=\"centered divider_bottom\" rowspan=\"2\">C</td> <td class=\"sublist1_start\">Risk cannot be ruled out</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal effects or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefits justify the potential risk to the fetus.</td> </tr> <tr> <td class=\"centered divider_bottom\" rowspan=\"2\">D</td> <td class=\"sublist1_start\">Positive evidence of risk</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (eg, if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).</td> </tr> <tr> <td class=\"centered\" rowspan=\"2\">X</td> <td class=\"sublist1_start\">Contraindicated in pregnancy</td> </tr> <tr> <td class=\"indent1\">Studies in animals or human beings have demonstrated fetal abnormalities or there is evidence of fetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In 2015, the US Food and Drug Administration (FDA) began overseeing the phase-out of pregnancy risk categories (A, B, C, D, and X) from prescription drug labeling and began requiring information from available human and animal studies of (1) known or potential maternal or fetal adverse reactions and (2) dose adjustments needed during pregnancy and the postpartum period. Additional information is available at the FDA website: <A href=\"http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm\" target=_blank>Pregnancy and Lactation Labeling Final Rule</A>.</div><div class=\"graphic_reference\">Reproduced with permission from: Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 50021 Version 28.0</div></div></div>"},"50022":{"type":"graphic_table","displayName":"Open globe rapid overview","title":"Overview of open globe injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of open globe injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">History</td> </tr> <tr> <td class=\"indent1\">May accompany multiple trauma or serious head injury</td> </tr> <tr> <td class=\"indent1\">Open globe laceration is considered a tetanus prone wound</td> </tr> <tr> <td class=\"indent1\">Open globe rupture may be occult</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td class=\"sublist2_start\">Inspection (with penlight or preferably a slit lamp):</td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Obvious corneal or scleral laceration </li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Volume loss to eye </li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Uveal (iris or ciliary body) prolapse </li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Other iris abnormalities (peaked pupil or eccentric pupil) </li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>360 degree, bullous subconjunctival hemorrhage (posterior rupture) </li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Intraocular or protruding foreign body </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Decreased visual acuity by Snellen or handheld chart, assess counting fingers, hand motion or light perception if unable to see chart</td> </tr> <tr> <td class=\"indent1\">Relative afferent pupillary defect by swinging penlight technique</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td class=\"indent1\"><span style=\"color: #ff0000;\"><strong>Immediate ophthalmology consultation for comprehensive eye examination if suspicion of an open globe</strong></span></td> </tr> <tr> <td class=\"indent1\">CT scan: non-contrast 1 to 2 mm cuts axial and coronal through the orbits</td> </tr> <tr> <td class=\"indent1\">Other studies based on presence and degree of traumatic injury to other anatomical regions (eg, head, thorax, abdomen)</td> </tr> <tr> <td class=\"subtitle1_single\">Initial treatment</td> </tr> <tr> <td class=\"indent1\">Ensure nothing by mouth (NPO)</td> </tr> <tr> <td class=\"indent1\">Assess and treat life-threatening injuries</td> </tr> <tr> <td class=\"indent1\">Avoid high dose ketamine if rapid sequence induction (RSI) is required</td> </tr> <tr> <td class=\"indent1\">If RSI is necessary, rocuronium is preferred to succinylcholine for muscle relaxation, although succinylcholine may be used with dexmedetomidine premedication</td> </tr> <tr> <td class=\"indent1\">Do not remove any protruding foreign bodies</td> </tr> <tr> <td class=\"indent1\">Avoid eye manipulation that will increase intraocular pressure (eg, lid retraction, intraocular pressure measurement, ocular ultrasound)</td> </tr> <tr> <td class=\"indent1\">Do <strong>not</strong> give any eye drops (eg, fluorescein, tetracaine, cycloplegics)</td> </tr> <tr> <td class=\"indent1\">Place eye shield after initial eye examination</td> </tr> <tr> <td class=\"indent1\">Put patient on bed rest with head of bed elevated to 30 degrees if hemodynamic condition allows</td> </tr> <tr> <td class=\"indent1\">Treat nausea aggressively and prevent vomiting (eg, ondansetron 0.15 mg/kg per dose, maximum dose: 16 mg, intravenously)*</td> </tr> <tr> <td class=\"indent1\">Provide sedation, as needed (eg, lorazepam 0.05 mg/kg, maximum dose: 2 mg)</td> </tr> <tr> <td class=\"indent1\">Provide analgesia (eg, IV fentanyl [1 to 2 mcg/kg per dose, maximum initial dose: 100 mcg] or IV/SQ morphine [0.1 mg/kg per dose, maximum initial dose: 10 mg])</td> </tr> <tr> <td class=\"sublist2_start\">Begin IV antibiotics:</td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Vancomycin (15 mg/kg IV, maximum dose: 1.5 g) PLUS either</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Ceftazidime (50 mg/kg IV, maximum dose: 2 g) or</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Fluoroquinolone for patients unable to tolerate ceftazidime&nbsp;(eg, ciprofloxacin 10 mg/kg IV, maximum dose: 400 mg) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Ensure definitive management by an ophthalmologist</td> </tr> <tr> <td class=\"indent1\">Urgent surgical repair, ideally within 24 hours of injury</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; IV: intravenous; SQ: subcutaneously.<br />* Ondansetron should be AVOIDED in patients with congenital long QT syndrome. ECG monitoring should be performed for patients receiving ondansetron who also have the following conditions: electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), congestive heart failure, or bradyarrhythmias, or are taking medications that prolong the QT interval.</div><div id=\"graphicVersion\">Graphic 50022 Version 14.0</div></div></div>"},"50023":{"type":"graphic_picture","displayName":"Severe neovascularization traction detachment","title":"Advanced traction retinal detachment due to severe neovascularization: Appearance on fundus photograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Advanced traction retinal detachment due to severe neovascularization: Appearance on fundus photograph</div><div class=\"cntnt\"><img style=\"width:432px; height:341px;\" src=\"images/ENDO/50023_Severe_neovasc_tract_detach.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color fundus photograph showing advanced traction retinal detachment due to extremely severe neovascularization on the disc and arcades, which has drawn the retina toward the vitreous cavity.</div><div id=\"graphicVersion\">Graphic 50023 Version 3.0</div></div></div>"},"50024":{"type":"graphic_picture","displayName":"OCT catheter","title":"Optical coherence tomography (OCT) catheter","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Optical coherence tomography (OCT) catheter</div><div class=\"cntnt\"><img style=\"width:468px; height:199px;\" src=\"images/GAST/50024_OCT_catheter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">OCT catheter shown exiting the accessory channel of a gastroscope.</div><div class=\"graphic_reference\">Courtesy of Shai Friedland, MD and Jacques Van Dam, MD, PhD.</div><div id=\"graphicVersion\">Graphic 50024 Version 1.0</div></div></div>"},"50025":{"type":"graphic_figure","displayName":"Prepubertal perineal anatomy","title":"Prepubertal perineal anatomy","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Prepubertal perineal anatomy</div><div class=\"cntnt\"><img style=\"width:512px; height:339px;\" src=\"images/PEDS/50025_prepubperinealanat.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Emans SJ. Office evaluation of the child and adolescent. In: Emans, Laufer, Goldstein's Pediatric&nbsp;and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50025 Version 9.0</div></div></div>"},"50027":{"type":"graphic_table","displayName":"Dx by pleural fluid analysis","title":"Diagnoses established \"definitively\" by pleural fluid analysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnoses established \"definitively\" by pleural fluid analysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Diagnostic pleural fluid tests</td> </tr> <tr> <td>Empyema</td> <td>Observation (pus, putrid odor), positive culture</td> </tr> <tr> <td>Malignancy</td> <td>Positive cytology</td> </tr> <tr> <td>Tuberculous pleurisy</td> <td>Positive AFB stain, culture</td> </tr> <tr> <td>Esophageal rupture</td> <td>High salivary isoenzyme form of amylase, low pH (often as low as 6), ingested vegetable or meat fragments</td> </tr> <tr> <td>Fungal-related effusions</td> <td>Positive fungal stain, culture</td> </tr> <tr> <td>Chylothorax</td> <td>Triglycerides &#62;110 mg/dL, chylomicrons by lipoprotein electrophoresis</td> </tr> <tr> <td>Cholesterol effusion</td> <td>Cholesterol &#62;200 mg/dL with a cholesterol to triglyceride ratio &#62;1, cholesterol crystals under polarizing light</td> </tr> <tr> <td>Hemothorax</td> <td>Ratio of pleural fluid to blood hematocrit &#62;0.5</td> </tr> <tr> <td>Urinothorax</td> <td>Pleural fluid creatinine to serum ratio always &#62;1 but diagnostic if &#62;1.7</td> </tr> <tr> <td>Peritoneal dialysis</td> <td>Protein &#60;0.5 mg/dL and pleural fluid to serum glucose ratio &#62;1 in peritoneal dialysis patient</td> </tr> <tr> <td>Extravascular migration or misplacement of a central venous catheter</td> <td>Pleural fluid to serum glucose ratio &#62;1, pleural fluid gross appearance mirrors infusate (eg, milky white if lipids infused)</td> </tr> <tr> <td>Rheumatoid pleurisy</td> <td>Cytologic evidence of elongated macrophages and distinctive multinucleated giant cells (tadpole cells) in a background of amorphous debris</td> </tr> <tr> <td>Glycinothorax</td> <td>Measurable glycine after bladder irrigation with glycine-containing solutions</td> </tr> <tr> <td>Cerebrospinal fluid leakage into pleural space</td> <td>Detection of beta-2 transferrin</td> </tr> <tr> <td>Parasite-related effusions</td> <td>Detection of parasites</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50027 Version 4.0</div></div></div>"},"50029":{"type":"graphic_picture","displayName":"Emergency thoracotomy aortic cross clamp","title":"Emergency thoracotomy showing aortic cross clamp","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Emergency thoracotomy showing aortic cross clamp</div><div class=\"cntnt\"><img style=\"width:490px; height:393px;\" src=\"images/SURG/50029_Em_thor_aort_cross_clamp.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 50029 Version 1.0</div></div></div>"},"50030":{"type":"graphic_picture","displayName":"Heller myotomy performed laparoscopically","title":"Heller myotomy performed laparoscopically","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heller myotomy performed laparoscopically</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/SURG/50030_Heller_myo_laparoscopically.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an intraoperative photograph of the laparoscopic performance of the myotomy on the esophagus.</div><div id=\"graphicVersion\">Graphic 50030 Version 2.0</div></div></div>"},"50031":{"type":"graphic_table","displayName":"Technique and findings with a digital rectal examination","title":"Components of the technique and expected findings with a detailed digital rectal examination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Components of the technique and expected findings with a detailed digital rectal examination</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Exam component</td> <td class=\"subtitle1\">Technique</td> <td class=\"subtitle1\">Findings and grading of response(s)</td> </tr> <tr> <td><strong>I. Inspection of the anus and surrounding tissue</strong></td> <td>Place patient in the left lateral position with hips flexed to 90&#176;. Inspect perineum under good light.</td> <td>Skin excoriation, skin tags, anal fissure, scars or hemorrhoids</td> </tr> <tr> <td><strong>II. Testing of perineal sensation and the anocutaneous reflex</strong></td> <td>Stroke the skin around the anus in a centripetal fashion, in all four quadrants, by using a stick with a cotton bud</td> <td> <p>Normal: Brisk contraction of the perianal skin, the anoderm and the external anal sphincter</p> <p>Impaired: No response with the soft cotton bud, but anal contractile response seen with the opposite (wooden) end</p> <p>Absent: No response with either end</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">III. Digital palpation and maneuvers to assess anorectal function</td> </tr> <tr> <td class=\"indent1\">Digital palpation</td> <td>Slowly advance a lubricated and gloved index finger into the rectum and feel the mucosa and surrounding muscle, bone, uterus, prostate and pelvic structures</td> <td>Tenderness, mass, stricture, or stool and the consistency of the stool</td> </tr> <tr> <td class=\"indent1\">Resting tone</td> <td>Assess strength of resting sphincter tone</td> <td>Normal, weak (decreased), or increased</td> </tr> <tr> <td class=\"indent1\">Squeeze maneuver</td> <td>Ask the patient to squeeze and hold as long as possible (up to 30 seconds)</td> <td>Normal, weak (decreased), or increased</td> </tr> <tr> <td class=\"indent1\">Pushing and bearing down maneuver</td> <td>In addition to the finger in the rectum, place a hand over the patient's abdomen to assess the push effort. Ask the patient to push and bear down as if to defecate.</td> <td> <ol> <li>Push effort: Normal, weak (decreased), excessive </li> <li>Anal relaxation: Normal, impaired, paradoxical contraction </li> <li>Perineal descent: Normal, excessive, absent </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Tantiphlachiva K, Rao P, Attaluri A, Rao SSC. Digital rectal examination is a useful tool for identifying patients with dyssynergia. Clin Gastroenterol Hepatol 2010; 8:955. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 50031 Version 1.0</div></div></div>"},"50032":{"type":"graphic_algorithm","displayName":"Diagnosis acute cholecystitis","title":"Algorithm for the diagnosis of acute cholecystitis","html":"<div class=\"graphic\"><div style=\"width: 812px\" class=\"figure\"><div class=\"ttl\">Algorithm for the diagnosis of acute cholecystitis</div><div class=\"cntnt\"><img style=\"width:792px; height:453px;\" src=\"images/GAST/50032_DX_acute_cholecystitis_edt1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GB: gallbladder; NSAIDs: nonsteroidal anti-inflammatory drugs; U/S: ultrasound.</div><div id=\"graphicVersion\">Graphic 50032 Version 5.0</div></div></div>"},"50033":{"type":"graphic_diagnosticimage","displayName":"Aldosterone-producing adenoma","title":"Aldosterone-producing adenoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aldosterone-producing adenoma</div><div class=\"cntnt\"><img style=\"width:351px; height:289px;\" src=\"images/ENDO/50033_Adrenal_mass_in_primary_ald.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abdominal CT scan shows a hypodense 1.5 cm right adrenal mass in a patient with biochemically confirmed primary aldosteronism.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of William F Young, MD.</div><div id=\"graphicVersion\">Graphic 50033 Version 3.0</div></div></div>"},"50037":{"type":"graphic_table","displayName":"Etiologies of bradyarrhythmias","title":"Major etiologies of bradyarrhythmias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major etiologies of bradyarrhythmias</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Sinus bradycardia and its variants - including sinoatrial block</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Atrioventricular heart block or dissociation - can occur with sinus rhythm or atrial fibrillation or flutter</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Second or third degree AV block</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Isorhythmic AV dissociation and related variants</td>\n    </tr>\n    <tr>\n\n      <td>Wandering atrial pacemaker</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Junctional (AV nodal) escape rhythms - can occur with sinus rhythm or atrial fibrillation or flutter</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ventricular escape (idioventricular) rhythms</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 50037 Version 1.0</div></div></div>"},"50039":{"type":"graphic_table","displayName":"Clinical characteristics of FMDs","title":"Clinical characteristics of functional movement disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical characteristics of functional movement disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Abrupt onset</td> </tr> <tr> <td>History of a precipitating event</td> </tr> <tr> <td>Fast progression to maximum symptom severity and disability</td> </tr> <tr> <td>Movement abnormality that is incongruent with organic disease (eg, bizarre, multiple or difficult to classify)</td> </tr> <tr> <td>Inconsistency over time with variable amplitude, frequency, or distribution of the movement</td> </tr> <tr> <td>Ability to trigger or relieve the abnormal movements with unusual or nonphysiologic intervention (eg, trigger points on the body, application of a tuning fork)</td> </tr> <tr> <td>Decreased movement of the affected body part with distraction</td> </tr> <tr> <td>Increased movement of the affected body part during observation or examination</td> </tr> <tr> <td>Entrainment of movement (eg, tremor) to the frequency of repetitive movements</td> </tr> <tr> <td>Coactivation sign of antagonist muscles</td> </tr> <tr> <td>Deliberate slowness of movement</td> </tr> <tr> <td>Association with false weakness, sensory loss, and pain</td> </tr> <tr> <td>Functional disability out of proportion to exam findings</td> </tr> <tr> <td>Unresponsiveness to drugs for organic movement disorders</td> </tr> <tr> <td>Response to placebo drugs and suggestion</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">10.0000000000000</mso:Specialty>\r\n<mso:Publishable_Version msdt:dt=\"string\">0</mso:Publishable_Version>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=94889&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Clinical_characteristics_of_PMDs.htm</title></head></div><div id=\"graphicVersion\">Graphic 50039 Version 2.0</div></div></div>"},"50040":{"type":"graphic_picture","displayName":"Ruptured vulva hematoma","title":"Spontaneous rupture of large vulvar hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spontaneous rupture of large vulvar hematoma</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/OBGYN/50040_Rupturedvulvahematoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Emans SJ, Laufer MR. Emans, Laufer &amp; Goldstein’s Pediatric&nbsp;and Adolescent Gynecology, 6th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50040 Version 8.0</div></div></div>"},"50042":{"type":"graphic_picture","displayName":"Knee-to-knee position","title":"Knee-to-knee position for oral health examination of young children","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Knee-to-knee position for oral health examination of young children</div><div class=\"cntnt\"><img style=\"width:752px; height:528px;\" src=\"images/PEDS/50042_Kneetokneeposition.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nowak AJ, Warren JJ. Infant oral health and oral habits. Pediatr Clin North Am 2000; 47:1043.</div><div id=\"graphicVersion\">Graphic 50042 Version 6.0</div></div></div>"},"50043":{"type":"graphic_diagnosticimage","displayName":"Pulm AVM CXR II","title":"Multiple non-communicating arteriovenous malformations detected on a routine chest radiograph in asymptomatic patient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple non-communicating arteriovenous malformations detected on a routine chest radiograph in asymptomatic patient</div><div class=\"cntnt\"><img style=\"width:360px; height:394px;\" src=\"images/PULM/50043_Pulm_AVM_CXR_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph shows multiple small nodular arteriovenous malformations with distorted peripheral vascularity of the lungs.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 50043 Version 2.0</div></div></div>"},"50044":{"type":"graphic_picture","displayName":"Nail capillaries in MCTD","title":"Fingernail capillaroscopy in mixed connective tissue disease (MCTD)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fingernail capillaroscopy in mixed connective tissue disease (MCTD)</div><div class=\"cntnt\"><img style=\"width:360px; height:276px;\" src=\"images/RHEUM/50044_Nail_capillaries_in_MCTD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Capillaroscopy showing widening and thickening of the nailfold capillary loops and patchy loss of capillary density (arrow) in a patient with mixed connective tissue disease. This pattern is also commonly seen in patients with scleroderma, but it is rare in those with classical SLE.</div><div class=\"graphic_reference\">Courtesy of Robert M Bennett, MD.</div><div id=\"graphicVersion\">Graphic 50044 Version 2.0</div></div></div>"},"50045":{"type":"graphic_picture","displayName":"Fusarium toe cellulitis","title":"<EM>Fusarium </EM>toe cellulitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Fusarium </EM>toe cellulitis</div><div class=\"cntnt\"><img style=\"width:297px; height:307px;\" src=\"images/ID/50045_Fusarium_toe_cellulitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Fusarium</EM> toe cellulitis developing at the site of onychomycosis after cytotoxic chemotherapy in a 45-year-old woman with lymphoma who underwent allogeneic hematopoietic cell transplantation.</div><div class=\"graphic_reference\">This research was originally published in Blood. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999. Copyright © 1997 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 50045 Version 4.0</div></div></div>"},"50051":{"type":"graphic_diagnosticimage","displayName":"Choroid plexus cysts","title":"Multiple views of bilateral choroid plexus cysts","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">Multiple views of bilateral choroid plexus cysts</div><div class=\"cntnt\"><img style=\"width:579px; height:194px;\" src=\"images/OBGYN/50051_Choroid_plexus_cysts.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 50051 Version 2.0</div></div></div>"},"50052":{"type":"graphic_diagnosticimage","displayName":"Avulsion anterior iliac spine","title":"Apophyseal avulsion injury of the right anterior superior iliac spine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apophyseal avulsion injury of the right anterior superior iliac spine</div><div class=\"cntnt\"><img style=\"width:432px; height:360px;\" src=\"images/PEDS/50052_Avulsion_ant_iliac_spine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apophyseal avulsion injury of the right anterior superior iliac spine at the site of insertion of the sartorius (arrow).</div><div class=\"graphic_reference\">Courtesy of Rajvee Shah, MD.</div><div id=\"graphicVersion\">Graphic 50052 Version 2.0</div></div></div>"},"50053":{"type":"graphic_figure","displayName":"Paradigm of sexuality","title":"Paradigm of sexuality","html":"<div class=\"graphic\"><div style=\"width: 664px\" class=\"figure\"><div class=\"ttl\">Paradigm of sexuality</div><div class=\"cntnt\"><img style=\"width:644px; height:812px;\" src=\"images/PEDS/50053_Paradigmsexuality.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Michelle Forcier, MD, MPH&nbsp;and Johanna Olson, MD.</div><div id=\"graphicVersion\">Graphic 50053 Version 4.0</div></div></div>"},"50055":{"type":"graphic_algorithm","displayName":"Nontraumatic neck stiffness in children","title":"Nontraumatic neck stiffness or torticollis in children","html":"<div class=\"graphic\"><div style=\"width: 844px\" class=\"figure\"><div class=\"ttl\">Nontraumatic neck stiffness or torticollis in children</div><div class=\"cntnt\"><img style=\"width:824px; height:515px;\" src=\"images/EM/50055_Neck_stiff_no_trauma_ed2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CNS: central nervous system; PCR: polymerase chain reaction.</div><div id=\"graphicVersion\">Graphic 50055 Version 8.0</div></div></div>"},"50056":{"type":"graphic_picture","displayName":"Resectoscope assembly 1","title":"Hysteroscopy: Resectoscope assembly 1","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hysteroscopy: Resectoscope assembly 1</div><div class=\"cntnt\"><img style=\"width:504px; height:261px;\" src=\"images/OBGYN/50056_Resectoscope_assembly_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Linda D Bradley, MD.</div><div id=\"graphicVersion\">Graphic 50056 Version 2.0</div></div></div>"},"50057":{"type":"graphic_picture","displayName":"Large CMN","title":"Giant congenital melanocytic nevus in a bathing trunk distribution","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Giant congenital melanocytic nevus in a bathing trunk distribution</div><div class=\"cntnt\"><img style=\"width:361px; height:504px;\" src=\"images/PEDS/50057_Large_CMN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypertrichosis and multiple satellite congenital nevi are evident.</div><div class=\"graphic_reference\">Courtesy of the Yale Dermatology Residents' Slide Collection.</div><div id=\"graphicVersion\">Graphic 50057 Version 1.0</div></div></div>"},"50058":{"type":"graphic_figure","displayName":"Effect of carbon monoxide on oxygen delivery","title":"Effect of carboxyhemoglobinemia on oxygen content and delivery","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Effect of carboxyhemoglobinemia on oxygen content and delivery</div><div class=\"cntnt\"><img style=\"width:524px; height:495px;\" src=\"images/PULM/50058_Effect_of_co_on_oxyhemoglob.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red curve demonstrates the normal relationship between arterial (A) and venous (V) oxygen content. In general, a difference in arterial and venous oxygen content of 5 mL per 100 mL blood is expected at rest. The green line depicts the effect of a 50 percent decrease in hemoglobin concentration, which decreases arterial (A') and venous (V'1) oxygen content but does not change the partial pressure at which hemoglobin is 50 percent saturated (P<sub>50</sub>). The blue curve shows the effect of a 50 percent carboxyhemoglobinemia (COHb), which both decreases oxygen carrying capacity (A') and impairs peripheral unloading of oxygen from hemoglobin under conditions of low oxygen tension (V'2), shifting P<sub>50</sub> to the left (P'<sub>50</sub>). These changes result in a profound reduction in both oxyhemoglobin saturation and delivery of oxygen to peripheral tissues.</div><div id=\"graphicVersion\">Graphic 50058 Version 2.0</div></div></div>"},"50060":{"type":"graphic_figure","displayName":"TMJ muscle anatomy","title":"Temporomandibular joint muscle anatomy","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Temporomandibular joint muscle anatomy</div><div class=\"cntnt\"><img style=\"width:498px; height:490px;\" src=\"images/EM/50060_TMJanatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomy of the temporomandibular joint with location of masseter and pterygoid muscles.</div><div class=\"graphic_reference\">Reproduced with permission from: Pratt A, Loiselle JM. Reduction of temporomandibular joint dislocation. In: Textbook of Pediatric Emergency Procedures, 2nd Edition, King C, Henretig FM (Eds). Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50060 Version 9.0</div></div></div>"},"50061":{"type":"graphic_table","displayName":"VCd CyBorD for multiple myeloma","title":"Bortezomib (Velcade) plus cyclophosphamide and dexamethasone (VCD or CyBorD) for multiple myeloma<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bortezomib (Velcade) plus cyclophosphamide and dexamethasone (VCD or CyBorD) for multiple myeloma<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 28 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Bortezomib</td> <td>1.5 mg/m<sup>2</sup> SC or IV*</td> <td>Given subcutaneously or as a rapid IV bolus over three to five seconds.</td> <td>Days 1, 8, 15, and 22</td> </tr> <tr> <td>Cyclophosphamide</td> <td>300 mg/m<sup>2</sup> by mouth, once weekly</td> <td>Dose rounding to the nearest 50 mg. Do not cut or crush. Take during or after meal in the morning.</td> <td>Days 1, 8, 15, and 22</td> </tr> <tr class=\"divider_bottom\"> <td>Dexamethasone</td> <td>40 mg by mouth, once weekly</td> <td>Take with food (after meals or with food or milk) in the morning.</td> <td>Days 1, 8, 15, and 22</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Patients receiving cyclophosphamide should maintain adequate oral hydration (2 to 3 L/day during administration and for one to two days thereafter) and void every two to three hours to reduce the risk of hemorrhagic cystitis.<sup>[2]</sup> Risk of bladder irritation is also decreased by avoiding bedtime administration. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>LOW or VERY LOW. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Routine premedication is not indicated. If a hypersensitivity reaction occurs with cyclophosphamide, then neither oral nor IV cyclophosphamide should be readministered. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Bortezomib therapy may be associated with an increased risk of herpes zoster and infections not related to neutropenia. Antiviral prophylaxis (eg, acyclovir 400 mg orally twice a day) should be administered to all patients receiving VCD/CyBorD. Some clinicians also administer trimethoprim-sulfamethoxazole double strength once daily on Mondays, Wednesdays, and Fridays during treatment. Primary prophylaxis with G-CSF is not indicated. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Antithrombotic prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>While patients with multiple myeloma have an increased risk of thrombosis, the risk of thrombosis with the VCD/CyBorD regimen was &#8804;7% in two trials.<sup>[3,4]</sup> Routine antithrombotic prophylaxis is not warranted. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li><strong>Bortezomib:</strong> No dosage adjustment for bortezomib secondary to renal insufficiency is necessary. For patients undergoing hemodialysis, bortezomib should be administered after dialysis. Patients with moderate or severe hepatic impairment (serum bilirubin level &#62;1.5 times the upper limit of normal) should be started on bortezomib at a reduced dose of 0.7 mg/m<sup>2</sup> per injection during the first cycle, with further dose modifications based upon patient tolerance. </li> <li><strong>Cyclophosphamide:</strong> For patients with preexisting hepatic impairment, dose adjustments in cyclophosphamide dose may be needed. The need for cyclophosphamide dose reduction in patients with renal impairment is controversial; some suggest dose reduction if the creatinine clearance is &#60;30 mL/minute. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess CBC with differential, electrolytes, renal function, liver function, and M protein prior to starting each cycle. A CBC should also be performed prior to the day 15 dose of bortezomib. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Weekly assessment for peripheral neuropathy and/or neuropathic pain. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for hypotension during therapy; adjustment of antihypertensives and/or administration of IV hydration may be needed. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>If platelets are &#60;50,000/microL or the absolute neutrophil count is &#60;1000 cells/microL on day 15, hold bortezomib and cyclophosphamide.<sup>[3]</sup> If several doses are held, reduce bortezomib dose by one level (from 1.5 mg/m<sup>2</sup> to 1.3 mg/m<sup>2</sup>; or from 1.3 mg/m<sup>2</sup> to 1 mg/m<sup>2</sup>; or from 1 mg/m<sup>2</sup> to 0.7 mg/m<sup>2</sup>) and decrease the number of doses of cyclophosphamide given each cycle by one level (serial levels are: Days 1, 8, 15, and 22; days 1, 8, and 15; days 1 and 8; day 1 only). </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neuropathy</strong></td> <td colspan=\"3\"> <ul> <li>Dose adjustment guidelines for bortezomib in patients who develop peripheral neuropathy or neuropathic pain are available:<sup>[5]</sup> <ul> <li>Grade 1 (asymptomatic, loss of deep tendon reflexes or paresthesia without pain or loss of function): No action required. </li> <li>Grade 1 (with pain) or Grade 2 (interfering function but not activities of daily living): Reduce by one level (from 1.5 mg/m<sup>2</sup> to 1.3 mg/m<sup>2</sup>; or from 1.3 mg/m<sup>2</sup> to 1 mg/m<sup>2</sup>; or from 1 mg/m<sup>2</sup> to 0.7 mg/m<sup>2</sup>). </li> <li>Grade 2 (with pain) or Grade 3 (interfering with activities of daily living): Hold until resolution, may reinitiate at 0.7 mg/m<sup>2</sup> once weekly. </li> <li>Grade 4 (life-threatening, disabling, eg, paralysis): Discontinue. </li> </ul> </li> <li>Rarely, bortezomib has been associated with reversible posterior leukoencephalopathy syndrome (RPLS), which can present with seizures, hypertension, headache, lethargy, confusion, blindness, or as other visual or neurological disturbances. Bortezomib should be discontinued if the diagnosis of RPLS is confirmed on brain MRI. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Cystitis</strong></td> <td colspan=\"3\"> <ul> <li>For grades 1 or 2 cystitis (minor symptoms responding to outpatient management), decrease the number of doses of cyclophosphamide given each cycle by one level (serial levels are: Days 1, 8, 15, and 22; days 1, 8, and 15; days 1 and 8; day 1 only).<sup>[2]</sup> Cyclophosphamide should be discontinued if cystitis symptoms are distressing or affect lifestyle (grade 3 or 4). </li> <li>Refer to UpToDate topic on \"Cystitis in patients with cancer\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other nonhematological toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For grade 3 or 4 nonhematologic toxicity other than neuropathy, bortezomib should be held. Once symptoms have resolved to grade 1 or baseline, bortezomib may be reinitiated with one dose level reduction (from 1.3 mg/m<sup>2</sup> to 1 mg/m<sup>2</sup>; or from 1 mg/m<sup>2</sup> to 0.7 mg/m<sup>2</sup>). Dexamethasone dose should be reduced for grade 2 muscle weakness, grade 3 gastrointestinal tract toxicity, hyperglycemia, confusion or mood alterations. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">SC: subcutaneous; IV: intravenous; G-CSF: granulocyte-colony stimulating factors; CBC: complete blood count.<br />* Subcutaneous administration is preferred due to a lower risk of neuropathy.<SUP>[6]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Reeder CB, et al. Blood 2010; 115:3416.</LI>&#xD;&#xA;<LI>Cyclophosphamide tablets. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 6, 2012).</LI>&#xD;&#xA;<LI>Reeder CB, et al. Leukemia 2009; 23:1337.</LI>&#xD;&#xA;<LI>Kropff M, et al. Br J Haemtol 2007; 138:330.</LI>&#xD;&#xA;<LI>Bortezomib injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 6, 2012).</LI>&#xD;&#xA;<LI>Moreau P, et al. Lancet Oncol 2011; 12:431.</LI></OL></div><div id=\"graphicVersion\">Graphic 50061 Version 17.0</div></div></div>"},"50062":{"type":"graphic_picture","displayName":"Ocular toxocariasis with peripheral granuloma","title":"Ocular toxocariasis with peripheral granuloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ocular toxocariasis with peripheral granuloma</div><div class=\"cntnt\"><img style=\"width:392px; height:294px;\" src=\"images/ID/50062_Ocular_toxocariasis_granulo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ocular toxocariasis with peripheral granuloma and vitreoretinal traction.</div><div class=\"graphic_reference\">Original figure from: Pivetti-Pezzi P. Ocular Toxocariasis. Int J Med Sci 2009; 6:129-130. <a href=\"http://www.medsci.org/v06p0129.htm\" target=\"_blank\">http://www.medsci.org/v06p0129.htm</a>. Reproduced with permission. Copyright © 2009 Ivyspring International Publisher.</div><div id=\"graphicVersion\">Graphic 50062 Version 3.0</div></div></div>"},"50064":{"type":"graphic_diagnosticimage","displayName":"Hepatic metastases CT","title":"Hepatic metastases","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatic metastases</div><div class=\"cntnt\"><img style=\"width:365px; height:288px;\" src=\"images/GAST/50064_Hepatic_metastases_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A contrast-enhanced computed tomography (CT) scan of the liver demonstrates multiple hypovascular metastases throughout all lobes of the liver. These lesions are typical of metastatic colon cancer. Ascites is also present.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 50064 Version 3.0</div></div></div>"},"50065":{"type":"graphic_algorithm","displayName":"CHH management","title":"Suggested paradigm for initial and long-term management of individuals with cartilage-hair hypoplasia","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Suggested paradigm for initial and long-term management of individuals with cartilage-hair hypoplasia</div><div class=\"cntnt\"><img style=\"width:544px; height:494px;\" src=\"images/ALLRG/50065_CHH_management_edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CBC: complete blood count; IgG: immunoglobulin G; IgA: immunoglobulin A; IgM: immunoglobulin M; NK: natural killer; TREC: T cell receptor excision circle; SCID: severe combined immunodeficiency; CHH: cartilage-hair hypoplasia.<br />* Our data suggest that many individuals with CHH can safely receive non-live vaccines during the first year of life. Live vaccines should be avoided in CHH patients with clinical and laboratory features concerning for immunodeficiency or in those who clearly have SCID.</div><div id=\"graphicVersion\">Graphic 50065 Version 4.0</div></div></div>"},"50067":{"type":"graphic_picture","displayName":"Cipro crystalluria shapes","title":"Photomicrographs showing urine sediment of a patient with ciprofloxacin crystalluria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Photomicrographs showing urine sediment of a patient with ciprofloxacin crystalluria</div><div class=\"cntnt\"><img style=\"width:372px; height:526px;\" src=\"images/NEPH/50067_Cipro_crystalluria_shapes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Needles, (B) sheaves, (C) stars, and (D) bizarre shape. Crystals in A, C, and D are visualized under phase contrast microscopy, while those in B are seen with bright field microscopy. The crystals are shown with polarizing microscopy on the inset panels.</div><div class=\"graphic_reference\">Reproduced with permission from: Fogazzi, GB, Garigali, G, Brambilla, C, Daudon, M. Ciprofloxacin crystalluria. Nephrol Dial Transplant 2006; 21:2982. Copyright ©2006 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 50067 Version 4.0</div></div></div>"},"50069":{"type":"graphic_diagnosticimage","displayName":"Membranous VSD long axis color still frame","title":"Membranous VSD long axis color still frame","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Membranous VSD long axis color still frame</div><div class=\"cntnt\"><img style=\"width:546px; height:336px;\" src=\"images/CARD/50069_Membran_VSD_long_axis_color.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long axis still frame from a two-dimensional transthoracic echocardiogram with and without color flow mapping. In the left hand panel, color flow mapping demonstrates the jet of left-to-right flow crossing the septum just apical to the aortic annulus. The ventricular septal defect (VSD) is shown without color flow mapping in the right hand panel (arrow).</div><div class=\"graphic_footnotes\">LA: left atrium; LV: left ventricle; RV: right ventricle; AO: aorta; arrow: VSD.</div><div id=\"graphicVersion\">Graphic 50069 Version 3.0</div></div></div>"},"50070":{"type":"graphic_picture","displayName":"HSTCL liver 40x magnification","title":"Hepatosplenic T-cell lymphoma tumor cells in the sinuses of the liver","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hepatosplenic T-cell lymphoma tumor cells in the sinuses of the liver</div><div class=\"cntnt\"><img style=\"width:504px; height:371px;\" src=\"images/HEME/50070_HSTCLtumorcellssinuses.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Higher magnification of the liver biopsy shows clusters of tumor cells in the sinuses. Hematoxylin and eosin, 40x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry and Immunochemistry for Hematologic Neoplasms, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50070 Version 7.0</div></div></div>"},"50071":{"type":"graphic_figure","displayName":"Isopropyl alcohol metabolism","title":"Isopropyl alcohol metabolism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Isopropyl alcohol metabolism</div><div class=\"cntnt\"><img style=\"width:204px; height:235px;\" src=\"images/EM/50071_Isopropyl_alcohol_metabolis.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 50071 Version 2.0</div></div></div>"},"50072":{"type":"graphic_table","displayName":"Diagnostic tests for physical and other inducible urticarias","title":"Inciting factors and diagnostic tests for physical and other inducible urticarias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Inciting factors and diagnostic tests for physical and other inducible urticarias</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Inciting trigger(s)</td> <td class=\"subtitle1\">Diagnostic test</td> </tr> <tr class=\"divider_bottom\"> <td>Symptomatic dermographism (urticaria factitia)</td> <td>Firm stroking, scratching, pressure</td> <td>Moderate stroking of the skin with a blunt, smooth object (eg, closed ballpoint pen tip, wooden tongue depressor) or dermographometer.</td> </tr> <tr class=\"divider_bottom\"> <td>Delayed pressure urticaria/angioedema</td> <td>Application of pressure <span style=\"font-size: 16px; font-family: calibri;\">&#189;</span> to 12 hours before onset of symptoms</td> <td> <p>Sling with weights placed over arm or shoulder for 15 minutes (7 kg weight on 3 cm wide shoulder strap). Patient reports symptoms over next 24 hours.</p> Dermographometers are used in research (100 grams/mm<sup>2</sup> for 70 seconds).</td> </tr> <tr class=\"divider_bottom\"> <td>Cholinergic urticaria</td> <td>Elevation of body temperature (exercise, hot water, strong emotion, hot or spicy food)</td> <td> <p>Exercise using a machine (stationary bicycle or treadmill) to the point of sweating. Then, continue for 15 minutes. If this test is positive, then passive heating of one/both arms in 42&#176;C warm water bath to cause increase in body temperature of &#8805;1&#176;C.</p> Some patients may react to skin testing with own sweat.</td> </tr> <tr class=\"divider_bottom\"> <td>Cold contact urticaria</td> <td>Exposure of skin to cold air, cold liquids, or cold objects</td> <td> <p>Ice cube test - Melting ice cube in thin plastic bag for&nbsp;5 minutes.</p> TempTest where available to determine patient's threshold.</td> </tr> <tr class=\"divider_bottom\"> <td>Heat contact urticaria</td> <td>Warm object in direct contact with affected skin</td> <td>Application of test tube containing 45&#176;C water or metal cylinder heated to 45&#176;C to skin for&nbsp;5 minutes.</td> </tr> <tr class=\"divider_bottom\"> <td>Exercise-induced urticaria/anaphylaxis</td> <td>Physical exertion</td> <td>Treadmill testing.</td> </tr> <tr class=\"divider_bottom\"> <td>Aquagenic urticaria</td> <td> <p>Skin contact with water of any temperature</p> Salinity of water important in some cases</td> <td>Application of 35&#176;C water in compress to upper body for 30 minutes.</td> </tr> <tr class=\"divider_bottom\"> <td>Solar urticaria</td> <td>Exposure of skin to sunlight (triggering wavelengths vary)</td> <td>Exposure of normally covered skin to UVA (6 J/cm<sup>2</sup>), UVB (60 mJ/cm<sup>2</sup>), and visible light (projector).</td> </tr> <tr> <td>Vibratory urticaria/angioedema</td> <td>Lawn mowing, riding a motorcycle, horseback riding, mountain biking, exposure to vibrating machinery, holding some steering wheels</td> <td>Vortex mixer is held against skin for 10 minutes.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">UVA: ultraviolet A radiation therapy; UVB: ultraviolet B radiation therapy.</div><div class=\"graphic_reference\">Consistent with the recommendations in Magerl M, Borzova E, Gim&eacute;nez-Arnau A, et al. The definition and diagnostic testing of physical and cholinergic urticarias - EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. Allergy 2009; 64:1715.</div><div id=\"graphicVersion\">Graphic 50072 Version 10.0</div></div></div>"},"50073":{"type":"graphic_table","displayName":"Coefficient for calculating volume for fetal transfusion","title":"Transfusion coefficient for calculating transfusion volume for fetal transfusion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Transfusion coefficient for calculating transfusion volume for fetal transfusion</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Target hematocrit minus beginning hematocrit = Desired increment in hematocrit\n   </td>\n   <td  class=\"subtitle1\">\n   Transfusion coefficient\n   </td>\n   </tr>\n   <tr>\n   <td>10</td>\n   <td>0.02</td>\n   </tr>\n   <tr>\n   <td>15</td>\n   <td>0.03</td>\n   </tr>\n   <tr>\n   <td>20</td>\n   <td>0.04</td>\n   </tr>\n   <tr>\n   <td>25</td>\n   <td>0.05</td>\n   </tr>\n   <tr>\n   <td>30</td>\n   <td>0.06</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=24211&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Transfusion_coefficient.htm</title></head></div><div class=\"graphic_lgnd\">As an example, to increase the hematocrit of a 1000 gram fetus from 20 percent to 40 percent, one multiplies 0.04 (coefficient for raising the hematocrit by 20) and 1000 (the estimated fetal weight in grams) to yield 40 mL (the volume that needs to be transfused).</div><div class=\"graphic_reference\">Data from: Moise KJ, Whitecar PW. Antenatal therapy for hemolytic disease. In: Alloimmune Disorders of Pregnancy. Anemia, thrombocytopenia and neutropenia in the fetus and newborn. Hadley A, Soothill P (Eds), Cambridge University Press, Cambridge, UK 2002. p.182.</div><div id=\"graphicVersion\">Graphic 50073 Version 4.0</div></div></div>"},"50075":{"type":"graphic_picture","displayName":"Assessment of optic disc A","title":"Assessment of the optic disc in healthy and glaucomatous eyes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Assessment of the optic disc in healthy and glaucomatous eyes</div><div class=\"cntnt\"><img style=\"width:406px; height:434px;\" src=\"images/PC/50075_Assessment_of_optic_disc_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Optic nerve photography: small central cup in healthy eye; enlarged cup and loss of inferotemporal neuroretinal rim in glaucomatous eye.<br />(B) Retinal nerve fibre layer photography: uniform reflections in healthy eye; poor reflections in inferotemporal region (arrows) in glaucomatous eye.</div><div class=\"graphic_reference\">Reprinted with permission from: Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004; 363:1711. Copyright © 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 50075 Version 3.0</div></div></div>"},"50077":{"type":"graphic_table","displayName":"Risk after reducing smoking","title":"Lung cancer risk by smoking status","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lung cancer risk by smoking status</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"5\">Smoking category</td> </tr> <tr> <td class=\"subtitle2\">Heavy smokers</td> <td class=\"subtitle2\">Reducers</td> <td class=\"subtitle2\">Light smokers</td> <td class=\"subtitle2\">Ex-smokers</td> <td class=\"subtitle2\">Never smokers</td> </tr> <tr> <td>Adjusted hazard ratio* (95% CI)</td> <td>1.00</td> <td>0.73 (0.54-0.98)</td> <td>0.44 (0.35-0.56)</td> <td>0.17 (0.13-0.23)</td> <td>0.09 (0.06-0.13)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Heavy smokers: &#8805;15 cigarettes or equivalent tobacco per day.<br> Reducers: Heavy smokers who decreased by &#8805;50 percent.<br> Light smokers: 1 to 14 cigarettes or equivalent tobacco per day.</div><div class=\"graphic_footnotes\">* Multivariate analysis adjusted for sex, cohort of origin, inhalation habits (yes/no), tobacco type (cigarettes, cigars/pipe/cheroots, mixed), and years as smokers (continuous).</div><div class=\"graphic_reference\">Data from: Godtfredsen N, Prescott E, Osler M. Effect of smoking reduction on lung cancer risk. JAMA 2005; 294:1505.</div><div id=\"graphicVersion\">Graphic 50077 Version 4.0</div></div></div>"},"50078":{"type":"graphic_diagnosticimage","displayName":"Cystic hygroma CT I","title":"Patient with a known cystic hygroma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patient with a known cystic hygroma</div><div class=\"cntnt\"><img style=\"width:396px; height:241px;\" src=\"images/PULM/50078_Cystic_hygroma_CT_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An ectatic superior vena cava is seen on a contrast-enhanced CT scan.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 50078 Version 3.0</div></div></div>"},"50080":{"type":"graphic_table","displayName":"Dx liver disease pregnancy","title":"Evaluation of liver disease in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of liver disease in pregnancy</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   History and review of systems\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   History of pruritus during previous pregnancies or while using oral contraceptives, abdominal pain, nausea or vomiting, polyuria and polydipsia, drugs, travel, exposure to viral hepatitis, history of gallstones. Note trimester of pregnancy.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   Physical examination\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Temperature, blood pressure, proteinuria, liver examination (difficult during late pregnancy)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   Blood tests\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Complete blood count including platelets\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Routine liver function tests including prothrombin time (see table on liver function tests in normal pregnancy)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Serum creatinine, electrolytes, glucose and uric acid levels\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Serology for viral hepatitis (A, B, C) and cytomegalovirus\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Test for hepatitis E if suspected (especially in endemic countries less commonly in non-endemic countries)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Measure serum total bile acids if cholestasis is suspected and not otherwise apparent (not a routine test)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   Urinalysis and culture\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   Ultrasonography of the liver and bile ducts\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   Monitor evolution of symptoms and liver function tests before and after delivery\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 50080 Version 1.0</div></div></div>"},"50081":{"type":"graphic_table","displayName":"Incidence of HCC","title":"Incidence of hepatocellular carcinoma in various countries and ethnic groups (per 100,000 per year)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of hepatocellular carcinoma in various countries and ethnic groups (per 100,000 per year)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Country </td>\n<td class=\"subtitle1\"> Males </td>\n<td class=\"subtitle1\">Females</td>\n</tr>\n<tr>\n<td>Mozambique </td>\n<td>112.9 </td>\n<td>30.8</td>\n</tr>\n<tr>\n<td>Zimbabwe </td>\n<td> 64.6</td>\n<td>25.4</td>\n</tr>\n<tr>\n<td>Gambia </td>\n<td>33.1</td>\n<td>12.6</td>\n</tr>\n<tr>\n<td>Senegal </td>\n<td>25.6</td>\n<td>9.0</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\" colspan=\"3\" rowspan=\"1\">South Africa (Cape)</td>\n\n\n</tr>\n<tr>\n<td class=\"sublist1\"> Black </td>\n<td class=\"sublist_other\">26.3 </td>\n<td class=\"sublist_other\">8.4</td>\n</tr>\n<tr>\n<td class=\"sublist1\"> Colored </td>\n<td class=\"sublist_other\">1.5</td>\n<td class=\"sublist_other\">0.7</td>\n</tr>\n<tr>\n<td class=\"sublist1\"> Caucasian </td>\n<td class=\"sublist_other\">1.2</td>\n<td class=\"sublist_other\">0.6</td>\n</tr>\n<tr>\n<td>Algeria </td>\n<td>1.6</td>\n<td>1.4</td>\n</tr>\n<tr>\n<td>Nigeria </td>\n<td>15.4 </td>\n<td>3.2</td>\n</tr>\n<tr>\n<td>Argentina </td>\n<td>9.9</td>\n<td>5.8</td>\n</tr>\n<tr>\n<td>Brazil </td>\n<td>3.5</td>\n<td>3.7</td>\n</tr>\n<tr>\n<td>Peru </td>\n<td>4.0</td>\n<td>2.9</td>\n</tr>\n<tr>\n<td>Jamaica </td>\n<td>6.1</td>\n<td>2.1</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\" colspan=\"3\" rowspan=\"1\">United States</td>\n\n\n</tr>\n<tr>\n<td class=\"sublist1\"> Chinese </td>\n<td class=\"sublist_other\">19.1 </td>\n<td class=\"sublist_other\">3.6</td>\n</tr>\n<tr>\n<td class=\"sublist1\"> Black </td>\n<td class=\"sublist_other\">3.9</td>\n<td class=\"sublist_other\">1.8</td>\n</tr>\n<tr>\n<td class=\"sublist1\"> Japanese </td>\n<td class=\"sublist_other\">3.0</td>\n<td class=\"sublist_other\">0.4</td>\n</tr>\n<tr>\n<td class=\"sublist1\"> Caucasian </td>\n<td class=\"sublist_other\">2.9</td>\n<td class=\"sublist_other\">1.1</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\" colspan=\"3\" rowspan=\"1\">Canada</td>\n\n\n</tr>\n<tr>\n<td class=\"sublist1\"> Eskimos </td>\n<td class=\"sublist_other\">6.9 </td>\n<td class=\"sublist_other\">3.7</td>\n</tr>\n<tr>\n<td class=\"sublist1\"> Alberta </td>\n<td class=\"sublist_other\">1.3 </td>\n<td class=\"sublist_other\">0.5</td>\n</tr>\n<tr>\n<td>Switzerland </td>\n<td>10.2 </td>\n<td>1.5</td>\n</tr>\n<tr>\n<td>Italy </td>\n<td>8.6</td>\n<td>3.3</td>\n</tr>\n<tr>\n<td>Spain </td>\n<td>7.2</td>\n<td>5.5</td>\n</tr>\n<tr>\n<td>France </td>\n<td>3.7</td>\n<td>1.0</td>\n</tr>\n<tr>\n<td>Germany </td>\n<td>4.5</td>\n<td>1.7</td>\n</tr>\n<tr>\n<td>Denmark </td>\n<td>3.6</td>\n<td>2.3</td>\n</tr>\n<tr>\n<td>Yugoslavia </td>\n<td>2.9</td>\n<td>1.2</td>\n</tr>\n<tr>\n<td>Czechoslovakia </td>\n<td>5.1</td>\n<td>2.8</td>\n</tr>\n<tr>\n<td>United Kingdom </td>\n<td>1.6</td>\n<td>0.8</td>\n</tr>\n<tr>\n<td>Ireland </td>\n<td>0.1</td>\n<td>0.3</td>\n</tr>\n<tr>\n<td>China </td>\n<td>34.4 </td>\n<td>11.6</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\" colspan=\"3\" rowspan=\"1\">Singapore</td>\n\n\n</tr>\n<tr>\n<td class=\"sublist1\"> Chinese </td>\n<td class=\"sublist_other\">31.6 </td>\n<td class=\"sublist_other\">7.2</td>\n</tr>\n<tr>\n<td class=\"sublist1\"> Malay </td>\n<td class=\"sublist_other\">15.6 </td>\n<td class=\"sublist_other\">5.3</td>\n</tr>\n<tr>\n<td class=\"sublist1\"> Indian </td>\n<td class=\"sublist_other\">14.1 </td>\n<td class=\"sublist_other\">2.8</td>\n</tr>\n<tr>\n<td>Korea </td>\n<td>13.8 </td>\n<td>3.2</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\" colspan=\"3\" rowspan=\"1\">Japan</td>\n\n\n</tr>\n<tr>\n<td class=\"sublist1\"> Miyagi </td>\n<td class=\"sublist_other\">11.2 </td>\n<td class=\"sublist_other\">4.0</td>\n</tr>\n<tr>\n<td class=\"sublist1\"> Nagasaki </td>\n<td class=\"sublist_other\">25.8</td>\n<td class=\"sublist_other\">7.9</td>\n</tr>\n<tr>\n<td>India </td>\n<td>4.9</td>\n<td>2.5</td>\n</tr>\n<tr>\n<td>Philippines </td>\n<td>19.9 </td>\n<td>6.2</td>\n</tr>\n<tr>\n<td>Hong Kong </td>\n<td>32.3 </td>\n<td>7.4</td>\n</tr>\n<tr>\n<td>Pakistan </td>\n<td>0.7</td>\n<td>0.8</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\" colspan=\"3\" rowspan=\"1\">New Zealand</td>\n\n\n</tr>\n<tr>\n<td class=\"sublist1\"> Maori </td>\n<td class=\"sublist_other\">11.2 </td>\n<td class=\"sublist_other\">4.2</td>\n</tr>\n<tr>\n<td class=\"sublist1\"> Non-Maori </td>\n<td class=\"sublist_other\">2.4</td>\n<td class=\"sublist_other\">1.1</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\" colspan=\"3\" rowspan=\"1\">Pacific Polynesian</td>\n\n\n</tr>\n<tr>\n<td class=\"sublist1\"> Islands </td>\n<td class=\"sublist_other\">26.6 </td>\n<td class=\"sublist_other\">2.3</td>\n</tr>\n<tr>\n<td>Australia </td>\n<td>2.0</td>\n<td>0.7</td>\n</tr>\n<tr>\n<td>Hawaii </td>\n<td>7.8</td>\n<td>2.4</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">6.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=27726&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Incidence_of_HCC.htm</title></head></div><div class=\"graphic_reference\">Reference: Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.</div><div id=\"graphicVersion\">Graphic 50081 Version 2.0</div></div></div>"},"50083":{"type":"graphic_diagnosticimage","displayName":"Melioidosis acute pneumonia","title":"Chest radiograph of acute pulmonary melioidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of acute pulmonary melioidosis</div><div class=\"cntnt\"><img style=\"width:354px; height:286px;\" src=\"images/ID/50083_Melioidosis_acute_pneumonia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute melioidosis presenting as a left upper lobe infiltrate.</div><div class=\"graphic_reference\">Courtesy of Bart Currie, FRACP.</div><div id=\"graphicVersion\">Graphic 50083 Version 4.0</div></div></div>"},"50085":{"type":"graphic_table","displayName":"Milk allergy presentation","title":"Presentation of cow's milk allergy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Presentation of cow's milk allergy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">IgE mediated</td> <td class=\"subtitle1\">Mixed IgE and non-IgE mediated</td> <td class=\"subtitle1\">Non-IgE mediated</td> </tr> <tr> <td>Anaphylaxis</td> <td>Eosinophilic gastrointestinal disorders</td> <td>Food protein-induced enterocolitis syndrome</td> </tr> <tr> <td>Urticaria and angioedema</td> <td>Atopic dermatitis</td> <td>Food protein-induced proctitis/proctocolitis</td> </tr> <tr> <td>Immediate oropharyngeal and gastrointestinal reactions</td> <td>&nbsp;</td> <td>Food protein-induced enteropathy</td> </tr> <tr> <td>Food-associated, exercise-induced anaphylaxis</td> <td>&nbsp;</td> <td>Gastroesophageal reflux</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Colic</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Constipation</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Heiner syndrome (pulmonary hemosiderosis)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.</div><div id=\"graphicVersion\">Graphic 50085 Version 4.0</div></div></div>"},"50086":{"type":"graphic_waveform","displayName":"Sinoatrial exit block tutorial","title":"Sinoatrial exit block","html":"<div class=\"graphic normal\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Sinoatrial exit block</div><div class=\"cntnt\"><img style=\"width:516px; height:102px;\" src=\"images/CARD/50086_Sinoatrial_exit_block_tutor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Failure of impulse conduction from the sinus node into the atrium results in sinoatrial block. This arrhythmia is characterized by an absent P wave and a prolongation of the RR cycle length (measured as P to P length in this tracing), usually twice the underlying sinus P-P interval. This is a distinguishing feature from sinus pause in which the beat after the pause has a P-P interval less than two times the underlying sinus P-P interval.</div><div id=\"graphicVersion\">Graphic 50086 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"50087":{"type":"graphic_diagnosticimage","displayName":"Tc99m sestamibi rest imaging","title":"Representative short axis (top row) vertical long axis (middle row) and horizontal long axis (bottom row) tomograms from the resting Tc-99m sestamibi scans of two patients referred for assessment of viability in the left anterior descending (LAD) coronary","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Representative short axis (top row) vertical long axis (middle row) and horizontal long axis (bottom row) tomograms from the resting Tc-99m sestamibi scans of two patients referred for assessment of viability in the left anterior descending (LAD) coronary</div><div class=\"cntnt\"><img style=\"width:432px; height:307px;\" src=\"images/CARD/50087_Tc99msestamibirestimagin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both patients had heart failure and extensive regional akinesis in the LAD territory. Patient A has minimal tracer uptake in the septum, apex, and anterior wall (white arrows) indicating predominantly scar tissue. Patient B has significant uptake of tracer in the septum and anterior wall (yellow arrows) indicative of the presence of viable myocardium, and predominantly scar in the apex. The inferior wall that was also dyskinetic shows only modest tracer uptake (extracardiac tracer activity in overlying gut is also seen).</div><div id=\"graphicVersion\">Graphic 50087 Version 3.0</div></div></div>"},"50088":{"type":"graphic_picture","displayName":"BL immunohistochemistry","title":"BL immunohistochemistry","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">BL immunohistochemistry</div><div class=\"cntnt\"><img style=\"width:583px; height:390px;\" src=\"images/HEME/50088_BLimmunohistochemistry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunostains of MIB-1 (A), Bcl-2 (B), CD10 (C), and Bcl-6 (D) in a case of classic Burkitt lymphoma. Note that all cells are proliferating as defined by positive MIB-1 staining, except the phagocytic histiocytes in the section. CD10 is strongly expressed by the malignant cells, and Bcl-2 is negative. Note several small, reactive lymphocytes in the section staining positively for Bcl-2 that serve as an internal control. Bcl-6 staining (D) shows strong nuclear expression.</div><div class=\"graphic_reference\">Reproduced with permission from: Non-Hodgkin Lymphomas, 2nd ed, Armitage JO, Mauch PM, Harris NL, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50088 Version 6.0</div></div></div>"},"50089":{"type":"graphic_diagnosticimage","displayName":"Tubal ring","title":"Tubal pregnancy with tubal ring","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tubal pregnancy with tubal ring</div><div class=\"cntnt\"><img style=\"width:354px; height:253px;\" src=\"images/OBGYN/50089_Tubal_ring.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal image of the adnexa shows a tubal ring (arrows) of an ectopic pregnancy.</div><div class=\"graphic_footnotes\">O: ovary; U: uterus.</div><div class=\"graphic_reference\">Courtesy of Tejas S Mehta, MD, MPH.</div><div id=\"graphicVersion\">Graphic 50089 Version 2.0</div></div></div>"},"50090":{"type":"graphic_table","displayName":"Effective dose estimates for imaging tests","title":"Representative values and ranges of effective dose estimates reported in the literature for selected radiological studies<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Representative values and ranges of effective dose estimates reported in the literature for selected radiological studies<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Exam</td> <td class=\"subtitle1\">Representative effective dose value (mSv)</td> <td class=\"subtitle1\">Range of reported effective dose values (mSv)</td> </tr> <tr> <td>Chest x-ray PA and lateral</td> <td>0.1</td> <td>0.05 to 0.24</td> </tr> <tr> <td>CT chest</td> <td>7</td> <td>4 to 18</td> </tr> <tr> <td>CT abdominal</td> <td>8</td> <td>4 to 25</td> </tr> <tr> <td>CT pelvis</td> <td>6</td> <td>3 to 10</td> </tr> <tr> <td>Coronary calcium CT*</td> <td>3</td> <td>1 to 12</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">64-slice coronary CTA<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist1\">Without tube current modulation</td> <td class=\"sublist_other\">15</td> <td class=\"sublist_other\">12 to 18</td> </tr> <tr> <td class=\"sublist1\">With tube current modulation<sup>[2]</sup></td> <td class=\"sublist_other\">9</td> <td class=\"sublist_other\">8 to 18</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Dual source coronary CTA<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist1\">With tube current modulation</td> <td class=\"sublist_other\">13</td> <td class=\"sublist_other\">6 to 17</td> </tr> <tr> <td>Prospectively triggered coronary CTA<sup>&#182;</sup><sup>[3]</sup></td> <td>3</td> <td>2 to 4</td> </tr> <tr> <td>Diagnostic invasive coronary angiogram</td> <td>7</td> <td>2 to 16</td> </tr> <tr> <td>Percutaneous coronary intervention or radiofrequency ablation</td> <td>15</td> <td>7 to 57</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; CTA: computed tomographic angiography; FDG: fluoro-deoxy glucose; PA: postero-anterior.<br />* Data combine prospectively triggered and retrospectively gated protocols. The Writing Group estimates the representative effective dose estimate for prospectively triggered coronary calcium CT scans to be approximately 1 mSv, and for retrospectively gated scans, 3 mSv.<br />¶ 64-slice MDCT and dual source CT studies published since 2005 only, data include a survey of the literature by the Writing Group.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Mettler FA Jr, Huda W, Yoshizumi TT, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008; 248:254. </li>&#xD;&#xA;    <li>Jakobs TF, Becker CR, Ohnesorge B, et al. Multislice helical CT of the heart with retrospective ECG gating: reduction of radiation exposure by ECG-controlled tube current modulation. Eur Radiol 2002; 12:1081. </li>&#xD;&#xA;    <li>Earls JP, Berman EL, Urban BA, et al. Prospectively gated transverse coronary CT angiography versus retrospectively gated helical technique: improved image quality and reduced radiation dose. Radiology 2008; 246:742. </li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Gerber TC, Carr JJ, Arai AE, et al. Ionizing Radiation in Cardiac Imaging: A Science Advisory From the American Heart Association Committee on Cardiac Imaging of the Council on Clinical Cardiology and Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention. Circulation 2009; 119:1056-1065. Copyright &copy; 2009 American Heart Association, Inc.</div><div id=\"graphicVersion\">Graphic 50090 Version 10.0</div></div></div>"},"50092":{"type":"graphic_picture","displayName":"Middle ear cholesteatoma","title":"Large middle ear cholesteatoma displacing the malleus posteriorly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large middle ear cholesteatoma displacing the malleus posteriorly</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PEDS/50092_Middle_ear_cholesteatoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large middle ear congenital cholesteatoma is visible displacing the malleus posteriorly. The eardrum has been reflected inferiorly.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 50092 Version 1.0</div></div></div>"},"50093":{"type":"graphic_picture","displayName":"Apley scratch sign","title":"Apley scratch sign","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apley scratch sign</div><div class=\"cntnt\"><img style=\"width:385px; height:425px;\" src=\"images/RHEUM/50093_Apley_scratch_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This maneuver screens the overall rotation function of the shoulder. The patient is asked to scratch the lower back and place the thumb as high up on the back in the midline as is comfortable. One side can be compared with the other side.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 50093 Version 7.0</div></div></div>"},"50095":{"type":"graphic_table","displayName":"Endotoxemia and outcomes","title":"Plasma levels of endotoxins and outcomes in patients with sepsis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Plasma levels of endotoxins and outcomes in patients with sepsis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">EA level<br /> (EA units)</td> <td class=\"subtitle1\">SOFA score on admission<br /> (mean &#177; SD)</td> <td class=\"subtitle1\">Shock<br /> (percent)</td> <td class=\"subtitle1\">PaO<sub>2</sub>:FiO<sub>2</sub> ratio<br /> (mmHg; mean &#177; SD)</td> <td class=\"subtitle1\">Hospital mortality<br /> (percent)</td> </tr> <tr> <td>Low (&#60;0.4)</td> <td class=\"centered\">4.3 &#177; 3.6</td> <td class=\"centered\">11.6</td> <td class=\"centered\">253 &#177; 111</td> <td class=\"centered\">16</td> </tr> <tr> <td>Intermediate (0.4 to 0.59)</td> <td class=\"centered\">4.9 &#177; 3.9</td> <td class=\"centered\">20.5</td> <td class=\"centered\">215 &#177; 98</td> <td class=\"centered\">23</td> </tr> <tr> <td>High (&#8805;0.6)</td> <td class=\"centered\">5.7 &#177; 4.1</td> <td class=\"centered\">22.7</td> <td class=\"centered\">205 &#177; 102</td> <td class=\"centered\">23</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EA: endotoxin activity; SOFA: sequential (or sepsis-related) organ dysfunction score; SD: standard deviation; PaO<sub>2</sub>: arterial pressure of oxygen; FiO<sub>2</sub>: fraction of inspired oxygen.</div><div class=\"graphic_reference\">Adapted from: Marshall JC, Foster D, Vincent JL, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 2004; 190:527.</div><div id=\"graphicVersion\">Graphic 50095 Version 4.0</div></div></div>"},"50096":{"type":"graphic_picture","displayName":"Iron overload liver Perls","title":"Liver biopsy in hereditary hemochromatosis (iron stain)","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Liver biopsy in hereditary hemochromatosis (iron stain)</div><div class=\"cntnt\"><img style=\"width:544px; height:237px;\" src=\"images/GAST/50096_Iron_overload_liver_Perls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perls' Prussian blue stain of a liver biopsy from a patient with hereditary hemochromatosis. Left panel: Low power view shows intense iron staining of hepatocytes. The blue-stained iron deposits typically start at the periphery of the liver lobule and extend centrally. Right panel: High power view shows intense iron staining (in blue) of hepatocytes.</div><div class=\"graphic_reference\">Courtesy of Stanley L Schrier, MD.</div><div id=\"graphicVersion\">Graphic 50096 Version 3.0</div></div></div>"},"50098":{"type":"graphic_table","displayName":"Management brain abscess","title":"Rapid empiric management of bacterial brain abscess in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid empiric management of bacterial brain abscess in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Empiric antibiotics</td> </tr> <tr> <td colspan=\"2\">Immediately begin empiric antibiotics following stereotactic or open biopsy/aspiration to obtain a specimen for Gram stain, culture, and pathology.</td> </tr> <tr> <td class=\"divider_bottom\" colspan=\"2\"><strong>The antibiotic regimen is dependent on Gram stain results, if available, and the likely source of abscess.</strong></td> </tr> <tr> <td class=\"subtitle2\">Origin of abscess and likely causative organisms</td> <td class=\"subtitle2\">Treatment regimen*</td> </tr> <tr> <td> <p>Oral, otogenic, or sinus source (aerobic and anaerobic streptococci, <em>Bacteroides </em>spp, <em>Haemophilus</em> spp, <em>Fusobacterium </em>spp; less commonly, <em>Pseudomonas aeruginosa</em> and Enterobacteriaceae)</p> </td> <td> <p>Metronidazole (15 mg/kg [usually 1 g] IV as a loading dose, followed by 7.5 mg/kg [usually 500 mg] IV every eight hours) <strong>PLUS</strong></p> <p><strong>Either</strong> penicillin G (20 to 24 million units per day IV in six equally divided doses) for a suspected oral focus <strong>OR</strong></p> Ceftriaxone (2 g IV every 12 hours) <strong>or</strong> cefotaxime (2 g IV every four to six hours) for a suspected sinus or otogenic source.</td> </tr> <tr> <td>Hematogenous spread (<em>Staphylococcus aureus</em>, <em>Streptococcus viridans</em>, other&nbsp; streptococci)</td> <td> <p>Vancomycin<sup>&#182;</sup> (15 to 20 mg/kg per dose every 8 to 12 hours, not to exceed 2 g per dose) for empiric coverage of methicillin-resistant <em>Staphylococcus aureus.</em></p> Metronidazole may be added for anaerobic coverage.</td> </tr> <tr> <td>Postoperative neurosurgical patients (<em>S. aureus</em>, streptococci, enterococci, <em>P. aeruginosa</em>)</td> <td> <p>Vancomycin<sup>&#182;</sup> (15 to 20 mg/kg per dose every 8 to 12 hours, not to exceed 2 g per dose) <strong>PLUS</strong></p> <strong>Either</strong> ceftazidime (2 g IV every eight hours) <strong>or</strong> cefepime (2 g IV every eight hours) <strong>or</strong> meropenem<sup>&#916;</sup> (2 g IV every eight hours). </td> </tr> <tr> <td>Penetrating head trauma (<em>S. aureus</em>, <em>Enterobacter</em> spp)</td> <td> <p>Vancomycin<sup>&#182;</sup> (15 to 20 mg/kg per dose every 8 to 12 hours, not to exceed 2 g per dose) <strong>PLUS<br /> Either</strong> ceftriaxone (2 g IV every 12 hours) <strong>or</strong> cefotaxime (2 g IV every four to six hours)</p> If the paranasal sinuses are involved, add metronidazole (15 mg/kg [usually 1 g] IV as a loading dose, followed by 7.5 mg/kg [usually 500 mg] IV every eight hours). </td> </tr> <tr> <td>Unknown source</td> <td>Vancomycin<sup>&#182;</sup> (15 to 20 mg/kg per dose every 8 to 12 hours, not to exceed 2 g per dose) <strong>PLUS</strong> <br /> <strong>Either</strong> ceftriaxone (2 g IV every 12 hours) <strong>or</strong> cefotaxime (2 g IV every four to six hours) <strong>PLUS<br /> </strong>Metronidazole (15 mg/kg [usually 1 g] IV as a loading dose, followed by 7.5 mg/kg [usually 500 mg] IV every eight hours).</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Glucocorticoids</td> </tr> <tr> <td colspan=\"2\">Glucocorticoids should be used when substantial mass effect can be demonstrated on imaging and the mental status is significantly depressed.</td> </tr> <tr> <td colspan=\"2\">Dexamethasone is administered at a loading dose of 10 mg IV, followed by 4 mg every six hours.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The antibiotic doses recommended above are intended for patients with normal renal function; dosing of many of these agents must be reduced in patients with renal dysfunction.<br />¶ If susceptibility testing reveals methicillin-sensitive <EM>S. aureus</EM>, vancomycin should be replaced with nafcillin (2 g IV every four hours) <STRONG>or</STRONG> oxacillin (2 g IV every four hours).<br />Δ If meropenem is not available, imipenem (500 mg or 1 g IV every six hours) can be used as an alternative agent. If both agents are available, we prefer meropenem since imipenem may increase the risk of seizures. The maximum daily dose of imipenem should not exceed 50 mg/kg per day or 4 g/day (whichever is lower).</div><div id=\"graphicVersion\">Graphic 50098 Version 11.0</div></div></div>"},"50099":{"type":"graphic_movie","displayName":"TEE IAS aneurysm","title":"Transesophageal echocardiogram showing an interatrial septal aneurysm","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiogram showing an interatrial septal aneurysm</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/50099_intsepanconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:237px; height:189px;\" src=\"images/CARD/50099_intsepan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram shows a large aneurysm of the interatrial septum.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 50099 Version 3.0</div></div></div>"},"50100":{"type":"graphic_diagnosticimage","displayName":"Calcifications in sponge kidney","title":"Calcifications in medullary sponge kidney","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcifications in medullary sponge kidney</div><div class=\"cntnt\"><img style=\"width:228px; height:274px;\" src=\"images/NEPH/50100_Calcifications_in_sponge_ki.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain film of the abdomen with tomography in a patient with medullary sponge kidney. There are clusters of calcium stones limited to the upper (not well seen) and lower calyces (arrows) which are the only involved pyramids.</div><div class=\"graphic_reference\">From Rose, BD, Pathophysiology of Renal Disease, 2d ed, McGraw-Hill, New York, 1987.</div><div id=\"graphicVersion\">Graphic 50100 Version 2.0</div></div></div>"},"50102":{"type":"graphic_table","displayName":"Regimens for drug-susceptible tuberculosis","title":"Regimens for treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Regimens for treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\"><span style=\"color: #000000;\">Intensive phase </span></td> <td class=\"subtitle1\" colspan=\"2\">Continuation phase </td> <td class=\"subtitle1\" rowspan=\"2\"> <p>Range of total doses </p> <p>(minimal duration)</p> </td> <td class=\"subtitle1\" rowspan=\"2\"> <p>Comments<sup>&#182;&#916;</sup></p> </td> </tr> <tr> <td class=\"subtitle2\">Drugs </td> <td class=\"subtitle2\">Interval and doses* (minimal duration) </td> <td class=\"subtitle2\">Drugs </td> <td class=\"subtitle2\">Interval and doses* (minimal duration) </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Regimen 1 </td> </tr> <tr> <td class=\"indent1\"> <p>INH</p> <p>RIF</p> <p>PZA</p> <p>EMB</p> </td> <td> <p><strong>Daily for 8 weeks</strong>&nbsp;</p> <p>7&nbsp;days per week for 56 doses (8 weeks), or </p> <p>5 days per week for 40 doses (8 weeks)<sup>&#9674;</sup></p> </td> <td> <p>INH</p> <p>RIF</p> </td> <td> <p>7 days per week for 126 doses (18 weeks), or&nbsp;</p> <p>5&nbsp;days per week for 90 doses (18 weeks)</p> </td> <td>182 to 130 (26 weeks)</td> <td>This is the preferred regimen for patients with newly diagnosed pulmonary tuberculosis.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Regimen 2 </td> </tr> <tr> <td class=\"indent1\"> <p>INH</p> <p>RIF</p> <p>PZA</p> <p>EMB</p> </td> <td> <p><strong>Daily for 8 weeks</strong></p> <p>7 days per week for 56 doses (8 weeks), or </p> <p>5 days per week for 40 doses (8 weeks)<sup>&#9674;</sup></p> </td> <td> <p>INH</p> <p>RIF</p> </td> <td>Three times weekly for 54 doses (18 weeks)</td> <td>110&nbsp;to&nbsp;94 (26 weeks)</td> <td>Preferred alternative regimen in situations in which more frequent DOT during continuation phase is difficult to achieve.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Regimen 3 </td> </tr> <tr> <td class=\"indent1\"> <p>INH</p> <p>RIF</p> <p>PZA</p> <p>EMB</p> </td> <td> <p><strong>Three times weekly for&nbsp;8 weeks</strong>&nbsp;</p> <p>Three times weekly for 24 doses (8 weeks)</p> </td> <td> <p>INH</p> <p>RIF</p> </td> <td>Three times weekly for 54 doses (18 weeks)</td> <td>78 (26 weeks)</td> <td>Use regimen with caution in patients with HIV and/or cavitary disease. Missed doses can lead to treatment failure, relapse, and acquired drug resistance. </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Regimen 4</td> </tr> <tr> <td class=\"indent1\"> <p>INH</p> <p>RIF</p> <p>PZA</p> <p>EMB</p> </td> <td> <p><strong>Daily for&nbsp;2 weeks,&nbsp;then twice weekly for 6 weeks</strong></p> <p>7&nbsp;days per week for&nbsp;14 doses (2 weeks), then twice weekly for 12 doses<sup>&#167;</sup></p> </td> <td> <p>INH</p> <p>RIF</p> </td> <td> <p>Twice weekly for 36 doses (18 weeks)</p> </td> <td>62 (26 weeks)</td> <td>Do not use twice-weekly regimens in HIV-infected patients or patients with smear-positive and/or cavitary disease. If doses are missed, then therapy is equivalent to once weekly, which is inferior.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><FONT color=black>INH: isoniazid; RIF: rifampin; RPT: rifapentine; PZA: pyrazinamide; EMB: ethambutol; DOT: directly observed therapy; HIV: human immunodeficiency virus.<br />* When DOT is used, drugs may be given&nbsp;five days per week and the necessary number of doses adjusted accordingly. Although there are no studies that compare five with seven daily doses, extensive experience indicates that this is an effective practice. DOT should be used when drugs are administered &lt;7 days per week.<br />¶&nbsp;Based on expert opinion, patients with cavitation on initial chest radiograph and positive cultures at completion of&nbsp;two months of therapy should receive a seven-month (31-week) continuation phase.<br />Δ Pyridoxine (vitamin B6; 25 to 50 mg/day) is given with isoniazid to individuals at risk for neuropathy (eg, pregnant women, breastfeeding infants, and individuals with HIV infection, diabetes, alcoholism, malnutrition, chronic renal failure, or advanced age). For patients with peripheral neuropathy, experts recommend increasing pyridoxine dose to 100 mg/day.<br />◊ Five-day-a-week administration is always given by DOT.<br />§ Alternatively, some United States tuberculosis control programs have administered intensive-phase regimens 5 days per week for 15 doses (3 weeks), then twice weekly for 12 doses.</FONT></div><div class=\"graphic_reference\">Reproduced from: Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63(7):e147-e195, by permission of Oxford University Press on behalf of the Infectious Diseases Society of America. Copyright © 2016 Oxford University Press. Available at: <A spellcheck=true href=\"http://www.idsociety.org/\" target=_blank>www.idsociety.org</A>.</div><div id=\"graphicVersion\">Graphic 50102 Version 14.0</div></div></div>"},"50104":{"type":"graphic_picture","displayName":"Mouth cancer PI","title":"Mouth cancer","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Mouth cancer</div><div class=\"cntnt\"><img style=\"width:584px; height:224px;\" src=\"images/PI/50104_Mouth_cancer_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These are 2 examples of mouth cancer. Photo A shows a white growth on the tongue, and photo B shows a red growth on the lip.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50104 Version 4.0</div></div></div>"},"50105":{"type":"graphic_picture","displayName":"Nasal polyps in nostril","title":"Nasal polyps in nostril","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nasal polyps in nostril</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/ALLRG/50105_Nasal_polyps_in_nostril.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nasal polyps appear as fixed, glistening, gray or white, mucoid masses in the nasal cavities.</div><div class=\"graphic_reference\">Courtesy of Glenis Scadding, MD and Peter Andrews, BSc, FRCS.</div><div id=\"graphicVersion\">Graphic 50105 Version 3.0</div></div></div>"},"50106":{"type":"graphic_figure","displayName":"Culprit lesion after CABG","title":"Graft versus native vessel disease as cause of unstable angina after CABG","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Graft versus native vessel disease as cause of unstable angina after CABG</div><div class=\"cntnt\"><img style=\"width:543px; height:295px;\" src=\"images/CARD/50106_Culprit_lesion_after_CABG.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among patients with unstable angina who have had previous coronary artery bypass surgery (CABG), the older the saphenous vein graft, the greater the likelihood that the symptoms result from a culprit lesion within the graft (solid blue columns) rather than from a lesion in a native coronary artery (red columns).</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Data from Chen L, Theroux P, Lesperance J, et al. J Am Coll Cardiol 1996; 28:1493.</div><div id=\"graphicVersion\">Graphic 50106 Version 2.0</div></div></div>"},"50107":{"type":"graphic_figure","displayName":"Critical pathways in controlling mycobacterial infection","title":"Critical pathways in controlling mycobacterial infection","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Critical pathways in controlling mycobacterial infection</div><div class=\"cntnt\"><img style=\"width:503px; height:618px;\" src=\"images/ALLRG/50107_Criticalpathwaynew.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mycobacterial infection induces IL-12 production by monocytes, which stimulates T-cells and NK cells to produce IFN-γ. After binding to its cognate receptor, IFN-γ activates macrophages to produce TNF-α and to kill mycobacteria intracellularly by mechanisms not yet defined. IFN-γ also drives IL-12 production forward.</div><div class=\"graphic_footnotes\">AFB: acid-fast bacilli; NO: nitric oxide; IFN-γR1: interferon-gamma receptor 2; IL-12Rβ1 and IL-12Rβ2: interleukin 12 receptor chains; TNF-α: tumor necrosis factor-alpha; TNF-αR: tumor necrosis factor-alpha receptors.</div><div class=\"graphic_reference\">Courtesy of Gulbu Uzel, MD.</div><div id=\"graphicVersion\">Graphic 50107 Version 7.0</div></div></div>"},"50109":{"type":"graphic_picture","displayName":"Achilles tendon xanthoma","title":"Achilles tendon xanthoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Achilles tendon xanthoma</div><div class=\"cntnt\"><img style=\"width:410px; height:249px;\" src=\"images/PC/50109_Achilles_tendon_xanthoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A xanthoma of the Achilles tendon in a patient with heterozygous familial hypercholesterolemia.</div><div class=\"graphic_reference\">Reproduced with permission from: Durrington P. Dyslipidaemia. Lancet 2003; 362:717. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 50109 Version 2.0</div></div></div>"},"50111":{"type":"graphic_picture","displayName":"Scabies wrists","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:396px; height:264px;\" src=\"images/PC/50111_Scabies_wrists.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scabies. Lesions are present on the flexor wrists.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright ©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50111 Version 3.0</div></div></div>"},"50112":{"type":"graphic_picture","displayName":"Squamous cell carcinoma skin","title":"Squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:393px; height:260px;\" src=\"images/GAST/50112_Squamouscellcarcinomaski.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Squamous cell carcinoma of the dorsum of the hand appearing as a firm, keratotic nodule in a patient who has undergone liver transplantation.</div><div class=\"graphic_reference\">Courtesy of Jean-François Dufour, MD.</div><div id=\"graphicVersion\">Graphic 50112 Version 2.0</div></div></div>"},"50113":{"type":"graphic_picture","displayName":"HGE in neutrophil EM","title":"Human granulocytic ehrlichiosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Human granulocytic ehrlichiosis</div><div class=\"cntnt\"><img style=\"width:288px; height:304px;\" src=\"images/ID/50113_HGE_in_neutrophil_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph showing the human granulocytic ehrlichiosis agent in intracytoplasmic vacuoles (morulae) in a neutrophil.</div><div class=\"graphic_reference\">Courtesy of Vsevolod Popov, PhD and Stephen Dumler, MD.</div><div id=\"graphicVersion\">Graphic 50113 Version 1.0</div></div></div>"},"50114":{"type":"graphic_algorithm","displayName":"Management algorithm bacterial meningitis","title":"Management algorithm for adults with suspected bacterial meningitis","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">Management algorithm for adults with suspected bacterial meningitis</div><div class=\"cntnt\"><img style=\"width:605px; height:462px;\" src=\"images/ID/50114_Initial_mgmt_bact_mening.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">\"STAT\" indicates that the intervention should be done emergently.</div><div class=\"graphic_footnotes\">CNS: central nervous system; CSF: cerebrospinal fluid; CT: computed tomography.<br />* Refer to UpToDate topic review on dexamethasone to prevent neurologic complications of bacterial meningitis in adults for specific recommendations.<br />¶ Refer to UpToDate table on recommendations for empiric antimicrobial therapy for purulent meningitis based on patient age and specific predisposing condition.<br />Δ Administer dexamethasone and antibiotic therapy immediately after CSF is obtained.<br /><FONT class=lozenge>◊</FONT> Refer to UpToDate table on recommendations for antimicrobial therapy in adults with presumptive pathogen identification by positive Gram stain.<br />§ If the diagnosis of bacterial meningitis is likely.</div><div class=\"graphic_reference\">Modified with permission from: Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267. Copyright &copy; 2004 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 50114 Version 5.0</div></div></div>"},"50115":{"type":"graphic_picture","displayName":"Lymphocutaneous sporotrichosis arm","title":"Lymphocutaneous sporotrichosis on upper limb with ulcerative fungating lesions typically spreading upward","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lymphocutaneous sporotrichosis on upper limb with ulcerative fungating lesions typically spreading upward</div><div class=\"cntnt\"><img style=\"width:504px; height:334px;\" src=\"images/ID/50115_Lymphocutaneoussporotrich.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: da Rosa AC, Scroferneker ML, Vettorato R, et al. Epidemiology of sporotrichosis:&nbsp;A study of 304 cases in Brazil. J Am Acad Dermatol 2005; 52:451. Copyright © 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 50115 Version 4.0</div></div></div>"},"50116":{"type":"graphic_movie","displayName":"Bleeding duodenal ulcer","title":"Bleeding duodenal ulcer","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bleeding duodenal ulcer</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/50116_bleedingduconv.mp4\" style=\"width:191px;height:180px\"></div><img style=\"width:290px; height:237px;\" src=\"images/CARD/50116_bleedingdu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An actively spurting artery can be seen in the base of this ulcer crater in the duodenal bulb.</div><div class=\"graphic_reference\">Courtesy of Rome Jutabha, MD and Dennis M Jensen, MD.</div><div id=\"graphicVersion\">Graphic 50116 Version 2.0</div></div></div>"},"50117":{"type":"graphic_movie","displayName":"Color flow doppler of aortic dissection","title":"Color flow doppler of aortic dissection","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Color flow doppler of aortic dissection</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/50117_teecdoadconv.mp4\" style=\"width:431px;height:322px\"></div><img style=\"width:251px; height:280px;\" src=\"images/CARD/50117_teecdoad.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram with color flow Doppler shows the intimal flap separating the true and false lumens. A jet of blood can be seen going from the true to the false lumen and spontaneous echo contrast in the false lumen is appreciated, suggesting turbulent blood flow.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 50117 Version 3.0</div></div></div>"},"50118":{"type":"graphic_table","displayName":"EGPA (Churg-Strauss) five-factor score","title":"Five-factor score in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Five-factor score in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">1996 five-factor score<sup>[1]</sup></td> <td class=\"subtitle1\">Revised 2011 five-factor score<sup>[2]</sup></td> </tr> <tr> <td>Cardiac involvement</td> <td>Age &#62;65 years</td> </tr> <tr> <td>Gastrointestinal disease (bleeding, perforation, infarction, or pancreatitis)</td> <td>Cardiac insufficiency</td> </tr> <tr> <td>Renal insufficiency (plasma creatinine concentration &#62;1.6 mg/dL [141 mmol/L])</td> <td>Renal insufficiency (stabilized peak creatinine 1.7 mg/dL [150 micromol/L])</td> </tr> <tr> <td>Proteinuria (&#62;1 g/day)</td> <td>Gastrointestinal involvement</td> </tr> <tr> <td>Central nervous system involvement</td> <td>Absence of ENT manifestations (presence is associated with a better prognosis)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The presence of each factor is given one point. The FFS score ranges from 0 to 2: a score of 0 is given when none of the factors is present, a score of 1 for one factor, and a score of 2 for two or more factors.</div><div class=\"graphic_footnotes\">FFS: five-factor score; ENT: ear, nose, and throat.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine 1996; 75:17.</li>&#xD;&#xA;    <li>Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011; 90:19.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 50118 Version 5.0</div></div></div>"},"50119":{"type":"graphic_table","displayName":"Histopathologic findings in atrophic rhinosinusitis","title":"Histopathologic findings in atrophic rhinosinusitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histopathologic findings in atrophic rhinosinusitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Epithelium</td> </tr> <tr> <td>Atrophy of serous and mucinous glands</td> </tr> <tr> <td>Loss of cilia and goblet cells</td> </tr> <tr> <td>Metaplasia of pseudostratified columnar to islands of squamous</td> </tr> <tr> <td>Lymphoplasmacytic inflammatory cell infiltrate</td> </tr> <tr> <td class=\"subtitle1_single\">Submucosa</td> </tr> <tr> <td>Inflammatory cell infiltrate</td> </tr> <tr> <td>Endarteritis obliterans</td> </tr> <tr> <td>Dilation of capillaries</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50119 Version 4.0</div></div></div>"},"50120":{"type":"graphic_figure","displayName":"Paranasal sinuses: Anatomy of the ostiomeatal complex","title":"Paranasal sinuses: Anatomy of the ostiomeatal complex","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Paranasal sinuses: Anatomy of the ostiomeatal complex</div><div class=\"cntnt\"><img style=\"width:541px; height:240px;\" src=\"images/ALLRG/50120_Ostio-meataL_complex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;figure on the left shows a coronal view of the ostiomeatal complex (OMC). Gray arrows indicate the direction of mucociliary flow, and blue circles mark areas that can become obstructed. The figure on the right, in which the middle turbinate has been removed, shows the remaining structures that comprise the OMC: the uncinate process, hiatus semilunaris, ethmoid bulla, and ostium of the maxillary sinus.</div><div id=\"graphicVersion\">Graphic 50120 Version 7.0</div></div></div>"},"50121":{"type":"graphic_figure","displayName":"Definitions of test accuracy","title":"Definition of sensitivity, specificity, and predictive values","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Definition of sensitivity, specificity, and predictive values</div><div class=\"cntnt\"><img style=\"width:303px; height:188px;\" src=\"images/CARD/50121_Definitions_of_test_accurac.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TN (true negative): negative exercise ECG and negative angiogram; TP (true positive): positive exercise ECG and positive angiogram; FM (false negative): negative exercise ECG and positive angiogram; FP (false positive): positive exercise ECG and negative angiogram.</div><div id=\"graphicVersion\">Graphic 50121 Version 2.0</div></div></div>"},"50122":{"type":"graphic_figure","displayName":"ECG generation in common AVNRT","title":"Generation of ECG in common form of atrioventricular nodal reentrant tachycardia (AVNRT)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Generation of ECG in common form of atrioventricular nodal reentrant tachycardia (AVNRT)</div><div class=\"cntnt\"><img style=\"width:431px; height:212px;\" src=\"images/CARD/50122_ECGgenerationincommonAV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ladder diagram of the common (slow-fast) form of AVNRT showing transmission of the impulse in atrial, atrioventricular (AV) nodal, and ventricular tissue and the resultant ECG. The first two cycles show the normal sinus beat (A<SUB>1</SUB>) conducting through the fast pathway (F) to the ventricle (V<SUB>1</SUB>) with the impulse blocked in the slow pathway. The premature atrial beat (A<SUB innerHtml>2</SUB> on ladder diagram, P on ECG) is timed critically; it finds the fast pathway refractory but is able to conduct through slow pathway, resulting in a long PR interval, and a ventricular depolarization (V<SUB innerHtml>2</SUB>). It is also able to reenter and conduct retrogradely up the now recovered fast pathway, resulting in an inverted P wave (A*) that is buried in the QRS complex.&nbsp; This atrial echo beat (A*) then reenters the now recovered slow pathway, which conducts anterogradely and results in ventricular depolarization (V*). The cycle repeats and AV nodal reentry is established.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 50122 Version 5.0</div></div></div>"},"50123":{"type":"graphic_table","displayName":"Solutions for standardized desensitization protocol","title":"Solutions for standardized desensitization protocol (using an example of a target drug dose of 1000 mg)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Solutions for standardized desensitization protocol (using an example of a target drug dose of 1000 mg)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Solution</td> <td class=\"subtitle1\">Volume in mL</td> <td class=\"subtitle1\">Concentration</td> <td class=\"subtitle1\">Dose (mg) in solution</td> </tr> <tr> <td>1</td> <td>250 mL</td> <td>0.04 mg/mL</td> <td>10 mg</td> </tr> <tr> <td>2</td> <td>250 mL</td> <td>0.4 mg/mL</td> <td>100 mg</td> </tr> <tr> <td>3</td> <td>250 mL</td> <td>4 mg/mL</td> <td>1000 mg</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The above three solutions are required for the standardized protocol for drug desensitizations for immediate hypersensitivity reactions. Solution 3 is the normal intravenous preparation of the drug as it is usually administered (ie, 1000 mg in 250 mL). Solution 2 is a 10-fold dilution of solution 3, and solution 1 is a 10-fold dilution of solution 2. Note that if the full amount of all three solutions were administered, a total of 1110 mg would be given. To avoid this, only part of solution 3 is infused.</div><div class=\"graphic_reference\">Courtesy of Mariana Castells, MD, PhD.</div><div id=\"graphicVersion\">Graphic 50123 Version 4.0</div></div></div>"},"50124":{"type":"graphic_figure","displayName":"Autosomal recessive pedigree","title":"Example of an autosomal recessive pedigree","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Example of an autosomal recessive pedigree</div><div class=\"cntnt\"><img style=\"width:254px; height:337px;\" src=\"images/PC/50124_Autosomal_recessive.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Autosomal recessive trait. Double line denotes consanguineous mating of first cousins. Features of autosomal recessive inheritance seen here include: absence of family history of disease in prior generations; 25% affected status rate among siblings of affected subject; history of consanguinity.</div><div id=\"graphicVersion\">Graphic 50124 Version 6.0</div></div></div>"},"50125":{"type":"graphic_figure","displayName":"Characteristics of pressure-induced injury by stage","title":"Characteristics of pressure-induced injury by stage","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Characteristics of pressure-induced injury by stage</div><div class=\"cntnt\"><img style=\"width:538px; height:690px;\" src=\"images/SURG/50125_Pressureulcerdrawing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These illustrations highlight the characteristics of the stages of pressure-induced injuries as defined by the National Pressure Ulcer Advisory Panel. Each panel demonstrates the clinical appearance of the involved skin as well as the cross section of the depth of injury. Most pressure-induced injuries are associated with an underlying bony prominence. There is always the potential for deeper tissue damage than appreciated on clinical examination, as illustrated by the panel&nbsp;\"Deep tissue pressure&nbsp;injury.\" </div><div class=\"graphic_reference\">Based on definitions from National Pressure Ulcer Advisory Panel. www.npuap.org (Accessed on January 11, 2018)</div><div id=\"graphicVersion\">Graphic 50125 Version 6.0</div></div></div>"},"50126":{"type":"graphic_algorithm","displayName":"Treatment of chronic venous insufficiency","title":"Treatment of chronic venous insufficiency","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Treatment of chronic venous insufficiency</div><div class=\"cntnt\"><img style=\"width:494px; height:425px;\" src=\"images/PC/50126_Rx_chronic_venous_insuff.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 50126 Version 2.0</div></div></div>"},"50127":{"type":"graphic_table","displayName":"Acute bleeding EVL vs ES","title":"Control of acute variceal bleeding - endoscopic variceal ligation versus endoscopic sclerotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Control of acute variceal bleeding - endoscopic variceal ligation versus endoscopic sclerotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Study</td>\n\n      <td class=\"subtitle1\">EVL, percent</td>\n\n      <td class=\"subtitle1\">ES, percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Jensen 1993</td>\n\n      <td>10/14 (71)</td>\n\n      <td>10/11 (91)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Laine 1993</td>\n\n      <td>8/9 (89)</td>\n\n      <td>8/9 (89)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lo 1995</td>\n\n      <td>17/18 (94)</td>\n\n      <td>12/15 (80)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Stiegman 1992</td>\n\n      <td>12/14 (86)</td>\n\n      <td>10/13 (77)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sarin 1997</td>\n\n      <td>47/59 (80) </td>\n\n      <td>48/56 (86)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hou 1995</td>\n\n      <td>20/20 (100)</td>\n\n      <td>14/16 (88)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Gimson 1993</td>\n\n      <td>54/59 (91)</td>\n\n      <td>49/53 (92)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chen 1995</td>\n\n      <td>11/12 (91)</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lo 1997</td>\n\n      <td>37/37 (100)</td>\n\n      <td>34/38 (89)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\">Total</td>\n\n      <td>216/242 (89)</td>\n\n      <td>185/211 (88)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 50127 Version 2.0</div></div></div>"},"50130":{"type":"graphic_table","displayName":"Differential diagnosis of claudication","title":"Differential diagnosis of claudication","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of claudication</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Location of pain or discomfort</td> <td class=\"subtitle1\">Character of discomfort</td> <td class=\"subtitle1\">Onset relative to exercise</td> <td class=\"subtitle1\">Effect of rest</td> <td class=\"subtitle1\">Effect of body position</td> <td class=\"subtitle1\">Other features</td> </tr> <tr class=\"divider_bottom\"> <td>Intermittent claudication</td> <td>Buttock, thigh, or calf muscles and rarely the foot</td> <td>Cramping, aching, fatigue, weakness, or pain</td> <td>After some degree of exercise</td> <td>Quickly relieved</td> <td>None</td> <td>Reproducible</td> </tr> <tr class=\"divider_bottom\"> <td>Nerve root compression (eg, herniated disc)</td> <td>Radiates down leg, usually posteriorly</td> <td>Sharp lancinating pain</td> <td>Soon after, if not immediately after onset</td> <td>Not quickly relieved. (Also, often present at rest)</td> <td>Adjusting back position may relieve pain</td> <td>History of back problems</td> </tr> <tr class=\"divider_bottom\"> <td>Spinal stenosis</td> <td>Hip, thigh, or&nbsp;buttock (within affected dermatome)</td> <td>Motor weakness more prominent than pain</td> <td>After walking or standing for some length of time</td> <td>Relieved by resting only if position changed</td> <td>Relieved by lumbar spine flexion (sitting or stooping forward)</td> <td>Frequent history of back problems, provoked by intraabdominal pressure</td> </tr> <tr class=\"divider_bottom\"> <td>Hip arthritis</td> <td>Hip, thigh, buttocks</td> <td>Aching discomfort, usually localized to hip and gluteal region</td> <td>After variable degree of exercise</td> <td>Not quickly relieved (and may be present at rest)</td> <td>More comfortable sitting (ie, weight taken off legs)</td> <td>Variable, may relate to activity level, weather changes</td> </tr> <tr class=\"divider_bottom\"> <td>Arthritic, inflammatory processes</td> <td>Foot, arch</td> <td>Aching pain</td> <td>After variable degree of exercise</td> <td>Not quickly relieved (and may be present at rest)</td> <td>May be relieved by not bearing weight</td> <td>Variable, may relate to activity level</td> </tr> <tr> <td>Venous claudication</td> <td>Entire leg, but usually worse in thigh and groin</td> <td>Tight, bursting pain</td> <td>After walking</td> <td>Subsides slowly</td> <td>Relief speeded by elevation of the extremity</td> <td>History of iliofemoral deep vein thrombosis, signs of venous congestion, edema</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). J Vasc Surg 2000; 31:S1.</div><div id=\"graphicVersion\">Graphic 50130 Version 3.0</div></div></div>"},"50131":{"type":"graphic_diagnosticimage","displayName":"Anencephaly ultrasound","title":"Anencephaly at 32 postmenstrual weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Anencephaly at 32 postmenstrual weeks of gestation</div><div class=\"cntnt\"><img style=\"width:572px; height:187px;\" src=\"images/OBGYN/50131_Anencephaly_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A coronal view of the face. the eyes are prominent and above them no cranial vault or brain tissue is seen (A). A longitudinal view of the neck region and upper thoracic vertebrae showing the disrupted bony structures as well as some disorganized neutral tissue (B). In a transverse view the typical U-shaped vertebrae with tissue protruding is evident. This is consistent with an open upper spina bifida which is commonly seen with anencephaly.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 50131 Version 2.0</div></div></div>"},"50132":{"type":"graphic_table","displayName":"Modified FOLFOX6","title":"Modified FOLFOX6 chemotherapy for gastrointestinal cancer<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified FOLFOX6 chemotherapy for gastrointestinal cancer<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 14 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Oxaliplatin</td> <td>85 mg/m<sup>2</sup> IV*</td> <td>Dilute with 500 mL 5% dextrose in water (D5W)<sup>&#182;</sup> and administer over two hours (on days 1 and 15, oxaliplatin and leucovorin can be administered concurrently in separate bags using a Y-connector).</td> <td>Day 1</td> </tr> <tr> <td>Leucovorin<sup>&#916;</sup></td> <td>400 mg/m<sup>2</sup> IV<sup>&#9674;</sup></td> <td>Dilute with 250 mL D5W<sup>&#182;</sup> and administer over two hours concurrent with oxaliplatin.</td> <td>Day 1</td> </tr> <tr> <td>Fluorouracil (FU)</td> <td>400 mg/m<sup>2</sup> IV bolus</td> <td>Slow IV push over five minutes (administer immediately after leucovorin).</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>FU</td> <td>2400 mg/m<sup>2</sup> IV</td> <td>Dilute with 500 to 1000 mL D5W and administer over 46 hours (begin immediately after FU IV bolus). To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL normal saline.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>There is no standard premedication regimen. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin and FU are classified as irritants, but oxaliplatin can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors is not justified (estimated risk of febrile neutropenia &#60;5%<sup>[2]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of oxaliplatin may be needed for severe renal impairment.<sup>[3]</sup> A lower starting dose of FU may be needed for patients with liver impairment. </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Maneuvers to prevent acute neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Counsel patients to avoid exposure to cold during and for approximately 72 hours after each infusion. Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>QT prolongation and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes (especially potassium and magnesium) and liver and renal function prior to each treatment. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each treatment. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Delay treatment cycle by one week for absolute neutrophil count &#60;1500/microL, or platelets &#60;75,000/microL on the day of treatment. If treatment is delayed for two weeks or delayed for one week on two separate occasions, eliminate FU bolus. With the second occurrence, reduce infusional FU by 20% and reduce oxaliplatin dose from 85 to 65 mg/m<sup>2</sup>. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For grade 2 symptoms lasting longer than seven days, decrease oxaliplatin dose by 20%. Discontinue oxaliplatin for grade 3 paresthesias/dysesthesias. The US Prescribing Information recommends a dose reduction in oxaliplatin (to 75 mg/m<sup>2</sup> in patients treated in the adjuvant setting and to 65 mg/m<sup>2</sup> in patients with advanced disease) for persistent grade 2 neurosensory events that do not resolve and discontinuation for persistent grade 3 neurosensory events.<sup>[3]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Diarrhea</strong></td> <td colspan=\"3\"> <ul> <li>Withhold treatment for grade 2 or worse diarrhea, and restart at a 20% lower dose of all agents after complete resolution. The US Prescribing Information recommends dose reduction of oxaliplatin (to 75 mg/m<sup>2</sup> in patients treated in the adjuvant setting and to 65 mg/m<sup>2</sup> for patients treated for advanced disease), as well as a reduction of bolus FU and infusional FU after recovery from grade 3 or 4 diarrhea during the prior cycle.<sup>[3]</sup> </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin has rarely been associated with pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; ECG: electrocardiogram; CBC: complete blood count.<br />* Many centers routinely infuse oxaliplatin through a central venous line because of local pain with infusion into a peripheral vein.<br />¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />Δ Leucovorin dose is given for d,l-racemic mixture.<SUP>[5]</SUP> Use half the dose for LEVOleucovorin (l-leucovorin).<br /><FONT class=lozenge>◊</FONT> The dose of leucovorin in the two trials of modified FOLFOX6 was 350 mg/m<SUP>2</SUP>. However, most clinicians use the standard 400 mg/m<SUP>2</SUP> dose as was used for original FOLFOX6.<SUP>[6]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Cheeseman SL, et al. Br J Cancer 2002; 87:393.</LI>&#xD;&#xA;<LI>Hochster HS, et al. J Clin Oncol 2008; 26:3523.</LI>&#xD;&#xA;<LI>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2015).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).</LI>&#xD;&#xA;<LI>Leucovorin calcium injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).</LI>&#xD;&#xA;<LI>Tournigand C, et al. J Clin Oncol 2004; 22:229.</LI></OL></div><div id=\"graphicVersion\">Graphic 50132 Version 35.0</div></div></div>"},"50133":{"type":"graphic_picture","displayName":"Keratoderma blennorrhagicum 2","title":"Keratoderma blennorrhagicum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Keratoderma blennorrhagicum</div><div class=\"cntnt\"><img style=\"width:360px; height:434px;\" src=\"images/RHEUM/50133_Keratoderma_blennorhagica_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This close-up photograph shows the erythematous, scaly plaques of keratoderma blennorrhagicum in a patient with reactive arthritis (formerly Reiter's Syndrome).</div><div class=\"graphic_reference\">Courtesy of Filip de Keyser.</div><div id=\"graphicVersion\">Graphic 50133 Version 2.0</div></div></div>"},"50135":{"type":"graphic_picture","displayName":"Botulinum toxin injection - lateral canthal rhytides","title":"Botulinum toxin injection for lateral canthal rhytides","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Botulinum toxin injection for lateral canthal rhytides</div><div class=\"cntnt\"><img style=\"width:586px; height:191px;\" src=\"images/DERM/50135_Bot_tox_injec_lat_cant_rhyt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Periocular wrinkles at maximal smile are shown before (A) and after (B) treatment with botulinum toxin.</div><div id=\"graphicVersion\">Graphic 50135 Version 1.0</div></div></div>"},"50136":{"type":"graphic_picture","displayName":"FAST pericardial subxiphoid probe position","title":"FAST: Pericardial subxiphoid probe position","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">FAST: Pericardial subxiphoid probe position</div><div class=\"cntnt\"><img style=\"width:504px; height:334px;\" src=\"images/EM/50136_FAST_pericardial_subxiphoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the proper probe position for obtaining a subxiphoid view of the pericardium.</div><div class=\"graphic_reference\">Courtesy of Manoj Pariyadath, MD.</div><div id=\"graphicVersion\">Graphic 50136 Version 2.0</div></div></div>"},"50137":{"type":"graphic_picture","displayName":"Angiodysplasia endosc","title":"Angiodysplasia in the colon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angiodysplasia in the colon</div><div class=\"cntnt\"><img style=\"width:253px; height:206px;\" src=\"images/GAST/50137_Angiodysplasia_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angiodysplasia appears endoscopically as peripherally expanding dilated capillaries with a central origin measuring between 0.1 to 1.0 cm in diameter.</div><div class=\"graphic_reference\">Courtesy of Rome Jutabha, MD.</div><div id=\"graphicVersion\">Graphic 50137 Version 3.0</div></div></div>"},"50141":{"type":"graphic_table","displayName":"Risks for child respiratory sx with parental smoking","title":"Pooled random effects (odds ratios) for respiratory symptoms in children associated with parental smoking","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pooled random effects (odds ratios) for respiratory symptoms in children associated with parental smoking</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"8%\"></colgroup><colgroup width=\"12%\"></colgroup><colgroup width=\"8%\"></colgroup><colgroup width=\"8%\"></colgroup><colgroup width=\"12%\"></colgroup><colgroup width=\"8%\"></colgroup><colgroup width=\"8%\"></colgroup><colgroup width=\"12%\"></colgroup><colgroup width=\"8%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Either parent smokes</td> <td class=\"subtitle1\" colspan=\"3\">One parent smokes</td> <td class=\"subtitle1\" colspan=\"3\">Both parents smoke</td> </tr> <tr> <td class=\"subtitle2\">OR</td> <td class=\"subtitle2\">95 percent CI</td> <td class=\"subtitle2\">N</td> <td class=\"subtitle2\">OR</td> <td class=\"subtitle2\">95 percent CI</td> <td class=\"subtitle2\">N</td> <td class=\"subtitle2\">OR</td> <td class=\"subtitle2\">95 percent CI</td> <td class=\"subtitle2\">N</td> </tr> <tr> <td>Asthma</td> <td>1.23</td> <td>(1.14 to 1.33)</td> <td>(31)</td> <td>1.01</td> <td>(0.84 to 1.22)</td> <td>(7)</td> <td>1.42</td> <td>(1.3 to 1.56)</td> <td>(10)</td> </tr> <tr> <td>Wheeze<sup>&#182;</sup></td> <td>1.26</td> <td>(1.2 to 1.33)</td> <td>(45)</td> <td>1.18</td> <td>(1.1 to 1.26)</td> <td>(13)</td> <td>1.41</td> <td>(1.23 to 1.63)</td> <td>(14)</td> </tr> <tr> <td>Cough</td> <td>1.35</td> <td>(1.27 to 1.43)</td> <td>(39)</td> <td>1.27</td> <td>(1.14 to 1.41)</td> <td>(18)</td> <td>1.64</td> <td>(1.48 to 1.81)</td> <td>(18)</td> </tr> <tr> <td>Phlegm<sup>&#916;</sup></td> <td>1.35</td> <td>(1.3 to 1.41)</td> <td>(10)</td> <td>1.24</td> <td>(1.1 to 1.39)</td> <td>(7)</td> <td>1.42</td> <td>(1.19 to 1.7)</td> <td>(6)</td> </tr> <tr> <td>Breathlessness<sup>&#916;</sup></td> <td>1.31</td> <td>(1.14 to 1.5)</td> <td>(6)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Note: Number of studies in parentheses.<br />¶ Excluding EC study, in which the pooled odds ratio was 1.2.<br />Δ Data for phlegm and breathlessness restricted as several comparisons are based on fewer than five studies.</div><div class=\"graphic_reference\">Adapted from USDHHS 2006, The Surgeon General's Report.</div><div id=\"graphicVersion\">Graphic 50141 Version 5.0</div></div></div>"},"50142":{"type":"graphic_picture","displayName":"Steroid atrophy post injection","title":"Steroid atrophy and loss of pigmentation from intralesional steroid therapy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Steroid atrophy and loss of pigmentation from intralesional steroid therapy</div><div class=\"cntnt\"><img style=\"width:396px; height:257px;\" src=\"images/PC/50142_Steroid_atrophy_post_inject.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These effects are usually temporary and self-resolving, but in this instance the result was permanent.</div><div class=\"graphic_reference\">Reproduced with permission from Mosby, Inc.</div><div id=\"graphicVersion\">Graphic 50142 Version 2.0</div></div></div>"},"50143":{"type":"graphic_picture","displayName":"Eosinophilic granulomatosis with polyangiitis pathology","title":"Granuloma in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Granuloma in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) </div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/PULM/50143_Churg_Strauss_granuloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph shows the palisading granuloma of&nbsp;eosinophilic granulomatosis with polyangiitis (Churg-Strauss) characterized by an area of necrobiosis (arrow) permeated by disintegrating neutrophils and palisaded by a histiocytic infiltrate. There may or may not be an accompanying vasculitis.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 50143 Version 3.0</div></div></div>"},"50144":{"type":"graphic_table","displayName":"General predictors of nonadherence with nasal CPAP","title":"General predictors of nonadherence with nasal CPAP","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">General predictors of nonadherence with nasal CPAP</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Patient related factors</td> </tr> <tr> <td class=\"indent1\">Failure to understand the importance of the therapy.</td> </tr> <tr> <td class=\"indent1\">Failure to understand instructions concerning the therapy.</td> </tr> <tr> <td class=\"indent1\">Concomitant self-administration of prescription or nonprescription medications or alcohol.</td> </tr> <tr> <td class=\"indent1\">Social isolation, thus lack of social support. (Patients with supportive families have been shown to be more compliant with prescription drugs - data not available for CPAP use.)</td> </tr> <tr> <td class=\"indent1\">Feeling ill, or being too tired to use the therapy.</td> </tr> <tr> <td class=\"indent1\">Physical limitations, including vision, hearing, hand coordination.</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Therapy and medication related factors</td> </tr> <tr> <td class=\"indent1\">Complexity of therapy, in device use, or medication dosing.</td> </tr> <tr> <td class=\"indent1\">Increased rate of adverse reactions. (Device use has complications, and the provider needs to meet with the patient periodically to determine adverse events and help address these issues.)</td> </tr> <tr> <td class=\"indent1\">Characteristics of illness; long-term or chronic illnesses are a problem, as compliance decreases over time.</td> </tr> <tr> <td class=\"indent1\">Expensive therapy (only a problem when a patient must pay out of pocket or has not met the deductible).</td> </tr> <tr> <td class=\"indent1\">Lack of efficacy.</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Health professional related factors</td> </tr> <tr> <td class=\"indent1\">Poor relationship with patient.</td> </tr> <tr> <td class=\"indent1\">Expression of doubt concerning therapeutic potential.</td> </tr> <tr> <td class=\"indent1\">Unwillingness to educate patients.</td> </tr> <tr> <td class=\"indent1\">Lack of knowledge of medications the patient is taking or has access to. (Sedatives and alcohol can compound OSA, and their use should be evaluated.)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CPAP: continuous positive airway pressure; OSA: obstructive sleep apnea.</div><div id=\"graphicVersion\">Graphic 50144 Version 4.0</div></div></div>"},"50146":{"type":"graphic_diagnosticimage","displayName":"Renal angiomyolipoma CT","title":"CT scan showing renal angiomyolipoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan showing renal angiomyolipoma</div><div class=\"cntnt\"><img style=\"width:328px; height:288px;\" src=\"images/NEPH/50146_Renal_angiomyolipoma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Single axial CT scan demonstrates a mass in the left kidney (arrow). The presence of fat within this mass is suggested by an attenuation similar to that of perirenal fat (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 50146 Version 5.0</div></div></div>"},"50147":{"type":"graphic_table","displayName":"GI abnormalities causing hydrops","title":"Gastrointestinal abnormalities associated with hydrops fetalis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gastrointestinal abnormalities associated with hydrops fetalis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Midgut volvulus</td> </tr> <tr> <td>Malrotation</td> </tr> <tr> <td>Duplication</td> </tr> <tr> <td>Gastrointestinal obstruction&nbsp;</td> </tr> <tr> <td>Jejunal atresia</td> </tr> <tr> <td>Meconium peritonitis</td> </tr> <tr> <td>Intestinal tumor</td> </tr> <tr> <td>Hepatic disease:&nbsp;fibrosis, cholestasis, vascular malformations, polycystic disease, hepatitis, cirrhosis</td> </tr> <tr> <td>Biliary atresia</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50147 Version 2.0</div></div></div>"},"50148":{"type":"graphic_figure","displayName":"Pendulum swing PI","title":"Pendulum swing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pendulum swing</div><div class=\"cntnt\"><img style=\"width:278px; height:330px;\" src=\"images/PI/50148_Pendulum_exercises_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To do this exercise, you can sit or stand. Relax your arm and let it hang down. Move your arm back and forth, then side to side, and then around in small circles in both directions. After about a week, you can make the exercise harder by making bigger movements or holding a weight in your hand.</div><div id=\"graphicVersion\">Graphic 50148 Version 3.0</div></div></div>"},"50150":{"type":"graphic_picture","displayName":"Superficial hair tourniquet","title":"Superficial hair tourniquet","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial hair tourniquet</div><div class=\"cntnt\"><img style=\"width:358px; height:379px;\" src=\"images/PEDS/50150_Hair_tourniquet_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Infant brought in by mother who noticed toe was red and swollen while bathing child. Note the grossly visible hair tourniquet at the base of the fourth toe. It was removed using fine forceps without difficulty and with return of normal appearance of the toe within 24 hours. </div><div class=\"graphic_reference\">Reproduced with permission from: William E Franklin, DO, FACEP. Copyright ©2003 William E Franklin, DO, FACEP.</div><div id=\"graphicVersion\">Graphic 50150 Version 3.0</div></div></div>"},"50151":{"type":"graphic_picture","displayName":"Urticaria 2","title":"Urticaria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urticaria</div><div class=\"cntnt\"><img style=\"width:324px; height:318px;\" src=\"images/ALLRG/50151_Urticaria_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin-colored wheals are present.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50151 Version 2.0</div></div></div>"},"50154":{"type":"graphic_table","displayName":"Surface markers resting mature T cells","title":"Surface markers of resting mature T cells","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Surface markers of resting mature T cells</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Name</td> <td class=\"subtitle1\">Functions</td> </tr> <tr> <td>CD2</td> <td>Binds CD58 (LFA-3), adhesion, SRBC receptor</td> </tr> <tr> <td>CD4</td> <td>Binds MHC class II, associated with lck tyrosine kinase</td> </tr> <tr> <td>CD5</td> <td>Binds CD72, inhibits activation</td> </tr> <tr> <td>CD8</td> <td>Binds MHC class I, associated with lck tyrosine kinase</td> </tr> <tr> <td>CD11a/CD18 (LFA-1)</td> <td>Binds CD54 (ICAM-1), adhesion, activation</td> </tr> <tr> <td>CD28</td> <td>Binds B7 molecules, regulates T cell activation</td> </tr> <tr> <td>CD45RA</td> <td>Tyrosine phosphatase, naive T cell marker</td> </tr> <tr> <td>CD45RO</td> <td>Tyrosine phosphatase, memory T cell marker</td> </tr> <tr> <td>CD69</td> <td>C-type lectin, unknown ligand, early activation marker, unknown function</td> </tr> <tr> <td>CD152 (CTLA-4)</td> <td>Activation marker, down-regulates T cell responses</td> </tr> <tr> <td>CD154 (CD40L)</td> <td>Activation marker for CD4 T cells</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICAM: intercellular adhesion molecule; IL: interleukin; LFA: leukocyte function antigen; MHC: major histocompatibility complex; SRBC: sheep red blood cell.</div><div class=\"graphic_reference\">Courtesy of Bonilla Francisco, MD.</div><div id=\"graphicVersion\">Graphic 50154 Version 5.0</div></div></div>"},"50155":{"type":"graphic_figure","displayName":"Rectovaginal exam during laparoscopy","title":"Rectovaginal examination during laparoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rectovaginal examination during laparoscopy</div><div class=\"cntnt\"><img style=\"width:432px; height:346px;\" src=\"images/OBGYN/50155_Rectovaginalexamlapar.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: LifeART. Copyright © 2011 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 50155 Version 1.0</div></div></div>"},"50156":{"type":"graphic_figure","displayName":"Mastectomy skin flap development","title":"Mastectomy skin flap development","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Mastectomy skin flap development</div><div class=\"cntnt\"><img style=\"width:526px; height:387px;\" src=\"images/SURG/50156_Mastskinflapdevelopment.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Development of the skin ﬂaps proceeds with retraction of the skin at a right angle to the table. With traction on the breast tissue, pressing down or pulling away from the skin ﬂap, the tissue plane is more readily identiﬁable. The plane between the adipose of the skin and that of the breast is usually found 2 to 4 mm below the dermis. The adipose of the skin is the thinnest near the areola and slowly becomes thicker toward the chest wall. Adair breast tenaculae are depicted here in the retraction, but other methods are utilized as well.</div><div class=\"graphic_reference\">Reproduced with permission from: Shaughnessy EA. Simple mastectomy. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50156 Version 7.0</div></div></div>"},"50157":{"type":"graphic_diagnosticimage","displayName":"Mallet finger with fracture","title":"Mallet finger with fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mallet finger with fracture</div><div class=\"cntnt\"><img style=\"width:432px; height:162px;\" src=\"images/EM/50157_Mallet_finger_fx_XR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral radiograph shows an avulsion fracture at the proximal portion of the distal phalanx in a patient with a mallet finger injury.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 50157 Version 2.0</div></div></div>"},"50158":{"type":"graphic_diagnosticimage","displayName":"PET FDG Hurthle cell","title":"PET scan with FDG from a patient with Hürthle cell thyroid cancer","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">PET scan with FDG from a patient with Hürthle cell thyroid cancer</div><div class=\"cntnt\"><img style=\"width:504px; height:174px;\" src=\"images/ENDO/50158_PET_fluorodeoxyglucose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this FDG-PET scan from a patient with Hürthle cell thyroid cancer, there is evidence of multiple small foci of increased radiotracer uptake. In the left neck, this focus may represent residual carcinoma in the region of the left thyroid bed or within an adjacent lymph node. In addition, foci are notable in the mediastinum and right lung, likely representing distant metastasis. A prior I-123 whole-body scan demonstrated no abnormal uptake.</div><div class=\"graphic_footnotes\">PET:&nbsp;positron emission tomography; FDG: fluorodeoxyglucose; I-123: iodine-123.</div><div class=\"graphic_reference\">Courtesy of Stephanie L&nbsp;Lee, MD, PhD.</div><div id=\"graphicVersion\">Graphic 50158 Version 6.0</div></div></div>"},"50159":{"type":"graphic_table","displayName":"Neonatal morbidity by delivery type (SVD, forceps, vacuum) in NJ","title":"Neonatal morbidity and mortality data by delivery type, New Jersey 1989 to 1993, rate per 10,000 deliveries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neonatal morbidity and mortality data by delivery type, New Jersey 1989 to 1993, rate per 10,000 deliveries</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Outcome</td> <td class=\"subtitle1\">Unassisted (spontaneous)&nbsp;delivery</td> <td class=\"subtitle1\">Forceps delivery</td> <td class=\"subtitle1\">Vacuum delivery</td> <td class=\"subtitle1\">Vacuum plus forceps</td> </tr> <tr> <td>Cephalohematoma</td> <td>167</td> <td>635</td> <td>1117</td> <td>1361</td> </tr> <tr> <td>Facial nerve injury</td> <td>2.4</td> <td>37.0</td> <td>5.2</td> <td>52.9</td> </tr> <tr> <td>Intracranial hemorrhage</td> <td>3.7</td> <td>17.0</td> <td>16.2</td> <td>26.5</td> </tr> <tr> <td>Mechanical ventilation</td> <td>23.5</td> <td>31.3</td> <td>40.3</td> <td>74.1</td> </tr> <tr> <td>Retinal hemorrhage</td> <td>18.2</td> <td>19.3</td> <td>15.7</td> <td>31.8</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data&nbsp;from: Demissie K, Rhoads GG, Smulian JC, et al. Operative vaginal delivery and neonatal and infant adverse outcomes: population based retrospective analysis. BMJ 2004; 329:24.</div><div id=\"graphicVersion\">Graphic 50159 Version 5.0</div></div></div>"},"50161":{"type":"graphic_table","displayName":"Causes central cyanosis newborn","title":"Causes of central cyanosis in the neonate","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of central cyanosis in the neonate</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease category</td> <td class=\"subtitle1\">Primary underlying mechanism</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Airway obstruction</td> </tr> <tr> <td class=\"indent1\">Choanal atresia</td> <td class=\"divider_bottom\" style=\"vertical-align: middle;\" rowspan=\"4\">Hypoventilation</td> </tr> <tr> <td class=\"indent1\">Laryngotracheomalacia</td> </tr> <tr> <td class=\"indent1\">Macroglossia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Micrognathia or retrognathia (eg, Pierre-Robin syndrome)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cardiac</td> </tr> <tr> <td class=\"indent1\">Congenital cyanotic heart disease</td> <td>Right-to-left shunting</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Heart failure/pulmonary edema</td> <td>Impaired alveolar-arterial diffusion and V/Q mismatch</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Hematologic</td> </tr> <tr> <td class=\"indent1\">Hemoglobinopathies (eg, methemoglobinemia)</td> <td>Impaired oxygen saturation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Polycythemia</td> <td>Elevated hemoglobin resulting in low oxygen saturation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Metabolic</td> </tr> <tr> <td class=\"indent1\">Severe hypoglycemia</td> <td class=\"divider_bottom\" style=\"vertical-align: middle;\" rowspan=\"2\">Hypoventilation due to decreased or absent respiratory effort secondary to lethargy, seizures, and/or apnea</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Inborn errors of metabolism</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neurologic</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Central nervous system depression</td> </tr> <tr> <td class=\"indent2\">Apnea of prematurity</td> <td style=\"vertical-align: middle;\" rowspan=\"5\">Hypoventilation</td> </tr> <tr> <td class=\"indent2\">Infection (eg,&nbsp;meningitis, encephalitis)</td> </tr> <tr> <td class=\"indent2\">Intraventricular hemorrhage</td> </tr> <tr> <td class=\"indent2\">Maternal sedation</td> </tr> <tr> <td class=\"indent2\">Seizure</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Neuromuscular disorder</td> </tr> <tr> <td class=\"indent2\">Neonatal myasthenia gravis</td> <td class=\"divider_bottom\" style=\"vertical-align: middle;\" rowspan=\"3\">Hypoventilation</td> </tr> <tr> <td class=\"indent2\">Phrenic nerve injury</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Spinal muscular atrophy type 1 (Wernig-Hoffman disease)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pulmonary</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Parenchymal disease</td> </tr> <tr> <td class=\"indent2\">Atelectasis</td> <td style=\"vertical-align: middle;\" rowspan=\"8\">V/Q mismatch</td> </tr> <tr> <td class=\"indent2\">Alveolar capillary dysplasia</td> </tr> <tr> <td class=\"indent2\">Lobar emphysema</td> </tr> <tr> <td class=\"indent2\">Pneumonia</td> </tr> <tr> <td class=\"indent2\">Pulmonary hypoplasia</td> </tr> <tr> <td class=\"indent2\">Pulmonary hemorrhage</td> </tr> <tr> <td class=\"indent2\">Respiratory distress syndrome (Hyaline membrane disease)</td> </tr> <tr> <td class=\"indent2\">Transient tachypnea of the newborn</td> </tr> <tr> <td class=\"indent2\">Pulmonary fibrosis</td> <td>Impaired alveolar-arterial diffusion</td> </tr> <tr> <td class=\"indent2\">Pulmonary edema</td> <td>Impaired alveolar-arterial diffusion and V/Q mismatch</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Nonparenchymal disease</td> </tr> <tr> <td class=\"indent2\">Pleural effusion</td> <td class=\"divider_bottom\" style=\"vertical-align: middle;\" rowspan=\"2\">V/Q mismatch</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Pneumothorax</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other</td> </tr> <tr> <td class=\"indent1\">Persistent pulmonary hypertension of the newborn</td> <td>Right-to-left shunting</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">V/Q: ventilation/perfusion.</div><div id=\"graphicVersion\">Graphic 50161 Version 5.0</div></div></div>"},"50163":{"type":"graphic_table","displayName":"Medicolegal considerations CAM","title":"Medicolegal considerations in the use of complementary therapies in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medicolegal considerations in the use of complementary therapies in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Do parents elect to abandon effective care when the child's condition is serious or life-threatening?</td> </tr> <tr> <td class=\"indent1\">Courts are likely to respect parental choices that are supported by some medical authority and that present reasonable alternatives as long as the child's life is not in danger and conventional care is not imminently necessary. The child's condition should be monitored so that conventional interventions can be used if necessary.</td> </tr> <tr> <td class=\"subtitle1_single\">Will the use of complementary and alternative medicine (CAM) therapy otherwise divert the child from imminently necessary conventional treatment?</td> </tr> <tr> <td class=\"indent1\">If not, a \"time-limited\" trial of the proposed approach may be appropriate<sup>[1,2]</sup>, provided that the child can be monitored conventionally and conventional therapy can be continued as appropriate<sup>[3,4]</sup>.</td> </tr> <tr> <td class=\"subtitle1_single\">Are the CAM therapies that have been selected known to be unsafe or ineffective?</td> </tr> <tr> <td class=\"sublist2_start\">The medical evidence can be categorized as follows, with increasing risk of liability<sup>[3]</sup>:</td> </tr> <tr> <td class=\"sublist2\">1) Medical evidence supports efficacy and safety&#8212;the therapy can be <strong>recommended</strong>; efficacy should be monitored.</td> </tr> <tr> <td class=\"sublist2\">2) Medical evidence supports safety, but evidence regarding efficacy is inconclusive&#8212;the therapy can be <strong>tolerated</strong>; efficacy should be monitored.</td> </tr> <tr> <td class=\"sublist2\">3) Medical evidence supports efficacy, but evidence regarding safety is inconclusive&#8212;the therapy should be <strong>monitored closely or discouraged</strong>.</td> </tr> <tr> <td class=\"sublist2\">4) Medical evidence indicates serious risk and inefficacy&#8212;the therapy should be <strong>avoided and actively discouraged</strong>.</td> </tr> <tr> <td class=\"indent1\">The clinician caring for the patient should continue to monitor the patient and the literature for new information that would change the category.</td> </tr> <tr> <td class=\"subtitle1_single\">Have the proper parties consented to the use of the CAM therapy?</td> </tr> <tr> <td class=\"indent1\">Informed consent is particularly important when informing the patient about CAM therapies that may affect the patient's choice of treatment<sup>[5]</sup>.</td> </tr> <tr> <td class=\"subtitle1_single\">Is the risk-benefit ratio of the proposed CAM therapy acceptable to a reasonable, similarly situated clinician, and does the therapy have at least minority acceptance or support in the medical literature?</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>American Academy of Pediatrics: Counseling families who choose complementary and alternative medicine for their child with chronic illness or disability. Committee on Children With Disabilities. Pediatrics 2001; 107:598. </li>&#xD;&#xA;    <li>Adams KE, Cohen MH, Eisenberg D, Jonsen AR. Ethical considerations of complementary and alternative medical therapies in conventional medical settings. Ann Intern Med 2002; 137:660. </li>&#xD;&#xA;    <li>Cohen MH, Eisenberg DM. Potential physician malpractice liability associated with complementary and integrative medical therapies. Ann Intern Med 2002; 136:596. </li>&#xD;&#xA;    <li>Eisenberg DM. Advising patients who seek alternative medical therapies. Ann Intern Med 1997; 127:61. </li>&#xD;&#xA;    <li>Ernst E, Cohen MH. Informed consent in complementary and alternative medicine. Arch Intern Med 2001; 161:2288. </li>&#xD;&#xA;</ol>&#xD;&#xA;<br />Adapted from: Cohen MH, Kemper KJ. Complementary therapies in pediatrics: a legal perspective. Pediatrics 2005; 115:774.</div><div id=\"graphicVersion\">Graphic 50163 Version 7.0</div></div></div>"},"50165":{"type":"graphic_picture","displayName":"Horizontal forehead rhytides at rest and contraction","title":"Horizontal forehead rhytides","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Horizontal forehead rhytides</div><div class=\"cntnt\"><img style=\"width:428px; height:512px;\" src=\"images/DERM/50165_Horiz_forehead_rhytides.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Horizontal wrinkles are present on the forehead. This patient has wrinkles that are visible at rest (top). The wrinkles are exacerbated during brow elevation (bottom).</div><div id=\"graphicVersion\">Graphic 50165 Version 2.0</div></div></div>"},"50166":{"type":"graphic_table","displayName":"Unique fracture terms","title":"Unique fracture terms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Unique fracture terms</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n <tr>\n    <td class=\"subtitle1_single\" colspan=\"2\">Finger</td>\n </tr>\n <tr>\n    <td class=\"indent1\">Mallet finger</td>\n    <td>Rupture of distal extensor tendon that may involve avulsion fracture of distal phalanx</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Jersey finger</td>\n    <td>Rupture of distal flexor tendon that may involve avulsion fracture of distal phalanx</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Boxer's fracture</td>\n    <td>Fracture of distal 5th metacarpal at the metaphyseal-diaphyseal junction with apex dorsal angulation</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle1_single\" colspan=\"2\">Wrist</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Colles fracture</td>\n    <td>Distal radius fracture with apex palmar angulation</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Smith's fracture</td>\n    <td>Distal radius fracture with apex dorsal angulation</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Styloid fracture</td>\n    <td>Fracture of the distal radius or distal ulna styloid process</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle1_single\" colspan=\"2\">Hip</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Femoral neck fracture</td>\n    <td>Proximal femur fracture between the trochanters and the femoral head</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Intertrochanteric fracture</td>\n    <td>Proximal femur fracture extending between the greater and lesser trochanters</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle1_single\" colspan=\"2\">Foot</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Jones fracture</td>\n    <td>Acute fracture in the metaphyseal-diaphyseal area of the proximal 5th metatarsal (often confused with avulsion or stress fractures)</td>\n  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted with permission from: McGowan HJ. In: Sports Medicine Resource Manual, 1st ed, Seidenberg P, Beutler AI (Eds), Saunders, Philadelphia, 2007, p.147-51. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &copy; 2007 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 50166 Version 3.0</div></div></div>"},"50167":{"type":"graphic_picture","displayName":"Polyp prolapsing pylorus","title":"Gastric hyperplastic polyp prolapsing through the pylorus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric hyperplastic polyp prolapsing through the pylorus</div><div class=\"cntnt\"><img style=\"width:324px; height:335px;\" src=\"images/GAST/50167_Polyp_prolapsing_pylorus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of a hyperplastic gastric polyp on a short stalk near the pylorus. The polyp prolapsed into the pylorus and duodenal bulb with peristalsis.</div><div class=\"graphic_reference\">Courtesy of David Y Graham, MD.</div><div id=\"graphicVersion\">Graphic 50167 Version 1.0</div></div></div>"},"50168":{"type":"graphic_algorithm","displayName":"Outcome recurrent cervical CA","title":"Algorithm showing theoretical outcome for patients diagnosed with recurrent cervical cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm showing theoretical outcome for patients diagnosed with recurrent cervical cancer</div><div class=\"cntnt\"><img style=\"width:426px; height:332px;\" src=\"images/OBGYN/50168_Outcome_recurrent_cervical.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 50168 Version 3.0</div></div></div>"},"50170":{"type":"graphic_table","displayName":"Types of heparin thrombocytopenia","title":"Distinguishing characteristics of the two types of heparin-induced thrombocytopenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinguishing characteristics of the two types of heparin-induced thrombocytopenia</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   &nbsp;\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Type 1\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Type 2\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Frequency</td>\r\n  \r\n   <td>10 to 20 percent</td>\r\n  \r\n   <td>1 to 3 percent</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Timing of onset</td>\r\n  \r\n   <td>1 to 4 days</td>\r\n  \r\n   <td>5 to 10 days after start of heparin</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Nadir platelet count</td>\r\n  \r\n   <td>100,000/microL</td>\r\n  \r\n   <td>usually &#62;20,000/microL; median nadir 60,000/microL</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Antibody mediated</td>\r\n  \r\n   <td>No</td>\r\n  \r\n   <td>Yes</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Thromboembolic sequelae</td>\r\n  \r\n   <td>None</td>\r\n  \r\n   <td>30 to 80 percent</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hemorrhagic sequelae</td>\r\n  \r\n   <td>None</td>\r\n  \r\n   <td>Rare</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Management</td>\r\n  \r\n   <td>Observe</td>\r\n  \r\n   <td>Cessation of heparin, alternative nonheparin anticoagulation to prevent thrombosis</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">7.00000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=26915&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Types_heparin_thrombocytope.htm</title></head></div><div class=\"graphic_reference\">Adapted from: Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998; 31:1449.</div><div id=\"graphicVersion\">Graphic 50170 Version 2.0</div></div></div>"},"50171":{"type":"graphic_figure","displayName":"Survivor bias","title":"Survivor bias","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Survivor bias</div><div class=\"cntnt\"><img style=\"width:507px; height:509px;\" src=\"images/PC/50171_Survivor_bias.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this case-control study, cases are drawn from a hospital population. Out of all those with disease in the hospital (16 blue circles), 4 cases agree to be part of the study (shaded square). These 4 may represent a biased sample in that those with severe disease or those who die before being approached for participation are not represented. Out of all those with no disease in the general population, 4 controls agree to be part of the study. By comparing these 4 cases and 4 controls, any genes found to be selectively enriched (or depleted) in the cases may be linked to occurrence of the disease but may also be linked to severity or survival.<br>In a prospective study, blood is taken at baseline so that even if someone develops disease and dies before recruitment into a case-control study could happen they are still represented in the cohort study, ie, the cases are more representative.</div><div id=\"graphicVersion\">Graphic 50171 Version 1.0</div></div></div>"},"50172":{"type":"graphic_algorithm","displayName":"Diagnostic evaluation of DPLD","title":"Diagnostic evaluation of diffuse parenchymal lung disease","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Diagnostic evaluation of diffuse parenchymal lung disease</div><div class=\"cntnt\"><img style=\"width:482px; height:411px;\" src=\"images/PULM/50172_Diagnostic_eval_DPLD_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The diagnostic process in diffuse&nbsp;parenchymal lung diseases begins with a clinical evaluation that includes a history, physical examination, chest radiograph, and lung function tests. On the basis of this information, the patients may be divided into two groups: cases that do not represent idiopathic interstitial pneumonia, owing to recognition of associated conditions or underlying exposures, and cases that could represent idiopathic interstitial pneumonia. Patients in the latter category typically undergo a high-resolution computerized tomography scan. This generally results in four categories of patients: (1) those with distinctive features that allow for a confident diagnosis of idiopathic pulmonary fibrosis/usual interstitial pneumonia in the appropriate clinical setting, (2) those with atypical clinical or high-resolution computerized tomography features for idiopathic pulmonary fibrosis, (3) those with features diagnostic of another diffuse&nbsp;parenchymal lung disease such as pulmonary Langerhans cell histiocytosis, and (4) those with suspected other forms of diffuse&nbsp;parenchymal lung disease. Although many patients will go directly to surgical lung biopsy, some patients may undergo transbronchial biopsy or bronchoalveolar lavage. If these findings are nondiagnostic, a surgical lung biopsy may be necessary to separate the various idiopathic interstitial pneumonias from non-idiopathic interstitial pneumonia.</div><div class=\"graphic_footnotes\">DPLD: diffuse&nbsp;parenchymal lung disease; IIP: idiopathic interstitial pneumonia; HRCT: high-resolution computerized tomography; IPF: idiopathic pulmonary fibrosis; TBBx: transbronchial biopsy; BAL: bronchoalveolar lavage; UIP: usual interstitial pneumonia; NSIP: nonspecific interstitial pneumonia; RB: respiratory bronchiolitis-associated interstitial pneumonia; DIP: desquamative interstitial pneumonia; DAD: diffuse alveolar damage; OP: organizing pneumonia; LIP: lymphoid interstitial pneumonia; PLCH: pulmonary Langerhans cell histiocytosis.</div><div id=\"graphicVersion\">Graphic 50172 Version 6.0</div></div></div>"},"50176":{"type":"graphic_table","displayName":"Algorithm for predicting peri-procedural bleeding during PCI","title":"Algorithm for prediction of peri-procedural bleeding risk in patients undergoing percutaneous coronary intervention","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Algorithm for prediction of peri-procedural bleeding risk in patients undergoing percutaneous coronary intervention</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Risk factors*</td> <td class=\"subtitle1\">Integer</td> </tr> <tr> <td>Intraaortic balloon pump</td> <td>5</td> </tr> <tr> <td>Age</td> <td>0 for &#8804;55 yrs; 3 for every 10 yrs over 55</td> </tr> <tr> <td>Female gender</td> <td>3</td> </tr> <tr> <td>Glycoprotein IIb/IIIa inhibitor</td> <td>3</td> </tr> <tr> <td>Baseline HCT &#60;39 percent for men, &#60;36 percent for women</td> <td>2</td> </tr> <tr> <td>LMWH within 48 hr pre-PCI</td> <td>2</td> </tr> <tr> <td class=\"subtitle1\">Risk score</td> <td class=\"subtitle1\">Major bleeding (percent)</td> </tr> <tr> <td>0</td> <td>1.0</td> </tr> <tr> <td>2 to 6</td> <td>1.5</td> </tr> <tr> <td>7 to 9</td> <td>2.6</td> </tr> <tr> <td>&#8805;10</td> <td>5.4</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">eGFR: estimated glomerular filtration rate; HCT: hematocrit; LMWH: low molecular weight heparin.<br> * The presence of these risk factors leads to assignment of the corresponding integer, which are summated into a score for estimation of risk of peri-procedural bleeding after percutaneous coronary intervention.</div><div class=\"graphic_reference\">Adapted from: Nikolsky E, Mehran R, Dangas G, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007; 2008:1936.</div><div id=\"graphicVersion\">Graphic 50176 Version 9.0</div></div></div>"},"50179":{"type":"graphic_table","displayName":"Heart rate maximum reserve","title":"Calculation of target heart rate maximum reserve","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Calculation of target heart rate maximum reserve</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">Lower Limit (60% capacity)</td>\n\n      <td class=\"subtitle1\">Upper Limit (80% capacity)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Maximal heart rate</td>\n\n      <td>180</td>\n\n      <td>180</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Resting heart rate</td>\n\n      <td>60</td>\n\n      <td>60</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Heart rate reserve</td>\n\n      <td>120</td>\n\n      <td>120</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Exercise intensity</td>\n\n      <td>0.6</td>\n\n      <td>0.8</td>\n\n    </tr>\n\n    <tr>\n\n      <td>&nbsp;</td>\n\n      <td>72</td>\n\n      <td>96 </td>\n\n    </tr>\n\n    <tr>\n\n      <td>Add resting heart rate</td>\n\n      <td>60</td>\n\n      <td>60</td>\n\n    </tr>\n\n    <tr>\n\n      <td><strong>Target\nheart rate</strong></td>\n\n      <td>132</td>\n\n      <td>156</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">2.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=5120&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Heart_rate_maximum_reserve.htm</title></head></div><div class=\"graphic_footnotes\">The resting heart rate is subtracted from the maximal; heart rate to calculate the heart rate reserve. The heart rate reserve is multiplied by the desired exercise intensity (0.6 or 0.8 in this example) and the resting heart rate is added to the value obtained to estimate the target heart rate during exercise. All heart rates are in beats per minute.</div><div id=\"graphicVersion\">Graphic 50179 Version 2.0</div></div></div>"},"50185":{"type":"graphic_picture","displayName":"Grade IV asbestosis","title":"H&E-stained section of lung showing Grade IV asbestosis with honeycombing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">H&amp;E-stained section of lung showing Grade IV asbestosis with honeycombing</div><div class=\"cntnt\"><img style=\"width:389px; height:307px;\" src=\"images/PULM/50185_Grade_IV_asbestosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The overlying pleura (bottom right) is also thickened.</div><div class=\"graphic_reference\">Am J Respir Crit Care Med 2004; 170:692; www.atsjournals.org.</div><div id=\"graphicVersion\">Graphic 50185 Version 1.0</div></div></div>"},"50187":{"type":"graphic_picture","displayName":"Staphylococcal folliculitis on leg","title":"Staphylococcal folliculitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Staphylococcal folliculitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/50187_Staph_folliculitis_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple follicularly-based inflammatory papules and pustules are present on the leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50187 Version 4.0</div></div></div>"},"50188":{"type":"graphic_figure","displayName":"Ripstein anterior rectopexy","title":"Ripstein anterior rectopexy","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Ripstein anterior rectopexy</div><div class=\"cntnt\"><img style=\"width:451px; height:504px;\" src=\"images/SURG/50188_Ripstein-ant-rectopexy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the classic Ripstein anterior rectopexy with mesh. The mesh should be wrapped around the rectum without tension to avoid complications of stenosis and obstruction.</div><div id=\"graphicVersion\">Graphic 50188 Version 1.0</div></div></div>"},"50189":{"type":"graphic_figure","displayName":"Value ETT Bayes theorem","title":"Calculation of probability of coronary artery disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calculation of probability of coronary artery disease</div><div class=\"cntnt\"><img style=\"width:386px; height:371px;\" src=\"images/CARD/50189_Value_ETT_Bayes_theorem.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The probability of coronary artery disease (CAD) based upon a positive exercise test depends upon the pre-test probability of CAD, ie, the prevalence of CAD in the population studied. The solid black bar indicates the results for a negative test (-ST) while the red bars indicate the results for a positive test (+ST). The results of a postive exercise test are less predictive in an asymptomatic population with a low pre-test probability of CAD while they are very predictive in patients with typical angina who have a high pretest probability of CAD. The posttest probability of CAD is optimal in patients with an intermediate prevalence of CAD, eg, the 45 year old with atypical chest pain.</div><div class=\"graphic_reference\">Data from: Patterson RE, Horowitz SF. J Am Coll Cardiol 1989; 13:1653.</div><div id=\"graphicVersion\">Graphic 50189 Version 2.0</div></div></div>"},"50190":{"type":"graphic_diagnosticimage","displayName":"Stress radiograph revealing Grade III MCL tear","title":"Stress radiograph revealing Grade III medial collateral ligament tear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stress radiograph revealing Grade&nbsp;III medial collateral ligament tear</div><div class=\"cntnt\"><img style=\"width:432px; height:342px;\" src=\"images/EM/50190_Knee_MCL_stress_XR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stress radiograph revealing gross medial joint line opening indicating complete tears of the medial collateral, anterior, and posterior cruciate ligaments.</div><div class=\"graphic_reference\">Reproduced with permission from: Bucholz, RW, Heckman, JD. Rockwood &amp; Green's Fractures in Adults, Fifth Edition. Lippincott Williams &amp; Wilkins, 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50190 Version 4.0</div></div></div>"},"50191":{"type":"graphic_figure","displayName":"Types of PD catheters","title":"Types of peritoneal dialysis catheters","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Types of peritoneal dialysis catheters</div><div class=\"cntnt\"><img style=\"width:301px; height:417px;\" src=\"images/NEPH/50191_Types_of_PD_catheters.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representations of the Tenckhoff, Toronto Western Hospital, and Swan Neck Missouri peritoneal dialysis catheters.</div><div class=\"graphic_reference\">Adapted from Khanna R, Nolph KD, Oreopoulos DG (Eds). The Essentials of Peritoneal Dialysis, Kluwer Academic Publishers, p. 20.</div><div id=\"graphicVersion\">Graphic 50191 Version 2.0</div></div></div>"},"50192":{"type":"graphic_picture","displayName":"Lichen sclerosus with squamous cell carcinoma 2","title":"Lichen sclerosus and squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen sclerosus and squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:310px; height:360px;\" src=\"images/OBGYN/50192_LS_SCC_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular plaque of&nbsp;lichen sclerosus&nbsp;around the vulva with periclitoral thickening and painful erosions on the left side. Biopsy site visible.</div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD,&nbsp;and Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 50192 Version 4.0</div></div></div>"},"50193":{"type":"graphic_table","displayName":"Chemotherapy neutrophilic eccrine hidradenitis","title":"Cytotoxic chemotherapy agents associated with neutrophilic eccrine hidradenitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cytotoxic chemotherapy agents associated with neutrophilic eccrine hidradenitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Bleomycin</td>\n</tr>\n<tr>\n<td>Chlorambucil</td>\n</tr>\n<tr>\n<td>Cyclophosphamide</td>\n</tr>\n<tr>\n<td>Cytarabine</td>\n</tr>\n<tr>\n<td>Doxorubicin</td>\n</tr>\n<tr>\n<td>Lomustine</td>\n</tr>\n<tr>\n<td>Mitoxantrone</td>\n</tr>\n<tr>\n<td>Topotecan</td>\n</tr>\n<tr>\n<td>Vincristine*</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=45600&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Chemo_neut_eccrine_hidraden.htm</title></head></div><div class=\"graphic_footnotes\">* In combination regimens.</div><div class=\"graphic_reference\">Modified from: Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J AM Acad Dermatol 1999; 40:367.</div><div id=\"graphicVersion\">Graphic 50193 Version 4.0</div></div></div>"},"50196":{"type":"graphic_table","displayName":"IH features morbidity","title":"Features of infantile hemangiomas with highest risk for morbidity according to anatomic location and/or morphology of the hemangioma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features of infantile hemangiomas with highest risk for morbidity according to anatomic location and/or morphology of the hemangioma</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Anatomic location/morphology\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Associated risk\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Facial, large segmental</td>\r\n  \r\n   <td>PHACES syndrome (posterior fossa malformations, hemangiomas, arterial anomalies, cardiac defects, eye abnormalities, sternal clefting)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Nasal tip, ear, large facial (especially with prominent dermal component)</td>\r\n  \r\n   <td>Permanent scarring, disfigurement</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Periorbital and retrobulbar</td>\r\n  \r\n   <td>Ocular axis occlusion, astigmatism, amblyopia, tear-duct occlusion</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Segmental \"beard area,\" central neck</td>\r\n  \r\n   <td>Airway hemangioma</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Perioral</td>\r\n  \r\n   <td>Ulceration, disfigurement, feeding difficulties</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Segmental overlying lumbosacral spine</td>\r\n  \r\n   <td>Tethered spinal cord, genitourinary anomalies</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Perineal, axilla, neck, perioral</td>\r\n  \r\n   <td>Ulceration</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Multiple hemangiomas</td>\r\n  \r\n   <td>Visceral involvement (especially liver, gastrointestinal tract)</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Media_Notes msdt:dt=\"string\">8/22/2008--Requested permission (JD). 10/22/2008--Permission invoice received; figure to Terrence, invoice to Susan (JD). 11/26/2008--Letter of Approval received (JD). 2/3/2010--Renewal granted via Rightslink free of charge for Dr. Metry (JD).</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=53115&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>IH_features_morbidity.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 122, Pages 360-67, Copyright © 2008 by the AAP.</div><div id=\"graphicVersion\">Graphic 50196 Version 13.0</div></div></div>"},"50197":{"type":"graphic_figure","displayName":"Allergic contact dermatitis mechanism","title":"Pathogenesis of contact allergic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of contact allergic dermatitis</div><div class=\"cntnt\"><img style=\"width:601px; height:453px;\" src=\"images/DERM/50197_Allerg_contact_derm_mech.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the afferent phase of ACD, a na&#239;ve host is exposed (over time) to a low molecular weight hapten, which chemically reacts with epidermal proteins. These epidermal proteins are taken up by cutaneous antigen presenting cells (Langerhans cells and other APC), and trafficked to the local lymph node where education of conventional T-cells occurs. This results in the development of T memory/effector lymphocytes. At the same time during the afferent phase of ACD, innate immunity is also activated. Epidermal glycolipids are released, and presented to invariant NKT-cells, which interact with CD1d bearing B-cells, which produce hapten specific IgM. During the efferent phase, upon re-exposure to the hapten, memory T-cells are mobilized to the site of hapten challenge by hapten specific IgM which fixes complement, and activates endothelial cells, promoting conventional T-lymphocyte trafficking into the challenge site. CD8+ T-lymphocytes, along with innate immune cells such as NK- and NKT-cells, are thought to be effector cells of ACD. This group of cells releases cytokines and mediates cytotoxicity to APC and epidermal KC, resulting in the clinical signs and symptoms of ACD.</div><div class=\"graphic_reference\">Reproduced with permission from: Gober MD, Gaspari AA. Allergic contact dermatitis. Curr Dir Autoimmun 2008; 10:1. Copyright &#169; 2008 S. Karger AG, Basel. All rights reserved.</div><div id=\"graphicVersion\">Graphic 50197 Version 6.0</div></div></div>"},"50198":{"type":"graphic_figure","displayName":"Regulation of ventilation","title":"Regulation of ventilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Regulation of ventilation</div><div class=\"cntnt\"><img style=\"width:356px; height:254px;\" src=\"images/NEPH/50198_Regulation_of_ventilation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship between arterial PCO<sub>2</sub> (left panel) and PO<sub>2</sub> (right panel) and minute ventilation in normal subjects. Stimulation of ventilation occurs with a small rise in PCO<sub>2</sub>, but requires a large fall in PO<sub>2</sub>.</div><div class=\"graphic_footnotes\">PCO<sub>2</sub>: arterial carbon dioxide tension; PO<sub>2</sub>: arterial oxyen tension.</div><div class=\"graphic_reference\">Adapted from: Hudgel DW. Control of breathing. In: Bronchial Asthma: Mechanisms and Therapeutics, 2d ed, Weiss EB, Segal MS, Stein M (Eds), Little, Brown, Boston, 1984, with permission.</div><div id=\"graphicVersion\">Graphic 50198 Version 2.0</div></div></div>"},"50199":{"type":"graphic_table","displayName":"High altitude sites","title":"High altitude cities and peaks","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">High altitude cities and peaks</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n   <tr>\n   <td class=\"container\"><table cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   City\n   </td>\n   <td  class=\"subtitle1\">\n   Altitude\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"2\">\n   The 10 highest cities in the world\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   1. Lhasa, Tibet, China\n   </td>\n   <td>12,002 ft./3658 m.</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   2. La Paz, Bolivia\n   </td>\n   <td>11,910 ft./3630 m.</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   3. Cuzco, Peru\n   </td>\n   <td>11,152 ft./3399 m.</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   4. Sucre, Bolivia\n   </td>\n   <td>9331 ft./2844 m.</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   5. Quito, Ecuador\n   </td>\n   <td>9249 ft./2819 m.</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   6. Toluca, Mexico\n   </td>\n   <td>8793 ft./2680 m.</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   7. Bogot&#225;, Colombia\n   </td>\n   <td>8675 ft./2644 m.</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   8. Cochabamba, Bolivia\n   </td>\n   <td>8390 ft./2557 m.</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   9. Addis Ababa, Ethiopia\n   </td>\n   <td>7900 ft./2408 m.</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   10. Asmara, Ethiopia\n   </td>\n   <td>7789 ft./2374 m.</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"2\">\n   Some large cities at high altitude\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Mexico City\n   </td>\n   <td>2240 meters</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Johannesburg\n   </td>\n   <td>1750 meters</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Nairobi\n   </td>\n   <td>1660 meters</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Denver\n   </td>\n   <td>1610 meters</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Guatemala City\n   </td>\n   <td>1530 meters</td>\n   </tr>\n   </table></td>\n   <td class=\"container\"><table cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Peak\n   </td>\n   <td  class=\"subtitle1\">\n   Altitude\n   </td>\n   <td  class=\"subtitle1\">\n   Location\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"3\">\n   The Seven Summits\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Mount Everest\n   </td>\n   <td>29,035 ft./8850 m.</td>\n   <td>Asia</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Mount Kilimanjaro\n   </td>\n   <td>19,563 ft./5963 m.</td>\n   <td>Africa</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Mount McKinley\n   </td>\n   <td>20,320 ft./6194 m.</td>\n   <td>North America</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Puncak Jaya\n   </td>\n   <td>16,023 ft./4884 m.</td>\n   <td>Australia/Oceania</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Vinson Massif\n   </td>\n   <td>16,066 ft./4897 m.</td>\n   <td>Antarctica</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Mount Elbrus\n   </td>\n   <td>18,510 ft./5642 m.</td>\n   <td>Europe</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Aconcagua\n   </td>\n   <td>22,841 ft./6962 m.</td>\n   <td>South America</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"3\">\n   8000m peaks\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Annapurna\n   </td>\n   <td>26,545 ft./8091 m.</td>\n   <td>Nepal</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Dhaulagiri\n   </td>\n   <td>26,794 ft./8167 m.</td>\n   <td>Nepal</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Mount Everest\n   </td>\n   <td>29,035 ft./8850 m.</td>\n   <td>Nepal</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   K2\n   </td>\n   <td>28,253 ft./8612 m.</td>\n   <td>Pakistan</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Kangchenjunga\n   </td>\n   <td>28,169 ft./8586 m.</td>\n   <td>Nepal</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Lhotse\n   </td>\n   <td>27,940 ft./8516 m.</td>\n   <td>Nepal</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Makalu\n   </td>\n   <td>27,765 ft./8462 m.</td>\n   <td>Nepal</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Manaslu\n   </td>\n   <td>26,758 ft./8156 m.</td>\n   <td>Nepal</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Nanga Parbat\n   </td>\n   <td>26,658 ft./8125 m.</td>\n   <td>Pakistan</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Broad Peak\n   </td>\n   <td>26,400 ft./8047 m.</td>\n   <td>Pakistan</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Gasherbrum II\n   </td>\n   <td>26,360 ft./8035 m.</td>\n   <td>Pakistan</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Shisha Pangma\n   </td>\n   <td>26,289 ft./8013 m.</td>\n   <td>Tibet</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Gasherbrum\n   </td>\n   <td>26,470 ft./8068 m.</td>\n   <td>Pakistan</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Cho Oyu\n   </td>\n   <td>26,906 ft./8201 m.</td>\n   <td>Nepal</td>\n   </tr>\n   </table></td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">ft: feet; m: meters.</div><div id=\"graphicVersion\">Graphic 50199 Version 1.0</div></div></div>"},"50201":{"type":"graphic_table","displayName":"Manifestations of PBC","title":"Manifestations of primary biliary cholangitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Manifestations of primary biliary cholangitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Manifestations of PBC</td> </tr> <tr> <td>Fatigue</td> </tr> <tr> <td>Pruritus</td> </tr> <tr> <td>Portal hypertension</td> </tr> <tr> <td>Metabolic bone disease</td> </tr> <tr> <td>Xanthomas</td> </tr> <tr> <td>Fat-soluble vitamin malabsorption</td> </tr> <tr> <td>Urinary tract infection</td> </tr> <tr> <td>Malignancy</td> </tr> <tr> <td class=\"subtitle1_single\">Associated disorders</td> </tr> <tr> <td>Thyroid dysfunction</td> </tr> <tr> <td>Sicca syndrome</td> </tr> <tr> <td> <p>Limited cutaneous systemic sclerosis or scleroderma overlap syndromes</p> </td> </tr> <tr> <td>Raynaud phenomenon</td> </tr> <tr> <td>Rheumatoid arthritis</td> </tr> <tr> <td>Celiac disease</td> </tr> <tr> <td>Inflammatory bowel disease</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">PBC: primary biliary cholangitis.</div><div class=\"graphic_reference\">Adapted from: Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000; 31:1005.</div><div id=\"graphicVersion\">Graphic 50201 Version 8.0</div></div></div>"},"50202":{"type":"graphic_figure","displayName":"Myomectomy of prolapsed fibroid","title":"Transvaginal removal of a prolapsed submucosal myoma","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Transvaginal removal of a prolapsed submucosal myoma</div><div class=\"cntnt\"><img style=\"width:481px; height:344px;\" src=\"images/OBGYN/50202_Myomectomy_of_prolapsed_fib.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 50202 Version 1.0</div></div></div>"},"50204":{"type":"graphic_figure","displayName":"Femoral artery puncture","title":"Femoral artery puncture","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Femoral artery puncture</div><div class=\"cntnt\"><img style=\"width:466px; height:256px;\" src=\"images/PULM/50204_Femoral_artery_puncture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Technique of femoral artery puncture. The femoral artery can be palpated just below the midpoint of the inguinal ligament. The needle should be inserted at a 90 degree angle toward the pulsation for a single sampling of arterial blood. For catheter placement, the needle should be inserted at a 45 degree&nbsp;angle in a cephalad direction (as shown).</div><div class=\"graphic_reference\">Adapted from the American Heart Association. Textbook of Advanced Cardiac Life Support 1994.</div><div id=\"graphicVersion\">Graphic 50204 Version 2.0</div></div></div>"},"50206":{"type":"graphic_table","displayName":"Burns epi deaths","title":"Estimated deaths from fire-related burn injuries* in 2015, by World Health Organization region","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated deaths from fire-related burn injuries* in 2015, by World Health Organization region</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Africa</td> <td class=\"subtitle1\">The Americas</td> <td class=\"subtitle1\">EMR<sup>&#182;</sup></td> <td class=\"subtitle1\">Europe</td> <td class=\"subtitle1\">SEAR<sup>&#916;</sup></td> <td class=\"subtitle1\">WPR<sup>&#9674;</sup></td> <td class=\"subtitle1\">World</td> </tr> <tr> <td>Population (000)</td> <td>989,173</td> <td>986,173</td> <td>643,784</td> <td>909,913</td> <td>1,928,174</td> <td>1,855,009</td> <td>7,344,362</td> </tr> <tr> <td>Burn deaths (000)</td> <td>57</td> <td>9</td> <td>14</td> <td>26</td> <td>59</td> <td>15</td> <td>180</td> </tr> <tr> <td>Percent of deaths<sup>&#167;</sup></td> <td>0.6</td> <td>0.1</td> <td>0.4</td> <td>0.3</td> <td>0.4</td> <td>0.1</td> <td>0.3</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Burns covering 20 percent or more of total body surface area.<br />¶ Eastern Mediterranean region.<br />Δ Southeast Asia region.<br /><FONT class=lozenge>◊</FONT> Western Pacific region.<br />§ Percent of all deaths attributed to burn injuries.</div><div class=\"graphic_reference\">Data from: World Health Organization. Disease and injury estimates for 2015. Morbidity and Mortality. Deaths. Summary: Deaths (000s) by cause, in WHO regions, estimates for 2015. http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html.</div><div id=\"graphicVersion\">Graphic 50206 Version 4.0</div></div></div>"},"50208":{"type":"graphic_picture","displayName":"Bronchoscopy forceps","title":"Bronchoscopy forceps","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchoscopy forceps</div><div class=\"cntnt\"><img style=\"width:303px; height:253px;\" src=\"images/PULM/50208_Bronchoscopyforceps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchoscopic biopsy forceps with jaws open.</div><div id=\"graphicVersion\">Graphic 50208 Version 1.0</div></div></div>"},"50209":{"type":"graphic_picture","displayName":"Congenital CMV","title":"Congenital cytomegalovirus (CMV) infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital cytomegalovirus (CMV) infection</div><div class=\"cntnt\"><img style=\"width:396px; height:281px;\" src=\"images/OBGYN/50209_Congenital_CMV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Congenital CMV infection with involvement of a renal tubule in a 32 week autolyzed stillbirth. In recurrent CMV infections which lead to fetal death, maternal evaluation for HIV infection is indicated.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 50209 Version 1.0</div></div></div>"},"50211":{"type":"graphic_picture","displayName":"ITGCNU pathology","title":"Intratubular germ cell neoplasia, unclassified","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intratubular germ cell neoplasia, unclassified</div><div class=\"cntnt\"><img style=\"width:440px; height:332px;\" src=\"images/ONC/50211_ITGCNU_pathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A microscopic image of intratubular germ cell neoplasia of unclassified type (ITGCNU) showing large neoplastic germ cells in the seminiferous tubules. Compared&nbsp;with the residual non-neoplastic germ cells, neoplastic germ cells are larger with clear cytoplasm and dark central nuclei, demonstrating so called \"fried egg\" appearance, resembling the seminoma cells. However, different from seminoma cells, the neoplastic cells in ITGCNU are not invasive, since they are confined within the basement membrane of the tubules. Occasional elongated sertoli cells with small nuclei can be seen in the tubules as well.</div><div class=\"graphic_reference\">Courtesy of Ximing Yang, MD, PhD.</div><div id=\"graphicVersion\">Graphic 50211 Version 2.0</div></div></div>"},"50212":{"type":"graphic_table","displayName":"Approach neo thrombocytopenia","title":"Approach to the thrombocytopenic newborn infant","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to the thrombocytopenic newborn infant</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Sick infant</td> </tr> <tr> <td class=\"subtitle2_single\">Neonatal history</td> </tr> <tr> <td class=\"indent1\">Is there a history of perinatal asphyxia?</td> </tr> <tr> <td class=\"indent1\">Does the child have meconium aspiration syndrome or respiratory distress syndrome?</td> </tr> <tr> <td class=\"sublist2_start\">Is there evidence of infection?</td> </tr> <tr> <td class=\"sublist2\">Necrotizing enterocolitis</td> </tr> <tr> <td class=\"sublist2\">Sepsis/DIC</td> </tr> <tr> <td class=\"sublist2_start\">Does the child look abnormal?</td> </tr> <tr> <td class=\"sublist2\">Toxoplasmosis, rubella, cytomegalovirus, herpes simplex</td> </tr> <tr> <td class=\"sublist2\">Chromosome abnormality</td> </tr> <tr> <td class=\"indent1\">Is the child small for gestational age?</td> </tr> <tr> <td class=\"indent1\">Could the child have a thrombus? Were there indwelling catheters?</td> </tr> <tr> <td class=\"indent1\">Did the child have an intracranial hemorrhage?</td> </tr> <tr> <td class=\"subtitle2_single\">Maternal history</td> </tr> <tr> <td class=\"indent1\">Prenatal or perinatal infection</td> </tr> <tr> <td class=\"indent1\">Preeclampsia, hemolytic anemia, elevated liver enzymes, low platelet count</td> </tr> <tr> <td class=\"indent1\">Abnormal placenta</td> </tr> <tr> <td class=\"subtitle2_single\">Neonatal examination</td> </tr> <tr> <td class=\"indent1\">Head circumference, weight percentile</td> </tr> <tr> <td class=\"indent1\">Congenital anomalies: radial rays, thumbs, dysmorphic features</td> </tr> <tr> <td class=\"indent1\">Hepatosplenomegaly</td> </tr> <tr> <td class=\"indent1\">Blueberry muffin rash</td> </tr> <tr> <td class=\"indent1\">Hemangioma</td> </tr> <tr> <td class=\"subtitle2_single\">Neonatal laboratory values</td> </tr> <tr> <td class=\"indent1\">Abnormalities in the white blood cell count or hematocrit</td> </tr> <tr> <td class=\"indent1\">Hyperbilirubinemia or liver function test abnormalitites</td> </tr> <tr> <td class=\"indent1\">Evidence of coagulopathy or DIC</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Well infant</td> </tr> <tr> <td class=\"subtitle2_single\">Maternal history</td> </tr> <tr> <td class=\"indent1\">History of immune thrombocytopenic purpura or systemic lupus erythematosus?</td> </tr> <tr> <td class=\"indent1\">Previous infant with thrombocytopenia or family history of thrombocytopenic neonate?</td> </tr> <tr> <td class=\"indent1\">Infections during pregnancy?</td> </tr> <tr> <td class=\"indent1\">Drug use during pregnancy?</td> </tr> <tr> <td class=\"sublist2_start\">Maternal platelet count</td> </tr> <tr> <td class=\"sublist2\">Decreased, suggests autoimmune</td> </tr> <tr> <td class=\"sublist2\">Normal, may be autoimmune or alloimmune process</td> </tr> <tr> <td class=\"subtitle2_single\">Neonatal examination</td> </tr> <tr> <td class=\"sublist2_start\">Does the child look abnormal?</td> </tr> <tr> <td class=\"sublist2\">Thrombocytopenia with absent radii Fanconi anemia</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DIC: disseminated intravascular coagulation. </div><div class=\"graphic_reference\">Reproduced with permission from: George D, Bussel JB. Neonatal thrombocytopenia. Semin Thromb Hemost 1995; 21:276. Copyright &copy; 1995 Theime.</div><div id=\"graphicVersion\">Graphic 50212 Version 5.0</div></div></div>"},"50214":{"type":"graphic_picture","displayName":"Uncovered biliary stent","title":"Uncovered biliary stent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uncovered biliary stent</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/GAST/50214_Self_expanding_metal_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representative photo of an uncovered biliary self-expanding metal stent.</div><div class=\"graphic_reference\">Courtesy of Douglas G. Adler, MD.</div><div id=\"graphicVersion\">Graphic 50214 Version 2.0</div></div></div>"},"50215":{"type":"graphic_figure","displayName":"Laparoscopic salpingectomy","title":"Laparoscopic total salpingectomy using electrosurgery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic total salpingectomy using electrosurgery</div><div class=\"cntnt\"><img style=\"width:423px; height:484px;\" src=\"images/OBGYN/50215_Laparoscopicsalpingectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bipolar forceps are used to fulgurate the mesosalpinx (A), which is followed by using scissors to cut the mesosalpinx (B), and the tube is removed (C).</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 50215 Version 3.0</div></div></div>"},"50216":{"type":"graphic_picture","displayName":"Retinopathy in WM","title":"Retinopathy in Waldenström macroglobulinemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retinopathy in Waldenström macroglobulinemia</div><div class=\"cntnt\"><img style=\"width:396px; height:263px;\" src=\"images/HEME/50216_Retinopathy_in_WM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retinal photograph from a patient with Waldenström macroglobulinemia shows multiple hemorrhages and dilated, segmented, and tortuous retinal veins.</div><div id=\"graphicVersion\">Graphic 50216 Version 3.0</div></div></div>"},"50217":{"type":"graphic_figure","displayName":"Polyadenylation polymorphism in FSHD","title":"Polyadenylation polymorphism in FSHD","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Polyadenylation polymorphism in FSHD</div><div class=\"cntnt\"><img style=\"width:551px; height:500px;\" src=\"images/NEURO/50217_PolyadenypolymorphismFSHD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An intact D4Z4 region in chromosome 4 leaves a condensed chromatin state that prevents transcription of the distal <em>DUX4</em> gene. Chromosome 10q (and non-FSHD chromosome 4 alleles) does not have functional <em>DUX4</em> transcription elements. In FSHD, D4Z4 contractions in chromosome 4 (4q) lead to an open chromatin that exposes the distal <em>DUX4</em> gene and a sequence (pLAM) that encodes a poly(A) signal. This results in the transcription of <em>DUX4</em>, which may be linked to muscle degeneration in FSHD.</div><div class=\"graphic_reference\">From: Mahadevan MS. Genetics. Exposing a DUX tale. Science 2010; 329:1607. Reprinted with permission from: AAAS. Copyright © 2010.</div><div id=\"graphicVersion\">Graphic 50217 Version 4.0</div></div></div>"},"50218":{"type":"graphic_picture","displayName":"Eosinophilic fasciitis thigh","title":"Eosinophilic fasciitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eosinophilic fasciitis</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/50218_Eosinophil_fasciitis_thigh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fibrotic changes resembling cellulite are present on the leg in this patient with eosinophilic fasciitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50218 Version 4.0</div></div></div>"},"50219":{"type":"graphic_waveform","displayName":"EP study tracing showing VPB during atrial tachycardia mapping","title":"Electrophysiologic (EP) study tracing showng a ventricular premature beat (VPB) during mapping of an atrial tachycardia","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Electrophysiologic (EP) study tracing showng a ventricular premature beat (VPB) during mapping of an atrial tachycardia</div><div class=\"cntnt\"><img style=\"width:582px; height:420px;\" src=\"images/CARD/50219_VPB_during_atrial_tachycard.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three surface ECG leads (I, aVF, V1) and intracardiac recordings from the high posterior right atrium (HRA); posterior left atrium (USER1 and USER 3); proximal, mid, and distal coronary sinus (CS9-10, CS5-6, CS1-2); and right ventricular apex (RVA) in a patient with atrial tachycardia. A ventricular premature beat (VPB) introduced from the right ventricular outflow tract has no effect on the underlying atrial tachycardia, but the onset of the P wave (P) in the surface ECG recordings can be seen more clearly as it is no longer superimposed on the T wave. The atrial electrogram (A) recorded from the right atrial catheter precedes the surface P wave by 30 msec, but the signal from the left atrial catheter (USER1) precedes the surface P wave by 50 msec (arrow).</div><div class=\"graphic_footnotes\">V: ventricular electrogram.</div><div id=\"graphicVersion\">Graphic 50219 Version 3.0</div></div></div>"},"50220":{"type":"graphic_diagnosticimage","displayName":"Posterior elbow dislocation","title":"Posterior elbow dislocation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior elbow dislocation</div><div class=\"cntnt\"><img style=\"width:442px; height:274px;\" src=\"images/EM/50220_Postelbowdislocation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiographic findings.<br />(A) Anterior posterior&nbsp;radiograph. The radial head is superimposed behind the distal humerus. There is increased cubitus valgus. The medial epicondyle has not been avulsed.<br />(B) Lateral radiograph showing that the proximal radius and ulna are both displaced posteriorly to the distal humerus.</div><div class=\"graphic_reference\">Reproduced with permission from: Stans AA, Heinrich SD. Dislocations of the elbow. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 50220 Version 13.0</div></div></div>"},"50222":{"type":"graphic_picture","displayName":"Red wale Endosc","title":"Endoscopic \"red wale\" sign on esophageal varices","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic &quot;red wale&quot; sign on esophageal varices</div><div class=\"cntnt\"><img style=\"width:371px; height:274px;\" src=\"images/GAST/50222_Red_wale_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy of a chain of varices in the distal esophagus showing erythematous raised areas indicating an increased risk of bleeding.</div><div class=\"graphic_reference\">Courtesy of Eric D Libby, MD.</div><div id=\"graphicVersion\">Graphic 50222 Version 2.0</div></div></div>"},"50223":{"type":"graphic_table","displayName":"Interpretation and outcome of antenatal fetal testing methods","title":"Interpretation and outcome of various antenatal fetal testing methods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interpretation and outcome of various antenatal fetal testing methods</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"12%\"></colgroup><colgroup span=\"2\" width=\"26%\"></colgroup><colgroup span=\"3\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Name</td> <td class=\"subtitle1\">Components</td> <td class=\"subtitle1\">Results/scoring</td> <td class=\"subtitle1\">False negative</td> <td class=\"subtitle1\">False positive</td> <td class=\"subtitle1\">References</td> </tr> <tr class=\"divider_bottom\"> <td>Contraction stress test (oxytocin challenge test)</td> <td> <p>Continuous FHR monitoring</p> At least 3 contractions of &#8805;40s duration within 10 minutes</td> <td> <p><strong>Negative:</strong> No late or significant variable decelerations</p> <p><strong>Positive:</strong> Late decelerations following &#8805;50 percent of contractions, even if there are &#60;3 contractions in 10 minutes</p> <p><strong>Equivocal - suspicious:</strong> Intermittent late decelerations or significant variable decelerations</p> <p><strong>Equivocal - hyperstimulatory:</strong> Decelerations with contractions occurring more frequently than every 2 minutes or lasting &#62;90s</p> <strong>Unsatisfactory:</strong> &#60;3 contractions in 10 minutes or uninterpretable FHR tracing</td> <td>0.04 percent</td> <td>35 to 65 percent</td> <td>[1,2]</td> </tr> <tr class=\"divider_bottom\"> <td>Nonstress test</td> <td> <p>Continuous FHR monitoring</p> <p>FHR accelerations: &#8805;32w: Reaching 15 bpm above baseline and lasting &#8805;15s</p> &#60;32w: Reaching 10 bpm above baseline and lasting &#8805;10s</td> <td> <p><strong>Reactive:</strong> &#8805;2 accelerations within 20 minutes (may be extended to 40 minutes)</p> <strong>Nonreactive:</strong> &#60;2 accelerations in 40 minutes</td> <td>0.2 to 0.65 percent</td> <td>55 to 90 percent</td> <td>[3-8]</td> </tr> <tr class=\"divider_bottom\"> <td>Biophysical profile</td> <td>Presence or absence of five components within 30 minutes: <ul class=\"decimal_heading\"> <li>Reactive NST </li> <li>&#8805;1 episode of fetal breathing movements lasting &#8805;30s </li> <li>&#8805;3 discrete body or limb movements </li> <li>&#8805;1 episode of extremity extension with return to flexion or opening or closing of a hand </li> <li>Maximum vertical AF pocket &#62;2 cm </li> </ul> </td> <td>Each component is assigned a score of 2 points if all criteria for the component are present and 0 points if all criteria for the component are not present; maximum score is 10/10 <ul class=\"decimal_heading\"> <li><strong>Normal:</strong> &#8805;8/10 or 8/8 excluding NST </li> <li><strong>Equivocal:</strong> 6/10 </li> <li><strong>Abnormal:</strong> &#8804;4/10 </li> </ul> </td> <td>0.07 to 0.08 percent</td> <td>40 to 50 percent</td> <td>[9-11]</td> </tr> <tr> <td>Modified biophysical profile</td> <td> <ul> <li>NST </li> <li>Maximum vertical AF pocket &#62;2 cm </li> </ul> </td> <td> <p><strong>Normal:</strong> Reactive NST <em>and</em> maximum vertical AF pocket &#62;2 cm</p> <strong>Abnormal:</strong> Nonreactive NST <em>and/or</em> maximum vertical AF pocket &#8804;2 cm</td> <td>0.08 percent</td> <td>60 percent</td> <td>[12-15]</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">s: seconds; NST: nonstress test; AFI: amniotic fluid index; FHR: fetal heart rate; w: weeks; bpm: beats per minute.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Freeman RK, Anderson G, Dorchester W. A prospective multi-institutional study of antepartum fetal heart rate monitoring. II. Contraction stress test versus nonstress test for primary surveillance. Am J Obstet Gynecol 1982; 143:778.</li>&#xD;&#xA;    <li>Lagrew DC Jr. The contraction stress test. Clin Obstet Gynecol 1995; 38:11.</li>&#xD;&#xA;    <li>Platt LD, Walla CA, Paul RH, et al. A prospective trial of the fetal biophysical profile versus the nonstress test in the management of high-risk pregnancies. Am J Obstet Gynecol 1985; 153:624.</li>&#xD;&#xA;    <li>Lavery JP. Nonstress fetal heart rate testing. Clin Obstet Gynecol 1982; 25:689.</li>&#xD;&#xA;    <li>Phelan JP, Cromartie AD, Smith CV. The nonstress test: the false negative test. Am J Obstet Gynecol 1982; 142:293.</li>&#xD;&#xA;    <li>Freeman RK, Anderson G, Dorchester W. A prospective multi-institutional study of antepartum fetal heart rate monitoring. I. Risk of perinatal mortality and morbidity according to antepartum fetal heart rate test results. Am J Obstet Gynecol 1982; 143:771.</li>&#xD;&#xA;    <li>Rochard F, Schifrin BS, Goupil F, et al. Nonstressed fetal heart rate monitoring in the antepartum period. Am J Obstet Gynecol 1976; 126:699.</li>&#xD;&#xA;    <li>Boehm FH, Salyer S, Shah DM, Vaughn WK. Improved outcome of twice weekly nonstress testing. Obstet Gynecol 1986; 67:566.</li>&#xD;&#xA;    <li>Manning FA, Morrison I, Harman CR, et al. Fetal assessment based on fetal biophysical profile scoring: experience in 19,221 referred high-risk pregnancies. II. An analysis of false-negative fetal deaths. Am J Obstet Gynecol 1987; 157:880.</li>&#xD;&#xA;    <li>Manning FA, Morrison I, Lange IR, et al. Fetal assessment based on fetal biophysical profile scoring: experience in 12,620 referred high-risk pregnancies. I. Perinatal mortality by frequency and etiology. Am J Obstet Gynecol 1985; 151:343.</li>&#xD;&#xA;    <li>Dayal AK, Manning FA, Berck DJ, et al. Fetal death after normal biophysical profile score: An eighteen-year experience. Am J Obstet Gynecol 1999; 181:1231.</li>&#xD;&#xA;    <li>Miller DA, Rabello YA, Paul RH. The modified biophysical profile: antepartum testing in the 1990s. Am J Obstet Gynecol 1996; 174:812.</li>&#xD;&#xA;    <li>Clark SL, Sabey P, Jolley K. Nonstress testing with acoustic stimulation and amniotic fluid volume assessment: 5973 tests without unexpected fetal death. Am J Obstet Gynecol 1989; 160:694.</li>&#xD;&#xA;    <li>Nageotte MP, Towers CV, Asrat T, et al. The value of a negative antepartum test: contraction stress test and modified biophysical profile. Obstet Gynecol 1994; 84:231.</li>&#xD;&#xA;    <li>Vintzileos AM, Knuppel RA. Multiple parameter biophysical testing in the prediction of fetal acid-base status. Clin Perinatol 1994; 21:823.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 50223 Version 4.0</div></div></div>"},"50224":{"type":"graphic_table","displayName":"Good sleep hygiene","title":"Good sleep hygiene","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Good sleep hygiene</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">During the day</td> </tr> <tr> <td>Exercise regularly. Even a 20-minute walk during the day can help you relax. Don't exercise in the evening.</td> </tr> <tr> <td>Limit naps if you can. If you must nap, limit your nap to 30 minutes.</td> </tr> <tr> <td class=\"subtitle1_single\">Before bedtime</td> </tr> <tr> <td>Avoid alcohol, caffeine, chocolate, and nicotine in the late afternoon and evening.</td> </tr> <tr> <td>Limit liquids in the evening before going to bed.</td> </tr> <tr> <td>Turn off the TV&nbsp;one hour before bedtime. Listen to quiet music or take a warm bath.</td> </tr> <tr> <td>If you worry or \"can't turn your brain off\" when you try to sleep, make a list of things you need to do before you go to bed and then stop thinking about them.</td> </tr> <tr> <td class=\"subtitle1_single\">At bedtime</td> </tr> <tr> <td>Go to bed and get up at the same time every day, even on weekends.</td> </tr> <tr> <td>A bedtime snack of warm milk, turkey, or a banana may make you sleepy.</td> </tr> <tr> <td>Use your bedroom only for sleep and sex, no reading, watching TV, or working.</td> </tr> <tr> <td>If you are a \"clock watcher,\" turn your clock so that you cannot see its face.</td> </tr> <tr> <td>To fall asleep, lie in the position that you normally find yourself in when you wake up.</td> </tr> <tr> <td>Go to bed at the same time with your spouse.</td> </tr> <tr> <td class=\"subtitle1_single\">If you can't fall asleep</td> </tr> <tr> <td>If you haven't fallen asleep in 15 minutes, go to another room. Listen to quiet music. Avoid things that stimulate your mind (TV, exciting books). Reading self-help books may help you feel drowsy. Go back to bed when you feel sleepy. If you still can't fall asleep, get up again and repeat as necessary.</td> </tr> <tr> <td class=\"subtitle1_single\">If you wake up during the night</td> </tr> <tr> <td>If you can't get back to sleep, follow the procedure above (if you can't fall asleep).</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50224 Version 3.0</div></div></div>"},"50225":{"type":"graphic_table","displayName":"Melanoma 7th TNM staging","title":"Seventh (2010) TNM staging system for cutaneous melanoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Seventh (2010) TNM staging system for cutaneous melanoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Primary tumor (T) </td> </tr> <tr> <td>TX</td> <td>Primary tumor cannot be assessed (eg, curettaged or severely regressed primary)</td> </tr> <tr> <td>T0</td> <td>No evidence of primary tumor</td> </tr> <tr> <td>Tis</td> <td>Melanoma in situ</td> </tr> <tr> <td rowspan=\"3\">T1 </td> <td class=\"sublist1_start\">&#8804;1.0 mm </td> </tr> <tr> <td class=\"sublist1\">a: without ulceration and mitoses &#60;1/mm<sup>2</sup> </td> </tr> <tr> <td class=\"sublist1\">b: with ulceration or mitoses &#8805;1/mm<sup>2</sup> </td> </tr> <tr> <td rowspan=\"3\">T2 </td> <td class=\"sublist1_start\">1.01-2.0 mm </td> </tr> <tr> <td class=\"sublist1\">a: without ulceration </td> </tr> <tr> <td class=\"sublist1\">b: with ulceration </td> </tr> <tr> <td rowspan=\"3\">T3 </td> <td class=\"sublist1_start\">2.01-4.0 mm </td> </tr> <tr> <td class=\"sublist1\">a: without ulceration </td> </tr> <tr> <td class=\"sublist1\">b: with ulceration </td> </tr> <tr> <td rowspan=\"3\">T4 </td> <td class=\"sublist1_start\">&#62;4.0 mm </td> </tr> <tr> <td class=\"sublist1\">a: without ulceration </td> </tr> <tr> <td class=\"sublist1\">b: with ulceration </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Regional lymph nodes (N) </td> </tr> <tr> <td>NX</td> <td>Patients in whom the regional nodes cannot be assessed (eg, previously removed for another reason)</td> </tr> <tr> <td>N0</td> <td>No regional metastases detected</td> </tr> <tr> <td rowspan=\"3\">N1 </td> <td class=\"sublist1_start\">One lymph node </td> </tr> <tr> <td class=\"sublist1\">a: micrometastases* </td> </tr> <tr> <td class=\"sublist1\">b: macrometastases<sup>&#182; </sup></td> </tr> <tr> <td rowspan=\"4\">N2 </td> <td class=\"sublist1_start\">Two or three lymph nodes </td> </tr> <tr> <td class=\"sublist1\">a: micrometastases* </td> </tr> <tr> <td class=\"sublist1\">b: macrometastases<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist1\">c: in-transit met(s)/satellite(s) without metastatic lymph nodes </td> </tr> <tr> <td>N3</td> <td>Four or more metastatic lymph nodes, or matted lymph nodes, or in-transit met(s)/satellite(s) with metastatic lymph node(s)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Distant metastasis (M) </td> </tr> <tr> <td>M0</td> <td>No detectable evidence of distant metastases</td> </tr> <tr> <td>M1a</td> <td>Metastases to skin, subcutaneous, or distant lymph node, normal serum LDH</td> </tr> <tr> <td>M1b</td> <td>Lung metastases, normal LDH</td> </tr> <tr> <td>M1c</td> <td>Metastasis to other visceral metastases with a normal LDH, or any distant metastases and an elevated LDH</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note: cTNM is the clinical classification, pTNM is the pathologic classification.</div><div class=\"graphic_footnotes\">LDH:&nbsp;lactic dehydrogenase.<br />* Micrometastases are diagnosed after sentinel lymph node biopsy and completion lymphadenectomy (if performed).<br />¶&nbsp;Macrometastases are defined as clinically detectable lymph node metastases confirmed by therapeutic lymphadenectomy or when any lymph node metastasis exhibits gross extracapsular extension.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 50225 Version 14.0</div></div></div>"},"50226":{"type":"graphic_picture","displayName":"Diaphragm PI","title":"Diaphragm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diaphragm</div><div class=\"cntnt\"><img style=\"width:320px; height:240px;\" src=\"images/PI/50226_Diaphragm_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo depicts a contraceptive diaphragm. The diaphragm in this photo (with a hole) is used for fitting; the diaphragm a woman uses will not have a hole.</div><div id=\"graphicVersion\">Graphic 50226 Version 1.0</div></div></div>"},"50227":{"type":"graphic_table","displayName":"Abnormal urine organic acids","title":"Abnormal metabolites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Abnormal metabolites</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Abnormal metabolite(s)*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Organic acidemias</td> </tr> <tr> <td class=\"indent1\">Methylmalonic acidemia</td> <td>Methylmalonic and methylcitric acids</td> </tr> <tr> <td class=\"indent1\">Propionic acidemia</td> <td>3-hydroxypropionic acid, propionylglycine, methylcitric acid</td> </tr> <tr> <td class=\"indent1\">Isovaleric acidemia</td> <td>Isovalerylglycine</td> </tr> <tr> <td class=\"indent1\">Glutaric acidemia type I</td> <td>Glutaric, 3-hydroxyglutaric, dicarboxylic acids, and acylglycine</td> </tr> <tr> <td class=\"indent1\">3-methylglutaconic aciduria</td> <td>3-methylglutaconic acid</td> </tr> <tr> <td class=\"indent1\">2-hydroxy-3-methylbutyryl-CoA dehydrogenase deficiency</td> <td>2-hydroxy-3-methylblutyric acid, tiglyglycine, 2-ethylhydracrylic acid</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">2-hydroxyglutaric aciduria</td> <td>2-hydroxyglutaric acid</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Disorders of ketogenesis</td> </tr> <tr> <td class=\"indent1\">Medium chain acyl-CoA dehydrogenase (MCAD) deficiency</td> <td>Hexanoylglycine and suberylglycine</td> </tr> <tr> <td class=\"indent1\">3-ketothiolase deficiency</td> <td>2-hydroxy-3-methylbutyric acid, tiglyglycine, 2-methyl-3-hydroxyacetoacetic acid</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">3-hydroxy-3-methylglutaryl (HMG)-CoA lyase deficiency</td> <td>3-hydroxy-3-methylglutaric, 3-methylglutaric, and 3-methylglutaconic acids</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other disorders</td> </tr> <tr> <td class=\"indent1\">Canavan disease</td> <td>N-acetylaspartic acid</td> </tr> <tr> <td class=\"indent1\">Glutaric acidemia type II (multiple acyl-CoA dehydrogenase deficiency)</td> <td>Glutaric and 2-hydroxyglutaric acids</td> </tr> <tr> <td class=\"indent1\">Mevalonate kinase deficiency</td> <td>Mevalonic acid</td> </tr> <tr> <td class=\"indent1\">Maple syrup urine disease</td> <td>2-hydroxyisovaleric, 2-hydroxy-3-methylvaleric, and 2-ketoisocaproic acids</td> </tr> <tr> <td class=\"indent1\">Phenylketonuria</td> <td>Phenylpyruvic and phenyllactic acids</td> </tr> <tr> <td class=\"indent1\">Fumarase deficiency</td> <td>Fumaric acid</td> </tr> <tr> <td class=\"indent1\">Glutathione synthetase deficiency</td> <td>5-oxoproline (pyroglutamic acid)</td> </tr> <tr> <td class=\"indent1\">Biotinidase deficiency<sup>&#182;</sup></td> <td>3-hydroxyisovaleric acid, methylcitric acid, 3-methylcrotonylglycine, propionylglycine</td> </tr> <tr> <td class=\"indent1\">Holocarboxylase synthetase deficiency<sup>&#182;</sup></td> <td>3-hydroxyisovaleric acid, methylcitric acid, 3-methylcrotonylglycine, propionylglycine</td> </tr> <tr> <td class=\"indent1\">Glycerol kinase deficiency</td> <td>Glycerol</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ethylmalonic encephalopathy</td> <td>Ethylmalonic and methylsuccinic acids</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Disorders of uncertain consequence</td> </tr> <tr> <td class=\"indent1\">3-methylcrotonyl-CoA carboxylase deficiency</td> <td>3-methylcrotonylglycine</td> </tr> <tr> <td class=\"indent1\">Short chain acyl-CoA dehydrogenase deficiency</td> <td>Ethylmalonic acid, butyrylglycine</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Other abnormal metabolites may be seen in these disorders, but these listed are the most characteristic for the diagnosis.<br />&para; Diagnosis by urine organic acid analysis is unreliable.</div><div class=\"graphic_reference\">Courtesy of V Reid Sutton, MD.</div><div id=\"graphicVersion\">Graphic 50227 Version 7.0</div></div></div>"},"50228":{"type":"graphic_figure","displayName":"Feminization scale","title":"Schematic representation of grading scheme for clinical classification of androgen insensitivity syndromes (AIS)","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Schematic representation of grading scheme for clinical classification of androgen insensitivity syndromes (AIS)</div><div class=\"cntnt\"><img style=\"width:588px; height:161px;\" src=\"images/PEDS/50228_Feminization_scale_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Grades are numbered 1-7 in order of increasing severity (more defective masculinization). Grade 1: normal masculinization in utero; grade 2: male phenotype with mild defect in masculinization eg, isolated hypospadias; grade 3: male phenotype with severe defect in masculinization-small penis, perineoscrotal hypospadias, bifid scrotum and/or cryptorchidism; grade 4: severe genital ambiguity-clitoral-like phallus, labioscrotal folds, single perineal orifice; grade 5: female phenotype with posterior labial fusion and clitoromegaly; grade 6/7: female phenotype (grade 6 if pubic hair present in adulthood, grade 7 if no pubic hair in adulthood).</div><div class=\"graphic_reference\">Reproduced with permission from: Quigley CA, De Bellis A, Marschke KB, et al. Androgen receptor defects: Historical, clinical, and molecular perspectives. Endocrine Reviews 1995; 16:271. Copyright &#169; 1995 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 50228 Version 8.0</div></div></div>"},"50229":{"type":"graphic_picture","displayName":"Alopecia totalis","title":"Alopecia totalis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alopecia totalis</div><div class=\"cntnt\"><img style=\"width:347px; height:422px;\" src=\"images/DERM/50229_Alopecia_totalis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Complete loss of scalp hair occurs in alopecia totalis.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50229 Version 1.0</div></div></div>"},"50230":{"type":"graphic_picture","displayName":"Oropharyngeal airways","title":"Oropharyngeal airways","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oropharyngeal airways</div><div class=\"cntnt\"><img style=\"width:434px; height:249px;\" src=\"images/EM/50230_Oropharyn_airways.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 50230 Version 2.0</div></div></div>"},"50231":{"type":"graphic_diagnosticimage","displayName":"CT of temporal skull fracture with epidural blood","title":"Temporal skull fracture with intracranial bleed","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Temporal skull fracture with intracranial bleed</div><div class=\"cntnt\"><img style=\"width:310px; height:396px;\" src=\"images/EM/50231_Skull_fx_temp_CT_epidural.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skull fracture in the left temporal region with epidural hematoma. CT image using brain windows shows the lentiform epidural hematoma (*) in the left frontal region. Notice the superficial hematoma and gas in the left temporal region (arrow) and compression of the left lateral ventricle.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright &#169; 2008.</div><div id=\"graphicVersion\">Graphic 50231 Version 2.0</div></div></div>"},"50233":{"type":"graphic_figure","displayName":"Spinal BMD with testosterone","title":"Spinal bone density in hypogonadal men receiving testosterone therapy","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Spinal bone density in hypogonadal men receiving testosterone therapy</div><div class=\"cntnt\"><img style=\"width:549px; height:367px;\" src=\"images/ENDO/50233_Spinal_BMD_with_testosteron.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Increases in bone mineral density, as measured by quantitative computed tomography, are shown in 72 men with hypogonadism receiving long-term testosterone therapy. The circles indicate men whose first measurement was made before initiation of testosterone therapy, the squares indicate men already receiving testosterone therapy at their first measurement. The dark shaded area indicates the range of high fracture risk, the light shaded area indicates the range of intermediate fracture risk, and the unshaded area indicates the range of low fracture risk. The greatest increase in bone density occurred in the first year of therapy.</div><div class=\"graphic_reference\">Reproduced with permission from Behre, HM, Kliesch, S, Leifke, F, et al, J Clin Endocrinol Metab 1997; 82:2386.</div><div id=\"graphicVersion\">Graphic 50233 Version 1.0</div></div></div>"},"50235":{"type":"graphic_figure","displayName":"Swan Ganz lung zones","title":"Effect of lung zones on pulmonary artery catheter monitoring","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of lung zones on pulmonary artery catheter monitoring</div><div class=\"cntnt\"><img style=\"width:428px; height:308px;\" src=\"images/PULM/50235_Swan_Ganz_lung_zones.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lung can be divided into three physiologic zones, based on the relationship of alveolar pressure (P<sub>A</sub>), mean pulmonary artery pressure (P<sub>a</sub>), and pulmonary capillary wedge pressure (P<sub>c</sub>). Pulmonary capillary wedge pressure approximates left atrial pressure (P<sub>LA</sub>) under zone three conditions, when vascular pressures exceed alveolar pressure. If the pulmonary artery catheter is wedged under non-zone three conditions, alveolar pressure swings interfere with accurate assessment of pulmonary capillary wedge pressure.</div><div id=\"graphicVersion\">Graphic 50235 Version 1.0</div></div></div>"},"50236":{"type":"graphic_diagnosticimage","displayName":"Rotator cuff tear US trans","title":"Transverse sonogram of rotator cuff tear","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Transverse sonogram of rotator cuff tear</div><div class=\"cntnt\"><img style=\"width:504px; height:358px;\" src=\"images/RHEUM/50236_Rotator_cuff_tear_US_trans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This transverse sonogram of the shoulder shows a full-thickness rotator cuff tear (arrows) and associated fluid-filled subdeltoid bursa (asterisks).</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 50236 Version 2.0</div></div></div>"},"50237":{"type":"graphic_table","displayName":"Burn class chart","title":"Modified Lund-Browder chart for assessing percentage total body surface area burn in children and adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Lund-Browder chart for assessing percentage total body surface area burn in children and adults</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Area*\n   </td>\n   <td  class=\"subtitle1\">\n   Birth to 1 year\n   </td>\n   <td  class=\"subtitle1\">\n   1 to 4 years\n   </td>\n   <td  class=\"subtitle1\">\n   5 to 9 years\n   </td>\n   <td  class=\"subtitle1\">\n   10 to 14 years\n   </td>\n   <td  class=\"subtitle1\">\n   Adult\n   </td>\n   </tr>\n   <tr>\n   <td>Head</td>\n   <td>9.5</td>\n   <td>8.5</td>\n   <td>6.5</td>\n   <td>5.5</td>\n   <td>4.5</td>\n   </tr>\n   <tr>\n   <td>Neck</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   </tr>\n   <tr>\n   <td>Trunk</td>\n   <td>13</td>\n   <td>13</td>\n   <td>13</td>\n   <td>13</td>\n   <td>13</td>\n   </tr>\n   <tr>\n   <td>Upper arm</td>\n   <td>2</td>\n   <td>2</td>\n   <td>2</td>\n   <td>2</td>\n   <td>2</td>\n   </tr>\n   <tr>\n   <td>Forearm</td>\n   <td>1.5</td>\n   <td>1.5</td>\n   <td>1.5</td>\n   <td>1.5</td>\n   <td>1.5</td>\n   </tr>\n   <tr>\n   <td>Hand</td>\n   <td>1.25</td>\n   <td>1.25</td>\n   <td>1.25</td>\n   <td>1.25</td>\n   <td>1.25</td>\n   </tr>\n   <tr>\n   <td>Thigh</td>\n   <td>2.75</td>\n   <td>3.25</td>\n   <td>4</td>\n   <td>4.25</td>\n   <td>4.5</td>\n   </tr>\n   <tr>\n   <td>Leg</td>\n   <td>2.5</td>\n   <td>2.5</td>\n   <td>2.5</td>\n   <td>3</td>\n   <td>3.25</td>\n   </tr>\n   <tr>\n   <td>Foot</td>\n   <td>1.75</td>\n   <td>1.75</td>\n   <td>1.75</td>\n   <td>1.75</td>\n   <td>1.75</td>\n   </tr>\n   <tr>\n   <td>Buttock</td>\n   <td>2.5</td>\n   <td>2.5</td>\n   <td>2.5</td>\n   <td>2.5</td>\n   <td>2.5</td>\n   </tr>\n   <tr>\n   <td>Genitalia</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   <td>1</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">20.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=72861&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Burn_class_chart.htm</title></head></div><div class=\"graphic_footnotes\">* Values listed are for one surface area and each individual extremity. Anterior and posterior surface area values are equivalent in estimating total body surface area (TBSA). For circumferential burns, multiply surface area burned by two.</div><div id=\"graphicVersion\">Graphic 50237 Version 3.0</div></div></div>"},"50239":{"type":"graphic_table","displayName":"Paris classification system of superficial lesions","title":"Paris classification system of superficial gastrointestinal neoplastic lesions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Paris classification system of superficial gastrointestinal neoplastic lesions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Subclasses</td> </tr> <tr> <td rowspan=\"2\"><strong>0-I: Polypoid</strong></td> <td>0-Ip: Protruded, pedunculated</td> </tr> <tr> <td>0-Is: Protruded, sessile</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>0-II: Nonpolypoid</strong></td> <td>0-IIa: Slightly elevated</td> </tr> <tr> <td>0-IIb: Flat</td> </tr> <tr> <td>0-IIc: Slightly depressed</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\"><strong>0-III: Excavated</strong></td> </tr> </tbody></table></div><div class=\"graphic_reference\">The Paris endoscopic classification of superficial neoplastic lesions: Esophagus, stomach and colon: November 30 to December 1, 2002. Gastrointest Endosc 2003; 58(6 suppl):S3.</div><div id=\"graphicVersion\">Graphic 50239 Version 5.0</div></div></div>"},"50241":{"type":"graphic_picture","displayName":"Hydropic placenta","title":"Hydropic placenta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hydropic placenta</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/OBGYN/50241_Hydropic_placenta.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 50241 Version 1.0</div></div></div>"},"50243":{"type":"graphic_figure","displayName":"Incidence prostate cancer","title":"Incidence of prostate cancer: International comparisons","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Incidence of prostate cancer: International comparisons</div><div class=\"cntnt\"><img style=\"width:497px; height:475px;\" src=\"images/ONC/50243_Incidence_prostate_cancer.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Netherlands Cancer Registry. Available online at www.ikcnet.nl/index.php (Accessed on March 6, 2007).</div><div id=\"graphicVersion\">Graphic 50243 Version 1.0</div></div></div>"},"50244":{"type":"graphic_picture","displayName":"Lone star tick PI","title":"An adult female Amblyomma americanum (lone star tick)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">An adult female Amblyomma americanum (lone star tick)</div><div class=\"cntnt\"><img style=\"width:180px; height:181px;\" src=\"images/PI/50244_Lone_star_tick_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Champman, AS, Bakken, JS, Folk, SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever, Ehrlichoioses, and Anaplasmosis-United States: A practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55(RR-4):1.</div><div id=\"graphicVersion\">Graphic 50244 Version 1.0</div></div></div>"},"50245":{"type":"graphic_diagnosticimage","displayName":"Tibial and fibular fracture ORIF","title":"Tibial and fibular fracture ORIF","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tibial and fibular fracture ORIF</div><div class=\"cntnt\"><img style=\"width:172px; height:396px;\" src=\"images/RHEUM/50245_Tibial_and_fibular_fx_ORIF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This antero-posterior radiograph shows the result following open reduction and internal fixation (ORIF) of an unstable lower leg fracture using an intramedullary rod in the tibia and plate and screws on the distal fibula.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 50245 Version 2.0</div></div></div>"},"50246":{"type":"graphic_picture","displayName":"Treponema pallidum silver stain","title":"Congenital syphilis: Treponema pallidum, silver stain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital syphilis: Treponema pallidum, silver stain</div><div class=\"cntnt\"><img style=\"width:360px; height:305px;\" src=\"images/PEDS/50246_Trep_pall_silver_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spirochetes of <EM>Treponema pallidum</EM>, visualized by silver impregnation, in the eye of a child with congenital syphilis.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd ed. Lippincott Williams &amp; Wilkins, Philadelphia 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50246 Version 2.0</div></div></div>"},"50249":{"type":"graphic_picture","displayName":"Staphylococcal scalded skin syndrome - face","title":"Staphylococcal scalded skin syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Staphylococcal scalded skin syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/50249_Staphscaldskinsyndface.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perioral crusting is present in this child with staphylococcal scalded skin syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50249 Version 4.0</div></div></div>"},"50250":{"type":"graphic_picture","displayName":"10-year-old boy with mucopolysaccharidosis type VI - MPS VI","title":"10-year-old boy with mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">10-year-old boy with mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome)</div><div class=\"cntnt\"><img style=\"width:323px; height:432px;\" src=\"images/ALLRG/50250_Boy_mucopolysaccharidoses.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 50250 Version 6.0</div></div></div>"},"50251":{"type":"graphic_diagnosticimage","displayName":"Ultrasound view needle","title":"Ultrasound view of penetrating needle","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Ultrasound view of penetrating needle</div><div class=\"cntnt\"><img style=\"width:518px; height:301px;\" src=\"images/EM/50251_USviewneedle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Transverse (short-axis) view of vein with penetrating needle. B) Longitudinal (long-axis) view of vein with penetrating needle. Turning the transducer 90 degrees clockwise or counterclockwise will move from one view to the other.</div><div class=\"graphic_reference\">Reproduced with permission from: Kost SI. Ultrasound-assisted venous access. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50251 Version 11.0</div></div></div>"},"50252":{"type":"graphic_figure","displayName":"PTH and calcium","title":"Serum parathyroid hormone (PTH) concentrations in hypercalcemia and hypocalcemia","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Serum parathyroid hormone (PTH) concentrations in hypercalcemia and hypocalcemia</div><div class=\"cntnt\"><img style=\"width:513px; height:564px;\" src=\"images/ENDO/50252_PTH_and_calcium.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serum PTH concentrations according to the serum total calcium concentration in various disease states. The normal range is shown in the white box. The sigmoidal curve (green stars) is derived from a calcium citrate infusion protocol administered to 38 normal subjects. Serum PTH and calcium values are low in hypoparathyroidism (open blue boxes) and high in primary hyperparathyroidism (blue squares). The serum calcium concentration is high and serum PTH is appropriately low in patients with non-PTH-induced hypercalcemia of malignancy (red circles).</div><div class=\"graphic_footnotes\">PTH: parathyroid hormone.</div><div class=\"graphic_reference\">Data from: Haden ST, Brown EM, Hurwitz S, et al. The effects of age and gender on parathyroid hormone dynamics. Clin Endocrinol 2000; 52:329.</div><div id=\"graphicVersion\">Graphic 50252 Version 3.0</div></div></div>"},"50253":{"type":"graphic_figure","displayName":"T and DHT in 5-alpha-reductase 2 deficiency","title":"Testosterone and DHT in 5-alpha-reductase 2 deficiency","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Testosterone and DHT in 5-alpha-reductase 2 deficiency</div><div class=\"cntnt\"><img style=\"width:550px; height:310px;\" src=\"images/ENDO/50253_TandDHT5AR2deficiency.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The effects of hCG and&nbsp;T administration on serum T and DHT concentrations and their ratio in subjects with steroid 5-alpha-reductase 2 deficiency. Serum hormones were measured in the basal state, 96 hours after the administration of hCG, and 48 hours after the administration of mixed testosterone esters. Patient values are the red circles, the green areas represent the results (±1 SD) in eight normals, and the blue areas the results in seven hypogonadal men on T replacement. Serum DHT is lower and the T/DHT ratio higher in the patients with 5-alpha-reductase 2 deficiency.</div><div class=\"graphic_footnotes\">DHT: dihydrotestosterone; hCG: human chorionic gonadotropin; T: testosterone; SD: standard deviation.</div><div class=\"graphic_reference\">Data from: Mendonca BB, Inacio M, Costa EM, et al. Male pseudohermaphroditism due to steroid 5alpha-reductase 2 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore)&nbsp;1996; 75:64.</div><div id=\"graphicVersion\">Graphic 50253 Version 5.0</div></div></div>"},"50254":{"type":"graphic_picture","displayName":"Biopsy eosinophil gastroent","title":"Eosinophilic gastroenteritis","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Eosinophilic gastroenteritis</div><div class=\"cntnt\"><img style=\"width:470px; height:351px;\" src=\"images/GAST/50254_Biopsy_eosinophil_gastroent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of a gastric mucosal biopsy of a patient with eosinophilic gastroenteritis with chronic nausea, vomiting, and early satiety. Gastric biopsy reveals intense infiltration of pink eosinophils in the lamina propria characteristic of eosinophilic gastritis.</div><div class=\"graphic_reference\">Courtesy of Calman Prussin, MD.</div><div id=\"graphicVersion\">Graphic 50254 Version 1.0</div></div></div>"},"50257":{"type":"graphic_figure","displayName":"Vertebral and spinal column","title":"Longitudinal organization of spinal cord, spinal nerves, and vertebrae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Longitudinal organization of spinal cord, spinal nerves, and vertebrae</div><div class=\"cntnt\"><img style=\"width:439px; height:618px;\" src=\"images/NEURO/50257_Vertebral_and_spinal_column.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 50257 Version 2.0</div></div></div>"},"50259":{"type":"graphic_diagnosticimage","displayName":"Osteomyelitis progression","title":"Progression of radiographic findings in a 6-year-old boy with osteomyelitis of the fibula","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Progression of radiographic findings in a 6-year-old boy with osteomyelitis of the fibula</div><div class=\"cntnt\"><img style=\"width:468px; height:502px;\" src=\"images/PEDS/50259_Osteomyelitis_progression.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Plain radiographs (after one week of swelling and pain in the calf) were initially interpreted as normal.<br />(B) A plain radiograph obtained four days after the initial films demonstrates periosteal reaction and cortical thickening.<br />(C) T1 weighted magnetic resonance image with gadolinium demonstrates enhancement of the fibula marrow space and surrounding soft tissues.</div><div class=\"graphic_reference\">Courtesy of Marvin B Harper, MD.</div><div id=\"graphicVersion\">Graphic 50259 Version 3.0</div></div></div>"},"50261":{"type":"graphic_diagnosticimage","displayName":"T2 rectal cancer EUS","title":"Rectal cancer seen on endoscopic ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rectal cancer seen on endoscopic ultrasound</div><div class=\"cntnt\"><img style=\"width:378px; height:270px;\" src=\"images/GAST/50261_T2_rectal_cancer_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic ultrasound image of a T2 rectal cancer with invasion of muscularis propria (arrow).</div><div class=\"graphic_reference\">Courtesy of Gavin C Harewood, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 50261 Version 3.0</div></div></div>"},"50262":{"type":"graphic_figure","displayName":"Hanks dilators","title":"Hanks cervical dilators","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hanks cervical dilators</div><div class=\"cntnt\"><img style=\"width:426px; height:201px;\" src=\"images/OBGYN/50262_Hanksdilators.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These dilators are sized for progressive cervical dilation.</div><div id=\"graphicVersion\">Graphic 50262 Version 1.0</div></div></div>"},"50265":{"type":"graphic_picture","displayName":"Double pigtail ureteral stent","title":"Double pigtail ureteral stent","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Double pigtail ureteral stent</div><div class=\"cntnt\"><img style=\"width:504px; height:194px;\" src=\"images/SURG/50265_Uret_pigtail.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ureteral stents are hollow tubes with multiple sideholes. The curls of the double pigtail stent are positioned in the renal pelvis proximally and bladder distally to limit stent migration.</div><div id=\"graphicVersion\">Graphic 50265 Version 3.0</div></div></div>"},"50266":{"type":"graphic_picture","displayName":"Endoscopic image of a transampullary plastic stent","title":"Endoscopic image of a transampullary plastic stent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic image of a transampullary plastic stent</div><div class=\"cntnt\"><img style=\"width:396px; height:298px;\" src=\"images/GAST/50266_Endo_img_transamp_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic image of a transampullary straight (Amsterdam) plastic stent.</div><div class=\"graphic_reference\">Courtesy of Douglas G. Adler, MD, FACG, FASGE.</div><div id=\"graphicVersion\">Graphic 50266 Version 1.0</div></div></div>"},"50267":{"type":"graphic_diagnosticimage","displayName":"Type III bipartite patella","title":"Type III bipartite patella","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Type III bipartite patella</div><div class=\"cntnt\"><img style=\"width:464px; height:466px;\" src=\"images/EM/50267_Type_3_bipartite_patella.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The smooth, regularly spaced separation between the main patella and unfused secondary ossification center is shown here (arrow).</div><div class=\"graphic_reference\">Courtesy of Jim Blount, MD.</div><div id=\"graphicVersion\">Graphic 50267 Version 3.0</div></div></div>"},"50268":{"type":"graphic_figure","displayName":"Genotype urine excretion T","title":"Genotype urine excretion of testosterone","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Genotype urine excretion of testosterone</div><div class=\"cntnt\"><img style=\"width:500px; height:349px;\" src=\"images/ENDO/50268_Genotype_urine_excret_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Men who have two copies of the gene uridine diphosphoglucuronosyl transferase (ins/ins) have much higher urinary excretion of testosterone glucuronide in the two weeks after a single 500 mg dose of testosterone enanthate than those with only a single copy (ins/del) or no copy (del/del). Because the glucuronidation of epitestosterone is not affected by this deletion, the testosterone/epitestosterone ratio also is lower in those with one or no copies of the gene than in those with two copies.</div><div class=\"graphic_reference\">Reproduced with permission from: Schulze JJ, Lundmark J, Garle M, et al. Doping Test Results Dependent on Genotype of UGT2B17, the Major Enzyme for Testosterone Glucuronidation. J Clin Endocrinol Metab 2008. Copyright &#169; 2008 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 50268 Version 7.0</div></div></div>"},"50271":{"type":"graphic_table","displayName":"Treatment of TB in children","title":"Treatment of tuberculosis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of tuberculosis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diagnostic category</td> <td class=\"subtitle1\" colspan=\"2\">Regimen<br /> (daily or three times weekly)*</td> </tr> <tr> <td class=\"subtitle2_left\">New cases</td> <td class=\"subtitle2_left\">Intensive phase</td> <td class=\"subtitle2_left\">Continuation phase</td> </tr> <tr> <td class=\"indent1\"> <p>New smear-positive pulmonary TB</p> <p>New smear-negative pulmonary TB with extensive parenchymal involvement</p> <p>Severe forms of extrapulmonary TB (not including meningitis or osteoarticular disease)</p> Severe concomitant HIV disease</td> <td> <p>INH</p> <p>RIF</p> <p>PZA</p> <p>EMB</p> (2 months)</td> <td> <p>INH</p> <p>RIF</p> (4 months)</td> </tr> <tr> <td class=\"indent1\">TB meningitis (see text)</td> <td> <p>INH<sup>&#182;</sup></p> <p>RIF</p> <p>PZA</p> <p>SM or AM or Eto</p> (2 months)</td> <td> <p>INH</p> <p>RIF</p> (7 to 10 months)<sup>[1]</sup></td> </tr> <tr> <td class=\"indent1\">Osteoarticular TB</td> <td> <p>INH<sup>&#182;</sup></p> <p>RIF</p> <p>PZA</p> <p>EMB</p> (2 months)</td> <td> <p>INH</p> <p>RIF</p> (7 to 10 months)<sup>[1]</sup></td> </tr> <tr> <td class=\"indent1\"> <p>New smear-negative pulmonary TB (other than above categories)</p> Less severe forms of extrapulmonary TB</td> <td> <p>INH<sup>&#916;</sup></p> <p>RIF</p> <p>PZA</p> (2 months)</td> <td> <p>INH</p> <p>RIF</p> (4 months)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Previously treated cases</td> </tr> <tr> <td class=\"indent1\">Smear-positive pulmonary TB <ul class=\"decimal_heading\"> <li>Relapse </li> <li>Treatment after interruption </li> <li>Treatment failure </li> </ul> </td> <td> <p>INH</p> <p>RIF</p> <p>PZA</p> <p>EMB</p> <p>SM</p> <p>(2 months)</p> <hr /> <p><strong>Followed by</strong></p> <p>INH</p> <p>RIF</p> <p>PZA</p> <p>EMB</p> (1 month)</td> <td> <p>INH</p> <p>RIF</p> <p>EMB</p> (5 months)</td> </tr> <tr> <td class=\"indent1\">Chronic and MDR-TB</td> <td colspan=\"2\">Individualized regimens</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TB: tuberculosis; INH: isoniazid; RIF: rifampin (rifampicin); PZA: pyrazinamide; EMB: ethambutol; SM: streptomycin; AM: amikacin; Eto: ethionomide; HIV: human immunodeficiency virus; MDR-TB: multidrug-resistant TB.<br />* Direct observation of drug administration is recommended. Intermittent therapy (two or three times weekly) is not recommended for children with HIV infection.<br />¶&nbsp;For treatment of meningitis, EMB is replaced by SM or Am or Eto. The decision about which drug to use may be guided by drug susceptibility data of the index case if available or country-level rates of specific drug resistance.<br />Δ&nbsp;EMB may be omitted during the initial phase of treatment for patients in the following categories: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Patients with non-cavitary, smear-negative pulmonary TB and known to be HIV negative</LI>&#xD;&#xA;<LI>Patients known to be infected with fully drug-susceptible bacilli</LI></UL></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Rapid Advice: Treatment of tuberculosis in children. World Health Organization, Geneva, 2010. (WHO/HTM/TB/2010.13).</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: World Health Organization, Childhood TB Subgroup. Guidance for national tuberculosis programmes on the management of tuberculosis in children, Geneva. Available at http://whqlibdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf. Copyright &copy; 2006 World Health Organization.</div><div id=\"graphicVersion\">Graphic 50271 Version 6.0</div></div></div>"},"50273":{"type":"graphic_picture","displayName":"Tubular carcinoma of the breast","title":"Tubular carcinoma of the breast","html":"<div class=\"graphic\"><div style=\"width: 609px\" class=\"figure\"><div class=\"ttl\">Tubular carcinoma of the breast</div><div class=\"cntnt\"><img style=\"width:589px; height:238px;\" src=\"images/ONC/50273_TubularbreastcaLight.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Low-power view of a tubular breast carcinoma shows that the tumor is composed of well-formed glands or tubules that invade the mammary stroma.<br />(Panel B) High-power view demonstrates that the tubules are composed of columnar cells with relatively uniform nuclei. Many of the cells show \"snouts\" of eosinophilic cytoplasm at their lumenal ends.</div><div class=\"graphic_reference\">Courtesy of Stuart Schnitt, MD.</div><div id=\"graphicVersion\">Graphic 50273 Version 4.0</div></div></div>"},"50274":{"type":"graphic_figure","displayName":"Metaphyseal corner (or bucket handle) fracture","title":"Metaphyseal corner (or bucket handle) fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metaphyseal corner (or bucket handle) fracture</div><div class=\"cntnt\"><img style=\"width:360px; height:492px;\" src=\"images/PEDS/50274_Metaphyseal_chip_frctr_Ed1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagrammatic representation of the classic metaphyseal fracture of child abuse, a metaphyseal corner (or bucket handle) fracture through the subphyseal region of the metaphysis.</div><div id=\"graphicVersion\">Graphic 50274 Version 2.0</div></div></div>"},"50275":{"type":"graphic_table","displayName":"Drug psychosis","title":"Drug toxicity and acute psychosis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug toxicity and acute psychosis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type of toxicity</td> <td class=\"subtitle1\">Substance</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Drug overdose or abuse*</td> <td>Anticholinergic agents (eg, atropine, diphenhydramine, scopolamine)</td> </tr> <tr> <td>Hallucinogens (eg, LSD, PCP, dextromethorphan, ketamine)</td> </tr> <tr> <td>Marijuana</td> </tr> <tr> <td>Salvia divinorum</td> </tr> <tr> <td class=\"divider_bottom\">Sympathomimetic agents (eg, cocaine, metamphetamine, ecstasy)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Drug related syndrome</td> <td>Baclofen withdrawal</td> </tr> <tr> <td>Benzodiazepine (sedative) withdrawal</td> </tr> <tr> <td>Neuroleptic malignant syndrome (typical and atypical antipsychotic agents)<sup>&#182;</sup></td> </tr> <tr> <td class=\"divider_bottom\">Serotonergic agents (serotonin syndrome)<sup>&#182;</sup></td> </tr> <tr> <td rowspan=\"4\">Drug induced psychosis<sup>&#182;</sup></td> <td>Antibiotic-induced mania (amoxicillin, clarithromycin, erythromycin)</td> </tr> <tr> <td>Anticonvulsants</td> </tr> <tr> <td>Corticosteroids</td> </tr> <tr> <td>Isoniazid</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LSD: lysergic acid diethylamide; PCP: phencyclidine.<br />* Most common.<br />&para; Psychosis associated with regular daily dosing of medication or medication class.</div><div id=\"graphicVersion\">Graphic 50275 Version 2.0</div></div></div>"},"50278":{"type":"graphic_table","displayName":"Infertility evaluation - history","title":"Infertility evaluation - history","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infertility evaluation - history</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Male </td> <td class=\"subtitle1\">Female </td> </tr> <tr> <td>Duration of infertility</td> <td>Duration of infertility</td> </tr> <tr> <td>Fertility in other relationships</td> <td>Number and outcome of any prior pregnancies (including ectopic and miscarriages) with the same or a different partner</td> </tr> <tr> <td rowspan=\"4\">Medical and surgical history, including testicular surgery and history of mumps </td> <td>Gynecologic history, including history of pelvic inflammatory disease, fibroids, endometriosis, cervical dysplasia; surgery of the cervix, ovary, uterus, fallopian tube, pelvis, or abdomen; intrauterine device use, other prior contraceptive use, diethylstilbestrol exposure in utero, uterine anomalies.</td> </tr> <tr> <td>Menstrual history (age at menarche, cycle length, and regularity), presence of molimina or vasomotor symptoms (hot flashes), dysmenorrhea</td> </tr> <tr> <td>Changes in hair growth, body weight, or breast discharge</td> </tr> <tr> <td>Other medical and surgical history</td> </tr> <tr> <td>Medications</td> <td>Medications</td> </tr> <tr> <td>History of chemotherapy or radiation</td> <td>History of chemotherapy or radiation</td> </tr> <tr> <td>Cigarette smoking, alcohol, marijuana and other drug use; environmental and occupational exposures</td> <td>Cigarette smoking, alcohol, marijuana and other drug use; environmental and occupational exposures</td> </tr> <tr> <td>Sexual dysfunction or impotence</td> <td>Exercise and dietary history</td> </tr> <tr> <td>Frequency of intercourse, use of lubricants (which may be toxic to sperm)</td> <td>Frequency of intercourse, use of lubricants (which may be toxic to sperm). Presence of deep dyspareunia suggestive of endometriosis.</td> </tr> <tr> <td>Previous infertility testing and therapies</td> <td>Previous infertility testing and therapies</td> </tr> <tr> <td>Family history of birth defects, mental retardation, or reproductive failure</td> <td>Family history of birth defects, mental retardation, or reproductive failure</td> </tr> <tr> <td>&nbsp;</td> <td>Pelvic or abdominal pain, symptoms of thyroid disease</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50278 Version 3.0</div></div></div>"},"50281":{"type":"graphic_table","displayName":"Complement and disease","title":"Role of complement in pathologic conditions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Role of complement in pathologic conditions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Complement profile</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td>Immune complex syndromes</td> <td> <p>Decreased CH50, C4, C3, and other components of classical pathway.*</p> <p>Immune complexes are often present in substantial quantities and activate the classical pathway. Tissue damage is partly mediated by complement.</p> </td> <td> <p>SLE, anti-cardiolipin syndrome, Sjogren's syndrome, MCTD, vasculitis, mixed cryoglobulinemia, serum sickness, some glomerulonephritides including post-streptococcal nephritis.</p> <p><span style=\"color: #ff0000;\"></span></p> </td> </tr> <tr> <td rowspan=\"5\">Autoantibody (IgG/IgM) binds to a plasma or membrane protein </td> <td rowspan=\"5\"> <p>Classical pathway activation profile similar to immune complex syndromes but serum levels usually normal (synthesis matches modest increase in catabolism).</p> <p>Complement activation is noted by the presence of C1q, C4, C3, and C5-9 at sites where the autoantibody is bound. IgM and IgG activate the classical pathway. Complement participates in local tissue damage at sites of antibody binding.</p> </td> <td>Neurologic: Anti-nerve sheath, some demyelinating syndromes, myasthenia gravis.</td> </tr> <tr> <td>Endocrinologic: Thyroiditis, adrenalitis, insulitis.</td> </tr> <tr> <td>Dermatologic: Bullous skin diseases, urticarial vasculitis.</td> </tr> <tr> <td>Renal: Anti-GBM disease (Goodpasture's syndrome), forms of glomerulonephritis.</td> </tr> <tr> <td>Hematologic: Autoimmune hemolytic anemia, immune thrombocytopenic purpura.</td> </tr> <tr> <td>Altered self (tissue injury and debris deposition)</td> <td>Normal serum levels. Deposition in tissue detected by immunofluorescence: Multiple pathways may be activated depending upon the nature of the debris.</td> <td>Acne, Alzheimer disease, ARDS, asthma, atheroma, inflammatory bowel disease, multiple sclerosis, myositis, preeclampsia, porphyrias, psoriasis, sarcoidosis, SSPE, vitiligo, AMD, hemolytic uremic syndrome.</td> </tr> <tr> <td>Foreign materials</td> <td>Alternative pathway activation with elevated C3a and C5a.</td> <td>Dialysis membrane, heart-lung bypass, some contrast dye reactions, foreign bodies.</td> </tr> <tr> <td>Ischemia reperfusion injury</td> <td>Both classical and alternative pathway activation deposits at sites of ischemia.</td> <td>Myocardial infarction, stroke, ischemic muscle, traumatic injury.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SLE: systemic lupus erythematosus; MCTD: mixed connective tissue disease; IgG: immunoglobulin G; IgM: immunoglobulin M; GBM: glomerular basement membrane; ARDS: acute respiratory distress syndrome;&nbsp;SSPE: subacute sclerosing panencephalitis;&nbsp;AMD: age-related macular degeneration.<br />* C4 may be low and C3 in normal range with classical pathway activation in SLE, mixed cryoglobulinemia, and&nbsp;membranoproliferative glomerulonephritis (MPGN)&nbsp;types I and II. The explanation for this is the formation of the C3 convertase is inefficient in plasma, such as on soluble immune complexes.</div><div id=\"graphicVersion\">Graphic 50281 Version 7.0</div></div></div>"},"50283":{"type":"graphic_figure","displayName":"Transabdominal preperitoneal hernia repair","title":"Transabdominal preperitoneal hernia repair","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Transabdominal preperitoneal hernia repair</div><div class=\"cntnt\"><img style=\"width:504px; height:444px;\" src=\"images/SURG/50283_TAPP_mesh_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Repair of a right inguinal hernia. Mesh fixation below the iliopubic tract is medial to the epigastric vessels and spermatic cord.</div><div class=\"graphic_reference\">Reproduced with permission from: Jones DB, Maithel SK, Schneider BE. Atlas of minimally invasive surgery. Ciné-Med, Woodbury, CT 2006. Copyright © 2006 Ciné-Med, Inc.</div><div id=\"graphicVersion\">Graphic 50283 Version 10.0</div></div></div>"},"50284":{"type":"graphic_picture","displayName":"Mastocytoma extremity","title":"Solitary cutaneous mastocytoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Solitary cutaneous mastocytoma</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/50284_Mastocytoma_extremity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A solitary, tan plaque is present on this infant.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50284 Version 6.0</div></div></div>"},"50285":{"type":"graphic_picture","displayName":"Elevated plaque with clearing","title":"Elevated plaque with clearing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Elevated plaque with clearing</div><div class=\"cntnt\"><img style=\"width:216px; height:238px;\" src=\"images/ID/50285_Elevated_plaque_with_cleari.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: A woman with fever and rash after African safari. Clin Infect Dis 2006; 43:609. Copyright &#169; 2006 University of Chicago.</div><div id=\"graphicVersion\">Graphic 50285 Version 1.0</div></div></div>"},"50288":{"type":"graphic_figure","displayName":"Cerebrovascular complications SCD","title":"Cerebrovascular complications with their locations in sickle cell disease","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Cerebrovascular complications with their locations in sickle cell disease</div><div class=\"cntnt\"><img style=\"width:538px; height:549px;\" src=\"images/PEDS/50288_Cerebrovasc_dis_sickle_cell.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cerebrovascular complications of the large and small vessels of the brain and their corresponding territories are shown. The most common complications are cerebral infarcts in major vessels and \"borderzone\" infarctions. Borderzone infarctions are most common in the areas between the middle and anterior cerebral arteries, and between the&nbsp;middle and posterior cerebral arteries. Fat embolism and venous side abnormalities are the least common lesions. Small white matter lesions visualized on magnetic resonance imaging can be seen in asymptomatic patients. Aneurysms can often multiply within the circle of Willis. </div><div class=\"graphic_footnotes\">ICA: internal carotid artery; MCA: middle cerebral artery; ACA: anterior cerebral artery;&nbsp;MRI: magnetic resonance imaging; BA: basilar artery.</div><div class=\"graphic_reference\">Modified from: Adams RJ. Neurologic complications. In: Sickle Cell Disease: Basic Principles and Clinical Practice, Embury SH, Robert P, Hebbel RP, et al (Eds), Raven Press, New York 1994.</div><div id=\"graphicVersion\">Graphic 50288 Version 3.0</div></div></div>"},"50289":{"type":"graphic_picture","displayName":"Congenital lip pits","title":"Lip pits in a child with van der Woude syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lip pits in a child with van der Woude syndrome</div><div class=\"cntnt\"><img style=\"width:380px; height:277px;\" src=\"images/PEDS/50289_Congenitallippits.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the bilateral, paramedian depressions in the lip mucosa. They contain salivary tissue and often secrete mucus.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 50289 Version 4.0</div></div></div>"},"50290":{"type":"graphic_picture","displayName":"Keratosis pilaris 2","title":"Keratosis pilaris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Keratosis pilaris</div><div class=\"cntnt\"><img style=\"width:396px; height:271px;\" src=\"images/PC/50290_Keratosis_pilaris_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acne-like lesions are seen on the upper outer arms.</div><div class=\"graphic_reference\">Reproduced with permission: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169;2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50290 Version 1.0</div></div></div>"},"50291":{"type":"graphic_table","displayName":"Clincial features of ZES","title":"Clinical features associated with peptic ulcer disease in patients with gastrinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features associated with peptic ulcer disease in patients with gastrinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical presentation</td> </tr> <tr> <td>Esophageal reflux disease, especially when severe</td> </tr> <tr> <td>Association with diarrhea, steatorrhea, or weight loss (due to the high rate of acid secretion and secondary disruption of digestion enzyme and absorptive function)</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical findings</td> </tr> <tr> <td>Multiple ulcers</td> </tr> <tr> <td>Peptic ulcers in <em>Helicobacter pylori</em>-negative, NSAID-negative subjects</td> </tr> <tr> <td>Ulcers beyond the duodenal bulb</td> </tr> <tr> <td>Increased gastric folds on upper GI series or endoscopy</td> </tr> <tr> <td>Findings suggestive of&nbsp;multiple endocrine neoplasia type I (see Family history)</td> </tr> <tr> <td class=\"subtitle1_single\">Family history</td> </tr> <tr> <td>Extensive family history of ulcer disease</td> </tr> <tr> <td class=\"sublist1_start\">Family history or other findings suggestive of multiple endocrine neoplasia type I</td> </tr> <tr> <td class=\"sublist1\">Hypercalcemia or nephrolithiasis due to primary hyperparathyroidism</td> </tr> <tr> <td class=\"sublist1\">Hypoglycemia due to insulinoma</td> </tr> <tr> <td class=\"sublist1\">Functioning or nonfunctioning pituitary tumor</td> </tr> <tr> <td class=\"sublist1\">Diarrhea due to VIPoma</td> </tr> <tr> <td class=\"subtitle1_single\">Natural history and response to treatment</td> </tr> <tr> <td>Ulcers resistant to medical therapy</td> </tr> <tr> <td>Frequent recurrences</td> </tr> <tr> <td>Ulcer recurrences after surgical treatment</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAID: nonsteroidal antiinflammatory drug; GI: gastrointestinal.</div><div id=\"graphicVersion\">Graphic 50291 Version 4.0</div></div></div>"},"50292":{"type":"graphic_table","displayName":"ESWL complications","title":"Side effects after ESWL and endoscopy for pancreatic stones","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Side effects after ESWL and endoscopy for pancreatic stones</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Author (year)</td> <td class=\"subtitle1\" rowspan=\"2\">Number of patients</td> <td class=\"subtitle1\" colspan=\"2\">Morbidity</td> <td class=\"subtitle1\" rowspan=\"2\">Hospital mortality (percent)</td> <td class=\"subtitle1\" rowspan=\"2\">Late mortality (percent)</td> </tr> <tr> <td class=\"subtitle2\">Overall (percent)</td> <td class=\"subtitle2\">AP (percent)</td> </tr> <tr> <td>Delhaye 1992</td> <td>123</td> <td>23</td> <td>4</td> <td>0</td> <td>1.7</td> </tr> <tr> <td>Sauerbruch 1992</td> <td>24</td> <td>&ndash;</td> <td>8</td> <td>0</td> <td>&ndash;</td> </tr> <tr> <td>Schneider 1994</td> <td>50</td> <td>14</td> <td>&ndash;</td> <td>0</td> <td>4</td> </tr> <tr> <td>Johanns 1996</td> <td>35</td> <td>23</td> <td>9</td> <td>0</td> <td>&ndash;</td> </tr> <tr> <td>Ohara 1996</td> <td>32</td> <td>25</td> <td>12.5</td> <td>0</td> <td>&ndash;</td> </tr> <tr> <td>Costamagna 1997</td> <td>35</td> <td>23</td> <td>&ndash;</td> <td>0</td> <td>3</td> </tr> <tr> <td>Adamek 1999</td> <td>80</td> <td>17.5</td> <td>0</td> <td>0</td> <td>6</td> </tr> <tr> <td>Brand 2000</td> <td>48</td> <td>10.5</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>Kozarek 2002</td> <td>40</td> <td>20</td> <td>2.5</td> <td>0</td> <td>10</td> </tr> <tr> <td>Inui 2005</td> <td>555</td> <td>6.3</td> <td>5.4</td> <td>0.2</td> <td>3.2</td> </tr> <tr> <td>Tadenuma 2005</td> <td>117</td> <td>8.5</td> <td>6</td> <td>0</td> <td>11.5</td> </tr> <tr> <td>Ong 2006</td> <td>250</td> <td>5.6</td> <td>0</td> <td>0</td> <td>&ndash;</td> </tr> <tr> <td>Tandan 2010</td> <td>1006</td> <td>&ndash;</td> <td>2.9</td> <td>0</td> <td>&ndash;</td> </tr> <tr> <td>Suzuki 2013</td> <td>479</td> <td>6.1</td> <td>2.7</td> <td>0</td> <td>&ndash;</td> </tr> <tr> <td>Li 2014</td> <td>634</td> <td>6.7</td> <td>4.4</td> <td>0</td> <td>&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ESWL: extracorporeal shock wave lithotripsy; AP: clinical attack of acute pancreatitis.</div><div id=\"graphicVersion\">Graphic 50292 Version 6.0</div></div></div>"},"50295":{"type":"graphic_table","displayName":"DSM-5 diagnostic criteria for other substance use disorder","title":"DSM-5 diagnostic criteria for other (or unknown) substance use disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-5 diagnostic&nbsp;criteria for other (or unknown) substance use disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td class=\"indent1\">A problematic pattern of use of an intoxicating substance not able to be classified within the alcohol; caffeine; cannabis; hallucinogen (phencyclidine and others); inhalant; opioid; sedative, hypnotic, or anxiolytic; stimulant; or tobacco categories and leading to clinically significant impairment or distress, as manifested by at least two of the following, occurring within a 12-month period: <ol class=\"decimal_heading\"> <li>The substance is often taken in larger amounts or over a longer period than was intended. </li> <li>There is a persistent desire or unsuccessful efforts to cut down or control use of the substance. </li> <li>A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects. </li> <li>Craving, or a strong desire or urge to use the substance. </li> <li>Recurrent use of the substance resulting in a failure to fulfill major role obligations at work, school, or home. </li> <li>Continued use of the substance despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of its use. </li> <li>Important social, occupational, or recreational activities are given up or reduced because of use of the substance. </li> <li>Recurrent use of the substance in situations in which it is physically hazardous. </li> <li>Use of the substance is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. </li> <li>Tolerance, as defined by either of the following: <p class=\"indent2\">a. A need for markedly increased amounts of the substance to achieve intoxication or desired effect.</p> <p class=\"indent2\">b. A markedly diminished effect with continued use of the same amount of the substance.</p> </li> <li>Withdrawal, as manifested by either of the following: <p class=\"indent2\">a. The characteristic withdrawal syndrome for other (or unknown) substance (refer to Criteria A and B of the criteria sets for other [or unknown] substance withdrawal, p. 583).</p> <p class=\"indent2\">b. The substance (or a closely related substance) is taken to relieve or avoid withdrawal symptoms.</p> </li> </ol> </td> </tr> <tr> <td class=\"subtitle2_single\">Specify if:</td> </tr> <tr> <td class=\"indent2\"><strong>In early remission:</strong> After full criteria for other (or unknown) substance use disorder were previously met, none of the criteria for other (or unknown) substance use disorder have been met for at least 3 months but for less than 12 months (with the exception that Criterion A4, \"Craving, or a strong desire or urge to use the substance,\" may be met).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><strong>In sustained remission:</strong> After full criteria for other (or unknown) substance use disorder were previously met, none of the criteria for other (or unknown) substance use disorder have been met at any time during a period of 12 months or longer (with the exception that Criterion A4, \"Craving, or a strong desire or urge to use the substance,\" may be met).</td> </tr> <tr> <td class=\"subtitle2_single\">Specify if:</td> </tr> <tr> <td class=\"indent2\"><strong>In a controlled environment:</strong> This additional specifier is used if the individual is in an environment where access to the substance is restricted.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Coding based on current severity:</strong> Note for ICD-1-CM codes: If an other (or unknown) substance intoxication, other (or unknown) substance withdrawal, or another other (or unknown) substance-induced mental disorder is present, do not use the codes below for other (or unknown) substance use disorder. Instead, the comorbid other (or unknown) substance use disorder is indicated in the 4th character of the other (or unknown) substance-induced disorder code (see the coding note for other (or unknown) substance intoxications, other (or unknown) substance withdrawal, or specific other (or unknown) substance-induced mental disorder). For example, if there is comorbid other (or unknown) substance-induced depressive disorder and other (or unknown) substance use disorder, only the other (or unknown) substance-induced depressive disorder code is given, with the 4th character indicating whether the comorbid other (or unknown) substance use disorder is mild, moderate, or severe: F19.14 for other (or unknown) substance use disorder with the other (or unknown) substance-induced depressive disorder or F19.24 for a moderate or severe other (or unknown) substance use disorder with other (or unknown) substance-induced depressive disorder.</td> </tr> <tr> <td class=\"subtitle2_single\">Specify current severity:</td> </tr> <tr> <td class=\"indent2\"><strong>305.9 (F19.1) Mild:</strong> Presence of 2&ndash;3 symptoms.</td> </tr> <tr> <td class=\"indent2\"><strong>304.9 (F19.2) Moderate:</strong> Presence of 4&ndash;5 symptoms.</td> </tr> <tr> <td class=\"indent2\"><strong>304.9 (F19.2) Severe:</strong> Presence of 6 or more symptoms.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright &copy; 2013). American Psychiatric Association. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 50295 Version 10.0</div></div></div>"},"50297":{"type":"graphic_diagnosticimage","displayName":"Extraarticular fracture of the first metacarpal","title":"Extraarticular fracture of the first metacarpal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extraarticular fracture of the first metacarpal</div><div class=\"cntnt\"><img style=\"width:264px; height:360px;\" src=\"images/EM/50297_First_metacarpal_fx_type_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior radiograph shows a type III fracture of the proximal first metacarpal with characteristic sparing of the articular surface. Significant shortening of the metacarpal is also apparent in this view.</div><div class=\"graphic_reference\">Courtesy of Kevin E&nbsp;Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 50297 Version 4.0</div></div></div>"},"50298":{"type":"graphic_figure","displayName":"Illustration of osteoblast and osteoclast formation","title":"Schematic illustration of the regulation of osteoblast and osteoclast formation by osteocytes","html":"<div class=\"graphic\"><div style=\"width: 589px\" class=\"figure\"><div class=\"ttl\">Schematic illustration of the regulation of osteoblast and osteoclast formation by osteocytes</div><div class=\"cntnt\"><img style=\"width:569px; height:317px;\" src=\"images/ENDO/50298_Illusosteoblastosteoclast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Increased production of sclerostin by osteocytes inhibits Wnt signaling and thereby suppresses the differentiation of osteoblasts from MSC. Osteocyte-derived RANKL, on the other hand, stimulates osteoclastogenesis from HSC. This allows osteocytes to independently alter the rate of remodeling and the balance between formation and resorption in response to mechanical needs or hormonal changes.</div><div class=\"graphic_footnotes\">MSC: mesenchymal stem cell; HSC: hematopoietic stem cell;&nbsp;OBs: osteoblasts; OC: osteoclast; RANKL: receptor activator of nuclear factor kappa-B ligand.</div><div class=\"graphic_reference\">Courtesy of Dr. Jinhu Xiong and Dr. Charles O'Brien, University of Arkansas for Medical Sciences.</div><div id=\"graphicVersion\">Graphic 50298 Version 3.0</div></div></div>"},"50299":{"type":"graphic_picture","displayName":"Chronic irritant contact dermatitis","title":"Chronic irritant contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic irritant contact dermatitis</div><div class=\"cntnt\"><img style=\"width:364px; height:272px;\" src=\"images/DERM/50299_Chronicirrcontdermat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ill-defined, dry, scaly patches with fissuring on the finger in a patient with chronic irritant contact dermatitis.</div><div class=\"graphic_reference\">Courtesy of Kulthanan K. Siriraj Hospital, Mahidol University, Bangkok, Thailand.</div><div id=\"graphicVersion\">Graphic 50299 Version 3.0</div></div></div>"},"50300":{"type":"graphic_picture","displayName":"Infantile myofibroma trunk","title":"Infantile myofibromatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infantile myofibromatosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/50300_Infantile_myofibroma_trunk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin-colored, firm nodules are present on the trunk.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50300 Version 4.0</div></div></div>"},"50301":{"type":"graphic_picture","displayName":"D latum egg iodine stain","title":"<em>Diphyllobothrium latum</em>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Diphyllobothrium latum</em></div><div class=\"cntnt\"><img style=\"width:369px; height:277px;\" src=\"images/ID/50301_D_latum_egg_iodine_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The egg of <EM>D. latum </EM>is visible in a stool specimen stained with iron.</div><div class=\"graphic_reference\">Figure contributed by Georgia Division of Public Health. http://www.dpd.cdc.gov/dpdx/HTML/ImageLibrary/Diphyllobrothiasis_il.html (Centers for Disease Control and Prevention, National Center for Infectious Diseases, Division of Parasitic Diseases. Public domain).</div><div id=\"graphicVersion\">Graphic 50301 Version 2.0</div></div></div>"},"50303":{"type":"graphic_table","displayName":"ABS guidelines prost brachyther","title":"American Brachytherapy Society criteria for permanent brachytherapy of the prostate: Contraindications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Brachytherapy Society criteria for permanent brachytherapy of the prostate: Contraindications</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical exclusion criteria</td> </tr> <tr> <td>Life expectancy &#60;5 years</td> </tr> <tr> <td>Large or poorly healed TURP defect</td> </tr> <tr> <td>Unacceptable operative risks</td> </tr> <tr> <td>Distant metastases</td> </tr> <tr> <td class=\"subtitle1_single\">Relative contraindications for brachytherapy</td> </tr> <tr> <td>These patients are not ideal candidates for brachytherapy but have nevertheless been successfully implanted. Beginners should not implant these patients.</td> </tr> <tr> <td class=\"subtitle2_single\">Patients at increased risk of developing complications</td> </tr> <tr> <td class=\"indent1\">Large median lobes</td> </tr> <tr> <td class=\"indent1\">Previous pelvic irradiation</td> </tr> <tr> <td class=\"indent1\">High AUA score</td> </tr> <tr> <td class=\"indent1\">History of multiple pelvic surgeries</td> </tr> <tr> <td class=\"indent1\">Severe diabetes with healing problems</td> </tr> <tr> <td class=\"subtitle2_single\">Technical difficulties that&nbsp;may result in inadequate dose coverage</td> </tr> <tr> <td class=\"indent1\">Previous TURP</td> </tr> <tr> <td class=\"indent1\">Gland size &#62;60 cc at time of implantation</td> </tr> <tr> <td class=\"indent1\">Prominent median lobe</td> </tr> <tr> <td class=\"indent1\">Positive seminal vesicles</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TURP: transurethral resection of the prostate; AUA: American Urological Association.</div><div class=\"graphic_reference\">Data from: Int J Radiat Oncol Biol Phys 1999; 44:790.</div><div id=\"graphicVersion\">Graphic 50303 Version 2.0</div></div></div>"},"50304":{"type":"graphic_table","displayName":"Paraneoplastic syndromes of the nervous system","title":"Paraneoplastic syndromes of the nervous system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Paraneoplastic syndromes of the nervous system</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Paraneoplastic syndromes of the central nervous system</td> </tr> <tr> <td class=\"indent1\">Encephalomyelitis*</td> </tr> <tr> <td class=\"indent1\">Myelitis*</td> </tr> <tr> <td class=\"indent1\">Limbic encephalitis*</td> </tr> <tr> <td class=\"indent1\">Brainstem encephalitis*</td> </tr> <tr> <td class=\"indent1\">Cerebellar degeneration*</td> </tr> <tr> <td class=\"indent1\">Opsoclonus myoclonus ataxia*</td> </tr> <tr> <td class=\"sublist2_start\">Visual syndromes</td> </tr> <tr> <td class=\"sublist2\">Cancer associated retinopathy*</td> </tr> <tr> <td class=\"sublist2\">Melanoma associated retinopathy*</td> </tr> <tr> <td class=\"sublist2\">Optic neuritis</td> </tr> <tr> <td class=\"indent1\">Necrotizing myelopathy</td> </tr> <tr> <td class=\"sublist2_start\">Motor neuron syndrome</td> </tr> <tr> <td class=\"sublist2\">Subacute motor neuronopathy</td> </tr> <tr> <td class=\"sublist2\">Other syndromes</td> </tr> <tr> <td class=\"indent1\">Stiff-person syndrome*</td> </tr> <tr> <td class=\"indent1\">Subacute sensory neuronopathy*</td> </tr> <tr> <td class=\"subtitle1_single\">Paraneoplastic syndromes of the peripheral nervous system</td> </tr> <tr> <td class=\"sublist2_start\">Chronic sensorimotor neuropathy</td> </tr> <tr> <td class=\"sublist2\">Association with plasma cell dyscrasias</td> </tr> <tr> <td class=\"sublist2_start\">Acute sensorimotor neuropathy</td> </tr> <tr> <td class=\"sublist2\">Guillain-Barr&#233; syndrome</td> </tr> <tr> <td class=\"sublist2\">Plexitis (eg, brachial neuritis)</td> </tr> <tr> <td class=\"indent1\">Autonomic neuropathy*</td> </tr> <tr> <td class=\"indent1\">Vasculitis of nerve and muscle</td> </tr> <tr> <td class=\"subtitle1_single\">Paraneoplastic syndromes of the neuromuscular junction and muscle</td> </tr> <tr> <td class=\"indent1\">Myasthenia gravis*</td> </tr> <tr> <td class=\"indent1\">Lambert-Eaton myasthenic syndrome*</td> </tr> <tr> <td class=\"indent1\">Dermatomyositis/polymyositis</td> </tr> <tr> <td class=\"indent1\">Neuromyotonia*</td> </tr> <tr> <td class=\"indent1\">Acute necrotizing myopathy</td> </tr> <tr> <td class=\"indent1\">Cachectic myopathy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Syndromes in which specific paraneoplastic markers have been identified in more than three patients. However, the absence of antibodies does not exclude a paraneoplastic etiology.</div><div id=\"graphicVersion\">Graphic 50304 Version 3.0</div></div></div>"},"50306":{"type":"graphic_waveform","displayName":"Intermediate case 21 answer","title":"Inferior MI with probable posterior involvement","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Inferior MI with probable posterior involvement</div><div class=\"cntnt\"><img style=\"width:492px; height:239px;\" src=\"images/CARD/50306_Intermediate_case_21_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram showing inferior myocardial infarction (Q waves and ST elevations in leads II, III, and aVF); with probable posterior extension (reciprocal ST depressions and tall R waves in leads V2 and V3). Reciprocal ST depressions are also seen in leads I and aVL.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 50306 Version 2.0</div></div></div>"},"50307":{"type":"graphic_table","displayName":"Causes of prerenal and intrinsic pediatric acute kidney injury","title":"Causes of prerenal and intrinsic pediatric acute kidney injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of prerenal and intrinsic pediatric acute kidney injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Mechanism</td> <td class=\"subtitle1\">Etiology</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Prerenal causes</td> </tr> <tr> <td class=\"indent1\">Decreased intravascular volume</td> <td>Dehydration, hemorrhage, diuretics, burns, shock, nephrotic syndrome</td> </tr> <tr> <td class=\"indent1\">Decreased cardiac function</td> <td>Heart failure, arrhythmias</td> </tr> <tr> <td class=\"indent1\">Peripheral vasodilatation</td> <td>Sepsis, anaphylaxis, antihypertensive medication</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Renal vasoconstriction</td> <td>Sepsis, nonsteroidal antiinflammatory drugs, ACE inhibitor</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Intrinsic causes</td> </tr> <tr> <td class=\"indent1\">Tubular injury (acute tubular necrosis)</td> <td>Prolonged ischemia, nephrotoxins, hypotension, sepsis</td> </tr> <tr> <td class=\"indent1\">Renal vascular diseases</td> <td>Hemolytic uremic syndrome, vasculitides, thrombosis</td> </tr> <tr> <td class=\"indent1\">Interstitial diseases</td> <td>Interstitial nephritis, infections, malignant infiltrations</td> </tr> <tr> <td class=\"indent1\">Glomerulonephritides</td> <td>Post-infectious glomerulonephritis, rapidly progressive glomerulonephritis, Henoch-Sch&#246;nlein purpura</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACE: angiotensin converting enzyme.</div><div id=\"graphicVersion\">Graphic 50307 Version 5.0</div></div></div>"},"50309":{"type":"graphic_diagnosticimage","displayName":"Crohn colitis ulcers BE","title":"Crohn colitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crohn colitis</div><div class=\"cntnt\"><img style=\"width:198px; height:288px;\" src=\"images/GAST/50309_Crohns_colitis_ulcers_BE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Double contrast barium enema in a patient with Crohn disease shows extensive ulceration of the wall of the colon associated with mucosal thickening and inflammation.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 50309 Version 3.0</div></div></div>"},"50310":{"type":"graphic_table","displayName":"Presentations of thrombocytopenia","title":"Common presentations of patients with thrombocytopenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common presentations of patients with thrombocytopenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Office presentation </td> </tr> <tr> <td class=\"subtitle2_single\">Asymptomatic, ISOLATED, incidentally-discovered thrombocytopenia </td> </tr> <tr> <td class=\"subtitle3_single\">Common </td> </tr> <tr> <td class=\"indent2\">Immune thrombocytopenia (ITP) </td> </tr> <tr> <td class=\"indent2\">Gestational thrombocytopenia during pregnancy</td> </tr> <tr> <td class=\"subtitle3_single\">Less common </td> </tr> <tr> <td class=\"indent2\">Occult liver disease </td> </tr> <tr> <td class=\"indent2\">Myelodysplastic syndrome </td> </tr> <tr> <td class=\"indent2\">Congenital thrombocytopenia </td> </tr> <tr> <td class=\"indent2\">HIV infection </td> </tr> <tr> <td class=\"subtitle2_single\">Symptomatic, severe thrombocytopenia </td> </tr> <tr> <td class=\"subtitle3_single\">Common </td> </tr> <tr> <td class=\"indent2\">Drug-induced thrombocytopenia </td> </tr> <tr> <td class=\"indent2\">Immune thrombocytopenia (ITP) </td> </tr> <tr> <td class=\"subtitle1_single\">Hospital presentation </td> </tr> <tr> <td class=\"subtitle2_single\">Thrombocytopenia as part of a multisystem illness </td> </tr> <tr> <td class=\"subtitle3_single\">Common </td> </tr> <tr> <td class=\"indent2\">Drug-induced thrombocytopenia</td> </tr> <tr> <td class=\"indent2\">Heparin-induced thrombocytopenia</td> </tr> <tr> <td class=\"indent2\">Liver disease </td> </tr> <tr> <td class=\"indent2\">Sepsis with disseminated intravascular coagulation (DIC) </td> </tr> <tr> <td class=\"indent2\">Cancer with DIC</td> </tr> <tr> <td class=\"sublist3_start\">Pregnancy </td> </tr> <tr> <td class=\"sublist3\">Preeclampsia </td> </tr> <tr> <td class=\"sublist3\">HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets) </td> </tr> <tr> <td class=\"sublist3\">Abruptio placentae with DIC</td> </tr> <tr> <td class=\"indent2\">Multi-organ failure syndromes </td> </tr> <tr> <td class=\"subtitle3_single\">Less common </td> </tr> <tr> <td class=\"indent2\">Thrombotic thrombocytopenic purpura (TTP, acquired or hereditary) </td> </tr> <tr> <td class=\"indent2\">&nbsp;Drug-induced thrombotic microangiopathy (DITMA)</td> </tr> <tr> <td class=\"indent2\">&nbsp;Hemolytic uremic syndrome (HUS)</td> </tr> <tr> <td class=\"indent2\">&nbsp;Lymphoma</td> </tr> <tr> <td class=\"indent2\">&nbsp;Acute leukemia</td> </tr> <tr> <td class=\"indent2\">&nbsp;Antiphospholipid syndrome</td> </tr> <tr> <td class=\"indent2\">&nbsp;Paroxysmal nocturnal hemoglobinuria (PNH)</td> </tr> <tr> <td class=\"indent2\">&nbsp;Nutrient deficiency (vitamin B12, folate, copper)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on thrombocytopenia for further details.</div><div id=\"graphicVersion\">Graphic 50310 Version 4.0</div></div></div>"},"50311":{"type":"graphic_figure","displayName":"Suprapubic aspiration technique","title":"Needle insertion technique for suprapubic aspiration","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Needle insertion technique for suprapubic aspiration</div><div class=\"cntnt\"><img style=\"width:508px; height:554px;\" src=\"images/PEDS/50311_Suprapubic_aspiration_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The needle is inserted one to two centimeters above the pubic symphysis and angled 10 to 20 degrees cephalad.</div><div class=\"graphic_reference\">Adapted from King C, Henreting FM. Pocket Atlas of Pediatric Emergency Procedures, Lippincott Williams and Wilkins, Philadelphia 2000.</div><div id=\"graphicVersion\">Graphic 50311 Version 4.0</div></div></div>"},"50315":{"type":"graphic_diagnosticimage","displayName":"MIBI SPECT images of parathyroid adenoma","title":"MIBI SPECT images of parathyroid adenoma","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">MIBI SPECT images of parathyroid adenoma</div><div class=\"cntnt\"><img style=\"width:463px; height:458px;\" src=\"images/SURG/50315_MIBI_SPECT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Anterior 10 min.<br />(B) Anterior delayed.<br />(C) SPECT.</div><div class=\"graphic_footnotes\">MIBI-SPECT: methoxyisobutyl isonitrile single-photon emission computed tomography; SPECT: single-photon emission computed tomography.</div><div class=\"graphic_reference\">Courtesy of Pierre J Sasson, MD.</div><div id=\"graphicVersion\">Graphic 50315 Version 6.0</div></div></div>"},"50316":{"type":"graphic_figure","displayName":"HPLC beta chain variants","title":"Beta chain hemoglobin variants on HPLC","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Beta chain hemoglobin variants on HPLC</div><div class=\"cntnt\"><img style=\"width:584px; height:451px;\" src=\"images/HEME/50316_HPLC_beta_chain_variants.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cation exchange HPLC patterns of beta chain variants. HbA, A2, A<sub>1C</sub>, A<sub>2</sub>, F, S, and C are highlighted.</div><div class=\"graphic_footnotes\">HPLC: high performance liquid chromatography.</div><div id=\"graphicVersion\">Graphic 50316 Version 2.0</div></div></div>"},"50318":{"type":"graphic_table","displayName":"DDx of syndromes after HCT","title":"Differential diagnosis of specific clinical syndromes after allogeneic hematopoietic cell transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of specific clinical syndromes after allogeneic&nbsp;hematopoietic cell transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Preengraftment, &#60;3 weeks</td> <td class=\"subtitle1\">Immediate postengraftment, 3 weeks to 3 months</td> <td class=\"subtitle1\">Late postengraftment, &#62;3 months</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">CNS manifestations</td> </tr> <tr> <td class=\"indent1\">Localized</td> <td>Bacteria, molds, <em>Candida</em> spp, stroke, drug toxicity</td> <td>Bacteria, toxoplasmosis, molds, tumor relapse, drug toxicity</td> <td>Bacteria, molds, PML, tumor relapse, drug toxicity, PRES</td> </tr> <tr> <td class=\"indent1\">Diffuse</td> <td>Bacteria, HSV, <em>Candida</em> spp, drug toxicity</td> <td>HHV-6, CMV, <em>Cryptococcus</em> spp, drug toxicity</td> <td>VZV, drug toxicity</td> </tr> <tr> <td>Ocular manifestations</td> <td><em>Candida</em> spp, molds</td> <td>CMV, <em>Pneumocystis jirovecii</em> (formerly <em>P. carinii</em>), toxoplasmosis</td> <td>VZV, CMV</td> </tr> <tr> <td>Sinusitis</td> <td>Bacteria, molds, respiratory viruses</td> <td>Bacteria, molds, respiratory viruses</td> <td>Bacteria, molds, respiratory viruses</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Mucositis, mucosal ulcerations</td> </tr> <tr> <td class=\"indent1\">Infectious</td> <td>HSV, <em>Candida</em> spp, agents of mucormycosis</td> <td>HSV, <em>Candida</em> spp, agents of mucormycosis, CMV (esophagitis), <em>Aspergillus</em> spp (small or large intestine)</td> <td>HSV, <em>Candida</em> spp, agents of mucormycosis, CMV (esophagitis), <em>Aspergillus</em> spp (small or large intestine)</td> </tr> <tr> <td class=\"indent1\">Other</td> <td>GVHD, drug toxicity</td> <td>GVHD, drug toxicity</td> <td>GVHD, drug toxicity</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Pneumonia</td> </tr> <tr> <td class=\"indent1\">Localized</td> <td>Bacteria, <em>Aspergillus</em> spp, other molds, pulmonary embolism, hemorrhage</td> <td>Bacteria, <em>Aspergillus</em> spp, other molds, <em>Nocardia</em> spp, TB, NTM, tumor relapse</td> <td>Bacteria, <em>Aspergillus</em> spp, other molds, <em>Nocardia </em>spp, VZV, EBV-associated PTLD, pulmonary calcinosis</td> </tr> <tr> <td class=\"indent1\">Diffuse</td> <td>Respiratory viruses, HSV, conditioning regimen, acute GVHD, pulmonary edema, radiation pneumonitis, alveolar hemorrhage, ARDS, hypersensitivity drug reaction, idiopathic interstitial pneumonitis, leukoagglutinin reaction, fluid overload, congestive heart failure</td> <td>CMV,<em>&nbsp;P. jirovecii</em>, respiratory viruses, <em>Legionella</em> spp, <em>Mycoplasma pneumoniae</em>, <em>Cryptococcus</em> spp, adenovirus, TB, NTM, acute GVHD, radiation pneumonitis, idiopathic interstitial pneumonitis, ARDS, hypersensitivity drug reaction, pulmonary VOD, congestive heart failure</td> <td>Chronic GVHD, EBV-associated lymphoma, ARDS, hypersensitivity drug reaction, alveolar proteinosis, radiation pneumonitis, idiopathic interstitial pneumonitis, COP (formerly BO or BOOP), congestive heart failure</td> </tr> <tr> <td>Esophagitis</td> <td><em>Candida</em> spp, HSV, drug toxicity</td> <td>CMV, drug toxicity, HSV</td> <td>Drug toxicity</td> </tr> <tr> <td>Diarrhea/colitis</td> <td>Bacteria (<em>Clostridium difficile</em>, <em>C. septicum</em>), neutropenic enterocolitis (typhlitis), drug toxicity, bleeding, infarction, enteroviruses</td> <td>Bacteria (<em>C. difficile</em>, <em>C. septicum</em>), CMV, enteroviruses, drug toxicity, acute GVHD, bleeding, infarction</td> <td>CMV, bacteria (<em>C. difficile</em>, <em>C. septicum</em>), enteroviruses, drug toxicity, acute or chronic GVHD, bleeding, infarction</td> </tr> <tr> <td>Hepatitis</td> <td>Bacteria, HSV, chronic disseminated candidiasis, hepatic SOS (formerly veno-occlusive disease), drug toxicity, acute GVHD, conditioning regimen</td> <td>HBV, HCV, HEV, EBV, HSV, CMV, HHV-6, <em>P. jirovecii</em>, chronic disseminated candidiasis (hepatosplenic candidiasis), SOS, drug toxicity, acute GVHD, conditioning regimen</td> <td>HBV, HCV, HEV, EBV, VZV, drug toxicity, chronic GVHD</td> </tr> <tr> <td>Hemorrhagic cystitis</td> <td>Adenovirus (rarely), cyclophosphamide toxicity</td> <td>BK virus, CMV, adenovirus, cyclophosphamide toxicity</td> <td>BK virus</td> </tr> <tr> <td>Nephritis</td> <td>Bacteria</td> <td>BK virus, CMV, adenovirus</td> <td>BK virus, JC virus</td> </tr> <tr> <td>Skin lesions</td> <td>Bacteria, HSV, <em>Candida</em> spp, molds, acute GVHD, drug toxicity</td> <td>Bacteria, <em>Candida</em> spp, molds, VZV, HHV-6, NTM, acute GVHD, drug toxicity</td> <td>VZV, molds, chronic GVHD, drug toxicity</td> </tr> <tr> <td>Bone marrow suppression</td> <td>CMV, HHV-6, graft failure, drug toxicity, acute GVHD</td> <td>CMV, HHV-6, graft failure, drug toxicity, acute GVHD</td> <td>Parvovirus, CMV, HHV-6, graft failure, drug toxicity, chronic GVHD</td> </tr> <tr> <td>Bloodstream infection</td> <td>Bacteria, <em>Candida</em> spp</td> <td>Bacteria (especially coagulase-negative staphylococci), <em>Candida</em> spp</td> <td><em>Streptococcus pneumoniae</em>, <em>Neisseria meningitidis</em></td> </tr> <tr> <td>Shock (including septic shock)</td> <td>Bacteria (eg, alpha-hemolytic streptococci, <em>Pseudomonas aeruginosa</em>), anaphylaxis, adrenal insufficiency, cardiovascular complications</td> <td>Same as for the preengraftment period</td> <td>Same as for the preengraftment period, <em>Streptococcus pneumoniae</em>, <em>Neisseria meningitidis</em></td> </tr> <tr> <td>Fever without localizing signs</td> <td>Bacterial sepsis, HSV, respiratory viruses, molds, chronic disseminated candidiasis, tumor fever, drug fever, adrenal insufficiency, acute GVHD, CVL-associated infection</td> <td>Bacterial sepsis, sinusitis, CMV, EBV, HHV-6, respiratory viruses, molds, chronic disseminated candidiasis, tumor fever, drug fever, acute GVHD, CVL-associated infection</td> <td>Bacterial sepsis, sinusitis, CMV, EBV, HHV-6, respiratory viruses, molds, chronic disseminated candidiasis, tumor fever, drug fever, chronic GVHD, pulmonary, cardiac, CVL-associated infection</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; PML: progressive multifocal leukoencephalopathy; PRES: posterior reversible encephalopathy syndrome; HSV: herpes simplex virus; HHV-6: human herpes virus 6; VZV: varicella-zoster virus; CMV: cytomegalovirus; GVHD: graft-versus-host disease; TB: tuberculosis; NTM: nontuberculous mycobacteria; EBV: Epstein-Barr virus; PTLD: post-transplant lymphoproliferative disease; ARDS: acute respiratory distress syndrome; VOD: veno-occlusive disease; COP: cryptogenic organizing pneumonia; BO: bronchiolitis obliterans; BOOP: bronchiolitis obliterans with organizing pneumonia; SOS: sinusoidal obstruction syndrome; HBV: hepatitis B virus; HCV: hepatitis C virus; HEV: hepatitis E virus; CVL: central venous line.</div><div id=\"graphicVersion\">Graphic 50318 Version 5.0</div></div></div>"},"50320":{"type":"graphic_picture","displayName":"Optic neuritis fundus","title":"Optic neuritis fundus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Optic neuritis fundus</div><div class=\"cntnt\"><img style=\"width:360px; height:341px;\" src=\"images/NEURO/50320_Optic_neuritis_fundus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papillitis: Note the absence of hemorrhages and exudates in the setting of optic neuritis.</div><div id=\"graphicVersion\">Graphic 50320 Version 1.0</div></div></div>"},"50321":{"type":"graphic_figure","displayName":"Neonatal BP gestational age","title":"Neonatal blood pressure based on gestational age","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Neonatal blood pressure based on gestational age</div><div class=\"cntnt\"><img style=\"width:460px; height:585px;\" src=\"images/PEDS/50321_Neonatal_BP_gestational_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear regression of mean systolic and diastolic blood pressure based&nbsp;on gestational age in 329 infants admitted to the neonatal intensive care unit (NICU) on day&nbsp;one of life. The mean systolic and diastolic blood pressure and 95 percent confidence limit (CL) for incremental gestational age are plotted about the respective regression lines.</div><div class=\"graphic_reference\">Adapted&nbsp;with permission from: Macmillan Publishers Ltd. Zubrow AB, Hulman S, Kushner H, Falkner B. Determinants of blood pressure in infants admitted to neonatal intensive care units: a prospective multicenter study. Philadelphia Neonatal Blood Pressure Study Group. J Perinatol 1995; 15:470. Copyright ©1995.</div><div id=\"graphicVersion\">Graphic 50321 Version 6.0</div></div></div>"},"50322":{"type":"graphic_waveform","displayName":"12-lead ECG left lateral WPW II","title":"12-lead electrocardiogram (ECG) of a left lateral accessory AV pathway","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) of a left lateral accessory AV pathway</div><div class=\"cntnt\"><img style=\"width:495px; height:281px;\" src=\"images/CARD/50322_Left_lateral_WPW_II.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram in sinus rhythm from a patient with Wolff-Parkinson-White syndrome shows a widened QRS complex which is not maximally preexcited. Although the delta wave and QRS are positive in lead I, the negative delta wave in lead aVL and the right bundle branch block morphology localize the accessory pathway to the left lateral mitral annulus.</div><div id=\"graphicVersion\">Graphic 50322 Version 3.0</div></div></div>"},"50323":{"type":"graphic_table","displayName":"Phototoxic and photoallergic reactions","title":"Differences between phototoxic and photoallergic reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differences between phototoxic and photoallergic reactions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Feature</td> <td class=\"subtitle1\">Phototoxicity</td> <td class=\"subtitle1\">Photoallergy</td> </tr> <tr> <td>Incidence</td> <td>High</td> <td>Low</td> </tr> <tr> <td>Amount of agent required for photosensitivity</td> <td>Large</td> <td>Small</td> </tr> <tr> <td>Onset after exposure to photosensitizer and light</td> <td>Minutes to hours</td> <td>24 hours or more</td> </tr> <tr> <td>Requirement for immunization</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Clinical characteristics</td> <td>Exaggerated sunburn</td> <td>Acute, subacute, or chronic dermatitis</td> </tr> <tr> <td>Distribution</td> <td>Exposed skin only</td> <td>Exposed skin; may spread to unexposed skin</td> </tr> <tr> <td>Pigmentary changes</td> <td>Frequent</td> <td>Unusual</td> </tr> <tr> <td>Histopathologic features</td> <td>Epidermal cell degeneration; dermal edema and vasodilatation; sparse mononuclear infiltrate</td> <td>Epidermal spongiosis; exocytosis of mononuclear cells; dermal mononuclear cell infiltrate</td> </tr> <tr> <td>Development of persistent light reaction</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Cross-reactions to related agents</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Covalent binding with carrier protein</td> <td>No</td> <td>Yes</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Gould JW, Mercurio MG, Elmets CA. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol 1995; 33:551. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 50323 Version 3.0</div></div></div>"},"50324":{"type":"graphic_table","displayName":"Atopic dermatitis differential diagnosis","title":"Differential diagnosis of severe atopic dermatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of severe atopic dermatitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Primary skin conditions</td> </tr> <tr> <td>Skin barrier dysfunction: Netherton syndrome, ichthyoses</td> </tr> <tr> <td>Inflammatory skin conditions: psoriasis, contact dermatitis (irritant or allergic)</td> </tr> <tr> <td class=\"subtitle1_single\">Primary immunodeficiencies and treatment complications</td> </tr> <tr> <td>Severe combined immunodeficiency</td> </tr> <tr> <td>Wiskott-Aldrich syndrome</td> </tr> <tr> <td>Hyper-IgE syndrome</td> </tr> <tr> <td>Graft-versus-host disease</td> </tr> <tr> <td class=\"subtitle1_single\">Primary metabolic conditions</td> </tr> <tr> <td>Mineral or vitamin deficiencies: zinc (acrodermatitis enteropathica), pyridoxine, and niacin</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td>Skin infections: HIV-associated, impetigo, seborrheic dermatitis</td> </tr> <tr> <td>Drug reactions</td> </tr> <tr> <td>Malignancies: cutaneous T cell lymphoma, Letterer-Siwe disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E;&nbsp;HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 50324 Version 2.0</div></div></div>"},"50325":{"type":"graphic_figure","displayName":"Electrophoresis Hgb H","title":"Electrophoresis for hemoglobin H: Alkaline cellulose acetate gel","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrophoresis for hemoglobin H: Alkaline cellulose acetate gel</div><div class=\"cntnt\"><img style=\"width:300px; height:401px;\" src=\"images/HEME/50325_Electrophoresis_hgb_H.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a hemoglobin electrophoresis run at alkaline pH on cellulose acetate gel. Lane 2 is a commercial standard containing approximately equal amounts of hemoglobins A, F, S, and C. Lane 1 is a hemoglobin sample from a patient with myelodysplastic syndrome/acute myeloid leukemia, a population of hypochromic-microcytic red cells, and acquired hemoglobin H disease. A minor fast-migrating band, hemoglobin H, is seen along with hemoglobin A.</div><div class=\"graphic_reference\">Kindly supplied by Dr. German Pihan, Department of Pathology, Beth Israel Deaconess Medical Center.</div><div id=\"graphicVersion\">Graphic 50325 Version 3.0</div></div></div>"},"50329":{"type":"graphic_diagnosticimage","displayName":"Autofluorescence recur lung CA","title":"Autofluorescence for recurrent cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Autofluorescence for recurrent cancer</div><div class=\"cntnt\"><img style=\"width:415px; height:200px;\" src=\"images/PULM/50329_Autofluorescence_recur_lung.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchoscopic images from a patient two years after lobectomy for adenocarcinoma. Left panel: White light bronchoscopy of the bronchial stump (arrow) appears normal. Right panel: Autofluorescence image from the same area is notable for lack of autofluorescence (arrow), suggesting local recurrence. Both images obtained using the STORZ system.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 50329 Version 2.0</div></div></div>"},"50331":{"type":"graphic_diagnosticimage","displayName":"2D TTE Parasternal short axis pap muscles","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the parasternal short axis view at the level of the papillary muscles and mitral valve","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the parasternal short axis view at the level of the papillary muscles and mitral valve</div><div class=\"cntnt\"><img style=\"width:525px; height:171px;\" src=\"images/CARD/50331_Parasternal_short_axis_TT2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parasternal short axis view from a transthoracic echocardiogram recorded in systole at the level of the papillary muscles (left) and&nbsp;mitral valve (right) shows the anterior and posterior leaflets.</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 50331 Version 3.0</div></div></div>"},"50336":{"type":"graphic_table","displayName":"Spinal cord disorders","title":"Important causes of spinal cord dysfunction*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important causes of spinal cord dysfunction*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Course</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Diagnosis</td> </tr> <tr> <td>Cervical spondylotic myelopathy</td> <td>Usually &#62;60 years</td> <td>Progressive or stepwise course</td> <td>Moderate-severe cases demonstrate gait and leg spasticity and amyotrophy of hand or arms</td> <td>MRI cervical spine</td> </tr> <tr> <td>Transverse myelitis</td> <td>Children, young adults</td> <td>Subacute</td> <td>Segmental cord syndrome</td> <td>MRI and CSF</td> </tr> <tr> <td>Viral myelitis</td> <td>Any age</td> <td>Acute-subacute</td> <td>Pure motor syndrome or Segmental cord syndrome</td> <td>MRI and CSF</td> </tr> <tr> <td>Epidural abscess</td> <td>Any age</td> <td>Subacute; may worsen abruptly</td> <td>Segmental cord syndrome</td> <td>MRI</td> </tr> <tr> <td>Infarction</td> <td>Usually &#62;60 years</td> <td>Abrupt onset</td> <td>Anterior cord syndrome</td> <td>MRI with diffusion weighted sequences</td> </tr> <tr> <td>Vascular malformation</td> <td> <p>&#62;40 years (dural fistula)</p> <p>20's (intramedullary AVM)</p> </td> <td>Acute and/or stepwise</td> <td>Radicuomyelopathy</td> <td>MRI, spinal angiography</td> </tr> <tr> <td>Subacute combined degeneration</td> <td>Any age</td> <td>Slowly progressive</td> <td>Dorsal cord syndrome</td> <td>Vitamin B12 levels</td> </tr> <tr> <td>Radiation</td> <td>Any age</td> <td>Slowly progressive; beginning 6-12 months after radiation therapy</td> <td>Segmental cord syndrome or Ventral cord syndrome</td> <td>MRI, clinical history</td> </tr> <tr> <td>Syringomyelia</td> <td>Children, young adults</td> <td>Slowly progressive</td> <td>Central cord syndrome</td> <td>MRI</td> </tr> <tr> <td>Epidural metastasis</td> <td>Usually &#62;50 years</td> <td>Subacute, may worsen abruptly</td> <td>Segmental cord syndrome</td> <td>MRI</td> </tr> <tr> <td>Intramedullary tumor</td> <td>Young adults</td> <td>Slowly progressive</td> <td>Central cord syndrome</td> <td>MRI with gadolinium enhancement</td> </tr> <tr> <td>ALS</td> <td>Usually &#62;60 years</td> <td>Progressive</td> <td>Pure motor syndrome</td> <td>Electromyography</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; CSF: cerebrospinal fluid; AVM: arteriovenous malformation; ALS: amyotrophic lateral sclerosis.<br>* This is a partial list of causes. Please see topic &quot;Disorders affecting the spinal cord&quot; for a more complete differential diagnosis.</div><div id=\"graphicVersion\">Graphic 50336 Version 2.0</div></div></div>"},"50337":{"type":"graphic_figure","displayName":"Triangular fibrocartilage complex compression test","title":"Triangular fibrocartilage complex (TFCC) compression test for TFCC tears","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Triangular fibrocartilage complex (TFCC) compression test for TFCC tears</div><div class=\"cntnt\"><img style=\"width:444px; height:482px;\" src=\"images/PEDS/50337_TFCC_compression_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform the TFCC compression test, the examiner applies axial compression to the ulnar side of the wrist during radial and ulnar deviation.</div><div id=\"graphicVersion\">Graphic 50337 Version 3.0</div></div></div>"},"50338":{"type":"graphic_algorithm","displayName":"Approach to the child with diplopia","title":"Approach to the child with diplopia","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Approach to the child with diplopia</div><div class=\"cntnt\"><img style=\"width:566px; height:763px;\" src=\"images/EM/50338_Appr_child_diplopia.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CN: cranial nerve; IIH: idiopathic intracranial hypertension.<br> * See table, &quot;Etiology third nerve palsy&quot;.<br> <span class=bullet>&#8226;</span> See table, &quot;Etiology fourth nerve palsy&quot;.<br> &#916; See table, &quot;Etiology sixth nerve palsy&quot;.<br> <span class=lozenge>&#9674;</span> Diplopia from causes other than CN VI palsy may occur with IIH.</div><div id=\"graphicVersion\">Graphic 50338 Version 1.0</div></div></div>"},"50339":{"type":"graphic_picture","displayName":"Back stretch","title":"Flexibility exercise: Back","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flexibility exercise: Back</div><div class=\"cntnt\"><img style=\"width:369px; height:297px;\" src=\"images/PC/50339_Back_stretch_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This exercise is for your back muscles. If you've had hip or back surgery, talk with your doctor before trying this stretch. <ol> <li>Sit securely toward the front of a sturdy, armless chair with your feet flat on the floor, shoulder-width apart. </li> <li>Slowly bend forward from your hips. Keep your back and neck straight. </li> <li>Slightly relax your neck and lower your chin. Slowly bend farther forward and slide your hands down your legs toward your shins. Stop when you feel a stretch or slight discomfort. </li> <li>Hold for 10 to 30 seconds. </li> <li>Straighten up slowly all the way to the starting position. </li> <li>Repeat at least three to five times. </li> </ol> As you progress, bend as far forward as you can and eventually touch your heels.</div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 50339 Version 2.0</div></div></div>"},"50340":{"type":"graphic_picture","displayName":"Granulomatous periorificial dermatitis","title":"Granulomatous periorificial dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Granulomatous periorificial dermatitis</div><div class=\"cntnt\"><img style=\"width:383px; height:504px;\" src=\"images/DERM/50340_Granulom_periorificial_derm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous, small erythematous papules are on the perinasal and perioral skin.</div><div id=\"graphicVersion\">Graphic 50340 Version 1.0</div></div></div>"},"50341":{"type":"graphic_table","displayName":"Clinical summary manual defibrillation in children","title":"Clinical summary: Manual defibrillation in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical summary: Manual defibrillation in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Perform defibrillation in children with ventricular fibrillation or ventricular tachycardia prior to establishing intravenous access or securing a definitive airway.</td> </tr> <tr> <td>2. Apply electrode conduction paste or gel to the paddles or open the electrode pads.</td> </tr> <tr> <td>3. Turn the machine on.</td> </tr> <tr> <td>4. If using paddles, select \"quick look\" to assess rhythm.</td> </tr> <tr> <td>5. Apply paddles or pad to appropriate positions on chest (anterior pad or paddle to right of sternum just under the clavicle, apex pad or paddle in the midaxillary line at the level of the nipple). Paddles must be applied firmly*.</td> </tr> <tr> <td>6. If ventricular fibrillation or ventricular tachycardia without a pulse is seen on the monitor, select an initial energy dose of 2 Joules/kg.</td> </tr> <tr> <td>7. Charge unit by simultaneously pressing the charge button on the paddles or by pressing the charge button on the machine if electrode pads are being used.</td> </tr> <tr> <td>8. Ensure all personnel are clear from the patient and the patient's stretcher by loudly stating \"All Clear!\" prior to shock delivery.</td> </tr> <tr> <td>9. Deliver current by either depressing discharge buttons simultaneously on the paddles or by pressing the discharge button on the machines if electrode pads are being used.</td> </tr> <tr> <td>10. Assess clinical and electrical response to shock delivery.</td> </tr> <tr> <td>11. Initiate or resume basic cardiopulmonary resuscitation if shock unsuccessful and proceed according to pediatric advanced life support guidelines.</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">3</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">8/19/2009--Requested permission (JD). 9/27/2009--Permission granted; figure to Terrence, agreement mailed back to Arnetta (JD).</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=10820&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">* Anterior/posterior paddle position is acceptable but less practical during a critical resuscitation.</div><div class=\"graphic_reference\">Reproduced with permission from: Scarfone RJ, Cho CS. Cardioversion and Defibrillation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50341 Version 13.0</div></div></div>"},"50344":{"type":"graphic_picture","displayName":"Candida albicans culture plate","title":"<EM>Candida albicans</EM>","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\"><EM>Candida albicans</EM></div><div class=\"cntnt\"><img style=\"width:504px; height:327px;\" src=\"images/PC/50344_Candidaalbicansculturepl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Candida albicans</EM> on a culture plate.</div><div class=\"graphic_reference\">Courtesy of Eva Rawlings Parker, MD.</div><div id=\"graphicVersion\">Graphic 50344 Version 5.0</div></div></div>"},"50345":{"type":"graphic_algorithm","displayName":"Diagnosing acute persistent visual loss","title":"Considerations in diagnosing acute persistent visual loss*","html":"<div class=\"graphic\"><div style=\"width: 865px\" class=\"figure\"><div class=\"ttl\">Considerations in diagnosing acute persistent visual loss*</div><div class=\"cntnt\"><img style=\"width:845px; height:451px;\" src=\"images/PC/50345_DiagnosingAPVL.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* These are considerations only. Clinical picture must otherwise fit.<br />&para; While corneal abrasion and keratitis are most common in patients who wear contact lenses, other sources of acute persistent visual loss should be considered if findings do not confirm abrasion or keratitis.</div><div id=\"graphicVersion\">Graphic 50345 Version 4.0</div></div></div>"},"50347":{"type":"graphic_table","displayName":"Workers comp reqs AMA Guide","title":"Workers' compensation requirements by AMA edition of \"Guides to the Evaluation of Permanent Impairment\" and US state","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Workers' compensation requirements&nbsp;by AMA edition of&nbsp;\"Guides to the Evaluation of Permanent Impairment\" and US state</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">AMA edition </td> <td class=\"subtitle1\">US state(s) using the edition</td> </tr> <tr> <td>AMA Guides 6th</td> <td>AK, AZ, IL, IN, LA, MA, MS, MT, NM, PA, RI, TN, WY</td> </tr> <tr> <td>AMA Guides 5th</td> <td>CA, CT, DE, GA, HI, IA, ID, KY, ND, NH, NV, OH, OK, VT, WA</td> </tr> <tr> <td>AMA Guides 4th</td> <td>AL, AR, KS, MD, ME, SD, TX, WV</td> </tr> <tr> <td>AMA Guides 3rd</td> <td>CO</td> </tr> <tr> <td>State-specific guidelines or AMA Guide not specified </td> <td>DC, FL, MI, MN, MO, NC, NE, NJ, NY, OR, SC, UT, VA, WI</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AMA: American Medical Association; US: United States.</div><div class=\"graphic_reference\">Data from: AMA Guides by State, updated July 2012. Available at: <A href=\"http://www.ncci.com/Articles/Documents/II_Impact_of_AMA_Guides.pdf\">www.ncci.com/Articles/Documents/II_Impact_of_AMA_Guides.pdf</A>. </div><div id=\"graphicVersion\">Graphic 50347 Version 4.0</div></div></div>"},"50348":{"type":"graphic_table","displayName":"Complications of bronchoscopy","title":"Complications of bronchoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of bronchoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Pre-medication</td>\n</tr>\n<tr>\n<td>Hypotension</td>\n</tr>\n<tr>\n<td>Tachycardia/arrhythmias</td>\n</tr>\n<tr>\n<td>Respiratory depression</td>\n</tr>\n<tr>\n<td>Agitation (paradoxical, especially in the elderly)</td>\n</tr>\n<tr>\n<td>Allergy/anaphylactoid reactions</td>\n</tr>\n<tr>\n<td>Nausea and vomiting</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Topical anesthesia</td>\n</tr>\n<tr>\n<td>Laryngospasm</td>\n</tr>\n<tr>\n<td>Bronchospasm</td>\n</tr>\n<tr>\n<td>Seizures</td>\n</tr>\n<tr>\n<td>Arrhythmias/arrest</td>\n</tr>\n<tr>\n<td>Nausea and vomiting</td>\n</tr>\n<tr>\n<td>Methemoglobinemia</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Bronchoscopy</td>\n</tr>\n<tr>\n<td>Epistaxis (with nasal approach)</td>\n</tr>\n<tr>\n<td>Laryngeal spasm/edema/injury</td>\n</tr>\n<tr>\n<td>Hypoxemia</td>\n</tr>\n<tr>\n<td>Arrhythmias</td>\n</tr>\n<tr>\n<td>Fever (approximately 16 percent, 6 percent with infiltrates)</td>\n</tr>\n<tr>\n<td>Bacteremia</td>\n</tr>\n<tr>\n<td>Dissemination of endogenous infection</td>\n</tr>\n<tr>\n<td>Infection (bacterial, mycobacterial, fungal, HIV)</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Biopsy or other procedures</td>\n</tr>\n<tr>\n<td>Bleeding</td>\n</tr>\n<tr>\n<td>Pneumothorax</td>\n</tr>\n<tr>\n<td>Pneumonia</td>\n</tr>\n<tr>\n<td>Broken equipment - foreign body in airway</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Rigid bronchoscopy</td>\n</tr>\n<tr>\n<td>Complications of general anesthesia</td>\n</tr>\n<tr>\n<td>Damage to teeth/oral mucosa/pharynx/glottis</td>\n</tr>\n<tr>\n<td>Perforation of airway/esophagus</td>\n</tr>\n<tr>\n<td>Tracheal fire (with laser)</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 50348 Version 1.0</div></div></div>"},"50349":{"type":"graphic_picture","displayName":"Kikuchi disease lymph node histopathology 2","title":"CD68-stained lymph node from a patient with Kikuchi disease","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">CD68-stained lymph node from a patient with Kikuchi disease</div><div class=\"cntnt\"><img style=\"width:480px; height:360px;\" src=\"images/ID/50349_Kikuchis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CD68-stained (monocyte/macrophage marker) lymph node at 200x magnification, showing the interface between residual normal lymph node and necrotic areas.</div><div class=\"graphic_reference\">Courtesy of Dr. Anthony Landgren.</div><div id=\"graphicVersion\">Graphic 50349 Version 2.0</div></div></div>"},"50350":{"type":"graphic_table","displayName":"Antivirals for influenza","title":"Recommended daily dose of influenza antiviral medications for treatment and prophylaxis of adults - United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended daily dose of influenza antiviral medications for treatment and prophylaxis of adults - United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Antiviral agent</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Oseltamivir</td> </tr> <tr> <td class=\"indent1\">Treatment, influenza A and B</td> <td>75 mg orally twice daily for five days*<sup><span style=\"font-size: 13px;\">&#182;</span></sup></td> </tr> <tr> <td class=\"indent1\">Chemoprophylaxis, influenza A and B</td> <td>75 mg orally once daily*<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Zanamivir<sup>&#9674;&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Treatment, influenza A and B</td> <td>10 mg (two inhalations) twice daily for five days</td> </tr> <tr> <td class=\"indent1\">Chemoprophylaxis, influenza A and B</td> <td>10 mg (two inhalations) once daily<sup>&#916;<span style=\"font-size: 13px;\"> </span></sup></td> </tr> <tr> <td colspan=\"2\"><strong>Peramivir</strong></td> </tr> <tr> <td class=\"indent1\">Treatment, influenza A and B</td> <td>600 mg intravenously as a single dose*</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to the UpToDate topic reviews on treatment and prevention of seasonal influenza for additional details about indications for use of an antiviral agent, choice of agent, dosing, and duration.</div><div class=\"graphic_footnotes\">* A reduction in the dose of oseltamivir and peramivir is recommended for persons with renal impairment. <br />¶ A longer duration of therapy can be considered in severely ill patients or immunocompromised individuals, particularly in those who continue to have viral RNA detected by polymerase chain reaction&nbsp;from a respiratory specimen.<br />Δ&nbsp;Duration of prophylaxis depends upon several factors. (Refer to the UpToDate&nbsp;topic review on prevention of seasonal influenza in adults.)<br />◊&nbsp;Zanamivir is administered through oral inhalation by using a plastic device included in the medication package. Patients will benefit from instruction and demonstration of the correct use of the device. Zanamivir is contraindicated in persons with asthma or chronic obstructive pulmonary disease. Zanamivir is also not recommended for the treatment of hospitalized patients with influenza due to limited data in patients with severe influenza.<br />§&nbsp;Zanamivir should be used during outbreaks caused by oseltamivir-resistant influenza virus. It is important to assess the risk of oseltamivir-resistant influenza before choosing an antiviral drug for influenza prophylaxis. Clinicians should review local or state influenza surveillance data to determine which types of influenza (A or B) and subtypes (pandemic or seasonal H1N1; H3N2) of influenza A are circulating, as well as resistance patterns. This information, which is updated weekly, is available via the&nbsp;United States Centers for Disease Control and Prevention&nbsp;through its website (<A href=\"http://www.cdc.gov/flu/weekly\">www.cdc.gov/flu/weekly</A>).</div><div class=\"graphic_reference\">Adapted from:&nbsp;<br /><OL>&#xD;&#xA;<LI>Influenza Division, National Center, for Immunization, and Respiratory. Antiviral agents for the treatment and chemoprophylaxis of influenza -- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-28.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (Accessed on January 05, 2018).</LI></OL></div><div id=\"graphicVersion\">Graphic 50350 Version 14.0</div></div></div>"},"50351":{"type":"graphic_picture","displayName":"Gonococcal urethral swab","title":"Gram stain of gonococcus in urethral discharge","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gram stain of gonococcus in urethral discharge</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/ID/50351_Gonococcalurethralswab.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of purulent exudate from the male urethra (x1000) shows polymorphonuclear leukocytes containing numerous intracellular gram-negative diplococci. As expected, <EM>Neisseria gonorrhoeae </EM>grew from this specimen.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 50351 Version 3.0</div></div></div>"},"50353":{"type":"graphic_table","displayName":"Sporo treatment recs","title":"Treatment of sporotrichosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of sporotrichosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Manifestation </td> <td class=\"subtitle1\">Preferred treatment </td> <td class=\"subtitle1\">Alternative treatment </td> <td class=\"subtitle1\">Comments </td> </tr> <tr> <td>Lymphocutaneous/cutaneous</td> <td>Itr 200 mg/day</td> <td>Itr 200 mg bid; or terbinafine 500 mg bid; or SSKI with increasing doses; or fluconazole 400 to 800 mg/day; or local hyperthermia</td> <td>Treat for 2 to 4 weeks after lesions resolved</td> </tr> <tr> <td>Osteoarticular</td> <td>Itr 200 mg bid</td> <td>Lipid AmB 3 to 5 mg/kg/day; or deoxycholate AmB 0.7 to 1 mg/kg/day</td> <td>Switch to Itr after favorable response if AmB used; treat for a total of at least 12 months</td> </tr> <tr> <td>Pulmonary</td> <td>Lipid AmB 3 to 5 mg/kg/day, then Itr 200 mg bid; or Itr 200 mg bid</td> <td>Deoxycholate AmB 0.7 to 1 mg/kg/d, then Itr 200 mg bid; surgical removal</td> <td>Treat severe disease with an AmB formulation followed by Itr; treat less severe disease with Itr; treat for a total of at least 12 months</td> </tr> <tr> <td>Meningitis</td> <td>Lipid AmB 5 mg/kg/day, then Itr 200 mg bid</td> <td>Deoxycholate AmB 0.7 to 1 mg/kg/day, then Itr 200 mg bid</td> <td>Length of therapy with AmB not established, but therapy for at least 4 to 6 weeks is recommended; treat for a total of at least 12 months; may require long-term suppression with Itr</td> </tr> <tr> <td>Disseminated</td> <td>Lipid AmB 3 to 5 mg/kg/day, then Itr 200 mg bid</td> <td>Deoxycholate AmB 0.7 to 1 mg/kg/day, then Itr 200 mg bid</td> <td>Therapy with AmB should be continued until the patient shows objective evidence of improvement; treat for a total of at least 12 months; may require long-term suppression with Itr</td> </tr> <tr> <td>Pregnant women</td> <td>Lipid AmB 3 to 5 mg/kg/day or deoxycholate AmB 0.7-1.0 mg/kg/day for severe sporotrichosis; local hyperthermia for cutaneous disease</td> <td>-</td> <td>It is preferable to wait until after delivery to treat non-life-threatening forms of sporotrichosis</td> </tr> <tr> <td>Children</td> <td>Itr 6 to 10 mg/kg/day (400 mg/day maximum) for mild disease; deoxycholate AmB 0.7 mg/kg/day for severe disease</td> <td>SSKI with increasing doses for mild disease</td> <td>Treat severe disease with an AmB formulation followed by Itr</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AmB: amphotericin B; bid: twice per day; Itr: itraconazole; SSKI: saturated solution potassium iodide.</div><div class=\"graphic_reference\">Reproduced with permission from: Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical Practice Guidelines for the Management of Sporotrichosis: 2007 Update by the Infectious Diseases Society of America. IDSA Guidelines for Management of Sporotrichosis. Clin Infect Dis 2007; 45:1255. Copyright ©2007 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 50353 Version 2.0</div></div></div>"},"50356":{"type":"graphic_picture","displayName":"Mixed histology thymoma","title":"Mixed lymphoepithelial, spindle cell-type thymoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mixed lymphoepithelial, spindle cell-type thymoma</div><div class=\"cntnt\"><img style=\"width:360px; height:231px;\" src=\"images/PULM/50356_Mixed_histology_thymoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The epithelial cells display a spindled appearance with fascicular architecture. (Hematoxylin and eosin, magnification 50x).</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 50356 Version 1.0</div></div></div>"},"50357":{"type":"graphic_picture","displayName":"Dyshidrosiform bullous pemphigoid","title":"Dyshidrosiform bullous pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dyshidrosiform bullous pemphigoid</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/50357_Dyshidrosiform_bullous_pemphigoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple eroded blisters with hemorrhagic bases on the palmar surface of the hands.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.&nbsp;&nbsp;</div><div id=\"graphicVersion\">Graphic 50357 Version 4.0</div></div></div>"},"50360":{"type":"graphic_figure","displayName":"Flecainide and exercise-induced ventricular arrhythmias","title":"Flecainide treatment prevents exercise induced ventricular arrhythmia in two subjects with CPVT refractory to conventional drug therapy","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Flecainide treatment prevents exercise induced ventricular arrhythmia in two subjects with CPVT refractory to conventional drug therapy</div><div class=\"cntnt\"><img style=\"width:608px; height:577px;\" src=\"images/CARD/50360_Flecainide_and_exercise_VA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panels A-D) Effect of flecainide treatment in a 12-year-old boy (subject 1) with a <em>CASQ2</em> mutation (Panels A and B) and in a 36-year-old female (subject 2) with an <em>RYR2</em> mutation (Panels C and D). Top of each panel, representative ECGs recorded during maximum stress; bottom of each panel, heart rate and rate of ventricular extrasystoles during an exercise test. Blue area indicates arrhythmia burden. Exercise protocol and ventricular extrasystole analysis are as previously described. Drug therapy during each exercise test: metroprolol 100 mg d<sup>-1</sup> plus verapamil 120 mg d<sup>-1</sup> (Panel A), metroprolol 100 mg d<sup>-1</sup> plus flecainide 150 mg d<sup>-1</sup> for 7 weeks (Panel B), bisoprolol 5 mg d<sup>-1</sup> plus verapamil 240 mg d<sup>-1</sup> (Panel C) or flecainide 150 mg d<sup>-1</sup> for 8 weeks (Panel D). Experiments involving human subjects were reviewed and approved by the University of Amsterdam Academic Medical Center Institutional Medical Ethical Review Board. Both human subjects (or their parents) provided informed consent.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd. Watanabe, H, Chopra, N, Laver, D, et al. Flecainide prevents catecholamineric polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009; 15:380. Copyright &#169;2009.</div><div id=\"graphicVersion\">Graphic 50360 Version 2.0</div></div></div>"},"50361":{"type":"graphic_table","displayName":"Physical findings in anemia","title":"Physical findings as clues to the etiology of anemia in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical findings as clues to the etiology of anemia in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Finding</td> <td class=\"subtitle1\">Possible etiology</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Skin</td> </tr> <tr> <td class=\"indent1\">Hyperpigmentation</td> <td>Fanconi anemia</td> </tr> <tr> <td class=\"indent1\">Petechiae, purpura</td> <td>Autoimmune hemolytic anemia with thrombocytopenia, hemolytic-uremic syndrome, bone marrow aplasia, bone marrow infiltration</td> </tr> <tr> <td class=\"indent1\">Carotenemia</td> <td>Suspect iron deficiency in infants</td> </tr> <tr> <td class=\"indent1\">Jaundice</td> <td>Hemolytic anemia, hepatitis, and aplastic anemia</td> </tr> <tr> <td class=\"indent1\">Cavernous hemangioma</td> <td>Microangiopathic hemolytic anemia</td> </tr> <tr> <td class=\"indent1\">Ulcers on lower extremities</td> <td>Sickle cell disease (S and C hemoglobinopathies), thalassemia</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Facies</td> </tr> <tr> <td class=\"indent1\">Frontal bossing, prominence of the malar and maxillary bones</td> <td>Congenital hemolytic anemias, thalassemia major, severe iron deficiency</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Eyes</td> </tr> <tr> <td class=\"indent1\">Microcornea</td> <td>Fanconi anemia</td> </tr> <tr> <td class=\"indent1\">Tortuosity of the conjunctival and retinal vessels</td> <td>Sickle cell disease (S and C hemoglobinopathies)</td> </tr> <tr> <td class=\"indent1\">Microaneurysms of retinal vessels</td> <td>Sickle cell disease (S and C hemoglobinopathies)</td> </tr> <tr> <td class=\"indent1\">Cataracts</td> <td>Glucose-6-phosphate dehydrogenase deficiency, galactosemia with hemolytic anemia in newborn period</td> </tr> <tr> <td class=\"indent1\">Vitreous hemorrhages</td> <td>S hemoglobinopathy</td> </tr> <tr> <td class=\"indent1\">Retinal hemorrhages</td> <td>Chronic, severe anemia</td> </tr> <tr> <td class=\"indent1\">Edema of the eyelids</td> <td>Infectious mononucleosis, exudative enteropathy with iron deficiency, renal failure</td> </tr> <tr> <td class=\"indent1\">Blindness</td> <td>Osteopetrosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Mouth</td> </tr> <tr> <td class=\"indent1\">Glossitis</td> <td>Vitamin B12 deficiency, iron deficiency</td> </tr> <tr> <td class=\"indent1\">Angular stomatitis</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Chest</td> </tr> <tr> <td class=\"indent1\">Unilateral absence of the pectoral muscles</td> <td>Poland's syndrome (increased incidence of leukemia)</td> </tr> <tr> <td class=\"indent1\">Shield chest</td> <td>Diamond-Blackfan syndrome</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Hands</td> </tr> <tr> <td class=\"indent1\">Triphalangeal thumbs</td> <td>Red cell aplasia</td> </tr> <tr> <td class=\"indent1\">Hypoplasia of the thenar eminence</td> <td>Fanconi anemia</td> </tr> <tr> <td class=\"indent1\">Spoon nails</td> <td>Iron deficiency</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Spleen</td> </tr> <tr> <td class=\"indent1\">Enlargement</td> <td>Congenital hemolytic anemia, leukemia, lymphoma acute infection, portal hypertension</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Oski FA, Brugnara G, Nathan DG. A diagnostic approach to the anemia patient. In: Nathan and Oski's Hematology of Infancy and Childhood. WB Sauders, Philadelphia. 1998. p.378.</div><div id=\"graphicVersion\">Graphic 50361 Version 4.0</div></div></div>"},"50362":{"type":"graphic_table","displayName":"Causes of endolymphatic hydrops","title":"Causes of endolymphatic hydrops*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of endolymphatic hydrops*</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td>Acoustic trauma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Autoimmune inner ear disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chronic otitis media</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cogan's syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Congenital deafness</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Endolymphatic sac tumors</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fenestration of the otic capsule</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Labyrinthine concussion</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Letterer-Siwe disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Leukemic infiltrates</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mondini dysplasia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Otosclerosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Paget's disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Serous labyrinthitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Surgical trauma to inner ear</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Syphilis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Temporal bone/head trauma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Viral labyrinthitis</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Endolymphatic hydrops determined at autopsy.</div><div class=\"graphic_reference\"><br> Adapted from Jackler, RK, Brackmann, DE, Eds, Neurotology, Mosby Year Book Inc, Missouri 1994, p. 635.</div><div id=\"graphicVersion\">Graphic 50362 Version 1.0</div></div></div>"},"50363":{"type":"graphic_table","displayName":"Alarm signs and symptoms in a patient with excessive flatulence","title":"Alarm signs and symptoms requiring work-up in a patient with excessive flatulence","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Alarm signs and symptoms requiring work-up in a patient with excessive flatulence</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Nocturnal abdominal pain (sleep awakening)</td>\n</tr>\n<tr>\n<td>Weight loss</td>\n</tr>\n<tr>\n<td>Blood in the stool</td>\n</tr>\n<tr>\n<td>Severely tender abdomen</td>\n</tr>\n<tr>\n<td>Succussion splash</td>\n</tr>\n<tr>\n<td>Fever</td>\n</tr>\n<tr>\n<td>Vomiting</td>\n</tr>\n<tr>\n<td>Steatorrhea</td>\n</tr>\n<tr>\n<td>New onset diarrhea</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 50363 Version 2.0</div></div></div>"},"50365":{"type":"graphic_picture","displayName":"CMV pneumonitis ","title":"CMV pneumonitis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CMV pneumonitis</div><div class=\"cntnt\"><img style=\"width:279px; height:186px;\" src=\"images/PULM/50365_CMV_pneumonitis_High_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph shows an infected pneumocyte in a patient with cytomegalovirus pneumonitis. The infected cell (arrow) is enlarged and contains an eosinophilic intranuclear inclusion and coarse basophilic cytoplasmic inclusions.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 50365 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lung</div><div class=\"cntnt\"><img style=\"width:360px; height:330px;\" src=\"images/PULM/80140_Normal_lung_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph shows alveoli containing capillaries within a narrow interstitium. The alveoli are lined with thin, elongated type I pneumocytes (arrow) and smaller numbers of cuboidal type II pneumocytes (dashed arrow).</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 80140 Version 2.0</div></div></div>"},"50368":{"type":"graphic_picture","displayName":"M mycetomatis skin biopsy","title":"<em>Madurella mycetomatis</em> skin biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Madurella mycetomatis</em> skin biopsy</div><div class=\"cntnt\"><img style=\"width:396px; height:285px;\" src=\"images/ID/50368_Mmycetomatisskinbiopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin biopsy demonstrating two grains of <EM>Madurella mycetomatis</EM> surrounded by granulomatous reaction (hematoxylin &amp; eosin stain x400).</div><div class=\"graphic_reference\">Courtesy of Beatriz Bustamante, MD.</div><div id=\"graphicVersion\">Graphic 50368 Version 2.0</div></div></div>"},"50373":{"type":"graphic_table","displayName":"Precip factors ADHF","title":"Common and uncommon precipitating factors associated with hospitalization for ADHF","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common and uncommon precipitating factors associated with hospitalization for ADHF</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Dietary and medication related causes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Dietary indiscretion - excessive salt or water intake</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Nonadherence to medications</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Iatrogenic volume expansion</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Progressive cardiac dysfunction</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Progression of underlying cardiac dysfunction</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Physical, emotional, and environmental stress</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cardiac toxins:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Alcohol</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Cocaine</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Right ventricular pacing</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Cardiac causes not primarily myocardial in origin</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cardiac arrhythmias:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Atrial fibrillation with a rapid ventricular response</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Ventricular tachycardia</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Marked bradycardia</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Conduction abnormalities</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Uncontrolled hypertension</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Acute myocardial infarction</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Myocardial ischemia</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Valvular disease:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Progressive mitral regurgitation</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Non-cardiac causes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Pulmonary disease - pulmonary embolus, COPD</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Anemia, from bleeding or relative lack of erythropoietin or bone marrow suppression</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Systemic infection; especially pulmonary infection</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Thyroid disorders</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Adverse cardiovascular effects of medications</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Cardiac depressant medications</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Nondihydropyridine calcium antagonists</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Type Ia and Ic antiarrhythmic agents</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Sodium retaining medications</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Steroids</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Nonsteroidal anti-inflammatory drugs</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Medications that reduce contractility</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Anthracyclines and other chemotherapeutic agents</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Heart Failure Society Of America. Evaluation and management of patients with acute decompensated heart failure. J Card Fail 2006; 12:e86. Copyright &#169;2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 50373 Version 1.0</div></div></div>"},"50374":{"type":"graphic_figure","displayName":"Vascular supply and drainage of the liver","title":"Vascular supply an drainage of the liver","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Vascular supply an drainage of the liver</div><div class=\"cntnt\"><img style=\"width:535px; height:489px;\" src=\"images/SURG/50374_Venous-drainage-of-the-liver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The segments of the liver are depicted together with their vascular supply and biliary drainage. Segment I, the caudate lobe, is located posteriorly.</div><div id=\"graphicVersion\">Graphic 50374 Version 4.0</div></div></div>"},"50376":{"type":"graphic_picture","displayName":"HME selection device for mechanical ventilator","title":"Heat and moisture exchange (HME) selection device","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Heat and moisture exchange (HME) selection device</div><div class=\"cntnt\"><img style=\"width:477px; height:404px;\" src=\"images/PULM/50376_HME_select_device_mech_vent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The heat and moisture exchange (HME) selection device uses a rotating collar to allow switching from HME mode for heat and moisture exchange to AEROSOL mode without opening the ventilator circuit. In HME mode, the unit functions as a heat and moisture exchanger. In AEROSOL mode, the heat and moisture function is bypassed for administration of an aerosolized or MDI medication.</div><div class=\"graphic_footnotes\">HME: heat and moisture exchanger; MDI: metered dose inhaler.</div><div class=\"graphic_reference\">Used with permission: Copyright &copy; 2012 Teleflex Incorporated.</div><div id=\"graphicVersion\">Graphic 50376 Version 1.0</div></div></div>"},"50378":{"type":"graphic_picture","displayName":"Papilledema","title":"Papilledema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Papilledema</div><div class=\"cntnt\"><img style=\"width:336px; height:297px;\" src=\"images/PEDS/50378_Papilledema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papilledema, characterized by blurring of the optic disc margins, loss of physiologic cupping, hyperemia, and fullness of the veins, in a 5-year-old girl with intracranial hypertension due to vitamin A intoxication.</div><div class=\"graphic_reference\">Courtesy of Gerald Striph, MD.</div><div id=\"graphicVersion\">Graphic 50378 Version 1.0</div></div></div>"},"50379":{"type":"graphic_table","displayName":"Drugs for adult ADHD","title":"Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication<br /> (trade name in United States)</td> <td class=\"subtitle1\">Onset of initial effect</td> <td class=\"subtitle1\">Duration of effect</td> <td class=\"subtitle1\">Initial dosage</td> <td class=\"subtitle1\">Titration</td> <td class=\"subtitle1\">Usual maintenance dosage</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Stimulants*</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"6\">Dexmethylphenidate</td> </tr> <tr> <td class=\"indent2\">Focalin and generic equivalents<sup>&#182;</sup><sup>&#916;</sup></td> <td>0.5 to 1 hour; delayed if taken with a high-fat meal</td> <td>5 to 6 hours</td> <td>5 mg twice per day</td> <td>Increase total daily dose by 10 mg at weekly intervals</td> <td>15 mg twice per day (maximum 20 mg twice per day)</td> </tr> <tr> <td class=\"indent2\">Focalin XR and generic equivalents<sup>&#182;</sup></td> <td>0.5 to 1 hour; a second peak effect occurs ~6.5 hours after dose</td> <td>12 hours</td> <td>10 mg once per day in morning</td> <td>Increase daily dose by 10 mg at weekly intervals</td> <td>30 mg once per day in morning (maximum 40 mg once per day)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"6\">Methylphenidate</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"6\">Short-acting</td> </tr> <tr> <td class=\"indent3\">Ritalin and generic equivalents</td> <td rowspan=\"3\">&#8804;1 hour; delayed if taken with a high-fat meal</td> <td rowspan=\"3\">3 to 5 hours</td> <td rowspan=\"3\">10 mg twice per day before breakfast and lunch</td> <td rowspan=\"3\">Increase total daily dose by 5 or 10 mg at weekly intervals</td> <td rowspan=\"3\">40 to 60 mg per day in two or three divided doses</td> </tr> <tr> <td class=\"indent3\">Methylin chewable</td> </tr> <tr> <td class=\"indent3\">Methylin oral solution</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"6\">Intermediate-acting</td> </tr> <tr> <td class=\"indent3\">Ritalin SR and generic equivalents</td> <td rowspan=\"2\">&#8804;1 hour</td> <td>4 to 8 hours</td> <td>20 mg once per day in morning</td> <td>Increase daily dose by 10 mg at weekly intervals</td> <td>40 to 60 mg once per day in morning</td> </tr> <tr> <td class=\"indent3\">Metadate ER and generic equivalents</td> <td>4 to 8 hours</td> <td>10 mg twice per day</td> <td>Increase daily dose by 10 mg at weekly intervals</td> <td>40 to 60 mg once per day in morning</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"6\">Long-acting</td> </tr> <tr> <td class=\"indent3\">Metadate CD and generic equivalents</td> <td>&#8804;1 hour; a second peak effect occurs ~4.5 hours after dose</td> <td>8 to 12 hours</td> <td>20 mg once per day in morning</td> <td>Increase daily dose by 10 or 20 mg at weekly intervals</td> <td>40 to 60 mg once per day in morning</td> </tr> <tr> <td class=\"indent3\">Quillivant XR oral suspension<sup>&#916;</sup></td> <td>&#8804;1 hour</td> <td>8 to 12 hours</td> <td>20 mg once per day in morning</td> <td>Increase daily dose by 10 or 20 mg at weekly intervals</td> <td>40 to 60 mg once per day in morning</td> </tr> <tr> <td class=\"indent3\">Ritalin LA and generic equivalent<sup>&#182;</sup></td> <td>&#8804;1 hour; a second peak effect occurs ~5.5 hours after dose</td> <td>8 to 12 hours</td> <td>10 or 20 mg once per day in morning</td> <td>Increase daily dose by 10 mg at weekly intervals</td> <td>40 to 60 mg once per day in morning</td> </tr> <tr> <td class=\"indent3\">Concerta and generic equivalents</td> <td>&#8804;1 hour; plateau at 1 to 4 hours and peak at 6 hours after dose</td> <td>10 to 12 hours</td> <td>18 or 36 mg once per day in morning</td> <td>Increase daily dose by 18 mg at weekly intervals</td> <td>54 to 72 mg once per day in morning</td> </tr> <tr> <td class=\"indent3\">Daytrana transdermal patch<sup>&#916;</sup></td> <td>&#8804;2 hours</td> <td>10 to 12 hours</td> <td> <p>30 mg patch on for 9 hours and off for 15 hours each day;</p> Apply patch 2 hours before needed onset</td> <td> <p>Increase to next higher patch strength at weekly intervals;</p> Available patch strengths: 10 mg, 15 mg, 20 mg and 30 mg per 9 hours</td> <td>60 mg patch on for 9 hours and off for 15 hours each day</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"6\">Dextroamphetamine</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"6\">Short-acting</td> </tr> <tr> <td class=\"indent3\">Generics<sup>&#182;</sup><sup>&#916;</sup></td> <td>&#8804;1 hour</td> <td>4 to 6 hours</td> <td>5 mg twice per day</td> <td>Increase total daily dose by 5 mg at weekly intervals</td> <td>20 mg twice per day</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"6\">Long-acting</td> </tr> <tr> <td class=\"indent3\">Dexedrine spansule and generic equivalents<sup>&#182;</sup><sup>&#916;</sup></td> <td>&#8804;1 hour</td> <td>6 to 8 hours</td> <td>5 mg twice per day</td> <td>Increase total daily dose by 5 mg at weekly intervals</td> <td>40 mg once per day in morning</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"6\">Dextroamphetamine and amphetamine (mixed salts)</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"6\">Short-acting</td> </tr> <tr> <td class=\"indent3\">Adderall and generic equivalents<sup>&#182;</sup></td> <td>&#8804;1 hour</td> <td>4 to 6 hours</td> <td>5 mg once or twice per day</td> <td>Increase total daily dose by 5 or 10 mg at weekly intervals</td> <td>40 to 60 mg per day in 1 to 3 divided doses</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"6\">Long-acting</td> </tr> <tr> <td class=\"indent3\">Adderall XR and generic equivalents<sup>&#182;</sup></td> <td>&#8804;1 hour</td> <td>8 to 10 hours</td> <td>20 mg once per day in morning</td> <td>Increase daily dose by 10 mg at weekly intervals</td> <td>40 to 60 mg once per day in morning</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"6\">Lisdexamfetamine</td> </tr> <tr> <td class=\"indent2\">Vyvanse</td> <td>&#8804;1 hour; onset delayed if taken with food</td> <td>~10 hours</td> <td>30 mg once per day in morning</td> <td>Increase daily dose by 10 or 20 mg at weekly intervals</td> <td>30 to 70 mg once per day in morning</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Non-stimulants</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"6\">Atomoxetine</td> </tr> <tr> <td class=\"indent2\">Strattera</td> <td>1 to 2 weeks</td> <td>24 hours</td> <td>40 mg once per day</td> <td>Increase after three or more days to 80 mg; after two to four additional weeks may increase to 100 mg per day</td> <td>80 mg once per day or in two equally divided doses (maximum 100 mg per day)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"6\">Clonidine extended-release</td> </tr> <tr> <td class=\"indent2\">Kapvay<sup>&#9674;</sup></td> <td>1 to 2 weeks based on data from immediate release preparation; adverse effects (eg, somnolence) may occur sooner</td> <td>12 hours</td> <td>0.1 mg once per day at bedtime</td> <td>Increase daily dose by 0.1 mg at weekly intervals</td> <td>0.1 to 0.3 mg once per day at bedtime or in two divided doses (maximum 0.4 mg per day)<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"6\">Guanfacine extended-release</td> </tr> <tr> <td class=\"indent2\">Intuniv<sup>&#167;</sup></td> <td>1 to 2 weeks; adverse effects may occur sooner</td> <td>8 to 14 hours</td> <td>1 mg once per day</td> <td>Increase daily dose by 1 mg at weekly intervals</td> <td>1 to 4 mg per day<sup>&#167;</sup></td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"6\">Bupropion</td> </tr> <tr> <td class=\"indent2\">Wellbutrin SR and generic equivalents</td> <td rowspan=\"2\">1 to 2 weeks</td> <td>12 hours</td> <td>100 mg once per day in morning</td> <td>After several weeks increase to 100 mg twice per day</td> <td>100 to 150 mg twice per day (maximum 200 mg twice per day)</td> </tr> <tr> <td class=\"indent2\">Wellbutrin XL and generic equivalents</td> <td>24 hours</td> <td>150 mg once per day in morning</td> <td>After several weeks increase to 300 mg once per day</td> <td>300 mg once per day (maximum 450 mg once per day)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Stimulants are United States Drug Enforcement Agency (DEA) Schedule II controlled substances.<br />&para; Should not be taken with antacids or other drugs that decrease gastric acidity.<br />&Delta; United States Food &amp; Drug Administration (US FDA) approval is for use in patients 6 to 17 years or children &ge;6 years old.<br /><span class=\"lozenge\">&loz;</span> Extended release clonidine up to 0.4 mg per day is US FDA approved but may be more likely to cause hypotension. When discontinued, dose should be tapered.<br />&sect; When discontinued extended release guanfacine dose should be tapered.</div><div class=\"graphic_reference\">Prepared with data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>The Medical Letter, March 16, 2015; Vol.&nbsp;57 (1464):37. <A href=\"http://www.medicalletter.org/\" target=_blank>www.medicalletter.org</A>. </LI>&#xD;&#xA;<LI>Lexicomp online Copyright © 1978-2018 by Lexicomp, Inc. All rights reserved. </LI>&#xD;&#xA;<LI>Santosh PJ, Sattar S, Canagaratnam M, et al. Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults. CNS Drugs 2011; 25:737.</LI>&#xD;&#xA;<LI>Coghill D, Banashewski T, Zuddas A. Long-acting methylphenidate formulations in the treatment of attention deficit/hyperactivity disorder. BMC Psychiatry 2013; 13:237.</LI>&#xD;&#xA;<LI>Reimherr FW, Hedges DW, Strong RE, Marchant BK, Williams ED. Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial. Neuropsychiatr Dis Treat. 2005;1:245.</LI></OL></div><div id=\"graphicVersion\">Graphic 50379 Version 11.0</div></div></div>"},"50380":{"type":"graphic_table","displayName":"Patient needs at discharge","title":"Model to categorize patient needs at discharge","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Model to categorize patient needs at discharge</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <p>Patient profiles are divided into four broad domains:</p> <p><strong>Domain I: Medical/surgical issues</strong></p> <p><strong>Domain II: Mental status/emotions/coping</strong></p> <p><strong>Domain III: Physical functioning</strong></p> <p><strong>Domain IV: Living environment - physical, social, financial</strong></p> <p>Patient-specific elements within each domain, characterized by intensity (high-medium-low), are then determined to create a profile that can be matched to the capabilities of alternative sites of care.</p> </td> </tr> <tr> <td class=\"subtitle1_single\">Domain I. Medical/surgical issues </td> </tr> <tr> <td>1. Clinical instability. The probability that the patient will need rapid intervention for an <strong>U</strong>nstable <strong>C</strong>linical <strong>C</strong>ondition (<strong>UCC</strong>).</td> </tr> <tr> <td>2. Complexity of care. The probability that the patient will need a <strong>C</strong>omplex diagnostic or therapeutic <strong>P</strong>rocedure (<strong>CP</strong>).</td> </tr> <tr> <td>3. The intensity of <strong>N</strong>ursing services (<strong>RN</strong>).</td> </tr> <tr> <td>4. The intensity of <strong>P</strong>hysician services (<strong>MD</strong>).</td> </tr> <tr> <td class=\"subtitle1_single\">Domain II. Mental status/emotions/coping </td> </tr> <tr> <td>5. The extent of <strong>C</strong>ognitive <strong>I</strong>mpairment or <strong>D</strong>epression (<strong>CID</strong>).</td> </tr> <tr> <td class=\"subtitle1_single\">Domain III. Physical functioning </td> </tr> <tr> <td>6. The presence of a <strong>W</strong>indow of <strong>O</strong>pportunity for <strong>R</strong>ehabilitation during which rehabilitation services are most effective and outcomes are optimal at a time when the patient has the physical capacity to participate (<strong>WOR</strong>).</td> </tr> <tr> <td class=\"subtitle1_single\">Domain IV. Living environment - physical, social, financial </td> </tr> <tr> <td>7. Limitations on care options due to <strong>M</strong>edical <strong>I</strong>nsurance <strong>C</strong>overage (<strong>MIC</strong>).</td> </tr> <tr> <td>8. Limitations on life-sustaining treatments/<strong>A</strong>dvanced <strong>D</strong>irective (<strong>AD</strong>).</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Based on data from: Siebens, H. Applying the Domain Management Model in Treating Patients with Chronic Disease. Jt Comm J Qual Improv 2001; 27:302.</div><div id=\"graphicVersion\">Graphic 50380 Version 3.0</div></div></div>"},"50381":{"type":"graphic_figure","displayName":"Spider anatomy","title":"Basic dorsal and ventral spider anatomy","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Basic dorsal and ventral spider anatomy</div><div class=\"cntnt\"><img style=\"width:571px; height:403px;\" src=\"images/PC/50381_Spider_anatomy_edt2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 50381 Version 3.0</div></div></div>"},"50382":{"type":"graphic_table","displayName":"BAL fluid in non smokers","title":"Expected values of BAL fluid constituents in healthy never smokers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Expected values of BAL fluid constituents in healthy never smokers</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Variable</td> <td class=\"subtitle1\">Mean &#177; SEM</td> <td class=\"subtitle1\">5th percentile*</td> <td class=\"subtitle1\">95th percentile<sup>&#182;</sup></td> </tr> <tr> <td>Percent recovery of lavagate</td> <td>63.4 &#177; 1.1</td> <td>40.8</td> <td>80.3</td> </tr> <tr> <td>Total cells, 10<sup>6</sup><sup>&#916;</sup></td> <td>18.1 &#177; 1.9</td> <td>5.2</td> <td>33.1</td> </tr> <tr> <td>Total cells/mL, 10<sup>4</sup><sup>&#916;</sup></td> <td>12.9 &#177; 2</td> <td>3.1</td> <td>35.1</td> </tr> <tr> <td>Macrophages, percent<sup>&#916;</sup></td> <td>85.2 &#177; 1.6</td> <td>54.6</td> <td>97.1</td> </tr> <tr> <td>Macrophages/mL, 10<sup>4</sup><sup>&#916;</sup></td> <td>9.9 &#177; 0.8</td> <td>2.7</td> <td>27.5</td> </tr> <tr> <td>Lymphocytes, percent<sup>&#916;</sup></td> <td>11.81 &#177; 1.1</td> <td>1.9</td> <td>34.3</td> </tr> <tr> <td>Lymphocytes/mL, 10<sup>4</sup><sup>&#916;</sup></td> <td>1.49 &#177; 0.25</td> <td>0.2</td> <td>4.9</td> </tr> <tr> <td>Neutrophils, percent<sup>&#916;</sup></td> <td>1.6 &#177; 0.7</td> <td>0</td> <td>3.1</td> </tr> <tr> <td>Neutrophils/mL, 10<sup>4</sup><sup>&#916;</sup></td> <td>1.2 &#177; 1.1</td> <td>0</td> <td>0.4</td> </tr> <tr> <td>Eosinophils, percent<sup>&#916;</sup></td> <td>0.19 &#177; 0.06</td> <td>0</td> <td>1.1</td> </tr> <tr> <td>Eosinophils/mL, 10<sup>4</sup><sup>&#916;</sup></td> <td>0.02 &#177; 0.007</td> <td>0</td> <td>0.2</td> </tr> <tr> <td>T cells, percent<sup>&#9674;</sup></td> <td>70.27 &#177; 3.56</td> <td>25.6</td> <td>94.9</td> </tr> <tr> <td>T-helper cells, percent<sup>&#9674;</sup></td> <td>44.4 &#177; 3.71</td> <td>7.6</td> <td>83.5</td> </tr> <tr> <td>T-suppressor cells, percent<sup>&#9674;</sup></td> <td>20.73 &#177; 2.17</td> <td>6.6</td> <td>49.4</td> </tr> <tr> <td>Helper/suppressor ratio<sup>&#9674;</sup></td> <td>2.61 &#177; 0.29</td> <td>0.5</td> <td>6.4</td> </tr> <tr> <td>B cells, percent<sup>&#9674;</sup></td> <td>3.23 &#177; 0.85</td> <td>0</td> <td>17.1</td> </tr> <tr> <td>IgG, mcg/mL<sup>&#167;</sup></td> <td>5.92 &#177; 0.48</td> <td>1.6</td> <td>14.5</td> </tr> <tr> <td>IgA, mcg/mL<sup>&#167;</sup></td> <td>6.22 &#177; 0.6</td> <td>1.1</td> <td>15.3</td> </tr> <tr> <td>IgM, mcg/mL<sup>&#167;</sup></td> <td>0.2 &#177; 0.019</td> <td>0.03</td> <td>0.6</td> </tr> <tr> <td>Albumin, mcg/mL<sup>&#167;</sup></td> <td>34.23 &#177; 1.67</td> <td>15.7</td> <td>59.3</td> </tr> <tr> <td>Total protein, mcg/mL<sup>&#167;</sup></td> <td>78.24 &#177; 4.04</td> <td>39.5</td> <td>140.7</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BAL: bronchoalveolar lavage.<br />* 5th percentile of the study population.<br />&para; 95th percentile of the study population.<br />&Delta; n = 77.<br /><span class=\"lozenge\">&loz;</span> n = 30.<br />&sect; n = 76.</div><div class=\"graphic_reference\">Data from: BAL Cooperative Group. Am Rev Respir Dis 1990; 141:S169 (BAL Cooperative Group, 1990 #261).</div><div id=\"graphicVersion\">Graphic 50382 Version 3.0</div></div></div>"},"50384":{"type":"graphic_table","displayName":"Rx for hepatic fibrosis","title":"Potential therapeutic strategies for hepatic fibrosis: current and in development","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential therapeutic strategies for hepatic fibrosis: current and in development</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Strategies</td> <td class=\"subtitle1\">Approach</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Remove injurious stimuli</td> <td>Abstinence from alcohol for alcoholic liver diseases</td> </tr> <tr> <td>Antiviral therapy for viral hepatitis</td> </tr> <tr> <td>Antihelminthic therapy for schistosomiasis</td> </tr> <tr> <td>Copper chelation for Wilson disease</td> </tr> <tr> <td>Phlebotomy for hemochromatosis</td> </tr> <tr class=\"divider_bottom\"> <td>Discontinue hepatotoxins (eg, methotrexate) in drug-induced liver injury</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"9\">Suppress or modulate hepatic inflammation</td> <td>Corticosteroids in autoimmune hepatitis and severe alcoholic liver diseases</td> </tr> <tr> <td>Caffeine (possibly)</td> </tr> <tr> <td>Farnesoid X receptor ligands</td> </tr> <tr> <td>Serum amyloid P pentamer</td> </tr> <tr> <td>Galectin-3 antagonists</td> </tr> <tr> <td>Chemokine and chemokine receptor antagonists</td> </tr> <tr> <td>LPA-1 antagonists</td> </tr> <tr> <td>Antioxidants (eg, vitamin E, cysteamine, butein)</td> </tr> <tr class=\"divider_bottom\"> <td>HMG-CoA reductase inhibition (eg, statins)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Hepatoprotectants</td> <td>Caspase inhibitors</td> </tr> <tr> <td>Farnesoid X receptor ligands</td> </tr> <tr> <td>PPAR alpha/delta agonists</td> </tr> <tr> <td>Hepatocyte growth factor mimetics</td> </tr> <tr class=\"divider_bottom\"> <td>Fatty acid/bile acid conjugates to reduce liver fat</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"19\">Downregulate stellate cell activation (proliferation, fibrogenesis and/or contractility)</td> <td>Stellate cell-targeted gamma interferon</td> </tr> <tr> <td>Antioxidants (eg, vitamin E, cysteamine, buteine)</td> </tr> <tr> <td class=\"sublist1_start\">Cytokine and chemokine-antagonists and agonists:</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Targeted TGF-beta antagonists (eg, integrin alpha V antagonists) </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Endothelin receptor antagonists; nitric oxide donors </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Hepatocyte growth factor mimetics </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Chemokine and chemokine receptor antagonists </li> </ul> </td> </tr> <tr> <td>Connective tissue growth factor inhibitors</td> </tr> <tr> <td>Receptor tyrosine kinase antagonists (eg, sorafenib, imatinib)</td> </tr> <tr> <td>Peripheral cannabinoid receptor antagonists</td> </tr> <tr> <td>Angiotensin receptor antagonists</td> </tr> <tr> <td>Liposomoal delivery of siRNA to Hsp-47</td> </tr> <tr> <td>HMG-CoA reductase inhibition (eg, statins)</td> </tr> <tr> <td>Bone morphogenic protein 7</td> </tr> <tr> <td>Histone deacetylase inhibitors</td> </tr> <tr> <td>Hedgehog pathway inhibitors</td> </tr> <tr> <td>Interleukin-22</td> </tr> <tr> <td>Perfenidone</td> </tr> <tr class=\"divider_bottom\"> <td>Herbal medicines: (eg, Sho-saiko-to [Xiao-Chaihu-Tang])</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Promote matrix degradation</td> <td>Lysyl oxidase-2 inhibitors</td> </tr> <tr class=\"divider_bottom\"> <td>Cell-specific TGF-beta inhibitors (eg, integrin alpha V antagonists)</td> </tr> <tr> <td>Promote specific apoptosis of hepatic stellate cells</td> <td>Gliotoxin, sulfasalazine</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">LPA: lysophosphatidic acid; HMG: hydroxy methylglutaryl; PPAR: peroxisome proliferator-activated receptor; TGF: transforming growth factor;&nbsp;siRNA: short-interfering ribonucleic acid; Hsp: heat-shock protein.</div><div id=\"graphicVersion\">Graphic 50384 Version 2.0</div></div></div>"},"50385":{"type":"graphic_picture","displayName":"Chancre of primary syphilis","title":"Primary syphilis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary syphilis</div><div class=\"cntnt\"><img style=\"width:372px; height:270px;\" src=\"images/ID/50385_Chancre_of_primary_syphilis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Primary chancre on the labia majora. Chancres are painless and frequently can be missed, especially in women.</div><div class=\"graphic_reference\">Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 50385 Version 5.0</div></div></div>"},"50388":{"type":"graphic_picture","displayName":"Deep hemangioma","title":"Deep hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Deep hemangioma</div><div class=\"cntnt\"><img style=\"width:393px; height:261px;\" src=\"images/PEDS/50388_Deep_hemangioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Deep hemangiomas are typically raised, flesh-colored nodules, which often have a bluish hue or an overlying telangiectatic patch.</div><div class=\"graphic_reference\">Courtesy of Denise W Metry, MD</div><div id=\"graphicVersion\">Graphic 50388 Version 1.0</div></div></div>"},"50389":{"type":"graphic_picture","displayName":"Glaucoma corneal enlargement","title":"Corneal enlargement in congenital glaucoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Corneal enlargement in congenital glaucoma</div><div class=\"cntnt\"><img style=\"width:356px; height:337px;\" src=\"images/PEDS/50389_Glaucoma_corneal_enlrgmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The right cornea is larger than the left.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50389 Version 2.0</div></div></div>"},"50390":{"type":"graphic_figure","displayName":"Tumor necrosis factor LV","title":"Tumor necrosis factor alpha reduces left ventricular function","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Tumor necrosis factor alpha reduces left ventricular function</div><div class=\"cntnt\"><img style=\"width:453px; height:283px;\" src=\"images/CARD/50390_Tumor_necrosis_factor_LV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In an animal study, a continuous infusion of tumor necrosis factor (TNF)-alpha for 15 days produces a reduction in left ventricular (LV) function, assessed by fractional shortening on an echocardiogram. With discontinuation of the infusion of TNF alpha, LV function improves.</div><div class=\"graphic_reference\">Data from Bozkurt B, Kribbs SB, Clubb FJ, et al. Circulation 1998; 97:1382.</div><div id=\"graphicVersion\">Graphic 50390 Version 2.0</div></div></div>"},"50391":{"type":"graphic_figure","displayName":"Double balloon technique","title":"Double balloon endoscopy technique","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Double balloon endoscopy technique</div><div class=\"cntnt\"><img style=\"width:538px; height:567px;\" src=\"images/GAST/50391_Double_balloon_technique.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 50391 Version 2.0</div></div></div>"},"50394":{"type":"graphic_table","displayName":"Commonly used functional assessment questionnaires","title":"Commonly used functional assessment questionnaires","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly used functional assessment questionnaires</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Questionnaire </td> <td class=\"subtitle1\">URL </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">General functional assessment </td> </tr> <tr> <td class=\"indent1\">Health Assessment Questionnaire </td> <td><span style=\"color: #3966bf;\"><a href=\"http://patienteducation.stanford.edu/research/haq20.html\" spellcheck=\"true\">patienteducation.stanford.edu/research/haq20.html</a></span></td> </tr> <tr> <td class=\"indent1\">Functional Activities Questionnaire </td> <td><a href=\"http://www.healthcare.uiowa.edu/familymedicine/fpinfo/Docs/functional-activities-assessment-tool.pdf\" spellcheck=\"true\">www.healthcare.uiowa.edu/familymedicine/fpinfo/Docs/functional-activities-assessment-tool.pdf</a></td> </tr> <tr> <td class=\"indent1\">SF-36 Physical Functioning Scale </td> <td><a href=\"http://www.sf-36.org/tools/SF36.shtml\" spellcheck=\"true\">www.sf-36.org/tools/SF36.shtml</a></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pain </td> </tr> <tr> <td class=\"indent1\">Pain Disability Index </td> <td><span style=\"color: #3966bf;\"><a href=\"http://www.med.umich.edu/1info/FHP/practiceguides/pain/detpdi.pdf\">www.med.umich.edu/1info/FHP/practiceguides/pain/detpdi.pdf</a></span></td> </tr> <tr> <td class=\"indent1\">McGill Pain Questionnaire </td> <td> <p><span style=\"color: #3966bf;\"><a href=\"https://www.gem-beta.org/public/DownloadMeasure.aspx?mid=1348\" spellcheck=\"true\" dir=\"ltr\"><span style=\"color: #1a0dab;\">https://www.gem-beta.org/public/DownloadMeasure.aspx?mid=1348</span></a></span></p> </td> </tr> <tr> <td class=\"indent1\">Medical Outcomes Study Pain Measures (MOS) </td> <td><a href=\"http://www.columbia.edu/cu/ssw/projects/pmap/docs/yoshiokamos.pdf\" spellcheck=\"true\">www.columbia.edu/cu/ssw/projects/pmap/docs/yoshiokamos.pdf</a></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Low back pain questionnaires </td> </tr> <tr> <td class=\"indent1\">Oswestry Disability Questionnaire </td> <td><a href=\"http://www.rehab.msu.edu/_files/_docs/Oswestry_Low_Back_Disability.pdf\" spellcheck=\"true\">www.rehab.msu.edu/_files/_docs/Oswestry_Low_Back_Disability.pdf</a></td> </tr> <tr> <td class=\"indent1\">Quebec Back Pain Disability Scale </td> <td><a href=\"http://www.tac.vic.gov.au/files-to-move/media/upload/quebec_scale.pdf\" spellcheck=\"true\">www.tac.vic.gov.au/files-to-move/media/upload/quebec_scale.pdf</a></td> </tr> <tr> <td class=\"indent1\">Roland Morris Disability Questionnaire</td> <td><a href=\"http://depts.washington.edu/anesth/education/forms/pain/Roland-Morris-Questionaire.pdf\" spellcheck=\"true\">depts.washington.edu/anesth/education/forms/pain/Roland-Morris-Questionaire.pdf</a></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Upper extremities </td> </tr> <tr> <td class=\"indent1\">DASH (Disabilities of the Arm, Shoulder and Hand) </td> <td><a href=\"http://www.dash.iwh.on.ca/sites/dash/files/downloads/DASH_questionnaire_2010.pdf\">http://www.dash.iwh.on.ca/sites/dash/files/downloads/DASH_questionnaire_2010.pdf</a></td> </tr> <tr> <td class=\"indent1\">Upper Extremity Function Scale </td> <td><span style=\"color: #3966bf;\"><a href=\"http://www.rehab.msu.edu/_files/_docs/Upper_Extremity.pdf\" spellcheck=\"true\">www.rehab.msu.edu/_files/_docs/Upper_Extremity.pdf</a></span></td> </tr> <tr> <td class=\"indent1\">Michigan Hand Outcomes Questionnaire </td> <td><span style=\"color: #3966bf;\"><a href=\"http://www.npionline.org/resources/MTAP.pdf\">www.npionline.org/resources/MTAP.pdf</a></span></td> </tr> <tr> <td class=\"indent1\">Multidimensional Task Ability Profile </td> <td> <p><a href=\"http://www.mtapsystems.com/sites/default/files/MTAP_PDC_rev2.pdf\" spellcheck=\"true\">http://www.mtapsystems.com/sites/default/files/MTAP_PDC_rev2.pdf</a></p> <p><a href=\"http://www.mtapsystems.com/\" spellcheck=\"true\">http://www.mtapsystems.com/</a></p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Lower extremities </td> </tr> <tr> <td class=\"indent1\">Lower Limb Outcomes Questionnaire </td> <td><a href=\"http://www.aaos.org/research/outcomes/Lower_Limb.pdf\" spellcheck=\"true\">www.aaos.org/research/outcomes/Lower_Limb.pdf</a></td> </tr> <tr> <td class=\"indent1\">MOS 36-item Short-Form Health Survey (SF-36) </td> <td><a href=\"http://www.rand.org/health/surveys_tools/mos/mos_core_36item.html#\" spellcheck=\"true\">www.rand.org/health/surveys_tools/mos/mos_core_36item.html#</a></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50394 Version 8.0</div></div></div>"},"50395":{"type":"graphic_figure","displayName":"APR ventilation","title":"Airway pressure release ventilation (APRV)","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Airway pressure release ventilation (APRV)</div><div class=\"cntnt\"><img style=\"width:510px; height:321px;\" src=\"images/PULM/50395_APR_ventilation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A: Continuous flow positive airway pressure (CPAP). B: During exhalation with CPAP, the CPAP valve opens and the airway pressure release (APR) valve closes. C: During airway pressure release from the preset CPAP level to ambient pressure, the CPAP valve closes and the APR valve opens. After closure of the APR valve, functional residual capacity (FRC) is re-established.</div><div class=\"graphic_reference\">Adapted from Downs JB, Stock MC, Crit Care Med 1987; 15:459.</div><div id=\"graphicVersion\">Graphic 50395 Version 2.0</div></div></div>"},"50397":{"type":"graphic_diagnosticimage","displayName":"Bakers cyst sonogram","title":"Baker's cyst sonogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Baker's cyst sonogram</div><div class=\"cntnt\"><img style=\"width:418px; height:278px;\" src=\"images/RHEUM/50397_Bakers_cyst_sonogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This transverse sonogram of the popliteal region shows a Baker's cyst taking the form of an X-shaped cross of St. Andrew. The gastrocnemius bursa lies around the medial head of the gastrocnemius tendon (GC) is filled with fluid (asterisks), as is the bursa of the semimembranosus tendon (SM), which lies just superficial to the femoral bone (B).</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 50397 Version 2.0</div></div></div>"},"50398":{"type":"graphic_figure","displayName":"Unstable fracture pattern of the shaft of the distal phalanx","title":"Unstable fracture pattern of the shaft of the distal phalanx: Transverse basal fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unstable fracture pattern of the shaft of the distal phalanx: Transverse basal fracture</div><div class=\"cntnt\"><img style=\"width:346px; height:452px;\" src=\"images/SURG/50398_Unstab_trans_dist_phal_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A transverse epiphyseal fracture at the base of the distal phalanx in children (Seymour's fracture) is an unstable fracture. These fractures are often associated with a transverse laceration of the nail bed that can get caught within the fracture and prevent reduction. These fractures require open reduction of the fracture and pinning, followed by nail bed repair.</div><div id=\"graphicVersion\">Graphic 50398 Version 6.0</div></div></div>"},"50405":{"type":"graphic_diagnosticimage","displayName":"Unicameral bone cyst","title":"Unicameral bone cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unicameral bone cyst</div><div class=\"cntnt\"><img style=\"width:420px; height:380px;\" src=\"images/PEDS/50405_Unicameral_bone_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the central location, slight expansion, thin but intact cortex, and scalloped endosteal margin.</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50405 Version 2.0</div></div></div>"},"50406":{"type":"graphic_diagnosticimage","displayName":"Normal CT scan of biliopancreatic diversion with duodenal switch","title":"Normal CT scan after biliopancreatic diversion/duodenal switch (BPD/DS)","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Normal CT scan after biliopancreatic diversion/duodenal switch (BPD/DS)</div><div class=\"cntnt\"><img style=\"width:487px; height:494px;\" src=\"images/SURG/50406_Normal_BPD_DS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT image shows the normal postoperative appearance after a biliopancreatic diversion with a duodenal switch (BPD/DS). Note that more of the contrast filled loops are on the right side of the abdomen.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 50406 Version 3.0</div></div></div>"},"50407":{"type":"graphic_figure","displayName":"Wisconsin card sort test","title":"Wisconsin card sort test","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Wisconsin card sort test</div><div class=\"cntnt\"><img style=\"width:525px; height:237px;\" src=\"images/NEURO/50407_Wisconsin-card-sort-test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Wisconsin Card Sorting Test assesses the ability to divide attention and to change sets.&#160; <br> The cards have different number, color, and type of shape on the face. A number of cards (in this example, four) are presented to the subject. The test administrator decides, but does not tell the subject, whether&#160;subsequent cards are to be matched based on number, color, or shape. The subject is asked to make&#160;a match and then is told whether the match was right or wrong. In subsequent attempts, the&#160;matching rule is learned.&#160;During the test, the rules are changed and the subject&#160;adapts.&#160;The time taken for the patient to learn the new rules are analysed to arrive at a test score.<br> Originally performed with a physical deck of cards, the test is now most commonly carried out and scored by computer.</div><div id=\"graphicVersion\">Graphic 50407 Version 1.0</div></div></div>"},"50408":{"type":"graphic_picture","displayName":"Appendiceal well-differentiated neuroendocrine tumor","title":"Appendiceal well-differentiated neuroendocrine tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Appendiceal well-differentiated neuroendocrine tumor</div><div class=\"cntnt\"><img style=\"width:396px; height:304px;\" src=\"images/GAST/50408_Appendicealcarcinoidtumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Neuroendocrine&nbsp;tumor in the appendix.</div><div class=\"graphic_reference\">Courtesy of Eric Libby, MD.</div><div id=\"graphicVersion\">Graphic 50408 Version 4.0</div></div></div>"},"50409":{"type":"graphic_picture","displayName":"Endosc eosinophil gastroent","title":"Eosinophilic gastroenteritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eosinophilic gastroenteritis</div><div class=\"cntnt\"><img style=\"width:360px; height:294px;\" src=\"images/GAST/50409_Endosc_eosinophil_gastroent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic photo of a patient with eosinophilic gastroenteritis involving the mucosa showing nodularity and polypoid mucosa of the antrum.</div><div class=\"graphic_reference\">Courtesy of Nirmala Gonsalves, MD.</div><div id=\"graphicVersion\">Graphic 50409 Version 1.0</div></div></div>"},"50410":{"type":"graphic_table","displayName":"Monitor during amiodarone","title":"Amiodarone monitoring and recommendations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Amiodarone monitoring and recommendations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"15%\"></colgroup><colgroup span=\"2\" width=\"27%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">System</td> <td class=\"subtitle1\" colspan=\"2\">Monitoring</td> <td class=\"subtitle1\" rowspan=\"2\">Possible adverse effect</td> <td class=\"subtitle1\" rowspan=\"2\">Recommendation</td> </tr> <tr> <td class=\"subtitle2\">Baseline</td> <td class=\"subtitle2\">Follow-up</td> </tr> <tr> <td rowspan=\"2\">Cardiac</td> <td rowspan=\"2\">ECG (at baseline and during loading dose)</td> <td rowspan=\"2\">Yearly</td> <td>QT prolongation; torsade de pointes</td> <td rowspan=\"2\">Reduce amiodarone dose or discontinue use</td> </tr> <tr> <td>Symptomatic sinoatrial or conduction system impairment</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Dermatologic</td> <td rowspan=\"2\">Physical examination</td> <td rowspan=\"2\">As needed for signs/symptoms</td> <td>Photosensitivity to UV light</td> <td>Avoid sunlight; use sunscreen</td> </tr> <tr> <td>Blue-gray skin discoloration</td> <td>Reduce amiodarone dose or discontinue use</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Endocrine</td> <td rowspan=\"2\">Thyroid function tests</td> <td rowspan=\"2\">Every 6 months</td> <td>Hyperthyroidism</td> <td>Discontinue amiodarone; refer to endocrinologist</td> </tr> <tr> <td>Hypothyroidism</td> <td>Treat with levothyroxine</td> </tr> <tr class=\"divider_top\"> <td>Hepatic</td> <td>AST or ALT</td> <td>Every 6 months</td> <td>AST or ALT elevation &#8805;2x upper limit of reference range</td> <td>Reduce amiodarone dose or discontinue use</td> </tr> <tr class=\"divider_top\"> <td>Neurologic</td> <td>Physical examination</td> <td>As needed for signs/symptoms</td> <td>Ataxia, dizziness, fatigue</td> <td>Reduce amiodarone dose or discontinue use</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Ophthalmologic</td> <td rowspan=\"2\">Eye examination</td> <td rowspan=\"2\">As needed for signs/symptoms</td> <td>Corneal microdeposits</td> <td>Continue amiodarone treatment</td> </tr> <tr> <td>Optic neuropathy</td> <td>Discontinue treatment</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Pulmonary</td> <td>Pulmonary function tests</td> <td>As needed for signs/symptoms</td> <td rowspan=\"2\">Pulmonary toxicity (cough, fever, dyspnea)</td> <td rowspan=\"2\">Discontinue amiodarone immediately; consider corticosteroid treatment</td> </tr> <tr> <td>Chest radiograph</td> <td>Yearly</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; AST: aspartate aminotransferase; ALT: alanine aminotransferase.</div><div class=\"graphic_reference\">Reproduced with permission from: Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007; 298:1312. Copyright &copy; American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 50410 Version 4.0</div></div></div>"},"50411":{"type":"graphic_diagnosticimage","displayName":"Myocardial bridging of the LAD","title":"Myocardial bridging of the left anterior descending coronary artery ","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Myocardial bridging of the left anterior descending coronary artery </div><div class=\"cntnt\"><img style=\"width:540px; height:237px;\" src=\"images/CARD/50411_Myocardial_bridging_LAD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left coronary angiogram is shown in diastole (left frame) and systole (right frame). There is marked systolic narrowing of the proximal left anterior descending artery (arrow) consistent with myocardial bridging.</div><div id=\"graphicVersion\">Graphic 50411 Version 4.0</div></div></div>"},"50414":{"type":"graphic_table","displayName":"Distinguishing among lethal skeletal dysplasias","title":"Common lethal skeletal dysplasias with severe micromelia and small thorax","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common lethal skeletal dysplasias with severe micromelia and small thorax</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">Bone mineralization</td> <td class=\"subtitle1\">Fractures</td> <td class=\"subtitle1\">Macrocranium</td> <td class=\"subtitle1\">Short trunk</td> </tr> <tr> <td>Thanatophoric dysplasia*</td> <td>Normal</td> <td>No</td> <td>Yes</td> <td>No</td> </tr> <tr> <td>Achondrogenesis</td> <td>Patchy demineralization</td> <td>Occasional</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>Osteogenesis imperfect type 2</td> <td>Generalized demineralization</td> <td>Innumerable</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Hypophosphatasia</td> <td>Patchy or generalized demineralization</td> <td>Occasional</td> <td>No</td> <td>No</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Distinguished from homozygous achondroplasia because in the latter both parents are affected heterozygotes. Distinguished from short-rib polydactyly syndrome because the latter has normal cranial size and polydactyl.</div><div id=\"graphicVersion\">Graphic 50414 Version 3.0</div></div></div>"},"50415":{"type":"graphic_waveform","displayName":"12-lead ECG right anterior septal WPW","title":"12-lead electrocardiogram (ECG) of a right anterior septal accessory AV pathway","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) of a right anterior septal accessory AV pathway</div><div class=\"cntnt\"><img style=\"width:503px; height:336px;\" src=\"images/CARD/50415_Right_anterior_septal_WPW.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram from a patient with Wolff-Parkinson-White syndrome during sinus tachycardia shows a maximally preexcited QRS complex which has a left bundle branch block pattern and is markedly positive in the inferior leads. The delta wave is isoelectric in leads aVL and V6. These features localize the accessory pathway to the right anterior septum.</div><div id=\"graphicVersion\">Graphic 50415 Version 4.0</div></div></div>"},"50416":{"type":"graphic_picture","displayName":"Capnocytophaga peripheral smear","title":"<EM>Capnocytophaga canimorsus</EM>, a potential emerging microorganism in splenectomized patients","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Capnocytophaga canimorsus</EM>, a potential emerging microorganism in splenectomized patients</div><div class=\"cntnt\"><img style=\"width:399px; height:257px;\" src=\"images/ID/50416_Capnocytophaga_peripheral_s.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 48-year-old splenectomized patient who had recent dog exposure was admitted with respiratory failure. The peripheral blood film was reviewed and showed the presence of bacteria within the neutrophils (note their characteristic filamentous rod-shape morphology). Blood culture and further sequencing of DNA confirmed the microorganism as <EM>Capnocytophaga canimorsus</EM>, part of the normal flora found within the oral cavity of dogs and cats. Subsequent to the diagnosis, the patient developed septic shock and disseminated intravascular coagulation, despite intravenous antibiotics administration, and died within a few days of commencing treatment. This case illustrates the importance of urgent screening of peripheral blood films for bacteria, especially in septic asplenic patients who have a history of domestic animal exposure. In addition, this group of patients should be given oral penicillin for prophylaxis.</div><div class=\"graphic_reference\">Reproduced with permission from: Yu RK, Shepherd LE, Rapson DA. Images in Haematology. British J Haematology 2000; 109:679. Copyright © 2000 Blackwell Science. <A spellcheck=true href=\"http://www.wiley.com/wiley-blackwell\" target=_blank>http://www.blackwell-science.com</A>.</div><div id=\"graphicVersion\">Graphic 50416 Version 6.0</div></div></div>"},"50418":{"type":"graphic_table","displayName":"Rx EC IE (S to PCN and gent)","title":"Suggested regimens for therapy of native or prosthetic valve endocarditis due to enterococcal strains susceptible to penicillin and gentamicin*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested regimens for therapy of native or prosthetic valve endocarditis due to enterococcal strains susceptible to penicillin and gentamicin*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">American Heart Association (AHA)</td> <td class=\"subtitle1\">European Society of Cardiology (ESC)</td> <td class=\"subtitle1\">British Society for Antimicrobial Therapy (BSAC)</td> </tr> <tr> <td class=\"subtitle2\">Adult dose</td> <td class=\"subtitle2\">Pediatric dose<sup>&#182;</sup></td> <td class=\"subtitle2\">Adult dose<sup>&#916;</sup></td> <td class=\"subtitle2\">Adult dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Aminoglycoside combination regimen<sup>&#9674;</sup></td> <td class=\"subtitle2_left\">Aminoglycoside combination regimen</td> <td class=\"subtitle2_left\">Aminoglycoside combination regimen</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Aqueous penicillin G 18 to 30 million units per 24 hours IV continuously or in six divided doses for four to six weeks<sup>&#167;</sup></p> <p><strong>or</strong></p> <p>Ampicillin 2 g IV every 4 hours for four to six weeks<sup>&#167;</sup></p> <p><strong>plus</strong></p> <p>Gentamicin<sup>&#165;</sup> 3 mg/kg per 24 hours IV or IM in three divided doses for four to six weeks<sup>&#167;</sup></p> </td> <td class=\"indent1\"> <p>Aqueous penicillin G 200,000 to 300,000 units/kg per 24 hours IV in six divided doses (maximum dose: 24 million units per 24 hours) for four to six weeks<sup>&#167;</sup></p> <p><strong>or</strong></p> <p>Ampicillin 200 to 300 mg/kg per 24 hours IV divided in four or six divided doses (maximum dose: 12 g per 24 hours) for four to six weeks<sup>&#167;</sup></p> <p><strong>plus</strong></p> <p>Gentamicin<sup>&#165;</sup> 3 to 6 mg/kg per 24 hours IV in two or three divided doses for four to six weeks<sup>&#167;</sup></p> </td> <td class=\"indent1\"> <p>Amoxicillin 200 mg/kg per 24 hours IV in four or six divided doses for four to six weeks</p> <p><strong>or</strong></p> <p>Ampicillin 12 g per 24 hours (200 mg/kg per 24 hours) IV in four or six divided doses for four to six weeks</p> <p><strong>plus</strong></p> <p>Gentamicin<sup>&#165;</sup> 3 mg/kg per 24 hours IV or IM in one dose for four to six weeks</p> </td> <td class=\"indent1\"> <p>Amoxicillin 2 g every&nbsp;4 hours IV for four to six weeks</p> <p><strong>or</strong></p> <p>Penicillin 2.4 g every&nbsp;4 hours IV for four to six weeks</p> <p><strong>plus</strong></p> <p>Gentamicin<sup>&#165;</sup> 1 mg/kg every 12 hours IV for four to six weeks</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Beta-lactam combination regimen<sup>&#135;</sup><sup>&#134;</sup></td> <td class=\"subtitle2_left\">Beta-lactam combination regimen<sup>&#134;</sup></td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <p>Ceftriaxone 2 g IV every 12 hours for six weeks</p> <p><strong>plus</strong></p> <p>Ampicillin 2 g IV every 4 hours for six weeks</p> </td> <td class=\"indent1\"> <p>Ceftriaxone 100 mg/kg per 24 hours IV in two divided doses or 80 mg/kg in one daily dose (maximum dose: 4 g per 24 hours; if dose is &#62;2 g per 24 hours, use divided dosing every 12 hours) for six weeks</p> <p><strong>plus</strong></p> <p>Ampicillin (dosing as above) for six weeks</p> </td> <td class=\"indent1\"> <p>Ceftriaxone 2 g IV every 12 hours for six weeks</p> <p><strong>plus</strong></p> <p>Ampicillin (dosing as above) for six weeks</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses in this table are intended for patients with normal renal and hepatic&nbsp;function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the Lexicomp drug-specific monographs for renal dose adjustments.</div><div class=\"graphic_footnotes\">NVE: native valve endocarditis; PVE: prosthetic valve endocarditis; IV: intravenously; IM: intramuscularly; HLAR: high-level aminoglycoside resistance.<br />* Patients unable to tolerate beta-lactams should receive treatment as for infection due to isolates with intrinsic penicillin resistance. Refer to UpToDate table on treatment regimens for native or prosthetic valve endocarditis due to an enterococcal strain resistant to penicillin and susceptible to vancomycin and aminoglycosides.<br />¶ Consultation with an infectious disease specialist is recommended for pediatric patients with enterococcal endocarditis.<br />Δ Pediatric doses (should not exceed adult doses): amoxicillin 200 mg/kg per 24 hours IV in four to six divided doses; ampicillin 300 mg/kg per 24 hours IV in four or six divided doses; ceftriaxone 100 mg/kg per 24 hours IV or IM in two divided doses; gentamicin 3 mg/kg per 24 hours IV or IM in three divided doses; vancomycin 40 mg/kg per 24 hours IV in two or three divided doses.<br /><FONT class=lozenge>◊</FONT> Recommended for patients with baseline creatinine clearance &gt;50 mL/min.<br />§ Patients with NVE and symptoms &lt;3 months may be treated for 4 weeks; patients with PVE or NVE with symptoms ≥3 months should be treated for at least 6 weeks. For adult patients with gentamicin-susceptible isolates, some experts shorten gentamicin component to two weeks when used in combination with a beta-lactam, particularly with emergence of nephrotoxicity (refer to text).<br />¥ Renal function and gentamicin serum concentrations should be monitored at least once per week. In adults, aminoglycosides are dosed based on ideal body weight. Gentamicin dosage adjusted for peak serum concentrations are 3 to 4 mcg/mL, trough &lt;1 mcg/mL when two to three divided doses used. When given in a single daily dose, pre-dose (trough) concentrations should be &lt;1 mcg/mL. Per ESC guidelines, post-dose (peak, one hour after injection) serum concentrations should be approximately 10 to 12 mcg/mL (per AHA guidelines, there is&nbsp;no role for measuring peak gentamicin concentration following single daily dosing).<br />‡ Recommended for patients with creatinine clearance ≤50 mL/min (either at baseline or while on therapy with aminoglycoside-containing regimen).<br />† The beta-lactam combination regimen is active against <EM>Enterococcus faecalis</EM> strains with and without HLAR and is the combination of choice in patients with HLAR <EM>E. faecalis</EM> endocarditis; it is not active against <EM>Enterococcus faecium</EM>. This regimen is reasonable for patients with normal or impaired renal function, abnormal cranial nerve VIII function, or if the laboratory is unable to provide rapid results of aminoglycoside serum concentration.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132:1435.</LI>&#xD;&#xA;<LI>Baltimore RS, Gewitz M, Baddour LM, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation 2015; 132:1487.</LI>&#xD;&#xA;<LI>Authors/Task Force Members, Habib G, Lancellotti P, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.</LI>&#xD;&#xA;<LI>Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012; 67:269.</LI></OL></div><div id=\"graphicVersion\">Graphic 50418 Version 12.0</div></div></div>"},"50419":{"type":"graphic_figure","displayName":"Lumbosacral dermatomes","title":"Lumbosacral dermatomes","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Lumbosacral dermatomes</div><div class=\"cntnt\"><img style=\"width:540px; height:506px;\" src=\"images/NEURO/50419_Lumbosacral_dermatomes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the lumbosacral dermatomes. Patients with sciatica may have pain, paresthesias, and diminished sensation in the dermatome of the nerve root that is involved.</div><div id=\"graphicVersion\">Graphic 50419 Version 2.0</div></div></div>"},"50420":{"type":"graphic_diagnosticimage","displayName":"Scans nasal ethmoid CA","title":"Patient with poorly-differentiated carcinoma of the nasal cavity and ethmoid sinus","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Patient with poorly-differentiated carcinoma of the nasal cavity and ethmoid sinus</div><div class=\"cntnt\"><img style=\"width:543px; height:235px;\" src=\"images/ONC/50420_ScansnasalethmoidCA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Coronal computed tomography (CT) shows mass filling left nasal cavity and sphenoid sinus, with aggressive bone destruction of the anterior skull base and medial wall of the orbit. B) Coronal contrast-enhanced T1 weighted magnetic resonance imaging (MRI) at nearly the same level shows the dura is irregularly thickened and enhanced, suggesting dural involvement by tumor.</div><div class=\"graphic_reference\">Reproduced with permission from: Parsons JT, Stringer SP, Mancuso AA, Million RR. Nasal vestibule, nasal cavity, and paranasal sinuses. In: Million RR, Cassisi NJ (Eds). Management of Head and Neck Cancer: A Multidisciplinary Approach. Philadelphia: J.B. Lippincott Company, 1994.&nbsp;Copyright © 1994 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50420 Version 13.0</div></div></div>"},"50421":{"type":"graphic_picture","displayName":"Surface anatomy anterior knee","title":"Surface anatomy of anterior knee","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Surface anatomy of anterior knee</div><div class=\"cntnt\"><img style=\"width:550px; height:397px;\" src=\"images/PEDS/50421_Surface_anatom_ant_knee_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Charlie Goldberg, MD. Image available at meded.ucsd.edu/clinicalmed/.</div><div id=\"graphicVersion\">Graphic 50421 Version 3.0</div></div></div>"},"50422":{"type":"graphic_figure","displayName":"Eustachian tube PI","title":"Eustachian tube","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eustachian tube</div><div class=\"cntnt\"><img style=\"width:306px; height:593px;\" src=\"images/PI/50422_Eustachian_tube_PI_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The eustachian tube is a tube that connects the middle ear (the part of the ear behind the eardrum) to the back of the nose and throat.</div><div id=\"graphicVersion\">Graphic 50422 Version 1.0</div></div></div>"},"50423":{"type":"graphic_table","displayName":"Burn resuscitation goals","title":"Physiologic goals for fluid resuscitation for burn patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physiologic goals for fluid resuscitation for burn patients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td>Mental status:</td>\n\t\t\t\t\t<td>Alert and comfortable</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Skin:</td>\n\t\t\t\t\t<td>Warm and well-perfused</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1_start\" colspan=\"2\">Urine output:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\" rowspan=\"2\">&nbsp;</td>\n\t\t\t\t\t<td class=\"sublist_other\">&#60;30 kg, 1 to 2 mL/kg per hour</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist_other\">&#8805;30 kg, 0.5 to 1 mL/kg per hour</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1_start\" colspan=\"2\">Heart rate: normal mean heart rate for age</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">Newborn to 3 months:</td>\n\t\t\t\t\t<td class=\"sublist_other\">140 beats per minute</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">3 months to 2 years:</td>\n\t\t\t\t\t<td class=\"sublist_other\">140 beats per minute</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">2 years to 10 years:</td>\n\t\t\t\t\t<td class=\"sublist_other\">80 beats per minute</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">&#62;10 years:</td>\n\t\t\t\t\t<td class=\"sublist_other\">75 beats per minute</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1_start\" colspan=\"2\">Systolic blood pressure (SBP): normal range for children &#62;1 year of age</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\" rowspan=\"2\">&nbsp;</td>\n\t\t\t\t\t<td class=\"sublist_other\">[Median SBP = 90 mm Hg + (2 x age in years)]</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist_other\">[Lower limit of SBP = 70mm Hg + (2 x age in years)]</td>\n\t\t\t\t</tr>\n\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 50423 Version 2.0</div></div></div>"},"50424":{"type":"graphic_figure","displayName":"Parathyroid hormone structure","title":"Parathyroid hormone structure","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Parathyroid hormone structure</div><div class=\"cntnt\"><img style=\"width:583px; height:395px;\" src=\"images/ENDO/50424_Parathyroid_horm_structure.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic presentation of PTH(1-84) and the approximate location of the peptide regions recognized by the antibodies used in displacement-type RIAs and in \"two-site\" IMAs.</div><div class=\"graphic_footnotes\">IMA: immunometric assay; PTH: parathyroid hormone; RIA: radioimmunoassay.</div><div class=\"graphic_reference\">Adapted with permission from: Henrich LM, Rogol AD, et al. Persistent Hypercalcemia After Parathyroidectomy in an Adolescent and Effect of Treatment With Cinacalcet HCl. Clinical Chemistry 2006; 52(12):2286. Copyright ©2006 American Association for Clinical Chemistry.</div><div id=\"graphicVersion\">Graphic 50424 Version 3.0</div></div></div>"},"50426":{"type":"graphic_picture","displayName":"Vulvar cancer 3","title":"Vulvar cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar cancer</div><div class=\"cntnt\"><img style=\"width:353px; height:500px;\" src=\"images/OBGYN/50426_Vulvar_cancer_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vulvar carcinoma in situ before application of 5 percent acetic acid.</div><div class=\"graphic_reference\">Reproduced with permission from: Scott, JR, Gibbs, RS. Danforth's Obstetrics and Gynecology, Ninth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50426 Version 1.0</div></div></div>"},"50427":{"type":"graphic_picture","displayName":"Glucagon kit PI","title":"Glucagon kit","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Glucagon kit</div><div class=\"cntnt\"><img style=\"width:504px; height:334px;\" src=\"images/PI/50427_Glucagon_kit_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a glucagon shot kit. The kit includes a syringe and needle, a small vial of glucagon powder, and a carrying case. The way to give a glucagon shot is:<br /><OL>&#xD;&#xA;<LI>Stick the needle into the top of the vial, and inject the fluid in the syringe into the vial of powder. </LI>&#xD;&#xA;<LI>Gently swirl the vial to mix the powder and liquid, until the powder dissolves. </LI>&#xD;&#xA;<LI>Draw up the liquid in the vial into the syringe. </LI>&#xD;&#xA;<LI>Stick the needle into the buttock, arm, or thigh,&nbsp;and inject the liquid. </LI></OL></div><div class=\"graphic_reference\">© Copyright Eli Lilly and Company. All rights reserved. Used with permission.</div><div id=\"graphicVersion\">Graphic 50427 Version 7.0</div></div></div>"},"50428":{"type":"graphic_diagnosticimage","displayName":"Amiodarone toxicity chest radiograph","title":"Amiodarone pulmonary toxicity","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Amiodarone pulmonary toxicity</div><div class=\"cntnt\"><img style=\"width:513px; height:219px;\" src=\"images/PULM/50428_Amiodarone_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiographs from a patient treated with amiodarone demonstrate left upper lobe consolidation (A) and six months later right upper lobe consolidation with residual scar in left upper lobe (B).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 50428 Version 3.0</div></div></div>"},"50429":{"type":"graphic_diagnosticimage","displayName":"Healed varicella pneumonia PA","title":"Healed varicella pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Healed varicella pneumonia</div><div class=\"cntnt\"><img style=\"width:361px; height:368px;\" src=\"images/PULM/50429_Healed_varicella_pneumonia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows multiple coarse nodular lung calcifications as sequelae of a previous acute varicella pneumonia.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 50429 Version 3.0</div></div></div>"},"50430":{"type":"graphic_figure","displayName":"Cervical rib causing thoracic outlet syndrome","title":"Cervical rib causing thoracic outlet syndrome","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Cervical rib causing thoracic outlet syndrome</div><div class=\"cntnt\"><img style=\"width:498px; height:412px;\" src=\"images/SURG/50430_Thoracicoutletcervicalrib.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thoracic outlet syndromes are due to compression of any of the structures (brachial plexus, subclavian artery, subclavian vein) that traverse the confined space between the clavicle and first rib. Anatomic abnormaliaties such as a cervical rib (shown), musculotendinous abnormalities or scarring can contribute to the pathology.</div><div id=\"graphicVersion\">Graphic 50430 Version 5.0</div></div></div>"},"50431":{"type":"graphic_diagnosticimage","displayName":"Obstructed Roux limb after gastric bypass","title":"Obstructed Roux limb after gastric bypass","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Obstructed Roux limb after gastric bypass</div><div class=\"cntnt\"><img style=\"width:559px; height:310px;\" src=\"images/SURG/50431_Obstr_Roux_limb_gast_bypass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Obstructed, contrast filled Roux limb after gastric bypass with collapse of the common channel on computed tomography (CT) imaging. The obstruction&nbsp; was a result of an adhesion at the level of the enteroenterostomy.</div><div id=\"graphicVersion\">Graphic 50431 Version 6.0</div></div></div>"},"50432":{"type":"graphic_table","displayName":"Pruritus topical therapy","title":"Topical therapies for pruritus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Topical therapies for pruritus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"30%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Notes</td> </tr> <tr class=\"divider_bottom\"> <td>Barrier repair creams/moisturizers/emollients</td> <td>Not applicable</td> <td>Low pH products may be particularly useful</td> </tr> <tr class=\"divider_bottom\"> <td>Topical corticosteroids</td> <td>Variable</td> <td>Not directly antipruritic, may be useful in pruritus due to inflammatory skin dermatoses</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Topical calcineurin inhibitors</td> <td>Tacrolimus 0.03% and 0.1% ointment</td> <td class=\"divider_bottom\" rowspan=\"2\">Particularly useful in anogenital pruritus, may experience transient burning and stinging</td> </tr> <tr class=\"divider_bottom\"> <td>Pimecrolimus 1% cream</td> </tr> <tr class=\"divider_bottom\"> <td>Doxepin</td> <td>5% cream</td> <td>Avoid in children, 20 to 25% risk of sedation</td> </tr> <tr class=\"divider_bottom\"> <td>Menthol</td> <td>1 to 3% cream or lotion</td> <td>Useful in patients who report cooling as an alleviating factor</td> </tr> <tr class=\"divider_bottom\"> <td>Capsaicin</td> <td>0.025 to 0.1% cream</td> <td>Particularly useful in neuropathic itch, may experience initial transient burning</td> </tr> <tr class=\"divider_bottom\"> <td>Salicylic acid</td> <td>2 to 6%</td> <td>Useful in lichen simplex chronicus, avoid in acute inflammatory dermatoses and children</td> </tr> <tr> <td rowspan=\"5\">Local anesthetics</td> <td>Pramoxine 1 to 2.5%</td> <td>Useful for pruritus on face and that associated with CKD</td> </tr> <tr> <td>Lidocaine patch 5%</td> <td>Useful in neuropathic pruritus</td> </tr> <tr> <td>Eutectic mixture of lidocaine 2.5% and prilocaine 2.5%</td> <td>Useful in neuropathic pruritus</td> </tr> <tr> <td>5% urea + 3% polidocanol</td> <td>Both moisturizing and anesthetic properties, not available in the United States</td> </tr> <tr> <td>Ketamine 5 or 10% + amitriptyline 5% + lidocaine 5%</td> <td>Compounded agent; may be useful for various forms of chronic pruritus</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CKD: chronic kidney disease.</div><div class=\"graphic_reference\">Adapted from: Patel T, Yosipovitch G. Therapy of pruritus. Expert Opin Pharmacother 2010; 11:1673. Copyright © 2010 Informa Healthcare. Reproduced with permission of Informa Healthcare.</div><div id=\"graphicVersion\">Graphic 50432 Version 3.0</div></div></div>"},"50433":{"type":"graphic_figure","displayName":"Antidromic AVRT","title":"Antidromic atrioventricular reentrant tachycardia (AVRT) in the setting of an accessory AV pathway","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Antidromic atrioventricular reentrant tachycardia (AVRT) in the setting of an accessory AV pathway</div><div class=\"cntnt\"><img style=\"width:450px; height:288px;\" src=\"images/CARD/50433_AntidromictachycardiaWPW.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The rhythm strip shows a sinus (S) beat that has a short PR interval and a wide QRS complex as a result of a delta wave (d). Panel A shows the activation sequence with an atrial premature beat (APB,*). The impulse reaches the atrioventricular node (N) before it has repolarized and hence is blocked in this structure. However, the accessory pathway (AP), which has a short refractory period, is able to conduct the impulse antegradely, resulting in an APB with a widened QRS morphology similar to the sinus beat. As seen in panel B, following myocardial activation, the impulse is conducted retrogradely along the His-Purkinje system and AV node, resulting in retrograde atrial activation, seen on the rhythm strip as an inverted P wave. If this activation sequence repeats itself (panel C), a wide QRS complex antidromic atrioventricular reentrant (or reciprocating) tachycardia (AVRT) is established.</div><div id=\"graphicVersion\">Graphic 50433 Version 4.0</div></div></div>"},"50435":{"type":"graphic_table","displayName":"Clinical manifestations and treatment of syphilis","title":"Clinical manifestations and treatment of syphilis in nonpregnant adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations and treatment of syphilis in nonpregnant adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"13%\"></colgroup><colgroup span=\"3\" width=\"29%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Clinical manifestations*</td> <td class=\"subtitle1\">Treatment<sup>&#182;</sup></td> <td class=\"subtitle1\">Monitoring after treatment<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Early syphilis</strong></td> <td> <p><strong>Primary syphilis:</strong><br /> Typically consists of a single painless chancre at the site of inoculation, accompanied by regional adenopathy.</p> <p><strong>Secondary syphilis:</strong><br /> A systemic illness that often includes a rash (disseminated and/or involving the palms and soles), fever, malaise, and other symptoms such as pharyngitis, hepatitis, mucous patches, condyloma lata, alopecia.</p> <strong>Early latent:</strong><br /> Refers to the period when a patient is infected with <em>Treponema pallidum</em> as demonstrated by serologic testing, but has no symptoms. Early latent syphilis occurs within the first year of initial infection.</td> <td><strong>Preferred:</strong> <ul> <li>Penicillin G benzathine 2.4 million units IM once </li> </ul> <strong>Alternatives (choose one)<sup>&#9674;</sup>: </strong> <ul> <li>Doxycycline 100 mg orally twice daily for 14 days&nbsp; </li> <li>Ceftriaxone 1 to 2 g daily IM or IV for 10 to 14 days </li> <li>Tetracycline 500 mg orally four times daily for 14 days </li> <li>Amoxicillin 3 g <strong>plus </strong>probenecid 500 mg, both given orally twice daily for 14 days </li> </ul> </td> <td> <p>Clinical exam and serologic testing with a nontreponemal test (eg, RPR) at 6 and 12 months.</p> <p>Titers can be checked more frequently if follow-up is uncertain or reinfection is a concern.</p> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Late syphilis</strong></td> <td> <p><strong>Tertiary syphilis:</strong><br /> Patients with late syphilis who have symptomatic manifestations involving the cardiovascular system or gummatous disease (granulomatous disease of the skin and subcutaneous tissues, bones, or viscera).</p> <strong>Late latent syphilis:</strong><br /> The period when a patient is infected with <em>T. pallidum</em> as demonstrated by serologic testing, but has no symptoms. Late latent syphilis by definition occurs more than one year after initial infection. If the timing of an infection is not known, late latent syphilis is presumed.</td> <td><strong>Preferred:</strong> <ul> <li>Penicillin G benzathine 2.4 million units IM once weekly for three weeks </li> </ul> <p><strong>Alternatives (choose one):</strong> </p> <ul> <li>Doxycycline 100 mg orally twice daily for four weeks </li> <li>Ceftriaxone 2 g daily IM or IV for 10 to 14 days </li> </ul> </td> <td>Clinical exam and serologic testing with a nontreponemal test (eg, RPR) at 6, 12, and 24 months.</td> </tr> <tr> <td><strong>Neurosyphilis</strong></td> <td> <p><strong>Neurosyphilis:</strong><br /> Can occur at any time during the course of infection.</p> <p><strong>Early neurosyphilis:</strong><br /> Patients with early neurosyphilis may have asymptomatic meningitis; symptomatic meningitis; or less commonly meningovascular disease (ie, meningitis and stroke). Vision or hearing loss with or without concomitant meningitis may also be present, and ocular/otologic syphilis is treated as neurosyphilis. &nbsp;</p> <strong>Late neurosyphilis:</strong><br /> The most common forms involve the brain and spinal cord (dementia [general paresis] and tabes dorsalis).</td> <td><strong>Preferred:</strong> <ul> <li>Aqueous penicillin G 3 to 4 million units IV every four hours (or 18 to 24 million units continuous IV infusion) for 10 to 14 days<sup>&#167;</sup> </li> <li>Penicillin G procaine 2.4 million units IM daily <strong>plus </strong>probenecid 500 mg orally&nbsp;four times daily, both for 10 to 14 days&nbsp; </li> <li>If possible, patients allergic to penicillin should be desensitized and treated with IV penicillin </li> </ul> <strong>Alternatives<sup>&#165;</sup>: </strong> <ul> <li>Ceftriaxone 2 g IV daily for 10 to 14 days </li> </ul> </td> <td> <p>Clinical and serologic monitoring with nontreponemal tests (eg, RPR). The frequency depends upon the stage of disease (eg, early or late).</p> CSF monitoring may be warranted.<sup>&#135;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; IM: intramuscular; IV: intravenous; RPR: rapid plasma reagin.<br />* Refer to the topics that discuss the clinical manifestations of syphilis and neurosyphilis for more detailed information. <br />¶ For the treatment of pregnant women and children, refer to the topics that discuss syphilis and pregnancy and congenital syphilis.<br />Δ HIV-infected patients are typically monitored more frequently. Refer to the topic that discusses the treatment of syphilis in patients with HIV infection.<br />◊ A single 2 g dose of azithromycin administered orally is an alternative <STRONG>only</STRONG> if other options are not possible since azithromycin resistance is a concern.<br />§ For patients with late neurosyphilis, some UpToDate authors administer a single dose of benzathine penicillin G upon completion of IV penicillin since the total duration of penicillin treatment for neurosyphilis is shorter than the regimens used for late syphilis.<br />¥&nbsp;Limited clinical experience suggests that doxycycline (200 mg orally twice daily) for 21 to 28 days may be effective as an alternative regimen. However, this regimen should be reserved for exceptional circumstances.<br />‡&nbsp;Refer to the topic on neurosyphilis for a more detailed discussion of monitoring after treatment.</div><div id=\"graphicVersion\">Graphic 50435 Version 7.0</div></div></div>"},"50437":{"type":"graphic_figure","displayName":"Posterior vaginal wall prolapse 3","title":"Repair of posterior vaginal wall prolapse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of posterior vaginal wall prolapse</div><div class=\"cntnt\"><img style=\"width:372px; height:451px;\" src=\"images/OBGYN/50437_Tx_post_vaginal_wall_def_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The rectovaginal musclaris is plicated in the midline using interrupted 0-delayed absorbable sutures.</div><div class=\"graphic_reference\">Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &#169;2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 50437 Version 2.0</div></div></div>"},"50438":{"type":"graphic_picture","displayName":"Calculus deposits","title":"Calculus deposits along the gingival margin on the lingual side of the lower teeth","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calculus deposits along the gingival margin on the lingual side of the lower teeth</div><div class=\"cntnt\"><img style=\"width:360px; height:256px;\" src=\"images/PEDS/50438_Calculus_deposits.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Heavy deposits are present on the left side, and gingivitis is more pronounced than on the right. A large carious lesion is evident on the lower left molar.</div><div class=\"graphic_reference\">Courtesy of Ann Griffen, DDS, MS.</div><div id=\"graphicVersion\">Graphic 50438 Version 1.0</div></div></div>"},"50439":{"type":"graphic_table","displayName":"Drugs and thyroid function","title":"Drugs that cause hypothyroidism, hyperthyroidism, or changes in thyroid function tests","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs that cause hypothyroidism, hyperthyroidism, or changes in thyroid function tests</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Drugs causing hypothyroidism</td> </tr> <tr> <td>Inhibition of thyroid hormone synthesis and/or release - thionamides, lithium, perchlorate, aminoglutethimide, thalidomide, and iodine and iodine-containing drugs including amiodarone, radiographic agents, expectorants (eg, guaifenesin), kelp tablets, potassium iodine solutions (SSKI), Betadine douches, topical antiseptics</td> </tr> <tr> <td>Decreased absorption of T4&nbsp;- cholestyramine, colestipol, colesevelam, aluminum hydroxide, calcium carbonate, sucralfate, iron sulfate, raloxifene, omeprazole, lansoprazole, and possibly other medications that impair acid secretion, sevelemer, lanthanum carbonate, and chromium; malabsorption syndromes can also diminish T4 absorption</td> </tr> <tr> <td>Immune dysregulation - interferon-alfa, interleukin-2, ipilimumab, alemtuzumab, pembrolizumab, nivolumab</td> </tr> <tr> <td>Suppression of TSH - dopamine</td> </tr> <tr> <td>Possible destructive thyroiditis - sunitinib</td> </tr> <tr> <td>Increased type 3 deiodination - sorafenib&nbsp;</td> </tr> <tr> <td>Increased T4 clearance and suppression of TSH - bexarotene</td> </tr> <tr> <td class=\"subtitle1_single\">Drugs causing hyperthyroidism</td> </tr> <tr> <td>Stimulation of thyroid hormone synthesis and/or release - iodine, amiodarone</td> </tr> <tr> <td>Immune dysregulation - interferon-alfa, interleukin-2, ipilimumab, alemtuzumab, pembrolizumab</td> </tr> <tr> <td class=\"subtitle1_single\">Drugs causing abnormal thyroid function tests without thyroid dysfunction</td> </tr> <tr> <td>Low serum TBG - androgens, danazol, glucocorticoids, slow-release niacin (nicotinic acid), l-asparaginase</td> </tr> <tr> <td>High serum TBG - estrogens, tamoxifen, raloxifene, methadone, 5-fluouracil, clofibrate, heroin, mitotane</td> </tr> <tr> <td>Decreased T4 binding to TBG - salicylates, salsalate, furosemide, heparin (via free fatty acids), certain NSAIDs</td> </tr> <tr> <td>Increased T4 clearance - phenytoin, carbamazepine, rifampin, phenobarbital</td> </tr> <tr> <td>Suppression of TSH secretion - dobutamine, glucocorticoids, octreotide</td> </tr> <tr> <td>Impaired conversion of T4 to T3 - amiodarone, glucocorticoids, contrast agents for oral cholecystography (eg, iopanoic acid), propylthiouracil, propanolol, nadolol</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">T4: thyroxine; TSH: thyroid-stimulating hormone; TBG: thyroxine-binding globulin; NSAIDs: nonsteroidal anti-inflammatory drugs; T3: triiodothyronine.</div><div id=\"graphicVersion\">Graphic 50439 Version 10.0</div></div></div>"},"50440":{"type":"graphic_table","displayName":"Precipitants of HE in cirrhosis","title":"Precipitants of hepatic encephalopathy in patients with cirrhosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Precipitants of hepatic encephalopathy in patients with cirrhosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Drugs</td> </tr> <tr> <td class=\"indent1\">Benzodiazepines</td> </tr> <tr> <td class=\"indent1\"><span style=\"color: black;\">Nonbenzodiazepine&nbsp;hypnotics (eg, zolpidem)</span><span style=\"color: black;\">&nbsp;</span>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Narcotics</td> </tr> <tr> <td class=\"indent1\">Alcohol</td> </tr> <tr> <td class=\"subtitle1_single\">Increased ammonia production, absorption or entry into the brain</td> </tr> <tr> <td class=\"indent1\">Excess dietary intake of protein</td> </tr> <tr> <td class=\"indent1\">Gastrointestinal bleeding</td> </tr> <tr> <td class=\"indent1\">Infection</td> </tr> <tr> <td class=\"indent1\">Electrolyte disturbances such as hypokalemia</td> </tr> <tr> <td class=\"indent1\">Constipation</td> </tr> <tr> <td class=\"indent1\">Metabolic alkalosis</td> </tr> <tr> <td class=\"subtitle1_single\">Dehydration</td> </tr> <tr> <td class=\"indent1\">Vomiting</td> </tr> <tr> <td class=\"indent1\">Diarrhea</td> </tr> <tr> <td class=\"indent1\">Hemorrhage</td> </tr> <tr> <td class=\"indent1\">Diuretics</td> </tr> <tr> <td class=\"indent1\">Large volume paracentesis</td> </tr> <tr> <td class=\"subtitle1_single\">Portosystemic shunting</td> </tr> <tr> <td class=\"indent1\">Radiographic or surgically placed shunts</td> </tr> <tr> <td class=\"indent1\">Spontaneous shunts</td> </tr> <tr> <td class=\"subtitle1_single\">Vascular occlusion</td> </tr> <tr> <td class=\"indent1\">Hepatic vein thrombosis</td> </tr> <tr> <td class=\"indent1\">Portal vein thrombosis</td> </tr> <tr> <td class=\"subtitle1_single\">Primary hepatocellular carcinoma</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50440 Version 4.0</div></div></div>"},"50442":{"type":"graphic_picture","displayName":"Inability to lift the tongue","title":"Inability to lift the tongue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inability to lift the tongue</div><div class=\"cntnt\"><img style=\"width:379px; height:327px;\" src=\"images/PEDS/50442_Inability_to_lift_tongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Difficulty lifting the tongue to the upper dental alveolus.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 50442 Version 2.0</div></div></div>"},"50443":{"type":"graphic_diagnosticimage","displayName":"Retropalatal anatomy MRI","title":"Normal retropalatal anatomy","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Normal retropalatal anatomy</div><div class=\"cntnt\"><img style=\"width:536px; height:357px;\" src=\"images/SLEEP/50443_Retropalatal_anatomy_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial spin echo MRI in a normal subject in the retropalatal region. The tongue, soft palate, parapharyngeal fat pads, lateral parapharyngeal walls, parotid gland, subcutaneous fat, teeth, and mandibular rami are all highlighted on this image.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Schwab RJ, Gupta KB, Gefter WB, et al. Upper airway and soft tissue anatomy in normal subjects and patients with sleep-disordered breathing. Significance of the lateral pharyngeal walls. Am J Respir Crit Care Med 1995; 152:1673. Official journal of the American Thoracic Society. Copyright ©1995 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 50443 Version 3.0</div></div></div>"},"50444":{"type":"graphic_picture","displayName":"Intense corneal inflammation RA","title":"Intense corneal inflammation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intense corneal inflammation</div><div class=\"cntnt\"><img style=\"width:398px; height:265px;\" src=\"images/RHEUM/50444_Intense_corneal_inflammatio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe intrastromal corneal inflammation in a patient with rheumatoid arthritis for many years.</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 50444 Version 2.0</div></div></div>"},"50445":{"type":"graphic_algorithm","displayName":"Algorithm for vascular testing in symptomatic PAD","title":"Algorithm for vascular testing in symptomatic PAD","html":"<div class=\"graphic\"><div style=\"width: 577px\" class=\"figure\"><div class=\"ttl\">Algorithm for vascular testing in symptomatic PAD</div><div class=\"cntnt\"><img style=\"width:557px; height:343px;\" src=\"images/SURG/50445_Algo_vasc_test_ED2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with diabetes or end-stage renal disesae may have falsely elevated ABIs as a result of arterial calcification. The toe-brachial index may be more accurate.</div><div class=\"graphic_footnotes\">ABI: ankle brachial index; PAD: peripheral artery disease; MRA: magnetic resonance angiography; CTA: computed tomographic angiography.<br />* Diagnostic for PAD.</div><div id=\"graphicVersion\">Graphic 50445 Version 3.0</div></div></div>"},"50447":{"type":"graphic_table","displayName":"Pharmacokinetic profile of common hallucinogens","title":"Pharmacokinetic profile of common hallucinogens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacokinetic profile of common hallucinogens</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"35%\"></colgroup><colgroup span=\"3\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Drug/substance</td> <td class=\"subtitle1\" rowspan=\"2\">Typical dose</td> <td class=\"subtitle1\" colspan=\"3\">Kinetics following ingestion (see NOTE)</td> </tr> <tr> <td class=\"subtitle2\">Onset (minutes)</td> <td class=\"subtitle2\">Peak effect (hours)</td> <td class=\"subtitle2\">Duration of effects (hours)</td> </tr> <tr> <td>25B-NBMOe&nbsp;</td> <td> <p>Oral (buccal) or nasal: 250-500 micrograms</p> </td> <td>20-40</td> <td>0.5-4</td> <td>12-16</td> </tr> <tr> <td>25C-NBOMe&nbsp;</td> <td> <p>Oral (buccal) or nasal: 200-1000 micrograms</p> </td> <td>1-15</td> <td>0.5-4</td> <td>4-10</td> </tr> <tr> <td>25I-NBOMe</td> <td>Oral (buccal) or nasal: 500-800 micrograms&nbsp;</td> <td>1-17&nbsp;</td> <td>0.5-2&nbsp;</td> <td>6-10&nbsp;</td> </tr> <tr> <td>AMT (&#945;-methyltryptamine)</td> <td> <p>Oral: 20-40 mg</p> Smoked: 6-10 mg</td> <td>20-30</td> <td>4-8</td> <td>12-16</td> </tr> <tr> <td>DMT (dimethyltryptamine; N,N-dimethyltryptamine)</td> <td> <p>Oral: 35-75 mg</p> IV, smoked: 30-150 mg</td> <td>20-60</td> <td>1-2</td> <td>2-8</td> </tr> <tr> <td>Dextromethorphan</td> <td>Oral: 100-600 mg</td> <td>15-30</td> <td>2.5</td> <td>4-6*</td> </tr> <tr> <td>5-MeO-DIPT (Foxy methoxy)</td> <td> <p>Oral: 5-30 mg</p> <p>Nasal: 5-20 mg</p> Smoked: 2-15 mg</td> <td>20-60</td> <td>1-2</td> <td>3-6</td> </tr> <tr> <td>Hawaiian baby woodrose (<em>Argyreia nervosa</em>)</td> <td>Oral: 5-10 seeds</td> <td>ND</td> <td>ND</td> <td>6-8</td> </tr> <tr> <td>Ibogaine</td> <td>Oral: 10 mg/kg</td> <td>45-120</td> <td>4-8</td> <td>18-24</td> </tr> <tr> <td>Ketamine</td> <td> <p>Oral: 200-300 mg</p> <p>IV: 50-100 mg</p> <p>IM: 75-125 mg</p> Nasal: 60-250 mg</td> <td>15-20</td> <td>0.5-1</td> <td>1.5-2</td> </tr> <tr> <td>LSD (lysergic acid diethylamide)</td> <td>Oral: 25-200 micrograms</td> <td>30-90</td> <td>3-5</td> <td>6-12</td> </tr> <tr> <td>Mescaline (peyote)</td> <td>Oral: 200-500 mg (6-12 dried buttons)</td> <td>30-120</td> <td>2-4</td> <td>6-12</td> </tr> <tr> <td>Morning glory (<em>Ipomoea violacae</em>)</td> <td>Oral: 200-300 seeds</td> <td>60</td> <td>ND</td> <td>6-10</td> </tr> <tr> <td>PCP (phencyclidine)</td> <td> <p>Oral: 2-6 mg</p> IV, nasal, smoked: 1-3 mg</td> <td>30-60</td> <td>1-4</td> <td>4-6</td> </tr> <tr> <td>Psilocybin</td> <td>Oral: 10 mg (20-30 g fresh mushrooms; 1-2 g dried mushroom powder)</td> <td>20-30</td> <td>1-2</td> <td>6-8</td> </tr> <tr> <td><em>Salvia divinorum</em></td> <td> <p>Oral: 1 mg (5-10 leaves)</p> Smoked: 200-500 micrograms</td> <td>3-15</td> <td>1</td> <td>1-3</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: Kinetics shown are for oral doses. For most substances, peak levels following injection, nasal insufflation, or smoking occur within 1 to 5 minutes.</div><div class=\"graphic_footnotes\">ND: no data available for this parameter.<br />* For rapid metabolizers (majority), who have high CYP2D6 activity; for poor metabolizers, duration of action can exceed 24 hours.</div><div class=\"graphic_reference\">Data for table adapted from:<br /><ol>&#xD;&#xA;    <li>Drug Enforcement Administration, US Department of Justice. Drugs and Chemicals of Concern. <a href=\"http://www.deadiversion.usdoj.gov/drug_chem_info/index.html\" target=\"_blank\">http://www.deadiversion.usdoj.gov/drug_chem_info/index.html</a>. (Accessed July 23, 2012).</li>&#xD;&#xA;    <li>Nichols DE. Hallucinogens. Pharmacol Ther 2004; 101:131.</li>&#xD;&#xA;    <li>The Vaults of Erowid. <a href=\"http://www.erowid.org/psychoactives\" target=\"_blank\">http://www.erowid.org/psychoactives</a>. (Accessed July 23, 2012).</li>&#xD;&#xA;    <li>Baselt RC. Disposition of Toxic Drugs in Man, 9th ed. Biomedical Publications, Foster City, 2011.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 50447 Version 5.0</div></div></div>"},"50448":{"type":"graphic_figure","displayName":"Risk of infection HCT","title":"Risk of infection following hematopoietic cell transplantation","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Risk of infection following hematopoietic cell transplantation</div><div class=\"cntnt\"><img style=\"width:541px; height:641px;\" src=\"images/ID/50448_Risk_of_infection_HCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CMV: cytomegalovirus; EBV: Epstein-Barr virus; HIV: human immunodeficiency virus; GVHD: graft-versus-host disease.</div><div id=\"graphicVersion\">Graphic 50448 Version 4.0</div></div></div>"},"50450":{"type":"graphic_table","displayName":"Adaption of 5 A's for use in smoking cessation during pregnancy","title":"Adaption of 5 A's for use in smoking cessation during pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adaption of 5 A's for use in smoking cessation during pregnancy</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">STEP 1: Ask</td> </tr> <tr> <td class=\"subtitle2_single\">Recommendation:</td> </tr> <tr> <td class=\"indent1\">Ask the patient about her smoking status.</td> </tr> <tr> <td class=\"subtitle2_single\">Action:</td> </tr> <tr> <td class=\"indent1\">Given high nondisclosure rates, identification of the pregnant smoker can be difficult. Specific strategies to identify smoking women include:</td> </tr> <tr> <td class=\"sublist2_start\">1. Use multiple choice questions when assessing whether a patient smokes. The following multiple choice question is recommended in either oral or written form.</td> </tr> <tr> <td class=\"sublist2\">Which of the following describes you best?</td> </tr> <tr> <td class=\"sublist3\">a. I have <strong>NEVER</strong> smoked, or I have smoked less than 100 cigarettes in my lifetime.</td> </tr> <tr> <td class=\"sublist3\">b. I stopped smoking <strong>BEFORE</strong> I found out I was pregnant, and I am not smoking now.</td> </tr> <tr> <td class=\"sublist3\">c. I stopped smoking <strong>AFTER</strong> I found out I was pregnant, and I am not smoking now.</td> </tr> <tr> <td class=\"sublist3\">d. I smoke some now, but I cut down on the number of cigarettes I smoke <strong>SINCE</strong> I found out I was pregnant.</td> </tr> <tr> <td class=\"sublist3\">e. I smoke regularly now, about the same as <strong>BEFORE</strong> I found out I was pregnant.</td> </tr> <tr> <td class=\"indent1\">2. Focus particular attention on women who report that they stopped smoking after conception. About half of nondisclosers in one series reported quitting after conception.</td> </tr> <tr> <td class=\"indent1\">3. Consider using urinary cotinine measurements in women who report smoking as an objective measure of smoking exposure: Set goals for lowering this level. The routine use of urinary cotinine to confirm nonsmoking status is controversial given the ethical concerns and potential negative impact on the patient-doctor relationship. Until further guidelines and recommendations are available, it is not recommended.</td> </tr> <tr> <td class=\"subtitle1_single\">STEP 2: Advise</td> </tr> <tr> <td class=\"subtitle2_single\">Recommendation:</td> </tr> <tr> <td class=\"indent1\">Provide clear strong advice to quit with personalized messages about the impact of smoking and quitting on mother and fetus.</td> </tr> <tr> <td class=\"subtitle2_single\">Action:</td> </tr> <tr> <td class=\"indent1\">1. Discuss the risks of smoking during pregnancy: low birth weight, placental abruption, placenta previa, premature delivery, stillbirth, preterm premature rupture of membranes.</td> </tr> <tr> <td class=\"indent1\">2. If the patient has had a history of a complicated pregnancy, discuss how smoking may have contributed to this complication.</td> </tr> <tr> <td class=\"indent1\">3. Discuss risks of secondary smoke, particularly for patients with children at home; SIDS, upper respiratory infections, otitis media asthma, pneumonia.</td> </tr> <tr> <td class=\"indent1\">4. Recommend that the patient quit as soon as possible for maximal benefit; however, quitting at any time during pregnancy has some benefit.</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">STEP 3: Assess</td> </tr> <tr> <td class=\"subtitle2_single\">Recommendation:</td> </tr> <tr> <td class=\"indent1\">Assess the willingness of the patient to make a quit attempt within the next month.</td> </tr> <tr> <td class=\"subtitle2_single\">Action:</td> </tr> <tr> <td class=\"indent1\">Ask, \"Quitting smoking is one of the most important things you can do for your health and the health of your baby. If we help you, are you willing to try?\"</td> </tr> <tr> <td class=\"subtitle1_single\">STEP 4: Assist</td> </tr> <tr> <td class=\"subtitle2_single\">Recommendation:</td> </tr> <tr> <td class=\"indent1\">Assist smoker in quitting.</td> </tr> <tr> <td class=\"subtitle2_single\">Action:</td> </tr> <tr> <td class=\"indent1\">1. Provide pregnancy-specific, self-help smoking cessation materials; multi-lingual educational packets available on the web: <a href=\"http://www.modimes.org/\" target=\"_blank\">http://www.modimes.org</a>.</td> </tr> <tr> <td class=\"sublist2_start\">2. Encourage the use of problem solving methods and skills for cessation:</td> </tr> <tr> <td class=\"sublist2\">Review withdrawal symptoms.</td> </tr> <tr> <td class=\"sublist2\">Identify \"high risk situations\" where they are more likely to relapse and set up strategies for avoiding them.</td> </tr> <tr> <td class=\"sublist2\">Strongly consider referral to social worker who can help patient gain access to services available to minimize stressors at home.</td> </tr> <tr> <td class=\"sublist2\">Consider referral to coping and stress management program.</td> </tr> <tr> <td class=\"sublist2_start\">3. Encourage patient to seek family and social support:</td> </tr> <tr> <td class=\"sublist2\">Identify non-smoking individuals, particularly successful quitters that can be supportive.</td> </tr> <tr> <td class=\"sublist2\">Offer referral to smoking partner for smoking cessation.</td> </tr> <tr> <td class=\"sublist2\">Patient should inform family that they intend to quit smoking during the pregnancy and ask for their support (ie, not smoking in the same room).</td> </tr> <tr> <td class=\"sublist2_start\">4. Consider pharmacotherapy for patients who smoke 10 cigarettes or more and are unable to quit. Use lowest dose necessary.</td> </tr> <tr> <td class=\"sublist2\">Bupropion</td> </tr> <tr> <td class=\"sublist2\">Nicotine replacement therapy</td> </tr> <tr> <td class=\"subtitle1_single\">STEP 5: Arrange</td> </tr> <tr> <td class=\"subtitle2_single\">Recommendation:</td> </tr> <tr> <td class=\"indent1\">Assess smoking status throughout pregnancy and encourage cessation for continuing smokers.</td> </tr> <tr> <td class=\"subtitle2_single\">Action:</td> </tr> <tr> <td class=\"indent1\">1. Place a label on each chart that identifies the patient as a smoker.</td> </tr> <tr> <td class=\"indent1\">2. Ask about smoking at each visit.</td> </tr> <tr> <td class=\"indent1\">3. If still smoking, encourage cessation and consider adjunct pharmacotherapy as outlined in next section.</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SIDS: sudden infant death syndrome.</div><div id=\"graphicVersion\">Graphic 50450 Version 9.0</div></div></div>"},"50453":{"type":"graphic_figure","displayName":"Retinoblastoma less than three years","title":"Unilateral and bilateral retinoblastoma age-specific incidence rates, age <3, all races both sexes, SEER, 1976-84 and 1986-94","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unilateral and bilateral retinoblastoma age-specific incidence rates, age &lt;3, all races both sexes, SEER, 1976-84 and 1986-94</div><div class=\"cntnt\"><img style=\"width:379px; height:430px;\" src=\"images/PEDS/50453_Retinoblastomalessthan3y.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from Young JL, Smith MA, Roffers SD, et al. Retinoblastoma. In: Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program, 1975-1995, Ries LA, Smith MA, Gurney JG, et al (Eds), National Cancer Institute, Bethesda, MD, 1999. p. 73.</div><div id=\"graphicVersion\">Graphic 50453 Version 3.0</div></div></div>"},"50454":{"type":"graphic_table","displayName":"Blunt trauma mechanism","title":"Blunt trauma mechanisms and associated injuries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Blunt trauma mechanisms and associated injuries</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Mechanism of injury</td> <td class=\"subtitle1\">Additional considerations</td> <td class=\"subtitle1\">Potential associated injuries</td> </tr> <tr> <td colspan=\"3\"><strong>Motor vehicle collisions</strong></td> </tr> <tr> <td class=\"indent1\">Head-on collision</td> <td>&nbsp;</td> <td> <p>Facial injuries</p> <p>Lower extremity injuries</p> Aortic injuries</td> </tr> <tr> <td class=\"indent1\">Rear-end collision</td> <td>&nbsp;</td> <td> <p>Hyperextension injuries of cervical spine</p> <p>Cervical spine fractures</p> Central cord syndrome</td> </tr> <tr> <td class=\"indent1\">Lateral (T-bone) collision</td> <td>&nbsp;</td> <td> <p>Thoracic injuries</p> <p>Abdominal injuries: spleen, liver</p> <p>Pelvic injuries</p> Clavicle, humerus, rib fractures</td> </tr> <tr> <td class=\"indent1\">Rollover</td> <td> <p>Greater chance of ejection</p> Significant mechanism of injury</td> <td> <p>Crush injuries</p> Compression fractures of spine</td> </tr> <tr> <td class=\"indent1\">Ejected from vehicle</td> <td> <p>Likely unrestrained</p> Significant mortality</td> <td>Spinal injuries</td> </tr> <tr> <td class=\"indent1\">Windshield damage</td> <td>Likely unrestrained</td> <td> <p>Closed head injuries, coup and countercoup injuries</p> <p>Facial fractures</p> <p>Skull fractures</p> Cervical spine fractures</td> </tr> <tr> <td class=\"indent1\">Steering wheel damage</td> <td>Likely unrestrained</td> <td>Thoracic injuries <ul class=\"decimal_heading\"> <li>Sternal and rib fractures, flail chest </li> <li>Cardiac contusion </li> <li>Aortic injuries </li> <li>Hemo/pneumothoraces </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Dashboard involvement/damage</td> <td>&nbsp;</td> <td> <p>Pelvic and acetabular injuries</p> Dislocated hip</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Restraint/seat belt use</td> </tr> <tr> <td class=\"sublist2\">Proper three-point restraint</td> <td class=\"sublist_other\">Decreased morbidity</td> <td class=\"sublist_other\">Sternal and rib fractures, pulmonary contusions</td> </tr> <tr> <td class=\"sublist2\">Lap belt only</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">Chance fractures, abdominal injuries, head and facial injuries/fractures</td> </tr> <tr> <td class=\"sublist2\">Shoulder belt only</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">Cervical spine injuries/fractures, \"submarine\" out of restraint devices (possible ejection)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Airbag deployment</td> <td> <p>Front-end collisions</p> <p>Less severe head/upper torso injuries</p> <p>Not effective for lateral impacts</p> More severe injuries in children (improper front seat placement)</td> <td> <p>Upper extremity soft tissue injuries/fractures</p> Lower extremity injuries/fractures</td> </tr> <tr> <td colspan=\"3\"><strong>Pedestrian versus automobile</strong></td> </tr> <tr> <td class=\"indent1\">Low speed (braking automobile)</td> <td>&nbsp;</td> <td>Tibia and fibula fractures, knee injuries</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">High speed</td> <td>&nbsp;</td> <td> <p>Waddle's triad - tibia/fibula or femur fractures, truncal injuries, craniofacial injuries</p> \"Thrown\" pedestrians at risk for multisystem injuries</td> </tr> <tr> <td colspan=\"3\"><strong>Bicycle</strong></td> </tr> <tr> <td class=\"indent1\">Automobile related</td> <td>&nbsp;</td> <td> <p>Closed head injuries</p> \"Handlebar\" injuries <ul class=\"decimal_heading\"> <li>Spleen/liver lacerations </li> <li>Additional intra-abdominal injuries </li> <li>Consider penetrating injuries </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Nonautomobile related</td> <td>&nbsp;</td> <td> <p>Extremity injuries</p> \"Handlebar\" injuries</td> </tr> <tr> <td><strong>Falls</strong></td> <td colspan=\"2\">LD<sub>50</sub> 36&nbsp;to 60 feet (11&nbsp;to 18 m)</td> </tr> <tr> <td class=\"indent1\">Vertical impact</td> <td>&nbsp;</td> <td> <p>Calcaneal and lower extremity fractures</p> <p>Pelvic fractures</p> <p>Closed head injuries</p> <p>Cervical spine fractures</p> Renal and renal vascular injuries</td> </tr> <tr> <td class=\"indent1\">Horizontal impact</td> <td>&nbsp;</td> <td> <p>Craniofacial fractures</p> <p>Hand and wrist fractures</p> <p>Abdominal and thoracic visceral injuries</p> Aortic injuries</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Gross E, Martel M. Multiple trauma. In: Rosen's Emergency Medicine: Concepts and Clinical Practice, 7th ed, Marx JA, Hockberger RS, Walls RM, et al (Eds), Mosby Elsevier, Philadelphia 2010. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 50454 Version 5.0</div></div></div>"},"50456":{"type":"graphic_table","displayName":"Risk factors complications","title":"Risk factors for the development of biliary complications after liver transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for the development of biliary complications after liver transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Roux-en-Y anastomosis</td> </tr> <tr> <td>Use of T-tubes</td> </tr> <tr> <td>Improper surgical technique</td> </tr> <tr> <td>Inappropriate suture material or excessive tension at the anastomosis</td> </tr> <tr> <td>Excessive use of electrocauterization for control of bile duct bleeding</td> </tr> <tr> <td>Mismatch in size between donor and recipient bile ducts</td> </tr> <tr> <td>ABO mismatched grafts</td> </tr> <tr> <td>Acute hepatic artery thrombosis</td> </tr> <tr> <td>Hepatic artery stenosis</td> </tr> <tr> <td>Ischemia/reperfusion injury (ischemic-type biliary lesions)</td> </tr> <tr> <td>Infections</td> </tr> <tr> <td>Non heart-beating donors</td> </tr> <tr> <td>Primary sclerosing cholangitis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Andres C&#225;rdenas, MD, MMSc.</div><div id=\"graphicVersion\">Graphic 50456 Version 3.0</div></div></div>"},"50457":{"type":"graphic_diagnosticimage","displayName":"Adhesive small bowel obstruction on computed tomography","title":"Adhesive small bowel obstruction on computed tomography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adhesive small bowel obstruction on computed tomography</div><div class=\"cntnt\"><img style=\"width:435px; height:203px;\" src=\"images/OBGYN/50457_CT_SBO_from_adhesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) of the abdomen demonstrates small bowel obstruction due to adhesive disease. The transition point is shown (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Imaging. Copyright &copy; British Institute of Radiology.</div><div id=\"graphicVersion\">Graphic 50457 Version 4.0</div></div></div>"},"50458":{"type":"graphic_figure","displayName":"rTPO to transplant donor","title":"Benefit of recombinant TPO to murine transplant donors","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Benefit of recombinant TPO to murine transplant donors</div><div class=\"cntnt\"><img style=\"width:529px; height:353px;\" src=\"images/HEME/50458_rTPO_to_transplant_donor.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mice were treated with lethal irradiation followed by the transplantation of 1 x 10<SUP>5</SUP> bone marrow cells and the recovery of the blood counts followed. Top panel: The administration of various doses of saline or thrombopoietin (TPO) after transplantation had no effect on platelet recovery. Bottom panel: Accelerated platelet recovery occurred when mice were transplanted with bone marrow from TPO-treated donors; the response was similar in recipients treated after transplantation with saline or TPO. Recipients of marrow from TPO-treated donors also had accelerated recovery of the red cell counts (not shown).</div><div class=\"graphic_reference\">Data from: Fibbe WE, Heemskerk DP, Laterveer L, et al. Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice. Blood 1995; 86:3308.</div><div id=\"graphicVersion\">Graphic 50458 Version 2.0</div></div></div>"},"50461":{"type":"graphic_figure","displayName":"Pain and global activity scales","title":"Pain and global activity scales","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pain and global activity scales</div><div class=\"cntnt\"><img style=\"width:440px; height:407px;\" src=\"images/RHEUM/50461_Pain_and_global_activity_sc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A. Visual analogue scales (VAS) for patient pain assessment, patient global assessment of disease activity and evaluator (physician) global assessment of disease activity. A mark is placed at the presumed level of pain or disease activity between the two ends of a 100 mm line. Vertical lines can also be used as can 11-point numerical scales (0-1-2-3-4-5-6-7-8-9-10 each 1 cm apart) or (B) Likert scales.</div><div id=\"graphicVersion\">Graphic 50461 Version 1.0</div></div></div>"},"50463":{"type":"graphic_diagnosticimage","displayName":"Renal stones in primary oxaluria","title":"Renal stones in primary oxaluria","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Renal stones in primary oxaluria</div><div class=\"cntnt\"><img style=\"width:504px; height:227px;\" src=\"images/PEDS/50463_Renal_stones_prim_oxaluria.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 50463 Version 2.0</div></div></div>"},"50464":{"type":"graphic_figure","displayName":"Rhomboid flap for closure of a vulvar defect","title":"Rhomboid flap for closure of a vulvar defect","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Rhomboid flap for closure of a vulvar defect</div><div class=\"cntnt\"><img style=\"width:548px; height:423px;\" src=\"images/SURG/50464_Rhomboidflap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The &quot;rhomboid flap&quot; is used to close a posterior vulvar defect.<br> (B) The pedicle grafts are bilateral &quot;Z-plasties&quot; that are sutured together in the midline.</div><div class=\"graphic_reference\">Reproduced with permission from: Berek JS, Hacker NF. Practical Gynecologic Oncology, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50464 Version 2.0</div></div></div>"},"50465":{"type":"graphic_figure","displayName":"Synergistic tox of analgesics","title":"Synergistic toxicity of analgesics","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Synergistic toxicity of analgesics</div><div class=\"cntnt\"><img style=\"width:535px; height:449px;\" src=\"images/NEPH/50465_Synergistic_tox_of_analgesi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As shown to the left, when phenacetin or acetaminophen is ingested with aspirin, there is a potentiating nephrotoxic effect. The aspirin is converted to salicylate, which becomes highly concentrated and depletes glutathione in both the cortex and papillae of the kidney. With the cellular glutathione depleted, the reactive metabolite of acetaminophen then produces lipid peroxides and arylation of tissue proteins, ultimately resulting in necrosis of the papillae. Patients taking analgesic mixtures that contain aspirin, acetaminophen, and/or phenacetin plus potentially addicting compounds, such as codeine and caffeine, are more likely to abuse such drugs, thereby further enhancing the risk of analgesic nephropathy (as shown in the upper right).</div><div class=\"graphic_reference\">Data from: Duggin G. Combination analgesic-induced kidney disease: the Australian experience.&nbsp;Am J Kidney Dis 1996; 28:S39.</div><div id=\"graphicVersion\">Graphic 50465 Version 2.0</div></div></div>"},"50466":{"type":"graphic_table","displayName":"Frequency of oral clefts in relatives by proband phenotype","title":"Frequency of oral clefts in relatives based on the proband's phenotype","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of oral clefts in relatives based on the proband's phenotype</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Relative\n   </td>\n   <td  class=\"subtitle1\">\n   CL (percent)\n   </td>\n   <td  class=\"subtitle1\">\n   CL/P (percent)\n   </td>\n   <td  class=\"subtitle1\">\n   CP (percent)\n   </td>\n   </tr>\n   <tr>\n   <td>Sibling</td>\n   <td>2.5</td>\n   <td>3.9</td>\n   <td>3.3</td>\n   </tr>\n   <tr>\n   <td>Half sibling</td>\n   <td>1.0</td>\n   <td>0.5</td>\n   <td>1.0</td>\n   </tr>\n   <tr>\n   <td>Parent</td>\n   <td>2.5</td>\n   <td>2.5</td>\n   <td>2.1</td>\n   </tr>\n   <tr>\n   <td>Offspring</td>\n   <td>3.5</td>\n   <td>4.1</td>\n   <td>4.2</td>\n   </tr>\n   <tr>\n   <td>Niece/nephew</td>\n   <td>0.9</td>\n   <td>0.8</td>\n   <td>1.1</td>\n   </tr>\n   <tr>\n   <td>Aunt/uncle</td>\n   <td>0.6</td>\n   <td>1.1</td>\n   <td>0.6</td>\n   </tr>\n   <tr>\n   <td>First cousin</td>\n   <td>0.3</td>\n   <td>0.5</td>\n   <td>0.4</td>\n   </tr>\n </table></div><div class=\"graphic_lgnd\">CL: cleft lip, CP: cleft palate, CL/P: cleft lip with or without cleft palate</div><div class=\"graphic_reference\">Data from: Grosen, D, Chavrier, C, Skytthe, A, et al. A cohort study of recurrence patterns among more than 54,000 relatives of oral cleft cases in Denmark: support for the multifactorial threshold model of inheritance. J Med Genet 2009.</div><div id=\"graphicVersion\">Graphic 50466 Version 2.0</div></div></div>"},"50467":{"type":"graphic_diagnosticimage","displayName":"Character photons b","title":"Comparative treatment plans for a large acoustic neuroma using proton radiosurgery (A) and conformal photon radiosurgery (B)","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Comparative treatment plans for a large acoustic neuroma using proton radiosurgery (A) and conformal photon radiosurgery (B)</div><div class=\"cntnt\"><img style=\"width:488px; height:240px;\" src=\"images/ONC/50467_Character_photons_b.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The various isodose lines are indicated in the right upper corner of each panel. The comparison reveals that proton radiosugery minimizes irradiation of the non-target tissues relative to photon radiosurgery.</div><div class=\"graphic_reference\">Courtesy of Massachusetts General Hospital.</div><div id=\"graphicVersion\">Graphic 50467 Version 2.0</div></div></div>"},"50469":{"type":"graphic_figure","displayName":"Probability resolution reflux","title":"Percent chance of reflux persistence for one to five years following presentation as a function of grade of reflux, laterality, and age","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Percent chance of reflux persistence for one to five years following presentation as a function of grade of reflux, laterality, and age</div><div class=\"cntnt\"><img style=\"width:512px; height:598px;\" src=\"images/PEDS/50469_Probability_resolution_refl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Grades I, II, and IV reflux. <br />B) Grade III reflux by patient age at presentation.</div><div class=\"graphic_reference\">Reproduced with permission from: Elder JS, Peters CA, Arant BS Jr, et al. Pediatric Vesicoureteral Reflux Guidelines Panel summary report on the management of primary vesicoureteral reflux in children. J Urol 1997; 157:1846. Copyright © 1997 American Urological Association.</div><div id=\"graphicVersion\">Graphic 50469 Version 5.0</div></div></div>"},"50472":{"type":"graphic_picture","displayName":"Melanosis coli Endosc","title":"Melanosis coli","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Melanosis coli</div><div class=\"cntnt\"><img style=\"width:368px; height:183px;\" src=\"images/GAST/50472_Melanosis_coli_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Colonoscopic views of a patient with chronic senna ingestion. The dark pigmentation with a reticulated pattern of striations (alligator-skin) and spots is characteristic of melanosis coli.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 50472 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal sigmoid colon</div><div class=\"cntnt\"><img style=\"width:216px; height:216px;\" src=\"images/GAST/55563_Normal_sigmoid_colon_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic appearance of the normal sigmoid colonic mucosa. The fine vasculature is easily visible, and the surface is shiny and smooth. The folds are of normal thickness.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 55563 Version 1.0</div></div></div>"},"50473":{"type":"graphic_figure","displayName":"HIT mechanism","title":"Mechanism of heparin induced thrombocytopenia (HIT)","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Mechanism of heparin induced thrombocytopenia (HIT)</div><div class=\"cntnt\"><img style=\"width:518px; height:474px;\" src=\"images/HEME/50473_HIT_mechanism.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mechanism of heparin induced thrombocytopenia (HIT). Some individuals&nbsp;produce IgG antibodies directed against heparin complexed with platelet factor 4 (PF4). Platelet Fc receptors&nbsp;bind the antibody-heparin-PF4 immune complex. This leads to platelet activation and microparticle release, which contribute to thrombosis. Thrombocytopenia occurs by two mechanisms: removal of platelets with bound IgG by splenic macrophages, and platelet consumption caused by thrombus formation. PF4 can also bind heparan sulfate on vascular endothelial cells; subsequent binding of the pathologic antibody to this PF4-heparan sulfate complex can&nbsp;injure the endothelium, which further promotes thrombosis.</div><div class=\"graphic_reference\">Courtesy of Laura Ibsen, MD.</div><div id=\"graphicVersion\">Graphic 50473 Version 4.0</div></div></div>"},"50474":{"type":"graphic_diagnosticimage","displayName":"Retinal disease in SLE","title":"Retinal disease in systemic lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retinal disease in systemic lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:336px; height:288px;\" src=\"images/RHEUM/50474_Retinal_disease_in_SLE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph of the retina from a patient with systemic lupus erythematosus shows multiple peripapillary cotton wool spots, hemorrhage, and a central retinal artery occlusion.</div><div class=\"graphic_reference\">Courtesy of Michael Tolentino, MD.</div><div id=\"graphicVersion\">Graphic 50474 Version 3.0</div></div></div>"},"50476":{"type":"graphic_diagnosticimage","displayName":"Coronal MRI showing perianal fistulas in Crohn disease","title":"Perianal fistulas in Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perianal fistulas in Crohn disease</div><div class=\"cntnt\"><img style=\"width:360px; height:350px;\" src=\"images/GAST/50476_Coron_MRI_perianal_fistula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2-weighted coronal magnetic resonance imaging (MRI) study showing a perianal fistula (arrows) in a patient with Crohn disease.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 50476 Version 5.0</div></div></div>"},"50477":{"type":"graphic_table","displayName":"Principles of risk management during opioid treatment for pain","title":"Principles of risk management during opioid treatment for pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Principles of risk management during opioid treatment for pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Goals</td> <td class=\"subtitle1\">Strategies</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td><strong>Stratification of risk</strong></td> <td>To clarify the likelihood of future aberrant drug-related behavior</td> <td> <p><strong>Regard as high risk if:</strong></p> <ul> <li>History of alcohol or drug misuse </li> <li>Family history of alcohol or drug misuse </li> <li>Major psychiatric disorder </li> </ul> <p>&nbsp;</p> <p><strong>Other factors that suggest risk:</strong></p> <ul> <li>Cancer associated with heavy alcohol use or smoking </li> <li>Current heavy smoking </li> <li>Young age </li> <li>History of automobile accidents, chronic unemployment, poor support system </li> </ul> <p>&nbsp;</p> <p><strong>Factors that can mitigate risk:</strong></p> <ul> <li>Poor performance status </li> <li>Restricted prognosis </li> <li>Active recovery program </li> </ul> </td> <td>All patients should undergo risk assessment and stratification; although many questionnaires have been developed to predict aberrant behavior or addiction, the clinical assessment is generally used in practice.</td> </tr> <tr class=\"divider_top\"> <td><strong>Structuring of treatment commensurate with risk</strong></td> <td>Practices to match monitoring with risk, and when needed to help patients maintain control</td> <td> <p><strong>Strategies include:</strong></p> <ul> <li>Use of drug monitoring (eg, urine drug testing) </li> <li>Small amounts prescribed </li> <li>No use of short-acting drugs </li> <li>Use of one pharmacy </li> <li>Pill counts at time of visit </li> <li>Compulsory consultations </li> </ul> </td> <td>The decision to implement one or more of these strategies is a matter of clinical judgment.</td> </tr> <tr class=\"divider_top\"> <td><strong>Assessment of drug-related behaviors over time</strong></td> <td>Track drug use in tandem with all relevant outcomes</td> <td> <p><strong>Monitor:</strong></p> <ul> <li>Drug-related behavior - eg, need for early refills, obtaining several prescriptions, etc </li> <li>Pain relief </li> <li>Adverse drug effects </li> <li>Effect of drug on other outcomes </li> </ul> </td> <td>Broad monitoring of outcomes is consistent with integration of pain management into a palliative care model.</td> </tr> <tr class=\"divider_top\"> <td><strong>Response to aberrant drug-related behaviors</strong></td> <td>Clinician compliance with laws and regulations; identification of patients needing additional management</td> <td> <p><strong>If the patient engages in aberrant drug-related behavior:</strong></p> <ul> <li>Reassess and diagnose (addiction, other psychiatric disorder, pseudoaddiction, family issues, criminal intent) </li> <li>If diversion into the illicit marketplace is discovered, stop prescribing </li> <li>Otherwise, restructure treatment to improve control and obtain consultative help as needed </li> </ul> </td> <td>Even advanced illness does not free the clinician from the requirement of compliance with laws and regulations.</td> </tr> <tr class=\"divider_top\"> <td><strong>Documentation and communication</strong></td> <td>Risk assessment and management should be viewed as integral to safe and effective prescribing</td> <td> <p><strong>Document:</strong></p> <ul> <li>Plan for monitoring and education of patient and family </li> <li>Monitoring of drug-related behavior on a regular basis </li> <li>Response should aberrant behavior occur </li> </ul> </td> <td>Open discussion of the need for universal risk management with other clinicians is valuable to reduce the risk of stigmatizing patients.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Portenoy RK. Treatment of cancer pain. Lancet 2011; 377:2236. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 50477 Version 2.0</div></div></div>"},"50479":{"type":"graphic_table","displayName":"Bisphosphonates in order of potency","title":"Bisphosphonates listed in order of increasing potency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bisphosphonates listed in order of increasing potency</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Simple bisphosphonates</td> </tr> <tr> <td>Etidronate</td> </tr> <tr> <td>Tiludronate</td> </tr> <tr> <td>Clodronate</td> </tr> <tr> <td class=\"subtitle1_single\">Nitrogen-containing bisphosphonates</td> </tr> <tr> <td>Pamidronate</td> </tr> <tr> <td>Alendronate</td> </tr> <tr> <td>Neridronate</td> </tr> <tr> <td>Ibandronate</td> </tr> <tr> <td>Risedronate</td> </tr> <tr> <td>Zoledronic acid</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50479 Version 4.0</div></div></div>"},"50480":{"type":"graphic_diagnosticimage","displayName":"CT CAA-related ICH","title":"Lobar hemorrhage in cerebral amyloid angiopathy","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Lobar hemorrhage in cerebral amyloid angiopathy</div><div class=\"cntnt\"><img style=\"width:545px; height:217px;\" src=\"images/NEURO/50480_Lobar_hemorrhage_CAA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute superficial lobar hemorrhage in the left frontal lobe seen on CT scan in a patient with cerebral amyloid angiopathy (Panel A). Flair MR image performed one week later shows the high signal intensity of subacute hemorrhage with surrounding edema extending into the subcortical white matter (Panel B). Hemorrhage (now low signal intensity consistent with hemosiderin) and edema are mostly resolved on a three-month follow-up study (Panel C).</div><div class=\"graphic_reference\">Courtesy of Eric D Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 50480 Version 3.0</div></div></div>"},"50481":{"type":"graphic_table","displayName":"Incidence of intracranial hemorrhage by mode of delivery","title":"Incidence of intracranial hemorrhage by mode of delivery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of intracranial hemorrhage by mode of delivery</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Delivery type</td> <td class=\"subtitle1\">Incidence</td> </tr> <tr> <td>Forceps</td> <td>1 in 664</td> </tr> <tr> <td>Vacuum extraction</td> <td>1 in 860&nbsp;</td> </tr> <tr> <td>Cesarean delivery with labor</td> <td>1 in 907</td> </tr> <tr> <td>Spontaneous vaginal birth</td> <td>1 in 1900&nbsp;</td> </tr> <tr> <td>Cesarean delivery without labor</td> <td>1 in 2750</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Towner D, Castro MA, Eby-Wilkens E, Gilbert WM. Effect of mode of delivery in nulliparous women on neonatal intracranial injury. N Engl J Med 1999; 341:1709.</div><div id=\"graphicVersion\">Graphic 50481 Version 6.0</div></div></div>"},"50482":{"type":"graphic_diagnosticimage","displayName":"Normal umbilical cord insertion ","title":"Normal umbilical cord insertion ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal umbilical cord insertion </div><div class=\"cntnt\"><img style=\"width:304px; height:241px;\" src=\"images/OBGYN/50482_Normal_cord_insertion_by_U-.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fetus&nbsp;at about 23 weeks of gestation with intact abdominal wall and normal umbilical cord insertion.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 50482 Version 3.0</div></div></div>"},"50484":{"type":"graphic_figure","displayName":"Hypothal pituitary testic axis","title":"Hypothalamic-pituitary-testicular axis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypothalamic-pituitary-testicular axis</div><div class=\"cntnt\"><img style=\"width:311px; height:367px;\" src=\"images/ONC/50484_Hypothal_pituitary_testic_a.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the hypothalamic-pituitary-testicular axis shows the site of action of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in the testes. Testosterone (T) and inhibin are produced by the testes. Testosterone has a negative feedback on hypothalamus and LH production, while inhibin has a negative feedback on FSH production.</div><div class=\"graphic_footnotes\">GnRH: gonadotropin-releasing hormone; C: cholesterol. </div><div class=\"graphic_reference\">Adapted from Griffin JE, Wilson JD. In: Metabolic Control and Disease, 8th ed, Bondy PK, Rosenberg LE (Eds), Saunders, Philadelphia 1980. p. 1535.</div><div id=\"graphicVersion\">Graphic 50484 Version 3.0</div></div></div>"},"50486":{"type":"graphic_table","displayName":"Classification of DR","title":"Classification of diabetic retinopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of diabetic retinopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Nonproliferative Diabetic Retinopathy (NPDR)</td> </tr> <tr> <td class=\"subtitle2_single\">Mild NPDR:</td> </tr> <tr> <td class=\"indent1\">At least one microaneurysm</td> </tr> <tr> <td class=\"indent1\">Criteria not met for other levels of DR</td> </tr> <tr> <td class=\"subtitle2_single\">Moderate NPDR:</td> </tr> <tr> <td class=\"indent1\"> <p>Hemorrhage/microaneurysm &#8805; standard photograph #2A </p> <p>OR</p> <p>Soft exudates (cotton wool spots), venous beading, and intraretinal microvascular abnormalities definitely present</p> </td> </tr> <tr> <td class=\"indent1\">Criteria not met for severe NPDR, very severe NPDR, or PDR</td> </tr> <tr> <td class=\"subtitle2_single\">Severe NPDR:</td> </tr> <tr> <td class=\"indent1\"> <p>Hemorrhage/microaneurysm &#8805; standard photograph #2A in all 4 quadrants </p> <p>OR</p> <p>Venous beading in at least two quadrants </p> <p>OR</p> <p>Intraretinal microvascular abnormalities &#8805; standard photograph #8A in at least one quadrant</p> </td> </tr> <tr> <td class=\"subtitle2_single\">Very severe NPDR:</td> </tr> <tr> <td class=\"indent1\">Any two or more of criteria for severe NPDR</td> </tr> <tr> <td class=\"indent1\">Criteria not met for PDR</td> </tr> <tr> <td class=\"subtitle1_single\">Proliferative Diabetic Retinopathy (PDR)</td> </tr> <tr> <td class=\"subtitle2_single\">Early PDR:</td> </tr> <tr> <td class=\"indent1\">New vessels</td> </tr> <tr> <td class=\"indent1\">Criteria not met for high-risk PDR</td> </tr> <tr> <td class=\"subtitle2_single\">High-risk PDR:</td> </tr> <tr> <td class=\"indent1\"> <p>Neovascularization of the disk &#8805;1/3 to 1/2 disk area </p> <p>OR</p> <p>Neovascularization of the disk and vitreous or preretinal hemorrhage </p> <p>OR</p> <p>Neovascularization elsewhere &#8805;1/2 disk area AND vitreous or pretretinal hemorrhage</p> </td> </tr> <tr> <td class=\"subtitle2_single\">Severe PDR:</td> </tr> <tr> <td class=\"indent1\"> <p>Posterior fundus obscured by preretinal or vitreous hemorrhage </p> <p>OR</p> <p>Center of macula detached</p> </td> </tr> <tr> <td class=\"subtitle1_single\">Clinically Significant Macular Edema (CSME)</td> </tr> <tr> <td> <p>Thickening of the retina &#8804;500 &#181;m from the center of the macula </p> <p>OR</p> <p>Hard exudates and adjacent retinal thickening &#8804;500 &#181;m from macular center </p> <p>OR</p> <p>Zone of retinal thickening at least 1 disc area in size located &#8804;1 disc diameter from the center of the macula</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003; 136:122.</div><div id=\"graphicVersion\">Graphic 50486 Version 2.0</div></div></div>"},"50488":{"type":"graphic_diagnosticimage","displayName":"Superior mesenteric artery stent","title":"Superior mesenteric artery stent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superior mesenteric artery stent</div><div class=\"cntnt\"><img style=\"width:251px; height:430px;\" src=\"images/SURG/50488_Normallateralarteriogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aortogram in the lateral projection. The arrow head shows the superior mesenteric artery (SMA) which contains a deployed stent and no evidence of stenosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Uflacker R. Mesenteric Ischemia. In: Peripheral Vascular Interventions, Kandarpa K (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50488 Version 9.0</div></div></div>"},"50489":{"type":"graphic_figure","displayName":"Jones metroplasty CD","title":"Jones metroplasty CD","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Jones metroplasty CD</div><div class=\"cntnt\"><img style=\"width:492px; height:638px;\" src=\"images/OBGYN/50489_Jones_metroplasty_CD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(C) Uterine closure is begun in the lower portion of the cavity. The anterior and then the posterior walls are closed, including the endometrium and a small portion of the myometrium. The suture may be continuous or interrupted. (D) Beginning inferiorly, a row of interrupted sutures is then placed in the remaining thickness of the uterine wall.</div><div id=\"graphicVersion\">Graphic 50489 Version 1.0</div></div></div>"},"50490":{"type":"graphic_diagnosticimage","displayName":"Lymphoma testis ultrasound","title":"Lymphoma of testis on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphoma of testis on ultrasound</div><div class=\"cntnt\"><img style=\"width:276px; height:371px;\" src=\"images/HEME/50490_Lymphoma_testis_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound examination of the right testis demonstrates a large anechoic mass lesion occupying most of the testis. The edges of the testis are outlined with arrows.</div><div class=\"graphic_reference\">Courtesy of Arnold S Freedman, MD, Jonathan W Friedberg, MD, and Pam DePiro, MD.</div><div id=\"graphicVersion\">Graphic 50490 Version 4.0</div></div></div>"},"50491":{"type":"graphic_diagnosticimage","displayName":"Nitrofurantoin lung injury","title":"Nitrofurantoin-induced pulmonary injury","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Nitrofurantoin-induced pulmonary injury</div><div class=\"cntnt\"><img style=\"width:514px; height:288px;\" src=\"images/PULM/50491_Nitrofurantoin_lung_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior and lateral chest radiographs show bilateral pleural effusions and parenchymal changes, predominantly located in the lower zones, in a 69-year-old woman who received nitrofurantoin for ten years because of recurrent urinary tract infections. Her symptoms consisted of dyspnea and a dry cough.</div><div class=\"graphic_reference\">Courtesy of Justus de Zeeuw, MD.</div><div id=\"graphicVersion\">Graphic 50491 Version 3.0</div></div></div>"},"50492":{"type":"graphic_picture","displayName":"Typical carcinoid organoid","title":"Typical carcinoid tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Typical carcinoid tumor</div><div class=\"cntnt\"><img style=\"width:387px; height:262px;\" src=\"images/PULM/50492_Typical_carcinoid_organoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph of a typical carcinoid tumor of the lung shows organoid architecture.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Myers, MD.</div><div id=\"graphicVersion\">Graphic 50492 Version 1.0</div></div></div>"},"50494":{"type":"graphic_picture","displayName":"Papular urticaria 2","title":"Papular urticaria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Papular urticaria</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ALLRG/50494_Papular_urticaria_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This healthy four-year-old boy developed a recurrent pruritic eruption on his arms and legs. Covered areas were only rarely involved. Note the healing lesions with postinflammatory hyperpigmentation and violaceous centers.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 50494 Version 7.0</div></div></div>"},"50495":{"type":"graphic_figure","displayName":"External carotid artery anatomy","title":"External carotid artery anatomy","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">External carotid artery anatomy</div><div class=\"cntnt\"><img style=\"width:580px; height:499px;\" src=\"images/SURG/50495_Ext_arotid_artery_anat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">External carotid artery and its branches in the lateral view.</div><div class=\"graphic_reference\">Reproduced with permission from: Uflacker R. Atlas Of Vascular Anatomy: An Angiographic Approach, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &#169; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50495 Version 1.0</div></div></div>"},"50496":{"type":"graphic_picture","displayName":"Angulated sleeve gastrectomy","title":"Angulated sleeve gastrectomy (corkscrew sleeve)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angulated sleeve gastrectomy (corkscrew sleeve)</div><div class=\"cntnt\"><img style=\"width:421px; height:432px;\" src=\"images/SURG/50496_Angulated_sleeve_gastrect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Corkscrew or angulated sleeve gastrectomy.</div><div id=\"graphicVersion\">Graphic 50496 Version 4.0</div></div></div>"},"50497":{"type":"graphic_table","displayName":"EEG findings in specific epilepsy syndromes","title":"Electroencephalographic features of some epilepsy syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Electroencephalographic features of some epilepsy syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Epilepsy syndromes</td> <td class=\"subtitle1\">EEG findings</td> <td class=\"subtitle1\">Additional EEG features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Generalized</td> </tr> <tr> <td class=\"indent1\">Absence epilepsy</td> <td>3-Hz generalized spike-and-slow wave; often repetitive trains of discharges</td> <td>Normal background; activation of IEDs and seizures with hyperventilation</td> </tr> <tr> <td class=\"indent1\">Atypical absence epilepsy</td> <td>1.5 to 2.5-Hz generalized spike-and-slow wave discharges</td> <td>IEDs may be asymmetric, with shifting focal features</td> </tr> <tr> <td class=\"indent1\">Juvenile myoclonic epilepsy</td> <td>4 to 6-Hz generalized spike and multiple spike-and-slow wave</td> <td>Normal background; activation of IEDs with photic stimulation is common; more typical 2.5 to 3-Hz spike-and-slow wave may be seen; IEDs may be asymmetric, with shifting focal features</td> </tr> <tr> <td class=\"indent1\">Infantile spasms</td> <td>Hypsarrhythmia and multifocal spikes and sharp waves</td> <td>No clearly normal background activity since the EEG is dominated by the hypsarrhythmia pattern</td> </tr> <tr> <td class=\"indent1\">Lennox-Gastaut syndrome</td> <td>&#60;2.5-Hz generalized sharp-and-slow wave discharges</td> <td>Generalized background slowing and paroxysmal fast activity; often multifocal spikes and sharp waves</td> </tr> <tr> <td class=\"indent1\">Progressive myoclonic epilepsy</td> <td>Generalized and multifocal spikes, multiple spikes, and sharp waves</td> <td>Progressive background slowing with disease progression; photic activation of IEDs in some cases</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Partial</td> </tr> <tr> <td class=\"indent1\">Benign rolandic epilepsy</td> <td>Large-amplitude spikes or sharp waves, maximal over the centrotemporal region</td> <td>Normal background; often prominent activation of IEDs with sleep; the discharge can be bilateral or unilateral and often has an anterior-posterior field of a tangential dipole</td> </tr> <tr> <td class=\"indent1\">Benign occipital epilepsy</td> <td>Bilateral or unilateral occipital spike-and-slow wave discharges</td> <td>Occipital IEDs often attenuate with eye opening; photic stimulation may precipitate seizures</td> </tr> <tr> <td class=\"indent1\">Temporal lobe epilepsy</td> <td>Temporal lobe spikes, sharp waves, and temporal intermittent rhythmic delta activity; often activated with drowsiness and sleep</td> <td>Often intermittent or persistent temporal slowing; may see independent IEDs from contralateral temporal lobe</td> </tr> <tr> <td class=\"indent1\">Frontal lobe epilepsy</td> <td>IEDs in the frontal region</td> <td>Mesial frontal discharges often are not detected by scalp EEG; secondary bilateral synchrony can occur</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EEG: electroencephalographic; IED: interictal epileptiform discharge.</div><div class=\"graphic_reference\">Reproduced with permission from: Worrell GA, Lagerlund TD, Buchhalter JR. Role and limitations of routine and ambulatory scalp electroencephalography in diagnosing and managing seizures. Mayo Clin Proc 2002; 77:991. Copyright &copy; 2002 Dowden Health Media.</div><div id=\"graphicVersion\">Graphic 50497 Version 7.0</div></div></div>"},"50499":{"type":"graphic_picture","displayName":"GBM Light","title":"Glioblastoma multiforme pathology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Glioblastoma multiforme pathology</div><div class=\"cntnt\"><img style=\"width:392px; height:261px;\" src=\"images/ONC/50499_GBM_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cellular neoplasm with nuclear pleomorphism, mitotic figures, endothelial vascular proliferation, and characteristic &quot;geographic&quot; necrosis rimmed by palisading nuclei. H and E stain, x 100.</div><div class=\"graphic_reference\">Prepared by Mila Blaivas, MD, PhD.</div><div id=\"graphicVersion\">Graphic 50499 Version 1.0</div></div></div>"},"50500":{"type":"graphic_picture","displayName":"Charcot foot PI","title":"Charcot arthropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Charcot arthropathy</div><div class=\"cntnt\"><img style=\"width:378px; height:244px;\" src=\"images/PI/50500_Charcot_foot_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This person with diabetes has joint and bone damage called Charcot arthropathy. The arch of the person's foot has collapsed and been replaced by a bony growth (see arrow). Several factors contribute to this painless condition, including the loss of muscle, decreased sensation, and inappropriate weight distribution.</div><div class=\"graphic_reference\">Courtesy of David McCulloch, MD.</div><div id=\"graphicVersion\">Graphic 50500 Version 2.0</div></div></div>"},"50501":{"type":"graphic_figure","displayName":"Distal sugar tong splint","title":"Distal sugar tong splint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal sugar tong splint</div><div class=\"cntnt\"><img style=\"width:324px; height:429px;\" src=\"images/PEDS/50501_Distal_sugar_tong_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Application of the distal sugar tong splint is shown in two steps. Figures A and B demonstrate the position of the fiberglass or plaster; figure C shows the finished splint.</div><div class=\"graphic_reference\">Reproduced with permission from: Shaw DC, Heckman JD. Principles and techniques of splinting musculocutaneous injuries. Emerg Med Clin North Am 1984; 2:391. Copyright ©1984 Elsevier.</div><div id=\"graphicVersion\">Graphic 50501 Version 3.0</div></div></div>"},"50502":{"type":"graphic_table","displayName":"WHO neuroendo tum lung 2015","title":"2015 WHO criteria for the diagnosis of pulmonary neuroendocrine tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2015 WHO criteria for the diagnosis of pulmonary neuroendocrine tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Tumor type</td> <td class=\"subtitle1\">Criteria</td> </tr> <tr> <td>Typical carcinoid</td> <td>Carcinoid morphology and &#60;2 mitoses/2 mm<sup>2</sup> (10 HPFs), lacking necrosis and &#62;0.5 cm</td> </tr> <tr class=\"divider_top\"> <td>Atypical carcinoid</td> <td>Carcinoid morphology with 2 to 10 mitoses/2 mm<sup>2</sup> (10 HPFs) or necrosis (often punctuate)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Large cell neuroendocrine carcinoma</td> <td>Neuroendocrine morphology (organoid nesting palisading rosettes, trabeculae);</td> </tr> <tr> <td>High mitotic rate &#62;10/2 mm<sup>2</sup> (10 HPFs), median of 70/2 mm<sup>2</sup>;</td> </tr> <tr> <td>Necrosis (often large zones);</td> </tr> <tr> <td>Cytologic features of a NSCLC: large cell size, low nuclear to cytoplasmic ratio, vesicular or fine chromatin, and/or frequent nucleoli; some tumors have fine nuclear chromatin and lack nucleoli but qualify as NSCLC because of large cell size and abundant cytoplasm; and</td> </tr> <tr> <td>Positive immunohistochemical staining for one or more NE markers (other than neuron-specific enolase) and/or NE granules by electron microscopy</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Small cell neuroendocrine carcinoma</td> <td>Small size (generally less than the diameter of three resting lymphocytes);</td> </tr> <tr> <td>Scant cytoplasm;</td> </tr> <tr> <td>Nuclei: finely granular nuclear chromatin, absent or faint nucleoli;</td> </tr> <tr> <td>High mitotic rate: &#62;11 mitoses/2 mm<sup>2</sup> (10 HPFs), median of 80/2 mm<sup>2</sup> (10 HPFs); and</td> </tr> <tr> <td>Frequent necrosis, often in large zones</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HPF: high-power field; NSCLC: non-small cell lung carcinoma; NE: neuroendocrine.</div><div id=\"graphicVersion\">Graphic 50502 Version 4.0</div></div></div>"},"50503":{"type":"graphic_diagnosticimage","displayName":"Substernal goiter scan I","title":"Substernal goiter: Radioiodine scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Substernal goiter: Radioiodine scan</div><div class=\"cntnt\"><img style=\"width:331px; height:320px;\" src=\"images/ENDO/50503_Substernal_goiter_Scan_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">123-Iodine scan of the thyroid suggesting a substernal component to the goiter. Substernal uptake is attenuated by the clavicles. SSN indicates the suprasternal notch.</div><div class=\"graphic_reference\">Courtesy of Douglas S Ross, MD.</div><div id=\"graphicVersion\">Graphic 50503 Version 4.0</div></div></div>"},"50505":{"type":"graphic_figure","displayName":"Cephalad retraction panniculus","title":"Panniculus retracted cephalad prior to incision","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Panniculus retracted cephalad prior to incision</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/SURG/50505_Cephalad_retraction_pannicu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panniculus retracted upward and held by wide tape to allow placement of incision below.</div><div id=\"graphicVersion\">Graphic 50505 Version 2.0</div></div></div>"},"50506":{"type":"graphic_picture","displayName":"Contracture of burned hand","title":"Contractures of the burned hand","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contractures of the burned hand</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/SURG/50506_Contracture_of_burned_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Syndactyly of the digits can occur following skin grafting of the burned hand.</div><div id=\"graphicVersion\">Graphic 50506 Version 2.0</div></div></div>"},"50507":{"type":"graphic_figure","displayName":"The autonomic ganglia in the retroperitoneum","title":"The autonomic ganglia in the retroperitoneum","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">The autonomic ganglia in the retroperitoneum</div><div class=\"cntnt\"><img style=\"width:527px; height:564px;\" src=\"images/SURG/50507_The-autonomic-ganglia-in-the-retroperitoneum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Innervation of the adrenal glands is via visceral afferent fibers arising from the celiac, aorticorenal, and renal ganglia.</div><div id=\"graphicVersion\">Graphic 50507 Version 1.0</div></div></div>"},"50508":{"type":"graphic_table","displayName":"Selection of appropriate bronchoscopic diagnostic procedures","title":"Selection of appropriate bronchoscopic diagnostic procedures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selection of appropriate bronchoscopic diagnostic procedures</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Brushing</td> <td class=\"subtitle1\">Broncho-alveolar lavage (BAL)</td> <td class=\"subtitle1\">Washing</td> <td class=\"subtitle1\">Endobronchial biopsy (EBB)</td> <td class=\"subtitle1\">Transbronchial biopsy (TBB)</td> <td class=\"subtitle1\">Endobronchial needle aspiration (EBNA)</td> <td class=\"subtitle1\">Transbronchial needle aspiration (TBNA)</td> <td class=\"subtitle1\">Additional guidance</td> </tr> <tr> <td>Endoluminal lesion</td> <td>+</td> <td>-</td> <td>+</td> <td>+++</td> <td>-</td> <td>+++</td> <td>-</td> <td>AFB or NBI if lesion is not distinct on routine examination</td> </tr> <tr> <td>Paratracheal mass, mediastinal or hilar lymphadenopathy</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>+++</td> <td>EBUS (radial or linear probe)</td> </tr> <tr> <td>Peripheral lung mass or nodule</td> <td>+/-</td> <td>+/-</td> <td>+/-</td> <td>-</td> <td>+</td> <td>-</td> <td>+</td> <td>ENB, EBUS (radial probe), XFL</td> </tr> <tr> <td>Peripheral pulmonary infiltrate (localized)</td> <td>+</td> <td>++</td> <td>+</td> <td>-</td> <td>++</td> <td>-</td> <td>+/-</td> <td>ENB or XFL</td> </tr> <tr> <td>Diffuse pulmonary infiltrate</td> <td>+</td> <td>+++</td> <td>-</td> <td>-</td> <td>++</td> <td>-</td> <td>+</td> <td>&nbsp;</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">14</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=86347&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">Cytological and microbiological specimens can be collected with all of the above procedures. Histological specimens can only be collected with endobronchial biopsy, transbronchial biopsy, or a needle core. If bronchoscopic procedure is not likely to yield diagnosis or is non-diagnostic, computed tomography (CT)-guided needle aspiration, mediastinoscopy, video-assisted thoracoscopic surgery (VATS), or thoracotomy may be indicated depending upon the location or size of the lesion or mass.</div><div class=\"graphic_footnotes\">-: unlikely to provide diagnostic information; +/-: uncertain diagnostic value; +: may provide diagnostic information; ++: more likely to provide diagnostic information; +++: most likely to provide diagnostic information; AFB: autofluorescence bronchoscopy; NBI: narrow band imaging; EBUS: endobronchial ultrasound; ENB: electromagnetic navigational bronchoscopy; XFL: x-ray fluoroscopy.</div><div id=\"graphicVersion\">Graphic 50508 Version 3.0</div></div></div>"},"50509":{"type":"graphic_table","displayName":"Diagnostic evaluation fever and neutropenia","title":"Diagnostic evaluation of patients with fever and neutropenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic evaluation of patients with fever and neutropenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Item</td> <td class=\"subtitle1\">Purpose</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Targeted history</td> <td>Seek sites suspicious for infection</td> <td>Allows detection of symptoms of infection</td> </tr> <tr class=\"divider_bottom\"> <td>Physical exam with emphasis on skin, oral cavity, oropharynx, lungs, abdomen, perianal area*</td> <td>Detection of sites suspicious for infection; guides selection of cultures and imaging</td> <td>Pain and/or erythema may point to infection; pus is not found due to lack of neutrophils; chest exam may be unremarkable even with pneumonia; abdominal tenderness may suggest neutropenic enterocolitis; perianal or hemorrhoidal tenderness may point to gram-negative or anaerobic infection</td> </tr> <tr class=\"divider_bottom\"> <td>Complete blood count with differential</td> <td>Defines the depth of neutropenia</td> <td>The lower the initial neutrophil count, the greater the likelihood of serious infection or bacteremia; daily counts allow prognostication</td> </tr> <tr class=\"divider_bottom\"> <td>Creatinine, liver function tests, electrolytes</td> <td>Defines comorbid conditions</td> <td>Allows optimal selection and dose of antimicrobial agent(s) and serial monitoring of toxicities</td> </tr> <tr class=\"divider_bottom\"> <td>Blood cultures (two sets: one peripheral and one from central venous catheter); antimicrobial susceptibility testing</td> <td>Detection of bacteremia</td> <td>Fever may be the only sign of bacteremia; allows adjustment of antibiotic regimen if necessary</td> </tr> <tr class=\"divider_bottom\"> <td>Cultures and stains of samples from suspected sites of infection</td> <td>Detection of infectious etiology</td> <td>Bacterial and fungal stains can be helpful</td> </tr> <tr> <td>Imaging studies (generally recommended only if site is suspected from history or exam)</td> <td>Detection of infectious site</td> <td>Computed tomography (CT) scans are generally more useful than plain radiographs; pulmonary infiltrates may be inapparent by plain radiography during deep neutropenia and may become manifest only upon neutrophil recovery; thickened bowel walls are seen by CT scan with neutropenic enterocolitis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Digital rectal examination is avoided in neutropenic patients.</div><div id=\"graphicVersion\">Graphic 50509 Version 6.0</div></div></div>"},"50510":{"type":"graphic_algorithm","displayName":"Assessment of airway pressures during mechanical ventilation","title":"Assessment of airway pressures during mechanical ventilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Assessment of airway pressures during mechanical ventilation</div><div class=\"cntnt\"><img style=\"width:441px; height:240px;\" src=\"images/EM/50510_Airway_press_approach.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ETT: Endotracheal tube; PE: Pulmonary embolism; PIP: Peak inspiratory pressure; Pplat: Plateau pressure; RMSB: Right main-stem bronchus</div><div class=\"graphic_reference\">Reproduced with permission from: Fessler, MB, Welsh, CH. Mechanical Ventilation: Invasive and Noninvasive. In: Current Diagnosis and Treatment in Pulmonary Medicine, McPhee, SJ, Papadakis, MA, Tierney, LM (Eds), McGrawHill 2003. Copyright © 2003 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 50510 Version 3.0</div></div></div>"},"50511":{"type":"graphic_picture","displayName":"Stockinette short arm","title":"Stockinette for a short arm cast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stockinette for a short arm cast</div><div class=\"cntnt\"><img style=\"width:355px; height:468px;\" src=\"images/EM/50511_Stockinette_short_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stockinette is the first layer of any cast. Take care to avoid wrinkles, which can contribute to pressure lesions.</div><div class=\"graphic_reference\">Courtesy of Stephen Titus, MD.</div><div id=\"graphicVersion\">Graphic 50511 Version 1.0</div></div></div>"},"50512":{"type":"graphic_waveform","displayName":"Atrial premature beat tutorial","title":"Atrial premature beats","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atrial premature beats</div><div class=\"cntnt\"><img style=\"width:300px; height:108px;\" src=\"images/CARD/50512_Atrial_premature_beat_tutor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The third beat is an atrial premature beat that is normally conducted. The interval between the second sinus beat and the ectopic beat is shorter than the interval between the first two sinus beats. The P wave morphology differs from that of sinus rhythm. Since the RR cycle length is shorter, there is a decrease in the rate of conduction of the ectopic beat through the atrioventricular node. The PR interval is therefore longer than that of the sinus beat. Activation of the ventricular myocardium occurs in a normal fashion; as a result, the QRS complex is unchanged from that of sinus rhythm.</div><div id=\"graphicVersion\">Graphic 50512 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"50515":{"type":"graphic_table","displayName":"Salt suppl CF","title":"Suggested salt supplementation for infants and children with cystic fibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested salt supplementation for infants and children with cystic fibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age</td> <td class=\"subtitle1\" colspan=\"2\"> <p>Usual conditions*</p> Salt (per day)</td> <td class=\"subtitle1\" colspan=\"2\"> <p>Extreme conditions<sup>&#182;</sup></p> Salt (teaspoons per day)</td> </tr> <tr> <td class=\"subtitle2\">Dose in teaspoons</td> <td class=\"subtitle2\">Dose in mg</td> <td class=\"subtitle2\">Dose in teaspoons</td> <td class=\"subtitle2\">Dose in mg</td> </tr> <tr> <td>0 to 6 months</td> <td><span style=\"font-size: 16px; font-family: calibri;\">&#8539;</span> to <span style=\"font-size: 16px; font-family: calibri;\">&#188;</span></td> <td>300 to 600 mg</td> <td><span style=\"font-size: 16px; font-family: calibri;\">&#188;</span> to <span style=\"font-size: 16px; font-family: calibri;\">&#189;</span></td> <td>600 to 1200 mg</td> </tr> <tr> <td>6 to 12 months</td> <td><span style=\"font-size: 16px; font-family: calibri;\">&#188;</span> to <span style=\"font-size: 16px; font-family: calibri;\">&#189;</span></td> <td>600 to 1200 mg</td> <td><span style=\"font-size: 16px; font-family: calibri;\">&#189;</span> to <span style=\"font-size: 16px; font-family: calibri;\">&#190;</span></td> <td>1200 to 1800 mg</td> </tr> <tr> <td>1 to 5 years</td> <td><span style=\"font-size: 16px; font-family: calibri;\">&#8531;</span> to <span style=\"font-size: 16px; font-family: calibri;\">&#8532;</span></td> <td>800 to 1600 mg</td> <td><span style=\"font-size: 16px; font-family: calibri;\">&#8532;</span> to 1<span style=\"font-size: 16px; font-family: calibri;\">&#8531;</span></td> <td>1600 to 3200 mg</td> </tr> <tr> <td>Over 5 years</td> <td><span style=\"font-size: 16px; font-family: calibri;\">&#190;</span> to 1</td> <td>1800 to 2400 mg</td> <td>1<span style=\"font-size: 16px; font-family: calibri;\">&#189;</span> to 2</td> <td>3600 to 4800 mg</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><span style=\"font-size: 16px; font-family: calibri;\">⅛</span> tsp salt provides approximately 300 mg or 11 mEq of sodium.</div><div class=\"graphic_footnotes\">* Moderate temperature and humidity, no excessive sweating, regular bowel movements, no vomiting or diarrhea.<br />&para; High temperature and/or humidity; dry, desert climate; strenuous and/or prolonged exercise, especially in heat; excessive sweating; fever, diarrhea, or vomiting.</div><div class=\"graphic_reference\">Courtesy of Chris Coburn-Miller, MSRD, CSP.</div><div id=\"graphicVersion\">Graphic 50515 Version 4.0</div></div></div>"},"50516":{"type":"graphic_table","displayName":"Diet stages LAGB","title":"Diet stages of laparoscopic adjustable gastric band","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diet stages of laparoscopic adjustable gastric band</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">LAGB diet stage*</td> <td class=\"subtitle1\">Begin</td> <td class=\"subtitle1\">Fluids/food</td> <td class=\"subtitle1\">Guidelines</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Stage I</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&nbsp;</td> <td>Postoperative days 1 and 2</td> <td> <p><strong>LAGB clear liquids:</strong></p> <p>Non-carbonated; no calories</p> No sugar; no caffeine</td> <td>Postoperative LAGB day 1, patients may begin sips of water, ice chips, and no sugar liquids; avoid carbonation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Stage II</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"6\"> <p><strong>Begin supplementation:</strong></p> <p><strong>Chewable</strong> multivitamin with minerals x 2/day</p> <strong>Chewable or liquid</strong> Calcium citrate with vitamin D</td> <td class=\"divider_bottom\" rowspan=\"6\">Postoperative days 2-3 (discharge diet)</td> <td class=\"divider_bottom\" rowspan=\"6\"> <p><strong>LAGB clear liquids:</strong></p> <p>Variety of no-sugar liquids or artificially sweetened liquids</p> <p><strong>Plus LAGB full liquids:</strong></p> No more than 3 g fat per serving protein-rich liquids</td> <td class=\"sublist1_start\">Patients should consume a minimum of 48-64 ounces of total fluids per day, 24-32 ounces or more ounces LAGB clear liquids, plus 24-32 ounces of any combination of full liquids:</td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>1% or skim milk mixed with: </li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Whey or soy protein powder if lactose intolerant </li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Lactaid milk or soy milk mix with soy protein powder </li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Light yogurt, blended </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\"> <ul> <li>Plain yogurt </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Stage III</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Week I </td> <td rowspan=\"4\">Postoperative days 10-14* </td> <td rowspan=\"4\"> <p>Increase LAGB clear liquids (total liquids 48-64 plus ounces per day) and replace full liquids with soft, moist, diced, ground, or pureed protein sources as tolerated - as evidenced by the absence of excessive fullness or bloating, nausea, or vomiting.</p> <strong>Stage III week 1:</strong> Eggs, ground meats, poultry, soft, moist fish, added gravy, bouillon, light mayo to moisten, cooked bean, hearty bean soups, cottage cheese, low fat cheese, yogurt</td> <td class=\"sublist1_start\"><strong>NOTE:</strong> Patients should be reassured that hunger is common and normal after LAGB</td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Protein food (moist, ground) choices are encouraged for 3-6 small meals per day, to help with satiety, since hunger is common within a week or so of LAGB </li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Mindful, slow eating is essential </li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Encourage patients not to drink with meals and to wait &sim;30 minutes after each meal before resuming fluids </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Week 2 </td> <td>4 weeks postoperatively</td> <td> <p>Advance diet as tolerated. </p> <p>Tofu is a good choice as it is soft.</p> <p>Dense, chewy foods such as tough meats and doughy breads should be avoided as they may cause obstruction.</p> Avoid high-calorie soft foods such as ice cream.</td> <td> <p>Adequate hydration is essential and a priority for all patients during the rapid weight loss phase. </p> Protein at every meal and snack, especially if increased hunger noted prior to initial fill or adjustment. Very well-cooked vegetables may also help to increase satiety.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Week 3</td> <td>5 weeks postoperatively</td> <td>Continue to consume protein with some fruit or vegetable at each meal.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Stage IV</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vitamin and mineral supplementation daily<sup>&#182;</sup></td> <td>As hunger increases and more food is tolerated</td> <td>Healthy solid food diet.</td> <td>Healthy, balanced diet consisting of adequate protein, fruits, vegetables, and whole grains; calorie needs based on height, weight, age. </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Post-LAGB fill/adjustment</td> </tr> <tr> <td>&nbsp;</td> <td>&sim;6 weeks postoperatively for&nbsp;LAGB, and possibly every 6 weeks until satiety reached</td> <td>Full liquids x 2 days post-fill; advance to Stage III, week 1 guidelines above, as tolerated. = x 4-5 days, then advance as above.</td> <td> <p>Same as Stage II liquids above x 48 hours (and/or as otherwise advised by surgeon).</p> <strong>NOTE:</strong> When diet advanced to soft solids, special attention to mindful eating and chewing until liquid is key, since more restriction may increase risk for food getting stuck above stoma of band if not properly chewed (eg, if not chewed until liquid).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LAGB: laparoscopic adjustable gastric band.<br />* There is no standardization of diet stages; there are a wide variety of diet protocols varying from how long patients stay on each stage and what types of fluids/foods are recommended.<br />¶ Nutritional labs should be drawn at&nbsp;2, 6, 12 months and yearly indefinitely; bone density test at baseline and every 2 years.</div><div class=\"graphic_reference\">Table provided with permission: Sue Cummings, MS, RD, LDN; MGH Weight Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 50516 Version 3.0</div></div></div>"},"50518":{"type":"graphic_diagnosticimage","displayName":"Cubitus valgus","title":"Cubitus valgus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cubitus valgus</div><div class=\"cntnt\"><img style=\"width:413px; height:310px;\" src=\"images/EM/50518_Cubitusvalgus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A 10-year-old boy with a right arm cubitus valgus (increased carrying angle with arm pointing farther away from the body in anatomic position) resulting from a fracture of the right lateral condylar physis with nonunion. <br />(B) Nonunion with cubitus valgus. Radiograph showing both angulation and translocation secondary to nonunion of the condylar fragment.</div><div class=\"graphic_reference\">Reproduced with permission from: Beaty JH, Kasser JR. The elbow: Physeal fractures, apophyseal injuries of the distal humerus, avascular necrosis of the trochlea, and T-condylar fractures. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beary JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50518 Version 15.0</div></div></div>"},"50522":{"type":"graphic_picture","displayName":"Cold agglutinin","title":"Red blood cell agglutination due to a cold agglutinin","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Red blood cell agglutination due to a cold agglutinin</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/HEME/50522_Cold_agglutinin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear from a patient with cold agglutinin hemolytic anemia shows marked red blood cell agglutination into irregular clumps.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 50522 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"50523":{"type":"graphic_waveform","displayName":"ECG atrial tachycardia from crista terminalis","title":"Electrocardiogram (ECG) showing atrial tachycardia originating from the crista terminalis.","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) showing atrial tachycardia originating from the crista terminalis.</div><div class=\"cntnt\"><img style=\"width:488px; height:393px;\" src=\"images/CARD/50523_Atrial_tachycardia_ECG_2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiographic tracing showing a narrow complex tachycardia with uniform P waves consistent with atrial tachycardia originating from the crista terminalis. Following the third beat there is spontaneous return to normal sinus rhythm with uniform P waves of a different morphology.</div><div class=\"graphic_reference\">Courtesy of Dr. Peter M Kistler.</div><div id=\"graphicVersion\">Graphic 50523 Version 7.0</div></div></div>"},"50524":{"type":"graphic_figure","displayName":"Atrial switch repair","title":"Diagram of the atrial switch repair","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagram of the atrial switch repair</div><div class=\"cntnt\"><img style=\"width:374px; height:403px;\" src=\"images/PEDS/50524_Atrial_switch_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram of the atrial switch repair (Mustard or Senning procedure). Patch material is used to create a baffle that diverts the deoxygenated systemic venous return from the inferior venous cava (IVC) and superior venous cava (SVC) into the left atrium (LA), where it crosses the mitral valve and into the left ventricle (LV), where it is pumped into the pulmonary circulation via the pulmonary artery (PA). The baffle is positioned in the atrium so that the pulmonary veins, which are located posteriorly, drain into the right atrium. This allows for flow across the tricuspid valve and into the right ventricle (RV), where blood is pumped into the systemic circulation via the aorta (Ao).</div><div class=\"graphic_reference\">From: the Multimedia Library of Congenital Heart Disease, Children's Hospital, Boston, MA, editor Robert Geggel, MD, www.childrenshospital.org/mml.cvp, with permission.</div><div id=\"graphicVersion\">Graphic 50524 Version 2.0</div></div></div>"},"50525":{"type":"graphic_figure","displayName":"Scaphoid arterial supply","title":"Scaphoid arterial supply and nonunion risk","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Scaphoid arterial supply and nonunion risk</div><div class=\"cntnt\"><img style=\"width:501px; height:267px;\" src=\"images/EM/50525_Scaphoidartsupply.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arterial flow to the scaphoid, provided by the palmar carpal branch of the radial artery, can be disrupted by a fracture, increasing the risk of nonunion.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Upper limb. In: Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins; Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50525 Version 10.0</div></div></div>"},"50526":{"type":"graphic_picture","displayName":"Sweet syndrome vesicles","title":"Sweet syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sweet syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/50526_Sweet_syndrome_vesicles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vesicles and&nbsp;inflammatory papules and plaques are present&nbsp;in this patient with Sweet syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50526 Version 2.0</div></div></div>"},"50527":{"type":"graphic_picture","displayName":"Severe perioral dermatitis","title":"Severe perioral dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Severe perioral dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/50527_Severe_perioral_dermatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules and confluent areas of erythema are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50527 Version 3.0</div></div></div>"},"50528":{"type":"graphic_figure","displayName":"Telogen and anagen hairs","title":"Telogen and anagen hairs","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Telogen and anagen hairs</div><div class=\"cntnt\"><img style=\"width:188px; height:382px;\" src=\"images/DERM/50528_Telogen_anagen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Telogen club hairs have a cornified, depigmented, rounded-up bulb without an attached root sheath (left). Normal anagen hairs have pigmented, distorted bulbs and an attached root sheath (right).</div><div class=\"graphic_reference\">Reproduced with permission from: Wolff K, Goldsmith LA, Katz S, et al. Fitzpatrick's Dermatology in General Medicine, 7th ed, McGraw-Hill Professional 2008. Copyright © 2008 The McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 50528 Version 16.0</div></div></div>"},"50531":{"type":"graphic_picture","displayName":"Petroleum gauze dressing","title":"Circumcised penis wrapped in petroleum gauze dressing","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Circumcised penis wrapped in petroleum gauze dressing</div><div class=\"cntnt\"><img style=\"width:468px; height:305px;\" src=\"images/OBGYN/50531_Petroleum_gauze_dressing.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of David G Weismiller, MD.</div><div id=\"graphicVersion\">Graphic 50531 Version 1.0</div></div></div>"},"50532":{"type":"graphic_picture","displayName":"Scoliosis truncal asymmetry","title":"Truncal asymmetry in scoliosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Truncal asymmetry in scoliosis</div><div class=\"cntnt\"><img style=\"width:266px; height:406px;\" src=\"images/PEDS/50532_Scoliosis_truncal_asymm_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scoliosis may be indicated by differences in the height of the shoulders or scapulae and asymmetry of the waistline, all of which are depicted in the above photograph.</div><div class=\"graphic_reference\">Courtesy of Susan&nbsp;A&nbsp;Scherl, MD.</div><div id=\"graphicVersion\">Graphic 50532 Version 4.0</div></div></div>"},"50533":{"type":"graphic_picture","displayName":"Finger digital block","title":"Finger digital block","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Finger digital block</div><div class=\"cntnt\"><img style=\"width:369px; height:277px;\" src=\"images/EM/50533_Digital_block_finger.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform a finger web space block, insert the needle into the subcutaneous tissue of the web space at the base of the finger, just distal to the MCP (metacarpal/phalangeal) joint. Slowly advance the needle straight through the web space toward the palmar surface, injecting as the needle is advanced. The black ink line illustrates the likely course of the dorsal digital nerve.</div><div class=\"graphic_reference\">Courtesy of Robert Baldor, MD.</div><div id=\"graphicVersion\">Graphic 50533 Version 3.0</div></div></div>"},"50536":{"type":"graphic_diagnosticimage","displayName":"Type III hiatal hernia upper GI","title":"Type III hiatal hernia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Type III hiatal hernia</div><div class=\"cntnt\"><img style=\"width:217px; height:358px;\" src=\"images/GAST/50536_Type_III_hiatal_hernia_UGI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper GI (gastrointestinal)&nbsp;series showing a type III hiatal hernia. Type III hernias have elements of both types I and II. With progressive enlargement of the hernia through the hiatus, the phrenoesophageal membrane stretches, displacing the gastroesophageal junction above the diaphragm, thereby adding a sliding element to the type II hernia.</div><div class=\"graphic_reference\">Reprinted with permission from: Peridikis G, Hinder RA. Paraesophageal hiatal hernia. In: Hernia, Nyhus LM, Condon RE (Eds), JB Lippincott, Philadelphia 1995. p.544.</div><div id=\"graphicVersion\">Graphic 50536 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal upper GI series</div><div class=\"cntnt\"><img style=\"width:286px; height:330px;\" src=\"images/GAST/81537_Normal_upper_GI_series.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal air-contrast upper gastrointestinal (GI)&nbsp;study showing normal gastric folds and small intestinal anatomy, and no masses.</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy III, MD.</div><div id=\"graphicVersion\">Graphic 81537 Version 4.0</div></div></div>"},"50537":{"type":"graphic_table","displayName":"Dyspareunia differential dx3","title":"Differential diagnoses for physical causes of dyspareunia (cont.)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnoses for physical causes of dyspareunia (cont.)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Location affected</td> <td class=\"subtitle1\">Specific condition</td> <td class=\"subtitle1\">Important history</td> <td class=\"subtitle1\">Physical source of dyspareunia</td> <td class=\"subtitle1\">Comments and caveats</td> </tr> <tr class=\"divider_bottom\"> <td>Vestibule only</td> <td>Vestibulodynia</td> <td>Pain mainly with penetration, tampon or speculum</td> <td>Tenderness on touch or pressure, erythema</td> <td>No cause for the pain is found</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Perineum and anus</td> <td>Episiotomy</td> <td>Vaginal delivery with episiotomy</td> <td>Non-healing, tenderness</td> <td>&nbsp;</td> </tr> <tr> <td>Dermatitis (eczema)</td> <td>Itching, irritation</td> <td>Erythema, edema, fissuring</td> <td>Look for Candida</td> </tr> <tr class=\"divider_bottom\"> <td>Inflammatory bowel: Crohn's</td> <td>Diarrhea, bleeding, pain</td> <td>Edema, tags, fissures, sinuses</td> <td>May precede bowel symptoms - often mistaken for hemorrhoids</td> </tr> <tr class=\"divider_bottom\"> <td>Rectum</td> <td>Rectocele</td> <td>Sensation of vaginal obstruction</td> <td>Protrusion of stool filled rectum</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Vagina</td> <td>Pelvic floor hypertonus</td> <td>Aching pain, vaginismus</td> <td>Levator spasm on palpation</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Congenital anomaly: vaginal agenesis, imperforate hymen</td> <td>Inability to be penetrated</td> <td>Absent vagina, abn hymen</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"6\">Pelvis</td> <td>Retroverted or prolapsed uterus</td> <td>Pain with thrusting</td> <td>Uterine retroversion or descent</td> <td>&nbsp;</td> </tr> <tr> <td>Leiomyomata</td> <td>Pain with thrusting</td> <td>Tender uterine masses</td> <td>Uncommon cause of pain</td> </tr> <tr> <td>Endometriosis, adenomyosis</td> <td>Cramping, deep dyspareunia; history of menorrhagia, dysmenorrhea</td> <td>Tender uterus, fixed uterus, nodules cul de sac rectovaginal septum, adnexal tenderness or masses</td> <td>&nbsp;</td> </tr> <tr> <td>Adnexal pathology</td> <td>Deep dyspareunia, cyclical</td> <td>Tenderness in adnexa</td> <td>&nbsp;</td> </tr> <tr> <td>Pelvic inflammatory disease</td> <td>Chronic pelvic pain, deep dyspareunia</td> <td>Uterine, cervical, adnexal tenderness</td> <td>&nbsp;</td> </tr> <tr> <td>Irritable bowel syndrome</td> <td>Deep dyspareunia</td> <td>None; or pelvic tenderness</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Elizabeth Gunther Stewart, MD.</div><div id=\"graphicVersion\">Graphic 50537 Version 4.0</div></div></div>"},"50539":{"type":"graphic_figure","displayName":"Component separation technique skin flap dissection","title":"Component separation technique skin flap dissection","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Component separation technique skin flap dissection</div><div class=\"cntnt\"><img style=\"width:498px; height:432px;\" src=\"images/SURG/50539_CST-skin-flap-dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The first surgical step for performing the component separation technique (CST) is to elevate the skin and subcutaneous tissues from the underlying fascia. The dissection extends from the costal margin cephalad to the pubis caudally, and to the anterior axillary line and iliac crest laterally.</div><div class=\"graphic_reference\">Nguyen VT, Shestak KC. Separation of anatomic components method of abdominal wall reconstruction--clinical outcome analysis and an update of surgical modifications using the technique. Clin Plast Surg. 2006; 33:247.</div><div id=\"graphicVersion\">Graphic 50539 Version 4.0</div></div></div>"},"50540":{"type":"graphic_figure","displayName":"Iliac aneurysm symptoms","title":"Iliac aneurysm symptoms","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Iliac aneurysm symptoms</div><div class=\"cntnt\"><img style=\"width:535px; height:585px;\" src=\"images/SURG/50540_Aortoiliac-aneurysm-symptoms-edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Iliac artery aneurysms behave similar to abdominal aortic aneurysms with symptoms related to aneurysm expansion including pain from arterial wall stretching, or compression and erosion of surrounding structures. Compressive symptoms of iliac artery aneurysm can involve the lower urinary tract (eg, ureteric colic, ureteral obstruction, pyelonephritis, urinary retention), lower gastrointestinal tract (eg, pain with defecation, tenesmus and constipation), or lumbar/pelvic nerves (paresthesia, sciatic neuralgia).</div><div id=\"graphicVersion\">Graphic 50540 Version 2.0</div></div></div>"},"50541":{"type":"graphic_diagnosticimage","displayName":"Drug packets on abdominal CT - Transverse image","title":"Drug packets on abdominal CT: Transverse image","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Drug packets on abdominal CT: Transverse image</div><div class=\"cntnt\"><img style=\"width:282px; height:273px;\" src=\"images/EM/50541_Drug_packet_transverse_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This transverse image from an abdominal CT performed with water soluble contrast shows the different appearances of drug packets as they align in or opposite to the plane of the image.</div><div class=\"graphic_reference\">Courtesy of Robert Hoffman, MD.</div><div id=\"graphicVersion\">Graphic 50541 Version 2.0</div></div></div>"},"50542":{"type":"graphic_diagnosticimage","displayName":"Anterior acetabular column fracture","title":"Anterior acetabular column fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior acetabular column fracture</div><div class=\"cntnt\"><img style=\"width:440px; height:522px;\" src=\"images/EM/50542_Acetabularfxantcolumn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The AP view demonstrates a fracture from the iliac crest to the hip joint with disruption of the roof of the acetabulum. Fractues of the pelvic brim and the ischial ramus are also noted.<br> (B) The obturator oblique view demonstrates a single break in the iliopectineal line where the anterior column fracture crosses the pelvic brim.<br> (C) The iliac oblique view shows that the posterior border is intact.</div><div class=\"graphic_reference\">Reproduced with permission from: Moed BR, Reilly MC. Lower extremity: Acetabulum fractures. In: Rockwood and Green's Fractures in Adults,&nbsp;7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50542 Version 15.0</div></div></div>"},"50544":{"type":"graphic_picture","displayName":"Disk diffusion test","title":"Disk diffusion test of Candida parapsilosis at 24 hours","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disk diffusion test of Candida parapsilosis at 24 hours</div><div class=\"cntnt\"><img style=\"width:400px; height:376px;\" src=\"images/ID/50544_Disk_diffusion_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Antifungal susceptibilities are determined by measuring the diameter of the zone of inhibition in millimeters for each of the different antifungal disks. These are converted to susceptible, intermediate, or resistant using reference ranges determined by the Clinical and Laboratory Standards Institute.</div><div class=\"graphic_reference\">Courtesy of Michael Pfaller, MD.</div><div id=\"graphicVersion\">Graphic 50544 Version 1.0</div></div></div>"},"50546":{"type":"graphic_table","displayName":"Post therapy histology prostate","title":"Posttherapy histologic features of the prostate gland","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Posttherapy histologic features of the prostate gland</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Treatment type</td>\n\n      <td class=\"subtitle1\">Changes in prostate cancer cells</td>\n\n      <td class=\"subtitle1\">Changes in benign epithelium</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Androgen ablation</td>\n\n      <td><p>Severe atrophic changes</p>\n\t\t<p>Clear or vacuolated cytoplasm</p>\n\t\t<p>Decreased nuclear atypia (Retained infiltrating pattern)</p></td>\n\n      <td><p>Severe atrophy</p>\n\t\t<p>Basal cell hyperplasia</p></td>\n\n    </tr>\n\n    \n    \n    <tr>\n\n      <td>Estrogen</td>\n\n      <td><p>Atrophic changes</p>\n\t\t<p>Squamous metaplasia</p></td>\n\n      <td><p>Squamous metaplasia</p></td>\n\n    </tr>\n\n    \n    <tr>\n\n      <td>Finasteride and dutasteride</td>\n\n      <td>Minimal changes</td>\n\n      <td>Mild atrophy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Radiation therapy</td>\n\n      <td>Degenerative changes (Retained infiltrating pattern)</td>\n\n      <td>Marked nuclear atypia</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 50546 Version 1.0</div></div></div>"},"50549":{"type":"graphic_diagnosticimage","displayName":"SFU grading fetal hydronephr","title":"Society of Fetal Urology grading system for hydronephrosis","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Society of Fetal Urology grading system for hydronephrosis</div><div class=\"cntnt\"><img style=\"width:539px; height:149px;\" src=\"images/PEDS/50549_SFU_grading_fetal_hydroneph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Grade 0: no dilation (not shown). Grade 1: renal pelvis is only visualized. Grade 2: renal pelvis as well as a few, but not all, calyces are visualized. Grade 3: virtually all calyces are visualized. Grade 4: similar to Grade 3, but when compared&nbsp;with the normal centralateral kidney, there is parenchymal thinning.</div><div id=\"graphicVersion\">Graphic 50549 Version 3.0</div></div></div>"},"50550":{"type":"graphic_diagnosticimage","displayName":"Fiducials pancreatic tumor","title":"Pancreatic tumor localization with fiducials","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic tumor localization with fiducials</div><div class=\"cntnt\"><img style=\"width:360px; height:397px;\" src=\"images/GAST/50550_Fiducials_pancreatic_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiographic image of fiducials (radiographic markers) in the region of the pancreatic tumor, which is marked by the metal stent within the common bile duct.</div><div class=\"graphic_reference\">Courtesy of Kenneth E Fasanella, MD, and Michael K Sanders, MD.</div><div id=\"graphicVersion\">Graphic 50550 Version 3.0</div></div></div>"},"50552":{"type":"graphic_figure","displayName":"Dorsal hand anatomy scheme: arteries and nerves","title":"Dorsal hand anatomy scheme: arteries and nerves","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dorsal hand anatomy scheme: arteries and nerves</div><div class=\"cntnt\"><img style=\"width:433px; height:443px;\" src=\"images/PC/50552_Dorsal_hand_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The path of dorsal arteries (red) and nerves (green) to the fingers is shown. Each digit is innervated by four digital nerves; the palmar arteries and nerves are not shown in this figure. In order to achieve a complete anesthetic effect, it is necessary to block all four nerves.</div><div id=\"graphicVersion\">Graphic 50552 Version 4.0</div></div></div>"},"50553":{"type":"graphic_table","displayName":"Features found more frequently with esophageal chest pain","title":"Features found more frequently in patients with esophageal chest pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features found more frequently in patients with esophageal chest pain</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Pain provoked by swallowing</td>\n</tr>\n<tr>\n<td>Pain provoked by postural changes</td>\n</tr>\n<tr>\n<td>Pain palliated by antacids</td>\n</tr>\n<tr>\n<td>An inconsistent relationship to exercise</td>\n</tr>\n<tr>\n<td>Substernal chest pain that does not radiate</td>\n</tr>\n<tr>\n<td>Frequent episodes of spontaneous pain</td>\n</tr>\n<tr>\n<td>Nocturnal pain</td>\n</tr>\n<tr>\n<td>Severe onset of pain, continuing as a background ache for several hours</td>\n</tr>\n<tr>\n<td>Pain associated with heartburn and regurgitation of acid into the mouth</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=58822&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Features_esophageal_chest_p.htm</title></head></div><div class=\"graphic_reference\">Data from Davies, HA, Jones, DB, Rhodes, J, Newcombe, RG, J Clin Gastroenterology 1985; 7:477.</div><div id=\"graphicVersion\">Graphic 50553 Version 2.0</div></div></div>"},"50555":{"type":"graphic_picture","displayName":"Adeno CA lung Light II","title":"Adenocarcinoma of the lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adenocarcinoma of the lung</div><div class=\"cntnt\"><img style=\"width:401px; height:284px;\" src=\"images/PULM/50555_Adeno_CA_lung_Light_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of a hematoxylin and eosin-stained section of solid adenocarcinoma of the lung.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Myers, MD.</div><div id=\"graphicVersion\">Graphic 50555 Version 1.0</div></div></div>"},"50556":{"type":"graphic_figure","displayName":"Waveforms volume cycle vent","title":"Waveforms for volume-cycle ventilator","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Waveforms for volume-cycle ventilator</div><div class=\"cntnt\"><img style=\"width:354px; height:264px;\" src=\"images/PULM/50556_Waveforms_volume_cycle_vent.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressure, flow, and volume waveforms for a volume-cycle ventilator using a constant flow generator (square wave) at baseline (A), and with increased delivered tidal volume (B), reduced lung compliance (C), and enhanced respiratory flow rate (D). An increase in peak airway pressure occurs in the last three settings.</div><div class=\"graphic_reference\">Adapted from Spearman, CB, Egan, DF, Egan, J, Fundamentals of respiratory therapy, 4th ed, Mosby, St Louis, 1982.</div><div id=\"graphicVersion\">Graphic 50556 Version 1.0</div></div></div>"},"50558":{"type":"graphic_picture","displayName":"Bat bite","title":"Bat bite (arrows) on the finger","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Bat bite (arrows) on the finger</div><div class=\"cntnt\"><img style=\"width:461px; height:280px;\" src=\"images/ID/50558_Bat_bite_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Photo used by permission of the Texas AgriLife Extension Service, Janet Hurley, Extension Program Specialist II&#8211;School IPM, and the Bats in Schools website, http://agrilife.org/batsinschools/.</div><div id=\"graphicVersion\">Graphic 50558 Version 5.0</div></div></div>"},"50560":{"type":"graphic_table","displayName":"Probiotic regimens","title":"Studies in which use of probiotics prevented <EM>Clostridium difficile</EM> infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Studies in which use of probiotics prevented <EM>Clostridium difficile</EM> infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"30%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"30%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Publication date</td> <td class=\"subtitle1\">Probiotic regimen studied</td> <td class=\"subtitle1\">Study population</td> <td class=\"subtitle1\">Study findings</td> <td class=\"subtitle1\">Similar (commercially available) product*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Studies in adults</td> </tr> <tr> <td class=\"indent1\">Beausoleil et al (2007)</td> <td><em>L. acidophilus</em> and <em>L. casei</em> (25 x 10<sup>9</sup> CFU/day for 2 days, then 50 x 10<sup>9</sup> CFU/day for duration of the antibiotic course)</td> <td>89 adults (inpatients)</td> <td>Antibiotic-associated diarrhea occurred in 16% of treated patients and 36% of patients in placebo group (OR 0.34; 95% CI 0.12 to 0.94; p = 0.05)</td> <td>Bio-K</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hickson et al (2007)</td> <td><em>L. casei</em> (19 x 10<sup>9</sup> CFU/day), <em>L. bulgaris</em> (1.9 x 10<sup>9</sup> CFU/day), and <em>S. thermophiles</em> (19 x 10<sup>9</sup> CFU/day) within 48 hours of starting antibiotic therapy until 7 days after discontinuation</td> <td>135 adults (inpatients)</td> <td>Antibiotic-associated diarrhea occurred in 12% of treated patients and 34% of patients in placebo group (p = 0.007; aRR 0.17 [0.07&ndash;0.27]). </td> <td>Actimel (also known as Danactive in United States and Canada)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Studies in children</td> </tr> <tr> <td class=\"indent1\">Kotowska et al (2005)</td> <td><em>S. boulardii</em> (10 x 10<sup>9</sup> CFU/day) for duration of the antibiotic course</td> <td>269 children (72 inpatients and 197 outpatients)</td> <td>Antibiotic-associated diarrhea occurred in 3% of treated patients and 17% of patients in placebo group. (RR 0.2, 95% CI 0.07&ndash;0.5).</td> <td>Florastor</td> </tr> <tr> <td class=\"indent1\">Ruszczyński et al (2008)</td> <td><em>L. rhamnosus</em> GG (2 x 10<sup>10</sup> CFU/day) for duration of the antibiotic course</td> <td>240 children (134 inpatients and 106 outpatients)</td> <td>Antibiotic-associated diarrhea occurred in 2.5% treated patients and 7.5% of patients in placebo group (RR 0.33, 95% CI 0.10&ndash;1.1).</td> <td>Culturelle</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The studies presented are randomized controlled clinical trials that demonstrated a significant effect in preventing <em>C. difficile</em> infection. Studies of probiotics that did not demonstrate benefit are not presented. The studies are presented in order of publication date; the sequence does not reflect clinical preference.</div><div class=\"graphic_footnotes\">CFU: colony forming units; OR: odds ratio; aRR: absolute risk reduction; RR: relative risk.<br />* Not approved by the United States Food and Drug Administration for prevention or treatment of <em>C. difficile</em> infection.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Beausoleil M, Fortier N, et al. Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Can J Gastroenterol 2007; 21:732.</li>&#xD;&#xA;    <li>Hickson M, D'Souza AL, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007; 335:80.</li>&#xD;&#xA;    <li>Kotowska M, Albrecht P, et al. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005; 21:583.</li>&#xD;&#xA;    <li>Ruszczyński M, Radzikowski A, et al. Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Aliment Pharmacol Ther 2008; 28:154.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 50560 Version 13.0</div></div></div>"},"50561":{"type":"graphic_picture","displayName":"Velamentous cord insertion","title":"Velamentous cord","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Velamentous cord</div><div class=\"cntnt\"><img style=\"width:432px; height:339px;\" src=\"images/OBGYN/50561_Velamentous_cord.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The umbilical cord placental insertion site is membranous. The velamentous vessels are surrounded only by fetal membranes, with no Wharton's jelly.</div><div class=\"graphic_reference\">Courtesy of Eduardo Zambrano, MD, MS.</div><div id=\"graphicVersion\">Graphic 50561 Version 2.0</div></div></div>"},"50564":{"type":"graphic_picture","displayName":"Centripetal obesity in Cushings","title":"Centipetal obesity in Cushing's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Centipetal obesity in Cushing's syndrome</div><div class=\"cntnt\"><img style=\"width:311px; height:324px;\" src=\"images/ENDO/50564_Centripetal_obesity_in_Cush.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">30-year-old woman with Cushing's disease showing centripetal obesity, relatively thin limbs, dorsal kyphosis, and thick neck.</div><div class=\"graphic_reference\">Reproduced with permission from Williams Textbook of Endocrinology, 8th ed, Foster DW, Wilson JD (Eds), WB Saunders, Philadelphia, 1996.</div><div id=\"graphicVersion\">Graphic 50564 Version 2.0</div></div></div>"},"50566":{"type":"graphic_diagnosticimage","displayName":"Endoscopic image of ring-like strictures in EoE","title":"Endoscopic image of the esophagus showing multiple ring-like strictures in a patient with eosinophilic esophagitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic image of the esophagus showing multiple ring-like strictures in a patient with eosinophilic esophagitis</div><div class=\"cntnt\"><img style=\"width:288px; height:251px;\" src=\"images/GAST/50566_Eos_esoph_rings_CPC_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This upper endoscopy in a patient with eosinophilic esophagitis showed multiple ring-like strictures in the proximal and mid-esophagus.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD and Anthony Lembo, MD.</div><div id=\"graphicVersion\">Graphic 50566 Version 3.0</div></div></div>"},"50571":{"type":"graphic_diagnosticimage","displayName":"Longitudinal temporal fracture","title":"Longitudinal temporal bone fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Longitudinal temporal bone fracture</div><div class=\"cntnt\"><img style=\"width:316px; height:324px;\" src=\"images/PC/50571_Longitudinal_temporal_fract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blunt trauma to the temporal parietal region, resulting in a line of fracture in the temporal bone&nbsp;(arrows).</div><div class=\"graphic_reference\">Courtesy of Peter C Weber, MD.</div><div id=\"graphicVersion\">Graphic 50571 Version 3.0</div></div></div>"},"50572":{"type":"graphic_diagnosticimage","displayName":"Acute eosinophilic pneumonia PA","title":"Acute eosinophilic pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute eosinophilic pneumonia</div><div class=\"cntnt\"><img style=\"width:302px; height:240px;\" src=\"images/PULM/50572_Acute_eosinophilic_pneumo1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior chest radiograph of a patient with idiopathic acute eosinophilic pneumonia demonstrating bilateral mixed alveolar and reticular opacities.</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 50572 Version 3.0</div></div></div>"},"50573":{"type":"graphic_picture","displayName":"Merkel cell carcinoma - face","title":"Merkel cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Merkel cell carcinoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/50573_Merkel_cell_carcinoma_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This blue-red, dome-shaped papule on the forehead is a Merkel cell carcinoma.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50573 Version 4.0</div></div></div>"},"50574":{"type":"graphic_picture","displayName":"Thumb spica cast 7","title":"Thumb spica cast: Step 7","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thumb spica cast: Step 7</div><div class=\"cntnt\"><img style=\"width:432px; height:408px;\" src=\"images/EM/50574_Thumb_spica_cast_7.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Before applying the final layer of casting material, fold back the ends of the stockinette. The cast underlayment should roll over the edge of the cast material providing cushioning.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 50574 Version 5.0</div></div></div>"},"50576":{"type":"graphic_figure","displayName":"Trunks and cords of the brachial plexus","title":"Trunks and cords of the brachial plexus","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Trunks and cords of the brachial plexus</div><div class=\"cntnt\"><img style=\"width:531px; height:497px;\" src=\"images/NEURO/50576_Anatomy_of_brachial_plexus.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 50576 Version 4.0</div></div></div>"},"50579":{"type":"graphic_picture","displayName":"Lichen planus wrist","title":"Lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen planus</div><div class=\"cntnt\"><img style=\"width:361px; height:283px;\" src=\"images/PC/50579_Lichen_planus_wrist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note discrete polygonal scaling erythematous papules on the wrist.</div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 50579 Version 1.0</div></div></div>"},"50580":{"type":"graphic_waveform","displayName":"Invasive hemodynamic tracing LV and aortic pressures HCM","title":"Invasive hemodynamic tracing obtained during cardiac catheterization showing left ventricular (LV) and aortic pressures in a patient with obstructive hypertrophic cardiomyopathy (HCM)","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Invasive hemodynamic tracing obtained during cardiac catheterization showing left ventricular (LV) and aortic pressures in a patient with obstructive hypertrophic cardiomyopathy (HCM)</div><div class=\"cntnt\"><img style=\"width:505px; height:348px;\" src=\"images/CARD/50580_LVaorticpressureHCMedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simultaneous left ventricular (LV) and aortic (Ao) pressures in a patient with obstructive hypertrophic cardiomyopathy show a significant gradient, and the LV pressure is higher than that in the Ao. The Ao pressure waveform has a rapid upstroke, and there is a spike and dome configuration. As the LV catheter is pulled back (arrow) to an LV position just below the aortic valve, the gradient is obliterated and the Ao and LV pressures become equal, indicating a transventricular and not a transvalvular gradient.</div><div class=\"graphic_reference\">Redrawn from: Kern MJ (ed). Cardiac Catheterization Handbook, 2nd ed. Mosby-Year Book, St. Louis, 1995.</div><div id=\"graphicVersion\">Graphic 50580 Version 6.0</div></div></div>"},"50581":{"type":"graphic_picture","displayName":"Epidermoid cyst","title":"Epidermoid cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epidermoid cyst</div><div class=\"cntnt\"><img style=\"width:364px; height:375px;\" src=\"images/DERM/50581_Epidermoid_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A skin-colored nodule is present on the chest. This particular lesion does not have a visible punctum.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50581 Version 1.0</div></div></div>"},"50582":{"type":"graphic_table","displayName":"Causes of Cushing's syndrome","title":"Frequency of causes of Cushing's syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of causes of Cushing's syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">Percent of patients</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">ACTH-dependent Cushing's syndrome</td> </tr> <tr> <td class=\"indent1\">Cushing's disease</td> <td class=\"centered\">68</td> </tr> <tr> <td class=\"indent1\">Ectopic ACTH syndrome</td> <td class=\"centered\">12</td> </tr> <tr> <td class=\"indent1\">Ectopic CRH syndrome</td> <td class=\"centered\">&#60;&#60;1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">ACTH-independent Cushing's syndrome</td> </tr> <tr> <td class=\"indent1\">Adrenal adenoma</td> <td class=\"centered\">10</td> </tr> <tr> <td class=\"indent1\">Adrenal carcinoma</td> <td class=\"centered\">8</td> </tr> <tr> <td class=\"indent1\">Micronodular hyperplasia</td> <td class=\"centered\">&#60;1</td> </tr> <tr> <td class=\"indent1\">Macronodular hyperplasia</td> <td class=\"centered\">&#60;1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pseudo-Cushing's syndrome</td> </tr> <tr> <td class=\"indent1\">Major depressive disorder</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Alcoholism</td> <td class=\"centered\">&#60;&#60;1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Relative prevalence of various causes of Cushing's syndrome in 630 patients (146 consecutive patients seen at Vanderbilt University Medical Center before 1993 and published reports describing 484 patients). The prevalence of pseudo-Cushing's syndrome depends upon the individual clinician's threshold of clinical suspicion; in our experience, it is very rare. The relative prevalence of various causes of Cushing's syndrome among children and adolescents may differ somewhat from that of adults. The ectopic ACTH syndrome, for example, is less common in children.</div><div class=\"graphic_footnotes\">ACTH: corticotropin; CRH: corticotropin-releasing hormone.</div><div id=\"graphicVersion\">Graphic 50582 Version 6.0</div></div></div>"},"50583":{"type":"graphic_table","displayName":"CT for gallbladder polyps","title":"Computed tomography of gallbladder polyps","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Computed tomography of gallbladder polyps</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Histopathology</td>\n<td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">No. of patients</td>\n<td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Plain CT</td>\n<td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Contrast CT</td>\n<td colspan=\"3\" class=\"subtitle1\">Type of lesion</td>\n<td colspan=\"2\" class=\"subtitle1\">Size of polyp</td>\n</tr>\n<tr>\n\n\n\n\n<td class=\"subtitle2\">Pedunculated</td>\n<td class=\"subtitle2\">Sessile</td>\n<td class=\"subtitle2\">Mass</td>\n<td class=\"subtitle2\">&#60;1 cm</td>\n<td class=\"subtitle2\">1-2 cm</td>\n</tr>\n<tr>\n<td>Cholesterol polyp</td>\n<td>9</td>\n<td>0</td>\n<td>8</td>\n<td>9</td>\n<td>0</td>\n<td>0</td>\n<td>4</td>\n<td>5</td>\n</tr>\n<tr>\n<td>Hyperplastic polyp</td>\n<td>2</td>\n<td>0</td>\n<td>2</td>\n<td>2</td>\n<td>0</td>\n<td>0</td>\n<td>2</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Adenomyomatosis</td>\n<td>2</td>\n<td>2</td>\n<td>2</td>\n<td>0</td>\n<td>0</td>\n<td>2</td>\n<td>0</td>\n<td>2</td>\n</tr>\n<tr>\n<td>Adenoma</td>\n<td>2</td>\n<td>2</td>\n<td>2</td>\n<td>1</td>\n<td>0</td>\n<td>1</td>\n<td>0</td>\n<td>2</td>\n</tr>\n<tr>\n<td>Adenocarcinoma</td>\n<td>5</td>\n<td>4</td>\n<td>5</td>\n<td>1</td>\n<td>4</td>\n<td>0</td>\n<td>0</td>\n<td>5</td>\n</tr>\n<tr>\n<td>Total</td>\n<td>20</td>\n<td>8</td>\n<td>20</td>\n<td>13</td>\n<td>4</td>\n<td>3</td>\n<td>6</td>\n<td>14</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from: Furukawa, H, Takayasu, K, Mukai, K, et al, Hepatogastroenterology 1995; 42:800.</div><div id=\"graphicVersion\">Graphic 50583 Version 1.0</div></div></div>"},"50584":{"type":"graphic_picture","displayName":"Esophageal adenocarcinoma","title":"Esophageal adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:423px; height:216px;\" src=\"images/GAST/50584_Esophageal_adenocarcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Esophageal adenocarcinoma at the gastroesophageal junction in a patient with Barrett's esophagus.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 50584 Version 1.0</div></div></div>"},"50585":{"type":"graphic_picture","displayName":"Inguinal lymph nodes vulvectomy","title":"Right groin node dissection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right groin node dissection</div><div class=\"cntnt\"><img style=\"width:432px; height:351px;\" src=\"images/OBGYN/50585_Inguinal_lymph_nodes_vulvec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lymph node bundle is shown entering the femoral canal. The tip of the scissors is placed at the distal end of the femoral canal.</div><div class=\"graphic_reference\">Courtesy of C William Helm, MD.</div><div id=\"graphicVersion\">Graphic 50585 Version 6.0</div></div></div>"},"50587":{"type":"graphic_table","displayName":"Histologic features UIP","title":"Histologic features of usual interstitial pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic features of usual interstitial pneumonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Key histologic features</td> </tr> <tr> <td>Dense fibrosis causing remodeling of lung architecture with frequent \"honycomb\" fibrosis.</td> </tr> <tr> <td>Fibroblastic foci typically scattered at the edges of dense scars.</td> </tr> <tr> <td>Patchy lung involvement.</td> </tr> <tr> <td>Frequent subpleural and paraseptal distribution.</td> </tr> <tr> <td class=\"subtitle1_single\">Pertinent negative findings</td> </tr> <tr> <td>Lack of active lesions of other interstitial diseases (ie, sarcoidosis or Langerhans cell histiocytosis).</td> </tr> <tr> <td>Lack of marked interstitial chronic inflammation.</td> </tr> <tr> <td>Granulomas: inconspicuous or absent.</td> </tr> <tr> <td>Lack of substantial inorganic dust deposits, ie, asbestos bodies (except for carbon black pigment).</td> </tr> <tr> <td>Lack of marked eosinophilia.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50587 Version 2.0</div></div></div>"},"50588":{"type":"graphic_figure","displayName":"Negative pressure wound therapy","title":"Negative pressure wound therapy","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Negative pressure wound therapy</div><div class=\"cntnt\"><img style=\"width:533px; height:279px;\" src=\"images/PULM/50588_VACfluidevacuation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Negative pressure wound therapy. The foam insert (sponge) is placed within the wound and covered by a clear, vapor-permeable, plastic dressing. Continuous subatmospheric pressure (suction) applied through the tube causes fluid to flow out of the wound (arrows).</div><div id=\"graphicVersion\">Graphic 50588 Version 5.0</div></div></div>"},"50590":{"type":"graphic_table","displayName":"Risk of various aneuploidies by maternal age","title":"Risk of various aneuploidies by maternal age, in rates per thousand","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk of various aneuploidies by maternal age, in rates per thousand</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Maternal age</td> <td class=\"subtitle1\">Down syndrome</td> <td class=\"subtitle1\">Edwards syndrome (trisomy 18)</td> <td class=\"subtitle1\">Patau syndrome (trisomy 13)</td> <td class=\"subtitle1\">XXY</td> <td class=\"subtitle1\">XYY</td> <td class=\"subtitle1\">Turner syndrome genotype</td> <td class=\"subtitle1\">Other clinically significant abnormality*</td> <td class=\"subtitle1\">Total<sup>&#182;</sup></td> </tr> <tr> <td>&#60;15</td> <td>1</td> <td>&#60;0.1</td> <td>&#60;0.1-0.1</td> <td>0.4</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>2.2</td> </tr> <tr> <td>15</td> <td>1</td> <td>&#60;0.1<sup>&#916;</sup></td> <td>&#60;0.1-0.1</td> <td>0.4</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>2.2</td> </tr> <tr> <td>16</td> <td>0.9</td> <td>&#60;0.1<sup>&#916;</sup></td> <td>&#60;0.1-0.1</td> <td>0.4</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>2.1</td> </tr> <tr> <td>17</td> <td>0.8</td> <td>&#60;0.1<sup>&#916;</sup></td> <td>&#60;0.1-0.1</td> <td>0.4</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>2</td> </tr> <tr> <td>18</td> <td>0.7</td> <td>&#60;0.1<sup>&#916;</sup></td> <td>&#60;0.1-0.1</td> <td>0.4</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>1.9</td> </tr> <tr> <td>19</td> <td>0.6</td> <td>&#60;0.1<sup>&#916;</sup></td> <td>&#60;0.1-0.1</td> <td>0.4</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>1.8</td> </tr> <tr> <td>20</td> <td>0.5-0.7</td> <td>&#60;0.1-0.1</td> <td>&#60;0.1-0.1</td> <td>0.4</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>1.9</td> </tr> <tr> <td>21</td> <td>0.5-0.7</td> <td>&#60;0.1-0.1</td> <td>&#60;0.1-0.1</td> <td>0.4</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>1.9</td> </tr> <tr> <td>22</td> <td>0.6-0.8</td> <td>&#60;0.1-0.1</td> <td>&#60;0.1-0.1</td> <td>0.4</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>2</td> </tr> <tr> <td>23</td> <td>0.6-0.8</td> <td>&#60;0.1-0.1</td> <td>&#60;0.1-0.1</td> <td>0.4</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>2</td> </tr> <tr> <td>24</td> <td>0.7-0.9</td> <td>0.1-0.1</td> <td>&#60;0.1-0.1</td> <td>0.4</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>2.1</td> </tr> <tr> <td>25</td> <td>0.7-0.9</td> <td>0.1-0.1</td> <td>&#60;0.1-0.1</td> <td>0.4</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>2.1</td> </tr> <tr> <td>26</td> <td>0.7-1</td> <td>0.1-0.1</td> <td>&#60;0.1-0.1</td> <td>0.4</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>2.1</td> </tr> <tr> <td>27</td> <td>0.8-1</td> <td>0.1-0.2</td> <td>&#60;0.1-0.1</td> <td>0.4</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>2.2</td> </tr> <tr> <td>28</td> <td>0.8-1.1</td> <td>0.1-0.2</td> <td>&#60;0.1-0.2</td> <td>0.4</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>2.3</td> </tr> <tr> <td>29</td> <td>0.8-1.2</td> <td>0.1-0.2</td> <td>&#60;0.1-0.2</td> <td>0.5</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>2.4</td> </tr> <tr> <td>30</td> <td>0.9-1.2</td> <td>0.1-0.2</td> <td>&#60;0.1-0.2</td> <td>0.5</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>2.6</td> </tr> <tr> <td>31</td> <td>0.9-1.3</td> <td>0.1-0.2</td> <td>&#60;0.1-0.2</td> <td>0.5</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>2.6</td> </tr> <tr> <td>32</td> <td>1.1-1.5</td> <td>0.1-0.2</td> <td>0.1-0.2</td> <td>0.6</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>3.1</td> </tr> <tr> <td>33</td> <td>1.4-1.9</td> <td>0.1-0.3</td> <td>0.1-0.2</td> <td>0.7</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>3.5</td> </tr> <tr> <td>34</td> <td>1.9-2.4</td> <td>0.2-0.4</td> <td>0.1-0.3</td> <td>0.7</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.2</td> <td>4.1</td> </tr> <tr> <td>35</td> <td>2.5-3.9</td> <td>0.3-0.5</td> <td>0.2-0.3</td> <td>0.9</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.3</td> <td>5.6</td> </tr> <tr> <td>36</td> <td>3.2-5</td> <td>0.3-0.6</td> <td>0.2-0.4</td> <td>1</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.3</td> <td>6.7</td> </tr> <tr> <td>37</td> <td>4.1-6.4</td> <td>0.4-0.7</td> <td>0.2-0.5</td> <td>1.1</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.3</td> <td>8.1</td> </tr> <tr> <td>38</td> <td>5.2-8.1</td> <td>0.5-0.9</td> <td>0.3-0.7</td> <td>1.3</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.3</td> <td>9.5</td> </tr> <tr> <td>39</td> <td>6.6-10.5</td> <td>0.7-1.2</td> <td>0.4-0.8</td> <td>1.5</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.3</td> <td>12.4</td> </tr> <tr> <td>40</td> <td>8.5-13.7</td> <td>0.9-1.6</td> <td>0.5-1.1</td> <td>1.8</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.3</td> <td>15.8</td> </tr> <tr> <td>41</td> <td>10.8-17.9</td> <td>1.1-2.1</td> <td>0.6-1.4</td> <td>2.2</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.3</td> <td>20.5</td> </tr> <tr> <td>42</td> <td>13.8-23.4</td> <td>1.4-2.7</td> <td>0.7-1.8</td> <td>2.7</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.3</td> <td>25.5</td> </tr> <tr> <td>43</td> <td>17.6-30.6</td> <td>1.8-3.5</td> <td>0.9-2.4</td> <td>3.3</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.3</td> <td>32.6</td> </tr> <tr> <td>44</td> <td>22.5-40</td> <td>2.3-4.6</td> <td>1.2-3.1</td> <td>4.1</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.3</td> <td>41.8</td> </tr> <tr> <td>45</td> <td>28.7-52.3</td> <td>2.9-6</td> <td>1.5-4.1</td> <td>5.1</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.3</td> <td>53.7</td> </tr> <tr> <td>46</td> <td>36.6-68.3</td> <td>3.7-7.9</td> <td>1.9-5.3</td> <td>6.4</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.3</td> <td>68.9</td> </tr> <tr> <td>47</td> <td>46.6-89.3</td> <td>4.7-10.3</td> <td>2.4-6.9</td> <td>8.2</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.3</td> <td>89.1</td> </tr> <tr> <td>48</td> <td>59.5-116.8</td> <td>6-13.5</td> <td>3-9</td> <td>10.6</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.3</td> <td>115</td> </tr> <tr> <td>49</td> <td>75.8-152.7</td> <td>7.6-17.6</td> <td>3.8-11.8</td> <td>13.8</td> <td>0.5</td> <td>&#60;0.1</td> <td>0.3</td> <td>149.3</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* XXX is excluded.<br />¶ Calculation of the total at each age assumes rate for autosomal aneuploidies is at the midpoints of the ranges given.<br />Δ No range may be constructed for those under 20 years by the same methods as for those 20 and over.</div><div class=\"graphic_reference\">Reproduced with permission from: Hook EB. Rates of chromosome abnormalities at different maternal ages. Obstet Gynecol 1981; 58:282. Copyright &copy; 1981 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50590 Version 11.0</div></div></div>"},"50591":{"type":"graphic_figure","displayName":"Common iliac artery aneurysm without distal landing zone","title":"Common iliac artery aneurysm without distal landing zone","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Common iliac artery aneurysm without distal landing zone</div><div class=\"cntnt\"><img style=\"width:456px; height:299px;\" src=\"images/SURG/50591_CIAA-no-distal-zone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An isolated common iliac artery aneurysm without a distal landing zone can be managed with coil embolization of the internal ilac artery and endograft placement to exclude the aneurysm with extension into the external iliac artery.</div><div id=\"graphicVersion\">Graphic 50591 Version 3.0</div></div></div>"},"50592":{"type":"graphic_picture","displayName":"Umbilical acanthosis nigricans","title":"Acanthosis nigricans","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acanthosis nigricans</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/50592_Umbilical_acanth_nigricans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A hyperpigmented, velvety plaque is present on the umbilicus.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50592 Version 4.0</div></div></div>"},"50593":{"type":"graphic_algorithm","displayName":"Management of HIV patients with CNS lesions algorithm","title":"Algorithm for the management of HIV-infected patients with central nervous system mass lesions","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Algorithm for the management of HIV-infected patients with central nervous system mass lesions</div><div class=\"cntnt\"><img style=\"width:523px; height:512px;\" src=\"images/ID/50593_CNS_lesions_AIDS_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Elements in <strong>bold</strong> represent data which contribute to the decision-making process (see text for details). </div><div class=\"graphic_footnotes\">Toxo: Toxoplasma encephalitis; LP: lumbar puncture; CSF: cerebrospinal fluid; Rx: treatment.</div><div id=\"graphicVersion\">Graphic 50593 Version 2.0</div></div></div>"},"50596":{"type":"graphic_figure","displayName":"Hormonal changes in nephrosis","title":"Volume regulatory hormones in glomerular disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Volume regulatory hormones in glomerular disease</div><div class=\"cntnt\"><img style=\"width:354px; height:225px;\" src=\"images/NEPH/50596_Hormonal_changes_in_nephros.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Levels of plasma renin activity (ng/L per sec) and atrial natriuretic peptide (fmol/mL) in normal subjects ingesting 20 and 130 meq of sodium per day and in patients with acute glomerulonephritis and nephrotic syndrome excreting 25 meq of sodium per day. Patients with nephrotic syndrome (fourth panel) show signs of renal sodium retention since they have a hormonal profile similar to those in normal subjects excreting 130 meq/day (second panel) despite having a much lower rate of sodium excretion. There is also evidence for a contribution from underfilling as these patients do not have the profile of pure volume expansion (very low renin, very high ANP) seen in acute glomerulonephritis.</div><div class=\"graphic_reference\">Data from Rodriguez-Iturbe, B, Colic, D, Parra, G, Gutkowska, J, Kidney Int 1990; 38:512.</div><div id=\"graphicVersion\">Graphic 50596 Version 1.0</div></div></div>"},"50597":{"type":"graphic_figure","displayName":"Mortality stage IA IIIB HL","title":"Causes of death in stage IA-IIIB Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Causes of death in stage IA-IIIB Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:293px; height:230px;\" src=\"images/ONC/50597_Mortality_stage_IA_IIIB_HL.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Competing causes of death in 794 patients with laparoscopically-stage IA-IIIB Hodgkin lymphoma. Deaths from Hodgkin lymphoma primarily occurred in the first 5 to 10 years and tended to plateau after 15 years, while deaths from second malignancy primarily occur after 10 years and continued to increase with time.</div><div class=\"graphic_reference\">Data from: Mauch PM, Kalish LA, Marcus KC, et al. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1995; 1:33.</div><div id=\"graphicVersion\">Graphic 50597 Version 2.0</div></div></div>"},"50598":{"type":"graphic_diagnosticimage","displayName":"Zonal anatomy of prostate","title":"Zonal anatomy of the prostate","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Zonal anatomy of the prostate</div><div class=\"cntnt\"><img style=\"width:504px; height:244px;\" src=\"images/ONC/50598_Zonal_anatomy_of_prostate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transition zone and peripheral zone on (a) T2-weighted magnetic resonance imaging and (b) ultrasound.</div><div class=\"graphic_footnotes\">AFS: anterior fibromuscular stroma; PZ: peripheral zone; TZ: transition zone.</div><div class=\"graphic_reference\">Reproduced with permission from: McLaughlin, PW, Troyer, S, Berri, S, et al. Functional anatomy of the prostate: Implications for treatment planning. Int J Radiation Oncology Biol Phys 2005; 63:479. Copyright ©2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 50598 Version 2.0</div></div></div>"},"50599":{"type":"graphic_picture","displayName":"Café-au-lait macule 2","title":"Café-au-lait macule","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Café-au-lait macule</div><div class=\"cntnt\"><img style=\"width:590px; height:525px;\" src=\"images/DERM/50599_Cafe-au-lait_macule_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This uniformly tan patch is a typical café-au-lait macule.</div><div id=\"graphicVersion\">Graphic 50599 Version 6.0</div></div></div>"},"50601":{"type":"graphic_picture","displayName":"Nucleated RBC in AIHA","title":"Peripheral smear in severe autoimmune hemolytic anemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral smear in severe autoimmune hemolytic anemia</div><div class=\"cntnt\"><img style=\"width:396px; height:258px;\" src=\"images/HEME/50601_Nucleated_RBC_in_AIHA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear from a patient with Coombs-positive autoimmune hemolytic anemia. The smear shows the presence of many spherocytes (red arrows), one nucleated red blood cell (blue arrow), and a number of larger polychromatophilic red cells (black arrows), representing a reticulocytosis in response to the anemia.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 50601 Version 3.0</div></div></div>"},"50602":{"type":"graphic_figure","displayName":"Anaerobic threshold","title":"V-slope method for determining anaerobic threshold","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">V-slope method for determining anaerobic threshold</div><div class=\"cntnt\"><img style=\"width:538px; height:280px;\" src=\"images/CARD/50602_Anaerobic_threshold.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Carbon dioxide output (VCO2) is plotted as a function of oxygen uptake (VO2). The intersection of the two regression lines indicates the anaerobic threshold.</div><div id=\"graphicVersion\">Graphic 50602 Version 1.0</div></div></div>"},"50603":{"type":"graphic_picture","displayName":"Epistaxis control","title":"Control of benign epistaxis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Control of benign epistaxis</div><div class=\"cntnt\"><img style=\"width:504px; height:337px;\" src=\"images/EM/50603_Epistaxis_control.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The child on the right is showing the correct way to stop a nosebleed. The nasal alae should be pressed together closing off the nasal airway. The incorrect way to stop a nosebleed is demonstrated by the child on the left.</div><div class=\"graphic_reference\">Courtesy of Anna H Messner, MD.</div><div id=\"graphicVersion\">Graphic 50603 Version 4.0</div></div></div>"},"50605":{"type":"graphic_picture","displayName":"HP granulomas Light","title":"Granulomas in hypersensitivity pneumonitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Granulomas in hypersensitivity pneumonitis</div><div class=\"cntnt\"><img style=\"width:431px; height:252px;\" src=\"images/PULM/50605_HP_granulomas_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph shows noncaseating granulomas (arrows) which, in this case, have a sarcoid-like appearance.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 50605 Version 1.0</div></div></div>"},"50607":{"type":"graphic_figure","displayName":"NB head position resuscitate","title":"Head position for neonatal resuscitation","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Head position for neonatal resuscitation</div><div class=\"cntnt\"><img style=\"width:479px; height:690px;\" src=\"images/PEDS/50607_NB head position resuscitate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The top panel demonstrates the correct head position with the baby positioned on the back with the neck slightly extended resulting in alignment of the posterior pharynx, larynx, and trachea, which allows unrestricted air entry.</div><div id=\"graphicVersion\">Graphic 50607 Version 2.0</div></div></div>"},"50608":{"type":"graphic_picture","displayName":"Psoriasiform sarcoidosis","title":"Psoriasiform sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Psoriasiform sarcoidosis</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/50608_Psoriasiform_sarcoidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented plaques are present on the knees of this patient with cutaneous sarcoidosis. The lesions resemble psoriasis.</div><div id=\"graphicVersion\">Graphic 50608 Version 1.0</div></div></div>"},"50609":{"type":"graphic_figure","displayName":"Clinical findings in histo","title":"Clinical findings in disseminated histoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Clinical findings in disseminated histoplasmosis</div><div class=\"cntnt\"><img style=\"width:542px; height:249px;\" src=\"images/ID/50609_Clinical_findings_in_histo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CNS: central nervous system.<br />Frequency of the major clinical findings in 66 episodes of disseminated histoplasmosis.</div><div class=\"graphic_reference\">Data from Sathapatayavongs B, Batteiger BE, Wheat LJ, et al. Medicine (Baltimore) 1983; 62:263.</div><div id=\"graphicVersion\">Graphic 50609 Version 2.0</div></div></div>"},"50611":{"type":"graphic_diagnosticimage","displayName":"Coronal brain MRI vanishing white matter disease","title":"Coronal brain MRI of a patient with vanishing white matter disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coronal brain MRI of a patient with vanishing white matter disease</div><div class=\"cntnt\"><img style=\"width:360px; height:391px;\" src=\"images/NEURO/50611_Coronal_MRI_VWM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T1 image shows severe cystic degeneration of cerebral white matter.</div><div id=\"graphicVersion\">Graphic 50611 Version 2.0</div></div></div>"},"50612":{"type":"graphic_figure","displayName":"Pelvic shapes","title":"Four basic female pelvic types","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Four basic female pelvic types</div><div class=\"cntnt\"><img style=\"width:543px; height:322px;\" src=\"images/OBGYN/50612_Pelvic_shapes.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 50612 Version 3.0</div></div></div>"},"50613":{"type":"graphic_picture","displayName":"Alopecia areata PI","title":"Alopecia areata","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Alopecia areata</div><div class=\"cntnt\"><img style=\"width:576px; height:431px;\" src=\"images/PI/50613_Alopecia_areata_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">People with alopecia areata lose hair in splotches rather than in a predictable pattern.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50613 Version 6.0</div></div></div>"},"50614":{"type":"graphic_figure","displayName":"Galactose metabolism","title":"Metabolic pathway of galactose","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metabolic pathway of galactose</div><div class=\"cntnt\"><img style=\"width:365px; height:444px;\" src=\"images/PEDS/50614_Galactose_metabolism.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Deficiency of any of the enzymes (in blue) may result in galactosemia. Galactose-1-phosphate is elevated if GALT or epimerase activity is absent or impaired.</div><div class=\"graphic_footnotes\">GALT: galactose-1-phosphate uridyl transferase; UDP: uridine diphosphate.</div><div id=\"graphicVersion\">Graphic 50614 Version 2.0</div></div></div>"},"50615":{"type":"graphic_picture","displayName":"Inverse psoriasis gluteal 1","title":"Inverse psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inverse psoriasis</div><div class=\"cntnt\"><img style=\"width:396px; height:263px;\" src=\"images/DERM/50615_Inverse_psoriasis_gluteal_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous, fissured plaque is present on the intergluteal skin.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50615 Version 3.0</div></div></div>"},"50616":{"type":"graphic_picture","displayName":"Hulka Clemens clip","title":"Hulka Clemens clip for female sterilization","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hulka Clemens clip for female sterilization</div><div class=\"cntnt\"><img style=\"width:360px; height:289px;\" src=\"images/OBGYN/50616_Hulka_Clemens_clip.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 50616 Version 2.0</div></div></div>"},"50617":{"type":"graphic_table","displayName":"Modified Hyper CVAD","title":"Modified Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (Hyper-CVAD) regimen for acute lymphoblastic leukemia (ALL) in adults<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (Hyper-CVAD) regimen for acute lymphoblastic leukemia (ALL) in adults<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\" colspan=\"4\">Dose intensive phase:</td>\r\n                </tr>\r\n                <tr>\r\n                    <td colspan=\"4\">The dose intensive phase consists of 8 courses of therapy administered at 21-day intervals. The drugs used in each course alternate such that Hyper-CVAD is used for courses 1, 3, 5, and 7 while high-dose methotrexate plus cytarabine is given for courses 2, 4, 6, and 8.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"4\">Hyper-CVAD (courses 1, 3, 5, and 7)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Cyclophosphamide</td>\r\n                    <td>IV</td>\r\n                    <td>300 mg/m<sup>2</sup> over 2 to 3 hours every 12 hours for 6 doses</td>\r\n                    <td>Days 1 to 3</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Mesna</td>\r\n                    <td>IV</td>\r\n                    <td>600 mg/m<sup>2</sup>/day administered as a continuous infusion starting with cyclophosphamide and ending 6 hours after last dose of cyclophosphamide</td>\r\n                    <td>Days 1 to 3</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Vincristine</td>\r\n                    <td>IV</td>\r\n                    <td>2 mg per day</td>\r\n                    <td>Days 4 and 11</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Doxorubicin</td>\r\n                    <td>IV</td>\r\n                    <td>\r\n                    <p>if LVEF &#8805;50 percent: 50 mg/m<sup>2</sup> over 24 hours</p>\r\n                    <p>if LVEF &#60;50 percent: 50 mg/m<sup>2</sup> over 48 hours<sup>[1,2]</sup></p>\r\n                    </td>\r\n                    <td>Day 4</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Dexamethasone</td>\r\n                    <td>PO or IV</td>\r\n                    <td>40 mg per day</td>\r\n                    <td>Days 1 to 4 and days 11 to 14</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"4\">High dose methotrexate plus cytarabine (courses 2, 4, 6, and 8)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Methotrexate</td>\r\n                    <td>IV</td>\r\n                    <td>200 mg/m<sup>2</sup> administered over first 2 hours then 800 mg/m<sup>2</sup> administered over 24 hours (total dose per cycle of 1 gram/m<sup>2</sup>)</td>\r\n                    <td>Day 1</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Leucovorin</td>\r\n                    <td>IV</td>\r\n                    <td>50 mg IV 12 hours after end of methotrexate; then 15 mg IV every 6 hours for 8 doses or until methotrexate level &#8804;0.1 micromol/L. Dose modifications made based upon methotrexate levels.</td>\r\n                    <td>Day 2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Cytarabine</td>\r\n                    <td>IV</td>\r\n                    <td>\r\n                    <p>for patients &#60;60 years old: 3 g/m<sup>2</sup> administered over 2 hours every 12 hours for 4 doses</p>\r\n                    <p>for patients &#8805;60 years old: 1 g/m<sup>2</sup> administered over 2 hours every 12 hours for 4 doses</p>\r\n                    </td>\r\n                    <td>Days 2 and 3</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Methylprednisolone</td>\r\n                    <td>IV</td>\r\n                    <td>50 mg twice daily</td>\r\n                    <td>Days 1 to 3</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"4\">Rituximab for CD20+ ALL (courses 1, 2, 3, 4)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Rituximab</td>\r\n                    <td>IV</td>\r\n                    <td>Give only if &#8805;20 percent of lymphoblasts are CD20 positive: 375 mg/m<sup>2</sup></td>\r\n                    <td>Days 1 and 11 of Hyper-CVAD and Days 1 and 8 of high dose methotrexate plus cytarabine</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"4\">CNS prophylaxis: total number of intrathecal treatments varies based upon risk factors*</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Methotrexate</td>\r\n                    <td>IT</td>\r\n                    <td>12 mg (6 mg if through Ommaya)<sup>[3,4]</sup></td>\r\n                    <td>Day 2 of each cycle</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Cytarabine</td>\r\n                    <td>IT</td>\r\n                    <td>100 mg</td>\r\n                    <td>Day 8 of each cycle</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\" colspan=\"4\">Maintenance phase:</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1_start\" colspan=\"4\">Therapy after the intensive phase varies depending upon ALL subtype:</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\" colspan=\"4\">&#8226; Patients with Burkitt leukemia (mature B-cell ALL) are not given maintenance</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\" colspan=\"4\">&#8226; Patients with Philadelphia chromosome positive ALL undergo allogeneic hematopoietic cell transplantation if they are candidates for this procedure and have a donor</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\" colspan=\"4\">&#8226; All other patients receive maintenance chemotherapy with POMP intensification plus intensification cycles of Hyper-CVAD and methotrexate plus L-asparaginase</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"4\">Maintenance POMP: administered months 1 through 5, 8 through 17, 20 through 30</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Mercaptopurine</td>\r\n                    <td>PO</td>\r\n                    <td>50 mg three times a day on an empty stomach</td>\r\n                    <td>Days 1 to 28</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Methotrexate</td>\r\n                    <td>PO</td>\r\n                    <td>20 mg/m<sup>2</sup></td>\r\n                    <td>Days 1, 8, 15, and 22</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Vincristine</td>\r\n                    <td>IV</td>\r\n                    <td>2 mg</td>\r\n                    <td>Day 1</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Prednisone</td>\r\n                    <td>PO</td>\r\n                    <td>200 mg per day</td>\r\n                    <td>Days 1 to 5</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"4\">Intensification Hyper-CVAD: administered months 6 and 18, plus rituximab on days 1 and 11 if CD20+</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"4\">Intensification methotrexate and L-asparaginase: administered months 7 and 19</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Methotrexate</td>\r\n                    <td>IV</td>\r\n                    <td>100 mg/m<sup>2</sup></td>\r\n                    <td>Day 1 weekly x 4</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">L-asparaginase</td>\r\n                    <td>IV</td>\r\n                    <td>20,000 units</td>\r\n                    <td>Day 2 weekly x 4</td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">7</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=25619&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_lgnd\">Details on dose modification, prophylactic antibiotics, growth factor support, and mediastinal irradiation can be found in the original articles. In addition, it is now standard practice to include a tyrosine kinase inhibitor for patients with Philadelphia chromosome positive ALL.</div><div class=\"graphic_footnotes\">LVEF: left ventricular ejection fraction.<br />* Patients were given central nervous system (CNS) prophylaxis based upon risk factors as follows: Patients with a lactate dehydrogenase level &gt;600 u/liter or with a proliferative index of 14 percent or above were considered \"High risk\" and received 8 intrathecal (IT) treatments. Patients with neither of these features were considered \"Low risk\" and received 6 IT treatments. Patients with unknown risk received 8 IT treatments<sup>[1]</sup>. Patients with cranial neuropathies or CNS involvement are given whole brain radiation therapy (24 to 30 Gy) at the time of diagnosis and receive even more frequent IT therapy.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010; 28:3880.</li>&#xD;&#xA;    <li>Thomas DA, O'Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004; 104:1624.</li>&#xD;&#xA;    <li>Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18:547.</li>&#xD;&#xA;    <li>Kantarjian HM, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101:2788.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 50617 Version 5.0</div></div></div>"},"50619":{"type":"graphic_table","displayName":"Impaired sensitivity to thyroid hormone","title":"Comparison of thyroid function test abnormalities in syndromes of impaired sensitivity to thyroid hormone","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of thyroid function test abnormalities in syndromes of impaired sensitivity to thyroid hormone</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"10%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">FT<sub>4</sub></td> <td class=\"subtitle1\">FT<sub>3</sub></td> <td class=\"subtitle1\">rT<sub>3</sub></td> <td class=\"subtitle1\">TSH</td> <td class=\"subtitle1\">Other manifestations</td> </tr> <tr class=\"divider_bottom\"> <td>Thyroid hormone cell membrane transport defect (THCMTD)</td> <td class=\"centered\"> <p><em>MCT8</em></p> (<em>SLC16A2</em>)</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8593; &#8593;</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">N, sl &#8593;</td> <td>Severe psychomotor impairment. Virtually all affected individuals are male.</td> </tr> <tr class=\"divider_bottom\"> <td>Thyroid hormone metabolism defect (THMD)</td> <td class=\"centered\"> <p><em>SBP2</em></p> (<em>SECISBP2</em>)</td> <td class=\"centered\">&#8593; &#8593;</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8593; &#8593;</td> <td class=\"centered\">N, sl &#8593;</td> <td>Growth delay</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"7\">Thyroid hormone action defects</td> </tr> <tr> <td class=\"indent1\">RTH beta*</td> <td class=\"centered\"> <p>TR&#946;</p> (<em>THRB</em>)</td> <td class=\"centered\" rowspan=\"2\">&#8593; &#8593;</td> <td class=\"centered\" rowspan=\"2\">&#8593; N</td> <td class=\"centered\" rowspan=\"2\">&#8593; &#8593;</td> <td class=\"centered\" rowspan=\"2\">N, sl &#8593;</td> <td rowspan=\"2\">Attention deficit disorder (ADD), tachycardia, goiter</td> </tr> <tr> <td class=\"indent1\">Non TR-RTH*</td> <td class=\"centered\">Unknown<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">RTH alpha</td> <td class=\"centered\"> <p>TR&#945;</p> (<em>THRA</em>)</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">N, sl &#8593;</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">N</td> <td>Delayed skeletal development, gastrointestinal dysmotility</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RTH: resistance to thyroid hormone; TR: thyroid hormone receptor; THCMTD: thyroid hormone cell membrane transport defect; THMD: thyroid hormone metabolism defect; sl: slight; N: normal; ↑: increased; ↓: decreased.<br />* The term, \"resistance to thyroid hormone\" (RTH) traditionally described a clinical and biochemical phenotype. Now, this phenotype is divided into the mechanistic categories of thyroid hormone receptor beta gene mutations (RTH beta) and nonthyroid hormone receptor RTH (non-TR RTH), which are distinguished by the presence or absence of a mutation in the TR beta gene.<br />¶ The mechanism for non-TR-RTH is unknown, but probably involves abnormal cofactors or substances that interfere with the action of thyroid hormone on its receptor.</div><div class=\"graphic_reference\">Reference (published simultaneously in these journals):&#xD;&#xA;<ol>&#xD;&#xA;    <li>Refetoff S, Bassett JHD, et al. Classification and proposed nomenclature for inherited defects of thyroid hormone action, cell transport, and metabolism. Thyroid 2014; 24:407.</li>&#xD;&#xA;    <li>Refetoff S, Bassett JHD, et al. Classification and proposed nomenclature for inherited defects of thyroid hormone action, cell transport, and metabolism. J Clin Endocrinol Metab 2014; 99:768.</li>&#xD;&#xA;    <li>Refetoff S, Bassett JHD, et al. Classification and proposed nomenclature for inherited defects of thyroid hormone action, cell transport, and metabolism. Eur Thyroid J 2014; 3:7.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 50619 Version 7.0</div></div></div>"},"50620":{"type":"graphic_form","displayName":"Asthma control test adults","title":"Asthma Control Test®","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Asthma Control Test®</div><div class=\"cntnt\"><img style=\"width:506px; height:578px;\" src=\"images/PULM/50620_Asthma_control_test_adults.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For information on the interpretation and scoring of the Asthma Control Test® (ACT®), visit www.qualitymetric.com/act.</div><div class=\"graphic_reference\">Reproduced with permission from: Kosinski, M, Bayliss, MS, Turner-Bowker, DM, Fortin, EW. Asthma Control Test: A User's Guide, Lincoln (RI): QualityMetric, Incorporated, 2004. Copyright ©2004 QualityMetric.</div><div id=\"graphicVersion\">Graphic 50620 Version 2.0</div></div></div>"},"50621":{"type":"graphic_diagnosticimage","displayName":"Idiopathic hemosiderosis CT","title":"Idiopathic pulmonary hemosiderosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Idiopathic pulmonary hemosiderosis</div><div class=\"cntnt\"><img style=\"width:385px; height:301px;\" src=\"images/PULM/50621_Idiopathic_hemosiderosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High resolution computed tomographic (HRCT) scanning of the chest in a 55 year old woman with idiopathic pulmonary hemosiderosis and daily hemoptysis for 6 months. There are several areas of ground- glass opacification (arrows) in both lungs, indicating alveolar filling.</div><div class=\"graphic_reference\">Courtesy of Nils Milman, MD.</div><div id=\"graphicVersion\">Graphic 50621 Version 2.0</div></div></div>"},"50622":{"type":"graphic_figure","displayName":"Nitrate induced vasodilation","title":"Nitrate-induced vasodilation","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Nitrate-induced vasodilation</div><div class=\"cntnt\"><img style=\"width:465px; height:228px;\" src=\"images/CARD/50622_Nitrate_induced_vasodilatio.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the mechanism by which nitroprusside and nitrates induce vasorelaxation via the formation of nitric oxide and subsequent activation of guanylate cyclase and generation of cyclic guanosine monophosphate (cGMP).</div><div id=\"graphicVersion\">Graphic 50622 Version 1.0</div></div></div>"},"50623":{"type":"graphic_diagnosticimage","displayName":"TPO CT","title":"Tracheopathia osteochondroplastica (TPO)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheopathia osteochondroplastica (TPO)</div><div class=\"cntnt\"><img style=\"width:400px; height:502px;\" src=\"images/PULM/50623_TPO_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic scans from two patients show narrowing of the trachea with protrusion of calcified nodules into the tracheal lumen. The posterior membranous wall is spared.</div><div id=\"graphicVersion\">Graphic 50623 Version 2.0</div></div></div>"},"50624":{"type":"graphic_figure","displayName":"MuSK-LRP4-ColQ complex","title":"Schematic view of MuSK-LRP4-ColQ complex","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Schematic view of MuSK-LRP4-ColQ complex</div><div class=\"cntnt\"><img style=\"width:578px; height:471px;\" src=\"images/NEURO/50624_MuSK_LRP4_ColQ_complex.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At the postsynaptic membrane, muscle-specific tyrosine kinase (MuSK) is associated with the low-density lipoprotein receptor-related protein 4 (Lrp4). MuSK activation through agrin-Lrp4 binding triggers a signaling pathway, which includes Dok7 recruitment, leading to AChR clustering. Acetylcholinesterase (AChE) binds through its collagen Q (ColQ) tail to perlecan and MuSK.</div><div class=\"graphic_reference\">Reproduced with permission from: Evoli A, Lindstrom J. Myasthenia gravis with antibodies to MuSK: another step toward solving mystery? Neurology 2011; 77:1783. Copyright © 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50624 Version 5.0</div></div></div>"},"50627":{"type":"graphic_picture","displayName":"Herpes zoster rash 1 PI","title":"Shingles (herpes zoster)","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Shingles (herpes zoster)</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/PI/50627_Herpes_zoster_rash_1_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Vaibhav Parekh, MD, MBA.</div><div id=\"graphicVersion\">Graphic 50627 Version 2.0</div></div></div>"},"50628":{"type":"graphic_figure","displayName":"Ectopic ureter duplex","title":"Ectopic ureter of left duplex system","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ectopic ureter of left duplex system</div><div class=\"cntnt\"><img style=\"width:398px; height:620px;\" src=\"images/PEDS/50628_Ectopic_ureter_duplex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figure demonstrates an ectopic ureter to the upper pole of the left kidney with a duplicated collecting system.</div><div id=\"graphicVersion\">Graphic 50628 Version 1.0</div></div></div>"},"50629":{"type":"graphic_table","displayName":"Fracture stages of healing","title":"Fractures: Stages of healing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fractures: Stages of healing</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Stage of healing\n   </td>\n   <td  class=\"subtitle1\">\n   Early\n   </td>\n   <td  class=\"subtitle1\">\n   Peak\n   </td>\n   <td  class=\"subtitle1\">\n   Late\n   </td>\n   </tr>\n   <tr>\n   <td>Resolution of soft-tissue swelling</td>\n   <td>2 to 5 days</td>\n   <td>4 to 10 days</td>\n   <td>10 to 21 days</td>\n   </tr>\n   <tr>\n   <td>Periosteal new bone</td>\n   <td>4 to 10 days</td>\n   <td>10 to 14 days</td>\n   <td>14 to 21 days</td>\n   </tr>\n   <tr>\n   <td>Loss of fracture line definition</td>\n   <td>10 to 14 days</td>\n   <td>14 to 21 days</td>\n   <td>---</td>\n   </tr>\n   <tr>\n   <td>Soft callus*</td>\n   <td>7 to 14 days</td>\n   <td>14 to 21 days</td>\n   <td>---</td>\n   </tr>\n   <tr>\n   <td>Hard callus*</td>\n   <td>14 to 21 days</td>\n   <td>21 to 42 days</td>\n   <td>42 to 90 days</td>\n   </tr>\n   <tr>\n   <td>Remodeling</td>\n   <td>3 months</td>\n   <td>1 year</td>\n   <td>2 years to epiphyseal closure</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">* The difference between soft and hard callus is that hard callus bridges the fracture site so that the fracture line begins to fill in.</div><div class=\"graphic_reference\">Adapted from Kocher, MS, Kasser, JR. J Am Acad Orthop Surg 2000; 8:10; and Morzaria, S, Walton, JM, MacMillan, A. J Pediatr Surg 1998; 33:871.</div><div id=\"graphicVersion\">Graphic 50629 Version 1.0</div></div></div>"},"50630":{"type":"graphic_picture","displayName":"Ranula","title":"Ranula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ranula</div><div class=\"cntnt\"><img style=\"width:432px; height:355px;\" src=\"images/PEDS/50630_Ranula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A ranula (arrows) is a pseudocyst associated with the sublingual glands and submandibular ducts. Ranulas appear as blue, fluctuant swellings lateral to the midline in the lower mouth.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 50630 Version 2.0</div></div></div>"},"50631":{"type":"graphic_picture","displayName":"Periocular hemangioma","title":"Periorbital hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Periorbital hemangioma</div><div class=\"cntnt\"><img style=\"width:379px; height:504px;\" src=\"images/DERM/50631_Periocular_hemangioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The majority of hemangiomas that lead to visual complications affect the upper medial eyelid. However, a hemangioma of any size, morphology, or periorbital location may pose a threat to vision.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50631 Version 3.0</div></div></div>"},"50632":{"type":"graphic_picture","displayName":"Generalized lichen planus","title":"Generalized lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Generalized lichen planus</div><div class=\"cntnt\"><img style=\"width:335px; height:396px;\" src=\"images/DERM/50632_Generalized_lichen_planus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Violaceous and hyperpigmented polygonal papules are present in a widespread distribution in this patient with generalized lichen planus.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright &#169; 2008.</div><div id=\"graphicVersion\">Graphic 50632 Version 1.0</div></div></div>"},"50633":{"type":"graphic_figure","displayName":"Ice ball formation","title":"Endometrial cryoablation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endometrial cryoablation</div><div class=\"cntnt\"><img style=\"width:372px; height:274px;\" src=\"images/OBGYN/50633_Ice_ball_formation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ice ball formation after two freezes (without probe).</div><div id=\"graphicVersion\">Graphic 50633 Version 2.0</div></div></div>"},"50634":{"type":"graphic_table","displayName":"IPSS in MDS","title":"International prognosis scoring system (IPSS) in myelodysplastic syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International prognosis scoring system (IPSS) in myelodysplastic syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"5\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Variable</td> <td class=\"subtitle1\" colspan=\"5\">Score</td> </tr> <tr> <td class=\"subtitle2\">0</td> <td class=\"subtitle2\">0.5</td> <td class=\"subtitle2\">1</td> <td class=\"subtitle2\">1.5</td> <td class=\"subtitle2\">2</td> </tr> <tr> <td class=\"subtitle2_left\">Bone marrow blasts (percent)</td> <td>&#60;5</td> <td>5 to 10</td> <td>-</td> <td>11 to 20</td> <td>21 to 30</td> </tr> <tr> <td class=\"subtitle2_left\">Karyotype*</td> <td>Good</td> <td>Intermediate</td> <td>Poor</td> <td>-</td> <td>-</td> </tr> <tr> <td class=\"subtitle2_left\">Cytopenias<sup>&#182;</sup></td> <td>0/1</td> <td>2/3</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td class=\"subtitle1\">Risk group</td> <td class=\"subtitle1\" colspan=\"5\">IPSS score</td> </tr> <tr> <td>Low</td> <td colspan=\"5\">0</td> </tr> <tr> <td>Intermediate-1</td> <td colspan=\"5\">0.5 to 1</td> </tr> <tr> <td>Intermediate-2</td> <td colspan=\"5\">1.5 to 2</td> </tr> <tr> <td>High</td> <td colspan=\"5\">2.5 to 3.5</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>Scoring system:</strong> A score from zero to two is determined for each of the three variables; the three values are added obtain the IPSS score. Thus, a patient with 12 percent bone marrow blasts (score 1.5), complex chromosomal changes (poor karyotype score 1), neutrophil count of 1000/microL, and platelet count of 50,000/microL (two cytopenias, score 0.5) would have an IPSS score of 3 (ie, high risk).</div><div class=\"graphic_footnotes\">* Karytope definitions:<br />Good: Normal;-Y; del (5q); del (20q).<br />Poor: Complex (&ge;3 abnormalities); abnormal chromosome 7.<br />Intermediate: All others.<br />&para; Cytopenia definitions: <br />Red blood cells: Hemoglobin &lt;10 g/dL (100 g/L).<br />White blood cells: Absolute neutrophil count &lt;1800/microL.<br />Platelets: Platelet count &lt;100,000/microL.</div><div class=\"graphic_reference\">Adapted from: Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079. Erratum in Blood 1998; 91:1100.</div><div id=\"graphicVersion\">Graphic 50634 Version 3.0</div></div></div>"},"50635":{"type":"graphic_diagnosticimage","displayName":"M mode scan I","title":"M-mode echocardiographic scan of the heart","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiographic scan of the heart</div><div class=\"cntnt\"><img style=\"width:472px; height:207px;\" src=\"images/CARD/50635_M_mode_scan_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transducer is positioned at the left parastenal region and is moved from the apex to the base of the heart. The scan shows the left ventricle (LV), the right ventricle (RV) and right ventricular outflow tract (RVOT), the mitral valve leaflets, the aorta (Ao), aortic valve (AV) and the left atrium (LA).</div><div id=\"graphicVersion\">Graphic 50635 Version 2.0</div></div></div>"},"50637":{"type":"graphic_table","displayName":"Key indicators diagnosis COPD","title":"Key indicators for considering a diagnosis of COPD","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key indicators for considering a diagnosis of COPD</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Symptoms</td> </tr> <tr> <td class=\"indent1\">Dyspnea</td> </tr> <tr> <td class=\"indent1\">Cough</td> </tr> <tr> <td class=\"indent1\">Sputum</td> </tr> <tr> <td class=\"subtitle1_single\">Risk factors</td> </tr> <tr> <td class=\"indent1\">Smoking</td> </tr> <tr> <td class=\"indent1\">Biomass fuel exposure</td> </tr> <tr> <td class=\"indent1\">Asthma</td> </tr> <tr> <td class=\"indent1\">Childhood infections</td> </tr> <tr> <td class=\"indent1\">Prematurity</td> </tr> <tr> <td class=\"indent1\">Family history</td> </tr> <tr> <td class=\"subtitle1_single\">Comorbidities</td> </tr> <tr> <td class=\"indent1\">Heart disease</td> </tr> <tr> <td class=\"indent1\">Metabolic syndrome</td> </tr> <tr> <td class=\"indent1\">Osteoporosis</td> </tr> <tr> <td class=\"indent1\">Sleep apnea</td> </tr> <tr> <td class=\"indent1\">Depression</td> </tr> <tr> <td class=\"indent1\">Lung cancer</td> </tr> <tr> <td class=\"indent1\">Skin wrinkling</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Consider the diagnosis of COPD and perform spirometry if any of these indicators are present. These indicators are not diagnostic by themselves, but the presence of multiple key indicators increases the probability of a diagnosis of COPD. Spirometry is needed to establish a diagnosis of COPD.</div><div id=\"graphicVersion\">Graphic 50637 Version 3.0</div></div></div>"},"50639":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph of supracardiac TAPVC","title":"Chest radiograph of supracardiac total anomalous pulmonary venous connection (TAPVC)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of supracardiac total anomalous pulmonary venous connection (TAPVC)</div><div class=\"cntnt\"><img style=\"width:432px; height:327px;\" src=\"images/PEDS/50639_Ch_radiogr_supra_TAPVC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posterior-anterior chest radiograph of a school-aged child with unrepaired supracardiac total anomalous pulmonary venous connection (TAPVC) demonstrating the findings that produce the classic snowman appearance. Note the marked dilation of the superior vena cava (SVC), innominate vein, and the silhouette produced by the vertical vein. Pulmonary vasculature is engorged, and the cardiac silhouette is mildly enlarged.</div><div id=\"graphicVersion\">Graphic 50639 Version 3.0</div></div></div>"},"50640":{"type":"graphic_picture","displayName":"Stasis dermatitis advanced","title":"Advanced stasis dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Advanced stasis dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/50640_Stasisdermatitisadvanced.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Increased scaling, peripheral edema, erosions, crusts, and secondary bacterial infection on the lower third of the leg in a&nbsp;patient with&nbsp;subacute stasis dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia, 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50640 Version 3.0</div></div></div>"},"50641":{"type":"graphic_diagnosticimage","displayName":"Aortic root enlargement","title":"Aortic root enlargement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic root enlargement</div><div class=\"cntnt\"><img style=\"width:338px; height:347px;\" src=\"images/CARD/50641_Aortic_root_enlargement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal aortic root (RT) and ascending aorta (AAo) are seen in panel A; slight prominence of the sinuses of Valsalva (SinV) can be appreciated. Panel B is the aortic RT and AAo from a patient with the Marfan syndrome; the SinV are large while the AAo is relatively normal, a pattern that seems unique to the Marfan syndrome. In panel C, a greatly enlarged aortic (Ao) RT is also seen, but the pattern differs from that seen in the Marfan patient; the dilatation begins at the aortic ring and continues beyond the sinotubular junction well into the AAo, considered to represent aortoannular ectasia.</div><div id=\"graphicVersion\">Graphic 50641 Version 3.0</div></div></div>"},"50643":{"type":"graphic_table","displayName":"Flu signs symptoms children","title":"Signs and symptoms and clinical diagnoses at the initial visit in different age groups of children with influenza","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms and clinical diagnoses at the initial visit in different age groups of children with influenza</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\" rowspan=\"2\">\n   Sign or symptom\n   </td>\n   <td  class=\"subtitle1\" colspan=\"3\">\n   Age group\n   </td>\n   <td  class=\"subtitle1\" rowspan=\"2\">\n   All (n = 353)\n   </td>\n   <td  class=\"subtitle1\" rowspan=\"2\">\n   <em>P</em>*\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2\">\n   &#60;3 yr (n = 101)\n   </td>\n   <td  class=\"subtitle2\">\n   3-6 yr (n = 160)\n   </td>\n   <td  class=\"subtitle2\">\n   7-13 yr (n = 92)\n   </td>\n   </tr>\n   <tr>\n   <td>Fever &#8805;37.5&#176;C</td>\n   <td>99 (98)</td>\n   <td>148 (93)</td>\n   <td>87 (95)</td>\n   <td>334 (95)</td>\n   <td>0.157</td>\n   </tr>\n   <tr>\n   <td>Fever &#8805;38.0&#176;C</td>\n   <td>95 (94)</td>\n   <td>145 (91)</td>\n   <td>77 (84)</td>\n   <td>317 (90)</td>\n   <td>0.053</td>\n   </tr>\n   <tr>\n   <td>Fever &#8805;39.0&#176;C</td>\n   <td>60 (59)</td>\n   <td>82 (51)</td>\n   <td>36 (39)</td>\n   <td>178 (50)</td>\n   <td>0.018</td>\n   </tr>\n   <tr>\n   <td>Fever &#8805;40.0&#176;C</td>\n   <td>20 (20)</td>\n   <td>19 (12)</td>\n   <td>4 (4)</td>\n   <td>43 (12)</td>\n   <td>0.005</td>\n   </tr>\n   <tr>\n   <td>Rhinitis</td>\n   <td>87 (86)</td>\n   <td>120 (75)</td>\n   <td>67 (73)</td>\n   <td>274 (78)</td>\n   <td>0.048</td>\n   </tr>\n   <tr>\n   <td>Cough</td>\n   <td>79 (78)</td>\n   <td>119 (74)</td>\n   <td>74 (80)</td>\n   <td>272 (77)</td>\n   <td>0.516</td>\n   </tr>\n   <tr>\n   <td>Sore throat</td>\n   <td>NA</td>\n   <td>39 (24)</td>\n   <td>51 (55)</td>\n   <td>90 (36)</td>\n   <td>&#60;0.001</td>\n   </tr>\n   <tr>\n   <td>Headache</td>\n   <td>NA</td>\n   <td>29 (18)</td>\n   <td>36 (39)</td>\n   <td>65 (26)</td>\n   <td>&#60;0.001</td>\n   </tr>\n   <tr>\n   <td>Myalgia</td>\n   <td>NA</td>\n   <td>5 (3)</td>\n   <td>12 (13)</td>\n   <td>17 (7)</td>\n   <td>0.006</td>\n   </tr>\n   <tr>\n   <td>Gastrointestinal symptoms</td>\n   <td>6 (6)</td>\n   <td>16 (10)</td>\n   <td>9 (10)</td>\n   <td>31 (9)</td>\n   <td>0.489</td>\n   </tr>\n   <tr>\n   <td>Tonsillar exudates</td>\n   <td>1 (1)</td>\n   <td>5 (3)</td>\n   <td>4 (4)</td>\n   <td>10 (3)</td>\n   <td>ND</td>\n   </tr>\n   <tr>\n   <td>Impaired general condition</td>\n   <td>10 (10)</td>\n   <td>14 (9)</td>\n   <td>12 (13)</td>\n   <td>36 (10)</td>\n   <td>0.552</td>\n   </tr>\n   <tr>\n   <td>Expiratory wheezing</td>\n   <td>2 (2)</td>\n   <td>6 (4)</td>\n   <td>1 (1)</td>\n   <td>9 (3)</td>\n   <td>ND</td>\n   </tr>\n   <tr>\n   <td>Laryngitis</td>\n   <td>6 (6)</td>\n   <td>10 (6)</td>\n   <td>7 (8)</td>\n   <td>23 (7)</td>\n   <td>0.881</td>\n   </tr>\n   <tr>\n   <td>Conjunctivitis</td>\n   <td>7 (7)</td>\n   <td>12 (8)</td>\n   <td>12 (13)</td>\n   <td>31 (9)</td>\n   <td>0.241</td>\n   </tr>\n   <tr>\n   <td>Acute otitis media</td>\n   <td>19 (19)</td>\n   <td>17 (11)</td>\n   <td>1 (1)</td>\n   <td>37 (10)</td>\n   <td>&#60;0.001</td>\n   </tr>\n   <tr>\n   <td>Pneumonia</td>\n   <td>2 (2)</td>\n   <td>3 (2)</td>\n   <td>0 (0)</td>\n   <td>5 (1)</td>\n   <td>ND</td>\n   </tr>\n   <tr>\n   <td>Maxillary sinusitis</td>\n   <td>0 (0)</td>\n   <td>4 (3)</td>\n   <td>2 (2)</td>\n   <td>6 (2)</td>\n   <td>ND</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">9/25/2009--Permission granted via Rightslink; figure to Terrence (JD).</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=52474&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Flu_signs_symptoms_children.htm</title></head></div><div class=\"graphic_lgnd\">Data are number of (percent) cases.</div><div class=\"graphic_footnotes\">NA: not applicable; ND: not done because of low frequencies.<br> * <em>P</em>: X<sup>2</sup> test.</div><div class=\"graphic_reference\">Reproduced with permission from: Silvennoinen H, Peltola V, Lehtinen P, et al. Clinical presentation of influenza in unselected children treated as outpatients. Pediatr Infect Dis J 2009; 28:372. Copyright © 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50643 Version 7.0</div></div></div>"},"50644":{"type":"graphic_table","displayName":"Nonverbal skills pt interview","title":"Nonverbal skills applying to all functions of medical interview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonverbal skills applying to all functions of medical interview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Strategy</td> <td class=\"subtitle1\">Rationale</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td>Professional appearance</td> <td>Conveys confidence and expertise</td> <td>Well-kempt; with or without white coat, depending on expectations of majority of patient population</td> </tr> <tr> <td>Comfortable office</td> <td>Helps patient and clinician relax, conveys professionalism, and can convey sense of clinician's level of organization and aesthetic taste</td> <td>Appropriate temperature; no barriers to direct eye contact; gowns that fit; efficient organization of exam room; attention to modesty; minimization of interruptions</td> </tr> <tr> <td>Calm, attentive, open posture</td> <td>Conveys readiness to listen</td> <td>Comfortable interpersonal distance; patient and clinician at eye level (consider implications of vertical distance on patient's comfort); clinician leans slightly forward, relaxed</td> </tr> <tr> <td>Eye contact</td> <td>Conveys focused interest on the patient; clinician is not distracted</td> <td>Clinician looks patient directly in the eye while talking and listening; consider the effect of note-taking style on the flow of the interview</td> </tr> <tr> <td>Voice quality: pitch, pace, tone, volume (paralanguage)</td> <td>Conveys much about clinician's tranquillity and readiness to hear patient; respectful of hearing deficits</td> <td>Calm versus brusque and hurried; loud/soft enough; avoid hostile, scolding, or irritated quality</td> </tr> <tr> <td>Clinician \"matches\" some of the patient's behaviors</td> <td>Subliminal enhancement of relationship</td> <td>Clinician's posture echoes patient's posture; clinician's voice tone, pace, and vocabulary matches patient's; clinician's gestures subtly echo patient's</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Doctors should be aware that many nonverbal behaviors have special cross-cultural implications.</div><div class=\"graphic_reference\">Adapted by permission from Clark W, Hewson M, Fry M, et al. American Academy on Physician and Patient (AAPP 1998), now the American Academy on Communication in Healthcare.</div><div id=\"graphicVersion\">Graphic 50644 Version 3.0</div></div></div>"},"50645":{"type":"graphic_table","displayName":"Minimizing exercise test risk","title":"Minimizing the risks of exercise testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Minimizing the risks of exercise testing</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n\n    <tr>\n\n      <td>Trained personnel (testing, treatment, CPR expertise, etc.)</td>\n\n    </tr>\n    <tr>\n      <td> Physician or other health care professional in attendance during testing</td>\n    </tr>\n    <tr>\n      <td> Continuous ECG monitoring during and after testing</td>\n    </tr>\n    <tr>\n      <td> Pretest history and physical examination </td>\n    </tr>\n    <tr>\n      <td>Resting ECG interpretation before exercise begins</td>\n    </tr>\n    <tr>\n      <td>Patient awareness of limiting signs and symptoms</td>\n    </tr>\n    <tr>\n      <td> Emergency resuscitation equipment and drugs</td>\n    </tr>\n    <tr>\n      <td>Attention to exercise test end points&nbsp;</td>\n    </tr>\n    <tr>\n      <td>No shower until cool-down finished</td>\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 50645 Version 1.0</div></div></div>"},"50646":{"type":"graphic_table","displayName":"Differential diagnosis of chronic insomnia","title":"Differential diagnosis of chronic insomnia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of chronic insomnia</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">I. Psychiatric conditions</td> </tr> <tr> <td>Depression</td> </tr> <tr> <td>Anxiety</td> </tr> <tr> <td>Substance abuse</td> </tr> <tr> <td>Post-traumatic stress</td> </tr> <tr> <td class=\"subtitle1_single\">II. Medical conditions</td> </tr> <tr> <td class=\"sublist1_start\">Pulmonary</td> </tr> <tr> <td class=\"sublist1\">Chronic obstructive pulmonary disease</td> </tr> <tr> <td class=\"sublist1\">Bronchial asthma including nocturnal asthma</td> </tr> <tr> <td class=\"sublist1_start\">Rheumatologic</td> </tr> <tr> <td class=\"sublist1\">Arthritis</td> </tr> <tr> <td class=\"sublist1\">Fibromyalgia</td> </tr> <tr> <td class=\"sublist1\">Chronic pain</td> </tr> <tr> <td class=\"sublist1_start\">Cardiovascular</td> </tr> <tr> <td class=\"sublist1\">Heart failure</td> </tr> <tr> <td class=\"sublist1\">Ischemic heart disease</td> </tr> <tr> <td class=\"sublist1\">Nocturnal angina</td> </tr> <tr> <td class=\"sublist1\">Hypertension</td> </tr> <tr> <td class=\"sublist1_start\">Endocrinologic</td> </tr> <tr> <td class=\"sublist1\">Hyperthyroidism</td> </tr> <tr> <td class=\"sublist1_start\">Urinary</td> </tr> <tr> <td class=\"sublist1\">Nocturia</td> </tr> <tr> <td class=\"sublist1_start\">Gastrointestinal</td> </tr> <tr> <td class=\"sublist1\">Gastroesophageal reflux</td> </tr> <tr> <td>Diabetes</td> </tr> <tr> <td>Cancer</td> </tr> <tr> <td>Menopause</td> </tr> <tr> <td>Lyme disease</td> </tr> <tr> <td>Acquired immunodeficiency syndromes (AIDS)</td> </tr> <tr> <td>Chronic fatigue syndrome</td> </tr> <tr> <td>Dermatologic (eg, pruritus)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">III. Neurological conditions</td> </tr> <tr> <td class=\"sublist1_start\">Neurodegenerative disease</td> </tr> <tr> <td class=\"sublist1\">Alzheimer disease</td> </tr> <tr> <td class=\"sublist1\">Parkinson disease</td> </tr> <tr> <td>Neuromuscular disorders including painful peripheral neuropathies</td> </tr> <tr> <td>Cerebral hemispheric and brainstem strokes</td> </tr> <tr> <td>Brain tumors</td> </tr> <tr> <td>Traumatic brain injury causing post-traumatic insomnia</td> </tr> <tr> <td>Headache syndromes (migraine, cluster, hypnic headache, and exploding head syndromes)</td> </tr> <tr> <td>Fatal familial insomnia, a rare prion disease</td> </tr> <tr> <td class=\"subtitle1_single\">IV. Medications</td> </tr> <tr> <td>Central nervous system stimulants</td> </tr> <tr> <td>Central nervous system depressants</td> </tr> <tr> <td>Bronchodilators</td> </tr> <tr> <td>Antidepressants</td> </tr> <tr> <td>Beta antagonists</td> </tr> <tr> <td>Glucocorticoids</td> </tr> <tr> <td class=\"subtitle1_single\">V. Other sleep disorders</td> </tr> <tr> <td>Restless legs syndrome/Willis-Ekbom disease</td> </tr> <tr> <td>Periodic limb movement disorder</td> </tr> <tr> <td>Sleep-disordered breathing</td> </tr> <tr> <td class=\"sublist1_start\">Circadian rhythm disorders</td> </tr> <tr> <td class=\"sublist1\">Delayed sleep-wake phase disorder</td> </tr> <tr> <td class=\"sublist1\">Advanced sleep-wake phase disorder</td> </tr> <tr> <td class=\"sublist1\">Irregular sleep-wake rhythm disorder&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Shift work disorder&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">VI. Independent insomnia disorders</td> </tr> <tr> <td>Short-term&nbsp;insomnia disorder</td> </tr> <tr> <td>Chronic insomnia disorder&nbsp;</td> </tr> <tr> <td>Other insomnia disorder</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50646 Version 7.0</div></div></div>"},"50647":{"type":"graphic_figure","displayName":"Effect of T4 on sleep apnea","title":"Frequency of episodes of obstructive sleep apnea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Frequency of episodes of obstructive sleep apnea</div><div class=\"cntnt\"><img style=\"width:402px; height:353px;\" src=\"images/ENDO/50647_Effect_of_T4_on_sleep_apnea.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Episodes of sleep apnea in six obese hypothyroid patients (shown in red bars) and three non-obese hypothyroid patients (blue bars) before and after 3 to 12 months of thyroxine therapy. The frequency of episodes decreased significantly without a change in weight.</div><div class=\"graphic_reference\">Data from: Rajagopal KR, Abbrecht PH, Derderian SS, et al. Obstructive sleep apnea in hypothyroidism.&nbsp;Ann Intern Med 1984; 101:491.</div><div id=\"graphicVersion\">Graphic 50647 Version 2.0</div></div></div>"},"50649":{"type":"graphic_picture","displayName":"EMR band snare technique","title":"Picture demonstrating the band and snare technique for endoscopic mucosal resection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Picture demonstrating the band and snare technique for endoscopic mucosal resection</div><div class=\"cntnt\"><img style=\"width:288px; height:354px;\" src=\"images/GAST/50649_EMR_band_snare_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The top panels show the lesion ensnared with a variceal band ligator. A polypectomy snare is used to remove the tissue (lower left panel), leaving the residual mucosal defects (lower right panel).</div><div class=\"graphic_reference\">Courtesy of Christopher Gostout, MD.</div><div id=\"graphicVersion\">Graphic 50649 Version 3.0</div></div></div>"},"50650":{"type":"graphic_picture","displayName":"Bone marrow megakaryocyte","title":"Bone marrow megakaryocyte","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone marrow megakaryocyte</div><div class=\"cntnt\"><img style=\"width:443px; height:288px;\" src=\"images/HEME/50650_Bone_marrow_megakaryocyte.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view (x1000) of a Wright-stained bone marrow. A large normal megakaryocyte is seen with a polyploid nucleus within one nuclear envelope. The staining characteristics of the cytoplasm are identical to those of the platelet. Adjacent cells include neutrophils, erythrocytes, and some myeloid precursors.</div><div class=\"graphic_reference\">Courtesy of David J Kuter, MD, DPhil.</div><div id=\"graphicVersion\">Graphic 50650 Version 2.0</div></div></div>"},"50651":{"type":"graphic_diagnosticimage","displayName":"M-mode hypertrophic CM","title":"M-mode echocardiogram of hypertrophic cardimyopathy with dynamic obstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiogram of hypertrophic cardimyopathy with dynamic obstruction</div><div class=\"cntnt\"><img style=\"width:400px; height:310px;\" src=\"images/CARD/50651_MmodehypertrophicCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The M-mode echocardiogram taken at rest (panel A) shows diastolic mitral valve (MV) septal contact, a low intensity murmur (SEM), and a modest degree of systolic anterior motion (SAM) of the mitral valve. In panel B, taken at peak amyl nitrite effect, the MV is in contact with the septum during much of diastole and during systole as a result of SAM; it gives the impression that the mitral apparatus is \"crowded.\" The presence of SAM and crowding, the carotid pulse (cp) configuration, and the now intense SEM are features that signify the dynamic nature of the obstruction and that the provoked obstruction is severe. In panel C, the obstruction has abated a few minutes after the peak amyl nitrate effect has subsided; however, obstruction remains detectable by cp configuration and by SEM intensity.</div><div id=\"graphicVersion\">Graphic 50651 Version 3.0</div></div></div>"},"50653":{"type":"graphic_picture","displayName":"Vitreous bleed in Eales disease","title":"Vitreous hemorrhage in Eales' disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vitreous hemorrhage in Eales' disease</div><div class=\"cntnt\"><img style=\"width:339px; height:288px;\" src=\"images/RHEUM/50653_Vitreous_bleed_in_Eales_dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Funduscopy in a patient with Eales' disease shows vitreous hemorrhage.</div><div class=\"graphic_reference\">Courtesy of Michael Tolentino, MD.</div><div id=\"graphicVersion\">Graphic 50653 Version 2.0</div></div></div>"},"50655":{"type":"graphic_diagnosticimage","displayName":"Retained surgical sponge on FDG-PET","title":"Retained surgical sponge on FDG-PET*","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Retained surgical sponge on FDG-PET*</div><div class=\"cntnt\"><img style=\"width:584px; height:375px;\" src=\"images/SURG/50655_Retained_surg_sponge_FDGPET.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraabdominal gossypiboma in a 42-year-old woman who had undergone cesarean sections twice previously.<br> (A) Transaxial positive emission tomography (PET) image with uneven fluorodeoxyglucose (FDG) uptake at the rim of a mass.<br> (B) Coronal reconstruction showing the retained sponge (arrow) on PET computed tomography (CT).<br> (C) Excised surgical specimen showing retained sponge in situ.</div><div class=\"graphic_footnotes\">* FDG-PET: fluorodeoxyglucose positive emission tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Yuh-Feng T, Chin-Chu W, Cheng-Tau S, Min-Tsung T. FDG PET CT Features of an intraabdominal gossypiboma. Clin Nucl Med 2005; 30:561. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50655 Version 8.0</div></div></div>"},"50656":{"type":"graphic_movie","displayName":"Side leg raise video","title":"Strength exercise video: Side leg raise","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Strength exercise video: Side leg raise</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PC/50656_Sidelegraisevideo.mp4\" style=\"width:480px;height:336px\"></div><img style=\"width:369px; height:297px;\" src=\"images/PC/50656_Sidelegraiseeximg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This exercise strengthens hips, thighs, and buttocks. For an added challenge, you can modify the exercise to improve your balance.<br> <ol> <li>Stand behind a sturdy chair with feet slightly apart, holding on for balance. Breathe in slowly. </li> <li>Breathe out and slowly lift one leg out to the side. Keep your back straight and your toes facing forward. The leg you are standing on should be slightly bent. </li> <li>Hold position for one second. </li> <li>Breathe in as you slowly lower your leg. </li> <li>Repeat 10 to 15 times. </li> <li>Repeat 10 to 15 times with other leg. </li> <li>Repeat 10 to 15 more times with each leg. </li> </ol> As you progress, you may want to add ankle weights.</div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 50656 Version 1.0</div></div></div>"},"50660":{"type":"graphic_table","displayName":"Continuous thoracic murmurs","title":"Differential diagnosis of continuous thoracic murmurs (in order of frequency)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of continuous thoracic murmurs (in order of frequency)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">Key findings</td> </tr> <tr> <td>Cervical venous hum</td> <td>Disappears on compression of the jugular vein</td> </tr> <tr> <td>Hepatic venous hum</td> <td>Often disappears with epigastric pressure</td> </tr> <tr> <td>Mammary souffle</td> <td>Disappears upon pressing hard with stethoscope</td> </tr> <tr> <td>Patent ductus arteriosus</td> <td>Loudest at 2nd left intercostal space</td> </tr> <tr> <td>Coronary arteriovenous fistula</td> <td>Loudest at lower sternal borders</td> </tr> <tr> <td>Ruptured aneurysm of sinus of Valsalva</td> <td>Loudest at upper right sternal border, sudden onset</td> </tr> <tr> <td>Bronchial collaterals</td> <td>Associated signs of congenital heart disease</td> </tr> <tr> <td>High-grade coarctation</td> <td>Brachial-pedal arterial pressure gradient</td> </tr> <tr> <td>Anomalous left coronary artery arising from pulmonary artery</td> <td>Electrocardiographic changes of myocardial infarction</td> </tr> <tr> <td>Truncus arteriosus</td> <td>&nbsp;</td> </tr> <tr> <td>Pulmonary artery branch stenosis</td> <td>Heard outside the area of cardiac dullness</td> </tr> <tr> <td>Pulmonary AV fistula</td> <td>Same as above</td> </tr> <tr> <td>Atrial septal defect with mitral stenosis or atresia</td> <td>Altered by the Valsalva maneuver</td> </tr> <tr> <td>Aortic-atrial fistulas</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from Sapira JD. The Art and Science of Bedside Diagnosis. Urban &amp; Schwartzenberg, Baltimore 1990. Copyright &copy; 1990 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 50660 Version 11.0</div></div></div>"},"50663":{"type":"graphic_table","displayName":"Disorders assoc with idiopathic noncirrhotic portal HTN","title":"Disorders and medications associated with idiopathic noncirrhotic portal hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders and medications associated with idiopathic noncirrhotic portal hypertension</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Hematologic/neoplastic</td> </tr> <tr> <td class=\"indent1\">Liver cancers</td> </tr> <tr> <td class=\"indent1\">Sacrococcygeal teratoma</td> </tr> <tr> <td class=\"indent1\">Essential thrombocytosis</td> </tr> <tr> <td class=\"indent1\">Polycythemia vera</td> </tr> <tr> <td class=\"indent1\">Myeloproliferative disorders</td> </tr> <tr> <td class=\"indent1\">Lymphoproliferative disorders</td> </tr> <tr> <td class=\"indent1\">Multiple myeloma</td> </tr> <tr> <td class=\"indent1\">Spherocytosis</td> </tr> <tr> <td class=\"indent1\">Sickle cell disease</td> </tr> <tr> <td class=\"indent1\">Protein S deficiency</td> </tr> <tr> <td class=\"indent1\">Factor V Leiden mutation</td> </tr> <tr> <td class=\"indent1\">Hyperhomocysteinemia</td> </tr> <tr> <td class=\"indent1\">Antiphospholipid syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Immune</td> </tr> <tr> <td class=\"indent1\">Primary biliary cholangitis</td> </tr> <tr> <td class=\"indent1\">Polymyositis</td> </tr> <tr> <td class=\"indent1\">Sj&#246;gren's syndrome</td> </tr> <tr> <td class=\"indent1\">Scleroderma</td> </tr> <tr> <td class=\"indent1\">CREST syndrome</td> </tr> <tr> <td class=\"indent1\">Still's syndrome</td> </tr> <tr> <td class=\"indent1\">Polyarteritis nodosa</td> </tr> <tr> <td class=\"indent1\">Rheumatoid arthritis</td> </tr> <tr> <td class=\"indent1\">Polymyalgia rheumatica</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"indent1\">Beh&#231;et's syndrome</td> </tr> <tr> <td class=\"indent1\">Cryoglobulinemia</td> </tr> <tr> <td class=\"indent1\">Idiopathic hypereosinophilic syndrome</td> </tr> <tr> <td class=\"indent1\">Idiopathic thrombocytopenic purpura</td> </tr> <tr> <td class=\"indent1\">Celiac disease</td> </tr> <tr> <td class=\"indent1\">Myasthenia gravis</td> </tr> <tr> <td class=\"indent1\">HIV infection</td> </tr> <tr> <td class=\"indent1\">Common variable immunodeficiency</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Medications</td> </tr> <tr> <td class=\"indent1\">Azathioprine</td> </tr> <tr> <td class=\"indent1\">Thioguanine</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide</td> </tr> <tr> <td class=\"indent1\">Chlorambucil</td> </tr> <tr> <td class=\"indent1\">Busulfan</td> </tr> <tr> <td class=\"indent1\">Doxorubicin</td> </tr> <tr> <td class=\"indent1\">Cytosine</td> </tr> <tr> <td class=\"indent1\">Arabinoside</td> </tr> <tr> <td class=\"indent1\">Bleomycin</td> </tr> <tr> <td class=\"indent1\">Carmustine</td> </tr> <tr> <td class=\"indent1\">Trastuzumab</td> </tr> <tr> <td class=\"indent1\">Interleukin-2</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Liver transplantation</td> </tr> <tr> <td class=\"indent1\">Renal transplantation</td> </tr> <tr> <td class=\"indent1\">Atrial septal defect</td> </tr> <tr> <td class=\"indent1\">Ventricular septal defect</td> </tr> <tr> <td class=\"indent1\">Pulmonary vein anomalies</td> </tr> <tr> <td class=\"indent1\">Congenital portal venous anomalies</td> </tr> <tr> <td class=\"indent1\">VATER syndrome</td> </tr> <tr> <td class=\"indent1\">Hereditary hemorrhagic telangiectasia</td> </tr> <tr> <td class=\"indent1\">Cystinosis</td> </tr> <tr> <td class=\"indent1\">Turner's syndrome</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; CREST: calcinosis cutis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia; VATER: Vertebral anomalies, anal atresia, TE fistula (tracheoesophageal fistula), renal defects.</div><div id=\"graphicVersion\">Graphic 50663 Version 6.0</div></div></div>"},"50664":{"type":"graphic_table","displayName":"MDS outcome by FAB subgroup","title":"Myelodysplastic syndrome: survival and leukemic evolution related to French-American-British (FAB) subgroups","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Myelodysplastic syndrome: survival and leukemic evolution related to French-American-British (FAB) subgroups</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">&nbsp;</td>\n<td class=\"subtitle1\">RA</td>\n<td class=\"subtitle1\">RARS</td>\n<td class=\"subtitle1\">RAEB</td>\n<td class=\"subtitle1\">RAEB-T</td>\n<td class=\"subtitle1\">CMML</td>\n</tr>\n\n<tr>\n<td>Proportion of all patients with MDS, percent</td>\n<td>25</td>\n<td>15</td>\n<td>35</td>\n<td>15</td>\n<td>10</td>\n</tr>\n<tr>\n<td>Median survival, months</td>\n<td>43</td>\n<td>73</td>\n<td>12</td>\n<td>5</td>\n<td>20</td>\n</tr>\n\n<tr>\n<td>Transformation to AML, percent</td>\n<td>15</td>\n<td>5</td>\n<td>40</td>\n<td>50</td>\n<td>35</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from a data meta-analysis and Greenberg PL. Myelodysplastic Syndrome. In: Hematology: Basic Principles and Practice, 3rd ed, Hoffman R, Benz EJ, Shattil SJ (Eds), Churchill Livingstone, New York 2000. p.1106.</div><div id=\"graphicVersion\">Graphic 50664 Version 3.0</div></div></div>"},"50665":{"type":"graphic_diagnosticimage","displayName":"Fusion of sacroiliac joints AS","title":"Fusion of sacroiliac joints in AS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fusion of sacroiliac joints in AS</div><div class=\"cntnt\"><img style=\"width:360px; height:233px;\" src=\"images/RHEUM/50665_Fusion_of_sacroiliac_joints.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ankylosis of the sacroiliac joint in advanced ankylosing spondylitis (AS)&nbsp;with complete obliteration of the joint space.</div><div class=\"graphic_reference\">Courtesy of Craig W Wiesenhutter, MD.</div><div id=\"graphicVersion\">Graphic 50665 Version 3.0</div></div></div>"},"50666":{"type":"graphic_table","displayName":"Probability of HF women","title":"Probability of heart failure within four years for women aged 45 to 94 years with coronary disease, hypertension, or valvular disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Probability of heart failure within four years for women aged 45 to 94 years with coronary disease, hypertension, or valvular disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n \r\n  <tr>\r\n \r\n  <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Variables</td>\r\n \r\n  <td class=\"subtitle1\" colspan=\"10\" rowspan=\"1\">Points</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td class=\"subtitle2\">0</td>\r\n \r\n  <td class=\"subtitle2\">+1</td>\r\n \r\n  <td class=\"subtitle2\">+2</td>\r\n \r\n  <td class=\"subtitle2\">+3</td>\r\n \r\n  <td class=\"subtitle2\">+4</td>\r\n \r\n  <td class=\"subtitle2\">+5</td>\r\n \r\n  <td class=\"subtitle2\">+6</td>\r\n \r\n  <td class=\"subtitle2\">+7</td>\r\n \r\n  <td class=\"subtitle2\">+8</td>\r\n \r\n  <td class=\"subtitle2\">+9</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td>Age, y</td>\r\n \r\n  <td>45-49</td>\r\n \r\n  <td>50-59</td>\r\n \r\n  <td>60-69</td>\r\n \r\n  <td>70-79</td>\r\n \r\n  <td>80-89</td>\r\n \r\n  <td>90-94</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td>Forced vital capacity, cL</td>\r\n \r\n  <td>&#62;299</td>\r\n \r\n  <td>250-299</td>\r\n \r\n  <td>200-249</td>\r\n \r\n  <td>150-199</td>\r\n \r\n  <td>&#60;150</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td>Systolic blood pressure, mmHg</td>\r\n \r\n  <td>&#60;130</td>\r\n \r\n  <td>130-189</td>\r\n \r\n  <td>&#62;189</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td>Heart rate, bpm</td>\r\n \r\n  <td>&#60;55</td>\r\n \r\n  <td>55-79</td>\r\n \r\n  <td>80-99</td>\r\n \r\n  <td>&#62;99</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td>LVH on ECG</td>\r\n \r\n  <td>No</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td colspan=\"1\">\r\n \r\n  Yes\r\n \r\n  </td>\r\n \r\n  <td>Yes</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td>Coronary heart disease</td>\r\n \r\n  <td>No</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>Yes</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td>Cardiomegaly</td>\r\n \r\n  <td>No</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>Yes</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>Yes</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td>Valve disease</td>\r\n \r\n  <td>No</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>Yes</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td>Diabetes, no valve disease</td>\r\n \r\n  <td>No</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>Yes</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td>Diabetes, valve disease</td>\r\n \r\n  <td>No</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>Yes</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  <td>&nbsp;</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">Points</td>\r\n \r\n  <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">4-Year probability of heart failure, percent</td>\r\n \r\n  <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">Points</td>\r\n \r\n  <td class=\"subtitle1\" rowspan=\"1\" colspan=\"4\">4-Year probability of heart failure, percent</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">5</td>\r\n \r\n  <td colspan=\"3\" rowspan=\"1\">&#60;1</td>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">26</td>\r\n \r\n  <td colspan=\"4\" rowspan=\"1\">18</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">10</td>\r\n \r\n  <td colspan=\"3\" rowspan=\"1\">1</td>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">27</td>\r\n \r\n  <td colspan=\"4\" rowspan=\"1\">21</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">12</td>\r\n \r\n  <td colspan=\"3\" rowspan=\"1\">1</td>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">28</td>\r\n \r\n  <td colspan=\"4\" rowspan=\"1\">24</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">14</td>\r\n \r\n  <td colspan=\"3\" rowspan=\"1\">2</td>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">29</td>\r\n \r\n  <td colspan=\"4\" rowspan=\"1\">28</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">16</td>\r\n \r\n  <td colspan=\"3\" rowspan=\"1\">3</td>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">30</td>\r\n \r\n  <td colspan=\"4\" rowspan=\"1\">32</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">18</td>\r\n \r\n  <td colspan=\"3\" rowspan=\"1\">4</td>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">31</td>\r\n \r\n  <td colspan=\"4\" rowspan=\"1\">37</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">20</td>\r\n \r\n  <td colspan=\"3\" rowspan=\"1\">9</td>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">32</td>\r\n \r\n  <td colspan=\"4\" rowspan=\"1\">42</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">22</td>\r\n \r\n  <td colspan=\"3\" rowspan=\"1\">13</td>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">33</td>\r\n \r\n  <td colspan=\"4\" rowspan=\"1\">46</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">24</td>\r\n \r\n  <td colspan=\"3\" rowspan=\"1\">13</td>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">34</td>\r\n \r\n  <td colspan=\"4\" rowspan=\"1\">51</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">25</td>\r\n \r\n  <td colspan=\"3\" rowspan=\"1\">15</td>\r\n \r\n  <td colspan=\"2\" rowspan=\"1\">35</td>\r\n \r\n  <td colspan=\"4\" rowspan=\"1\">56</td>\r\n \r\n  </tr>\r\n </table></div><div class=\"graphic_footnotes\">LVH: left ventricular hypertrophy; ECG: electrocardiogram; cL: centiliter; y: years; bpm: beats per minute.</div><div class=\"graphic_reference\">Data reproduced with permission from: Kannel WB, D'Agostino RB, Silbershatz H, et al. Arch Intern Med 1999; 159:1192.</div><div id=\"graphicVersion\">Graphic 50666 Version 2.0</div></div></div>"},"50667":{"type":"graphic_picture","displayName":"Cutaneous horn on the cheek","title":"Cutaneous horn","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cutaneous horn</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/50667_Cutaneous_horn_cheek.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A horn-like keratotic projection is present on the skin. Lesions such as squamous cell carcinoma, viral warts, actinic keratoses, and seborrheic keratoses may underly cutaneous horns.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50667 Version 3.0</div></div></div>"},"50669":{"type":"graphic_diagnosticimage","displayName":"Corpus luteum","title":"Corpus luteum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Corpus luteum</div><div class=\"cntnt\"><img style=\"width:366px; height:279px;\" src=\"images/ENDO/50669_Corpus_luteum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasonography of the ovary showing a corpus luteum.</div><div class=\"graphic_reference\">Courtesy of Judith Adams, DMU.</div><div id=\"graphicVersion\">Graphic 50669 Version 2.0</div></div></div>"},"50670":{"type":"graphic_picture","displayName":"Balloon dilation of an NSAID-induced ileal stricture","title":"Balloon dilation of an NSAID-induced ileal stricture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Balloon dilation of an NSAID-induced ileal stricture</div><div class=\"cntnt\"><img style=\"width:273px; height:576px;\" src=\"images/GAST/50670_Balloon_dil_NSAID_stricture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Nonsteroidal antiinflammatory drug (NSAID)-induced ileal stricture.<br />(B) Through-the-scope balloon dilation of stricture.<br />(C) Post-dilation appearance of stricture.</div><div class=\"graphic_reference\">Courtesy of Louis-Michel Wong Kee Song, MD, FRCP(C).</div><div id=\"graphicVersion\">Graphic 50670 Version 3.0</div></div></div>"},"50672":{"type":"graphic_figure","displayName":"Developmental pathogenesis of acute osteomyelitis","title":"Developmental pathogenesis of acute osteomyelitis","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Developmental pathogenesis of acute osteomyelitis</div><div class=\"cntnt\"><img style=\"width:472px; height:624px;\" src=\"images/PEDS/50672_Developmentalpathosteo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) In newborns, infection commonly spreads along the subperiosteal space and ruptures through the cortex into soft tissue or adjacent joint spaces.<br />(B and&nbsp;C) In infants and older children, capillaries do not cross the physis. Infection in older children is generally confined to the metaphysis, and the thicker cortex and denser periosteum limit spread to soft tissues.</div><div id=\"graphicVersion\">Graphic 50672 Version 5.0</div></div></div>"},"50673":{"type":"graphic_diagnosticimage","displayName":"MPS I chest radiograph","title":"Chest radiograph in a patient with mucopolysaccharidosis type I (MPS I)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph in a patient with mucopolysaccharidosis type I (MPS I)</div><div class=\"cntnt\"><img style=\"width:288px; height:370px;\" src=\"images/PEDS/50673_MPS_I_chest_radiograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ribs are broadened distally and narrowed at the takeoff from the vertebral bodies, resulting in the oar shape. The clavicle is also abnormally curved.</div><div class=\"graphic_reference\">Courtesy of Emil Kakkis, MD, PhD.</div><div id=\"graphicVersion\">Graphic 50673 Version 3.0</div></div></div>"},"50675":{"type":"graphic_picture","displayName":"Peritonsillar abscess I and D","title":"Surgical drainage of peritonsillar abscess","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Surgical drainage of peritonsillar abscess</div><div class=\"cntnt\"><img style=\"width:507px; height:439px;\" src=\"images/PEDS/50675_Peri_abscess_I_and_D_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Incision.<br> (B) Opening of abscess.<br> (C) Completed incision and drainage.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 50675 Version 4.0</div></div></div>"},"50677":{"type":"graphic_table","displayName":"Features of tickborne infx","title":"Selected features of Rocky Mountain spotted fever,<sup>[1]</sup> human monocytotropic ehrlichiosis, human granulocytotropic anaplasmosis,<sup>[2]</sup> and Ehrlichia ewingii infection - United States*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected features of Rocky Mountain spotted fever,<sup>[1]</sup> human monocytotropic ehrlichiosis, human granulocytotropic anaplasmosis,<sup>[2]</sup> and Ehrlichia ewingii infection - United States*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent (disease)</td> <td class=\"subtitle1\">Primary vector(s)</td> <td class=\"subtitle1\">Approximate distribution<sup>&#182;</sup></td> <td class=\"subtitle1\">Incubation period (days)</td> <td class=\"subtitle1\">Common initial signs and symptoms</td> <td class=\"subtitle1\">Common laboratory abnormalities</td> <td class=\"subtitle1\">Rash</td> <td class=\"subtitle1\">Case-fatality rate</td> </tr> <tr class=\"divider_bottom\"> <td>Rickettsia rickettsii (Rocky Mountain spotted fever)</td> <td>Dermacentor variabilis (American dog tick), Dermacentor andersoni (Rocky Mountain wood tick), and Rhipicephalus sanguineus (brown dog tick) in AZ<sup>[3]</sup></td> <td>Widespread in the United States, especially South Atlantic and South Central states</td> <td>2-14</td> <td>Fever, nausea, vomiting, myalgia, anorexia, and headache</td> <td>Thrombocytopenia, mild hyponatremia, and mildly elevated hepatic transaminase levels</td> <td>Maculopapular rash approximately 2-4 days after fever onset in about 90 percent<sup>&#916;</sup> of patients; might involve palms and soles</td> <td>5-10 percent</td> </tr> <tr class=\"divider_bottom\"> <td>Ehrlichia chaffeensis (human monocytotropic ehrlichiosis)</td> <td>Amblyomma americanum (lone star tick)</td> <td>South and Mid-Atlantic, North/South Central United States, and isolated areas of New England</td> <td>5-14</td> <td>Fever, headache, malaise, and myalgia</td> <td>Leukopenia, thromobocytopenia, and elevated serum transaminase levels</td> <td>Rash in &#60;30 percent of adults and approximately 60 percent of children</td> <td>2-3 percent</td> </tr> <tr class=\"divider_bottom\"> <td>Anaplasma phagocytophilum (human granulocytotropic anaplasmosis)</td> <td>Ixodes scapularis and Ixodes pacificus (blacklegged tick) in the United States</td> <td>New England, North Central and Pacific states</td> <td>5-21</td> <td>Fever, headache, malaise, myalgia, and vomiting</td> <td>Leukopenia, thrombocytopenia, elevated serum transaminase levels</td> <td>Rare</td> <td>&#60;1 percent</td> </tr> <tr> <td>Ehrlichia ewingii infection</td> <td>Amblyomma americanum (lone star tick)</td> <td>South Atlantic and South Central United States to isolated areas of New England</td> <td>5-14</td> <td>Fever, headache, myalgia, nausea, and vomiting</td> <td>Leukopenia, thrombocytopenia, and elevated serum transaminase levels</td> <td>Rare</td> <td>No documented fatalities</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Treatment for each of these diseases is the same: adults, doxycycline 100 mg orally (PO) or intravenously (IV) twice daily; and children, doxycycline 2.2 mg/kg administered PO or IV twice daily.<br />¶ Mountain: Montana, Idaho, Wyoming, Colorado, New Mexico, Arizona, Utah, Nevada. East South Central: Kentucky, Tennessee, Alabama, Mississippi. East North Central: Ohio, Indiana, Illinois, Michigan, Wisconsin. West South Central: Arkansas, Louisiana, Oklahoma, Texas. West North Central: Minnesota, Iowa, Missouri, North Dakota, South Dakota, Nebraska, Kansas. Pacific: Washington, Oregon, California. New England: Massachusetts, Connecticut, Rhode Island, New Hampshire. South Atlantic: Delaware, Maryland, Virginia, District of Columbia, West Virginia, North Carolina, South Carolina, Georgia, Florida. Mid-Atlantic: New York, New Jersey, Pennsylvania.<br />Δ Although rash is present in approximately 90 percent of patients with RMSF, it is commonly absent at the time of a patient's first medical contact.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Walker DH, Raoult D. Rickettsia rickettsii and other spotted fever group rickettsiae (Rocky Mountain spotted fever and other spotted fevers). In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 6th ed. Philadelphia, PA: Churchill Livingstone; 2005:2287-95.</LI>&#xD;&#xA;<LI>Walker DH, Dumler JS. Ehrlichia chaffeensis (human monocytotropic ehrlichiosis), Anaplasma phagocytophilum (human granulocytotropic anaplasmosis) and other ehrlichiae. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 6th ed. Philadelphia, PA: Churchill Livingstone; 2005:2310-8.</LI>&#xD;&#xA;<LI>Demma LJ, Traeger MS, Nicholson WL, et al. Rocky Mountain spotted fever from an unexpected tick vector in Arizona. N Engl J Med 2005; 353:587-94.</LI>&#xD;&#xA;<LI>Champman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever, Ehrlichioses, and Anaplasmosis -- United States: A practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55(RR-4):1.</LI></OL></div><div id=\"graphicVersion\">Graphic 50677 Version 3.0</div></div></div>"},"50679":{"type":"graphic_table","displayName":"Treatment of parvovirus B19","title":"Treatment options for symptomatic parvovirus B19 infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment options for symptomatic parvovirus B19 infection</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Manifestation</td>\n\n      <td class=\"subtitle1\">Treatment options</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Erythema infectiosum</td>\n\n      <td>None or symptomatic</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Arthritis or arthralgia</td>\n\n      <td>Nonsteroidal antiinflammatory drugs</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Transient aplastic crisis</td>\n\n      <td>Transfusions and oxygen, if needed</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fetal hydrops</td>\n\n      <td>Intrauterine blood transfusion (?)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chronic infection with anemia</td>\n\n      <td>Intravenous immune globulin and transfusions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chronic infection without anemia</td>\n\n      <td>Intravenous immune globulin (?)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 50679 Version 1.0</div></div></div>"},"50680":{"type":"graphic_picture","displayName":"Capillary microthrombi mixed cryo light","title":"Capillary microthrombi in mixed cryoglobulinemia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Capillary microthrombi in mixed cryoglobulinemia</div><div class=\"cntnt\"><img style=\"width:378px; height:257px;\" src=\"images/NEPH/50680_CryoglobulinemiaLightII.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph in mixed cryoglobulinemia showing large cryoprecipitates occluding many of the capillary loops (arrows), called microthrombi.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50680 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"50682":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image of body stalk malformation","title":"Body stalk malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Body stalk malformation</div><div class=\"cntnt\"><img style=\"width:228px; height:446px;\" src=\"images/OBGYN/50682_U-S_body_stalk_malformation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple defects are evident in&nbsp;this fetus with a body stalk malformation. The upper and middle&nbsp;images show severe kyphoscoliosis. The lower&nbsp;image shows the abdominal wall defect with ectopia cordis (HT) and&nbsp;an omphalocele containing liver and bowel.</div><div class=\"graphic_footnotes\">Liv: liver; Bow: bowel.</div><div id=\"graphicVersion\">Graphic 50682 Version 3.0</div></div></div>"},"50683":{"type":"graphic_table","displayName":"Diabetic neuropathy score","title":"Michigan Diabetic Neuropathy Score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Michigan Diabetic Neuropathy Score</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td colspan=\"5\" rowspan=\"1\" class=\"subtitle1\">Sensory impairment</td>\n\n\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_left\">Right</td>\n\n\n      <td>Normal</td>\n\n\n      <td>Decreased</td>\n\n\n      <td>Absent</td>\n\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Vibration at big toe</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">10-g filament</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"1\" rowspan=\"2\" class=\"indent1\">Pin prick on dorsum of great toe</td>\n\n\n      <td>Painful</td>\n\n\n      <td>Not Painful</td>\n\n\n      <td colspan=\"1\" rowspan=\"1\">&nbsp;</td>\n\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      <td>0</td>\n\n\n      <td>2</td><td>&nbsp;</td>\n\n\n\n      \n\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_left\">Left</td>\n\n\n      <td>Normal</td>\n\n\n      <td>Decreased</td>\n\n\n      <td>Absent</td>\n\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Vibration at big toe</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">10-g filament</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"1\" rowspan=\"2\" class=\"indent1\">Pin prick on dorsum of great toe</td>\n\n\n      <td>Painful</td>\n\n\n      <td>Not Painful</td>\n\n\n      <td colspan=\"1\" rowspan=\"1\">&nbsp;</td>\n\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      <td>0</td>\n\n\n      <td>2</td><td>&nbsp;</td>\n\n\n\n      \n\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"5\" rowspan=\"1\" class=\"subtitle1\">Muscle strength testing</td>\n\n\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_left\">Right</td>\n\n\n      <td>Normal</td>\n\n\n      <td>Mild to moderate</td>\n\n\n      <td>Severe</td>\n\n\n      <td>Absent</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Finger spread</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n      <td>3</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Great toe extension</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n      <td>3</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Ankle dorsiflexion</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n      <td>3</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_left\">Left</td>\n\n\n      <td>Normal</td>\n\n\n      <td>Normal</td>\n\n\n      <td>Severe</td>\n\n\n      <td>Absent</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Finger spread</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n      <td>3</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Great toe extension</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n      <td>3</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Ankle dorsiflexion</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n      <td>3</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"5\" rowspan=\"1\" class=\"subtitle1\">Reflexes</td>\n\n\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_left\">Right</td>\n\n\n      <td>Present</td>\n\n\n      <td>Present with reinforcement</td>\n\n\n      <td>Absent</td>\n\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Biceps brachii</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Triceps brachii</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Quadriceps femoris</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Achilles</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_left\">Left</td>\n\n\n      <td>Present</td>\n\n\n      <td>Present with reinforcement</td>\n\n\n      <td>Absent</td>\n\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Biceps brachii</td>\n\n\n      <td>0</td>\n\n\n      <td>1</td>\n\n\n      <td>2</td>\n\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">Triceps brachii</td>\n\n      <td>0</td>\n\n      <td>1</td>\n\n      <td>2 </td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Quadriceps femoris</td>\n\n      <td>0 </td>\n\n      <td>1 </td>\n\n      <td>2 </td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Achilles</td>\n\n      <td>0</td>\n\n      <td>1</td>\n\n      <td>2</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n\n      <td colspan=\"5\" rowspan=\"1\"><strong>Total: 46 points</strong></td>\n</tr>\n\n\n  \n  </tbody>\n</table></div><div class=\"graphic_lgnd\">The findings from the clinical examination are scored on this form. Nerve conduction studies&nbsp;(of sural, peroneal motor, median sensory and motor, and ulnar sensory nerves) are graded separately. A composite score is then derived,&nbsp;based upon the number of points scored on the clinical examination (this form) and the number of abnormal nerve conductions.</div><div class=\"graphic_reference\">Adapted from: Feldman EL, Stevens MJ, Thomas PK, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17:1281.</div><div id=\"graphicVersion\">Graphic 50683 Version 2.0</div></div></div>"},"50684":{"type":"graphic_table","displayName":"Clin char Rx opts chondro","title":"Overview of clinical characteristics and therapeutic options in all subtypes of chondrosarcoma of bone","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of clinical characteristics and therapeutic options in all subtypes of chondrosarcoma of bone</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Conventional central chondrosarcoma</td> <td class=\"subtitle1\">Conventional peripheral chondrosarcoma</td> <td class=\"subtitle1\">Periosteal chondrosarcoma</td> <td class=\"subtitle1\">Dedifferentiated chondrosarcoma</td> <td class=\"subtitle1\">Mesenchymal chondrosarcoma</td> <td class=\"subtitle1\">Clear cell chondrosarcoma</td> </tr> <tr> <td><strong>Percent of all chondrosarcomas</strong></td> <td>~75 percent</td> <td>~10 percent</td> <td>&#60;1 percent</td> <td>~10 percent</td> <td>&#60;2 percent</td> <td>&#60;2 percent</td> </tr> <tr> <td><strong>Precursor lesion</strong></td> <td>Enchondroma (up to 40 percent?)</td> <td>Osteochondromas (100 percent)</td> <td>None</td> <td>Conventional chondrosarcoma</td> <td>None</td> <td>None</td> </tr> <tr> <td><strong>Occurrence within syndrome</strong></td> <td>Enchondromatosis (Ollier disease)</td> <td>Multiple osteochondromas</td> <td>None</td> <td>Rarely in multiple osteochondromas or enchondromatosis</td> <td>None</td> <td>None</td> </tr> <tr> <td><strong>Age</strong></td> <td>&#62;50 years</td> <td>Younger than central chondrosarcoma</td> <td>Peak at fourth decade</td> <td>Median age 59 years</td> <td>Any age (peak at second to third decade)</td> <td>Any age (peak in third to fifth decade)</td> </tr> <tr> <td><strong>Preferential location</strong></td> <td>Pelvis, proximal femur, proximal humerus, distal femur, ribs</td> <td>Pelvis, shoulder girdle bones</td> <td>Distal femur and humerus</td> <td>Femur and pelvis</td> <td> <p>65 to 86 percent skeleton (jawbones, ribs, ilium, vertebrae)</p> 14 to 43 percent extraosseous (meninges)</td> <td>Epiphysis of humeral or femoral head</td> </tr> <tr> <td><strong>Histological grading</strong></td> <td colspan=\"2\">Atypical cartilaginous tumour/chondrosarcoma grade 1 (ACT/CS1), grade 2 or 3</td> <td rowspan=\"2\">Prognosis usually good despite worrisome histology</td> <td>High grade</td> <td>High grade</td> <td>Low grade</td> </tr> <tr> <td><strong>Survival</strong></td> <td colspan=\"2\"> <p>ACT/CS1: 83 percent</p> <p>Grade 2: 64 percent</p> <p>Grade 3: 29 percent</p> All at 10 years</td> <td>24 percent at five years</td> <td>28 percent at 10 years</td> <td>89 percent at 10 years</td> </tr> <tr> <td><strong>Sensitivity to conventional chemotherapy</strong></td> <td>None</td> <td>None</td> <td>None</td> <td>Uncertain</td> <td>Possibly, if high percentage round cells</td> <td>None</td> </tr> <tr> <td><strong>Sensitivity to radiotherapy</strong></td> <td>Low</td> <td>Low</td> <td>Low</td> <td>Low</td> <td>Possibly high</td> <td>Low</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50684 Version 3.0</div></div></div>"},"50687":{"type":"graphic_table","displayName":"Treatments for hiccups","title":"Modalities used in the treatment of hiccups","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modalities used in the treatment of hiccups</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Physical maneuvers</td> </tr> <tr> <td>Breath holding</td> </tr> <tr> <td>Valsalva maneuver</td> </tr> <tr> <td>Breathing into bag</td> </tr> <tr> <td>Ice water gargles</td> </tr> <tr> <td>Swallowing granulated sugar, hard bread, or peanut butter</td> </tr> <tr> <td>Drinking from opposite side of glass</td> </tr> <tr> <td>Catheter or cotton swab stimulation of nasooropharynx</td> </tr> <tr> <td>Forceable traction on the tongue</td> </tr> <tr> <td>Biting on a lemon</td> </tr> <tr> <td>Fright</td> </tr> <tr> <td>Noxious odors (inhaling ammonia)</td> </tr> <tr> <td>Pressing on the eyeballs</td> </tr> <tr> <td>Pulling knees to chest or leaning forward to compress the chest</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Drug therapy</td> </tr> <tr> <td>Antipsychotics - chlorpromazine, haloperidol</td> </tr> <tr> <td>Anticonvulsants - phenytoin, valproic acid, carbamazepine, gabapentin</td> </tr> <tr> <td>Muscle relaxants - baclofen, cyclobenzaprine</td> </tr> <tr> <td>CNS stimulants - methylphenidate</td> </tr> <tr> <td>Antiarrhythmic drugs - quinidine sulfate</td> </tr> <tr> <td>Dopamine antagonists - metoclopramide</td> </tr> <tr> <td>Tricyclic antidepressants - amitriptyline</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50687 Version 5.0</div></div></div>"},"50688":{"type":"graphic_figure","displayName":"Flow by triggering","title":"Flow-by triggering in mechanical ventilation","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Flow-by triggering in mechanical ventilation</div><div class=\"cntnt\"><img style=\"width:460px; height:324px;\" src=\"images/PULM/50688_Flow_by_triggering.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow-by triggering involves the monitoring of gas flow through the circuit as it is passed by the patient. The machine is triggered once the return flow is less than delivered flow, due to the patient's inspiratory effort. The ventilator monitors return flow (left upper panel), which decreases as patient effort begins (left middle panel). The airway pressure and inspiratory flow required by flow triggering (red dashed arrows) are less than those required to trigger a demand valve (black solid arrows). Once the return flow has diminished, the base flow increases as the machine is triggered; increased gas flow is then delivered to the patient as shown in the graph in the upper right</div><div class=\"graphic_reference\">Adapted from Puritan Bennett 1994, Form AA-1495</div><div id=\"graphicVersion\">Graphic 50688 Version 1.0</div></div></div>"},"50690":{"type":"graphic_picture","displayName":"Retinal whitening","title":"Retinal whitening","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retinal whitening</div><div class=\"cntnt\"><img style=\"width:360px; height:375px;\" src=\"images/ID/50690_Retinal_whitening.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Whitening, a change seen in areas of the retina in patients with cerebral malaria. This mosaic-like appearance is the result of capillary non-perfusion. In the image on the lower right, the pathological whitening is in the perimacular area, similar to the upper left image. The extra-macular changes are reflections from flash on the fundus camera.</div><div class=\"graphic_reference\">Courtesy of Susan Lewallen and Nicholas Beare.</div><div id=\"graphicVersion\">Graphic 50690 Version 4.0</div></div></div>"},"50691":{"type":"graphic_algorithm","displayName":"Amniochorionic inflammation","title":"Amniochorionic inflammation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amniochorionic inflammation</div><div class=\"cntnt\"><img style=\"width:326px; height:314px;\" src=\"images/OBGYN/50691_Amniochorionic_inflammation.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CRH: corticotropin releasing hormone; TNF: tumor necrosis factor; IL: interleukin; PG: prostaglandins.</div><div class=\"graphic_reference\">Courtesy of Charles Lockwood, MD.</div><div id=\"graphicVersion\">Graphic 50691 Version 2.0</div></div></div>"},"50692":{"type":"graphic_picture","displayName":"Severe neutrophilic chorioamnionitis","title":"Severe neutrophilic (acute) chorioamnionitis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Severe neutrophilic (acute) chorioamnionitis</div><div class=\"cntnt\"><img style=\"width:540px; height:384px;\" src=\"images/OBGYN/50692_Severe_acute_chorioamnionit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrow points to amniotic epithelium. Yellow asterisk shows inflammation in severe neutrophilic (acute) chorioamnionitis.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 50692 Version 3.0</div></div></div>"},"50693":{"type":"graphic_figure","displayName":"Trachelectomy cerclage PI","title":"Cerclage placed after trachelectomy","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Cerclage placed after trachelectomy</div><div class=\"cntnt\"><img style=\"width:543px; height:314px;\" src=\"images/PI/50693_Trachelectomy_cerclage_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radical trachelectomy is defined as partial or complete surgical removal of the cervix and parametria (connective tissue next to the uterus and cervix). Trachelectomy may be done through an incision in the vagina or abdomen, depending upon the surgeon's preference. The cervix and upper portion of the vagina may be completely or partially removed, depending upon the size and depth of the cancer. A permanent purse-string (cerclage) is placed at the lower end of the uterus or remaining cervix.</div><div id=\"graphicVersion\">Graphic 50693 Version 4.0</div></div></div>"},"50695":{"type":"graphic_table","displayName":"Treatment of neuronopathic GD","title":"Summary of European consensus guidelines for treatment of neuronopathic Gaucher disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of European consensus guidelines for treatment of neuronopathic Gaucher disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">ERT with imiglucerase</td> </tr> <tr> <td class=\"subtitle2_single\">Indications:</td> </tr> <tr> <td class=\"indent1\">Patients with <strong>chronic neuronopathic</strong> (type 3) GD*.</td> </tr> <tr> <td class=\"indent1\">Siblings of patients with chronic neuronopathic GD who are proven to have GD.</td> </tr> <tr> <td class=\"indent1\">Patients with the following high-risk genotypes:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>L444P/L444P (c.1448T&#62;C homozygote) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>D409H/D409H (c.1342G&#62;C homozygote) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>L444P/D409H (c.1448T&#62;C/c.1342G&#62;C heterozygote) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Onset of severe systemic GD at &#8804;2 years of age.</td> </tr> <tr> <td class=\"subtitle2_single\">Dose:</td> </tr> <tr> <td class=\"indent1\">60 units/kg every two weeks<sup>&#916;</sup>, initiated as soon as possible after diagnosis or identification.</td> </tr> <tr> <td class=\"subtitle2_single\">Duration:</td> </tr> <tr> <td class=\"indent1\">Treatment with 60 units/kg every two weeks should be continued until the patient attains adulthood and clearly has mild GD and stable neurologic involvement. At this point a dose reduction (to as low as 30 units/kg every two weeks) may be considered.</td> </tr> <tr> <td class=\"subtitle2_single\">Splenectomy:</td> </tr> <tr> <td class=\"indent1\">Total splenectomy should be avoided if at all possible. Partial, rather than total, splenectomy should be considered if splenectomy is required in an emergency situation.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ERT: enzyme-replacement therapy; GD: Gaucher disease.<br />* ERT is <strong>not</strong> recommended for patients with acute neuronopathic disease (type 2 GD). ERT for nonneuronopathic GD is reviewed separately.<br />&Delta; Higher doses may be necessary to control visceral disease.</div><div class=\"graphic_reference\">Adapted from: Vellodi A, Bembi B, de Villemeur TB, et al. Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 2001; 24:319 and Vellodi A, Tylki-Szymanska A, Davies EH, et al. Management of neuronopathic Gaucher disease: Revised recommendations. J Inherit Metab Dis 2009; 32:660.</div><div id=\"graphicVersion\">Graphic 50695 Version 6.0</div></div></div>"},"50696":{"type":"graphic_diagnosticimage","displayName":"CMV pneumonitis 1","title":"Cytomegalovirus pneumonitis in an immunosuppressed patient","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Cytomegalovirus pneumonitis in an immunosuppressed patient</div><div class=\"cntnt\"><img style=\"width:514px; height:175px;\" src=\"images/ID/50696_CMVpneumon1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A and B) Acute cytomegalovirus pneumonitis in an immunosuppressed patient. Patchy ground-glass opacities are&nbsp;visible bilaterally.</div><div class=\"graphic_reference\">Reproduced with permission from: Webb WR, Muller NL, Naidich DP. Infections. In: High-resolution CT of the Lung, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50696 Version 11.0</div></div></div>"},"50697":{"type":"graphic_picture","displayName":"Nodular sarcoidosis - rhinophymatous","title":"Nodular sarcoidosis - rhinophymatous","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular sarcoidosis - rhinophymatous</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/50697_Nodular_sarcoidosis_rhino.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rhinophymatous nodular sarcoidosis. Diffuse enlargement of the nose with granulomatous infiltration resembling rhinophyma is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50697 Version 3.0</div></div></div>"},"50698":{"type":"graphic_table","displayName":"Cisplatin and paclitaxel for SCC of cervix","title":"Cisplatin and paclitaxel for stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cisplatin and paclitaxel for stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Paclitaxel</td> <td>135 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL normal saline (NS) or 5% dextrose in water (D5W) and administer over 24 hours.*</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Cisplatin</td> <td>50 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 mL 0.09% sodium chloride for injection and administer at a rate of 1 mg/min immediately after paclitaxel. Do not administer with aluminum needles or intravenous sets.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Induction of diuresis using intravenous NS minimizes the risk of cisplatin nephrotoxicity. Fluid administration should be adequate to establish a urine flow of at least 100 mL/hour for two hours prior to and two hours after cisplatin administration. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on prevention. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedicate with dexamethasone plus both an H1 and an H2 receptor antagonist prior to paclitaxel administration. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Paclitaxel and cisplatin are irritants but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF not indicated. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Dose reductions are required for cisplatin in renal insufficiency. The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Patients with a serum creatinine level &#62;2 mg/dL were excluded from the original trial.<sup>[1]</sup> For patients with preexisting hepatic impairment, dose adjustments for paclitaxel may be needed.<sup>[2]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Basic metabolic panel (creatinine and electrolytes) prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Liver function tests prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor neurotoxicity and monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Repeat cycles should not begin until the ANC count is &#62;1500 cells/microL and platelets are &#62;100,000/microL. Reduce paclitaxel to 110 mg/m<sup>2</sup> for grade 3 or 4 neutropenic fever or grade 4 thrombocytopenia. If patients have an episode of febrile neutropenia or persistent neutropenia that prevents treatment on schedule, secondary prevention with support-CSF is suggested in addition to a reduction in paclitaxel dose to 110 mg/m<sup>2</sup>. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Reduce cisplatin dose to 25 mg/m<sup>2</sup> and paclitaxel dose to 90 mg/m<sup>2</sup> for grade 2 neurotoxicity or ototoxicity and discontinue treatment for &#8805;grade 3 neurotoxicity.<sup>[1]</sup> Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of non-platinum cancer chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Nephrotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Withhold treatment for persistent elevation of creatinine to &#62;2 mg/dL.<sup>[1]</sup> If elevation persists more than six weeks after a previous dose, discontinue cisplatin. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Nausea and vomiting</strong></td> <td colspan=\"3\"> <ul> <li>Reduce cisplatin dose to 37.5 mg/m<sup>2</sup> for grade 4 nausea and vomiting uncontrolled with appropriate anti-emesis support (refer to \"Emesis risk\" above). </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Repeat cycles should not begin until the bilirubin &#8804;1.5 times normal, and aspartate aminotransferase and alkaline phosphatase are &#8804;3 times normal.<sup>[1]</sup> Discontinue paclitaxel for grade 3 or 4 hepatotoxicity. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony-stimulating factors; CBC: complete blood count; ANC: absolute neutrophil count; CSF: colony-stimulating factors.<br />* Paclitaxel can be administered in NS, D5W, or NS/D5W at varying concentrations between 0.3 to 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-lined administration sets with a microporous membrane 0.22 microns or less.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Moore DB, et al. J Clin Oncol 2004; 22:3113.</LI>&#xD;&#xA;<LI>Paclitaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 20, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 50698 Version 12.0</div></div></div>"},"50700":{"type":"graphic_table","displayName":"Bleeding risk GI procedure","title":"Procedure-related bleeding risk from gastrointestinal procedures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Procedure-related bleeding risk from gastrointestinal procedures</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Higher-risk procedures</td> </tr> <tr> <td class=\"indent1\">Polypectomy*</td> </tr> <tr> <td class=\"indent1\">Biliary or pancreatic sphincterotomy</td> </tr> <tr> <td class=\"indent1\">Treatment of varices</td> </tr> <tr> <td class=\"indent1\">PEG placement<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Therapeutic balloon-assisted enteroscopy</td> </tr> <tr> <td class=\"indent1\">EUS with FNA<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Endoscopic hemostasis</td> </tr> <tr> <td class=\"indent1\">Tumor ablation</td> </tr> <tr> <td class=\"indent1\">Cystgastrostomy</td> </tr> <tr> <td class=\"indent1\">Ampullary resection</td> </tr> <tr> <td class=\"indent1\">EMR</td> </tr> <tr> <td class=\"indent1\">Endoscopic submucosal dissection</td> </tr> <tr> <td class=\"indent1\">Pneumatic or bougie dilation</td> </tr> <tr> <td class=\"indent1\">PEJ</td> </tr> <tr> <td class=\"subtitle1_single\">Low-risk procedures</td> </tr> <tr> <td class=\"indent1\">Diagnostic (EGD, colonoscopy, flexible sigmoidoscopy) including mucosal biopsy</td> </tr> <tr> <td class=\"indent1\">ERCP with stent (biliary or pancreatic) placement or papillary balloon dilation without sphincterotomy</td> </tr> <tr> <td class=\"indent1\">Push enteroscopy and diagnostic balloon-assisted enteroscopy</td> </tr> <tr> <td class=\"indent1\">Capsule endoscopy</td> </tr> <tr> <td class=\"indent1\">Enteral stent deployment (controversial)</td> </tr> <tr> <td class=\"indent1\">EUS without FNA</td> </tr> <tr> <td class=\"indent1\">Argon plasma coagulation</td> </tr> <tr> <td class=\"indent1\">Barrett's ablation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EGD: esophagogastroduodenoscopy; ERCP: endoscopic retrograde cholangiopancreatography; PEG: percutaneous endoscopic gastrostomy; EUS: endoscopic ultrasound; FNA: fine-needle aspiration; EMR: endoscopic mucosal resection; PEJ: percutaneous endoscopic jejunostomy.<br />* Among patients undergoing colonic polypectomy, the size of the polyp influences the risk of bleeding, and it may be more appropriate to categorize polyps less than 1 cm in size as low-risk for bleeding.<br />¶ PEG on aspirin or clopidogrel therapy is low risk. Does not apply to dual antiplatelet therapy.<br />Δ EUS-FNA of solid masses on <SPAN style=\"COLOR: black\">aspirin</SPAN>/nonsteroidal anti-inflammatory drugs&nbsp;is low risk.</div><div class=\"graphic_reference\">Reproduced from: ASGE Standards of Practice Committee, Acosta RD, Abraham NS, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc 2016; 83:3. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 50700 Version 7.0</div></div></div>"},"50701":{"type":"graphic_picture","displayName":"Giardia trophozoite","title":"<EM>Giardia</EM> trophozoite","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Giardia</EM> trophozoite</div><div class=\"cntnt\"><img style=\"width:380px; height:252px;\" src=\"images/PC/50701_Giardia_trophozoite.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power microscopy revealing <EM>Giardia</EM> trophozoite with easily identified flagella. <EM>Giardia</EM> trophozoites measure 10 to 20 micrometers in length. &nbsp;</div><div class=\"graphic_reference\">Courtesy of Jack D Sobel, MD.</div><div id=\"graphicVersion\">Graphic 50701 Version 4.0</div></div></div>"},"50703":{"type":"graphic_table","displayName":"Bursae assessable by ultrasound","title":"Bursae of the human body that may become inflamed","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bursae of the human body that may become inflamed</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\t\t<tr>\r\t\t\t\t\t\t<td rowspan=\"2\">Shoulder</td>\r\t\t\t\t\t\t<td>Subdeltoid-subacromial bursa</td>\r\t\t\t\t\t\t\r\t\t\t\t\t</tr>\r\t\t\t\t\t<tr>\r\t\t\t\t\t\t\r\t\t\t\t\t\t<td>Subcoracoideal bursa*</td>\r\t\t\t\t\t\t\r\t\t\t\t\t</tr>\r\t\t\t\t\t<tr>\r\t\t\t\t\t\t<td>Elbow</td>\r\t\t\t\t\t\t<td>Olecranon bursa</td>\r\t\t\t\t\t\t\r\t\t\t\t\t</tr>\r\t\t\t\t\t<tr>\r\t\t\t\t\t\t<td>Hip</td>\r\t\t\t\t\t\t<td>Iliopsoas bursa*, trochanteric bursa</td>\r\t\t\t\t\t\t\r\t\t\t\t\t</tr>\r\t\t\t\t\t<tr>\r\t\t\t\t\t\t<td>Knee</td>\r\t\t\t\t\t\t<td>Suprapatellar bursa (also called superior recess or pouch), prepatellar bursa, superficial and deep infrapatellar bursa, gastrocnemius-semimembranosus bursa*, iliotibial tract bursa, medial and lateral collateral ligament bursa, anserine bursa</td>\r\t\t\t\t\t\t\r\t\t\t\t\t</tr>\r\t\t\t\t\t<tr>\r\t\t\t\t\t\t<td>Ankle</td>\r\t\t\t\t\t\t<td>Superficial and deep (retrocalcaneal) Achilles bursa</td>\r\t\t\t\t\t\t\r\t\t\t\t\t</tr>\r\t\t\t\t\t<tr>\r\t\t\t\t\t\t<td>Forefoot</td>\r\t\t\t\t\t\t<td>4 intermetatarsophalangeal bursae</td>\r\t\t\t\t\t\t\r\t\t\t\t\t</tr>\r\r\t\t</table></div><div class=\"graphic_footnotes\">* Bursa communicates with joint.</div><div id=\"graphicVersion\">Graphic 50703 Version 1.0</div></div></div>"},"50704":{"type":"graphic_diagnosticimage","displayName":"Hip arthritis in HH","title":"Hip arthritis in hemochromatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hip arthritis in hemochromatosis</div><div class=\"cntnt\"><img style=\"width:212px; height:292px;\" src=\"images/RHEUM/50704_Hip_arthritis_in_HH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hip radiograph from a patient with hereditary haemochromatosis. The most prominent abnormality is a zone of subchondral radiolucency in the superior pole with some adjacent sclerosis. There is also modest overall hyaline cartilage thinning and minor osteophytosis.</div><div class=\"graphic_reference\">Courtesy of John S Axford, BSc, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 50704 Version 2.0</div></div></div>"},"50705":{"type":"graphic_diagnosticimage","displayName":"Popliteal aneurysm on CT angiography","title":"Popliteal aneurysm on CT angiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Popliteal aneurysm on CT angiography</div><div class=\"cntnt\"><img style=\"width:300px; height:506px;\" src=\"images/SURG/50705_Pop_aneur_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT angiogram demonstrates a large right popliteal artery aneurysm and tortuous distal superficial femoral artery. The true diameter of the aneurysm must be measured from cross-sectional two-dimensional images; this three-dimensional CT reconstruction shows only regions where intravenous contrast is present.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Amy B Reed, MD.</div><div id=\"graphicVersion\">Graphic 50705 Version 4.0</div></div></div>"},"50706":{"type":"graphic_figure","displayName":"SEER incidence prostate 2000 to 2006","title":"Age-specific (crude) SEER* prostate cancer<SUP>•</SUP> incidence rates, all ages, all races, male (2000 to 2006)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Age-specific (crude) SEER* prostate cancer<SUP>•</SUP> incidence rates, all ages, all races, male (2000 to 2006)</div><div class=\"cntnt\"><img style=\"width:417px; height:384px;\" src=\"images/ONC/50706_SEER_incidence_graph.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SEER: Surveillance, Epidemiology and End Results.<br> * SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey).<br> <span class=bullet>•</span> Cancer sites include invasive cases unless otherwise noted.</div><div class=\"graphic_reference\">Data from: <a href=\"http://seer.cancer.gov/\">seer.cancer.gov</a>.</div><div id=\"graphicVersion\">Graphic 50706 Version 6.0</div></div></div>"},"50707":{"type":"graphic_table","displayName":"Causes of aortic regurgitation","title":"Causes of aortic regurgitation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of aortic regurgitation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Primary cause of aortic regurgitation</td> <td class=\"subtitle1\">Valve disease</td> <td class=\"subtitle1\">Aortic root dilation</td> </tr> <tr> <td>Calcific aortic valve disease</td> <td class=\"centered\">X</td> <td>&nbsp;</td> </tr> <tr> <td>Myxomatous degeneration</td> <td class=\"centered\">X</td> <td>&nbsp;</td> </tr> <tr> <td>Congenital heart disease</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Bicuspid aortic valve</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">High ventricular septal defect (infundibular or membranous)</td> <td class=\"centered\">X</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Sinus of valsalva aneurysm</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Fenestrated leaflet*</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Rheumatic heart disease</td> <td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;X</td> <td>&nbsp;</td> </tr> <tr> <td>Genetic syndromes</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Marfan syndrome</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Familial thoracic aneurysm</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Ehlers-Danlos syndrome</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Osteogenesis imperfecta</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Pseudoxanthoma elasticum</td> <td class=\"centered\">X</td> <td>&nbsp;</td> </tr> <tr> <td>Systemic rheumatic disorders</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Giant cell arteritis</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Takayasu arteritis</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Ankylosing spondylitis</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Rheumatoid arthritis</td> <td class=\"centered\">X</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">&nbsp;Systemic lupus erythematosus</td> <td class=\"centered\">X</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">&nbsp;Antiphospholipid syndrome</td> <td class=\"centered\">X</td> <td>&nbsp;</td> </tr> <tr> <td>Drug-induced valve disease (eg, fenfluramine-phentermine)</td> <td class=\"centered\">X</td> <td>&nbsp;</td> </tr> <tr> <td>Infection</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Endocarditis</td> <td class=\"centered\">X</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Infectious aortitis (eg, syphilis)</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td>Aortic dissection</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td>Hypertension</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td>Trauma (causing aortic dissection or aortic valve injury)</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td>Other genetic and acquired causes of annuloaortic ectasia</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Aortic leaflet fenestration or perforation may also be seen with myxomatous degeneration or endocarditis.</div><div id=\"graphicVersion\">Graphic 50707 Version 7.0</div></div></div>"},"50708":{"type":"graphic_figure","displayName":"Effects of diet and exercise on lipids are sex dependent ","title":"The effects of diet and exercise on lipids are different in men and women","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">The effects of diet and exercise on lipids are different in men and women</div><div class=\"cntnt\"><img style=\"width:502px; height:218px;\" src=\"images/CARD/50708_Exercise_diet_men_women.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The effects of a prudent weight-reducing diet with (DE) or without exercise (D) in overweight men and women compared to control (C) on serum triglycerides (T), low density lipoprotein cholesterol (LDL), and high density lipoprotein cholesterol (HDL). In men, diet plus exercise reduced serum triglycerides and raised serum HDL cholesterol compared to control or diet alone. In women, exercise abolished the increase in serum triglycerides and reduction in serum HDL cholesterol levels that occurred with diet alone.</div><div class=\"graphic_reference\">Data from Wood PD, Stefanick ML, Williams PT, et al. N Engl J Med 1991; 325:461.</div><div id=\"graphicVersion\">Graphic 50708 Version 3.0</div></div></div>"},"50710":{"type":"graphic_diagnosticimage","displayName":"Malignant mesothelioma II MRI","title":"Malignant mesothelioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant mesothelioma</div><div class=\"cntnt\"><img style=\"width:360px; height:325px;\" src=\"images/PULM/50710_Malignant_mesothelioma_II_M.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI scan, axial, T2 weighted spin-echo sequence, shows pleural effusion displays high signal intensity. No chest wall invasion is present.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 50710 Version 4.0</div></div></div>"},"50711":{"type":"graphic_form","displayName":"Monthly pain scale","title":"Monthly pain scale","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Monthly pain scale</div><div class=\"cntnt\"><img style=\"width:590px; height:387px;\" src=\"images/PULM/50711_Pain_scale_edit.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 50711 Version 5.0</div></div></div>"},"50712":{"type":"graphic_table","displayName":"Differential dx fibromyalgia","title":"Differential diagnosis of fibromyalgia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of fibromyalgia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Diagnosis</td>\n<td class=\"subtitle1\">Helpful features</td>\n</tr>\n<tr>\n<td>Rheumatoid arthritis or lupus</td>\n<td>Symmetrical polyarthritis, systemic features (dermatitis,\nnephritis), elevated erythrocyte sedimentation rate, serologic\nabnormalities (rheumatoid factor, anti-DNA antibodies)</td>\n</tr>\n<tr>\n<td>Polymyalgia rheumatica</td>\n<td>Elderly, elevated erythrocyte sedimentation rate, stiffness&#62;pain, responds well and quickly to steroids</td>\n</tr>\n<tr>\n<td>Myositis</td>\n<td>Muscle weakness, elevated muscle enzymes</td>\n</tr>\n<tr>\n<td>Hypothyroidism</td>\n<td>Abnormal thyroid function tests</td>\n</tr>\n<tr>\n<td>Hyperparathyroidism</td>\n<td>Hypercalcemia</td>\n</tr>\n<tr>\n<td>Neuropathies</td>\n<td>Clinical and electrical evidence of neuropathy</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 50712 Version 1.0</div></div></div>"},"50715":{"type":"graphic_picture","displayName":"Helmet cells","title":"Helmet cells in microangiopathic hemolytic anemia","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Helmet cells in microangiopathic hemolytic anemia</div><div class=\"cntnt\"><img style=\"width:472px; height:295px;\" src=\"images/HEME/50715_Helmet_cells.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral smears from two patients with microangiopathic hemolytic anemia, showing a number of red cell fragments (ie, schistocytes), some of which take the form of combat (arrow), bicycle (arrowhead), or football (short arrow) \"helmets.\" Microspherocytes are also seen (dashed arrows), along with a nucleated red cell (thick arrow).</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 50715 Version 4.0</div></div></div>"},"50716":{"type":"graphic_table","displayName":"Antiarrhythmic drugs in pregnancy","title":"Antiarrhythmic drugs in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antiarrhythmic drugs in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Pregnancy</td> <td class=\"subtitle1\">Breastfeeding</td> </tr> <tr> <td>Amiodarone</td> <td>Has been associated with serious adverse effects. Congenital goiter/hypothyroidism and hyperthyroidism can occur after in utero exposure. Other potential risks include prolonged QT interval in neonates.</td> <td>Not recommended because of potential risk of hypothyroidism in neonate.</td> </tr> <tr> <td>Beta blockers</td> <td> <p>No evidence of increased risk of teratogenesis, but some (particularly atenolol) may impair fetal growth when used for a prolonged duration in the second and third trimesters. Use only in the third trimester is associated with reduced placental weight.</p> <p>Newborns of women taking these drugs near delivery are at risk of bradycardia, hypoglycemia, and other symptoms of beta-blockade.</p> <p>Among this class of drugs, atenolol appears to have the most unfavorable effect on birthweight.</p> </td> <td> <p>AAP considers these agents compatible with breastfeeding, but newborns should be observed for signs of beta-blockade.</p> <p>Atenolol is a weak base that will accumulate in milk. Accumulation is enhanced by its water-soluble, low protein binding, little or no hepatic metabolism, and renal excretion properties. Because it has been associated with beta-blocking effects and cyanosis in nursing infants, it is best avoided during breastfeeding.</p> </td> </tr> <tr> <td>Sotalol</td> <td>Sotalol, which has both beta blocker and type III antiarrhythmic properties, is not teratogenic, and its use has not been associated with fetal growth restriction. Its use near birth has been associated with newborn bradycardia.</td> <td>Sotalol is concentrated in breast milk, with milk levels several-fold higher than those in maternal plasma, so close monitoring for bradycardia, hypotension, respiratory distress, and hypoglycemia is advised.</td> </tr> <tr> <td>Adenosine</td> <td>No evidence of increased risk of teratogenesis or increased risk of adverse fetal/neonatal effects.</td> <td>No information. Because of very short half-life, it is unlikely to have any adverse effects on the neonate.</td> </tr> <tr> <td>Digoxin</td> <td>No evidence of increased risk of teratogenesis or increased risk of adverse fetal/neonatal effects.</td> <td>AAP considers digoxin compatible with breastfeeding.</td> </tr> <tr> <td>Verapamil</td> <td>No evidence of increased risk of teratogenesis or increased risk of adverse fetal/neonatal effects.</td> <td>AAP considers verapamil compatible with breastfeeding.</td> </tr> <tr> <td>Procainamide</td> <td>No evidence of increased risk of teratogenesis or increased risk of adverse fetal/neonatal effects.</td> <td>AAP classifies procainamide as compatible with breastfeeding. However, the long-term effects of exposure in the nursing infant are unknown, particularly with respect to potential drug toxicity (eg, development of antinuclear antibodies and lupus-like syndrome).</td> </tr> <tr> <td>Quinidine</td> <td>No evidence of increased risk of teratogenesis. In therapeutic doses, the oxytocic properties of quinidine have been rarely observed, but high doses can produce this effect and may result in preterm labor or abortion.</td> <td>AAP considers quinidine compatible with breastfeeding.</td> </tr> <tr> <td>Flecainide</td> <td>Developmental toxicity has been noted in animals, but limited information on human risk from early pregnancy exposure. This risk appears to be low when used for refractory fetal arrhythmia. It may be the treatment of choice for tachycardia in hydropic fetuses.</td> <td>AAP considers flecainide compatible with breastfeeding.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation, 8th edition. Philadelphia: Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50716 Version 7.0</div></div></div>"},"50718":{"type":"graphic_table","displayName":"Alternate forms of tobacco","title":"Alternate forms of tobacco","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Alternate forms of tobacco</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup span=\"2\" width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Alternate names</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Smoked tobacco</td> </tr> <tr> <td class=\"indent1\">Cigar</td> <td>Cigarillo, figurado</td> <td>&nbsp;</td> <td>Depending on size, nicotine content may be up to 4 times that of a cigarette.</td> </tr> <tr> <td class=\"indent1\">Hookah</td> <td>Pipes, waterpipe, hubble bubble, narghile, shisha</td> <td>Lit tobacco bubbles through water and inhaled through a shared mouthpiece.</td> <td>Use of black 'air-cured' tobacco has higher risk of esophageal cancer. The filtering effect of water does not make it less dangerous.</td> </tr> <tr> <td class=\"indent1\">Bidi</td> <td>&nbsp;</td> <td>Hand-rolled, leaf-wrapped cigarette, often with sweet flavors such as chocolate or cherry.</td> <td>Nicotine content is 3 to 5 times that of a cigarette.</td> </tr> <tr> <td class=\"indent1\">Kretek</td> <td>Clove cigarette</td> <td>Rolled mixture of tobacco, cloves, and other additives.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Heat-not-burn tobacco cigarette&nbsp;</td> <td>HNB cigarette</td> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Electric blade heats tobacco stick to much lower temperature than a tobacco cigarette.</span></td> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Nicotine content is &#62;80 percent of a traditional tobacco cigarette. Contains lower amounts of&nbsp;some other&nbsp;harmful constituents&nbsp;compared with&nbsp;the smoke of a traditional cigarette.<sup>[1]</sup></span>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Smokeless tobacco</td> </tr> <tr> <td class=\"indent1\">Chewing tobacco</td> <td>Chew, spit tobacco</td> <td>Shredded tobacco leaves, often sweetened, and available as loose-leaf, \"plug\" or \"twist\". It is used by holding it in the mouth between the gum and cheek.</td> <td>Chewing tobacco is associated with substantial risks for gum disease, mouth cancer, and oral sores; it also causes stained teeth, bad breath, and loss of taste.</td> </tr> <tr> <td class=\"indent1\">Snuff</td> <td>Pinch, dip</td> <td>Finely ground tobacco, either dry or moist. Dry snuff is usually inhaled through the nostrils; moist snuff is usually held in the mouth for absorption, similar to chewing tobacco.</td> <td>Similar to above chewing tobacco.</td> </tr> <tr> <td class=\"indent1\">Snus</td> <td>&nbsp;</td> <td>A form of moist snuff, dispensed in packets or sachets. These are held in the mouth for absorption, similar to chewing tobacco, but designed so that spitting is not required.</td> <td>Nicotine content is 2 to 6 times that of a cigarette.</td> </tr> <tr> <td class=\"indent1\">Dissolvable tobacco</td> <td>&nbsp;</td> <td>Dissolvable tobacco strips, sticks, or orbs (pellets similar to tic-tac candies).</td> <td>Delivers 1/2 to 2 times the nicotine of a cigarette. Allows for covert use of tobacco; risk of inadvertent toxic ingestion by young children. High content of un-ionized nicotine leads to rapid absorption and potentially increases nicotine toxicity.</td> </tr> <tr> <td class=\"indent1\">Electronic cigarette</td> <td>e-cigarette, vapor cigarette, electronic nicotine delivery system (ENDS)</td> <td>Battery powered device that provides doses of nicotine for inhalation. A nicotine-containing liquid is put into the device in a cartridge or in drops. Available in a variety of flavors.</td> <td>E-cigarettes are widely available from internet sources. Health risks relative to cigarette smoking, and value in smoking cessation, if any, remain unclear.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>​Auer R, Concha-Lozano N, Jacot-Sadowski I, et al. Heat-Not-Burn Tobacco Cigarettes: Smoke by Any Other Name. JAMA Intern Med 2017; 177:1050.</LI></OL></div><div id=\"graphicVersion\">Graphic 50718 Version 9.0</div></div></div>"},"50719":{"type":"graphic_figure","displayName":"Ileocolic anastomosis created with a circular stapler","title":"Ileocolic anastomosis created with a circular stapler","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ileocolic anastomosis created with a circular stapler</div><div class=\"cntnt\"><img style=\"width:363px; height:413px;\" src=\"images/SURG/50719_Ileocoloic-anastomosis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 50719 Version 2.0</div></div></div>"},"50722":{"type":"graphic_table","displayName":"Extended-interval initial dosing","title":"Extended interval aminoglycoside dose and dosing interval in adults by renal function","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Extended interval aminoglycoside dose and dosing interval in adults by renal function</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Creatinine clearance* (mL/min/70 kg)</td> <td class=\"subtitle1\">Initial and maintenance dose<sup>&#182;</sup></td> <td class=\"subtitle1\">Initial dosing interval (hours)</td> </tr> <tr> <td>&#8805;120</td> <td colspan=\"2\">Use traditional intermittent dosing</td> </tr> <tr> <td rowspan=\"3\">60 to 119</td> <td class=\"sublist1_start\">Infuse over 1 hour:</td> <td rowspan=\"3\">24</td> </tr> <tr> <td class=\"indent1\">7 mg/kg for gentamicin or tobramycin</td> </tr> <tr> <td class=\"indent1\">15 mg/kg for amikacin</td> </tr> <tr> <td rowspan=\"3\">40 to 59</td> <td class=\"sublist1_start\">Infuse over 1 hour:</td> <td rowspan=\"3\">36 (or use traditional intermittent dosing)</td> </tr> <tr> <td class=\"indent1\">7 mg/kg for gentamicin or tobramycin</td> </tr> <tr> <td class=\"indent1\">15 mg/kg for amikacin</td> </tr> <tr> <td>&#60;40<sup>&#916;</sup></td> <td colspan=\"2\">Use traditional intermittent dosing</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The maintenance dose and dosing intervals may need to be adjusted based on results of serum drug concentration monitoring. This is discussed in the topic review of aminoglycoside dosing, section on drug concentration monitoring. Extended interval aminoglycoside dosing is not recommended for particular indications and populations. As an example, the doses listed in this table do NOT apply to aminoglycosides being used as synergistic therapy for gram positive infections or aminoglycoside use in cystic fibrosis patients. Such exclusions are discussed in more detail in the topic on aminoglycoside dosing.</div><div class=\"graphic_footnotes\">* Creatinine clearance may be estimated by use of Cockroft-Gault equation. Calculators for estimation of creatinine clearance are available in UpToDate.<br />&para; The appropriate dosing weight to use for dose calculation is discussed in the topic on aminoglycoside dosing.<br />&Delta; Some institutions use a lower threshold of 20 to 30 mL/min for using traditional intermittent instead of extended interval dosing. In such cases, for patients who have a creatinine clearance between this lower limit and 40 mL/min, the calculated aminoglycoside dose is administered at a 48-hour interval.</div><div id=\"graphicVersion\">Graphic 50722 Version 6.0</div></div></div>"},"50724":{"type":"graphic_movie","displayName":"Anterior wall MI four chamber echo 2","title":"Anterior wall myocardial infarction","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior wall myocardial infarction</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/50724_4chanmi2conv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:264px; height:449px;\" src=\"images/CARD/50724_4chanmi2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four chamber view from a 2-D echocardiogram shows a large area of hypokinesis and akinesis of the anterior wall and apex of the left ventricle. The left ventricular wall and interventricular septum are thin and fail to thicken during systole.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 50724 Version 2.0</div></div></div>"},"50725":{"type":"graphic_table","displayName":"Hypertension treatment for thrombolysis","title":"Options to treat to hypertension before and during reperfusion therapy for acute ischemic stroke","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Options to treat to hypertension&nbsp;before and during&nbsp;reperfusion therapy for acute ischemic stroke</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Patient otherwise eligible for acute reperfusion therapy except that blood pressure is &#62;185/110 mmHg*</td> </tr> <tr> <td class=\"indent2\">Labetalol 10 to 20 mg intravenously over 1 to 2 minutes, may repeat one time; <strong>or</strong></td> </tr> <tr> <td class=\"indent2\">Nicardipine 5 mg/hour intravenously, titrate up by 2.5 mg/hour every 5 to 15 minutes, maximum 15 mg/hour; when desired blood pressure reached, adjust to maintain proper blood pressure limits; <strong>or</strong></td> </tr> <tr> <td class=\"indent2\">Clevidipine 1 to 2 mg/hour intravenously, titrate by doubling the dose every 2 to 5 minutes, maximum 21 mg/hour, until desired blood pressure reached<sup>&#182;</sup>; <strong>or</strong></td> </tr> <tr> <td class=\"indent2\">Other agents (hydralazine, enalaprilat, etc) may also be considered</td> </tr> <tr> <td class=\"indent1\">If blood pressure is not maintained at or below 185/110 mmHg, do <strong>not</strong> administer alteplase</td> </tr> <tr> <td class=\"subtitle1_single\">Management to maintain blood pressure at or below 180/105 mmHg during and after acute reperfusion therapy*</td> </tr> <tr> <td class=\"indent1\">Monitor blood pressure every 15 minutes for 2 hours from the start of rtPA therapy, then every 30 minutes for 6 hours, and then every hour for 16 hours</td> </tr> <tr> <td class=\"indent1\">If systolic blood pressure is &#62;180 to 230 mmHg or diastolic is &#62;105 to 120 mmHg:</td> </tr> <tr> <td class=\"indent2\">Labetalol 10 mg intravenously followed by continuous infusion 2 to 8 mg/min; <strong>or</strong></td> </tr> <tr> <td class=\"indent2\">Nicardipine 5 mg/hour intravenously, titrate up to desired effect by 2.5 mg/hour every 5 to 15 minutes, maximum 15 mg/hour; <strong>or</strong></td> </tr> <tr> <td class=\"indent2\">Clevidipine 1 to 2 mg/hour intravenously, titrate by doubling the dose every 2 to 5 minutes, maximum 21 mg/hour, until desired blood pressure reached<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">If blood pressure is not controlled or diastolic blood pressure &#62;140 mmHg, consider intravenous sodium nitroprusside</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Different treatment options may be appropriate in patients who have comorbid conditions that may benefit from acute reductions in blood pressure, such as acute coronary event, acute heart failure, aortic dissection, or preeclampsia/eclampsia.<br />¶ Clevidipine has been included as part of the 2018 guidelines for the early management of patients with acute ischemic stroke<SUP>[1]</SUP>.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2018; 49:e46.</LI></OL>Adapted with permission. Stroke. 2013: 44:870-947. Copyright © 2013 American Heart Association, Inc.</div><div id=\"graphicVersion\">Graphic 50725 Version 14.0</div></div></div>"},"50727":{"type":"graphic_diagnosticimage","displayName":"CT scan UPJ obstruction","title":"CT scan: Transverse view of bilateral ureteropelvic junction obstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan: Transverse view of bilateral ureteropelvic junction obstruction</div><div class=\"cntnt\"><img style=\"width:420px; height:294px;\" src=\"images/PEDS/50727_CT_scan_UPJ_obstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 50727 Version 3.0</div></div></div>"},"50728":{"type":"graphic_picture","displayName":"Linear IgA bullous dermatosis of childhood on face","title":"Linear IgA bullous dermatosis of childhood","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Linear IgA bullous dermatosis of childhood</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/50728_Line_IgA_bull_derm_ch_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple tense bullae and inflammatory plaques are present. Note the perioral involvement.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50728 Version 3.0</div></div></div>"},"50731":{"type":"graphic_diagnosticimage","displayName":"2 D echo dilated cardiomyopathy","title":"Dilated cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Dilated cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:531px; height:244px;\" src=\"images/CARD/50731_2Dechodilatedcardioedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are the precordial long axis (panel A) and apical four-chamber views (panel B) from a patient with dilated cardiomyopathy. The long axis view demonstrates increased sphericity of the left ventricle (LV) and the long axis and short axis ratio approaches unity (normal 2:1). There is left atrial (LA) enlargment and a very large \"residual\" left ventricular end-systolic volume (ie, at end-systole there is a large unejected volume remaining in a dilated LV). The impression of increased sphericity is reinforced in the four-chamber view. In addition, there is also dilation of the right atrium (RA) and right ventricle (RV) four chamber dilation, connoting a poor prognosis.</div><div class=\"graphic_footnotes\">MV: mitral valve; AV: aortic valve; Ao: aorta; TV: tricuspid valve; IVS: interventricular septum; IAS: interatrial septum.</div><div id=\"graphicVersion\">Graphic 50731 Version 6.0</div></div></div>"},"50732":{"type":"graphic_table","displayName":"EUS FNA periintestinal nodes","title":"Diagnostic characteristics of endoscopic ultrasound-guided fine-needle aspiration (EUS FNA) for periintestinal lymph nodes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic characteristics of endoscopic ultrasound-guided fine-needle aspiration (EUS FNA) for periintestinal lymph nodes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">n</td> <td class=\"subtitle1\">Sensitivity (percent)</td> <td class=\"subtitle1\">Specificity (percent)</td> <td class=\"subtitle1\">Accuracy (percent)</td> </tr> <tr> <td>Bhutani, 1997</td> <td class=\"centered\">22</td> <td class=\"centered\">100</td> <td class=\"centered\">100</td> <td class=\"centered\">100</td> </tr> <tr> <td>Chang, 1997</td> <td class=\"centered\">14</td> <td class=\"centered\">83</td> <td class=\"centered\">100</td> <td class=\"centered\">88</td> </tr> <tr> <td>Erickson, 1997</td> <td class=\"centered\">14</td> <td class=\"centered\">100</td> <td class=\"centered\">100</td> <td class=\"centered\">100</td> </tr> <tr> <td>Gress, 1997</td> <td class=\"centered\">56</td> <td class=\"centered\">--</td> <td class=\"centered\">--</td> <td class=\"centered\">93</td> </tr> <tr> <td>Wiersema, 1997</td> <td class=\"centered\">192</td> <td class=\"centered\">92</td> <td class=\"centered\">93</td> <td class=\"centered\">92</td> </tr> <tr> <td>Binmoeller, 1998</td> <td class=\"centered\">43</td> <td class=\"centered\">91</td> <td class=\"centered\">100</td> <td class=\"centered\">95</td> </tr> <tr> <td>Reed, 1999</td> <td class=\"centered\">57</td> <td class=\"centered\">72</td> <td class=\"centered\">97</td> <td class=\"centered\">86</td> </tr> <tr> <td>Williams, 1999</td> <td class=\"centered\">160</td> <td class=\"centered\">85</td> <td class=\"centered\">100</td> <td class=\"centered\">89</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Norton ID, Wiersema MJ. Endoscopic ultrasound-guided fine needle aspiration biopsy. In: Endoscopic Ultrasonography. Gress F, Bhattacharya I (Eds). Blackwell Science, Malden, MA 2001. p.136. Reprinted with permission of Blackwell Science, Inc. <A spellcheck=true href=\"http://www.wiley.com/wiley-blackwell\" target=_blank>http://www.blackwell-science.com</A>.</div><div id=\"graphicVersion\">Graphic 50732 Version 5.0</div></div></div>"},"50733":{"type":"graphic_figure","displayName":"Unicornuate uter and xtra hornD","title":"Unicornuate uterus with communicating uterine horn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unicornuate uterus with communicating uterine horn</div><div class=\"cntnt\"><img style=\"width:373px; height:244px;\" src=\"images/OBGYN/50733_Unicornuateuterandxtra3.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50733 Version 10.0</div></div></div>"},"50738":{"type":"graphic_figure","displayName":"Tracheal wall perforation","title":"Posterior tracheal perforation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior tracheal perforation</div><div class=\"cntnt\"><img style=\"width:434px; height:202px;\" src=\"images/PULM/50738_Tracheal_wall_perforation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left panel shows the tracheal dilator correctly advanced, following the guiding catheter and guidewire. However, if the guiding catheter is inadvertantly withdrawn into the dilator during dilation (right panel), force is directed to the posterior tracheal wall and can result in perforation.</div><div class=\"graphic_reference\">Reproduced with permission from Trottier, SJ, Hazard, PB, Sakabu, SA, et al, Chest 1999; 115:1383.</div><div id=\"graphicVersion\">Graphic 50738 Version 1.0</div></div></div>"},"50739":{"type":"graphic_picture","displayName":"Laceration through the eyelid margin","title":"Laceration through the eyelid margin","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Laceration through the eyelid margin</div><div class=\"cntnt\"><img style=\"width:468px; height:296px;\" src=\"images/EM/50739_Lacerat_eyelid_margin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lacerations through the eyelid margin require meticulous layered closure to prevent excessive scarring and notching of the eyelid.</div><div class=\"graphic_reference\">Courtesy of Peter A D Rubin, MD.</div><div id=\"graphicVersion\">Graphic 50739 Version 1.0</div></div></div>"},"50740":{"type":"graphic_movie","displayName":"Tricuspid regurgitation subcostal echocardiogram","title":"Tricuspid regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tricuspid regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/50740_subtrireconv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:263px; height:218px;\" src=\"images/CARD/50740_subtrire.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subcostal view from a 2-D echocardiogram shows significant dilatation of the hepatic veins as a result of significant tricuspid regurgitation.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 50740 Version 3.0</div></div></div>"},"50743":{"type":"graphic_algorithm","displayName":"Acute evaluation of an adult with mild head trauma","title":"Acute evaluation of an adult with mild head trauma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute evaluation of an adult with mild head trauma</div><div class=\"cntnt\"><img style=\"width:399px; height:815px;\" src=\"images/NEURO/50743_AcuteevlmildTBIadlted2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mild head trauma is typically defined as head injury due to contact and/or acceleration/deceleration forces and a score on the Glasgow Coma Scale of 13 to 15.</div><div class=\"graphic_footnotes\">CT: computed tomography; NEXUS: National Emergency X-ray Utilization Study; MRI: magnetic resonance imaging; MR: magnetic resonance.<br />* Combined from Canadian CT head rule<SUP>[1]</SUP>, New Orleans criteria<SUP>[2]</SUP>, and NEXUS-II criteria<SUP>[3]</SUP>. Including all features will lead to a very high sensitivity (&gt;99%) and low specificity for identifying a patient with an important brain injury. The features below the dashed line are included in only one of the three validated criteria, while others are included in at least two of them.<br />¶ If trauma occurred &gt;7 days ago, head MRI without contrast, if available, is more appropriate. If noncontrast images suggest a vascular injury, intravenous contrast may be administered for CT or MR angiography of the head and neck.<br />Δ These represent general guidelines for when neurosurgical consultation is indicated. It may be prudent to obtain neurosurgical consultation for less severe and other CT abnormalities.<br /><FONT class=lozenge>◊</FONT> If there is no responsible caregiver at home, consider inpatient observation or CT, if it has not been performed already.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Stiell IG, Wells GA, Vandemheen K, et al. The Canadian CT Head Rule for patients with minor head injury. Lancet 2001; 357:1391.</LI>&#xD;&#xA;<LI>Haydel MJ, Preston CA, Mills TJ, et al. Indications for computed tomography in patients with minor head injury. N Engl J Med 2000; 343:100.</LI>&#xD;&#xA;<LI>Mower WR, Hoffman JR, Herbert M, et al. Developing a decision instrument to guide computed tomographic imaging of blunt head injury patients. J Trauma 2005; 59:954.</LI></OL></div><div id=\"graphicVersion\">Graphic 50743 Version 5.0</div></div></div>"},"50744":{"type":"graphic_picture","displayName":"Prion protein immunoperox prep","title":"Medium power photomicrograph of prion protein immunoperoxidase preparation revealing a diffuse and granular synaptic distribution pattern","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Medium power photomicrograph of prion protein immunoperoxidase preparation revealing a diffuse and granular synaptic distribution pattern</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/NEURO/50744_Prion_protein_immunoperox_p.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">(Immunoperoxidase preparation courtesy of the National Prion Disease Surveillance Center). Courtesy of Henry G Brown, MD, PhD.</div><div id=\"graphicVersion\">Graphic 50744 Version 1.0</div></div></div>"},"50746":{"type":"graphic_picture","displayName":"Perioral rhytides","title":"Perioral rhytides","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Perioral rhytides</div><div class=\"cntnt\"><img style=\"width:503px; height:288px;\" src=\"images/DERM/50746_Perioral_rhytides_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vertical wrinkles extending from the lip vermillion border are present. In this patient, the wrinkles are most evident on the lateral upper lip.</div><div id=\"graphicVersion\">Graphic 50746 Version 2.0</div></div></div>"},"50747":{"type":"graphic_diagnosticimage","displayName":"Comminuted fracture of the great toe","title":"Comminuted fracture of the distal phalanx of the great toe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comminuted fracture of the distal phalanx of the great toe</div><div class=\"cntnt\"><img style=\"width:361px; height:364px;\" src=\"images/EM/50747_Comm_fx_dist_phalanx_great.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the incidental finding of a benign exostosis at the medial base of the distal phalanx (arrow). Such exostoses of the toes are relatively common. The halo-effect in the soft tissue is a common artifact that results from adjusting the brightness of radiographs when using certain digital radiographic systems.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 50747 Version 4.0</div></div></div>"},"50749":{"type":"graphic_table","displayName":"Down syndrome monitoring PI","title":"When to check for health problems in children with Down syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">When to check for health problems in children with Down syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Possible problem</td> <td class=\"subtitle1\">When your doctor or nurse should check</td> </tr> <tr> <td rowspan=\"4\">Growth</td> <td class=\"sublist1_start\">Your child's growth will be checked at each routine check-up, including:</td> </tr> <tr> <td class=\"sublist1\">&#8226; At the first visit</td> </tr> <tr> <td class=\"sublist1\">&#8226; At 2, 4, 6, 9, 12, 15, 18, and 24 months; and</td> </tr> <tr> <td class=\"sublist1\">&#8226; Once a year after age 2 years (until he or she is an adult)</td> </tr> <tr class=\"divider_top\"> <td>Sleep</td> <td>Starting when your child turns 1 year, your doctor or nurse should ask about your child's sleep habits. Tell your doctor or nurse if your child snores, sleeps in an unusual position, or does not sleep well. Also, make sure your child has a sleep test by the time he or she turns four.</td> </tr> <tr class=\"divider_top\"> <td>Thyroid hormones</td> <td>Your child's thyroid hormones should be checked at birth, 6 months, 12 months, and then once a year after that.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Hearing</td> <td class=\"sublist1_start\">Your child's hearing should be checked at each routine check-up. But it is especially important that hearing be checked:</td> </tr> <tr> <td class=\"sublist1\">&#8226; At birth</td> </tr> <tr> <td class=\"sublist1\">&#8226; At 6 months and at least once a year after that</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Vision</td> <td class=\"sublist1_start\">Your child's vision should be checked at each routine check-up. But it is especially important that vision be checked:</td> </tr> <tr> <td class=\"sublist1\">&#8226; By an eye doctor at 6 months and then every year until age 5</td> </tr> <tr> <td class=\"sublist1\">&#8226; By an eye doctor every 2 years from ages 5 to 13 years</td> </tr> <tr> <td class=\"sublist1\">&#8226; By an eye doctor every 3 years from ages 13 to 21 years</td> </tr> <tr class=\"divider_top\"> <td>Heart</td> <td>Your child's heart should be checked for problems before and after he or she is born. To do this, your doctor will do an imaging test called an ultrasound that can create images of the heart.</td> </tr> <tr class=\"divider_top\"> <td>Blood</td> <td>Your child's blood should be checked for problems at birth. Every year from ages 1 to 21 years, his or her blood should also be checked for a blood disorder called \"anemia.\" To do this, your doctor will order a blood test called a \"Hemoglobin.\"</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Muscle and nerve problems</td> <td class=\"sublist1_start\">At any visit, tell your child's doctor if your child:</td> </tr> <tr> <td class=\"sublist1\">&#8226; Has any problems walking</td> </tr> <tr> <td class=\"sublist1\">&#8226; Begins using his or her hands or arms differently</td> </tr> <tr> <td class=\"sublist1\">&#8226; Has problems controlling his or her bowel or bladder</td> </tr> <tr> <td class=\"sublist1\">&#8226; Has neck pain or tilts his or her head to one side</td> </tr> <tr> <td class=\"sublist1\">&#8226; Has muscle weakness</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50749 Version 12.0</div></div></div>"},"50750":{"type":"graphic_picture","displayName":"Omphalitis shoelace","title":"Omphalitis shoelace","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Omphalitis shoelace</div><div class=\"cntnt\"><img style=\"width:432px; height:255px;\" src=\"images/PEDS/50750_Omphalitis_shoelace.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Omphalitis with induration and erythema surrounding the umbilicus in a newborn Native American infant. The umbilicus was tied with a shoelace.</div><div class=\"graphic_reference\">Courtesy of Martin I Lorin, MD.</div><div id=\"graphicVersion\">Graphic 50750 Version 3.0</div></div></div>"},"50751":{"type":"graphic_table","displayName":"Prevalence of celiac disease in special populations","title":"Prevalence of celiac disease in special populations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of celiac disease in special populations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Percent of group affected</td> <td class=\"subtitle1\">Fold increase in risk as compared to general population</td> </tr> <tr> <td>General population (US and Europe)<sup>[1]</sup></td> <td>0.7 to 1.0</td> <td>-</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Relatives of patient with celiac disease<sup>[1,2]</sup></td> </tr> <tr> <td class=\"sublist1\">first-degree relatives</td> <td class=\"sublist_other\">4 to 5</td> <td class=\"sublist_other\">6</td> </tr> <tr> <td class=\"sublist1\">second degree relatives</td> <td class=\"sublist_other\">3</td> <td class=\"sublist_other\">3</td> </tr> <tr> <td>Down syndrome<sup>[2,3]</sup></td> <td>5 to 12</td> <td>7 to 18</td> </tr> <tr> <td>Type 1 diabetes<sup>[2,4]</sup></td> <td>5 to 10</td> <td>7 to 13</td> </tr> <tr> <td>IgA deficiency<sup>[5]</sup></td> <td>8</td> <td>11</td> </tr> <tr> <td>Autoimmune thyroid disease<sup><span style=\"font-size: 13px;\">[2,6]</span></sup>&nbsp;</td> <td>2 to 7&nbsp;</td> <td>6 (less in children)&nbsp;</td> </tr> <tr> <td>Turner syndrome<sup>[2]</sup></td> <td>4 to 8</td> <td>5 to 11</td> </tr> <tr> <td>Williams syndrome<sup><span style=\"font-size: 13px;\">[7]</span></sup></td> <td>8</td> <td>11</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: A large multicenter study. Arch Intern Med 2003; 163:286.</LI>&#xD;&#xA;<LI>Hill ID, Dirks MH, Liptak GS, et al. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2005; 40:1.</LI>&#xD;&#xA;<LI>&nbsp;Rostom A, Murray JA, Kagnoff MF. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006; 131:1981.</LI>&#xD;&#xA;<LI>Crone J, Rami B, Huber WD, et al. Prevalence of celiac disease and follow-up of EMA in children and adolescents with type 1 diabetes mellitus. J Pediatr Gastroenterol Nutr 2003; 37:67.</LI>&#xD;&#xA;<LI>Meini A, Pillan NM, Villanacci V, et al. Prevalence and diagnosis of celiac disease in IgA-deficient children. Ann Allergy Asthma Immunol 1996; 77:333.</LI>&#xD;&#xA;<LI>Ch'ng CL, Biswas M, Benton A, et al. Prospective screening for coeliac disease in patients with Graves' hyperthyroidism using anti-gliadin and tissue transglutaminase antibodies. Clin Endocrinol (Oxf) 2005; 62:303.</LI>&#xD;&#xA;<LI>Giannotti A, Tiberio G, Castro M, et al. Coeliac disease in Williams syndrome. J Med Genet 2001; 38:767.</LI></OL></div><div id=\"graphicVersion\">Graphic 50751 Version 3.0</div></div></div>"},"50753":{"type":"graphic_table","displayName":"Risk classific exercise class A","title":"Risk classification for exercise training: class A: apparently healthy individuals","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk classification for exercise training: class A: apparently healthy individuals</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">This classification includes:</td> </tr> <tr> <td class=\"indent1\">1. Children, adolescents, men &#60;45 years, and women &#60;55 years who have no symptoms or known presence of heart disease or major coronary risk factors.</td> </tr> <tr> <td class=\"indent1\">2. Men &#8805;45 years and women &#8805;55 years who have no symptoms or known presence of heart disease and with &#60;2 major cardiovascular risk factors.</td> </tr> <tr> <td class=\"indent1\">3. Men &#8805;45 years and women &#8805;55 years who have no symptoms or known presence of heart disease and with &#8805;2 major cardiovascular risk factors.</td> </tr> <tr> <td class=\"subtitle1_single\">Activity guidelines:</td> </tr> <tr> <td class=\"indent1\">No restrictions other than basic guidelines.</td> </tr> <tr> <td class=\"subtitle1_single\">Supervision required</td> </tr> <tr> <td class=\"indent1\">None*</td> </tr> <tr> <td class=\"subtitle1_single\">ECG and blood pressure monitoring:</td> </tr> <tr> <td class=\"indent1\">Not required</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram.<br />* It is suggested that persons classified as Class A-2 and particularly Class A-3 undergo a medical examination and possibly a medically supervised exercise test before engaging in vigorous exercise.</div><div class=\"graphic_reference\">Reproduced with permission from: Fletcher GF, Balady GJ, Amsterdam EA, et al. Circulation 2001; 104:1694. Copyright &copy; 2001 Lippincott Williams and Wilkins.</div><div id=\"graphicVersion\">Graphic 50753 Version 6.0</div></div></div>"},"50754":{"type":"graphic_figure","displayName":"Deflation of the LMA cuff","title":"Deflation of the laryngeal mask airway cuff","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Deflation of the laryngeal mask airway cuff</div><div class=\"cntnt\"><img style=\"width:526px; height:286px;\" src=\"images/EM/50754_Deflation_LMA_cuff.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cuff of the laryngeal mask airway is deflated by pressing it against a flat surface.</div><div class=\"graphic_reference\">Reproduced with permission from: Murphy MF. Extraglottic devices. In: Manual of Emergency Airway Management, 3rd edition. Walls RM, Murphy MF (Eds). Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50754 Version 5.0</div></div></div>"},"50755":{"type":"graphic_movie","displayName":"Knee jerk hyperreflexia in ALS","title":"Knee jerk hyperreflexia in a patient with amyotrophic lateral sclerosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Knee jerk hyperreflexia in a patient with amyotrophic lateral sclerosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/NEURO/50755_alsknrflconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:324px; height:238px;\" src=\"images/NEURO/50755_alsknrfl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An upper motor neuron sign, hyperreflexia is noted with testing deep tendon reflexes at the knees.</div><div class=\"graphic_reference\">Courtesy of Nestor Galvez- Jimenez, MD, FACP.</div><div id=\"graphicVersion\">Graphic 50755 Version 3.0</div></div></div>"},"50757":{"type":"graphic_table","displayName":"Causes of NAION","title":"Causes and risk factors for NAION (nonarteritic anterior ischemic optic neuropathy)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes and risk factors for NAION (nonarteritic anterior ischemic optic neuropathy)</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Atherosclerosis risk factors, especially hypertension, diabetes</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Small optic cup, \"disc at risk\"</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Surgery\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Coronary bypass\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Spine surgery\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Radical neck dissection\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Cataract surgery\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Others, especially if major blood loss, hypotension\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Major blood loss from other causes, eg, trauma, gastrointestinal bleeding</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Prothrombotic conditions</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Nocturnal hypotension</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Sleep apnea</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Renal Failure</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Drugs\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Phophodiesterase-5 inhibitors\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Interferon-alpha\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Amiodarone\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Sympathomimetics\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Migraine</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Carotid dissection</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Genetic factors</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">* Not all have been proven associated in case-control studies.</div><div id=\"graphicVersion\">Graphic 50757 Version 2.0</div></div></div>"},"50758":{"type":"graphic_figure","displayName":"Uveal melanoma threeD XRT","title":"Charged particle radiation of uveal melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Charged particle radiation of uveal melanoma</div><div class=\"cntnt\"><img style=\"width:364px; height:279px;\" src=\"images/ONC/50758_Uveal_melanoma_threeD_XRT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three dimensional model of eye with a 13 mm (diameter) tumor. Magenta outline corresponds to the shape of the treatment aperture. The lens (area outlined in blue), optic disc and nerve (areas outlined in yellow) are excluded from the beam field.</div><div class=\"graphic_reference\">Reproduced with permission from Gragoudas ES, Char DH. Charged particle irradiation of uveal melanomas. In: Principles and Practice of Ophthalmology, vol. 5, Albert DM, Jakobiec FA (Eds), WB Saunders, Philadelphia 1994. Copyright 1994 W.B. Saunders.</div><div id=\"graphicVersion\">Graphic 50758 Version 3.0</div></div></div>"},"50760":{"type":"graphic_diagnosticimage","displayName":"Nasolacrimal duct cyst","title":"Bilateral nasolacrimal duct cysts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral nasolacrimal duct cysts</div><div class=\"cntnt\"><img style=\"width:368px; height:276px;\" src=\"images/PEDS/50760_Nasolacrimal_duct_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography image of bilateral nasolacrimal duct cysts (c) causing upper airway obstruction in this neonate.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 50760 Version 3.0</div></div></div>"},"50763":{"type":"graphic_figure","displayName":"Impact of a two-week difference in gestational age on MoM values","title":"Impact of a two-week difference in gestational age on MoM values","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Impact of a two-week difference in gestational age on MoM values</div><div class=\"cntnt\"><img style=\"width:459px; height:175px;\" src=\"images/OBGYN/50763_VariationofMoMvaluesby.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient's gestational age at the time of blood draw was calculated to be 18 weeks based on her last menstrual period and 16 weeks based on an early ultrasound examination. The AFP, uE3, and hCG mass values calculated to a low AFP, low uE3, and elevated hCG MoM for a pregnancy at 18 gestational weeks (green circles), leading to calculation of high risk of Down syndrome. However, the same mass values for a pregnancy at 16 gestational weeks (yellow circles) were on the unaffected median (1 MoM) for each analyte, leading to calculation of low risk of Down syndrome.</div><div class=\"graphic_footnotes\">MoM: multiples of the median; AFP: alpha-fetoprotein; gest. wk: gestational weeks; uE3: unconjugated estriol; hCG: human chorionic gonadotropin.</div><div id=\"graphicVersion\">Graphic 50763 Version 2.0</div></div></div>"},"50764":{"type":"graphic_picture","displayName":"Convex probe","title":"Endobronchial ultrasound (EBUS) convex probe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endobronchial ultrasound (EBUS) convex probe</div><div class=\"cntnt\"><img style=\"width:355px; height:385px;\" src=\"images/PULM/50764_Convex_probe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Linear curved array ultrasonic transducer on the end of an ultrasonic puncture bronchoscope. Used to perform convex probe endobronchial ultrasound. B) The balloon sheath that surrounds the ultrasonic transducer is inflated with water. A 22-gauge needle used for real-time transbronchial fine needle aspiration extends from the bronchoscope.</div><div id=\"graphicVersion\">Graphic 50764 Version 3.0</div></div></div>"},"50765":{"type":"graphic_picture","displayName":"Neuroendocrine high power","title":"Large cell neuroendocrine carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large cell neuroendocrine carcinoma</div><div class=\"cntnt\"><img style=\"width:389px; height:260px;\" src=\"images/PULM/50765_Neuroendocrine_high_power.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph showing cells with an organoid architecture. The cells have a modest amount of eosinophilic cytoplasm and nuclei with coarse chromatin and prominent nucleoli. An area of necrosis (N) is seen in the lower right hand portion of the photomicrograph, which is characteristic of large cell neuroendocrine carcinoma.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Myers, MD.</div><div id=\"graphicVersion\">Graphic 50765 Version 3.0</div></div></div>"},"50767":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph depicting a retrocardiac mass","title":"Chest radiograph depicting a retrocardiac mass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph depicting a retrocardiac mass</div><div class=\"cntnt\"><img style=\"width:431px; height:357px;\" src=\"images/SURG/50767_Chest_radiograph_retrocard.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;anteroposterior view of the chest radiograph demonstrates a paraesophageal hernia identified as a retrocardiac mass.</div><div class=\"graphic_reference\">Courtesy of Michael Rosen, MD.</div><div id=\"graphicVersion\">Graphic 50767 Version 4.0</div></div></div>"},"50769":{"type":"graphic_picture","displayName":"Granuloma faciale","title":"Granuloma faciale","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Granuloma faciale</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/50769_Granuloma_faciale.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A red-brown plaque is present on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50769 Version 3.0</div></div></div>"},"50771":{"type":"graphic_picture","displayName":"Lues maligna","title":"Secondary syphilis: Lues maligna","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Secondary syphilis: Lues maligna</div><div class=\"cntnt\"><img style=\"width:295px; height:453px;\" src=\"images/ID/50771_Lues_maligna.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lues maligna is a severe form of secondary syphilis that occurs in severely immunocompromised patients and is characterized by non-resolving ulcerative skin lesions.</div><div class=\"graphic_reference\">Courtesy of Dr. Charles Hicks.</div><div id=\"graphicVersion\">Graphic 50771 Version 6.0</div></div></div>"},"50772":{"type":"graphic_figure","displayName":"Bifurcated modular aortic endograft","title":"Bifurcated modular aortic endograft","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bifurcated modular aortic endograft</div><div class=\"cntnt\"><img style=\"width:184px; height:432px;\" src=\"images/CARD/50772_Bifurcate_modular_endograft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a representation of the Talent bifurcated, modular endograft.</div><div class=\"graphic_reference\">World Medical/Medtronics. Santa Rosa, CA.</div><div id=\"graphicVersion\">Graphic 50772 Version 3.0</div></div></div>"},"50773":{"type":"graphic_figure","displayName":"Differential splicing mu and delta mRNA","title":"Differential splicing of µ and δ mRNA","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Differential splicing of µ and δ mRNA</div><div class=\"cntnt\"><img style=\"width:564px; height:228px;\" src=\"images/ALLRG/50773_Differential_splicing_u_mRN.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A single primary RNA transcript extending over both mu (µ) and delta (δ) loci, if spliced in the two different ways shown, may generate a mature mRNA encoding the IgM heavy chain, or a different one encoding IgD. The IgD hinge region is encoded by a separate exon between Cδ1 and Cδ2 (not shown).</div><div class=\"graphic_footnotes\">L: light chain gene segment; V<SUB>H</SUB>: variable region of heavy chain; D: diversity; J<SUB>H</SUB>: joining region of heavy chain; IgM: immunoglobulin M; IgD: immunoglobulin D.</div><div class=\"graphic_reference\">Reproduced with permission from Bona C, Bonilla FA. Textbook of Immunology, 2nd ed. Harwood Academic Publishers GmbH, Amsterdam 1996. Copyright © 1996 Overseas Publishers Association, NV. Permission granted by Gordon and Breach Publishers.</div><div id=\"graphicVersion\">Graphic 50773 Version 4.0</div></div></div>"},"50774":{"type":"graphic_picture","displayName":"Urethrocutaneous fistula","title":"Urethrocutaneous fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urethrocutaneous fistula</div><div class=\"cntnt\"><img style=\"width:325px; height:360px;\" src=\"images/PEDS/50774_Urethrocutaneous_fistula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urethrocutaneous fistula caused by circumcision.</div><div class=\"graphic_reference\">Courtesy of Laurence S Baskin, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 50774 Version 3.0</div></div></div>"},"50775":{"type":"graphic_table","displayName":"Contact lens care tips","title":"Contact lens care tips","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contact lens care tips</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>&#8226; Follow recommended wearing schedule.</td> </tr> <tr> <td>&#8226; Do <strong>not</strong> substitute sterile saline solutions for multipurpose solutions.</td> </tr> <tr> <td>&#8226; Rub and rinse your contact lenses as directed by your eye care professional.</td> </tr> <tr> <td>&#8226; Do not \"top-off\" the solutions in your case. Always discard all of the leftover contact lens solution after each use. Never reuse any lens solution.</td> </tr> <tr> <td>&#8226; Clean, rinse, and air-dry your lens case each time lenses are removed.</td> </tr> <tr> <td>&#8226; Do not expose your contact lenses to any water: tap, bottled, distilled, lake, or ocean water.</td> </tr> <tr> <td>&#8226; Contact your eye care professional if you experience any symptoms of eye irritation or infection.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: US Food and Drug Administration, Medical Devices, Contact Lenses. Available at: www.fda.gov/cdrh/contactlenses/lenslist.html (Accessed on August 20th, 2009).</div><div id=\"graphicVersion\">Graphic 50775 Version 2.0</div></div></div>"},"50777":{"type":"graphic_diagnosticimage","displayName":"SIS submucous myoma1","title":"Saline infusion sonohysterogram of a submucous myoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Saline infusion sonohysterogram of a submucous myoma</div><div class=\"cntnt\"><img style=\"width:385px; height:268px;\" src=\"images/OBGYN/50777_SIS_submucous_myoma1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A posterior mid-segment submucous myoma measuring 1.6 x 1.9 cm is identified after infusion of saline. The distance from the back of the myoma to the serosal surface measures 1.2 cm (calipers). The endometrium surrounding the fluid is thin, compatible with early proliferative phase.</div><div class=\"graphic_reference\">Courtesy of Steven Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 50777 Version 4.0</div></div></div>"},"50778":{"type":"graphic_figure","displayName":"Survival restrictive CM","title":"Survival is reduced with an idiopathic restrictive cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Survival is reduced with an idiopathic restrictive cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:536px; height:272px;\" src=\"images/CARD/50778_SurvivalrestrictiveCM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier survival curves in 94 patients with an idiopathic restrictive cardiomyopathy and in an age- and sex-matched control group (expected) show survival with a restrictive cardiomyopathy at 5 (64 versus 85 percent expected) and 10 years (37 versus 70 percent, p &lt;0.0001).</div><div class=\"graphic_reference\">Data from Ammash NM, Seward JB, Bailey KR, et al. Circulation 2000; 101:2490.</div><div id=\"graphicVersion\">Graphic 50778 Version 2.0</div></div></div>"},"50779":{"type":"graphic_figure","displayName":"Fascioliasis life cycle","title":"Fascioliasis life cycle","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Fascioliasis life cycle</div><div class=\"cntnt\"><img style=\"width:588px; height:477px;\" src=\"images/ID/50779_Fascioliasis_life_cycle_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immature eggs are discharged in the biliary ducts and in the stool <strong>(1)</strong>. Eggs become embryonated in water <strong>(2)</strong>, eggs release miracidia <strong>(3)</strong>, which invade a suitable snail intermediate host <strong>(4)</strong>, including the genera <em>Galba</em>, <em>Fossaria</em>, and <em>Pseudosuccinea</em>. In the snail, the parasites undergo several developmental stages (sporocysts <strong>(4a)</strong>, rediae <strong>(4b)</strong>, and cercariae <strong>(4c)</strong>). The cercariae are released from the snail <strong>(5)</strong> and encyst as metacercariae on aquatic vegetation or other surfaces. Mammals acquire the infection by eating vegetation containing metacercariae. Humans can become infected by ingesting metacercariae-containing freshwater plants, especially watercress <strong>(6)</strong>. After ingestion, the metacercariae excyst in the duodenum <strong>(7)</strong> and migrate through the intestinal wall, the peritoneal cavity, and the liver parenchyma into the biliary ducts, where they develop into adults <strong>(8)</strong>. In humans, maturation from metacercariae into adult flukes takes approximately three to four months. The adult flukes (<em>Fasciola hepatica</em>: up to 30 mm by 13 mm; <em>F. gigantica</em>: up to 75 mm) reside in the large biliary ducts of the mammalian host. <em>Fasciola hepatica</em> infect various animal species, mostly herbivores.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Fascioliasis. Available at: <A href=\"http://www.cdc.gov/parasites/fasciola/\">http://www.cdc.gov/parasites/fasciola/</A>.</div><div id=\"graphicVersion\">Graphic 50779 Version 3.0</div></div></div>"},"50780":{"type":"graphic_picture","displayName":"Multiple keratoacanthomas","title":"Multiple keratoacanthomas","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Multiple keratoacanthomas</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/50780_Multikeratoacanthomas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Crater-shaped, nodular lesions of varying size in a patient with multiple keratoacanthomas.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50780 Version 7.0</div></div></div>"},"50781":{"type":"graphic_picture","displayName":"Necrobiosis lipoidica 2","title":"Necrobiosis lipoidica, early lesions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Necrobiosis lipoidica, early lesions</div><div class=\"cntnt\"><img style=\"width:300px; height:417px;\" src=\"images/DERM/50781_Necrobiosis_lipoidica_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Necrobiosis lipoidica diabeticorum. This diabetic patient has early lesions that consist of yellow-red plaques. Epidermal atrophy and telangiectasias tend to occur later.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50781 Version 1.0</div></div></div>"},"50782":{"type":"graphic_diagnosticimage","displayName":"Adult elbow with fat pad sign","title":"Adult elbow with fat pad sign","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adult elbow with fat pad sign</div><div class=\"cntnt\"><img style=\"width:364px; height:434px;\" src=\"images/EM/50782_Elbow_XR_adult_fat_pad.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this radiograph, the anterior and posterior fat-pads are elevated away from the humeral surface as a result of joint effusion or hemarthrosis (arrows). This \"fat pad sign\" is associated with a subtle impaction fracture of the radial neck, manifested only by a sharp, angular change in the contour of the ventral cortex (arrowhead).</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum, TR, Rowe, LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50782 Version 5.0</div></div></div>"},"50783":{"type":"graphic_diagnosticimage","displayName":"Pelvic AP compression fracture type I","title":"Pelvic AP compression fracture: Type I","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Pelvic AP compression fracture: Type I</div><div class=\"cntnt\"><img style=\"width:526px; height:207px;\" src=\"images/EM/50783_Pelvicantpostfx1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two images of a Type I AP compression fracture: (A) schematic; (B) plain radiograph with outlet view.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Reproduced with permission from: Sagi C. Lower extremity: Pelvic ring fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp;  Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 50783 Version 13.0</div></div></div>"},"50784":{"type":"graphic_table","displayName":"Disorders that mimic OSA","title":"Sleep disorders that mimic obstructive sleep apnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sleep disorders that mimic obstructive sleep apnea</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody><tr><td>Primary snoring</td></tr>\n\t\t\t\t\t\t<tr><td>Underlying pulmonary disease</td></tr>\n\t\t\t\t\t\t<tr><td>Sleep-related laryngospasm</td></tr>\n\t\t\t\t\t\t<tr><td>Abnormal swallowing disorder</td></tr>\n\t\t\t\t\t\t<tr><td>Panic attacks</td></tr>\n\t\t\t\t\t\t<tr><td>Nocturnal asthma</td></tr>\n\t\t\t\t\t\t<tr><td>Gastroesophageal reflux disease</td></tr>\n\t\t\t\t\t\t<tr><td>Sleep-choking disorder</td></tr>\n\t\t\t\t\t\t<tr><td>Nocturnal seizures</td></tr>\n\t\t\t\t\t\t<tr><td>Insomnia (repetitive awakenings)</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table></div><div id=\"graphicVersion\">Graphic 50784 Version 2.0</div></div></div>"},"50788":{"type":"graphic_diagnosticimage","displayName":"Sagittal airway 20 week fetus","title":"Sagittal airway 20-week fetus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sagittal airway 20-week fetus</div><div class=\"cntnt\"><img style=\"width:375px; height:396px;\" src=\"images/ALLRG/50788_Sagittal_airway_20wk_fetus.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">e: epiglotis; l: larynx; t: trachea; l: lung; h: heart.</div><div id=\"graphicVersion\">Graphic 50788 Version 3.0</div></div></div>"},"50789":{"type":"graphic_table","displayName":"The hydration debate","title":"The hydration debate","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The hydration debate</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Arguments for hydration</td> </tr> <tr> <td>Provides a basic human need</td> </tr> <tr> <td>Provides comfort and prevents uncomfortable symptoms: confusion, agitation, and neuromuscular irritability</td> </tr> <tr> <td>Prevents complications (eg, neurotoxicity with high-dose narcotics)</td> </tr> <tr> <td>Relieves thirst, recognized as a sign of fluid needs</td> </tr> <tr> <td>Does not \"artificially\" prolong life to any meaningful degree</td> </tr> <tr> <td>Allows providers to continue their efforts to find ways to improve comfort and life quality, despite the perception of a poor quality of life</td> </tr> <tr> <td>Provides minimum standards of care; not doing so would break a bond with the patient</td> </tr> <tr> <td>Denying hydration may set a precedent to withhold therapies from other patients who are compromised</td> </tr> <tr> <td class=\"subtitle1_single\">Arguments against hydration</td> </tr> <tr> <td>Interferes with acceptance of the terminal condition</td> </tr> <tr> <td>Intravenous therapy is painful and intrusive</td> </tr> <tr> <td>Prolongs suffering and the dying process</td> </tr> <tr> <td>Unnecessary since unconscious patients do not experience uncomfortable symptoms, such as pain or thirst</td> </tr> <tr> <td>Less urine output means less need for bed pan, urinal, commode, or catheter</td> </tr> <tr> <td>Less fluid in the GI tract and less vomiting</td> </tr> <tr> <td>Less pulmonary secretions and less cough, choking, and congestion</td> </tr> <tr> <td>Minimizes edema and ascites</td> </tr> <tr> <td>Ketones and other metabolic by-products in dehydration act as natural anesthetics for the central nervous system, causing decreased levels of consciousness and decreased suffering</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Bruera E, Dalal S. Dehydration in cancer patients: To treat or not to treat. J Support Oncol 2004; 2:467. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 50789 Version 2.0</div></div></div>"},"50791":{"type":"graphic_table","displayName":"Enterovirus receptors","title":"Enterovirus receptors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Enterovirus receptors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Viruses</td> <td class=\"subtitle1\">Receptor(s)</td> <td class=\"subtitle1\">Characteristics of the receptor(s)</td> </tr> <tr> <td>Polioviruses 1-3</td> <td>PVR</td> <td>Member of immunoglobulin superfamily; function unknown</td> </tr> <tr> <td>Enterovirus 71&nbsp;</td> <td>P-selectin glycoprotein ligand-1&nbsp;</td> <td>Transmembrane protein&nbsp;</td> </tr> <tr> <td>Coxsackie A virus, 16&nbsp;</td> <td>Scavenger&nbsp;receptor class B, member 2 (SCARB2)&nbsp;</td> <td>Transmembrane protein&nbsp;</td> </tr> <tr> <td rowspan=\"2\">Coxsackie B viruses</td> <td>CAR</td> <td>&nbsp;</td> </tr> <tr> <td>DAF (CD55)</td> <td>Complement regulatory protein</td> </tr> <tr> <td>Echoviruses 1, 8</td> <td>VLA-2</td> <td>Integrin</td> </tr> <tr> <td>Echoviruses 6, 7, 9, 11, 11, 12, 20-22, 25</td> <td>DAF (CD55)</td> <td>Complement regulatory protein</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50791 Version 2.0</div></div></div>"},"50792":{"type":"graphic_table","displayName":"Systemic infections associated with skin lesions","title":"Selected systemic infections associated with skin lesions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected systemic infections associated with skin lesions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Bartonellosis</td> </tr> <tr> <td>Brucellosis</td> </tr> <tr> <td>Ehrlichiosis (rash in &#60;5 percent human granulocytotropic anaplasmosis; 20 to 30 percent in human monocytotropic ehrlichiosis)</td> </tr> <tr> <td>Enteroviral infections (eg, Coxsackie, other)</td> </tr> <tr> <td>Dengue, chikungunya, Zika&nbsp;(and other arboviruses)</td> </tr> <tr> <td>Gonococcemia</td> </tr> <tr> <td>HIV (acute, primary)</td> </tr> <tr> <td>Leishmaniasis, visceral</td> </tr> <tr> <td>Leptospirosis</td> </tr> <tr> <td>Lyme disease</td> </tr> <tr> <td>Measles</td> </tr> <tr> <td>Melioidosis</td> </tr> <tr> <td>Meningococcemia</td> </tr> <tr> <td>Parvovirus</td> </tr> <tr> <td>Ratbite fever</td> </tr> <tr> <td>Relapsing fever (louseborne and tickborne)</td> </tr> <tr> <td>Rickettsial infections (many)</td> </tr> <tr> <td>Rubella</td> </tr> <tr> <td>Syphilis</td> </tr> <tr> <td>Trypanosomiasis, African</td> </tr> <tr> <td>Tularemia</td> </tr> <tr> <td>Typhoid and paratyphoid (enteric) fever</td> </tr> <tr> <td>Varicella</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">List is not comprehensive. Many arboviruses (arthropod-borne viruses) can have an associated rash.</div><div id=\"graphicVersion\">Graphic 50792 Version 4.0</div></div></div>"},"50794":{"type":"graphic_picture","displayName":"Olfactory neuroblastoma light","title":"Olfactory neuroblastoma","html":"<div class=\"graphic\"><div style=\"width: 757px\" class=\"figure\"><div class=\"ttl\">Olfactory neuroblastoma</div><div class=\"cntnt\"><img style=\"width:737px; height:272px;\" src=\"images/ONC/50794_Olfctry_nrblstm_lght.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Well-differentiated olfactory neuroblastoma (Hyams Grade I). Beneath the respiratory epithelium is a slightly lobulated diffuse growth of tumor. The cells are small with uniform nuclei and indistinct cytoplasmic borders. The background is diffusely fibrillary with pseudorosette formations.<br />(B) High power photomicrograph of olfactory neuroblastoma, also called esthesioneuroblastoma. When present, rosette formation (arrows) and a neurofibrillary background are helpful features in separating these lesions from other small blue cell tumors.</div><div class=\"graphic_reference\">Courtesy of G. Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 50794 Version 2.0</div></div></div>"},"50795":{"type":"graphic_figure","displayName":"Bone tumor locations","title":"Common locations of bone tumors","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Common locations of bone tumors</div><div class=\"cntnt\"><img style=\"width:529px; height:444px;\" src=\"images/PEDS/50795_Bone_tumor_locations.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chondroblastoma favors the epiphysis in the skeletally immature patient. Round cell lesions favor the diaphysis. The majority of other lesions favor the metaphysis. Giant cell tumors will extend to the joint surface in a skeletally mature patient.</div><div class=\"graphic_reference\">Reproduced with permission from: Daffner RH. Clinical Radiology: The Essentials, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &#169; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50795 Version 2.0</div></div></div>"},"50798":{"type":"graphic_table","displayName":"Drugs for PH","title":"Characteristics of medications used in the treatment of pulmonary hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of medications used in the treatment of pulmonary hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Route of administration</td> <td class=\"subtitle1\">Dose range (adult)</td> <td class=\"subtitle1\">Half-life</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Prostacyclin pathway agonists</td> </tr> <tr> <td class=\"indent1\">Epoprostenol</td> <td>Continuous IV infusion via central venous catheter</td> <td> <p>1 to 12 nanograms/kg/minute initially</p> Dose titrated up every one to two weeks until therapeutic response or dose limiting toxicity occurs</td> <td> <p>3 to 5 minutes (single dose)</p> 15 minutes (continuous infusion)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Treprostinil</td> <td>Continuous IV infusion via central venous catheter or continuous subcutaneous infusion</td> <td> <p>0.625 to 1.25 nanograms/kg/minute initially</p> Dose titrated up every one to two weeks until therapeutic response or dose limiting toxicity occurs</td> <td>4 hours</td> </tr> <tr> <td>Inhaled</td> <td> <p>One to three inhalations (ie, 6 to 18 micrograms), four times daily initially</p> Maintenance dose may be gradually titrated up to nine inhalations (ie, 54 micrograms), four times daily</td> <td>4 hours</td> </tr> <tr> <td class=\"indent1\">Iloprost</td> <td>Inhaled</td> <td>2.5 to 5 micrograms, six to nine times daily</td> <td>20 to 30 minutes (half-life of pulmonary vasodilating effect)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Selexipag</td> <td>Oral</td> <td> <p>200 to 1600 micrograms twice daily</p> Dose titrated up every one to two weeks until therapeutic response or dose limiting toxicity occurs</td> <td> <p>0.8 to 2.5 hours (selexipag)</p> 6.2 to 13.5 hours (active metabolite)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Endothelin receptor antagonists</td> </tr> <tr> <td class=\"indent1\">Bosentan</td> <td>Oral</td> <td> <p>62.5 to 125 mg, two times daily</p> Dose is adjusted for low body weight or drug interactions*</td> <td>5 hours</td> </tr> <tr> <td class=\"indent1\">Ambrisentan</td> <td>Oral</td> <td>5 to 10 mg daily</td> <td>9 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Macitentan</td> <td>Oral</td> <td>3 to 10 mg per day</td> <td>14 to 18 hours (parent drug)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Nitric oxide-cyclic guanosine monophosphate enhancers</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"><strong>Soluble guanylate cyclase stimulant</strong></td> </tr> <tr> <td class=\"indent2\">Riociguat</td> <td>Oral</td> <td>Initial dose 0.5 to 1 mg three times daily, titrated up by 0.5 mg three times per day every two weeks until therapeutic response or dose limiting toxicity occurs (maximum dose 2.5 mg three times daily)</td> <td>12 hours</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"><strong>Phosphodiesterase type 5 inhibitors</strong></td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\">Sildenafil</td> <td>Oral</td> <td>20 mg, three times daily</td> <td>4 hours</td> </tr> <tr> <td>IV</td> <td> <p>10 mg, three times daily</p> Dose is adjusted for drug interactions*</td> <td>4 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Tadalafil</td> <td>Oral</td> <td> <p>40 mg daily</p> Dose is adjusted for drug interactions*</td> <td>35 hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Calcium channel blockers<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Nifedipine</td> <td>Oral</td> <td>Rapid titration every hour with short acting nifedipine in intensive care unit setting with right heart catheter in place. Effective dose converted to once daily equivalent (maximum dose 240 mg daily).</td> <td>7 hours</td> </tr> <tr> <td class=\"indent1\">Diltiazem extended-release</td> <td>Oral</td> <td>Rapid titration every hour with short acting agent nifedipine in intensive care unit setting with right heart catheter in place. Effective dose converted to once daily equivalent (maximum dose 900 mg daily).</td> <td>6 to 9 hours</td> </tr> <tr> <td class=\"indent1\">Amlodipine</td> <td>Oral</td> <td>Rapid titration every hour with short acting nifedipine in intensive care unit setting with right heart catheter in place. Effective dose converted to once daily equivalent (maximum dose 20 mg daily).</td> <td>30 to 50 hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For patients on medications for other conditions, specific drug interactions and management suggestions may be determined by using Lexi-Interact, the drug interactions program included with UpToDate.</div><div class=\"graphic_footnotes\">* Refer to individual Lexicomp drug monographs included with UpToDate.<br />&para; Choice of calcium channel blocker is based upon the patient's heart rate. Refer to text.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Montani D, Gunther S, Dorfmuller P, et al. Pulmonary arterial hypertension. ORJD 2013; 8:97.</li>&#xD;&#xA;    <li>Coghlan G, Geaine S, Gatzoulis M, et al. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Thorax 2008; 63:ii1.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 50798 Version 8.0</div></div></div>"},"50804":{"type":"graphic_figure","displayName":"Biliary transport proteins","title":"Hepatocellular and biliary epithelial transport proteins","html":"<div class=\"graphic\"><div style=\"width: 663px\" class=\"figure\"><div class=\"ttl\">Hepatocellular and biliary epithelial transport proteins</div><div class=\"cntnt\"><img style=\"width:643px; height:389px;\" src=\"images/GAST/50804_Biliary_trnsprt_prtn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilirubin glucuronides, reduced glutathione (GSH), and many other organic anions (except most bile salts) are actively transported across the bile canalicular membrane of hepatocytes by ABCC2 (also known as MRP2) against a concentration gradient. Bilirubin glucuronide transport is assisted by the –35mV intracellular potential maintained by Na+/K+ ATPase and the K+ channel on the sinusoidal and contiguous surfaces of the hepatocyte. The sinusoidal surface sodium-taurocholate cotransporting polypeptide, NTCP (encoded by SLC10A1), cotransports Na+ and bile salts from plasma into hepatocytes. The bile salt export protein BSEP (ABCB11) actively transports bile salts out of the hepatocyte into the bile canaliculus, stimulating bile flow. The canalicular surface multidrug resistance-3-P-glycoprotein MDR3 (ABCB4) mediates ATP-dependent translocation of phosphatidyl choline from the inner to the outer leaflet of the membrane bilayer, and from there to the bile, thereby protecting the canalicular membrane from the high concentration of bile salts actively transported into the bile. Canalicular ATP8B1 (FIC1) transports aminophospholipids from the outer to the inner leaflet of the membrane bilayer. A fraction of the bilirubin glucuronides is actively transported out of the sinusoidal surface membrane into the sinusoidal blood by ABCC3 (MRP3). Reuptake of the bilirubin glucuronides is by OATP1B1 and OATP1B3 (SLC01B1 and SLC01B3), which are located in the sinusoidal surface membrane of hepatocytes downstream of the sinusoidal blood flow.</div><div id=\"graphicVersion\">Graphic 50804 Version 2.0</div></div></div>"},"50805":{"type":"graphic_picture","displayName":"Cryptococcal cellulitis","title":"Cryptococcal cellulitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cryptococcal cellulitis</div><div class=\"cntnt\"><img style=\"width:266px; height:382px;\" src=\"images/ID/50805_Cryptococcal_cellulitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This renal transplant recipient developed cellulitis over the ankle due to <EM>Cryptococcus neoformans</EM>.</div><div class=\"graphic_reference\">Courtesy of Charles V Sanders, MD.</div><div id=\"graphicVersion\">Graphic 50805 Version 2.0</div></div></div>"},"50806":{"type":"graphic_table","displayName":"Histoplasma meningitis","title":"Recommendations for evaluation of suspected <em>Histoplasma</em> meningitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for evaluation of suspected <em>Histoplasma</em> meningitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Specimen type, class of case, recommended test or procedure </td> </tr> <tr> <td class=\"subtitle2_single\">CSF; all cases, repeat at least once, and preferably twice, if there is no diagnosis </td> </tr> <tr> <td class=\"indent1\">Culture of a large-volume sample (&#62;10 mL) </td> </tr> <tr> <td class=\"indent1\"><em>Histoplasma</em> antigen testing </td> </tr> <tr> <td class=\"indent1\">Anti-<em>Histoplasma </em>antibody testing by complement fixation, beginning with undiluted CSF </td> </tr> <tr> <td class=\"subtitle2_single\">Blood; all cases </td> </tr> <tr> <td class=\"indent1\">Fungal culture,&nbsp;three sets </td> </tr> <tr> <td class=\"indent1\"><em>Histoplasma</em> antigen testing, to assist in determination if CSF antigen positivity may have been caused by contamination of the CSF with blood </td> </tr> <tr> <td class=\"indent1\">Anti-<em>Histoplasma </em>antibody testing </td> </tr> <tr> <td class=\"subtitle2_single\">Urine; all cases </td> </tr> <tr> <td class=\"indent1\"><em>Histoplasma</em> antigen testing </td> </tr> <tr> <td class=\"subtitle2_single\">Biopsy of non-CNS site, if there is a clinical or laboratory finding indicating involvement at the site </td> </tr> <tr> <td class=\"indent1\">Histopathologic examination for fungi </td> </tr> <tr> <td class=\"indent1\">Fungal culture </td> </tr> <tr> <td class=\"subtitle2_single\">Cisternal or ventricular fluid, if the diagnosis is uncertain after the performance of the evaluations above </td> </tr> <tr> <td class=\"indent1\">Microscopic examination for fungi </td> </tr> <tr> <td class=\"indent1\">Fungal culture </td> </tr> <tr> <td class=\"indent1\"><em>Histoplasma</em> antigen </td> </tr> <tr> <td class=\"indent1\">Anti-<em>Histoplasma </em>antibody </td> </tr> <tr> <td class=\"subtitle2_single\">Brain or meninges, if the diagnosis is uncertain after the performance of the evaluations above </td> </tr> <tr> <td class=\"indent1\">Histopathologic examination for fungi </td> </tr> <tr> <td class=\"indent1\">Fungal culture </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">CNS: central nervous system; CSF: cerebrospinal fluid.</div><div class=\"graphic_reference\">Reproduced with permission from: Wheat LJ, Musial CE, Jenny-Avital E. Diagnosis and management of central nervous system histoplasmosis. Clin Infect Dis 2005; 40:844. Copyright © 2005 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 50806 Version 4.0</div></div></div>"},"50807":{"type":"graphic_figure","displayName":"NHL in transplant recipients","title":"Incidence of non Hodgkin lymphoma in transplant recipients","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incidence of non Hodgkin lymphoma in transplant recipients</div><div class=\"cntnt\"><img style=\"width:435px; height:242px;\" src=\"images/NEPH/50807_NHL_in_transplant_recipient.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yearly incidence of non-Hodgkin lymphoma after transplantation in heart and kidney transplant recipients over time. The risk is greatest with higher degrees of immunosuppression: in the first year and in heart transplant recipients.</div><div class=\"graphic_reference\">Data from Opelz, G, Henderson, R, for the Collaborative Transplant Study, Lancet 1993; 342:1514.</div><div id=\"graphicVersion\">Graphic 50807 Version 2.0</div></div></div>"},"50808":{"type":"graphic_figure","displayName":"Steady state response to K load","title":"Response to potassium load","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Response to potassium load</div><div class=\"cntnt\"><img style=\"width:420px; height:270px;\" src=\"images/NEPH/50808_Steady_state_response_to_K.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Response to increasing potassium intake from 100 to 400 meq/day in normal subjects. Urinary potassium excretion rises to over 300 meq/day within two days, a response that is driven by increases in both aldosterone release and the plasma potassium concentration. By day 20, potassium excretion is almost 400 meq/day, the plasma aldosterone level is near normal, and there is only a small rise in the plasma potassium concentration to 4.2 meq/L.</div><div class=\"graphic_reference\">Data from: Rabelink TJ, Koomans HA, Hené RJ,&nbsp;et al.&nbsp;Kidney Int 1990; 38:942.</div><div id=\"graphicVersion\">Graphic 50808 Version 2.0</div></div></div>"},"50809":{"type":"graphic_figure","displayName":"Stroke with carotid stenosis","title":"Cause of stroke in patients with carotid stenosis","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Cause of stroke in patients with carotid stenosis</div><div class=\"cntnt\"><img style=\"width:464px; height:227px;\" src=\"images/NEURO/50809_Stroke_carotid_stenosis_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this analysis of the NASCET cohort, the risk of a first ipsilateral stroke of cardioembolic, lacunar, or large-artery origin at five years after study entry is presented, according to the degree of asymptomatic carotid-artery stenosis. The risk of stroke was higher in patients with 60 to 99 percent stenosis compared&nbsp;with those with less than 60 percent stenosis in the asymptomatic carotid artery. However, approximately one-half of strokes were cardioembolic or lacunar in origin. The cause-specific risks are not additive; some patients had more than one stroke of more than one cause.</div><div class=\"graphic_footnotes\">&nbsp;NASCET: North American Symptomatic Carotid Endarterectomy Trial.</div><div class=\"graphic_reference\">Data from: Inzitari, D, Eliasziw, M, Gates, P, et al, N Engl J Med 2000; 342:1693.</div><div id=\"graphicVersion\">Graphic 50809 Version 4.0</div></div></div>"},"50810":{"type":"graphic_figure","displayName":"Snellen chart","title":"Snellen chart to test visual acuity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Snellen chart to test visual acuity</div><div class=\"cntnt\"><img style=\"width:372px; height:572px;\" src=\"images/PC/50810_Snellen_chart.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 50810 Version 2.0</div></div></div>"},"50811":{"type":"graphic_figure","displayName":"Orexin neurons CNS","title":"Orexin neurons in the lateral hypothalamus innervate and excite many wake-promoting brain regions","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Orexin neurons in the lateral hypothalamus innervate and excite many wake-promoting brain regions</div><div class=\"cntnt\"><img style=\"width:494px; height:407px;\" src=\"images/PULM/50811_Orexin_neurons_CNS_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Targets of the orexin-producing neurons include monoaminergic areas such as the locus coeruleus, raphe nuclei, ventral tegmental area, periaqueductal grey, and tuberomammillary nucleus as well as cholinergic areas such as the basal forebrain and pedunculopontine and laterodorsal tegmental nuclei (PPT/LDT). Increased activity in these monoaminergic areas promotes wakefulness, inhibits REM sleep, and suppresses REM sleep-related phenomena including cataplexy.</div><div id=\"graphicVersion\">Graphic 50811 Version 2.0</div></div></div>"},"50812":{"type":"graphic_table","displayName":"NK deficiency syndromes","title":"Natural killer (NK) cell deficiency disorders and syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Natural killer (NK) cell deficiency disorders and syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Responsible gene</td> <td class=\"subtitle1\">Deficiency</td> <td class=\"subtitle1\">Infectious susceptibility</td> </tr> <tr> <td>CNKD</td> <td> <p>CNKD1 - GATA2 gene</p> <p>CNKD2 - MCM4 gene</p> Others unknown</td> <td>Absence of CD56+/CD3&ndash; cells</td> <td>CMV, VZV, HSV, MAI, HPV, Trichophyton</td> </tr> <tr> <td rowspan=\"2\">FNKD</td> <td>FNKD1 - FCRG3A</td> <td>NK cytotoxicity</td> <td>HSV, VZV, EBV</td> </tr> <tr> <td>Others unknown</td> <td>NK cytotoxicity, NK cytokine production</td> <td>EBV, HSV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NK: natural killer cell; CNKD: classical natural killer cell deficiency; FNKD: functional natural killer cell deficiency; MCM4: minichromosome maintenance complex component 4; CMV: cytomegalovirus; VZV: varicella zoster virus; HSV: herpes simplex virus; MAI: mycobacterium avium intracellulare; HPV: human papilloma virus; EBV: Epstein Barr virus.</div><div id=\"graphicVersion\">Graphic 50812 Version 5.0</div></div></div>"},"50813":{"type":"graphic_figure","displayName":"Standard needle knife approach","title":"Needle-knife approach for precut sphincterotomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Needle-knife approach for precut sphincterotomy</div><div class=\"cntnt\"><img style=\"width:403px; height:245px;\" src=\"images/GAST/50813_Standard_needle_knife_appro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A common method of performing needle-knife sphincterotomy is to use the elevator to direct the needle-knife while incising the papilla.</div><div class=\"graphic_reference\">Courtesy of Douglas A Howell, MD and David J Desilets, MD.</div><div id=\"graphicVersion\">Graphic 50813 Version 2.0</div></div></div>"},"50815":{"type":"graphic_figure","displayName":"RCC incidence mortality trends","title":"Temporal trends in renal cell cancer incidence and mortality in the United States","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Temporal trends in renal cell cancer incidence and mortality in the United States</div><div class=\"cntnt\"><img style=\"width:488px; height:303px;\" src=\"images/ONC/50815_RCC_incidence_mortality_tre.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As noted, incidence rates are rising three times faster than mortality rates, suggesting an improvement in overall survival in patients with renal cell cancer over the last 25 years.</div><div class=\"graphic_reference\">Data from Pantuck, AJ, et al, J Urology 2001; 166:1612.</div><div id=\"graphicVersion\">Graphic 50815 Version 1.0</div></div></div>"},"50816":{"type":"graphic_picture","displayName":"Anatomy choanal atresia","title":"Anatomic section of choanal atresia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomic section of choanal atresia</div><div class=\"cntnt\"><img style=\"width:410px; height:339px;\" src=\"images/PEDS/50816_Anatomy_choanal_atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomic section of bilateral choanal atresia, the obliteration or blockage of the posterior nasal aperture.</div><div class=\"graphic_footnotes\">*: choanae, u: uvula.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 50816 Version 2.0</div></div></div>"},"50818":{"type":"graphic_table","displayName":"SSRI dosing adolescents","title":"Dosing of selective serotonin reuptake inhibitors (SSRIs) for adolescent depression","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing of selective serotonin reuptake inhibitors (SSRIs) for adolescent depression</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Starting dose</td> <td class=\"subtitle1\">Average effective dose</td> <td class=\"subtitle1\">Maximum dose</td> </tr> <tr> <td>Fluoxetine* (Prozac)</td> <td>10 mg every morning<sup>&#182;</sup></td> <td>20 mg every morning</td> <td>60 mg every morning</td> </tr> <tr> <td>Citalopram (Celexa)</td> <td>10 mg every morning<sup>&#182;</sup></td> <td>20 mg every morning</td> <td>40 mg every morning</td> </tr> <tr> <td>Fluvoxamine (Luvox)</td> <td>50 mg every morning<sup>&#182;</sup></td> <td>100 - 150 mg each day</td> <td>100 mg twice per day</td> </tr> <tr> <td>Paroxetine (Paxil)</td> <td>10 mg every morning<sup>&#182;</sup></td> <td>20 mg every morning</td> <td>60 mg every morning</td> </tr> <tr> <td>Sertraline (Zoloft)</td> <td>25 mg every morning<sup>&#182;</sup></td> <td>50 to 100 mg every morning</td> <td>150 mg every morning</td> </tr> <tr> <td>Escitalopram (Lexapro)</td> <td>5 mg every morning</td> <td>10 mg every morning</td> <td>20 mg every morning</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Fluoxetine is considered the first-line agent and is the only one of these drugs that is approved by the US Food and Drug Administration for the treatment of depression in children and adolescents.<br />&para; If medication causes continued sedation, it is appropriate to switch dose to evening instead of morning.</div><div class=\"graphic_reference\">Adapted from Hagman, J Adolescent Health Update 2001; 13(3):1.</div><div id=\"graphicVersion\">Graphic 50818 Version 2.0</div></div></div>"},"50819":{"type":"graphic_picture","displayName":"Recurrent cellulitis","title":"Eczema of the breast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eczema of the breast</div><div class=\"cntnt\"><img style=\"width:432px; height:280px;\" src=\"images/PC/50819_Eczema_of_the_breast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cellulitis of the breast can be a consequence of an overlying skin abnormality such as eczema.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 50819 Version 2.0</div></div></div>"},"50820":{"type":"graphic_diagnosticimage","displayName":"CBD obstruction OLT","title":"Common bile duct obstruction following liver transplantation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Common bile duct obstruction following liver transplantation</div><div class=\"cntnt\"><img style=\"width:293px; height:324px;\" src=\"images/GAST/50820_CBD_obstruction_OLT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography in a patient with jaundice after liver transplantation demonstrates almost complete obstruction of the bile duct anastomosis (large arrow) with minimal passage of contrast throughout the obstruction (small arrows). This lesion was successfully treated with balloon dilation</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 50820 Version 3.0</div></div></div>"},"50821":{"type":"graphic_picture","displayName":"Cutaneous melioidosis","title":"Cutaneous melioidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous melioidosis</div><div class=\"cntnt\"><img style=\"width:392px; height:260px;\" src=\"images/ID/50821_Cutaneous_melioidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Purplish, palpable skin lesions in a case of melioidosis.</div><div class=\"graphic_reference\">Courtesy of Bart Currie, FRACP.</div><div id=\"graphicVersion\">Graphic 50821 Version 2.0</div></div></div>"},"50823":{"type":"graphic_picture","displayName":"Dermatographism 1","title":"Urticaria: Dermatographism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urticaria: Dermatographism</div><div class=\"cntnt\"><img style=\"width:395px; height:396px;\" src=\"images/ALLRG/50823_Dermatographism_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These lesions of dermatographism developed&nbsp;five minutes after stroking the skin with a wooden stick.</div><div class=\"graphic_reference\">Reproduced with permission from: Fitzpatrick TB, Johnson RA, Wolff K, et al. (Eds). Color Atlas and Synopsis of Clinical Dermatology, 3rd ed, McGraw-Hill, New York, 1997. Copyright © 1997 McGraw Hill.</div><div id=\"graphicVersion\">Graphic 50823 Version 4.0</div></div></div>"},"50824":{"type":"graphic_figure","displayName":"Anom omphalomesenteric duct","title":"Anomalies of the omphalomesenteric duct","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anomalies of the omphalomesenteric duct</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/PEDS/50824_Anom_omphalomesenteric_duct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Umbilical polyp. B) Meckel's diverticulum. C) Fibrous band. D) Omphalomesenteric duct cyst. E) Patent omphalomesenteric duct. F) Patent omphalomesenteric duct with prolapse.</div><div class=\"graphic_reference\">Reproduced with permission from: The American Pediatric Surgical Association. http://www.eapsa.org/.</div><div id=\"graphicVersion\">Graphic 50824 Version 1.0</div></div></div>"},"50827":{"type":"graphic_table","displayName":"Capnography for management chemical terrorism agents","title":"Capnography for management chemical terrorism agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Capnography for management chemical terrorism agents</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n<tbody>\r\n\r\n\t<tr>\r\n\t\t\t\t\t<td class=\"subtitle1\">Agent</td>\r\n\t\t\t\t\t<td class=\"subtitle1\">Effects</td>\r\n\t\t\t\t\t<td class=\"subtitle1\">Capnography</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"subtitle2_left\">Nerve gas</td>\r\n\t\t\t\t\t<td rowspan=\"5\">Seizures, diaphragmatic weakening or paralysis, hypoventilation, respiratory depression, apnea, loss of consciousness/coma</td>\r\n\t\t\t\t\t<td rowspan=\"5\"><p>Accurate readings during seizure activity (RR, EtCO<sub>2</sub>, capnogram)</p><p>Earliest indicator of respiratory compromise </p><p>Direct measure of ventilatory status</p></td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"indent1\">Tabun</td>\r\n\t\t\t\t\t</tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"indent1\">Sarin</td>\r\n\t\t\t\t\t</tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"indent1\">Soman</td>\r\n\t\t\t\t\t</tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"indent1\">VX</td>\r\n\t\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"subtitle2_left\">Vesicants</td>\r\n\t\t\t\t\t<td rowspan=\"3\">Airway edema, upper airway obstruction, bronchospasm</td>\r\n\t\t\t\t\t<td rowspan=\"3\"><p>Rapid identification of upper airway obstruction</p>\r\n\t\t\t\t\t<p>Rapid identification of bronchospasm</p></td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"indent1\">Mustard gas</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"indent1\">Lewisite</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"subtitle2_left\">Choking agents</td>\r\n\t\t\t\t\t<td rowspan=\"6\">Rapid, progressive, non-cardiogenic pulmonary edema and acute lung injury, bronchospasm, laryngospasm</td>\r\n\t\t\t\t\t<td rowspan=\"6\"><p>Earliest indicator of respiratory compromise</p><p>Rapid identification of bronchospasm</p><p>Rapid identification of laryngospasm</p></td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"indent1\">Chlorine</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"indent1\">Phosgene</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"indent1\">Diphosgene</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"indent1\">Chloropicrin</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"indent1\">Ricin</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"subtitle2_left\">Cyanide</td>\r\n\t\t\t\t\t<td>Sudden loss of consciousness/coma, seizures, metabolic acidosis with tachypnea, apnea</td>\r\n\t\t\t\t\t<td><p>Direct measure of ventilatory status</p>\r\n\t\t\t\t\t<p>Accurate readings during seizure activity</p>\r\n\t\t\t\t\t<p>Earliest indicator of respiratory compromise</p>\r\n\t\t\t\t\t<p>Non-invasive identification of metabolic acidosis</p></td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"subtitle2_left\">Incapacitating agents</td>\r\n\t\t\t\t\t<td rowspan=\"3\">Laryngospasm, bronchospasm, respiratory failure</td>\r\n\t\t\t\t\t<td rowspan=\"3\"><p>Rapid identification of laryngospasm</p>\r\n\t\t\t\t\t<p>Rapid identification of bronchospasm</p>\r\n\t\t\t\t\t<p>Earliest indicator of respiratory compromise</p></td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"indent1\">Lacrimators (Mace)</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"indent1\">Capsaicin</td>\r\n\t\t\t\t</tr>\r\n</tbody>\r\n</table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">3.00000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Media_Notes msdt:dt=\"string\">1/4/2007 added to spreadsheet and sent to Terrence 1/5/2007 granted 11/29/2007--renewal requested. EM 2/6/2008--not using Lippincott figures any more due to price increase. EM 2/11/2008--per MN, this is a same author request, sent to Laura.EM 2/14/2008--renewal granted. EM 1/2/2009--Renewal requested (JD). 1/17/2009--Renewal granted, mailed back agreement (JD). 1/9/2010--Renewal granted via Rightslink (JD).</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=11283&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>EtCO2_chem_terrorism.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from: Krauss B. Capnography as a rapid assessment and triage tool for chemical terrorism. Pediatr Emerg Care 2005; 21:493. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50827 Version 11.0</div></div></div>"},"50829":{"type":"graphic_figure","displayName":"Schematic of gastrointestinal greater nervous system","title":"Schematic of gastrointestinal greater nervous system","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic of gastrointestinal greater nervous system</div><div class=\"cntnt\"><img style=\"width:319px; height:256px;\" src=\"images/OBGYN/50829_Schematic_GI_nervous_system.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CNS: central nervous system; ENS: enteric nervous system; ANS: autonomic nervous system.</div><div id=\"graphicVersion\">Graphic 50829 Version 2.0</div></div></div>"},"50830":{"type":"graphic_waveform","displayName":"Advanced case 12","title":"Advanced case 12","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Advanced case 12</div><div class=\"cntnt\"><img style=\"width:540px; height:325px;\" src=\"images/CARD/50830_Advanced_case_12.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 50830 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"50831":{"type":"graphic_picture","displayName":"Communicating hydrocele 2","title":"Communicating hydrocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Communicating hydrocele</div><div class=\"cntnt\"><img style=\"width:432px; height:274px;\" src=\"images/EM/50831_Communicating_hydrocele_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Communicating hydroceles usually develop as a result of failure of the processus vaginalis to close during development. The patent processus vaginalis is demonstrated in Panel B.</div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 50831 Version 2.0</div></div></div>"},"50832":{"type":"graphic_figure","displayName":"Veins upper extremity","title":"Upper extremity veins","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Upper extremity veins</div><div class=\"cntnt\"><img style=\"width:411px; height:256px;\" src=\"images/PEDS/50832_Veins_upper_extremity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cephalic, basilic, and median cubital veins can be cannulated to provide a route for rapid drug and fluid delivery in children.</div><div id=\"graphicVersion\">Graphic 50832 Version 1.0</div></div></div>"},"50833":{"type":"graphic_table","displayName":"Irritant herbal ingredients","title":"Irritant herbal ingredients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Irritant herbal ingredients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Drug</td>\n<td class=\"subtitle1\">Effect</td>\n</tr>\n<tr>\n<td>Alfalfa</td>\n<td>Irritant, canavanine in seeds</td>\n</tr>\n<tr>\n<td>Arnica</td>\n<td>Irritant to mucous membranes</td>\n</tr>\n<tr>\n<td>Asafoetida</td>\n<td>Irritant gum</td>\n</tr>\n<tr>\n<td>Blue flag</td>\n<td>Irritant gum and oil</td>\n</tr>\n<tr>\n<td>Bogbean</td>\n<td>Irritant to GI tract</td>\n</tr>\n<tr>\n<td>Boldo</td>\n<td>Irritant oil</td>\n</tr>\n<tr>\n<td>Buchu</td>\n<td>Irritant oil</td>\n</tr>\n<tr>\n<td>Capsicum</td>\n<td>Capsaicinoids, mucosal irritants</td>\n</tr>\n<tr>\n<td>Cassia</td>\n<td>Irritant to mucous membranes, oil</td>\n</tr>\n<tr>\n<td>Cinnamon</td>\n<td>Irritant to mucous membranes, oil</td>\n</tr>\n<tr>\n<td>Cohosh, blue</td>\n<td>Irritant to mucous membranes; spasmogenic in vitro</td>\n</tr>\n<tr>\n<td>Cowslip</td>\n<td>Irritant saponins</td>\n</tr>\n<tr>\n<td>Drosera</td>\n<td>Plubagin, irritant</td>\n</tr>\n<tr>\n<td>Eucalyptus</td>\n<td>Irritant oil</td>\n</tr>\n<tr>\n<td>False unicorn</td>\n<td>Large doses may cause vomiting</td>\n</tr>\n<tr>\n<td>Figwort</td>\n<td>Purgative effect</td>\n</tr>\n<tr>\n<td>Garlic</td>\n<td>Raw clove</td>\n</tr>\n<tr>\n<td>Ground ivy</td>\n<td>Irritant oil</td>\n</tr>\n<tr>\n<td>Guaiacum</td>\n<td>Avoid if inflammatory condition</td>\n</tr>\n<tr>\n<td>Horse-chestnut</td>\n<td>Saponin constituents, contraindicated in existing renal disease</td>\n</tr>\n<tr>\n<td>Horseradish</td>\n<td>Irritant oil</td>\n</tr>\n<tr>\n<td>Hydrangea</td>\n<td>May cause gastroenteritis, hydrangin</td>\n</tr>\n<tr>\n<td>Jamaica dogwood</td>\n<td>Irritant to humans</td>\n</tr>\n<tr>\n<td>Juniper</td>\n<td>Irritant oil</td>\n</tr>\n<tr>\n<td>Lemon verbena</td>\n<td>Irritant oil</td>\n</tr>\n<tr>\n<td>Lime flower</td>\n<td>Irritant to kidney, oil</td>\n</tr>\n<tr>\n<td>Nettle</td>\n<td>Tea irritant to stomach</td>\n</tr>\n<tr>\n<td>Parsley</td>\n<td>Irritant oil</td>\n</tr>\n<tr>\n<td>Pennyroyal</td>\n<td>Toxic and irritant oil</td>\n</tr>\n<tr>\n<td>Pilewort</td>\n<td>Irritant sap</td>\n</tr>\n<tr>\n<td>Pleurisy root</td>\n<td>Gastrointestinal irritant</td>\n</tr>\n<tr>\n<td>Pokeroot</td>\n<td>Irritant saponins</td>\n</tr>\n<tr>\n<td>Pulsatilla</td>\n<td>Irritant to mucous membranes</td>\n</tr>\n<tr>\n<td>Queen's delight</td>\n<td>Diterpene constituents</td>\n</tr>\n<tr>\n<td>Sarsaparilla</td>\n<td>Saponins</td>\n</tr>\n<tr>\n<td>Senega</td>\n<td>Saponins</td>\n</tr>\n<tr>\n<td>Skunk cabbage</td>\n<td>Inflammatory and blistering to skin</td>\n</tr>\n<tr>\n<td>Squill</td>\n<td>Saponins</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996, p.284.</div><div id=\"graphicVersion\">Graphic 50833 Version 2.0</div></div></div>"},"50834":{"type":"graphic_picture","displayName":"Extensor nodules in scleroderma","title":"Extensor nodules in scleroderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extensor nodules in scleroderma</div><div class=\"cntnt\"><img style=\"width:427px; height:253px;\" src=\"images/RHEUM/50834_Extensor_nodules_in_sclerod.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodules at the elbows in a child with a variant of localized scleroderma. Similar nodules may be present in the extensor and/or flexor tendons in the hands, and at the knees or ankle joints.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 50834 Version 1.0</div></div></div>"},"50835":{"type":"graphic_picture","displayName":"AIDS-related Kaposis sarcoma - palate","title":"AIDS-related Kaposi's sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AIDS-related Kaposi's sarcoma</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/50835_Kaposis_sarcoma_palate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodules of Kaposi's sarcoma are present on the palate.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50835 Version 3.0</div></div></div>"},"50836":{"type":"graphic_table","displayName":"Permissible fracture displacement for conservative treatment","title":"Permissible fracture displacement for conservative treatment of phalangeal and metacarpal fractures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Permissible fracture displacement for conservative treatment of phalangeal and metacarpal fractures</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Bone</td> <td class=\"subtitle1\">Sub-location</td> <td class=\"subtitle1\">Finger</td> <td class=\"subtitle1\">Angulation (degrees)</td> <td class=\"subtitle1\">Rotation (degrees)</td> <td class=\"subtitle1\">Shortening (mm)</td> <td class=\"subtitle1\">Bony apposition (percentage)</td> </tr> <tr> <td>Phalanx</td> <td>Shaft</td> <td>All</td> <td>10</td> <td>0</td> <td>2</td> <td>50</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"8\">Metacarpal</td> <td rowspan=\"4\">Neck</td> <td>Small</td> <td>40</td> <td>0</td> <td>5</td> <td>50</td> </tr> <tr> <td>Ring</td> <td>30</td> <td>0</td> <td>5</td> <td>50</td> </tr> <tr> <td>Long</td> <td>15</td> <td>0</td> <td>5</td> <td>50</td> </tr> <tr> <td>Index</td> <td>10</td> <td>0</td> <td>5</td> <td>50</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Shaft</td> <td>Small</td> <td>30</td> <td>0</td> <td>5</td> <td>50</td> </tr> <tr> <td>Ring</td> <td>20</td> <td>0</td> <td>5</td> <td>50</td> </tr> <tr> <td>Long</td> <td>10</td> <td>0</td> <td>5</td> <td>50</td> </tr> <tr> <td>Index</td> <td>10</td> <td>0</td> <td>5</td> <td>50</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50836 Version 2.0</div></div></div>"},"50840":{"type":"graphic_diagnosticimage","displayName":"Goiter MRI","title":"Coronal (top) and axial (bottom) MRI scan of a giant intrathoracic goiter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coronal (top) and axial (bottom) MRI scan of a giant intrathoracic goiter</div><div class=\"cntnt\"><img style=\"width:402px; height:537px;\" src=\"images/PULM/50840_Goiter_MRI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marked tracheal narrowing; venous collaterals in the subcutaneous fat of the anterior chest wall suggest chronic superior vena cava (SVC) compression.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 50840 Version 6.0</div></div></div>"},"50841":{"type":"graphic_picture","displayName":"Erythema marginatum on trunk","title":"Erythema marginatum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema marginatum</div><div class=\"cntnt\"><img style=\"width:291px; height:335px;\" src=\"images/RHEUM/50841_Erythema_marginatum_on_trun.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image of the back of a patient with acute rheumatic fever shows the characteristic rash, erythema marginatum. Note the erythematous lesions with pale centers and rounded or serpiginous margins.</div><div class=\"graphic_reference\">Reproduced with permission from: Binotto MA, Guilherme L, Tanaka AC. Rheumatic fever. Images Paediatr Cardiol 2002; 11:12. Copyright © 2002 Images in Paediatric Cardiology.</div><div id=\"graphicVersion\">Graphic 50841 Version 2.0</div></div></div>"},"50842":{"type":"graphic_diagnosticimage","displayName":"Fourth metacarpal oblique shaft fracture","title":"Fourth metacarpal oblique shaft fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fourth metacarpal oblique shaft fracture</div><div class=\"cntnt\"><img style=\"width:384px; height:288px;\" src=\"images/EM/50842_Metacarpal_shaft_fx_long_ob.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral radiograph shows a long oblique fracture of 4th metacarpal shaft. Although minimally displaced, this fracture is at high risk for subsequent proximal displacement (ie, shortening)&nbsp;due to the length of the fracture (fracture length is greater than two times bone diameter).</div><div class=\"graphic_reference\">Courtesy of Josh Bloom, MD, MPH.</div><div id=\"graphicVersion\">Graphic 50842 Version 3.0</div></div></div>"},"50844":{"type":"graphic_picture","displayName":"Narrow band imaging Endosc I","title":"Narrow band imaging of Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Narrow band imaging of Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:540px; height:229px;\" src=\"images/GAST/50844_Narrow_band_imaging_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An area with nondysplastic Barrett's mucosa at the squamo-columnar junction imaged with high resolution endoscopy (left) and with narrow band imaging (right).</div><div class=\"graphic_reference\">Reproduced with permission from: www.Barrett.nl. Copyright &#169; Amsterdam Esophageal Research Foundation.</div><div id=\"graphicVersion\">Graphic 50844 Version 1.0</div></div></div>"},"50845":{"type":"graphic_figure","displayName":"Atrial activation after maze or radial procedure","title":"Schematic representation of atrial activation in sinus rhythm and after the maze procedure or the radial approach","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Schematic representation of atrial activation in sinus rhythm and after the maze procedure or the radial approach</div><div class=\"cntnt\"><img style=\"width:532px; height:391px;\" src=\"images/CARD/50845_Activation_maze_vs_radial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal activation sequence of the left atrium is maintained with the radial approach while it is altered with the Maze procedure. Thick lines represent the surgical incisions and the solid areas represent parts of the atria surgically isolated or excised; dashed lines represent normal conduction pathways between the atrial appendages, the interatrial septum, and the crista terminalis. Arrows indicate the activation sequence.</div><div class=\"graphic_footnotes\">AVN: atrioventricular node; SAN: sinoatrial node; RAA: right atrial appendage; LAA: left atrial appendage; SVC: superior vena cava; IVC: inferior vena cava; PVs: pulmonary veins.</div><div class=\"graphic_reference\">Reprinted with permission from the Society of Thoracic Surgeons. Netta T, Cox R, Schuessler RB, et al. Ann Thorac Surg 1999; 67:27.</div><div id=\"graphicVersion\">Graphic 50845 Version 3.0</div></div></div>"},"50846":{"type":"graphic_picture","displayName":"Cutis marmorata - legs","title":"Cutis marmorata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutis marmorata</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/50846_Cutis_marmorata_legs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A net-like, violaceous pattern is visible on the legs of this infant.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50846 Version 3.0</div></div></div>"},"50847":{"type":"graphic_picture","displayName":"Hidradenitis suppurativa sinus tract","title":"Hidradenitis suppurativa sinus tract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hidradenitis suppurativa sinus tract</div><div class=\"cntnt\"><img style=\"width:396px; height:370px;\" src=\"images/SURG/50847_Discsinusscissorsedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a sinus tract related to a hidradenitis suppurativa inflamed nodule. The tract is identified by probing the margins of the wound. The procedure is performed using a local anesthetic with epinephrine.</div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD. Copyright © 2011.</div><div id=\"graphicVersion\">Graphic 50847 Version 6.0</div></div></div>"},"50848":{"type":"graphic_picture","displayName":"Acute hemorrhagic edema of infancy","title":"Acute hemorrhagic edema of infancy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acute hemorrhagic edema of infancy</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/50848_Acute_hemorr_edema_infancy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular purpuric plaques are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50848 Version 3.0</div></div></div>"},"50849":{"type":"graphic_figure","displayName":"Angiostrongylus life cycle","title":"<EM>Angiostrongylus</EM> life cycle","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\"><EM>Angiostrongylus</EM> life cycle</div><div class=\"cntnt\"><img style=\"width:471px; height:504px;\" src=\"images/ID/50849_Angiostrongyliasis_life_cyc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adult worms of <EM>A. cantonensis</EM> live in the pulmonary arteries of rats. The females lay eggs that hatch, yielding first-stage larvae in the terminal branches of the pulmonary arteries. The first-stage larvae migrate to the pharynx, are swallowed, and are passed in the feces. They penetrate, or are ingested by, an intermediate host (snail or slug). After two molts, third-stage larvae are produced, which are infective to mammalian hosts. When the mollusk is ingested by the definitive host, the third-stage larvae migrate to the brain where they develop into young adults. The young adults return to the venous system and then the pulmonary arteries where they become sexually mature. Of note, various animals act as paratenic (transport) hosts. After ingesting the infected snails, they carry the third-stage larvae, which can resume their development when the paratenic host is ingested by a definitive host. Humans can acquire the infection by eating raw or undercooked snails or slugs infected with the parasite; they may also acquire the infection by eating raw produce that contains a small snail or slug or part of one. There is some question whether or not larvae can exit the infected mollusks in slime (which may be infective to humans if ingested, for example, on produce). The disease can also be acquired by ingestion of contaminated or infected paratenic animals (crabs, freshwater shrimps). In humans, juvenile worms migrate to the brain, or rarely in the lungs, where the worms ultimately die. The life cycle of <EM>Angiostrongylus (Parastrongylus) costaricensis</EM> is similar, except that the adult worms reside in the arterioles of the ileocecal area of the definitive host. In humans, <EM>A. costaricensis</EM> often reaches sexual maturity and release eggs into the intestinal tissues. The eggs and larvae degenerate and cause intense local inflammatory reactions and do not appear to be shed in the stool.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Angiostrongyliasis. Available at: <A href=\"http://www.cdc.gov/parasites/angiostrongylus/\">http://www.cdc.gov/parasites/angiostrongylus/</A>.</div><div id=\"graphicVersion\">Graphic 50849 Version 4.0</div></div></div>"},"50850":{"type":"graphic_figure","displayName":"Child vs adult airway 1","title":"Anatomic differences between the pediatric and adult airway","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Anatomic differences between the pediatric and adult airway</div><div class=\"cntnt\"><img style=\"width:541px; height:390px;\" src=\"images/EM/50850_Child_vs_adult_airway_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relative to adults, children have 1) large tongues relative to the size of the oral cavity 2) larger tonsils and adenoids 3) a more superior location of the larynx in the neck 4) a larger and floppy epiglottis and 5) the narrowest portion of the airway functionally occuring below the vocal cords. All of these differences make endotracheal intubation in children potentially more difficult than in adults.</div><div id=\"graphicVersion\">Graphic 50850 Version 3.0</div></div></div>"},"50851":{"type":"graphic_figure","displayName":"Mechanism for neonatal humeral fracture","title":"Mechanism for neonatal humeral fracture","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Mechanism for neonatal humeral fracture</div><div class=\"cntnt\"><img style=\"width:454px; height:251px;\" src=\"images/EM/50851_Mechhumeralfx1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperextension or rotation of the ipsilateral arm may result in a proximal humeral or midshaft injury during birth.</div><div class=\"graphic_reference\">Reproduced with permission from: Sarwark JF, King EC, Luhmann SJ. Proximal humerus, scalpula, and clavicle. In: Rockwood and Wilkins' Fractures in Children, 6th edition, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50851 Version 13.0</div></div></div>"},"50854":{"type":"graphic_figure","displayName":"Live births per embryo transfer by maternal age","title":"Percentages of transfers that resulted in live births for ART cycles using fresh embryos from own and donor eggs, by ART patient's age, 2006","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Percentages of transfers that resulted in live births for ART cycles using fresh embryos from own and donor eggs, by ART patient's age, 2006</div><div class=\"cntnt\"><img style=\"width:519px; height:371px;\" src=\"images/OBGYN/50854_Live_births_per_transfer.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The above figure compares percentages of transfers resulting in live births for ART cycles using fresh embryos from donor eggs with those for ART cycles using a woman's own eggs, among women of different ages. The likelihood of a fertilized egg implanting is related to the age of the woman who produced the egg. Thus, the percentage of transfers resulting in live births for cycles using embryos from women's own eggs declines as women get older. In contrast, since egg donors are typically in their 20s or early 30s, the percentage of transfers resulting in live births for cycles using embryos from donor eggs remained consistently high at above 40 percent.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. 2006 Assisted Reproductive Technology Success Rates: National Summary and Fertility Clinic Reports, Atlanta: Centers for Disease Control and Prevention, 2008.</div><div id=\"graphicVersion\">Graphic 50854 Version 2.0</div></div></div>"},"50856":{"type":"graphic_figure","displayName":"Neurovascular anatomy knee","title":"Neurovascular anatomy of the knee","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Neurovascular anatomy of the knee</div><div class=\"cntnt\"><img style=\"width:462px; height:422px;\" src=\"images/PEDS/50856_Neurovascular_anatomy_knee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The position of the popliteal artery and peroneal nerve make them vulnerable to injury when the knee is dislocated.</div><div id=\"graphicVersion\">Graphic 50856 Version 2.0</div></div></div>"},"50857":{"type":"graphic_table","displayName":"Dx gingivitis periodontitis","title":"Clinical parameters for diagnosing and classifying gingivitis and periodontitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical parameters for diagnosing and classifying gingivitis and periodontitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Diagnosis and classification: </td> <td class=\"subtitle1\" colspan=\"3\">Severity </td> </tr> <tr> <td class=\"subtitle2\"> <p>Main criteria:</p> <p><em>Attachment loss*</em></p> </td> <td class=\"subtitle2\"> <p>Secondary criteria:</p> <p><em>Probing depth</em></p> </td> <td class=\"subtitle2\"> <p>Additional criteria:</p> <p><em>Radiographic alveolar bone loss</em></p> </td> </tr> <tr> <td>Gingivitis</td> <td>0</td> <td>&#8804;3 mm</td> <td>None</td> </tr> <tr> <td>Slight periodontitis</td> <td>1 or 2 mm</td> <td>1 to 4 mm</td> <td>1 to 2 mm</td> </tr> <tr> <td>Moderate periodontitis</td> <td>3 or 4 mm</td> <td>4 to 6 mm</td> <td>1/3 of root length</td> </tr> <tr> <td>Severe periodontitis</td> <td>&#8805;5 mm</td> <td>&#8805;6 mm</td> <td>&#62;50% of root length</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">As a general guide, extent can be characterized as localized = ≤30% of sites involved and generalized = &gt;30% of sites involved. Diseased and active sites have a higher chance to bleed upon probing or even present suppuration. Increased tooth mobility and furcation involvement may be clinically detectable in cases of moderate and severe periodontitis. Treatment decisions are usually based on probing depths rather than attachment loss.</div><div class=\"graphic_footnotes\">* Data from: Armitage, GC. Development of a Classification System for Periodontal Diseases and Conditions. Ann Periodontol 1999; 4:1-6.</div><div id=\"graphicVersion\">Graphic 50857 Version 2.0</div></div></div>"},"50859":{"type":"graphic_figure","displayName":"Peptide hormone synthesis","title":"Peptide hormone synthesis","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Peptide hormone synthesis</div><div class=\"cntnt\"><img style=\"width:517px; height:343px;\" src=\"images/GAST/50859_Peptide_hormone_synthesis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peptide hormone synthesis begins with transcription of genomic DNA into messenger RNA (mRNA), which is then translated into protein. Preprohormone in ribosomes is modified by posttranslational processing in the Golgi apparatus into various peptide cleavage products that are eventually secreted.</div><div id=\"graphicVersion\">Graphic 50859 Version 2.0</div></div></div>"},"50860":{"type":"graphic_picture","displayName":"Adenosarcoma uterus","title":"Uterine adenosarcoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Uterine adenosarcoma</div><div class=\"cntnt\"><img style=\"width:504px; height:381px;\" src=\"images/OBGYN/50860_Adenosarcoma_uterus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This cellular stroma of this tumor forms hypercelluar cuffs surrounding the benign-appearing, mostly slit-like glands. Foci of squamous metaplasia are present.</div><div class=\"graphic_reference\">Reproduced with permission from: Silverberg SG, Kurman RJ. Tumors of the Uterine Corpus and Gestational Trophoblastic Disease. AFIP Atlas of Tumor Pathology, version 2.0, American Registry of Pathology, Washington DC, 1995.</div><div id=\"graphicVersion\">Graphic 50860 Version 3.0</div></div></div>"},"50861":{"type":"graphic_figure","displayName":"Modified Epley Left","title":"Modified Epley maneuver for self-treatment of benign positional vertigo (left)","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Modified Epley maneuver for self-treatment of benign positional vertigo (left)</div><div class=\"cntnt\"><img style=\"width:510px; height:435px;\" src=\"images/PC/50861_Modified_Epleys_Left.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This maneuver should be carried out three times a day. Repeat this daily until you are free from positional vertigo for 24 hours.</div><div class=\"graphic_reference\">Reproduced from Http://www.charite.de/ch/neuro/englishL.htm</div><div id=\"graphicVersion\">Graphic 50861 Version 2.0</div></div></div>"},"50864":{"type":"graphic_figure","displayName":"Techniques myocardial viability","title":"Predictive accuracy of imaging tests for myocardial viability","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Predictive accuracy of imaging tests for myocardial viability</div><div class=\"cntnt\"><img style=\"width:440px; height:481px;\" src=\"images/CARD/50864_Techniquesmyocardialviabi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Weighted mean positive and negative predictive accuracy of the different imaging tests for predicting recovery of segmental function after revascularization from a meta-analysis of 52 studies that included 1367 patients with ischemic left ventricular dysfunction. The rectangles are centered on the weighted means, and the size of the rectangles indicates 95 percent confidence intervals. The highest negative predictive values were seen with FDG-PET, reinjection thallium SPECT, and dobutamine echocardiography, while the highest positive predictive value was seen with dobutamine echocardiography.</div><div class=\"graphic_footnotes\">FDG-PET: fluorodeoxyglucose-positron emission tomography; SPECT: single-photon emission computed tomography.</div><div class=\"graphic_reference\">Adapted with permission from: Bax JJ, Poldermans D, Elhendy A, et al. Curr Probl Cardiol 2001; 26:141. Copyright © 2001 Elsevier.</div><div id=\"graphicVersion\">Graphic 50864 Version 3.0</div></div></div>"},"50866":{"type":"graphic_picture","displayName":"Inferior shoulder dislocation reduction","title":"Inferior shoulder dislocation reduction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inferior shoulder dislocation reduction</div><div class=\"cntnt\"><img style=\"width:401px; height:373px;\" src=\"images/EM/50866_Inferior_shoulder_disloc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The traction-countertraction approach is employed to reduce inferior dislocations. Forces are aligned with the abducted arm.</div><div class=\"graphic_reference\">Courtesy of Scott C Sherman, MD.</div><div id=\"graphicVersion\">Graphic 50866 Version 5.0</div></div></div>"},"50868":{"type":"graphic_picture","displayName":"Perihepatitis in Chlamydia","title":"Perihepatitis in chlamydia infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perihepatitis in chlamydia infection</div><div class=\"cntnt\"><img style=\"width:360px; height:267px;\" src=\"images/ID/50868_Perihepatitis_in_Chlamydia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflammation of the liver capsule and adjacent peritoneum can be seen via laparascope as an uncommon finding in women with Chlamydial infection.</div><div class=\"graphic_reference\">Reproduced from the Centers for Disease Control and Prevention.</div><div id=\"graphicVersion\">Graphic 50868 Version 2.0</div></div></div>"},"50871":{"type":"graphic_diagnosticimage","displayName":"MRI subdural hematoma","title":"MRI of the brain demonstrates a spontaneous subdural hematoma over the right cerebral hemisphere","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of the brain demonstrates a spontaneous subdural hematoma over the right cerebral hemisphere</div><div class=\"cntnt\"><img style=\"width:396px; height:396px;\" src=\"images/NEURO/50871_MRI_right_SDH.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div class=\"graphic_reference\">Courtesy of Neuroradiology Department, Thomas Jefferson University, Philadelphia, PA.</div><div id=\"graphicVersion\">Graphic 50871 Version 4.0</div></div></div>"},"50872":{"type":"graphic_table","displayName":"Fetal hemoglobin by GA","title":"Hemoglobin, g/dL","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hemoglobin, g/dL</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">GA</td>\n<td class=\"subtitle1\">5th percentile</td>\n<td class=\"subtitle1\">Mean</td>\n<td class=\"subtitle1\">95th percentile</td>\n</tr>\n<tr>\n<td>20</td>\n<td>9.7</td>\n<td>11.3</td>\n<td>12.8</td>\n</tr>\n<tr>\n<td>22</td>\n<td>10.0</td>\n<td>11.6</td>\n<td>13.1</td>\n</tr>\n<tr>\n<td>24</td>\n<td>10.3</td>\n<td>11.9</td>\n<td>13.4</td>\n</tr>\n<tr>\n<td>26</td>\n<td>10.7</td>\n<td>12.2</td>\n<td>13.8</td>\n</tr>\n<tr>\n<td>28</td>\n<td>11.0</td>\n<td>12.5</td>\n<td>14.1</td>\n</tr>\n<tr>\n<td>30</td>\n<td>11.3</td>\n<td>12.8</td>\n<td>14.4</td>\n</tr>\n<tr>\n<td>32</td>\n<td>11.6</td>\n<td>13.1</td>\n<td>14.7</td>\n</tr>\n<tr>\n<td>34</td>\n<td>11.9</td>\n<td>13.5</td>\n<td>15.0</td>\n</tr>\n<tr>\n<td>36</td>\n<td>12.2</td>\n<td>13.8</td>\n<td>15.3</td>\n</tr>\n<tr>\n<td>38</td>\n<td>12.5</td>\n<td>14.1</td>\n<td>15.6</td>\n</tr>\n<tr>\n<td>40</td>\n<td>12.8</td>\n<td>14.4</td>\n<td>16.0</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 50872 Version 1.0</div></div></div>"},"50873":{"type":"graphic_table","displayName":"Risk factors for dehiscence","title":"Factors associated with increased risk of fascial disruption","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors associated with increased risk of fascial disruption</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Age &#62;65 years</td> </tr> <tr> <td>Emergency surgery</td> </tr> <tr> <td>Malignancy</td> </tr> <tr> <td>Anemia: hemotocrit &#60;30 percent</td> </tr> <tr> <td>Obesity: body mass index &#62;30 kg/m2</td> </tr> <tr> <td>Ascites</td> </tr> <tr> <td>Diabetes mellitus</td> </tr> <tr> <td>Pulmonary disease, COPD, chronic cough</td> </tr> <tr> <td>Shock</td> </tr> <tr> <td>Poor nutrition: albumin &#60;3.5 g/dL</td> </tr> <tr> <td>Infection</td> </tr> <tr> <td>Immunosuppressive therapy, glucocorticoids, antineoplastic agents</td> </tr> <tr> <td>Jaundice</td> </tr> <tr> <td>Male gender</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50873 Version 2.0</div></div></div>"},"50875":{"type":"graphic_table","displayName":"EORTC trial 22921 rectal cancer","title":"EORTC trial of neoadjuvant chemoradiotherapy versus radiotherapy prior to surgery for rectal cancer and adjuvant chemotherapy versus no adjuvant chemotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">EORTC trial of neoadjuvant chemoradiotherapy versus radiotherapy prior to surgery for rectal cancer and adjuvant chemotherapy versus no adjuvant chemotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tr>\n\t\t\t\t<td class=\"subtitle1\">&nbsp;</td>\n\t\t\t\t<td class=\"subtitle1\">Preop RT</td>\n\t\t\t\t<td class=\"subtitle1\">Preop RT + adjuvant chemo</td>\n\t\t\t\t<td class=\"subtitle1\">Preop CRT + adjuvant chemo</td>\n\t\t\t\t<td class=\"subtitle1\">Preop CRT</td>\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Number of patients</td>\n\t\t\t\t<td>252</td>\n\t\t\t\t<td>253</td>\n\t\t\t\t<td>253</td>\n\t\t\t\t<td>253</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Treatment-related grade &#8805;2 diarrhea, percent</td>\n\t\t\t\t<td>17.3</td>\n\t\t\t\t<td>17.3</td>\n\t\t\t\t<td>37.6</td>\n\t\t\t\t<td>37.6</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Sphincter preserving surgery, percent</td>\n\t\t\t\t<td>50.5</td>\n\t\t\t\t<td>50.5</td>\n\t\t\t\t<td>52.8</td>\n\t\t\t\t\t<td>52.8</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>5 year cumulative rate of local relapse, percent</td>\n\t\t\t\t<td>17.1</td>\n\t\t\t\t<td>9.6</td>\n\t\t\t\t<td>7.6</td>\n\t\t\t\t<td>8.7</td>\n\t\t\t</tr>\n\t</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=46097&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>EORTC_trial_22921_rectal_ca.htm</title></head></div><div class=\"graphic_footnotes\">EORTC: European Organisation for Research and Treatment of Cancer; Preop: preoperative; RT: radiation therapy; chemo: chemotherapy; CRT: chemoradiotherapy;.</div><div class=\"graphic_reference\">Data from: Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355:1114.</div><div id=\"graphicVersion\">Graphic 50875 Version 4.0</div></div></div>"},"50876":{"type":"graphic_table","displayName":"Diagnostic criteria migraine","title":"Diagnostic criteria for migraine","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for migraine</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Migraine without aura</td> </tr> <tr> <td class=\"indent1\">A. At least five attacks fulfilling criteria B through D</td> </tr> <tr> <td class=\"indent1\">B. Headache attacks lasting 4 to 72 hours (untreated or unsuccessfully treated)</td> </tr> <tr> <td class=\"sublist2_start\">C. Headache has at least two of the following characteristics:</td> </tr> <tr> <td class=\"sublist3\">Unilateral location</td> </tr> <tr> <td class=\"sublist3\">Pulsating quality</td> </tr> <tr> <td class=\"sublist3\">Moderate or severe pain intensity</td> </tr> <tr> <td class=\"sublist3\">Aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs)</td> </tr> <tr> <td class=\"sublist2_start\">D. During headache at least one of the following:</td> </tr> <tr> <td class=\"sublist3\">Nausea, vomiting, or both</td> </tr> <tr> <td class=\"sublist3\">Photophobia and phonophobia</td> </tr> <tr> <td class=\"indent1\">E. Not better accounted for by another ICHD-3b diagnosis</td> </tr> <tr> <td class=\"subtitle1_single\">Migraine with aura</td> </tr> <tr> <td class=\"indent1\">A. At least two attacks fulfilling criterion B and C</td> </tr> <tr> <td class=\"sublist2_start\">B. One or more of the following fully reversible aura symptoms:</td> </tr> <tr> <td class=\"sublist3\">Visual</td> </tr> <tr> <td class=\"sublist3\">Sensory</td> </tr> <tr> <td class=\"sublist3\">Speech and/or language</td> </tr> <tr> <td class=\"sublist3\">Motor</td> </tr> <tr> <td class=\"sublist3\">Brainstem</td> </tr> <tr> <td class=\"sublist3\">Retinal</td> </tr> <tr> <td class=\"sublist2_start\">C. At least two of the following four characteristics:</td> </tr> <tr> <td class=\"sublist3\">At least one aura symptom spreads gradually over &#8805;5 minutes, and/or two or more symptoms occur in succession</td> </tr> <tr> <td class=\"sublist3\">Each individual aura symptom lasts 5 to 60 minutes</td> </tr> <tr> <td class=\"sublist3\">At least one aura symptom is unilateral</td> </tr> <tr> <td class=\"sublist3\">The aura is accompanied, or followed within 60 minutes, by headache</td> </tr> <tr> <td class=\"indent1\">D. Not better accounted for by another ICHD-3b diagnosis, and transient ischemic attack has been excluded</td> </tr> <tr> <td class=\"subtitle1_single\">Features of migraine in children and adolescents </td> </tr> <tr> <td class=\"indent1\">Attacks may last 2 to 72 hours*</td> </tr> <tr> <td class=\"indent1\">Headache is more often bilateral than in adults; an adult pattern of unilateral pain usually emerges in late adolescence or early adulthood</td> </tr> <tr> <td class=\"indent1\">Occipital headache is rare and raises diagnostic caution for structural lesions</td> </tr> <tr> <td class=\"indent1\">Photophobia and phonophobia may be inferred by behavior in young children</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICHD-3b: International Classification of Headache Disorders, 3<SUP>rd</SUP> edition (beta version).<br />* The evidence for untreated durations of less than&nbsp;two hours in children has not been substantiated.<br /></div><div class=\"graphic_reference\">Adapted from: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3<SUP>rd</SUP> edition (beta version). Cephalalgia 2013; 33:629.</div><div id=\"graphicVersion\">Graphic 50876 Version 9.0</div></div></div>"},"50878":{"type":"graphic_table","displayName":"Muscle innervation part B","title":"Function and peripheral and segmental innervation of muscles: part B","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Function and peripheral and segmental innervation of muscles: part B</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Function</td>\n\n      <td class=\"subtitle1\">Muscle</td>\n\n      <td class=\"subtitle1\">Nerve</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">Plexus brachialis: C5-T1 (cont'd)</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Abduction of metacarpal I</td>\n\n      <td>Abductor pollicis brevis</td>\n\n      <td>C7-T1</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Flexion of proximal phalanx of thumb</td>\n\n      <td>Flexor pollicis brevis</td>\n\n      <td>C7-T1</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Opposition of metacarpal I</td>\n\n      <td>Opponens pollicis brevis</td>\n\n      <td>C6-C7</td>\n\n    </tr>\n\n    <tr><td colspan=\"2\" rowspan=\"1\">&nbsp;</td><td class=\"subtitle2_left\">Median nerve</td></tr><tr>\n\n      <td class=\"indent1\">Flexion of proximal phalanges and extension of other joints</td>\n\n      <td>Lumbricales: Index and middle fingers</td>\n\n      <td class=\"\">C8-T1</td>\n\n    </tr>\n\n    \n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;</td>\n\n      \n\n      <td class=\"subtitle2_left\">Ulnar nerve</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"indent1\" rowspan=\"1\">Flexion of proximal phalanges and extension of other joints</td><td>Lumbricales: Fourth and little fingers</td>\n\n      <td>C8-T1</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;</td>\n\n      <td class=\"subtitle2_left\">Ulnar nerve</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Flexion and ulnar bending of hand</td>\n\n      <td>Flexor carpi ulnaris</td>\n\n      <td>C7-T1</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Flexion of proximal phalanges of fourth and little fingers</td>\n\n      <td>Flexor digitorum profundus (ulnar portion)</td>\n\n      <td>C7-T1</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Adduction of metacarpal I</td>\n\n      <td>Adductor pollicis</td>\n\n      <td>C8-T1</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Abduction of middle finger</td>\n\n      <td>Abductor digiti V</td>\n\n      <td>C8-T1</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Opposition of little finger</td>\n\n      <td>Opponens digiti V</td>\n\n      <td>C7-T1</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;&nbsp;</td>\n\n      \n\n      <td class=\"subtitle2_left\">Ulnar nerve</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Flexion of little finger in metacarpo- phalangeal joint</td>\n\n      <td>Flexor digiti brevis V</td>\n\n      <td>C7-T1</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Bending of proximal phalanges; stretching of fingers III, IV,\nand V in middle and distal joints as well as spreading and closing of\nthese fingers</td>\n\n      <td><p>Interossei palmares and dorsales</p>\n\t\t\t<p>Lumbricales 3 and 4</p></td>\n\n      <td>C8-T1</td>\n\n    </tr>\n\n\n    \n\n    <tr>\n\n      \n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;</td>\n\n      <td class=\"subtitle2_left\">Radial nerve</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Extension of elbow</td>\n\n      <td>Triceps brachii and M. anconeus</td>\n\n      <td>C6-C8</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">Flexion of elbow</td>\n\n      <td>Brachioradialis</td>\n\n      <td>C5-C6</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"indent1\">Extension and radial abduction of hand </td>\n      <td>Extensor carpi radialis</td>\n      <td>C6-C8</td>\n    </tr>\n    <tr>\n      <td class=\"indent1\"><p>Extension of proximal phalanges II-V</p>\n\t\t\t<p>Extension and dorsoflexion of hand; stretching and spreading of fingers</p></td>\n      <td>Extensor digitorum</td>\n      <td>C6-C8</td>\n    </tr>\n    \n\n    <tr>\n\n      <td class=\"indent1\">Extension of proximal phalanx of little finger</td>\n\n      <td>Extensor digiti V</td>\n\n      <td>C6-C8</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">Extension and ulnar deviation of hand</td>\n\n      <td>Extensor carpi ulnaris </td>\n\n      <td>C6-C8</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"indent1\">Supination of forearm </td>\n      <td>Supinator</td>\n      <td>C5-C7</td>\n    </tr>\n    <tr>\n\n      <td class=\"indent1\">Abduction of metacarpal I; radial extension of hand</td>\n\n      <td>Abductor pollicis longus</td>\n\n      <td>C6-C7</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Extension of thumb in proximal phalanx</td>\n\n      <td>Extensor pollicis brevis</td>\n\n      <td>C7-C8</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"indent1\">Extension of distal phalanges of thumb</td>\n      <td>Extensor pollicis longus</td>\n      <td>C7-C8</td>\n    </tr>\n    <tr>\n\n      <td class=\"indent1\">Extension of proximal phalanx of index finger</td>\n\n      <td>Extensor indicis proprius</td>\n\n      <td>C6-C8</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;</td>\n\n      <td class=\"subtitle2_left\">Thoracic nerves</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Elevation of ribs; expiration; abdominal compression; anteroflexion and lateroflexion of trunk</td>\n\n      <td>Thoracis and abdominalis</td>\n\n      <td>T1-L1</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">3/23/99-Perm requested. 5/18/99-Perm granted for 1 edition. 11/18/99-perm requested for 8.1. 2/23/00-perm granted for 8.2 and 8.3 (put back in gold). \r\n10/16/2000-may not be in gold. 11/29/2000-renewal sent. 12/4/2000-perm granted 9.1-9.3; 11/7/2001 -renewal requested -jm;  11/13/2001 -renewal granted -jm; 5/14/2002 - received invoice for figure 1 - $85.00.  Gave to ajeah -jm\r\n10/4/2002 - renewal requested -jm; 10/9/2002 -renewal granted, no charge.   CD-Rom granted for 1 year, and internet perm expires after 2 years -jm\r\n10/8/2003 perm granted for 2 years\r\n11/14/2005 renewal requested 11/17/2005 granted - they will send invoice 1/10/2006 invoice to susan\r\n10/10/2006 renewal requested 1/9/2007 renewal granted (online perm until 2008) - invoice to come\r\n2/23/2007 - Inovice to Tammy.mt\r\n11/28/2007--renewal requested. EM\r\n1/8/2008--renewal granted, invoice to Tammy. EM\r\n\r\n1/13/2009--Requested renewal (JD).\r\n2/9/2009--Renewal granted via permissions agreement, awaiting formal invoice (JD).\r\n4/8/2009--Formal invoice received, to Catherine for payment (JD).\r\n\r\n The total fee of $&amp;quot;120.00&amp;quot;was originally charged to\r\nMuscle_innervation_part_A\r\nMuscle_innervation_part_B\r\nMuscle_innervation_part_C</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=59939&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Muscle_innervation_part_B.htm</title></head></div><div class=\"graphic_reference\">Data from Duus, P. Topical Diagnosis in Neurology, 2nd ed. Thieme Medical Publishers, New York, 1989.</div><div id=\"graphicVersion\">Graphic 50878 Version 2.0</div></div></div>"},"50881":{"type":"graphic_figure","displayName":"RR stroke lisin vs chlor ALLHAT","title":"Stroke with lisinopril versus chlorthalidone in ALLHAT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stroke with lisinopril versus chlorthalidone in ALLHAT</div><div class=\"cntnt\"><img style=\"width:400px; height:333px;\" src=\"images/NEPH/50881_RR_stroke_lisin_vs_chlor_AL.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Increased relative risk of stroke with lisinopril. Graph, with natural logarithmic scale, showing the relative risk of stroke in all studied patients (total) and prespecified subgroups given either lisinopril or chlorthalidone in the ALLHAT study. Compared with chlorthalidone, lisinopril increased the risk of stroke in total and in some specific subgroups.</div><div class=\"graphic_reference\">Data from the ALLHAT investigators, JAMA 2002; 288:2981.</div><div id=\"graphicVersion\">Graphic 50881 Version 1.0</div></div></div>"},"50882":{"type":"graphic_table","displayName":"Western blot diagnosis of Lyme","title":"Criteria for western blot diagnosis of Lyme disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for western blot diagnosis of Lyme disease</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Type of infection\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Isotype\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Bands to be considered\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>First few weeks</td>\r\n  \r\n   <td>IgM</td>\r\n  \r\n   <td>Two of the following: ospC (24), 39, 41</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>After first few weeks</td>\r\n  \r\n   <td>IgG</td>\r\n  \r\n   <td>Five of the following: 18, 23, 28, 30, 39, 41, 45, 58,66, 93</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">Criteria for positive western blot (immunoblot) analysis in the serologic confirmation of infection with Borrelia burgdorferi (Lyme disease).</div><div class=\"graphic_reference\">Criteria derived from Dressler, F, Whalen, JA, Reinhardt BN, Steere AC, J Infect Dis 1993; 167:392. *Alternate criteria for IgM reactivity, proposed by a Centers for Disease Control and Prevention conference. Other points noted at that conference were the need for standardization of the antigen preparation and techniques used.</div><div id=\"graphicVersion\">Graphic 50882 Version 1.0</div></div></div>"},"50884":{"type":"graphic_diagnosticimage","displayName":"Color flow Doppler main PA","title":"Doppler color flow of the main pulmonary artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Doppler color flow of the main pulmonary artery</div><div class=\"cntnt\"><img style=\"width:297px; height:231px;\" src=\"images/CARD/50884_Color_flow_Doppler_main_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A short axis cut through the cardiac base demonstrates the long axis projection of the main pulmonary artery (MPA). The Doppler flow information is color encoded so that flow in all parts of the artery can be displayed. In this systolic frame, flow should be entirely toward the transducer, or blue in color; however, much of the color shown is red hued, indicating that flow exceeds 0.48 m/sec. This color change indicates aliasing, not reversed flow.</div><div class=\"graphic_footnotes\">RVOT: right ventricular outflow tract; Ao: aorta; RA: right atrium; LA: left atrium.</div><div id=\"graphicVersion\">Graphic 50884 Version 2.0</div></div></div>"},"50886":{"type":"graphic_algorithm","displayName":"Algorithm for the diagnosis of cystic fibrosis","title":"Algorithm for the diagnosis of cystic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Algorithm for the diagnosis of cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:476px; height:604px;\" src=\"images/PEDS/50886_Algorithm_CF_Dx.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CF: cystic fibrosis; IRT: immunoreactive trypsinogen; DNA: genetic screen for CF transmembrane conductance regulator (CFTR) gene mutations.<br />* For asymptomatic infants with intermediate sweat chloride results, test should be repeated at 1 to 2 months of age.<br />&para; DNA testing may not be necessary at this stage if newborn screen included DNA testing and identified two CF-causing mutations.<br />&Delta; \"CF-related mutations\" denotes mutations in the CFTR gene that are known to cause disease.</div><div class=\"graphic_reference\">Courtesy of Julie P Katkin, MD.</div><div id=\"graphicVersion\">Graphic 50886 Version 4.0</div></div></div>"},"50887":{"type":"graphic_diagnosticimage","displayName":"Posterior acetabular and femoral head fractures","title":"Posterior acetabular and femoral head fractures","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Posterior acetabular and femoral head fractures</div><div class=\"cntnt\"><img style=\"width:522px; height:447px;\" src=\"images/EM/50887_Pelvis_post_wall_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Anterior posterior view.<br />(B) Right iliac oblique view illustrating posterior column and anterior wall.<br />(C) Right obturator oblique view demonstrating the anterior column and posterior wall fracture.</div><div class=\"graphic_reference\">Courtesy of Jim Fiechtl, MD.</div><div id=\"graphicVersion\">Graphic 50887 Version 4.0</div></div></div>"},"50892":{"type":"graphic_diagnosticimage","displayName":"Metastatic choriocarcinoma PA","title":"Metastatic choriocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metastatic choriocarcinoma</div><div class=\"cntnt\"><img style=\"width:333px; height:307px;\" src=\"images/PULM/50892_Metastatic_choriocarcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A&nbsp;posteroanterior chest radiograph demonstrates fuzzy-bordered multiple nodules in a patient with metastatic choriocarcinoma. The indistinct borders are due to local areas of hemorrhage.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 50892 Version 3.0</div></div></div>"},"50894":{"type":"graphic_figure","displayName":"Scapular motion","title":"Scapular motion","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">Scapular motion</div><div class=\"cntnt\"><img style=\"width:606px; height:867px;\" src=\"images/EM/50894_Scapularmotion.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Boldface indicates prime or essential mover(s). Numbers refer to the figure.<br> <span class=bullet>•</span> The glenoid cavity moves superiorly, as in abduction of the arm.<br> Δ The glenoid cavity moves inferiorly, as in adduction of the arm.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th Edition. Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50894 Version 7.0</div></div></div>"},"50896":{"type":"graphic_algorithm","displayName":"Classification jaundice I","title":"Classification of jaundice due to mainly unconjugated hyperbilirubinemia","html":"<div class=\"graphic\"><div style=\"width: 656px\" class=\"figure\"><div class=\"ttl\">Classification of jaundice due to mainly unconjugated hyperbilirubinemia</div><div class=\"cntnt\"><img style=\"width:636px; height:268px;\" src=\"images/GAST/50896_Classification_jaundice_I.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 50896 Version 6.0</div></div></div>"},"50899":{"type":"graphic_figure","displayName":"HCM anatomy PI","title":"Heart with hypertrophic cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Heart with hypertrophic cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:564px; height:374px;\" src=\"images/PI/50899_HCM_anatomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The heart on the left is normal. The heart on the right has hypertrophic cardiomyopathy. The condition causes the walls of the lower chambers of the heart (called the ventricles) to thicken.</div><div id=\"graphicVersion\">Graphic 50899 Version 5.0</div></div></div>"},"50900":{"type":"graphic_figure","displayName":"Sensitivity cancer screening","title":"Calculating sensitivity of a cancer screening test according to the detection method and the incidence method","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Calculating sensitivity of a cancer screening test according to the detection method and the incidence method</div><div class=\"cntnt\"><img style=\"width:479px; height:303px;\" src=\"images/PC/50900_Sensitivitycancerscreenin.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Fletcher RH, Fletcher SW, Fletcher GS. Clinical Epidemiology: The Essentials, 5th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50900 Version 12.0</div></div></div>"},"50901":{"type":"graphic_picture","displayName":"Airway granulomas Endosc","title":"Airway granulomas","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Airway granulomas</div><div class=\"cntnt\"><img style=\"width:469px; height:243px;\" src=\"images/PULM/50901_Airway_granulomas_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchoscopic images of airway granulomas involving the vocal cords (left) and trachea (right).</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 50901 Version 1.0</div></div></div>"},"50902":{"type":"graphic_figure","displayName":"MRD inv16 AML","title":"Minimal residual disease in acute myeloid leukemia with inv(16)","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Minimal residual disease in acute myeloid leukemia with inv(16)</div><div class=\"cntnt\"><img style=\"width:486px; height:322px;\" src=\"images/HEME/50902_Min_resid_dis_inv_AML.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this study, minimal residual disease in 21 patients with acute myeloid leukemia and inv(16) was studied by real-time polymerase chain reaction, using the ratio of the abnormal gene product (CBFβ-MYH11) to an uninvolved gene (ABL). Results are shown for three patient groups: Group A: samples obtained during or after treatment in patients who did not subsequently relapse; Group B: samples obtained at any time during follow-up prior to clinical relapse; Group C: samples obtained at the time of disease diagnosis or clinical relapse. When values of this ratio were lower than 0.12 percent, no subsequent relapse was recorded; when values were greater than 0.25 percent, relapse always occurred. Values fell within the intermediate gray zone (0.12 to 0.25 percent) for only 6 of the 121 samples. Median values of each group are shown with the solid bar.</div><div class=\"graphic_reference\">Data from:&nbsp;Buonamici S, Ottaviani E, Testoni N, et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002; 99:443.</div><div id=\"graphicVersion\">Graphic 50902 Version 3.0</div></div></div>"},"50903":{"type":"graphic_picture","displayName":"Diphyllobothriasis proglottids","title":"Diphyllobothriasis proglottids","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Diphyllobothriasis proglottids</div><div class=\"cntnt\"><img style=\"width:582px; height:582px;\" src=\"images/ID/50903_Diphyllobothriasis_proglott.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Section of an adult&nbsp;<EM>Diphyllobothrium latum</EM> containing many proglottids. The scolex was not present in this specimen.<br />(B) Close-up of a few of the proglottids from the specimen in figure A, showing the rosette-shaped uterus at the center of each proglottid.<br />(C, D) Carmine-stained proglottids of <EM>D. latum</EM>, showing the rosette-shaped ovaries.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Diphyllobothriasis. Available at: <A href=\"http://www.cdc.gov/dpdx/diphyllobothriasis/index.html/\">http://www.cdc.gov/dpdx/diphyllobothriasis/index.html/</A>.</div><div id=\"graphicVersion\">Graphic 50903 Version 6.0</div></div></div>"},"50905":{"type":"graphic_diagnosticimage","displayName":"Cushings disease MRI II","title":"Magnetic resonance imaging in Cushing's disease","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging in Cushing's disease</div><div class=\"cntnt\"><img style=\"width:532px; height:284px;\" src=\"images/ENDO/50905_Cushings_disease_MRI_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MR images (coronal sections) of the sella turcica in the same patient with Cushing's disease. Left: Unenhanced image shows that most of the right side of the pituitary gland is occupied by an area of decreased signal intensity (arrows). Right: Gadolinium-enhanced image more clearly shows a 6 mm microadenoma as an area of decreased signal intensity (arrows).</div><div class=\"graphic_footnotes\">MR: magnetic resonance.</div><div class=\"graphic_reference\">Reprinted with permission from Williams Textbook of Endocrinology, 8th ed, Foster DW, Wilson JD (Eds), WB Saunders, Philadelphia 1996.</div><div id=\"graphicVersion\">Graphic 50905 Version 3.0</div></div></div>"},"50907":{"type":"graphic_picture","displayName":"Barretts post PDT","title":"Photodynamic therapy in a patient with Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Photodynamic therapy in a patient with Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:314px; height:327px;\" src=\"images/GAST/50907_Barretts_post_PDT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Segment of Barrett's esophagus two days after photodynamic therapy using Photofrin&#174;.</div><div class=\"graphic_reference\">Courtesy of Marta Davila, MD and Jacques Van Dam, MD, PhD.</div><div id=\"graphicVersion\">Graphic 50907 Version 2.0</div></div></div>"},"50909":{"type":"graphic_picture","displayName":"Gottrons sign in DM II","title":"Gottron's sign in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Gottron's sign in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:504px; height:367px;\" src=\"images/RHEUM/50909_Gottrons_sign_DM_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous to violaceous patches with overlying scale are present on the extensor surfaces of both knees in this child with dermatomyositis.</div><div class=\"graphic_reference\">Copyright © 2017 American College of Rheumatology. Used with permission.</div><div id=\"graphicVersion\">Graphic 50909 Version 15.0</div></div></div>"},"50910":{"type":"graphic_figure","displayName":"Tarsal tunnel anatomy","title":"Tarsal tunnel anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tarsal tunnel anatomy</div><div class=\"cntnt\"><img style=\"width:373px; height:252px;\" src=\"images/RHEUM/50910_Tarsal_tunnel_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tarsal tunnel syndrome is caused by entrapment of the posterior tibial nerve beneath the flexor retinaculum on the medial side of the ankle. Entrapment may also include the two branches, the medial and lateral plantar nerves.</div><div class=\"graphic_reference\">Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 50910 Version 1.0</div></div></div>"},"50911":{"type":"graphic_table","displayName":"Etiologies of expressive delay","title":"Selected causes of and contributing factors to expressive language delay in young children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected causes of and contributing factors to expressive language delay in young children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Cause/Contributing factor</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td>Maturational language delay* (constitutional language delay)</td> <td>&nbsp;</td> </tr> <tr> <td>Hearing impairment</td> <td>&nbsp;</td> </tr> <tr> <td>Prematurity and/or low birth weight</td> <td>&nbsp;</td> </tr> <tr> <td>Infectious diseases</td> <td>Intrauterine infection, meningitis, HIV/AIDS</td> </tr> <tr> <td>Neurologic conditions</td> <td>Seizures, cerebral palsy, apraxia of speech, etc</td> </tr> <tr> <td>Metabolic conditions</td> <td>Hypothyroidism, phenylketonuria, etc</td> </tr> <tr> <td>Toxicologic conditions</td> <td>Lead poisoning</td> </tr> <tr> <td>Genetic conditions</td> <td>Down syndrome, fragile X syndrome, Williams syndrome, neurofibromatosis, tuberous sclerosis, etc</td> </tr> <tr> <td>Family history</td> <td>Language delay, learning problems, dyslexia, cognitive disability, etc</td> </tr> <tr> <td>Socioeconomic factors</td> <td>Poverty, low parental educational attainment</td> </tr> <tr> <td>Lack of language stimulation, parent-child dysfunction, or disruption in parenting</td> <td>Maternal depression, child neglect or abuse, time spent in an orphanage, multiple foster care placements, etc</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Maturational language delay is a diagnosis made in younger children who are in the early developmental period. These delays may resolve in some children or progress to a more specific diagnosis by the age of school entry. However, making the functional diagnosis of maturational language delay may allow the child to receive treatment services while the other causes of language delay are being evaluated.</div><div id=\"graphicVersion\">Graphic 50911 Version 2.0</div></div></div>"},"50912":{"type":"graphic_picture","displayName":"Excessive femoral anteversion","title":"Excessive femoral anteversion","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Excessive femoral anteversion</div><div class=\"cntnt\"><img style=\"width:527px; height:312px;\" src=\"images/PEDS/50912_Excess_fem_anteversion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Femoral anteversion is the angular difference between the axis of the femoral neck and the transcondylar axis of the femur. In this photograph, the femur on the right has normal anteversion: the plane of the proximal femur (the femoral head, neck and greater trochanter) is about 10 to 15 degrees anterior to the plane of the femoral condyles of the distal femur. The femur on the left has excessive femoral anteversion: the plane of the proximal femur is about 60 degrees from the plane of the distal femur. Note that as the femoral head rotates anteriorly, the greater trochanter rotates posteriorly.</div><div class=\"graphic_reference\">Courtesy of William Phillips, MD.</div><div id=\"graphicVersion\">Graphic 50912 Version 1.0</div></div></div>"},"50913":{"type":"graphic_figure","displayName":"Langers lines of the face","title":"Langer's lines of the face","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Langer's lines of the face</div><div class=\"cntnt\"><img style=\"width:338px; height:498px;\" src=\"images/SURG/50913_Langers_lines_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Blackbourne LH. Advanced Surgical Recall, 2nd ed, Lippincott Williams &amp; Wilkins, Baltimore 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50913 Version 1.0</div></div></div>"},"50914":{"type":"graphic_table","displayName":"ACD differential diagnosis","title":"Differential diagnosis of allergic contact dermatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of allergic contact dermatitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Atopic dermatitis</td> </tr> <tr> <td>Flexural areas, face, eyelids, and hands frequently involved</td> </tr> <tr> <td>Personal or family history of flexural eczema, asthma, allergic rhinitis or hay fever during infancy or childhood</td> </tr> <tr> <td class=\"subtitle1_single\">Irritant contact dermatitis</td> </tr> <tr> <td>History of irritant exposure</td> </tr> <tr> <td>More demarcated and less itchy than allergic contact dermatitis</td> </tr> <tr> <td>Patch testing usually negative; may coexist with allergic contact dermatitis</td> </tr> <tr> <td class=\"subtitle1_single\">Seborrheic dermatitis</td> </tr> <tr> <td>Greasy scaly plaques in the central part of the face</td> </tr> <tr> <td>Frequent involvement of scalp, eyebrows, and eyelids</td> </tr> <tr> <td>Central chest and folds sometimes involved</td> </tr> <tr> <td>Absence of edema and vesiculation</td> </tr> <tr> <td class=\"subtitle1_single\">Dyshidrotic eczema</td> </tr> <tr> <td>Recurrent vesicular eczema of the hands and/or feet</td> </tr> <tr> <td>Deep-seated multilocular vesicles on the sides of the digits and on palmar or plantar skin</td> </tr> <tr> <td>Dorsal surfaces usually not involved</td> </tr> <tr> <td class=\"subtitle1_single\">Psoriasis</td> </tr> <tr> <td>Demarcated, erythematous, and scaly plaques; frequent involvement of elbows and knees; nail pitting may be seen at close inspection</td> </tr> <tr> <td>Absence of vesiculation, but pustules may be present on palms and soles</td> </tr> <tr> <td>When limited to palms and soles, may be difficult to distinguish from chronic ACD</td> </tr> <tr> <td class=\"subtitle1_single\">Stasis dermatitis</td> </tr> <tr> <td>Medial aspects of lower legs usually involved; skin color changes are frequent</td> </tr> <tr> <td>Other signs of chronic venous insufficiency usually present</td> </tr> <tr> <td>Persistent stasis dermatitis suggests secondary contact sensitization</td> </tr> <tr> <td class=\"subtitle1_single\">Asteatotic eczema (eczema craquel&#233;)</td> </tr> <tr> <td>Crackled patches of dry skin on the lower legs</td> </tr> <tr> <td>Lack of inflammation</td> </tr> <tr> <td class=\"subtitle1_single\">Tinea manuum</td> </tr> <tr> <td>Typically unilateral and asymmetrical</td> </tr> <tr> <td>Inflammatory edge</td> </tr> <tr> <td>Sometimes associated with an autoeczematization reaction</td> </tr> <tr> <td class=\"subtitle1_single\">Autoeczematization (autosensitization) reaction</td> </tr> <tr> <td>Diffuse, pruritic papulovesicular eruption</td> </tr> <tr> <td>May be associated with ACD, stasis dermatitis, and bacterial or fungal infection</td> </tr> <tr> <td class=\"subtitle1_single\">Mycosis fungoides (patch and plaque stage)</td> </tr> <tr> <td>Scaly patches or plaques, often pruritic, most frequently located on the trunk</td> </tr> <tr> <td>History of lesions waxing and waning over years</td> </tr> <tr> <td>Absence of edema and vesiculation</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50914 Version 1.0</div></div></div>"},"50915":{"type":"graphic_movie","displayName":"Mitral stenosis M mode","title":"Mitral stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/50915_mmodemstconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:320px; height:240px;\" src=\"images/CARD/50915_mmodemst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The M-mode echocardiogram shows severely limited movement of the anterior mitral leaflet which is also thickened. The E-F slope is markedly reduced and the A wave is absent, suggesting significant mitral stenosis.</div><div id=\"graphicVersion\">Graphic 50915 Version 2.0</div></div></div>"},"50916":{"type":"graphic_table","displayName":"Umbilical cord gases at term","title":"Reference range for umbilical artery blood gas values in term newborns","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reference range for umbilical artery blood gas values in term newborns</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Umbilical arterial blood</td> <td class=\"subtitle1\">Mean</td> <td class=\"subtitle1\">5th to 95th percentile</td> </tr> <tr> <td>pH</td> <td class=\"centered\">7.27</td> <td class=\"centered\">7.15 to 7.38</td> </tr> <tr> <td>PCO<sub>2</sub> (mmHg)</td> <td class=\"centered\">50.3</td> <td class=\"centered\">32 to 68</td> </tr> <tr> <td>HCO<sub>3</sub> (mEq/L)</td> <td class=\"centered\">22</td> <td class=\"centered\">15.4 to 26.8</td> </tr> <tr> <td>Base excess (mEq/L)</td> <td class=\"centered\">&ndash;2.7</td> <td class=\"centered\">&ndash;8.1 to 0.9</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Values represent findings from umbilical artery cord blood analysis after vaginal delivery of 3522 unselected term infants delivered at Shands Hospital, University of Florida, 1992-1993.</div><div class=\"graphic_reference\">Data from: Riley RJ, Johnson JWC. Collecting and analyzing cord blood gases. Clin Obstet Gynecol 1993; 36:13.</div><div id=\"graphicVersion\">Graphic 50916 Version 2.0</div></div></div>"},"50919":{"type":"graphic_form","displayName":"Nutrition consult form","title":"Nutrition consult form","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Nutrition consult form</div><div class=\"cntnt\"><img style=\"width:564px; height:760px;\" src=\"images/PC/50919_Nutritionconsultform.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CHO: carbohydrates.</div><div id=\"graphicVersion\">Graphic 50919 Version 6.0</div></div></div>"},"50922":{"type":"graphic_figure","displayName":"Modified Martius fat pad graft3","title":"Modified Martius fat pad graft","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Modified Martius fat pad graft</div><div class=\"cntnt\"><img style=\"width:369px; height:438px;\" src=\"images/OBGYN/50922_Modified_Martius_fat_pad_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The graft is tunneled subcutaneously beneath the vaginal mucosa.</div><div id=\"graphicVersion\">Graphic 50922 Version 1.0</div></div></div>"},"50923":{"type":"graphic_diagnosticimage","displayName":"Adult three part humerus fracture","title":"Three-part proximal humerus fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Three-part proximal humerus fracture</div><div class=\"cntnt\"><img style=\"width:396px; height:348px;\" src=\"images/EM/50923_Adult_three_part_humerus_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior radiograph shows a fracture of the surgical neck of the humerus. A portion of the surgical neck and the greater tuberosity are displaced from head and shaft. In the Neer classification system this is categorized as a three-part proximal humerus fracture.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 50923 Version 2.0</div></div></div>"},"50924":{"type":"graphic_figure","displayName":"Leukotriene synthesis AERD","title":"5-LO pathway products: Key inflammatory mediators","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">5-LO pathway products: Key inflammatory mediators</div><div class=\"cntnt\"><img style=\"width:360px; height:504px;\" src=\"images/RHEUM/50924_Leukotriene_synt_AERD_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of leukotriene synthetic pathways and the enzymes catalyzing the specific reactions. The leukotrienes are shaded.</div><div class=\"graphic_footnotes\">FLAP: 5-lipoxygenase activating protein; HPETE: hydroperoxyeicosatetraenoic acid; HETE: hydroxyeicosatetraenoic acid; ETE: eicosatetraenoic acid; LT: leukotriene.</div><div id=\"graphicVersion\">Graphic 50924 Version 6.0</div></div></div>"},"50925":{"type":"graphic_figure","displayName":"Anterior retraction thyroid","title":"Anterior retraction thyroid","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Anterior retraction thyroid</div><div class=\"cntnt\"><img style=\"width:501px; height:448px;\" src=\"images/SURG/50925_Anteriorretractionthyroid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior/medial retraction of thyroid, showing recurrent laryngeal nerve and parathyroid gland anatomy.</div><div class=\"graphic_reference\">Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50925 Version 11.0</div></div></div>"},"50926":{"type":"graphic_figure","displayName":"Motor unit loss in ALS","title":"Motor unit loss revealed by incremental motor unit number estimation (MUNE) in patients with amyotrophic lateral sclerosis","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Motor unit loss revealed by incremental motor unit number estimation (MUNE) in patients with amyotrophic lateral sclerosis</div><div class=\"cntnt\"><img style=\"width:490px; height:290px;\" src=\"images/NEURO/50926_Motor_unit_loss_ALS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Average motor unit decline in a group of ten ALS control subjects receiving placebo in a therapeutic trial, as measured by multiple point stimulation MUNE in the thenar muscle group. Patients were tracked at one to two month intervals over 18 months. Motor unit loss averaged 30 to 40 percent for every six months of disease progression.</div><div class=\"graphic_reference\">Courtesy of Clifton Gooch, MD.</div><div id=\"graphicVersion\">Graphic 50926 Version 2.0</div></div></div>"},"50927":{"type":"graphic_picture","displayName":"C3 glomerulonephritis EM","title":"Electron microscopy in C3 glomerulonephritis","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Electron microscopy in C3 glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:560px; height:479px;\" src=\"images/NEPH/50927_EM_C3_glom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph in C3 glomerulonephritis showing numerous mesangial (white arrows) and capillary wall deposits. Capillary wall deposits are noted in the subendothelial, intramembranous (yellow arrow), and subepithelial (red arrow) locations.</div><div class=\"graphic_reference\">Provided by Dr. Sanjeev Sethi, Department of Laboratory Medicine and Pathology, Mayo Clinic.</div><div id=\"graphicVersion\">Graphic 50927 Version 5.0</div></div></div>"},"50928":{"type":"graphic_picture","displayName":"Linear porokeratosis 2","title":"Linear porokeratosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Linear porokeratosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/50928_Linear_porokeratosis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Slightly atrophic erythematous plaques with peripheral keratotic rims are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50928 Version 3.0</div></div></div>"},"50931":{"type":"graphic_table","displayName":"ACMG fragile X screening","title":"American College of Medical Genetics and Genomics Populations to test for fragile X syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American College of Medical Genetics and Genomics Populations to test for fragile X syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Individuals of either sex with intellectual disability, developmental delay, or autism, especially if they have:</td> </tr> <tr> <td class=\"sublist1\">Physical or behavioral characteristics of fragile X</td> </tr> <tr> <td class=\"sublist1\">Family history of fragile X or a relative of either sex with undiagnosed intellectual disability</td> </tr> <tr> <td class=\"sublist1_start\">Individuals seeking reproductive counseling with:</td> </tr> <tr> <td class=\"sublist1\">Family history of fragile X syndrome</td> </tr> <tr> <td class=\"sublist1\">Family history of undiagnosed intellectual disability</td> </tr> <tr> <td>Fetuses of carrier mothers</td> </tr> <tr> <td>Affected individuals or relative in whom the diagnosis was made by cytogenetic studies</td> </tr> <tr> <td>Women with elevated levels of follicle-stimulating hormone, especially with a family history of premature ovarian insufficiency, fragile X syndrome, or a relative of either sex with undiagnosed intellectual disability</td> </tr> <tr> <td>Men or women with late-onset intention tremor or ataxia, especially with a family history of movement disorders, fragile X, or undiagnosed intellectual disability</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: Diagnostic and carrier testing. Genet Med 2005; 7:584.</div><div id=\"graphicVersion\">Graphic 50931 Version 7.0</div></div></div>"},"50932":{"type":"graphic_table","displayName":"Treatment of complicated vaginal candidiasis","title":"Treatment of complicated vaginal candidiasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of complicated vaginal candidiasis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Severe vaginitis symptoms</td> </tr> <tr> <td>Oral fluconazole 150 mg every 72 hours for&nbsp;two or&nbsp;three doses (depending on severity).</td> </tr> <tr> <td class=\"indent1\"><strong>OR</strong></td> </tr> <tr> <td>Topical azole antifungal therapy daily for 7 to 14 days. A low potency topical corticosteroid can be applied to the vulva for 48 hours to relieve symptoms until the antifungal drug exerts its effect.</td> </tr> <tr> <td class=\"subtitle1_single\">Recurrent vulvovaginal candidiasis</td> </tr> <tr> <td> <p>Induction with fluconazole 150 mg every 72 hours for&nbsp;three doses, followed by maintenance fluconazole 150 mg once per week for&nbsp;six months.</p> If fluconazole is not feasible, options include 10 to 14 days of a topical azole or alternate oral azole (eg, itraconazole) followed by topical maintenance therapy for&nbsp;six months (eg, clotrimazole 200 mg [eg, 10 g of 2%] vaginal cream twice weekly or 500 mg vaginal suppository once weekly).</td> </tr> <tr> <td class=\"subtitle1_single\">Nonalbicans <em>Candida</em> vaginitis</td> </tr> <tr> <td>Therapy depends upon species identified:</td> </tr> <tr> <td><em>C. glabrata</em>: Intravaginal boric acid* 600 mg daily for 14 days</td> </tr> <tr> <td class=\"indent1\">If failure occurs: 17% topical flucytosine cream, 5 g nightly for 14 days</td> </tr> <tr> <td><em>C. krusei</em>: Intravaginal clotrimazole, miconazole, or terconazole for 7 to 14 days</td> </tr> <tr> <td>All other species: Conventional dose fluconazole</td> </tr> <tr> <td class=\"subtitle1_single\">Compromised host (eg, poorly controlled diabetes, immunosuppression, debilitation) and <em>Candida</em> isolate susceptible to azoles</td> </tr> <tr> <td>Oral or topical therapy for 7 to 14 days</td> </tr> <tr> <td class=\"subtitle1_single\">Pregnancy</td> </tr> <tr> <td>Topical clotrimazole or miconazole for&nbsp;7 days</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Boric acid capsules and flucytosine cream are not commercially available, but can be made by a compounding pharmacy.</div><div class=\"graphic_footnotes\">* Boric acid capsules can be fatal if swallowed.</div><div class=\"graphic_reference\">Data from: Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.</div><div id=\"graphicVersion\">Graphic 50932 Version 12.0</div></div></div>"},"50935":{"type":"graphic_table","displayName":"Healthy weight nutrition tips A","title":"Tips for maintaining a healthy weight: Nutrition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tips for maintaining a healthy weight: Nutrition</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Phase I</td> </tr> <tr> <td class=\"subtitle2_single\">Choose sugar-free beverages or low-fat milk only</td> </tr> <tr> <td class=\"indent1\">Choose sugar-free beverages, water or low-fat (skim, one-half percent, and 1 percent) milk.</td> </tr> <tr> <td class=\"indent1\">Limit milk to 16 to 24 ounces per day. Avoid flavored milks, including fat-free versions.</td> </tr> <tr> <td class=\"subtitle2_single\">Have fast food no more than once a week, and try the following healthier options:</td> </tr> <tr> <td class=\"indent1\">Choose plain hamburger kid's meal with water, diet soda, or skim milk.</td> </tr> <tr> <td class=\"indent1\">Try a grilled chicken sandwich ordered without mayonnaise with a piece of fruit from home.</td> </tr> <tr> <td class=\"indent1\">Try a 6-inch, low-fat Subway sandwich (ordered without mayonnaise, cheese, or oils), with baked chips or pretzels.</td> </tr> <tr> <td class=\"indent1\">Avoid burgers with double meat, cheese, bacon, mayonnaise, and super-sized french fries.</td> </tr> <tr> <td class=\"subtitle2_single\">Choose three meals with one snack per day</td> </tr> <tr> <td class=\"indent1\">Healthy breakfast ideas: two pieces whole wheat toast with a glass of skim milk; small bowl of cereal such as bran flakes, Cheerios or old-fashioned oat meal with skim milk; or a fat-free yogurt and a piece of fresh fruit.</td> </tr> <tr> <td class=\"indent1\">Healthy snacks include fresh fruit, fat-free yogurt, or low-fat popcorn.</td> </tr> <tr> <td class=\"indent1\">Limit snacks to one serving size.</td> </tr> <tr> <td class=\"indent1\">Try the Plate Method at dinner. Design a dinner plate with one-half a plate of vegetables, one-quarter plate of lean meat, and one-quarter plate of starch or starchy vegetables (potatoes, corn, or peas) (see <a href=\"http://www.choosemyplate.gov/\" target=\"_blank\">www.choosemyplate.gov</a>). Avoid second helpings.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 50935 Version 3.0</div></div></div>"},"50936":{"type":"graphic_picture","displayName":"RTT regression","title":"Rett syndrome, regression","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rett syndrome, regression</div><div class=\"cntnt\"><img style=\"width:252px; height:378px;\" src=\"images/PEDS/50936_RS_stage_II_deteriorate_reg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">From ages one to four year, many girls with RTT experience periods of inconsolable irritability. Hand stereotypes may consist of repetitious finger-rubbing movements.</div><div class=\"graphic_reference\">Reproduced with permission from: Glaze DG, Schultz RJ. Rett syndrome: Meeting the challenge of this gender-specific neurodevelopmental disorder. Medscape Women's Health 1997; 2. Copyright © 1997 Medscape.</div><div id=\"graphicVersion\">Graphic 50936 Version 4.0</div></div></div>"},"50939":{"type":"graphic_table","displayName":"Types genital tract anomalies","title":"Acien classification of genital tract anomalies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acien classification of genital tract anomalies</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td colspan=\"1\" class=\"subtitle1_single\">Agenesis or hypoplasia of the entire urogenital ridge</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"1\">Unicornuate uterus with uterine, tubal, ovarian, and renal agenesis on the contralateral side</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n      <td colspan=\"1\" class=\"subtitle1_single\">Mesonephric anomalies with\nabsence of both opening of the Wolffian duct to the urogenital sinus\nand ureteral bud sprouting leading to utero-vaginal duplicity and a\nblind hemivagina ipsilateral with renal agenesis:</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Unilateral hematocolpos</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Gartner's pseudocyst on the anterolateral wall of the vagina</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Partial reabsorption of intervaginal septum</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"1\">Vaginal\nor complete cervico-vaginal unilateral agenesis, ipsilateral with the\nrenal agenesis, and (1) with no communication, or (2) with\ncommunication between both hemiuteri</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Isolated M&#252;llerian anomalies:</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"1\">M&#252;llerian ducts: unicornuate (generally, with rudimentary uterine horn), bicornuate, septate and didelphys uterus.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"1\">M&#252;llerian tubercle: cervico-vaginal atresia and segmentary anomalies such as transverse vaginal septum.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">M&#252;llerian tubercle and ducts: (uni- or bilateral) Mayer-Rokitansky-Kuster-Hauser syndrome.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Anomalies of the urogenital sinus:</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Cloacal anomalies etc.</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Malformative combinations:</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Wolfian, M&#252;llerian and cloacal anomalies.</td>\n\n\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Acien, P, Acien, M, Sanchez-Ferrer, M. Human Reproduction 2004; 19:2377.</div><div id=\"graphicVersion\">Graphic 50939 Version 1.0</div></div></div>"},"50940":{"type":"graphic_figure","displayName":"Warfarin and clotting proteins","title":"Effect of warfarin on blood clotting proteins","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Effect of warfarin on blood clotting proteins</div><div class=\"cntnt\"><img style=\"width:552px; height:356px;\" src=\"images/HEME/50940_Warfarin_and_clotting_prote.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The activity of various clotting proteins (logarithmic scale) is shown here as a function of time after ingestion of warfarin (10 mg/day PO for four consecutive days) by a normal subject. Factor VII activity, to which the prothrombin time is most sensitive, is the first to decrease. Full anticoagulation, however, does not occur until factors IX, X, and prothrombin are sufficiently reduced. Protein C activity falls quickly, and, in some patients, a transient hypercoagulable state may ensue (eg, coumarin necrosis).</div><div class=\"graphic_reference\">Redrawn from: Furie B. Oral anticoagulant therapy. In: Hematology: Basic Principles and Practice, 3rd ed, Hoffman R, Benz EJ, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 2000. p.2040.</div><div id=\"graphicVersion\">Graphic 50940 Version 2.0</div></div></div>"},"50941":{"type":"graphic_figure","displayName":"Cardiovascular event vs LV mass","title":"The risk of a cerebrovascular event in hypertensives is related to left ventricular mass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The risk of a cerebrovascular event in hypertensives is related to left ventricular mass</div><div class=\"cntnt\"><img style=\"width:442px; height:402px;\" src=\"images/CARD/50941_Cardiovascular_event_vs_LV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 1033 hypertensive subjects the age-adjusted five-year probability of cerebrovascular events is related to left ventricular mass, as assessed with echocardiography.</div><div class=\"graphic_reference\">Data from Verdecchia, P, Porcellati, C, Reboldi, G, et al, Circulation 2001; 104:2039.</div><div id=\"graphicVersion\">Graphic 50941 Version 1.0</div></div></div>"},"50944":{"type":"graphic_diagnosticimage","displayName":"Fetal femur length","title":"Fetal femur length","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fetal femur length</div><div class=\"cntnt\"><img style=\"width:423px; height:434px;\" src=\"images/OBGYN/50944_Femur_length.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal view of a fetal femur of a second-trimester fetus. The femur is hyperechoic with shadowing as compared&nbsp;with the surrounding soft tissue. The length of the femur is indicated by the calipers, which are placed on the proximal and distal diaphyseal borders.</div><div class=\"graphic_reference\">Courtesy of Thomas Shipp, MD.</div><div id=\"graphicVersion\">Graphic 50944 Version 4.0</div></div></div>"},"50945":{"type":"graphic_diagnosticimage","displayName":"Chondrosarc endoprosthesis","title":"Endoprosthetic reconstruction after resection of a lower extremity chondrosarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoprosthetic reconstruction after resection of a lower extremity chondrosarcoma</div><div class=\"cntnt\"><img style=\"width:274px; height:376px;\" src=\"images/ONC/50945_Chondrosarc_endoprosthesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 45-year-old man underwent resection of a chondrosarcoma with reconstruction of the osseous defect with a metal endoprosthesis.</div><div class=\"graphic_reference\">Courtesy of Francis J Hornicek, MD, PhD.</div><div id=\"graphicVersion\">Graphic 50945 Version 4.0</div></div></div>"},"50946":{"type":"graphic_figure","displayName":"Symptothermal chart","title":"Symptothermal chart","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Symptothermal chart</div><div class=\"cntnt\"><img style=\"width:550px; height:439px;\" src=\"images/OBGYN/50946_Symptothermal_chart.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: The Institute for Reproductive Health, Georgetown University.</div><div id=\"graphicVersion\">Graphic 50946 Version 1.0</div></div></div>"},"50947":{"type":"graphic_table","displayName":"Perioperative VTE prevention ","title":"Hospital Quality Alliance/Centers for Medicare & Medicaid Services (CMS) Surgical Care Improvement quality measures for perioperative VTE prevention*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hospital Quality Alliance/Centers for Medicare &amp; Medicaid Services (CMS) Surgical Care Improvement quality measures for perioperative VTE prevention*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Surgery type</td> <td class=\"subtitle1\">Recommended prophylaxis options<sup>&#916;</sup></td> </tr> <tr> <td rowspan=\"5\">Intracranial neurosurgery</td> <td class=\"sublist1_start\">Any of the following:</td> </tr> <tr> <td class=\"sublist1\">&#8226; Intermittent pneumatic compression devices (IPC) with or without graduated compression stockings (GCS)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Low-dose unfractionated heparin (LDUH)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Low molecular weight heparin (LMWH)<sup>&#9674;</sup></td> </tr> <tr> <td class=\"sublist1\">&#8226; LDUH or LMWH<sup>&#9674;</sup> combined with IPC or GCS</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">General surgery</td> <td class=\"sublist1_start\">Any of the following:</td> </tr> <tr> <td class=\"sublist1\">&#8226; Low-dose unfractionated heparin (LDUH)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Low molecular weight heparin (LMWH)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Factor Xa Inhibitor (fondaparinux)</td> </tr> <tr> <td class=\"sublist1\">&#8226; LDUH or LMWH or Factor Xa Inhibitor&nbsp;combined with intermittent pneumatic compression devices&nbsp;(IPC) or graduated compression&nbsp;stockings&nbsp;(GCS)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">General surgery with contraindications to pharmacological prophylaxis</td> <td class=\"sublist1_start\">Any of the following:</td> </tr> <tr> <td class=\"sublist1\">&#8226; Graduated compression stockings (GCS)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Intermittent pneumatic compression devices (IPC)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Gynecologic surgery</td> <td class=\"sublist1_start\">Any of the following:</td> </tr> <tr> <td class=\"sublist1\">&#8226; Low-dose unfractionated heparin (LDUH)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Low molecular weight heparin (LMWH)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Factor Xa Inhibitor (fondaparinux)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Intermittent pneumatic compression devices (IPC)</td> </tr> <tr> <td class=\"sublist1\">&#8226; LDUH or LMWH or Factor Xa Inhibitor combined with IPC or graduated compression stockings (GCS)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"7\">Urologic surgery</td> <td class=\"sublist1_start\">Any of the following:</td> </tr> <tr> <td class=\"sublist1\">&#8226; Low-dose unfractionated heparin (LDUH)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Low molecular weight heparin (LMWH)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Factor Xa Inhibitor (fondaparinux)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Intermittent pneumatic compression devices (IPC)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Graduated compression stockings (GCS)</td> </tr> <tr> <td class=\"sublist1\">&#8226; LDUH or LMWH or Factor Xa Inhibitor&nbsp;combined with IPC or GCS</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Elective total hip replacement</td> <td class=\"sublist1_start\">Any of the following started within 24 hours of surgery:</td> </tr> <tr> <td class=\"sublist1\">&#8226; Low molecular weight heparin (LMWH)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Factor Xa Inhibitor (fondaparinux)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Warfarin</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Excluded populations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">&#8226; Patients less than 18 years of age</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">&#8226; Patients who have a length of stay &#62;120 days</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">&#8226; Burn patients</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">&#8226; Patients with procedures performed entirely by laparoscope</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">&#8226; Patients enrolled in clinical trials</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">&#8226; Patients who are on warfarin prior to admission</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">&#8226; Patients whose ICD-9-CM principal procedure occurred prior to the date of admission</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">&#8226; Patients whose total surgery time is less than or equal to 60 minutes</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">&#8226; Patients who stayed less than or equal to&nbsp;three calendar days postoperatively</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">&#8226; Patients with contraindications to both mechanical and pharmacological prophylaxis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Taken from: Specifications Manual for National Hospital Inpatient Quality Measures. Available at: www.qualitynet.org.<br> Δ Patients who receive neuraxial anesthesia or have a documented contraindication to pharmacological prophylaxis may pass the performance measure if either appropriate pharmacological or mechanical prophylaxis is ordered.<br> <span class=lozenge>◊</span> Current guidelines recommend postoperative low molecular weight heparin for intracranial neurosurgery.</div><div id=\"graphicVersion\">Graphic 50947 Version 5.0</div></div></div>"},"50949":{"type":"graphic_picture","displayName":"Actinic keratosis - dorsal hand","title":"Actinic keratosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Actinic keratosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/50949_Actinic_kerato_dorsal_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Actinic keratosis. Scale overlies erythematous macules.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 50949 Version 3.0</div></div></div>"},"50950":{"type":"graphic_table","displayName":"Pain control during minor procedures in children","title":"Behavioral methods and pharmacologic options for minor procedures (eg, venipuncture or IV placement) in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Behavioral methods and pharmacologic options for minor procedures (eg, venipuncture or IV placement) in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Start time before procedure (minutes)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Behavioral methods*</td> </tr> <tr> <td class=\"indent1\">Preparation</td> <td>60</td> </tr> <tr> <td class=\"indent1\">Relaxation</td> <td>30</td> </tr> <tr> <td class=\"indent1\">Breathing</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Distraction</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Encourage coping</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Positioning</td> <td>2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Positive reinforcement</td> <td>After procedure</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Selected pharmacologic options<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Lidocaine/prilocaine cream (eg, EMLA&#174;)</td> <td>60</td> </tr> <tr> <td class=\"indent1\">Liposomal lidocaine (eg, LMX&#174;) or Tetracaine gel (eg, Ametop&#174;<sup>&#916;</sup>)</td> <td>30</td> </tr> <tr> <td class=\"indent1\">Lidocaine iontophoresis</td> <td>15</td> </tr> <tr> <td class=\"indent1\">Needle-free lidocaine delivery</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Lidocaine infiltration</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Vapocoolant spray</td> <td>15 seconds</td> </tr> <tr> <td class=\"indent1\">Nitrous oxide</td> <td>&#60;1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* All behavioral methods should be continued throughout the procedure, preferably by a dedicated child life specialist.<br />¶ The provider should select only one type of topical agent based upon available time prior to the procedure. Refer to UpToDate topics on topical analgesia during minor procedures. When properly maintained equipment and personnel are available and per caregiver and provider preference, nitrous oxide may be used to augment topical analgesia.<br />Δ&nbsp;Tetracaine gel is an ester type local anesthetic and is not commercially available in the US. It is widely available elsewhere.</div><div class=\"graphic_reference\">Data from: Zempsky, WT. Optimizing the management of peripheral venous access pain in children: Evidence, impact, and implementation. Pediatrics 2008; 122 Suppl 3:S121.</div><div id=\"graphicVersion\">Graphic 50950 Version 4.0</div></div></div>"},"50951":{"type":"graphic_figure","displayName":"Low dose E and BMD","title":"Effect of estrogen dose on change in bone mineral density (BMD) in postmenopausal women","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Effect of estrogen dose on change in bone mineral density (BMD) in postmenopausal women</div><div class=\"cntnt\"><img style=\"width:472px; height:322px;\" src=\"images/ENDO/50951_Low_dose_E_and_BMD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean percentage of change from baseline in lumbar spine (L1-4) BMD measured by dual x-ray absorptiometry (DXA). Placebo (diamonds), esterified estrogens: 0.3 mg (squares), 0.625 mg (triangles), 1.25 mg (circles). BMD changes at all timepoints and at all esterified estrogens doses were significantly different from those occurring with placebo use.</div><div class=\"graphic_reference\">Data from: Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group.&nbsp;Arch Intern Med 1997; 157:2609.</div><div id=\"graphicVersion\">Graphic 50951 Version 2.0</div></div></div>"},"50952":{"type":"graphic_figure","displayName":"Neuropathy and glycemic control II","title":"Glycemic control prevents diabetic neuropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Glycemic control prevents diabetic neuropathy</div><div class=\"cntnt\"><img style=\"width:424px; height:285px;\" src=\"images/NEURO/50952_Neuropathy_and_control_II.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prevalence of clinically evident diabetic neuropathy (abnormal neurologic examination), abnormal autonomic function, or abnormal nerve conduction in patients with type 1 diabetes who had no neuropathy at baseline and who received either intensive or conventional therapy for five years. Patients treated with intensive insulin had a lower rate of development of neuropathy by all three evaluations.</div><div class=\"graphic_reference\">Data from The Diabetes Control and Complications Trial Research Group, N Engl J Med 1993; 329:977.</div><div id=\"graphicVersion\">Graphic 50952 Version 2.0</div></div></div>"},"50953":{"type":"graphic_picture","displayName":"Eosinophilic esophagitis mucosal tear post-dilation Endosc","title":"Eosinophilic esophagitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eosinophilic esophagitis</div><div class=\"cntnt\"><img style=\"width:252px; height:238px;\" src=\"images/GAST/50953_EE_tear_post_dilat_Endo_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy performed after passing a dilator and prior to passage of the next size dilator. A deep mucosal tear is evident in the mid esophagus (arrow). There were no clinical signs of immediate perforation. Esophagography (initially with Gastrografin&#174;, a water-soluble contrast agent, and then with barium) was negative for a perforation.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD and Anthony Lembo, MD.</div><div id=\"graphicVersion\">Graphic 50953 Version 4.0</div></div></div>"},"50955":{"type":"graphic_figure","displayName":"Trans-urethral bladder catheterization girls","title":"Catheter insertion into the bladder in females","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Catheter insertion into the bladder in females</div><div class=\"cntnt\"><img style=\"width:395px; height:303px;\" src=\"images/PEDS/50955_TUBC_girls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The catheter is inserted into the urethral meatus until urine returns. Catheters that are inadvertently placed in the vagina may be left in place to serve as a landmark for subsequent attempts.</div><div class=\"graphic_reference\">Adapted from King&nbsp;C, Henretig FM. Pocket Atlas of Pediatric Emergency Procedures, Lippincott Williams and Wilkins, Philadelphia 2000.</div><div id=\"graphicVersion\">Graphic 50955 Version 2.0</div></div></div>"},"50956":{"type":"graphic_table","displayName":"Mechanisms benefit exercise","title":"Biological mechanisms for benefit of exercise","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Biological mechanisms for benefit of exercise</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Antiatherogenic effects</td> </tr> <tr> <td class=\"sublist1\">Reduction of adiposity, particularly in those with excess upper body and abdominal fat</td> </tr> <tr> <td class=\"sublist1\">Reduction of elevated blood pressure</td> </tr> <tr> <td class=\"sublist1\">Reduction of elevated plasma triglycerides (and associated small dense LDL particles)</td> </tr> <tr> <td class=\"sublist1\">Increase in HDL cholesterol levels</td> </tr> <tr> <td class=\"sublist1\">Improvement in insulin sensitivity and glucose use and reduction in risk of type 2 diabetes</td> </tr> <tr> <td>Antithrombotic effects</td> </tr> <tr> <td>Endothelial function alteration</td> </tr> <tr> <td>Autonomic functional changes</td> </tr> <tr> <td>Anti-ischemic effects</td> </tr> <tr> <td>Antiarrhythmic effects</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LDL: low-density lipoprotein; HDL: high-density lipoprotein.</div><div class=\"graphic_reference\">Reproduced with permission from: Fletcher GF, Balady GJ, Amsterdam EA, et al. Circulation 2001; 104:1694.</div><div id=\"graphicVersion\">Graphic 50956 Version 3.0</div></div></div>"},"50957":{"type":"graphic_diagnosticimage","displayName":"Fibrosing mediastinitis PAgram","title":"Pulmonary arteriogram in fibrosing mediastinitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary arteriogram in fibrosing mediastinitis</div><div class=\"cntnt\"><img style=\"width:260px; height:303px;\" src=\"images/PULM/50957_Fibrosing_mediastinitis_PAg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulmonary arteriogram reveals an abrupt cutoff (red arrow) of a right pulmonary artery branch in a patient with fibrosing mediastinitis.</div><div class=\"graphic_reference\">Courtesy of Joseph Wheat, MD.</div><div id=\"graphicVersion\">Graphic 50957 Version 4.0</div></div></div>"},"50958":{"type":"graphic_diagnosticimage","displayName":"Prevascular adenopathy CT","title":"N3 involvement in lung cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">N3 involvement in lung cancer</div><div class=\"cntnt\"><img style=\"width:394px; height:258px;\" src=\"images/PULM/50958_Prevascular_adenopathy_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows extensive mediastinal and prevascular lymph node involvement, indicating N3 disease.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 50958 Version 3.0</div></div></div>"},"50959":{"type":"graphic_picture","displayName":"Sausage digit second toe","title":"Sausage digit (left 2nd toe)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sausage digit (left 2nd toe)</div><div class=\"cntnt\"><img style=\"width:349px; height:504px;\" src=\"images/RHEUM/50959_Sausage_digit_second_toe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sausage like swelling of the left second toe is apparent in this photograph of a patient with reactive arthritis.</div><div class=\"graphic_reference\">Courtesy of Henning Zeidler.</div><div id=\"graphicVersion\">Graphic 50959 Version 1.0</div></div></div>"},"50961":{"type":"graphic_movie","displayName":"Echo apical long axis view MR ","title":"Echocardiogram apical long axis view of mitral regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiogram apical long axis view of mitral regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/50961_aplamrciconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:246px; height:441px;\" src=\"images/CARD/50961_aplamrci.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical long axis view from 2-D echocardiogram shows mitral regurgitation with a circular &quot;jet&quot; directed toward the posterior wall of the left atrium as well as anteriorly toward the interatrial septum.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 50961 Version 3.0</div></div></div>"},"50962":{"type":"graphic_table","displayName":"Immunosuppressive agents used in heart transplantation","title":"Immunosuppressive agents used in heart transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunosuppressive agents used in heart transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dosing</td> <td class=\"subtitle1\">Target levels</td> <td class=\"subtitle1\">Major toxicities</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Calcineurin inhibitors</td> </tr> <tr> <td class=\"indent1\">Cyclosporine</td> <td>4-8 mg/kg/day in 2 divided doses, titrated to keep target 12-hr trough levels</td> <td> <p><strong>0-6 months:</strong></p> <p>250-350 ng/mL</p> <p><strong>6-12 months:</strong></p> <p>200-250 ng/mL</p> <p><strong>&#62;12 months:</strong></p> <p>100-200 ng/mL</p> </td> <td> <p>Renal insufficiency</p> <p>Hypertension</p> <p>Dyslipidemia</p> <p>Hypokalemia and hypomagnesemia</p> <p>Hyperurecemia</p> <p>Neurotoxicity (encephalopathy, seizures, tremors, neuropathy)</p> <p>Gingival hyperplasia</p> <p>Hirsutism</p> </td> </tr> <tr> <td class=\"indent1\">Tacrolimus</td> <td>0.05-0.1 mg/kg/day in 2 divided doses, titrated to keep target 12-hr trough levels</td> <td> <p><strong>0-6 months:</strong></p> <p>10-15 ng/mL</p> <p><strong>6-12 months:</strong></p> <p>8-12 ng/mL</p> <p><strong>&#62;12 months:</strong></p> <p>5-10 ng/mL</p> </td> <td> <p>Renal dysfunction</p> <p>Hypertension</p> <p>Hyperglycemia and diabetes mellitus</p> <p>Dyslipidemia</p> <p>Hyperkalemia</p> <p>Hypomagnesemia</p> <p>Neurotoxicity (tremors, headaches)</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Cell cycle agents</td> </tr> <tr> <td class=\"indent1\">Azathioprine</td> <td>1.5-3.0 mg/kg/day, titrated to keep WBC &sim;3K</td> <td>None</td> <td> <p>Bone marrow suppression</p> <p>Hepatitis (rare)</p> <p>Pancreatitis</p> <p>Malignancy</p> </td> </tr> <tr> <td class=\"indent1\">Mycophenolate mofetil</td> <td>2000-3000 mg/day in 2 divided doses</td> <td>Mycophenolic acid (MPA): 2-5 mcg/mL</td> <td> <p>Gastrointestinal disturbances (nausea, gastritis, and diarrhea)</p> <p>Leukopenia</p> </td> </tr> <tr> <td class=\"indent1\">Mycophenolate sodium</td> <td>1440-2160 mg/day in 2 divided doses</td> <td>None</td> <td> <p>Fewer gastrointestinal disturbances compared with mycophenolate mofetil</p> Leukopenia</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Proliferation signal inhibitors</td> </tr> <tr> <td class=\"indent1\">Sirolimus</td> <td>1-3 mg/day, titrated to keep therapeutic 24-hr trough levels</td> <td>5-10 ng/mL</td> <td> <p>Oral ulcerations</p> <p>Hypercholesterolemia and hypertriglyceridemia</p> <p>Poor wound healing</p> <p>Lower extremity edema</p> <p>Pulmonary toxicities (pneumonitis, alveolar hemorrhage)</p> <p>Leukopenia, anemia, and thrombocytopenia</p> <p>Potentiation of CNI nephrotoxicity</p> </td> </tr> <tr> <td class=\"indent1\">Everolimus</td> <td>1.5 mg/day in 2 divided doses&nbsp;</td> <td>3-8 ng/mL&nbsp;</td> <td>Similar to sirolimus&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Corticosteroids</td> </tr> <tr> <td class=\"indent1\">Prednisone</td> <td>1 mg/kg/day in 2 divided doses, tapered to 0.05 mg/kg/day by 6-12 mo</td> <td>None</td> <td> <p>Weight gain</p> <p>Hypertension</p> <p>Hyperlipidemia</p> <p>Osteopenia</p> <p>Hyperglycemia</p> <p>Poor wound healing</p> <p>Salt and water retention</p> <p>Proximal myopathy</p> <p>Cataracts</p> <p>Peptic ulcer disease</p> <p>Growth retardation</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WBC: white blood cell; CNI: calcineurin inhibitor.</div><div class=\"graphic_reference\">Adapted and updated from: Pham MX, Chen JM, Berry GJ, Rose EA, Schroeder JS. Surgical Treatment of Heart Failure, Cardiac Transplantation, and Mechanical Ventricular Support. In: Hurst's The Heart, 12th ed, V, Fuster R, O'Rourke R, Walsh P, Poole-Wilson (eds). McGraw-Hill, New York 2007. Copyright © 2007 McGraw-Hill Companies Inc.</div><div id=\"graphicVersion\">Graphic 50962 Version 11.0</div></div></div>"},"50963":{"type":"graphic_diagnosticimage","displayName":"Congenital TEF fluoro","title":"Congenital tracheoesophageal fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital tracheoesophageal fistula</div><div class=\"cntnt\"><img style=\"width:450px; height:300px;\" src=\"images/PULM/50963_Congenital_TEF_fluoro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Congenital fistula visualized after aspiration of barium. A distal tracheoesophageal fistula connects the esophagus with the airway at the level of the carina.</div><div id=\"graphicVersion\">Graphic 50963 Version 2.0</div></div></div>"},"50964":{"type":"graphic_figure","displayName":"NYHA CABG outcome MV surgery","title":"Survival after mitral valve surgery is better for patients in NYHA class I/II independent of CABG","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Survival after mitral valve surgery is better for patients in NYHA class I/II independent of CABG</div><div class=\"cntnt\"><img style=\"width:504px; height:305px;\" src=\"images/CARD/50964_NYHACABGoutcomeMVsurger.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long-term patient survival after mitral valve surgery for chronic mitral regurgitation is better in those in NYHA class I/II compared to those in NYHA class III/IV at the time of surgery. The benefit is independent of whether or not coronary artery bypass grafting (CABG) is also performed.</div><div class=\"graphic_reference\">Data from Tribouilloy CM, Enriquez-Sarano M, Schaff HV, et al. Circulation 1999; 99:400.</div><div id=\"graphicVersion\">Graphic 50964 Version 3.0</div></div></div>"},"50965":{"type":"graphic_table","displayName":"Radiopaque toxins","title":"Agents possibly radiopaque on plain x-ray","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Agents possibly radiopaque on plain x-ray</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"centered\" rowspan=\"3\"><strong>C</strong></td> <td>Chlorinated hydrocarbons (eg, chloral hydrate, carbon tetrachloride)</td> </tr> <tr> <td>Calcium salts (eg, calcium carbonate)</td> </tr> <tr> <td>Crack vials</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\"><strong>H</strong></td> <td>Heavy metals (eg, iron, arsenic, mercury, thallium, lead)</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\"><strong>I</strong></td> <td>Iodinated compounds (eg, thyroxine)</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\" rowspan=\"4\"><strong>P</strong></td> <td>Psychotropics (eg, phenothiazines, lithium, cyclic antidepressants)</td> </tr> <tr> <td>Packets of drugs (eg, cocaine and heroin \"body packers\")</td> </tr> <tr> <td>Play-Doh</td> </tr> <tr> <td>Potassium salts</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\"><strong>E</strong></td> <td>Enteric-coated tablets (eg, aspirin)</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\" rowspan=\"3\"><strong>S</strong></td> <td>Salicylates</td> </tr> <tr> <td>Sodium salts</td> </tr> <tr> <td>Sustained-release preparations</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50965 Version 3.0</div></div></div>"},"50967":{"type":"graphic_table","displayName":"Levels of IgG subclasses","title":"Levels of immunoglobulin G (IgG) subclasses in sera of normal subjects by age*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Levels of immunoglobulin G (IgG) subclasses in sera of normal subjects by age*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age, year</td> <td class=\"subtitle1\">Number of subjects</td> <td class=\"subtitle1\">IgG</td> <td class=\"subtitle1\">IgG1</td> <td class=\"subtitle1\">IgG2</td> <td class=\"subtitle1\">IgG3</td> <td class=\"subtitle1\">IgG4<sup>&#182;</sup></td> </tr> <tr> <td>0 to 1</td> <td>22</td> <td>420<sup>&#916;</sup> (250 to 690)</td> <td>340 (190 to 620)</td> <td>59 (30 to 140)</td> <td>39 (9 to 62)</td> <td>19 (6 to 63)</td> </tr> <tr> <td>1 to 2</td> <td>42</td> <td>470 (270 to 810)</td> <td>410 (230 to 710)</td> <td>68 (30 to 170)</td> <td>34 (11 to 98)</td> <td>13 (4 to 43)</td> </tr> <tr> <td>2 to 3</td> <td>36</td> <td>540 (300 to 980)</td> <td>480 (280 to 830)</td> <td>98 (40 to 240)</td> <td>28 (6 to 130)</td> <td>18 (3 to 120)</td> </tr> <tr> <td>3 to 4</td> <td>52</td> <td>600 (400 to 910)</td> <td>530 (350 to 790)</td> <td>120 (50 to 260)</td> <td>30 (9 to 98)</td> <td>32 (5 to 180)</td> </tr> <tr> <td>4 to 6</td> <td>31</td> <td>660 (440 to 1000)</td> <td>540 (360 to 810)</td> <td>140 (60 to 310)</td> <td>39 (9 to 160)</td> <td>39 (9 to 160)</td> </tr> <tr> <td>6 to 8</td> <td>24</td> <td>890 (560 to 1400)</td> <td>560 (280 to 1120)</td> <td>150 (30 to 630)</td> <td>48 (40 to 250)</td> <td>81 (11 to 620)</td> </tr> <tr> <td>8 to 10</td> <td>21</td> <td>1000 (530 to 1900)</td> <td>690 (280 to 1740)</td> <td>210 (80 to 550)</td> <td>85 (22 to 320)</td> <td>42 (10 to 170)</td> </tr> <tr> <td>10 to 13</td> <td>33</td> <td>910 (500 to 1660)</td> <td>590 (270 to 1290)</td> <td>240 (110 to 550)</td> <td>58 (13 to 250)</td> <td>60 (7 to 530)</td> </tr> <tr> <td>13 to 16</td> <td>19</td> <td>910 (580 to 1450)</td> <td>540 (280 to 1020)</td> <td>210 (60 to 790)</td> <td>58 (14 to 240)</td> <td>60 (11 to 330)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Levels were determined by radial diffusion using monospecific antisera.<br />¶ IgG4 levels appear to be absent in 10% of individuals.<br />Δ Geometric means are presented for each immunoglobulin at every age. The normal bounds, given in parentheses, are obtained by taking the mean logarithm, ±2 standard deviations of the logarithms and then taking the anti-logs of the results.</div><div class=\"graphic_reference\">Reproduced with permission from: Immunodeficiency Disorders-General Considerations. In: Immunologic disorders in infants and children, 5th edition, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier, Philadelphia 2004. Copyright © 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 50967 Version 6.0</div></div></div>"},"50968":{"type":"graphic_figure","displayName":"Finger tendons expanded view","title":"Finger tendons: Expanded view","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Finger tendons: Expanded view</div><div class=\"cntnt\"><img style=\"width:472px; height:280px;\" src=\"images/EM/50968_Finger_tendons_exp_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture reveals the complex relationships among the tendons and bones of the finger and clearly shows how the flexor digitorum profundus travels through the flexor digitorum superficialis to insert on the distal phalanx.</div><div class=\"graphic_reference\">Reproduced with permission from: Harwood-Nuss A, MD FACEP, Wolfson AB, MD, FACEP, FACP, et al. The Clinical Practice of Emergency Medicine, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &#169;2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50968 Version 2.0</div></div></div>"},"50969":{"type":"graphic_figure","displayName":"Percutaneous transtracheal ventilation stopcock","title":"Percutaneous transtracheal ventilation via three-way stopcock","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Percutaneous transtracheal ventilation via three-way stopcock</div><div class=\"cntnt\"><img style=\"width:300px; height:444px;\" src=\"images/EM/50969_PTVstopcock.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PTV setup utilizing a three-way stopcock.</div><div class=\"graphic_reference\">Reproduced with permission from: Mittal MK, Baren JM. Percutaneous Transtracheal Ventilation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 50969 Version 11.0</div></div></div>"},"50972":{"type":"graphic_picture","displayName":"Lichen sclerosus pallor","title":"Lichen sclerosus pallor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen sclerosus pallor</div><div class=\"cntnt\"><img style=\"width:257px; height:397px;\" src=\"images/OBGYN/50972_Lichen_sclerosus_pallor.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Ridley, CM, Neill, SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright © 1999 Blackwell Science.</div><div id=\"graphicVersion\">Graphic 50972 Version 2.0</div></div></div>"},"50973":{"type":"graphic_diagnosticimage","displayName":"Traumatic intubation CXR","title":"Traumatic intubation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traumatic intubation</div><div class=\"cntnt\"><img style=\"width:407px; height:538px;\" src=\"images/PULM/50973_Traumatic_intubation_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A demonstrates an endotracheal tube with its tip (arrow) descending below the level of the carina (arrowhead).<br />Image B shows massive pneumomediastinum and subcutaneous emphysema caused by a tear in the posterior membranous tracheal wall; the endotracheal tube has been repositioned.</div><div id=\"graphicVersion\">Graphic 50973 Version 3.0</div></div></div>"},"50974":{"type":"graphic_figure","displayName":"Port placement for laparoscopic cholecystectomy","title":"Port placement for laparoscopic cholecystectomy*","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Port placement for laparoscopic cholecystectomy*</div><div class=\"cntnt\"><img style=\"width:484px; height:587px;\" src=\"images/SURG/50974_Port_sites_lap_chole.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An open (Hasson) technique is used to enter the peritoneal cavity and place a 5 to 12 mm Hasson trocar at the umbilicus. The laparoscope is introduced through this port and three additional 5 mm ports are placed under direct vision 1 to 2 cm inferior to the right subcostal margin. The surgeon operates from the patient's left side using subxiphoid and typically the medial subcostal port (shown in red). The assistant works from patient's right side using the lateral subcostal port and periumbilical port (shown in blue).<br />The surgeon manipulates the infundibulum of the gallbladder to provide counter-retraction with the left hand and uses a dissector with the right hand through the subxiphoid port. The assistant uses the left hand to retract the fundus superiorly and operates the camera with the right hand. The gallbladder is usually removed through the umbilical port.</div><div class=\"graphic_footnotes\">* Port placement and technique may vary amongst laparoscopic surgeons.</div><div id=\"graphicVersion\">Graphic 50974 Version 7.0</div></div></div>"},"50975":{"type":"graphic_table","displayName":"Childhood diarrhea etiologies","title":"Major etiologies of childhood diarrhea in developing countries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major etiologies of childhood diarrhea in developing countries</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Etiologic agents</td> <td class=\"subtitle1\">Features</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"> <p><strong>Acute watery diarrhea</strong></p> Watery stools; may contain mucous. Fever may be present.</td> <td>Rotavirus</td> <td>Leading cause of gastroenteritis in children younger than two years.</td> </tr> <tr> <td>Enterotoxigenic <em>Escherichia coli</em> (ETEC)</td> <td>Leading cause of gastroenteritis in older children and adults.</td> </tr> <tr> <td><em>Vibrio cholerae</em> O1 and O139</td> <td>Associated with endemic and epidemic disease. Vomiting and voluminous \"rice-water diarrhea\" in severe cases.</td> </tr> <tr> <td>Cryptosporidium</td> <td>Common in infants (younger than one year) even in the absence of HIV; infrequently seen in older children.</td> </tr> <tr class=\"divider_bottom\"> <td>Norovirus</td> <td>Abrupt onset of vomiting and diarrhea with low grade fever.</td> </tr> <tr> <td rowspan=\"7\"> <p><strong>Invasive diarrhea</strong></p> Gross blood in stool. Often associated with fever, vomiting, abdominal pain.</td> <td>Shigella spp.</td> <td>Leading cause of invasive diarrhea. <em>S. dysenteriae</em> serotype I produces Shiga-toxin and is associated with epidemics of severe disease. Complications include toxic megacolon, rectal prolapse, intestinal perforation, seizures, encephalopathy and sepsis.</td> </tr> <tr> <td>Nontyphoidal <em>Salmonella enterica</em></td> <td>Several serotypes cause gastroenteritis. Infants, elderly, and immunocompromised at increased risk for disseminated infection.</td> </tr> <tr> <td>Campylobacter spp.</td> <td>Predominantly <em>C. jejuni</em> and <em>C. coli</em>. May mimic appendicitis. Complications include Guillain-Barr&#233; syndrome.</td> </tr> <tr> <td>Enteroinvasive <em>Escherichia coli</em> (EIEC)</td> <td>EIEC are closely related to Shigella and cause a syndrome essentially identical to shigellosis.</td> </tr> <tr> <td>Enterohemorrhagic <em>Escherichia coli</em> (EHEC)</td> <td>EHEC produce Shiga toxin identical to that produced by <em>S. dysenteriae</em> serotype I, associated with increased risk of hemolytic uremic syndrome.</td> </tr> <tr> <td><em>Entamoeba histolytica</em></td> <td><em>E. histolytica</em> is a protozoal organism which causes intestinal infection which may be indistinguishable from Shigella and other bacteria. Rare complications include extraintestinal infections, most commonly hepatic abscess.</td> </tr> <tr> <td>Adenovirus types 40/41</td> <td>Also cause watery diarrhea.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 50975 Version 4.0</div></div></div>"},"50976":{"type":"graphic_picture","displayName":"Molluscum in AIDS 1","title":"Molluscum in AIDS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Molluscum in AIDS</div><div class=\"cntnt\"><img style=\"width:432px; height:305px;\" src=\"images/DERM/50976_Molluscum_AIDS_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Confluent nodules of molluscum contagiosum are present on the eyelids in this patient with acquired immunodeficiency syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: Henry Perry, MD. Photo from Gold DH, Weingeist TA. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright © 2001.</div><div id=\"graphicVersion\">Graphic 50976 Version 3.0</div></div></div>"},"50978":{"type":"graphic_picture","displayName":"Pyogenic granuloma histology 2","title":"Pyogenic granuloma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pyogenic granuloma</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/50978_Pyogenic_granuloma hist_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pyogenic granuloma from the neck of a 4-year-old boy. At higher power, the lesion consists of condensed small-caliber vessels with scattered red blood cells. The stroma is fibromyxoid with scattered inflammatory cells. Cytologic atypia and mitoses are not present, but can be seen.</div><div class=\"graphic_reference\">Copyright © Greg Hosler, MD, PhD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 50978 Version 3.0</div></div></div>"},"50980":{"type":"graphic_figure","displayName":"Breech extraction3","title":"Delivery of the arms","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Delivery of the arms</div><div class=\"cntnt\"><img style=\"width:454px; height:298px;\" src=\"images/OBGYN/50980_Breech_extraction3.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: LifeART, Obstetrics &amp; Gynecology. Copyright &#169;2009 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 50980 Version 1.0</div></div></div>"},"50982":{"type":"graphic_picture","displayName":"Hypophosphatasia dental effects","title":"Early loss of central incisors in hypophosphatasia","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Early loss of central incisors in hypophosphatasia</div><div class=\"cntnt\"><img style=\"width:506px; height:188px;\" src=\"images/PEDS/50982_Hypophosphatasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dentition of a child four years of age with early loss of upper and lower central incisors due to hypophosphatasia.<br />(A) Note the lack of gingival inflammation. The lower incisors, exfoliated at 13 months of age.<br />(B) Note the incomplete root development at the time the teeth were exfoliated.</div><div class=\"graphic_reference\">Reproduced with permission from: Griffen AL. Periodontal problems in children and adolescents. In: Pediatric Dentistry, Infancy Through Adolescence, 3<SUP>rd</SUP> ed, Pinkham JR, Casamassimo PS, Fields HW, et al (Eds), W.B. Saunders, 1999. p.376. Copyright © 1999 Elsevier.</div><div id=\"graphicVersion\">Graphic 50982 Version 5.0</div></div></div>"},"50983":{"type":"graphic_table","displayName":"Amine alkaloid sympath herbs A","title":"Herbal ingredients with amines, alkaloids or sympathomimetic action: part A","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Herbal ingredients with amines, alkaloids or sympathomimetic action: part A</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Drug</td>\n\n      <td class=\"subtitle1\">Effect</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Agnus Castus</td>\n\n      <td>Alkaloids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Alfalfa</td>\n\n      <td>Alkaloids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Aniseed</td>\n\n      <td>Alkaloids, sympathomimetic</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Arnica</td>\n\n      <td>Betaines, choline</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bloodroot</td>\n\n      <td>Alkaloids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bogbean</td>\n\n      <td>Alkaloids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Boldo</td>\n\n      <td>Alkaloids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Borage</td>\n\n      <td>Alkaloids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Broom</td>\n\n      <td>Alkaloids, amines</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Calamus</td>\n\n      <td>Amines</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Capsicum</td>\n\n      <td>Sympathomimetic</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Centaury</td>\n\n      <td>Alkaloids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cereus</td>\n\n      <td>Tyramine</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cohosh, black</td>\n\n      <td>Alkaloids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cohosh, blue</td>\n\n      <td>Alkaloids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cola</td>\n\n      <td>Alkaloids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Coltsfoot</td>\n\n      <td>Alkaloids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Comfrey</td>\n\n      <td>Alkaloids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cornsilk</td>\n\n      <td>Amines</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Echinacea</td>\n\n      <td>Alkaloids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Eyebright</td>\n\n      <td>Alkaloids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fenugreek</td>\n\n      <td>Choline, trigonelline</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fumitory</td>\n\n      <td>Alkaloids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Gentian</td>\n\n      <td>Alkaloids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ginseng, Panax</td>\n\n      <td>MAOI potentiation, suspected phenelzine interaction</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996, p.284.</div><div id=\"graphicVersion\">Graphic 50983 Version 2.0</div></div></div>"},"50984":{"type":"graphic_figure","displayName":"Tonsillectomy technique","title":"Tonsillectomy","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Tonsillectomy</div><div class=\"cntnt\"><img style=\"width:463px; height:502px;\" src=\"images/PC/50984_Tonsillectomy_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An Allis clamp is used to grasp the upper portion of the tonsil. As it is pulled anteriorly and medially, the anterior tonsillar pillar mucosa is divided superiorly to inferiorly. With the superior pole of the tonsil freed, the Allis clamp can be repositioned as needed to grasp the inferior tonsil and the tonsil dissected out of its bed. Control of perforating vessels is performed as they are encountered.</div><div id=\"graphicVersion\">Graphic 50984 Version 1.0</div></div></div>"},"50985":{"type":"graphic_picture","displayName":"PCFCL scalp","title":"Primary cutaneous follicle center lymphoma with confluent skin tumors on the scalp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary cutaneous follicle center lymphoma with confluent skin tumors on the scalp</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/HEME/50985_PCFCL_scalp_PR.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 50985 Version 1.0</div></div></div>"},"50986":{"type":"graphic_picture","displayName":"Ulcerated stricture on cholangioscopy","title":"Ulcerated stricture on cholangioscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ulcerated stricture on cholangioscopy</div><div class=\"cntnt\"><img style=\"width:400px; height:371px;\" src=\"images/GAST/50986_Ulcerated_strict_cholang_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Catheter-based cholangioscopy showing an ulcerated bile duct stricture.</div><div id=\"graphicVersion\">Graphic 50986 Version 2.0</div></div></div>"},"50988":{"type":"graphic_diagnosticimage","displayName":"Paratracheal lymph node CT","title":"Paratracheal lymph node enlargement in lung cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paratracheal lymph node enlargement in lung cancer</div><div class=\"cntnt\"><img style=\"width:394px; height:260px;\" src=\"images/PULM/50988_Paratracheal_lymph_node_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows right high paratracheal lymph node (arrow). This indicates an N2 lesion, provided that the primary cancer is on the ipsilateral side.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 50988 Version 3.0</div></div></div>"},"50989":{"type":"graphic_diagnosticimage","displayName":"RML atelectasis Lateral","title":"Right middle lobe atelectasis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right middle lobe atelectasis</div><div class=\"cntnt\"><img style=\"width:388px; height:379px;\" src=\"images/PULM/50989_RML_atelectasis_Lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral view of the chest in the same patient. The minor and major fissures are parallel to each other (arrows), and the atelectatic lobe can be seen as a band of opacity between the fissures projecting over the cardiac silhouette.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 50989 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lateral chest radiograph</div><div class=\"cntnt\"><img style=\"width:252px; height:368px;\" src=\"images/PULM/57909_Normal_chest_film_Lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Steven Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 57909 Version 1.0</div></div></div>"},"50992":{"type":"graphic_figure","displayName":"Jugular venous sampling of PTH","title":"Jugular venous sampling of parathyroid hormone (PTH)","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Jugular venous sampling of parathyroid hormone (PTH)</div><div class=\"cntnt\"><img style=\"width:520px; height:544px;\" src=\"images/SURG/50992_Jugular_venous_samp_PTH_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Differential jugular venous sampling has been used to lateralize the side of the neck harboring the most hyperfunctioning parathyroid gland(s) and thus avoid bilateral neck exploration. When performed intraoperatively, samples from both internal jugular veins, preferably guided by ultrasound, are taken before skin incision for rapid PTH measurement as shown here. This technique guides the surgeon to the side of the neck containing the highest PTH level. In this illustration, the PTH levels are higher on the right, which indicates that the disease is on the right side of the neck.</div><div id=\"graphicVersion\">Graphic 50992 Version 3.0</div></div></div>"},"50993":{"type":"graphic_algorithm","displayName":"Lab confirm of LGV","title":"Laboratory confirmation of lymphogranuloma venereum (LGV) proctocolitis diagnosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laboratory confirmation of lymphogranuloma venereum (LGV) proctocolitis diagnosis</div><div class=\"cntnt\"><img style=\"width:403px; height:537px;\" src=\"images/ID/50993_Lab_confirm_of_LGV.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* For patients with classic LGV symptoms (eg, genital papule or ulcer and inguinal lymphadenopathy) and for patients who are asymptomatic sex partners of LGV case patients, collect urethral (or urine) specimens and test locally for CT. If positive for CT, urethral/urine specimen and serum specimen may be sent to CDC for typing.</div><div class=\"graphic_reference\">Centers for Disease Control and Prevention. Lymphogranuloma Venereum, revised June 19, 2006.</div><div id=\"graphicVersion\">Graphic 50993 Version 1.0</div></div></div>"},"50994":{"type":"graphic_movie","displayName":"Left ventricular tumor 4 chamber view","title":"Intracardiac tumor","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intracardiac tumor</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/50994_4chlvtumconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:320px; height:240px;\" src=\"images/CARD/50994_4chlvtum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical four-chamber view from a two-dimensional echocardiogram shows a tumor mass within the left ventricle, attached to the left ventricular wall.</div><div id=\"graphicVersion\">Graphic 50994 Version 2.0</div></div></div>"},"50996":{"type":"graphic_diagnosticimage","displayName":"Brain sites associated with cardiac troponin T elevation","title":"Brain MRI map of cerebral infarction sites associated with cardiac troponin T (cTnT) elevation","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Brain MRI map of cerebral infarction sites associated with cardiac troponin T (cTnT) elevation</div><div class=\"cntnt\"><img style=\"width:523px; height:408px;\" src=\"images/NEURO/50996_Brain_sites_cTnT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A diffusion weighted MRI map of cerebral sites in patients with ischemic stroke highlights areas of infarction associated with cardiac troponin T (cTnT) elevation. The highlighted regions represent voxels linked to cTnT elevation with a p value of &lt;0.05 and include the right insula (posterior, superior, and medial regions) and the right inferior parietal lobe. The color bar indicates voxel-wise p values.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Ay H, Koroshetz WJ, Benner T, et al. Neuroanatomic correlates of stroke-related myocardial injury. Neurology 2006; 66:1325. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 50996 Version 15.0</div></div></div>"},"50997":{"type":"graphic_picture","displayName":"Fetal vascular malperfusion","title":"Fetal stem/chorionic vessel obliteration (fetal vascular malperfusion)","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Fetal stem/chorionic vessel obliteration (fetal vascular malperfusion)</div><div class=\"cntnt\"><img style=\"width:540px; height:384px;\" src=\"images/OBGYN/50997_Hemorrhagicendovasculitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemorrhagic endovasculitis in the stem villus of a liveborn infant with cardiac failure.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 50997 Version 3.0</div></div></div>"},"50998":{"type":"graphic_diagnosticimage","displayName":"CT vascular encasement","title":"Detecting vascular encasement","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Detecting vascular encasement</div><div class=\"cntnt\"><img style=\"width:503px; height:409px;\" src=\"images/ONC/50998_CT_vascular_encasement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of a contrast enhanced CT angiography demonstrating different degrees of vascular encasement by a pancreatic adenocarcinoma; axial images.<br />(A) Adenocarcinoma of the head of the pancreas with &lt;25 percent of involvement of the superior mesenteric vein (SMV) circumference.<br />(B) Adenocarcinoma of the head pancreas which is contacting 50 percent of the circumference of the SMV.<br />(C) Adenocarcinoma of the uncinate process of the pancreas involving &gt;75 percent of the circumference of the SMV as well as narrowing of its lumen.<br />(D) Adenocarcinoma of the body of the pancreas extending superiorly and encasing the celiac trunk (V-shaped structure containing contrast).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Dr. Rocio Perez-Johnston.</div><div id=\"graphicVersion\">Graphic 50998 Version 3.0</div></div></div>"}};